FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Dalrymple, LS Katz, R Kestenbaum, B de Boer, IH Fried, L Sarnak, MJ Shlipak, MG AF Dalrymple, Lorien S. Katz, Ronit Kestenbaum, Bryan de Boer, Ian H. Fried, Linda Sarnak, Mark J. Shlipak, Michael G. TI The Risk of Infection-Related Hospitalization With Decreased Kidney Function SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Renal disease; chronic kidney disease; infection; clinical epidemiology ID GLOMERULAR-FILTRATION-RATE; SERUM CYSTATIN-C; STAGE RENAL-DISEASE; CARDIOVASCULAR EVENTS; DEATH; CREATININE; MORBIDITY; DIALYSIS; DEFECTS; ADULTS AB Background: Moderate kidney disease may predispose to infection. We sought to determine whether decreased kidney function, estimated by serum cystatin C level, was associated with the risk of infection-related hospitalization in older individuals. Study Design: Cohort study. Setting & Participants: 5,142 Cardiovascular Health Study (CHS) participants with measured serum creatinine and cystatin C and without estimated glomerular filtration rate (eGFR) <15 mL/min/1.73m(2) at enrollment. Predictor: The primary exposure of interest was eGFR using serum cystatin C level (eGFR(SCysC)). Outcome: Infection-related hospitalizations during a median follow-up of 11.5 years. Results: In adjusted analyses, eGFR(SCysC) categories of 60-89, 45-59, and 15-44 mL/min/1.73 m(2) were associated with 16%, 37%, and 64% greater risk of all-cause infection-related hospitalization, respectively, compared with eGFRSCysC >= 90 mL/min/1.73 m2. When cause-specific infection was examined, eGFR(SCysC) of 15-44 mL/min/1.73 m2 was associated with an 80% greater risk of pulmonary and 160% greater risk of genitourinary infection compared with eGFR(SCysC) >= 90 mL/min/1.73 m(2). Limitations: No measures of urinary protein, study limited to principal discharge diagnosis. Conclusions: Lower kidney function, estimated using cystatin C level, was associated with a linear and graded risk of infection-related hospitalization. These findings highlight that even moderate degrees of decreased kidney function are associated with clinically significant higher risks of serious infection in older individuals. Am J Kidney Dis. 59(3): 356-363. (C) 2012 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Dalrymple, Lorien S.] Univ Calif Davis, Dept Med, Davis, CA 95616 USA. [Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Dept Med, Seattle, WA USA. [Fried, Linda] VA Pittsburgh Hlth Care Syst, Renal Sect, Pittsburgh, PA USA. [Fried, Linda] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Fried, Linda] Univ Pittsburgh, Dept Epidemiol, Sch Med, Pittsburgh, PA 15261 USA. [Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Boston, MA USA. [Shlipak, Michael G.] Vet Affairs Med Ctr, Med Serv, Gen Internal Med Sect, San Francisco, CA 94121 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Dalrymple, LS (reprint author), Div Nephrol, 4150 V St,Ste 3500, Sacramento, CA 95817 USA. EM lorien.dalrymple@ucdmc.ucdavis.edu FU National Heart, Lung, and Blood Institute (NHLBI) [HL080295]; National Institute of Neurological Disorders and Stroke; National Institute on Aging [AG-023629, AG-15928, AG-20098, AG-027058, AG-027002]; National Center for Research [UL1 RR024146]; NHLBI; [N01-HC-85239]; [N01-HC-85079]; [N01-HC-85080]; [N01-HC-85081]; [N01-HC-85082]; [N01-HC-85083]; [N01-HC-85084]; [N01-HC-85085]; [N01-HC-85086]; [N01-HC-35129]; [N01 HC-15103]; [N01 HC-55222]; [N01-HC-75150]; [N01-HC-45133] FX This research was supported by contracts N01-HC-85239, N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, and grant HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided through AG-023629, AG-15928, AG-20098, AG-027058, and AG-027002 from the National Institute on Aging and UL1 RR024146 from the National Center for Research. The CHS was funded through contracts with NHLBI and included substantial NHLBI involvement in the design and conduct of the study and the collection and management of the data. The funding source was not involved in data analysis, interpretation of the data, preparation, review, or approval of the manuscript. The contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Institutes of Health. A full list of principal CHS investigators and institutions can be found at www.chs-nhlbi.org/pi.htm. NR 25 TC 20 Z9 20 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2012 VL 59 IS 3 BP 356 EP 363 DI 10.1053/j.ajkd.2011.07.012 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 898WE UT WOS:000300772300009 PM 21906862 ER PT J AU Anderson, S Oyama, TT Lindsley, JN Schutzer, WE Beard, DR Gattone, VH Komers, R AF Anderson, Sharon Oyama, Terry T. Lindsley, Jessie N. Schutzer, William E. Beard, Douglas R. Gattone, Vincent H., II Komers, Radko TI 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE gender; estrogen; mammalian target of rapamycin 2; hydroxyestradiol p21; hypoxia-inducible factor-1 alpha ID HAN-SPRD RATS; ACTIVATED PROTEIN-KINASE; EPITHELIAL-CELL PROLIFERATION; RENAL-DISEASE; SIGNALING PATHWAY; INHIBITION SLOWS; CYSTIC-DISEASE; MTOR PATHWAY; CANCER CELLS; GROWTH AB Anderson S, Oyama TT, Lindsley JN, Schutzer WE, Beard DR, Gattone VH 2nd, Komers R. 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease. Am J Physiol Renal Physiol 302: F636-F645, 2012. First published December 7, 2011; doi: 10.1152/ajprenal.00265.2011.-Male gender is a risk factor for progression of polycystic kidney disease (PKD). 17 beta-Estradiol (E2) protects experimentally, but clinical use is limited by adverse effects. Novel E2 metabolites provide many benefits of E2 without stimulating the estrogen receptor, and thus may be safer. We hypothesized that E2 metabolites are protective in a model of PKD. Studies were performed in male control Han:SPRD rats, and in cystic males treated with orchiectomy, 2-methoxyestradiol, 2-hydroxyestradiol (2-OHE), or vehicle, from age 3 to 12 wk. Cystic rats exhibited renal functional impairment (similar to 50% decrease in glomerular filtration and renal plasma flow rates, P < 0.05) and substantial cyst development (20.5 +/- 2.0% of cortex area). 2-OHE was the most effective in limiting cysts (6.0 +/- 0.7% of cortex area, P < 0.05 vs. vehicle-treated cystic rats) and preserving function, in association with suppression of proliferation, apoptosis, and angiogenesis markers. Downregulation of p21 expression and increased expression of Akt, the mammalian target of rapamycin (mTOR), and some of its downstream effectors were significantly reversed by 2-OHE. Thus, 2-OHE limits disease progression in a cystic rodent model. Mechanisms include reduced renal cell proliferation, apoptosis, and angiogenesis. These effects may be mediated, at least in part, by preservation of p21 and suppression of Akt and mTOR. Estradiol metabolites may represent a novel, safe intervention to slow progression of PKD. C1 [Anderson, Sharon; Oyama, Terry T.; Lindsley, Jessie N.; Schutzer, William E.; Komers, Radko] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Anderson, Sharon] Portland VA Med Ctr, Med Serv, Portland, OR USA. [Schutzer, William E.; Beard, Douglas R.] Portland VA Med Ctr, Res Serv, Portland, OR USA. [Gattone, Vincent H., II] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA. RP Anderson, S (reprint author), Oregon Hlth & Sci Univ, Div Nephrol, CH12R,3303 SW Bond St, Portland, OR 97239 USA. EM anderssh@ohsu.edu FU National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [DK 078807]; Polycystic Kidney Research Foundation FX These studies were supported by grants from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (DK 078807) and the Polycystic Kidney Research Foundation. NR 76 TC 5 Z9 5 U1 0 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD MAR PY 2012 VL 302 IS 5 BP F636 EP F645 DI 10.1152/ajprenal.00265.2011 PG 10 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 901BG UT WOS:000300936100014 PM 22160773 ER PT J AU Martin, TR Snapp, DL Tomita, DM AF Martin, Thomas R. Snapp, Deborah L. Tomita, Diane M. TI The Parker B. Francis Fellowship Program Analysis of 31 Years of Career Development Support SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE research training; fellowship support; survey; career development ID ORGANIZATIONAL-CLIMATE; MEDICAL-SCHOOL; RESPONSE RATES; WOMEN FACULTY AB Rationale: The Parker B. Francis (PBF) Fellowship Program has supported more than 750 M.D., M.D./Ph.D., and Ph.D. fellows since 1976, but there is little information about the effectiveness of the program in fostering successful careers and producing important research. Objectives: To survey all past PBF Fellows to obtain information about their productivity and career pathways. Methods: We obtained e-mail addresses for 526 (74%) of the 712 PBF awardees from 1976 to 2006, then sent an e-mail survey to the 526 past fellows and received 365 replies (69% response rate, 49% overall). Survey questions addressed time in research, areas of research, current position and responsibilities, and research funding. Measurements and Main Results: Seventy percent of the 365 respondents spend 25% or greater effort in research and 56% report 50% or more effort in research. Respondents have published an average of 2.7 peer-reviewed publications per year, totaling more than 15,678 peer-reviewed publications, of which 1,875 appeared in high-impact journals. Respondents have received more than $1.8 billion in direct research funding since their PBF Fellowships began. Ph.D. awardees spend more time in research than M.D. awardees, and current research effort did not differ by gender. PBF awardees have become prominent leaders in universities, the National Institutes of Health, health care, and industry. Conclusions: The PBF Program has been highly successful in producing a large number of scientific and clinical leaders in pulmonary and critical care medicine. The results provide comprehensive data about the success of this career development program and provide a model for programs designed to build the workforce in pulmonary and critical care medicine. C1 [Martin, Thomas R.] Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Martin, Thomas R.] VA Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA USA. RP Martin, TR (reprint author), Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. EM trmartin@u.washington.edu FU Francis Family Foundation, Kansas City, MO; Francis Family Foundation FX Supported by the Francis Family Foundation, Kansas City, MO.; The authors thank the Francis Family members and the Francis Family Foundation Board of Directors for their steadfast support of the Parker B. Francis Fellowship Program and the Parker B. Francis Council of Scientific Advisors for advice during the preparation of this report. The data in this report reflect the leadership of the past Scientific Directors of the PBF Program, S. Marsh Tenney, M.D., Donald F. Tierney, M.D. and Joseph D. Brain, Sc.D. NR 10 TC 2 Z9 2 U1 1 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAR 1 PY 2012 VL 185 IS 5 BP 479 EP 485 DI 10.1164/rccm.201108-1390PP PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 900AG UT WOS:000300858400008 PM 22095548 ER PT J AU Wong, VM Wenk, JF Zhang, ZH Cheng, GM Acevedo-Bolton, G Burger, M Saloner, DA Wallace, AW Guccione, JM Ratcliffe, MB Ge, L AF Wong, Vincent M. Wenk, Jonathan F. Zhang, Zhihong Cheng, Guangming Acevedo-Bolton, Gabriel Burger, Mike Saloner, David A. Wallace, Arthur W. Guccione, Julius M. Ratcliffe, Mark B. Ge, Liang TI The Effect of Mitral Annuloplasty Shape in Ischemic Mitral Regurgitation: A Finite Element Simulation SO ANNALS OF THORACIC SURGERY LA English DT Article ID DILATED CARDIOMYOPATHY; LEFT-VENTRICLE; WALL STRESS; VALVE; REPAIR; MODEL; RECONSTRUCTION; PATHOGENESIS; HYPERTROPHY; DIMENSIONS AB Background. Undersized mitral annuloplasty (MA) is the preferred surgical treatment for chronic ischemic mitral regurgitation. However, the preferred shape of undersized MA is unclear. Methods. A previously described finite element model of the left ventricle with mitral valve based on magnetic resonance images of a sheep with chronic ischemic mitral regurgitation after posterolateral myocardial infarction was used. Saddle-shape (Edwards Physio II) and asymmetric (IMR ETlogix) MA rings were digitized and meshed. Virtual annuloplasty was performed using virtual sutures to attach the MA ring. Left ventricular diastole and systole were performed before and after virtual MA of each type. Results. Both types of MA reduced the septolateral dimension of the mitral annulus and abolished mitral regurgitation. The asymmetric MA was associated with lower virtual suture force in the P2 region but higher force in P1 and P3 regions. Although both types of MA reduced fiber stress at the left ventricular base, fiber stress reduction after asymmetric MA was slightly greater. Neither type of MA affected fiber stress at the left ventricular equator or apex. Although both types of MA increased leaflet curvature and reduced leaflet stress, stress reduction with saddle-shape MA was slightly greater. Both MA types reduced stress on the mitral chordae. Conclusions. The effects of saddle-shape and asymmetric MA rings are similar. Finite element simulations are a powerful tool that may reduce the need for animal and clinical trials. (Ann Thorac Surg 2012; 93: 776-82) (C) 2012 by The Society of Thoracic Surgeons C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Livermore Software Technol Corp, Livermore, CA USA. Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@va.gov FU NIH [R01-HL-084431, R01-HL-077921, 86400] FX We thank Edwards Lifesciences for providing samples of the annuloplasty rings used in this work. This study was supported by NIH grants R01-HL-084431 (M.B.R.) and R01-HL-077921 and 86400 (J.M.G.). NR 39 TC 23 Z9 24 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAR PY 2012 VL 93 IS 3 BP 776 EP 782 DI 10.1016/j.athoracsur.2011.08.080 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 899RB UT WOS:000300832700028 PM 22245588 ER PT J AU Hirata, H Hinoda, Y Ueno, K Nakajima, K Ishii, N Dahiya, R AF Hirata, Hiroshi Hinoda, Yuji Ueno, Koji Nakajima, Koichi Ishii, Nobuhisa Dahiya, Rajvir TI MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer SO CARCINOGENESIS LA English DT Article ID CELL CARCINOMA; KIDNEY CANCER; IN-VIVO; THERAPY; EXPRESSION; THERAPEUTICS; INHIBITOR; PATHWAY; GROWTH AB The aim of this project is to identify new therapeutic microRNAs (miRNAs) for von Hippel-Lindau (VHL)-inactivated renal cancer cells. We initially identified several potential miRNAs targeting CTNNB1 and MEK1 using several targets scan algorithms. Only miR-1826 was found to target CTNNB1 and MEK1. Therefore, we focused on miRNA-1826 and performed 3' untranslated region (UTR) luciferase assay, functional analyses and association study between miR-1826 expression and renal cancer patient outcomes. miR-1826 expression was significantly lower in renal cancer tissues compared with non-neoplastic areas and lower expression was significantly associated with overall shorter survival and earlier recurrence after radical nephrectomy. Following miR-1826 transfection, 3' UTR luciferase activity and protein expression of beta-catenin and MEK1 were significantly downregulated in renal cancer cells. Introduction of miR-1826 also inhibited renal cancer cell proliferation, invasion and migration. Additionally, miR-1826 promoted apoptosis and G(1) arrest in VHL-inactivated renal cancer cells. Knockdowns of CTNNB1 and MEK1 by small interfering RNAs reproduced the tumor-suppressive effect of miR-1826. Our data suggest that the miR-1826 plays an important role as a tumor suppressor by downregulating beta-catenin and MEK1 in VHL-inactivated renal cancers. C1 [Hirata, Hiroshi; Ueno, Koji; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. [Hirata, Hiroshi; Ueno, Koji; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94121 USA. [Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi 7558505, Japan. [Nakajima, Koichi; Ishii, Nobuhisa] Toho Univ, Dept Urol, Fac Med, Tokyo 1438540, Japan. RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Dept Urol, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA. EM rdahiya@urology.ucsf.edu FU National Institutes of Health [RO1CA130860, RO1CA160079, RO1CA138642, T32-DK07790, 1I01BX001123]; VA Research Enhancement Award Program (REAP); Merit Review grants; Yamada Science Foundation FX This study was supported by grants (RO1CA130860, RO1CA160079, RO1CA138642, T32-DK07790, 1I01BX001123) from the National Institutes of Health, VA Research Enhancement Award Program (REAP), Merit Review grants and Yamada Science Foundation. NR 29 TC 29 Z9 33 U1 2 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD MAR PY 2012 VL 33 IS 3 BP 501 EP 508 DI 10.1093/carcin/bgr302 PG 8 WC Oncology SC Oncology GA 901SW UT WOS:000300988100004 PM 22180573 ER PT J AU Verma, A Matsunaga, J Artiushin, S Pinne, M Houwers, DJ Haake, DA Stevenson, B Timoney, JF AF Verma, Ashutosh Matsunaga, James Artiushin, Sergey Pinne, Marija Houwers, Dirk J. Haake, David A. Stevenson, Brian Timoney, John F. TI Antibodies to a Novel Leptospiral Protein, LruC, in the Eye Fluids and Sera of Horses with Leptospira-Associated Uveitis SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID EQUINE RECURRENT UVEITIS; SURFACE-EXPOSED LIPOPROTEIN; OUTER-MEMBRANE; SIGNAL PEPTIDES; INTERROGANS; PATHOGENESIS; PREDICTION; IDENTIFICATION; INFECTION; FAMILY AB Screening of an expression library of Leptospira interrogans with eye fluids from uveitic horses resulted in identification of a novel protein, LruC. LruC is located in the inner leaflet of the leptospiral outer membrane, and an lruC gene was detected in all tested pathogenic L. interrogans strains. LruC-specific antibody levels were significantly higher in eye fluids and sera of uveitic horses than healthy horses. These findings suggest that LruC may play a role in equine leptospiral uveitis. C1 [Verma, Ashutosh; Artiushin, Sergey; Timoney, John F.] Univ Kentucky, Dept Vet Sci, MH Gluck Equine Res Ctr, Lexington, KY 40546 USA. [Matsunaga, James; Pinne, Marija] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Matsunaga, James; Pinne, Marija; Haake, David A.] UCLA Sch Med, Dept Med, Los Angeles, CA USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Verma, Ashutosh; Stevenson, Brian] Univ Kentucky, Coll Med, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40506 USA. [Houwers, Dirk J.] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Vet Microbiol Diagnost Ctr, Utrecht, Netherlands. RP Verma, A (reprint author), Univ Kentucky, Coll Med, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40506 USA. FU Keeneland Endowment; Paul Mellon Fellowship; Public Health Service from National Institute of Allergy and Infectious Diseases [AI-34431]; VA FX This work was supported by the Keeneland Endowment. A. Verma was funded by a Paul Mellon Fellowship in Equine Studies. The support of Public Health Service grant AI-34431 (to D. A. H.) from the National Institute of Allergy and Infectious Diseases and VA Medical Research Funds (to D. A. H. and J. M.) is also acknowledged. NR 39 TC 9 Z9 9 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD MAR PY 2012 VL 19 IS 3 BP 452 EP 456 DI 10.1128/CVI.05524-11 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 899UF UT WOS:000300841200026 PM 22237897 ER PT J AU McGlone, SM Bailey, RR Zimmer, SM Popovich, MJ Tian, Y Ufberg, P Muder, RR Lee, BY AF McGlone, S. M. Bailey, R. R. Zimmer, S. M. Popovich, M. J. Tian, Y. Ufberg, P. Muder, R. R. Lee, B. Y. TI The economic burden of Clostridium difficile SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Article DE Burden; Clostridium difficile; cost; economics; stochastic model ID INTENSIVE-CARE-UNIT; HYPERVIRULENT STRAIN; COST-EFFECTIVENESS; RISK-FACTORS; DISEASE; INFECTION; COLECTOMY; DIARRHEA; COLITIS; MORTALITY AB lthough Clostridium difficile (C. difficile) is the leading cause of infectious diarrhoea in hospitalized patients, the economic burden of this major nosocomial pathogen for hospitals, third-party payers and society remains unclear. We developed an economic computer simulation model to determine the costs attributable to healthcare-acquired C. difficile infection (CDI) from the hospital, third-party payer and societal perspectives. Sensitivity analyses explored the effects of varying the cost of hospitalization, C. difficile-attributable length of stay, and the probability of initial and secondary recurrences. The median cost of a case ranged from $9179 to $11 456 from the hospital perspective, $8932 to $11 679 from the third-party payor perspective, and $13 310 to $16 464 from the societal perspective. Most of the costs incurred were accrued during a patients primary CDI episode. Hospitals with an incidence of 4.1 CDI cases per 100 000 discharges would incur costs =$3.2 million (hospital perspective); an incidence of 10.5 would lead to costs =$30.6 million. Our model suggests that the annual US economic burden of CDI would be =$496 million (hospital perspective), =$547 million (third-party payer perspective) and =$796 million (societal perspective). Our results show that C. difficile infection is indeed costly, not only to third-party payers and the hospital, but to society as well. These results are consistent with current literature citing C. difficile as a costly disease. C1 [McGlone, S. M.; Bailey, R. R.; Popovich, M. J.; Tian, Y.; Ufberg, P.; Lee, B. Y.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [McGlone, S. M.; Bailey, R. R.; Popovich, M. J.; Tian, Y.; Ufberg, P.; Lee, B. Y.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Zimmer, S. M.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Muder, R. R.] VA Pittsburgh Hlth Syst, Div Infect Dis, Pittsburgh, PA USA. RP McGlone, SM (reprint author), Univ Pittsburgh, Sch Med, Dept Biomed Informat, 3520 Forbes Ave,1st Floor, Pittsburgh, PA 15213 USA. EM smm168@pitt.edu OI Slayton, Rachel/0000-0003-4699-8040 FU National Institute General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) [5U54GM088491-02]; Pennsylvania Department of Health (DOH) FX This study was supported by the National Institute General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) (grant number 5U54GM088491-02) and the Pennsylvania Department of Health (DOH). The funders had no role in the design and conduct of the study, collection, management, analysis and interpretation of the data, and preparation, review or approval of the manuscript. NR 45 TC 89 Z9 93 U1 2 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1198-743X J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD MAR PY 2012 VL 18 IS 3 BP 282 EP 289 DI 10.1111/j.1469-0691.2011.03571.x PG 8 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 899SX UT WOS:000300837600019 PM 21668576 ER PT J AU David, CM AF David, Charlene M. TI Clinical Nurse Specialist Practice in Fall Prevention: Comparing, Sharing, and Improving SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [David, Charlene M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2012 VL 26 IS 2 BP E12 EP E12 PG 1 WC Nursing SC Nursing GA 897FS UT WOS:000300632600033 ER PT J AU Valdez, C Richardson, J Holmquist, J Tjoelker, R AF Valdez, Christine Richardson, Jenny Holmquist, Jennifer Tjoelker, Rita TI Back to the Future: Building a Clinical Nurse Specialist Residency Program SO CLINICAL NURSE SPECIALIST LA English DT Meeting Abstract C1 [Valdez, Christine; Richardson, Jenny; Holmquist, Jennifer; Tjoelker, Rita] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0887-6274 J9 CLIN NURSE SPEC JI Clin. Nurse Spec. PD MAR-APR PY 2012 VL 26 IS 2 BP E6 EP E6 PG 1 WC Nursing SC Nursing GA 897FS UT WOS:000300632600015 ER PT J AU Bromley, E AF Bromley, Elizabeth TI The Texture of the Real: Experimentation and Experience in Schizophrenia SO CULTURE MEDICINE AND PSYCHIATRY LA English DT Article DE Cognition; Reductionism; Stigma; Schizophrenia; Neuroscience ID MENTAL-ILLNESS; SOCIOLOGY; COGNITION; MATRICS; PSYCHOLOGY; SCIENCE; BRAIN; SELF; NEUROCOGNITION; CONSTRUCTION AB The dominance of the neurosciences in psychiatric research raises questions about the relationship between research practices and the lived experience of mental illness. Here, I use data from a group of researchers focusing on neurocognition in schizophrenia to explore the problem of representation in psychiatric research and the forms that neuroscientific evidence assumes for those who produce it. These researchers grappled with the complexity of schizophrenia not by narrowing disease concepts to biological facts but by referencing measurement techniques to generate new versions of schizophrenia. By linking experimental findings to inchoate concepts of personhood and social experience, I found that they reframed and reinforced cultural values, including that those with schizophrenia are destined to a debased and deficient existence. I argue that cognition has emerged as an essential feature of schizophrenia not only because of its representational utility but also because of the ontological work the concept performs. In closing, I present some implications for the neurobiological and social sciences. C1 [Bromley, Elizabeth] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Ctr Hlth Serv & Soc, Los Angeles, CA 90024 USA. [Bromley, Elizabeth] Desert Pacific Mental Illness Res Educ & Clin Ctr, W Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Bromley, E (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Ctr Hlth Serv & Soc, Los Angeles, CA 90024 USA. EM ebromley@mednet.ucla.edu NR 93 TC 1 Z9 1 U1 4 U2 12 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0165-005X J9 CULT MED PSYCHIAT JI Cult. Med. Psychiatr. PD MAR PY 2012 VL 36 IS 1 BP 154 EP 174 DI 10.1007/s11013-011-9241-z PG 21 WC Anthropology; Psychiatry; Social Sciences, Biomedical SC Anthropology; Psychiatry; Biomedical Social Sciences GA 899WQ UT WOS:000300847700011 PM 22183201 ER PT J AU Provenzale, D AF Provenzale, Dawn TI A Guide for Success as a Clinical Investigator SO GASTROENTEROLOGY LA English DT Editorial Material C1 [Provenzale, Dawn] Duke Univ, Med Ctr, Durham, NC 27705 USA. [Provenzale, Dawn] US Dept Vet Affairs, Durham, NC USA. RP Provenzale, D (reprint author), Duke Univ, Med Ctr, 508 Fulton St 152, Durham, NC 27705 USA. EM dawn.provenzale@dm.duke.edu NR 5 TC 4 Z9 4 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2012 VL 142 IS 3 BP 418 EP 421 DI 10.1053/j.gastro.2012.01.009 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 898XC UT WOS:000300774700013 PM 22266151 ER PT J AU Raddi, G Morado, DR Yan, J Haake, DA Yang, XF Liu, J AF Raddi, Gianmarco Morado, Dustin R. Yan, Jie Haake, David A. Yang, X. Frank Liu, Jun TI Three-Dimensional Structures of Pathogenic and Saprophytic Leptospira Species Revealed by Cryo-Electron Tomography SO JOURNAL OF BACTERIOLOGY LA English DT Article ID BORRELIA-BURGDORFERI; ELECTRON TOMOGRAPHY; FLAGELLAR MOTOR; CELLULAR ARCHITECTURE; PERIPLASMIC FLAGELLA; TREPONEMA-PRIMITIA; FINE-STRUCTURE; MOTILITY; INTERROGANS; BACTERIA AB Leptospira interrogans is the primary causative agent of the most widespread zoonotic disease, leptospirosis. An in-depth structural characterization of L. interrogans is needed to understand its biology and pathogenesis. In this study, cryo-electron tomography (cryo-ET) was used to compare pathogenic and saprophytic species and examine the unique morphological features of this group of bacteria. Specifically, our study revealed a structural difference between the cell envelopes of L. interrogans and Leptospira biflexa involving variations in the lipopolysaccharide (LPS) layer. Through cryo-ET and subvolume averaging, we determined the first three-dimensional (3-D) structure of the flagellar motor of leptospira, with novel features in the flagellar C ring, export apparatus, and stator. Together with direct visualization of chemoreceptor arrays, DNA packing, periplasmic filaments, spherical cytoplasmic bodies, and a unique "cap" at the cell end, this report provides structural insights into these fascinating Leptospira species. C1 [Yang, X. Frank] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN USA. [Raddi, Gianmarco; Morado, Dustin R.; Liu, Jun] Univ Texas Med Sch Houston, Dept Pathol & Lab Med, Houston, TX USA. [Yan, Jie] Zhejiang Univ, Coll Med, Dept Med Microbiol & Parasitol, Hangzhou 310003, Zhejiang, Peoples R China. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Haake, David A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Haake, David A.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Haake, David A.] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA USA. RP Yang, XF (reprint author), Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN USA. EM xfyang@iupui.edu; jun.liu.1@uth.tmc.edu FU National Institute of Allergy and Infectious Diseases (NIAID) [R01AI087946, 5R01AI034431]; Welch Foundation [AU-1714]; VA FX This work was supported in part by grants R01AI087946 (to J. Liu) and 5R01AI034431 (to D. A. Haake) from the National Institute of Allergy and Infectious Diseases (NIAID), by grant AU-1714 from the Welch Foundation (to J. Liu), and by VA Medical Research funds (to D. A. Haake). NR 50 TC 22 Z9 23 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD MAR PY 2012 VL 194 IS 6 BP 1299 EP 1306 DI 10.1128/JB.06474-11 PG 8 WC Microbiology SC Microbiology GA 899WI UT WOS:000300846900003 PM 22228733 ER PT J AU Murrell, DF Daniel, BS Joly, P Borradori, L Amagai, M Hashimoto, T Caux, F Marinovic, B Sinha, AA Hertl, M Bernard, P Sirois, D Cianchini, G Fairley, JA Jonkman, MF Pandya, AG Rubenstein, D Zillikens, D Payne, AS Woodley, D Zambruno, G Aoki, V Pincelli, C Diaz, L Hall, RP Meurer, M Mascaro, JM Schmidt, E Shimizu, H Zone, J Swerlick, R Mimouni, D Culton, D Lipozencic, J Bince, B Grando, SA Bystryn, JC Werth, VP AF Murrell, Dedee F. Daniel, Benjamin S. Joly, Pascal Borradori, Luca Amagai, Masayuki Hashimoto, Takashi Caux, Frederic Marinovic, Branka Sinha, Animesh A. Hertl, Michael Bernard, Philippe Sirois, David Cianchini, Giuseppe Fairley, Janet A. Jonkman, Marcel F. Pandya, Amit G. Rubenstein, David Zillikens, Detlef Payne, Aimee S. Woodley, David Zambruno, Giovanna Aoki, Valeria Pincelli, Carlo Diaz, Luis Hall, Russell P. Meurer, Michael Mascaro, Jose M., Jr. Schmidt, Enno Shimizu, Hiroshi Zone, John Swerlick, Robert Mimouni, Daniel Culton, Donna Lipozencic, Jasna Bince, Benjamin Grando, Sergei A. Bystryn, Jean-Claude Werth, Victoria P. TI Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Review DE bullous pemphigoid; consensus; definitions; outcome measures; severity score ID TOPICAL CORTICOSTEROIDS AB Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies in BP. A major obstacle in sharing multicenter-based evidences for therapeutic efforts is the lack of generally accepted definitions for the clinical evaluation of patients with BP. Common terms and end points of BP are needed so that experts in the field can accurately measure and assess disease extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials. These recommendations from the International Pemphigoid Committee represent 2 years of collaborative efforts to attain mutually acceptable common definitions for BP and proposes a disease extent score, the BP Disease Area Index. These items should assist in the development of consistent reporting of outcomes in future BP reports and studies. (J Am Acad Dermatol 2012;66:479-85.) C1 [Murrell, Dedee F.; Daniel, Benjamin S.] Univ New S Wales, St George Hosp, Dept Dermatol, Sydney, NSW, Australia. [Joly, Pascal] Univ Rouen, Rouen Univ Hosp, Dermatol Clin, Dept Dermatol,INSERM,U905, F-76821 Mont St Aignan, France. [Borradori, Luca] Univ Hosp Bern, Dept Dermatol, Bern, Switzerland. [Amagai, Masayuki] Keio Univ, Sch Med, Tokyo, Japan. [Hashimoto, Takashi] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan. [Caux, Frederic] Univ Paris 08, Dept Dermatol, Bobigny, France. [Marinovic, Branka; Lipozencic, Jasna] Univ Zagreb, Hosp Ctr & Sch Med, Dept Dermatol & Venereol, Zagreb 41000, Croatia. [Sinha, Animesh A.] SUNY Buffalo, Dept Dermatol, Buffalo, NY 14260 USA. [Hertl, Michael] Univ Hosp, Dept Dermatol, Marburg, Germany. [Sirois, David] NYU, Coll Dent, Dept Oral Med, New York, NY 10003 USA. [Cianchini, Giuseppe] IRCCS, Inst Dermopat Immacolata, Immunodermatol Dept, Rome, Italy. [Zambruno, Giovanna] IRCCS, Inst Dermopat Immacolata, Lab Mol & Cell Biol, Rome, Italy. [Fairley, Janet A.] Univ Iowa, Dept Dermatol, Iowa City, IA USA. [Fairley, Janet A.] Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA. [Jonkman, Marcel F.] Univ Groningen, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands. [Rubenstein, David; Diaz, Luis; Culton, Donna] Univ N Carolina, Dept Dermatol, Chapel Hill, NC 27514 USA. [Pandya, Amit G.] Univ Texas SW Med Ctr Dallas, Dallas, TX USA. [Zillikens, Detlef; Schmidt, Enno] Univ Lubeck, Dept Dermatol, Lubeck, Germany. [Woodley, David] Univ So Calif, Dept Dermatol, Keck Sch Med, Los Angeles, CA 90089 USA. [Payne, Aimee S.; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Aoki, Valeria] Univ Sao Paulo, Dept Dermatol, BR-05508 Sao Paulo, Brazil. [Pincelli, Carlo] Univ Modena & Reggio Emilia, Inst Dermatol, Sch Biosci & Biotechnol, Modena, Italy. [Hall, Russell P.] Duke Med Ctr, Div Dermatol, Durham, NC USA. [Shimizu, Hiroshi] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan. [Meurer, Michael] Tech Univ Dresden, Carl Gustav Carus Med Sch, Dresden, Germany. [Mascaro, Jose M., Jr.] Univ Barcelona, Dept Dermatol, E-08007 Barcelona, Spain. [Zone, John] Univ Utah, Dept Dermatol, Salt Lake City, UT 84112 USA. [Bince, Benjamin] Jose R Reyes Mem Med Ctr, Dept Dermatol, Manila, Philippines. [Swerlick, Robert] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA. [Bystryn, Jean-Claude] NYU, Med Ctr, New York, NY 10003 USA. [Mimouni, Daniel] Rabin Med Ctr, Dept Dermatol, Petah Tiqwa, Israel. [Bernard, Philippe] Robert Debre Univ Hosp, Dept Dermatol, Reims, France. [Grando, Sergei A.] Univ Calif Irvine, Dept Biol Chem, Dept Dermatol, Ctr Canc, Irvine, CA 92717 USA. [Grando, Sergei A.] Univ Calif Irvine, Res Inst, Inst Immunol, Irvine, CA USA. [Werth, Victoria P.] Philadelphia Dept Vet Affairs Med Ctr, Philadelphia, PA USA. RP Murrell, DF (reprint author), Univ New S Wales, St George Hosp, Dept Dermatol, Sydney, NSW, Australia. EM d.murrell@unsw.edu.au RI Cianchini, Giuseppe/I-8877-2012; Amagai, Masayuki/K-5325-2013; Schmidt, Enno/C-4008-2009; Jonkman, Marcel/H-4647-2011; Pincelli, Carlo/A-7288-2012; Aoki, Valeria/H-1415-2012 OI Amagai, Masayuki/0000-0003-3314-7052; Schmidt, Enno/0000-0002-1206-8913; Pincelli, Carlo/0000-0003-4416-2637; Marinovic, Branka/0000-0001-8441-5016; Hashimoto, Takashi/0000-0002-0144-3255 FU International Pemphigus and Pemphigoid Foundation; National Institutes of Health [K24-AR 02207] FX The International Pemphigus and Pemphigoid Foundation generously supported renting rooms at the American Academy of Dermatology and audiovisual equipment; the European Society for Dermatological Research and European Academy of Dermatology provided meeting rooms. This report was supported in part by a grant from the National Institutes of Health (K24-AR 02207) to Dr Werth. NR 10 TC 60 Z9 63 U1 6 U2 12 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD MAR PY 2012 VL 66 IS 3 BP 479 EP 485 DI 10.1016/j.jaad.2011.06.032 PG 7 WC Dermatology SC Dermatology GA 901CJ UT WOS:000300939000026 PM 22056920 ER PT J AU Levy, C Hutt, E Pointer, L AF Levy, Cari Hutt, Evelyn Pointer, Lauren TI Site of Death Among Veterans Living in Veterans Affairs Nursing Homes SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Site of death; nursing home; veterans; hospice; end-of-life ID HOSPICE CARE; LIFE; END; MORTALITY; RESIDENTS; TURNOVER; SERVICES; QUALITY; BENEFIT; INDEX AB Objectives: To determine predictors of dying in VA nursing homes, community living centers (CLCs), compared with dying in a hospital. Design: Retrospective cohort study. Setting: VA CLCs. Participants: Included were 7408 CLC decedents from FY2005 to FY2007. Measurements: Outcome: Site of death obtained from VA Vital Statistics files. Predictors of Death Site: VA-MDS variables defining patient demographics, functional status, cognitive status, major diagnostic categories, and care planning documentation. Analysis: Logistic regression was used to estimate the odds ratio of death in the CLC relative to the hospital for patient and facility characteristics. Results: Among decedents, 87% died in the CLC and 13% in a hospital. More than half of all decedents were neither enrolled in hospice nor designated as having end-stage disease. The strongest predictor of site of death in a CLC relative to a hospital was being enrolled in hospice (OR = 20.94; 95% CI: 12.38, 35.44). A designation of end-stage disease increased the odds of death in a CLC by 3.9 times (95% CI: 2.78, 5.47) compared with death in a hospital. Advance directive rates in CLCs were high (73.4%); having any advance directive increased the odds of death in a CLC by 1.57 times (95% CI: 1.35, 1.82). Conclusion: Recognition of end-stage disease and documentation of advance directives are powerful determinants of site of death for CLC residents. Receipt of hospice care in a CLC is a strong predictor of site of death in a CLC even in the absence of collaboration with community-based hospice and financial incentives to avoid hospitalization. Copyright (C) 2012 - American Medical Directors Association, Inc. C1 [Levy, Cari; Hutt, Evelyn] Univ Colorado Denver, Div Hlth Care Policy & Res, Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Levy, C (reprint author), Univ Colorado Denver, Div Hlth Care Policy & Res, Denver Vet Affairs Med Ctr, 1055 Clermont,Mailstop 151, Denver, CO 80220 USA. EM cari.levy@va.gov FU Veterans Affairs Career Development Award FX This research was funded by a Veterans Affairs Career Development Award. NR 26 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAR PY 2012 VL 13 IS 3 BP 199 EP 201 DI 10.1016/j.jamda.2011.08.004 PG 3 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 898IE UT WOS:000300734700004 PM 21945536 ER PT J AU Yarbrough, WM Mukherjee, R Ikonomidis, JS Zile, MR Spinale, FG AF Yarbrough, William M. Mukherjee, Rupak Ikonomidis, John S. Zile, Michael R. Spinale, Francis G. TI Myocardial remodeling with aortic stenosis and after aortic valve replacement: Mechanisms and future prognostic implications SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID LEFT-VENTRICULAR HYPERTROPHY; HYPERTENSIVE HEART-DISEASE; OVERLOADED HUMAN HEART; C-REACTIVE PROTEIN; GROWTH-FACTOR-BETA; MATRIX METALLOPROTEINASES; PRESSURE-OVERLOAD; DIASTOLIC DYSFUNCTION; TISSUE INHIBITOR; NATRIURETIC PEPTIDE AB Aortic valve stenosis is a common cause of left ventricular pressure overload, a pathologic process that elicits myocyte hypertrophy and alterations in extracellular matrix composition, both of which contribute to increases in left ventricular stiffness. However, clinical and animal studies suggest that increased myocardial extracellular matrix fibrillar collagen content occurs later in the time course of left ventricular pressure overload at a time coincident with severe abnormalities in diastolic function followed by the development of symptomatic heart failure. Aortic valve replacement remains the most effective treatment for elimination of chronic pressure overload secondary to aortic stenosis but has traditionally been recommended only after the onset of clinical symptoms. Long-termfollow-up of patients with symptomatic aortic stenosis after aortic valve replacement suggests that valve replacement may not result in complete reversal of the maladaptive changes that occur within the myocardial extracellular matrix secondary to the pressure overload state. To the contrary, residual left ventricular extracellular matrix abnormalities such as these are likely responsible for persistent abnormalities in diastolic function and increased morbidity and mortality after aortic valve replacement. Defining the mechanisms and pathways responsible for regulating the myocardial extracellular matrix during the natural history of aortic stenosis may provide a means by which to detect crucial structural milestones and thereby permit more precise identification of the development of maladaptive left ventricular remodeling. (J Thorac Cardiovasc Surg 2012;143:656-64) C1 [Yarbrough, William M.; Mukherjee, Rupak; Ikonomidis, John S.; Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Dept Med, Charleston, SC 29425 USA. [Zile, Michael R.] Med Univ S Carolina, Div Cardiol, Dept Med, Charleston, SC 29425 USA. [Zile, Michael R.; Spinale, Francis G.] Ralph H Johnson Vet Assoc Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Strom Thurmond Res Ctr, 114 Doughty St,Suite 625, Charleston, SC 29425 USA. EM wilburnm@musc.edu FU American Association for Thoracic Surgery; National Institutes of Health [HL 57952]; Veterans' Affairs Health Administration FX This work was supported by the Third Edward D. Churchill Research Scholarship (American Association for Thoracic Surgery), a National Institutes of Health Supplement award (HL 57952), and the Veterans' Affairs Health Administration. NR 58 TC 22 Z9 23 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2012 VL 143 IS 3 BP 656 EP 664 DI 10.1016/j.jtcvs.2011.04.044 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 897BX UT WOS:000300617300024 PM 21762938 ER PT J AU Tolpin, DA Collard, CD Lee, VV Virani, SS Allison, PM Elayda, MA Pan, W AF Tolpin, Daniel A. Collard, Charles D. Lee, Vei-Vei Virani, Salim S. Allison, Paul M. Elayda, MacArthur A. Pan, Wei TI Subclinical changes in serum creatinine and mortality after coronary artery bypass grafting SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; GELATINASE-ASSOCIATED LIPOCALIN; CARDIAC-SURGERY; CARDIOTHORACIC SURGERY; BIOMARKER; OUTCOMES; IMPACT; STRATIFICATION; SEVERITY AB Background: Changes in postoperative serum creatinine levels have been used to define acute renal injury in patients undergoing cardiac surgery with cardiopulmonary bypass. It remains unclear, however, whether subclinical increases in serum creatinine that do not meet current Acute Kidney Injury Network or RIFLE (risk, injury, failure, loss, and end-stage kidney disease) criteria for acute renal injury are predictive of mortality after cardiac surgery. Methods: Multivariate logistic regression was performed in a retrospective cohort of 3914 consecutive patients undergoing primary, isolated coronary artery bypass grafting with cardiopulmonary bypass to determine whether postoperative serum creatinine change independently predicts 30-day all-cause mortality in patients with normal renal function and with varying levels of preoperative renal insufficiency. To control further for selection bias, multivariate logistic regression was performed on a propensity-matched cohort (n = 2042) to determine whether subclinical increases in serum creatinine predict mortality. Results: Negative change in serum creatinine was associated with reduced 30-day all-cause mortality. Even subclinical increases in serum creatinine were associated with increased mortality relative to patients with negative changes in serum creatinine (odds ratio, 3.93; 95% confidence interval, 1.68-9.22; P <.01). After propensity matching, subclinical increases in serum creatinine were still associated with increased mortality (odds ratio, 4.13; 95% confidence interval, 1.37-12.45; P = .01). Conclusions: Subclinical increases in serum creatinine that do not meet acute renal injury criteria are independently associated with 30-day all-cause mortality in patients with normal renal function or preoperative renal insufficiency undergoing coronary artery bypass grafting. (J Thorac Cardiovasc Surg 2012;143:682-8) C1 [Tolpin, Daniel A.; Collard, Charles D.; Pan, Wei] St Lukes Episcopal Hosp, Texas Heart Inst, Div Cardiovasc Anesthesiol, Houston, TX 77030 USA. [Lee, Vei-Vei; Elayda, MacArthur A.] St Lukes Episcopal Hosp, Texas Heart Inst, Div Biostat & Epidemiol, Houston, TX 77030 USA. [Tolpin, Daniel A.; Collard, Charles D.; Pan, Wei] Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Allison, Paul M.] St Lukes Episcopal Hosp, Dept Pathol, Chem Coagulat & Blood Donor Ctr, Houston, TX 77030 USA. RP Pan, W (reprint author), St Lukes Episcopal Hosp, Texas Heart Inst, Div Cardiovasc Anesthesiol, 6720 Bertner Ave,Room 0520, Houston, TX 77030 USA. EM wpan@heart.thi.tmc.edu OI Virani, Salim/0000-0001-9541-6954 NR 23 TC 24 Z9 25 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2012 VL 143 IS 3 BP 682 EP + DI 10.1016/j.jtcvs.2011.09.044 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 897BX UT WOS:000300617300027 PM 22054657 ER PT J AU Dolan, S Martindale, S Robinson, J Kimbrel, NA Meyer, EC Kruse, MI Morissette, SB Young, KA Gulliver, SB AF Dolan, Sara Martindale, Sarah Robinson, Jennifer Kimbrel, Nathan A. Meyer, Eric C. Kruse, Marc I. Morissette, Sandra B. Young, Keith A. Gulliver, Suzy Bird TI Neuropsychological Sequelae of PTSD and TBI Following War Deployment among OEF/OIF Veterans SO NEUROPSYCHOLOGY REVIEW LA English DT Review DE PTSD; TBI; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MEDIAL PREFRONTAL CORTEX; VIETNAM COMBAT VETERANS; SYMPTOM VALIDITY TEST; HIPPOCAMPAL VOLUME; IRAQ-WAR; TEST-PERFORMANCE; INTELLECTUAL RESOURCES; COGNITIVE-ABILITY AB Posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) are highly prevalent among Veterans of the conflicts in Iraq and Afghanistan. These conditions are associated with common and unique neuropsychological and neuroanatomical changes. This review synthesizes neuropsychological and neuroimaging studies for both of these disorders and studies examining their co-occurrence. Recommendations for future research, including use of combined neuropsychological and advanced neuroimaging techniques to study these disorders alone and in concert, are presented. It is clear from the dearth of literature that addiitonal studies are required to examine and understand the impact of specific factors on neurocognitive outcome. Of particular relevance are temporal relationships between PTSD and mTBI, risk and resilience factors associated with both disorders and their co-occurrence, and mTBI-specific factors such as time since injury and severity of injury, utilizing comprehensive, yet targeted cognitive tasks. C1 [Dolan, Sara; Martindale, Sarah] Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA. [Dolan, Sara; Robinson, Jennifer; Kimbrel, Nathan A.; Meyer, Eric C.; Kruse, Marc I.; Morissette, Sandra B.; Young, Keith A.; Gulliver, Suzy Bird] US Dept Vet Affairs, Ctr Excellence Res Returning War Vet, Waco, TX USA. [Dolan, Sara; Kimbrel, Nathan A.; Meyer, Eric C.; Kruse, Marc I.; Morissette, Sandra B.; Young, Keith A.; Gulliver, Suzy Bird] Texas A&M Hlth Sci Ctr, Coll Med, Dept Psychiat & Behav Sci, Temple, TX USA. [Robinson, Jennifer] Scott & White Healthcare, Neurosci Inst, Temple, TX USA. [Kruse, Marc I.] City Austin Travis Cty Emergency Med Serv Dept, Austin, TX USA. [Kruse, Marc I.] Austin Fire Dept, Austin, TX USA. RP Dolan, S (reprint author), Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA. EM sara_dolan@baylor.edu RI Schueter, nicos/A-3625-2014; Kimbrel, Nathan/P-3109-2016 OI Kimbrel, Nathan/0000-0001-7218-1005; Dolan, Sara/0000-0002-0156-8226; Martindale, Sarah/0000-0002-0059-3454 FU Department of Veterans Affairs (VA) [I01RX000304]; Rehabilitation Research and Development Service of the VA Office of Research and Development FX This research was supported by the Department of Veterans Affairs (VA) VISN 17 Center of Excellence for Research on Returning War Veterans, a Merit Award (I01RX000304) to Sandra B. Morissette, Ph.D. from the Rehabilitation Research and Development Service of the VA Office of Research and Development entitled, "Functional Outcomes in OEF/OIF Veterans with PTSD and Alcohol Misuse," a DVA VISN 17 New Investigator Award to Nathan A. Kimbrel, Ph.D. entitled, "Genetic and Environmental Effects on PTSD, Depression, and Alcohol Misuse," and a DVA VISN 17 New Investigator Award to Eric C. Meyer, Ph.D. entitled, "Experiential Avoidance, Neurocognition, and Functional Outcomes in PTSD." NR 116 TC 33 Z9 34 U1 5 U2 19 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1040-7308 J9 NEUROPSYCHOL REV JI Neuropsychol. Rev. PD MAR PY 2012 VL 22 IS 1 BP 21 EP 34 DI 10.1007/s11065-012-9190-5 PG 14 WC Psychology, Clinical; Neurosciences SC Psychology; Neurosciences & Neurology GA 900MU UT WOS:000300892100004 PM 22350690 ER PT J AU Lee, ACW Harada, N AF Lee, Alan Chong W. Harada, Nancy TI Telehealth as a Means of Health Care Delivery for Physical Therapist Practice SO PHYSICAL THERAPY LA English DT Editorial Material ID TELEREHABILITATION; OUTCOMES; REHABILITATION C1 [Lee, Alan Chong W.] Mt St Marys Coll, Doctor Phys Therapy Program, Los Angeles, CA 90007 USA. [Lee, Alan Chong W.] Scripps Mercy Hosp, San Diego, CA USA. [Lee, Alan Chong W.] Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA. [Harada, Nancy] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Harada, Nancy] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Lee, ACW (reprint author), Mt St Marys Coll, Doctor Phys Therapy Program, 10 Chester Pl, Los Angeles, CA 90007 USA. EM allee@msmc.la.edu NR 33 TC 4 Z9 5 U1 2 U2 4 PU AMER PHYSICAL THERAPY ASSOC PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA SN 0031-9023 J9 PHYS THER JI Phys. Ther. PD MAR PY 2012 VL 92 IS 3 BP 463 EP 468 DI 10.2522/ptj.20110100 PG 6 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA 901CY UT WOS:000300940500011 PM 22135703 ER PT J AU Horan, WP Foti, D Hajcak, G Wynn, JK Green, MF AF Horan, William P. Foti, Dan Hajcak, Greg Wynn, Jonathan K. Green, Michael F. TI Intact motivated attention in schizophrenia: Evidence from event-related potentials SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia Event-Related Potentials (ERP); Late Positive Potential; P300; Emotion ID EMOTION AB Emotionally significant stimuli typically capture attention (called motivated attention) even when they are irrelevant to tasks where attention is directed. Previous studies indicate that several components of emotional processing are intact in schizophrenia when subjects are instructed to attend to emotionally-evocative stimuli. However, few studies have examined whether emotional stimuli capture attention to a normal degree in people with schizophrenia when attention is directed elsewhere. The current event-related potential study examined motivated attention to task-irrelevant emotional stimuli in 35 stabilized outpatients and 26 healthy controls with a modified visual P300 oddball detection task. Participants viewed images of rare target and commonly occurring standard letter stimuli, as well as intermixed emotional (unpleasant, pleasant, neutral) pictures. Subjects were instructed to count the number of rare targets; the emotional valence of the picture stimuli was, therefore, task-irrelevant. We separately evaluated the Early Posterior Negativity (EPN) and Late Positive Potential (LPP) to emotional pictures and the P300 to target stimuli. Patients and controls showed similar patterns of EPN and LPP amplitude to the emotional stimuli, such that the EPN and LPP were larger for both pleasant and unpleasant versus neutral pictures. Although patients performed worse than controls on the target counting task, both groups showed comparable P300 differentiation between target versus non-target stimuli. Emotional stimuli captured attentional resources in people with schizophrenia even when the emotional stimuli were task-irrelevant, suggesting intact motivated attention at the level of early electrophysiological responding. (C) 2011 Elsevier B.V. All rights reserved. C1 [Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, Los Angeles, CA 90073 USA. [Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Foti, Dan; Hajcak, Greg] SUNY Stony Brook, Stony Brook, NY USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU NARSAD; National Institute of Mental Health [MH082782, MH065707, MH43292] FX This work was supported by a NARSAD Young Investigator Award (to WPH) and the National Institute of Mental Health (MH082782 to WPH; MH065707, MH43292 to MFG). Funding sources had no role in study design or in the collection, analysis and interpretation of data; or in the writing of this report. NR 20 TC 22 Z9 22 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAR PY 2012 VL 135 IS 1-3 BP 95 EP 99 DI 10.1016/j.schres.2011.11.005 PG 5 WC Psychiatry SC Psychiatry GA 901CT UT WOS:000300940000017 PM 22126898 ER PT J AU Schnelldorfer, T AF Schnelldorfer, Thomas TI Image-enhanced laparoscopy: A promising technology for detection of peritoneal micrometastases SO SURGERY LA English DT Article ID GREEN FLUORESCENT PROTEIN; ACID-INDUCED FLUORESCENCE; 5-AMINOLEVULINIC ACID; PHOTODYNAMIC DIAGNOSIS; ENDOMETRIOTIC LESIONS; CANCER METASTASES; SERUM ALBUMIN; FLUOROPHORE; ANTIBODY; SURGERY C1 [Schnelldorfer, Thomas] Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. [Schnelldorfer, Thomas] Philadelphia Vet Affairs Med Ctr, Sect Gen Surg, Philadelphia, PA USA. RP Schnelldorfer, T (reprint author), Univ Penn, Sch Med, Dept Surg, 3400 Spruce St, Philadelphia, PA 19104 USA. EM thomas.schnelldorfer@va.gov NR 38 TC 5 Z9 5 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAR PY 2012 VL 151 IS 3 BP 345 EP 350 DI 10.1016/j.surg.2011.12.012 PG 6 WC Surgery SC Surgery GA 902CP UT WOS:000301016500001 PM 22329962 ER PT J AU Melendez, RI McGinty, JF Kalivas, PW Becker, HC AF Melendez, Roberto I. McGinty, Jacqueline F. Kalivas, Peter W. Becker, Howard C. TI Brain region-specific gene expression changes after chronic intermittent ethanol exposure and early withdrawal in C57BL/6J mice SO ADDICTION BIOLOGY LA English DT Article DE Alcohol dependence; alcohol withdrawal; brain regional adaptations; chronic intermittent alcohol exposure; gene expression profiling; microarray analysis ID FRONTAL-CORTEX; MICROARRAY ANALYSIS; ALCOHOL-DRINKING; SYNAPTIC PLASTICITY; NEUROTROPHIC FACTOR; NONPREFERRING RATS; NUCLEUS-ACCUMBENS; DENDRITIC SPINES; DRUG-ADDICTION; DEFICIENT MICE AB Neuroadaptations that participate in the ontogeny of alcohol dependence are likely a result of altered gene expression in various brain regions. The present study investigated brain region-specific changes in the pattern and magnitude of gene expression immediately following chronic intermittent ethanol (CIE) exposure and 8 hours following final ethanol exposure [i.e. early withdrawal (EWD)]. High-density oligonucleotide microarrays (Affymetrix 430A 2.0, Affymetrix, Santa Clara, CA, USA) and bioinformatics analysis were used to characterize gene expression and function in the prefrontal cortex (PFC), hippocampus (HPC) and nucleus accumbens (NAc) of C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA). Gene expression levels were determined using gene chip robust multi-array average followed by statistical analysis of microarrays and validated by quantitative real-time reverse transcription polymerase chain reaction and Western blot analysis. Results indicated that immediately following CIE exposure, changes in gene expression were strikingly greater in the PFC (284 genes) compared with the HPC (16 genes) and NAc (32 genes). Bioinformatics analysis revealed that most of the transcriptionally responsive genes in the PFC were involved in Ras/MAPK signaling, notch signaling or ubiquitination. In contrast, during EWD, changes in gene expression were greatest in the HPC (139 genes) compared with the PFC (four genes) and NAc (eight genes). The most transcriptionally responsive genes in the HPC were involved in mRNA processing or actin dynamics. Of the few genes detected in the NAc, the most representatives were involved in circadian rhythms. Overall, these findings indicate that brain region-specific and time-dependent neuroadaptive alterations in gene expression play an integral role in the development of alcohol dependence and withdrawal. C1 [Becker, Howard C.] Med Univ S Carolina, Charleston Alcohol Res Ctr, Ctr Drug & Alcohol Programs, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Becker, Howard C.] Ralph H Johnson Dept Vet Affairs, Charleston, SC USA. [Melendez, Roberto I.; McGinty, Jacqueline F.; Kalivas, Peter W.; Becker, Howard C.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Becker, HC (reprint author), Med Univ S Carolina, Charleston Alcohol Res Ctr, Ctr Drug & Alcohol Programs, Dept Psychiat & Behav Sci, 67 President St,MSC-861, Charleston, SC 29425 USA. EM beckerh@musc.edu FU [R01 AA013885]; [P50 AA010761]; [P50 DA015369] FX This study was supported by grants R01 AA013885 (H.C.B.), P50 AA010761 (H.C.B.) and P50 DA015369 (P.W.K.). The authors thank Rolf Fritz and Kay Fernandez for excellent technical assistance and Saurin Jani for assistance with bioinformatics analysis. NR 83 TC 31 Z9 32 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 J9 ADDICT BIOL JI Addict. Biol. PD MAR PY 2012 VL 17 IS 2 BP 351 EP 364 DI 10.1111/j.1369-1600.2011.00357.x PG 14 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA 896LT UT WOS:000300568500012 PM 21812870 ER PT J AU Wray, LO Mavandadi, S Klaus, JR Tew, JD Oslin, DW Sweet, RA AF Wray, Laura O. Mavandadi, Shahrzad Klaus, Johanna R. Tew, James D., Jr. Oslin, David W. Sweet, Robert A. TI The Association Between Mental Health and Cognitive Screening Scores in Older Veterans SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Cognitive impairment; mental health screening; older adults; primary care ID PRIMARY-CARE SETTINGS; LATE-LIFE DEPRESSION; ALZHEIMERS-DISEASE; COMMUNITY POPULATION; RISK-FACTOR; DEMENTIA; IMPAIRMENT; METAANALYSIS; RELIABILITY; VALIDATION AB Objectives: To examine overall cognitive screening results and the relationship between cognitive screen score and sociodemographic characteristics, reason for referral, and clinical outcomes of older veterans referred by primary care for a behavioral health assessment. Design: Cross-sectional, naturalistic study. Setting: Primary care clinics affiliated with two VA Medical Centers. Participants: The sample included 4,325 older veterans referred to the Behavioral Health Laboratory who completed an initial mental health/substance abuse assessment. Veterans were categorized into the following three groups on the basis of cognitive status: within normal limits, possible cognitive impairment, and possible dementia. Measurements: Sociodemographic and clinical data on reason for referral, cognitive functioning (i.e., Blessed Orientation-Memory-Concentration test), and behavioral health assessment outcomes were extracted from patients' medical records. Data were analyzed using multiple linear and logistic regressions. Results: Results of cognitive screenings indicated that the majority of the sample was within normal limits (62.5%), with 25.8%, 8.1%, and 3.6% of patients evidencing possible cognitive impairment, possible dementia, and Blessed Orientation-Memory-Concentration scores of 17 or more, respectively. With regard to reason for referral, patients with greater cognitive impairment were more likely to be identified by the antidepressant case finder than patients with less impairment. Increased age, non-white ethnicity, self-perceived inadequate finances, major depressive disorder, and symptoms of psychosis were associated with greater cognitive impairment. Conclusions: Findings highlight the importance of evaluating cognitive status in older adults who are referred for a behavioral health assessment and/or receive a new mental health/substance abuse diagnosis. Doing so has the potential to improve recognition and treatment of cognitive impairment and dementia, thereby improving quality of care for many older adults. (Am J Geriatr Psychiatry 2012; 20:215-227) C1 [Wray, Laura O.] Ctr Integrated Healthcare, Dept Vet Affairs, Buffalo, NY 14215 USA. [Wray, Laura O.] SUNY Buffalo, Sch Med & Biomed Sci, Div Geriatr, Buffalo, NY 14260 USA. [Mavandadi, Shahrzad; Klaus, Johanna R.; Oslin, David W.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Mavandadi, Shahrzad; Klaus, Johanna R.; Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Tew, James D., Jr.; Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Tew, James D., Jr.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. RP Wray, LO (reprint author), Ctr Integrated Healthcare, Dept Vet Affairs, VAWNYHS 116N,3495 Bailey Ave, Buffalo, NY 14215 USA. EM laura.wray@va.gov FU USPHS [AG027224] FX This study was supported in part by USPHS grant AG027224. NR 51 TC 3 Z9 3 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 BP 215 EP 227 DI 10.1097/JGP.0b013e3182410cdb PG 13 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 897IH UT WOS:000300642300004 PM 22251868 ER PT J AU Shah, A Fried, LF Chen, SC Qiu, Y Li, SY Cavanaugh, KL Norris, KC Whaley-Connell, AT McCullough, PA Mehrotra, R AF Shah, Anuja Fried, Linda F. Chen, Shu-Cheng Qiu, Yang Li, Suying Cavanaugh, Kerri L. Norris, Keith C. Whaley-Connell, Adam T. McCullough, Peter A. Mehrotra, Rajnish CA KEEP Investigators TI Associations Between Access to Care and Awareness of CKD SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Access to care; awareness; chronic kidney disease; health insurance ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; HEALTH-CARE; US ADULTS; POPULATION; PREVALENCE; PATIENT; TRENDS AB Background: Most individuals with chronic kidney disease (CKD) in the United States are unaware of their condition, creating challenges in implementing early interventions to delay disease progression. Whether characteristics expected to enhance health care access are associated with greater CKD awareness has not been studied adequately. Method: Data from volunteer participants in the National Kidney Foundation's Kidney Early Evaluation Program (KEEP), 2000-2010, with presumed CKD (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m(2) or albumin-creatinine ratio >30 mg/g) were analyzed. Given that the diagnosis of CKD was based on a single measurement of kidney function, the diagnosis is presumed, but not confirmed. Associations of CKD awareness with measures of access to care (health insurance coverage, type of health insurance, prescription drug coverage, and self-reported level of difficulty obtaining care) were examined using logistic regression. Results: Of 29,144 participants with CKD, 6,751 (23%) reported CKD awareness. No significant association was found between availability of health insurance or prescription drug coverage and CKD awareness; results did not vary by diabetic status or in analyses restricted to participants with eGFR <60 mL/min/1.73 m(2). Participants reporting extreme or some difficulty obtaining medical care were more likely than those reporting no difficulty to be aware of CKD (adjusted OR, 1.25; 95% CI, 1.05-1.50). Conclusions: Most KEEP participants with CKD are unaware of the condition, results that are not modified by the availability of health insurance or prescription drug coverage. The mechanisms underlying the association of perceived difficulty in access to care with greater CKD awareness require further study. Am J Kidney Dis. 59(3)(S2):S16-S23. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Shah, Anuja; Mehrotra, Rajnish] Harbor UCLA, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Chen, Shu-Cheng; Qiu, Yang; Li, Suying] Minneapolis Med Res Fdn Inc, Chron Kidney Dis Res Grp, Minneapolis, MN USA. [Cavanaugh, Kerri L.] Vanderbilt Univ, Nashville, TN USA. [Norris, Keith C.] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA. [Whaley-Connell, Adam T.] Univ Missouri, Columbia Sch Med, Harry S Truman VA Med Ctr, Columbia, MO USA. [Whaley-Connell, Adam T.] Univ Missouri, Columbia Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Columbia, MO USA. [McCullough, Peter A.] St John Providence Hlth Syst, Providence Pk Heart Inst, Novi, MI USA. RP Mehrotra, R (reprint author), Harbor UCLA, Los Angeles Biomed Res Inst, 1124 W Carson St, Torrance, CA 90502 USA. EM rmehrotra@labiomed.org OI Whaley-Connell, Adam/0000-0001-8955-5560 FU Amgen; Abbott; Siemens; Astellas; Fresenius Medical Care; Genzyme; LifeScan; Nephroceuticals; Pfizer; National Kidney Foundation of Southern California; National Institutes of Health (NIH) [R21 DK077341, RR026138, MD000182, R03AG040638-01]; DaVita Inc.; Department of Veteran's Affairs [CDA-2]; American Society of Nephrology-Association of Specialty Professors-National Institute on Aging; [DK K23080952] FX The KEEP is a program of the National Kidney Foundation Inc and is supported by Amgen, Abbott, Siemens, Astellas, Fresenius Medical Care, Genzyme, LifeScan, Nephroceuticals, and Pfizer. Dr Shah is supported by a research grant from the National Kidney Foundation of Southern California and a Genzyme Fellowship Grant. Dr Mehrotra is supported by National Institutes of Health (NIH) grant R21 DK077341 and a research grant from DaVita Inc. Dr Cavanaugh is supported by DK K23080952. Dr Norris receives support from NIH grants RR026138 and MD000182. Dr Whaley-Connell is supported by the Department of Veteran's Affairs CDA-2, the NIH grant R03AG040638-01, and the American Society of Nephrology-Association of Specialty Professors-National Institute on Aging Development Grant in Geriatric Nephrology. NR 17 TC 11 Z9 11 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2012 VL 59 IS 3 SU 2 BP S16 EP S23 DI 10.1053/j.ajkd.2011.10.042 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 896ZA UT WOS:000300608900003 PM 22339898 ER PT J AU Miranda, A Figoni, SF Cha, T Flanagan, T Mandal, O Silva, M Scremin, AME Scremin, OU AF Miranda, Alberto Figoni, Stephen F. Cha, Tha Flanagan, Terrance Mandal, Oanh Silva, Mariana Scremin, A. M. Erika Scremin, Oscar U. TI Calf Tissue Oxygenation During Exercise in Men with and Without Risk Factors for Developing Peripheral Arterial Disease SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Rehabilitation; Exercise Test; Spectroscopy; Near-Infrared; Peripheral Vascular Diseases ID NEAR-INFRARED SPECTROSCOPY; INTERMITTENT CLAUDICATION; SHORT-TERM; VASCULAR-DISEASE; LOWER-EXTREMITY; SMOKING; POPULATION; SATURATION; REHABILITATION; DYSFUNCTION AB Miranda A, Figoni SF, Cha T, Flanagan T, Mandal O, Silva M, Scremin AME, Scremin OU: Calf tissue oxygenation during exercise in men with and without risk factors for developing peripheral arterial disease. Am J Phys Med Rehabil 2012;91:200Y210. Objective: This study aimed to compare calf tissue oxygenation responses to calf exercise in men without diagnosed peripheral arterial disease but with selected risk factors for peripheral arterial disease with those without risk factors. Design: A cross-sectional quasi-experimental design was used. The no-risk group (n = 20) had none of the risk factors (diabetes, hypertension, hyperlipidemia, obesity, current or 10 pack-yr smoking history, or age >= 65 yrs). The at-risk group (n = 45) had one to six risk factors. Medial calf tissue oxygenation (percentage saturation) was determined using near-infrared spectroscopy during seven consecutive 5-min test stages: rest, O-W active plantar/dorsiflexion, rest, 4-W resistive plantar flexion, rest, 8-W resistive plantar flexion, and rest. Resistive exercise was performed on the Stresst'er calf ergometer. Results: Compared with the no-risk group, decrements in calf tissue oxygenation induced by light-to-moderate resistive calf exercise in the at-risk group was significantly greater (by 9% saturation) (4-W: P < 0.001; 8-W: P = 0.002). Conclusions: Men with risk factors for developing peripheral arterial disease but without such diagnosis demonstrated greater decrements in calf tissue oxygenation during calf exercise compared with men without risk factors. Further development of this test may lead to early diagnosis and intervention to modify risk factors and prevent co-morbidities. C1 [Scremin, A. M. Erika] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, VA Greater Los Angeles Healthcare Syst,Phys Med &, Los Angeles, CA 90095 USA. [Miranda, Alberto; Figoni, Stephen F.; Cha, Tha; Flanagan, Terrance; Mandal, Oanh; Silva, Mariana; Scremin, A. M. Erika] VA Greater Los Angeles Healthcare Syst, Rehabil Serv, Los Angeles, CA USA. [Scremin, Oscar U.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Scremin, Oscar U.] Univ Calif Los Angeles, Dept Physiol, Geffen Sch Med, VA Greater Los Angeles Healthcare Syst,Phys Med &, Los Angeles, CA 90024 USA. RP Miranda, A (reprint author), VA W Los Angeles Healthcare Ctr, PM&RS 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 35 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD MAR PY 2012 VL 91 IS 3 BP 200 EP 210 DI 10.1097/PHM.0b013e3182411df9 PG 11 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 898BA UT WOS:000300708900003 PM 22257970 ER PT J AU Saladin, ME Santa Ana, EJ LaRowe, SD Simpson, AN Tolliver, BK Price, KL McRae-Clark, AL Brady, KT AF Saladin, Michael E. Santa Ana, Elizabeth J. LaRowe, Steven D. Simpson, Annie N. Tolliver, Bryan K. Price, Kimber L. McRae-Clark, Aimee L. Brady, Kathleen T. TI Does Alexithymia Explain Variation in Cue-Elicited Craving Reported by Methamphetamine-Dependent Individuals? SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID PSYCHOACTIVE SUBSTANCE DEPENDENCE; MAINTAINING ABSTINENCE; SCALE; ALCOHOL; ABUSERS; VALIDATION; DEPRESSION; REACTIVITY; DISORDERS; WOMEN AB Drug craving is an important motivational phenomenon among addicted individuals, and successful management of craving is essential to both the initiation and maintenance of abstinence. Although craving in response to drug cues is common in drug-dependent individuals, it is not universal. At the present time, it is not known why approximately 2030% of all addicted persons fail to report appreciable craving in laboratory-based cue reactivity studies. This study examined the possibility that alexithymia, a personality attribute characterized by a difficulty identifying and describing emotions, may contribute to the impoverished cue-elicited craving experienced by some addicts. Specifically, we tested the hypothesis that alexithymia, as measured by the Toronto Alexithymia Scale (TAS), would be inversely related to the magnitude of cue-elicited craving obtained in a cue reactivity protocol. Forty methamphetamine-dependent individuals completed the TAS and provided craving ratings for methamphetamine after presentation of methamphetamine-associated cues. Thirteen participants (32%) reported no methamphetamine cue-elicited craving. Contrary to expectation, TAS factor 1 (a measure of difficulty identifying feelings) scores were positively associated with cue-elicited craving. Thus, the results suggest that increasing difficulty-identifying feelings may be associated with higher cue-elicited craving. Clinical implications for this finding are discussed. (Am J Addict 2012:21:130135) C1 [Saladin, Michael E.] Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Saladin, Michael E.; Santa Ana, Elizabeth J.; Simpson, Annie N.; Tolliver, Bryan K.; Price, Kimber L.; McRae-Clark, Aimee L.; Brady, Kathleen T.] Med Univ S Carolina, Clin Neurosci Div, Charleston, SC 29425 USA. [Santa Ana, Elizabeth J.; LaRowe, Steven D.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Subst Abuse Treatment Ctr, Charleston, SC USA. [LaRowe, Steven D.] Med Univ S Carolina, Ctr Drug & Alcohol Programs, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Simpson, Annie N.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. RP Saladin, ME (reprint author), Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, 77 President St,Room 222,MSC700, Charleston, SC 29425 USA. EM saladinm@musc.edu RI McRae-Clark, Aimee/I-3341-2013 OI McRae-Clark, Aimee/0000-0002-9774-318X; LaRowe, Steven/0000-0002-7664-2451 FU NCRR NIH HHS [KL2 RR029880, KL2 RR029880-01, KL2 RR029880-02, KL2 RR029880-03, TL1 RR029881, TL1 RR029881-01, TL1 RR029881-02, TL1 RR029881-03, UL1 RR029882, UL1 RR029882-01, UL1 RR029882-02, UL1 RR029882-03]; NIDA NIH HHS [U10 DA013727-10, P20 DA022658, P20 DA022658-01, P20 DA022658-02, P20 DA022658-02S1, P20 DA022658-03, P20 DA022658-04, R25 DA020537, U10 DA013727, U10 DA013727-10S1, U10 DA013727-10S2, U10 DA013727-10S3, U10 DA013727-11, U10 DA013727-11S1, U10 DA013727-12] NR 47 TC 7 Z9 8 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD MAR-APR PY 2012 VL 21 IS 2 BP 130 EP 135 DI 10.1111/j.1521-0391.2011.00214.x PG 6 WC Substance Abuse SC Substance Abuse GA 894SO UT WOS:000300447300006 PM 22332856 ER PT J AU Tian, L Luo, NL Zhu, XL Chung, BH Garvey, WT Fu, YC AF Tian, Ling Luo, Nanlan Zhu, Xiaolin Chung, Byung-Hong Garvey, W. Timothy Fu, Yuchang TI Adiponectin-AdipoR1/2-APPL1 signaling axis suppresses human foam cell formation: Differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses SO ATHEROSCLEROSIS LA English DT Article DE Adiponectin; Adiponectin receptor; APPL1; Macrophages; Foam cells; Atherosclerosis; Inflammation ID MONOCYTE-DERIVED MACROPHAGES; PLASMA-PROTEIN ADIPONECTIN; LIPID-ACCUMULATION; METABOLIC SYNDROME; RECEPTORS; ATHEROSCLEROSIS; DISEASE; OBESITY; PERSPECTIVE; ACTIVATION AB Objective: Adiponectin is an adipokine that exerts anti-inflammatory and anti-atherogenic effects during macrophage transformation into foam cells. To further understand the signaling pathways of adiponectin involved in macrophage foam cell transformation, we investigated the roles of two adiponectin receptors (AdipoR1 and AdipoR2) and their downstream adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 (APPL1) in mediating adiponectin action on foam cell transformation. Methods and Results: Transfections were performed to overexpress or knockdown AdipoR1 or AdipoR2 genes in human THP-1 monocytes. Lentiviral-shRNAs were also used to knockdown APPL1 gene in these cells. Foam cell transformation was induced via exposure to oxidized low-density lipoprotein (oxLDL). Our results showed that both AdipoR1 and AdipoR2 were critical for transducing the adiponectin signal that suppresses lipid accumulation and inhibits transformation from macrophage to foam cell. However, AdipoR1 and AdipoR2 were found to have differential effects in diminishing proinflammatory responses. While AdipoR1 was required by adiponectin to suppress tumor necrosis factor alpha (TNF alpha) and monocyte chemotactic protein 1 (MCP-1) gene expression, AdipoR2 served as the dominant receptor for adiponectin suppression of scavenger receptor A type 1 (SR-AI) and upregulation of interleukin-1 receptor antagonist (IL-1Ra). Knockdown of APPL1 significantly abrogated the ability of adiponectin to inhibit lipid accumulation, SR-AI and nuclear factor-kappa B (NF-kappa B) gene expression, and Akt phosphorylation in macrophage foam cells. Conclusions: In current studies, we have demonstrated that adiponectin's abilty to suppress macrophage lipid accumulation and foam cell formation is mediated through AdipoR1 and AdipoR2 and the APPL1 docking protein. However, AdipoR1 and AdipoR2 exhibited a differential ability to regulate inflammatory cytokines and SR-A1. These novel data support the idea that the adiponectin-AdipoR1/ 2-APPL1 axis may serve as a potential therapeutic target for preventing macrophage foam cell formation and atherosclerosis. (C) 2011 Elsevier Ireland Ltd. All rights reserved. C1 [Tian, Ling; Luo, Nanlan; Chung, Byung-Hong; Garvey, W. Timothy; Fu, Yuchang] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. [Zhu, Xiaolin] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Fu, YC (reprint author), Univ Alabama, Dept Nutr Sci, 1675 Univ Blvd, Birmingham, AL 35294 USA. EM yfu@uab.edu RI 王, 强/F-4212-2011 FU UAB Diabetes Research and Training Center [P60-DK079626]; American Diabetes Association [1-07-RA-49]; National Institutes of Health [DK-083562, DK-038764]; Department of Veterans Affairs; research core facilities of the UAB Diabetes Research and Training Center [P60-DK079626] FX We are grateful to Dr. Feng Liu, and Dr. Lily Q. Dong (University of Texas Health Science Center at San Antonio) for their generous provision of reagents. We thank Drs. Stacey Cofield, Katherine Ingram, Nianjun Liu, Guodong Wu and Rongbing Xie (University of Alabama at Birmingham) for their help on statistical analysis. This work was supported by a pilot & feasibility grant from the UAB Diabetes Research and Training Center (P60-DK079626), a grant from American Diabetes Association (1-07-RA-49) to YF, grants from the National Institutes of Health (DK-083562 and DK-038764) to WTG, and a Merit Review grant from the Department of Veterans Affairs to WTG. We also gratefully acknowledge the support of the research core facilities of the UAB Diabetes Research and Training Center (P60-DK079626). NR 30 TC 34 Z9 37 U1 0 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD MAR PY 2012 VL 221 IS 1 BP 66 EP 75 DI 10.1016/j.atherosclerosis.2011.12.014 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 897EV UT WOS:000300629500010 PM 22227293 ER PT J AU Huang, G Wang, D Zeb, I Budoff, MJ Harman, SM Miller, V Brinton, EA El Khoudary, SR Manson, JE Sowers, MR Hodis, HN Merriam, GR Cedars, MI Taylor, HS Naftolin, F Lobo, RA Santoro, N Wildman, RP AF Huang, Gary Wang, Dan Zeb, Irfan Budoff, Matthew J. Harman, S. Mitchell Miller, Virginia Brinton, Eliot A. El Khoudary, Samar R. Manson, JoAnn E. Sowers, MaryFran R. Hodis, Howard N. Merriam, George R. Cedars, Marcelle I. Taylor, Hugh S. Naftolin, Frederick Lobo, Rogerio A. Santoro, Nanette Wildman, Rachel P. TI Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS) SO ATHEROSCLEROSIS LA English DT Article DE Coronary calcification; Ectopic fat; Cardiac fat; Hepatic fat; Risk factors; Women ID EPICARDIAL ADIPOSE-TISSUE; CORONARY-ARTERY-DISEASE; VISCERAL ABDOMINAL FAT; INTIMA-MEDIA THICKNESS; PERICARDIAL FAT; LIVER-DISEASE; METABOLIC SYNDROME; INSULIN-RESISTANCE; ASSOCIATION; OBESITY AB Objective: To examine the correlations between intra-hepatic and intra-thoracic (total, epicardial, and pericardial) fat deposition with cardiovascular disease (CVD) risk factors and subclinical atherosclerosis burden in healthy, recently postmenopausal women. Methods: Women screened for the Kronos Early Estrogen Prevention Study (mean age 52.9 years) who underwent electron beam or multidetector computed tomography (CT) imaging for the quantification of intra-hepatic fat and thoracic adipose tissue, and coronary artery calcification (CAC) were included (n = 650). Results: Higher levels of intra-hepatic and thoracic fat were each associated with CVD risk markers. After adjustment for BMI, the associations for intra-hepatic fat with hs-CRP and insulin persisted (r = 0.21 and 0.19, respectively; P < 0.001), while those between thoracic fat indices and lipids persisted (r for total thoracic fat with HDL, LDL, and triglycerides = -0.16, 0.11, and 0.11, respectively, P < 0.05). Total thoracic fat was associated with CAC after initial multivariable adjustment (odds ratio [OR] of 2nd, 3rd, and 4th vs. 1st quartile and [95% confidence intervals]: 0.8 [0.4-1.6], 1.5 [0.8-2.9], and 1.8 [1.0-3.4]; p for linear trend = 0.017) and was only slightly attenuated after additional adjustment for BMI. Associations between total thoracic fat and CVD risk markers and CAC appeared due slightly more to associations with epicardial than pericardial fat. Conclusion: While hepatic fat is related to hs-CRP and insulin, cardiac fat is associated with subclinical atherosclerosis as demonstrated by CAC. Cardiac fat may represent a useful marker for increased CVD risk beyond the standard adiposity measures of BMI and WC. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Huang, Gary; Wang, Dan; Wildman, Rachel P.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA. [Zeb, Irfan; Budoff, Matthew J.] Harbor UCLA, Los Angeles Biomed Res Inst, Div Cardiol, Torrance, CA USA. [Harman, S. Mitchell] Kronos Longev Res Inst, Phoenix, AZ USA. [Miller, Virginia] Mayo Clin, Dept Surg, Rochester, MN USA. [Miller, Virginia] Mayo Clin, Dept Physiol, Rochester, MN USA. [Brinton, Eliot A.] Univ Utah, Sch Med, Dept Cardiovasc Genet, Salt Lake City, UT USA. [El Khoudary, Samar R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Manson, JoAnn E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Sowers, MaryFran R.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Hodis, Howard N.] Univ So Calif, Keck Sch Med, Atherosclerosis Res Unit, Los Angeles, CA 90033 USA. [Merriam, George R.] Univ Washing, Sch Med, Dept Med, Seattle, WA USA. [Cedars, Marcelle I.] Univ Washing, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Cedars, Marcelle I.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Taylor, Hugh S.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA. [Naftolin, Frederick] NYU, Dept Obstet & Gynecol, Sch Med, New York, NY 10016 USA. [Lobo, Rogerio A.] Columbia Univ, Coll Med, Dept Obstet & Gynecol, New York, NY USA. [Santoro, Nanette] Univ Colorado, Denver Sch Med, Dept Obstet & Gynecol & Womens Hlth, Aurora, CO USA. RP Wildman, RP (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, 1300 Morris Pk Ave,Belfer Bldg,Room 1309, Bronx, NY 10461 USA. EM rachel.wildman@einstein.yu.edu OI El Khoudary Abushaban, Samar/0000-0003-2913-0821 FU Aurora Foundation; National Institutes of Health (NIH) [HL90639]; Mayo CTSA [1 UL1 RR024150]; Mayo Foundation; National Center for Research Resources (NCRR), a component of at NIH [CTSA UL1 RR024139, UL1 RR024131]; NIH Roadmap for Medical Research FX KEEPS is funded by grants from the Aurora Foundation to the Kronos Longevity Research Institute, National Institutes of Health (NIH) HL90639 to VMM, 1 UL1 RR024150, Mayo CTSA 1 UL1 RR024150, the Mayo Foundation, CTSA UL1 RR024139 and UL1 RR024131 from the National Center for Research Resources (NCRR), a component of at NIH and NIH Roadmap for Medical Research. The manuscript's contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov. Study medications were supplied in part by Bayer Health Care and by Abbott Pharmaceuticals. NR 30 TC 18 Z9 18 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD MAR PY 2012 VL 221 IS 1 BP 198 EP 205 DI 10.1016/j.atherosclerosis.2011.12.004 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 897EV UT WOS:000300629500029 PM 22209479 ER PT J AU Doss, BD Rowe, LS Morrison, KR Libet, J Birchler, GR Madsen, JW McQuaid, JR AF Doss, Brian D. Rowe, Lorelei Simpson Morrison, Kristen R. Libet, Julian Birchler, Gary R. Madsen, Joshua W. McQuaid, John R. TI Couple Therapy for Military Veterans: Overall Effectiveness and Predictors of Response SO BEHAVIOR THERAPY LA English DT Article DE couple therapy; marital therapy; effectiveness; veterans; military ID RANDOMIZED CLINICAL-TRIAL; MARITAL-THERAPY; OUTCOME RESEARCH; COMMUNITY SAMPLE; MARRIED-COUPLES; COMBAT VETERANS; CLIENT FEEDBACK; PSYCHOTHERAPY; METAANALYSIS; DISSATISFACTION AB Despite the numerous challenges facing U.S. veterans and their relationships, there have been no examinations of the effectiveness of couple therapy for relationship distress provided to veterans. In the present study, 177 couples presenting for couple therapy at two Veteran Administration Medical Centers completed assessments of relationship satisfaction prior to therapy and weekly during therapy. Results revealed that the average couple showed significant gains in relationship satisfaction during treatment (d=0.44 for men; d=0.47 for women); gains were larger for couples beginning therapy in the distressed range (d=0.61 for men; d=0.58 for women) than for couples in the nondistressed range (d=0.19 for men; d=0.22 for women). Rates of premature termination were high, with 19% of couples completing fewer than three sessions and 62% rated as not completing a "full course" of therapy. Benchmarking analyses demonstrated that the average gains were larger than would be expected from natural remission and similar to previous effectiveness trials; however, average gains were smaller than those observed in couple therapy efficacy trials. Relationship, psychological, and demographic characteristics were generally unrelated to the amount of change in therapy after controlling for initial satisfaction. However, African American couples showed significantly larger gains than Caucasian, non-Hispanic couples. Thus, though yielding smaller effects than those shown in efficacy trials, the impact of couple therapy for veterans' relationship problems appears to generalize across various demographic, psychological, and relationship characteristics. C1 [Doss, Brian D.] Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA. [Rowe, Lorelei Simpson] So Methodist Univ, Dallas, TX 75275 USA. [Birchler, Gary R.; Madsen, Joshua W.] VA San Diego Healthcare Syst, San Diego, CA USA. [Madsen, Joshua W.] Univ Calif San Diego, San Diego, CA 92103 USA. [McQuaid, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [McQuaid, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Doss, BD (reprint author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA. EM bdoss@miami.edu NR 51 TC 14 Z9 14 U1 1 U2 6 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 J9 BEHAV THER JI Behav. Therapy PD MAR PY 2012 VL 43 IS 1 BP 216 EP 227 PG 12 WC Psychology, Clinical SC Psychology GA 897JQ UT WOS:000300647400019 PM 22304892 ER PT J AU LeTourneau, JL Pinney, J Phillips, CR AF LeTourneau, Jennifer L. Pinney, Jamie Phillips, Charles R. TI Extravascular lung water predicts progression to acute lung injury in patients with increased risk SO CRITICAL CARE MEDICINE LA English DT Article DE acute lung injury; extravascular lung water; physiologic dead-space fraction; pulmonary edema; pulmonary permeability index; thermodilution; transpulmonary ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; CRITICALLY ILL PATIENTS; INTENSIVE-CARE-UNIT; LOWER TIDAL VOLUMES; TRANSPULMONARY THERMODILUTION; BODY-WEIGHT; CLINICAL-TRIAL; VENTILATION; SEVERITY AB Objectives: To compare the extravascular lung water index and other markers of disease severity in patients with acute lung injury vs. patients at risk for development of acute lung injury and to determine their ability to predict progression to acute lung injury in patients at risk. Design: Extravascular lung water index, dead space fraction, Pao(2)/Fio(2), and other markers of disease severity were measured prospectively in 29 patients daily for 5 days after admission to the intensive care unit. Patients had acute lung injury as defined by the American European Consensus Committee criteria or had risk factors for development of it. Setting: The intensive care units of an academic tertiary referral hospital. Measurements and Main Results: The mean extravascular lung water index on day 1 for patients who progressed to acute lung injury was higher than for those who did not (15.5 +/- 7.4 mL/kg vs. 8.7 +/- 2.3 mL/kg; p = .04). None of the other physiologic parameters tested discriminated progression to acute lung injury to include the mean physiologic dead space (0.61 +/- 0.06] vs. 0.59 +/- 0.10; p = .67), Pao(2)/Fio(2) ratio (322 +/- 35 vs. 267 +/- 98; p = .15), and static lung compliance (30.9 +/- 13.5 vs. 38.5 +/- 11.7; p = .24). An extravascular lung water index cutoff value on day 1 of 10 mL/kg had a 63% sensitivity, 88% specificity, positive predictive value of 83%, and negative predictive value of 70% to predict progression to acute lung injury. There was no difference in extravascular lung water index between those who progressed to acute lung injury vs. those who had acute lung injury (14.3 +/- 4.7 vs. 15.5 +/- 7.4; P = .97). Conclusions: Elevated extravascular lung water index is a feature of early acute lung injury and discriminates between those with acute lung injury and those without. Furthermore, extravascular lung water index predicts progression to acute lung injury in patients with risk factors for development of acute lung injury 2.6 +/- 0.3 days before the patients meet American European Consensus Committee criteria for it. These 2.6 +/- 0.3 days may then represent missed opportunity for therapeutic intervention and improved outcome. (Crit Care Med 2012; 40:847-854) C1 [LeTourneau, Jennifer L.] Portland VA Med Ctr, Pulm Dis Sect, Portland, OR 97239 USA. [LeTourneau, Jennifer L.; Pinney, Jamie; Phillips, Charles R.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Ctr Intens Care Res, Portland, OR 97201 USA. RP LeTourneau, JL (reprint author), Portland VA Med Ctr, Pulm Dis Sect, 3710 SW US Vet Hosp Rd,P3PULM, Portland, OR 97239 USA. EM Jennifer.Letourneau@va.gov FU Medical Research Foundation, Oregon Health & Science University, Portland, Oregon; Center of Excellence in Human Research, Oregon Health & Science University, Portland, Oregon; Oregon Clinical and Translational Research Institute (OCTRI); National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1 RR024140]; NIH Roadmap for Medical Research; MAB FX Supported, in part, by Medical Research Foundation, Oregon Health & Science University, Portland, Oregon; Center of Excellence in Human Research, Oregon Opportunity Funds, Oregon Health & Science University, Portland, Oregon; the Oregon Clinical and Translational Research Institute (OCTRI); grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH); and NIH Roadmap for Medical Research.; Dr. Phillips consulted for and received honoraria/speaking fees from MAB. The remaining authors have not disclosed any potential conflicts of interest. NR 43 TC 41 Z9 48 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD MAR PY 2012 VL 40 IS 3 BP 847 EP 854 DI 10.1097/CCM.0b013e318236f60e PG 8 WC Critical Care Medicine SC General & Internal Medicine GA 895YO UT WOS:000300532800019 PM 22036857 ER PT J AU Benedict, C Brooks, SJ Kullberg, J Burgos, J Kempton, MJ Nordenskjold, R Nylander, R Kilander, L Craft, S Larsson, EM Johansson, L Ahlstrom, H Lind, L Schioth, HB AF Benedict, Christian Brooks, Samantha J. Kullberg, Joel Burgos, Jonathan Kempton, Matthew J. Nordenskjold, Richard Nylander, Ruta Kilander, Lena Craft, Suzanne Larsson, Elna-Marie Johansson, Lars Ahlstrom, Hakan Lind, Lars Schioth, Helgi B. TI Impaired Insulin Sensitivity as Indexed by the HOMA Score Is Associated With Deficits in Verbal Fluency and Temporal Lobe Gray Matter Volume in the Elderly SO DIABETES CARE LA English DT Article ID MIDDLE-AGED ADULTS; ALZHEIMERS-DISEASE; BRAIN; MEMORY; HUMANS; SEGMENTATION; PATHOGENESIS; RESISTANCE; LANGUAGE; ANATOMY AB OBJECTIVE-Impaired insulin sensitivity is linked to cognitive deficits and reduced brain size. However, it is not yet known whether insulin sensitivity involves regional changes in gray matter volume. Against this background, we examined the association between insulin sensitivity, cognitive performance, and regional gray matter volume in 285 cognitively healthy elderly men and women aged 75 years from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. RESEARCH DESIGN AND METHODS-Insulin sensitivity was calculated from fasting serum insulin and plasma glucose determinations using the homeostasis model assessment of insulin resistance (HOMA-IR) method. Cognitive performance was examined by a categorical verbal fluency. Participants. also underwent a magnetic resonance imaging (MRI) brain scan. Multivariate analysis using linear regression was conducted, controlling for potential confounders (sex, education, serum LDL cholesterol, mean arterial blood pressure, and abdominal visceral fat volume). RESULTS-The HOMA-IR was negatively correlated with verbal fluency performance, brain size, and temporal lobe gray matter volume in regions known to be involved in speech production (Brodmann areas 21 and 22, respectively). No such effects were observed when examining diabetic (n = 55) and cognitively impaired (n = 27) elderly subjects as separate analyses. CONCLUSIONS-These cross-sectional findings suggest that both pharmacologic and lifestyle interventions improving insulin signaling may promote brain health in late life but must be confirmed in patient studies. C1 [Benedict, Christian; Brooks, Samantha J.; Burgos, Jonathan; Schioth, Helgi B.] Uppsala Univ, Dept Neurosci, Uppsala, Sweden. [Kullberg, Joel; Nordenskjold, Richard; Nylander, Ruta; Larsson, Elna-Marie; Johansson, Lars; Ahlstrom, Hakan] Uppsala Univ, Dept Radiol, Uppsala, Sweden. [Kempton, Matthew J.] Kings Coll London, Dept Neuroimaging, London WC2R 2LS, England. [Kilander, Lena] Uppsala Univ, Dept Publ Hlth & Caring Sci Geriatr, Uppsala, Sweden. [Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Vet Affairs Puget Sound Hlth Care Syst,Geriatr Re, Seattle, WA 98195 USA. [Lind, Lars] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. RP Benedict, C (reprint author), Uppsala Univ, Dept Neurosci, Uppsala, Sweden. EM christian.benedict@neuro.uu.se RI Kempton, Matthew/F-8683-2011 OI Kempton, Matthew/0000-0003-3541-9947; Benedict, Christian/0000-0002-8911-4068 FU Swedish Research Council; Brain Research Foundation (Sweden); Olle Engkvist Byggmastare Foundation (Sweden); Tore Nilsons Foundation (Sweden); Gunvor och Josef Aners Foundation (Sweden); Ake Wibergs Foundation (Sweden); Ahlens Foundation (Sweden); Uppsala University (Sweden); Novo Nordisk (Denmark); AstraZeneca (Sweden) FX This study was funded by the Swedish Research Council, the Brain Research Foundation (Sweden), the Olle Engkvist Byggmastare Foundation (Sweden), the Tore Nilsons Foundation (Sweden), the Gunvor och Josef Aners Foundation (Sweden), the Ake Wibergs Foundation (Sweden), the Ahlens Foundation (Sweden), and Uppsala University (Sweden).; Funding for the study also was provided by Novo Nordisk (Denmark) and AstraZeneca (Sweden). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; and preparation, review, or approval of the manuscript. No other potential conflicts of interest relevant to this article were reported. NR 41 TC 43 Z9 45 U1 0 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD MAR PY 2012 VL 35 IS 3 BP 488 EP 494 DI 10.2337/dc11-2075 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 899FI UT WOS:000300801400009 PM 22301128 ER PT J AU Taborsky, GJ Mundinger, TO AF Taborsky, Gerald J., Jr. Mundinger, Thomas O. TI Minireview: The Role of the Autonomic Nervous System in Mediating the Glucagon Response to Hypoglycemia SO ENDOCRINOLOGY LA English DT Review ID PANCREATIC SYMPATHETIC-NERVES; INSULIN-INDUCED HYPOGLYCEMIA; DIABETIC-RATS; VENTROMEDIAL HYPOTHALAMUS; SECRETION; DOG; HORMONE; HUMANS; ISLETS; COUNTERREGULATION AB In type 1 diabetes, the impairment of the glucagon response to hypoglycemia increases both its severity and duration. In nondiabetic individuals, hypoglycemia activates the autonomic nervous system, which in turn mediates the majority of the glucagon response to moderate and marked hypoglycemia. The first goal of this minireview is therefore to illustrate and document these autonomic mechanisms. Specifically we describe the hypoglycemic thresholds for activating the three autonomic inputs to the islet (parasympathetic nerves, sympathetic nerves, and adrenal medullary epinephrine) and their magnitudes of activation as glucose falls from euglycemia to near fatal levels. The implication is that their relative contributions to this glucagon response depend on the severity of hypoglycemia. The second goal of this minireview is to discuss known and suspected down-regulation or damage to these mechanisms in diabetes. We address defects in the central nervous system, the peripheral nervous system, and in the islet itself. They are categorized as either functional defects caused by glucose dysregulation or structural defects caused by the autoimmune attack of the islet. In the last section of the minireview, we outline approaches for reversing these defects. Such reversal has both scientific and clinical benefit. Scientifically, one could determine the contribution of these defects to the impairment of glucagon response seen early in type 1 diabetes. Clinically, restoring this glucagon response would allow more aggressive treatment of the chronic hyperglycemia that is linked to the debilitating long-term complications of this disease. (Endocrinology 153: 1055-1062, 2012) C1 [Taborsky, Gerald J., Jr.; Mundinger, Thomas O.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Taborsky, GJ (reprint author), Div Endocrinol & Metab 151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM taborsky@u.washington.edu FU NIDDK NIH HHS [P30 DK017047, R01 DK050154] NR 35 TC 38 Z9 38 U1 1 U2 12 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD MAR PY 2012 VL 153 IS 3 BP 1055 EP 1062 DI 10.1210/en.2011-2040 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 897JG UT WOS:000300645600012 PM 22315452 ER PT J AU Nordenstedt, H Younes, M El-Serag, HB AF Nordenstedt, Helena Younes, Mamoun El-Serag, Hashem B. TI Expression of Androgen Receptors in Barrett Esophagus SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Letter ID ADENOCARCINOMA; SEX; HORMONES; CANCER C1 [Nordenstedt, Helena; El-Serag, Hashem B.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. [Nordenstedt, Helena; El-Serag, Hashem B.] Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. [Nordenstedt, Helena] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. [Younes, Mamoun] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. RP Nordenstedt, H (reprint author), Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. OI Younes, Mamoun/0000-0001-9618-3451 FU NCI NIH HHS [P30 CA125123, R01 CA116845]; NIDDK NIH HHS [K24 DK078154, T32 DK083266]; PHS HHS [NIDDK K24-04-107, R01 116845] NR 8 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD MAR PY 2012 VL 46 IS 3 BP 251 EP 252 DI 10.1097/MCG.0b013e318238353e PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 895TG UT WOS:000300518700014 PM 22327304 ER PT J AU Sonnenberg, A Boardman, CR AF Sonnenberg, Amnon Boardman, Charles R. TI Is it Justifiable to Withhold Endoscopic Information? SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Letter ID BARRETTS-ESOPHAGUS; DIAGNOSIS C1 [Sonnenberg, Amnon; Boardman, Charles R.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol, Portland, OR 97201 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD MAR PY 2012 VL 46 IS 3 BP 252 EP 253 DI 10.1097/MCG.0b013e318238e7d1 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 895TG UT WOS:000300518700015 PM 22186741 ER PT J AU Ochsenbauer, C Edmonds, TG Ding, HT Keele, BF Decker, J Salazar, MG Salazar-Gonzalez, JF Shattock, R Haynes, BF Shaw, GM Hahn, BH Kappes, JC AF Ochsenbauer, Christina Edmonds, Tara G. Ding, Haitao Keele, Brandon F. Decker, Julie Salazar, Maria G. Salazar-Gonzalez, Jesus F. Shattock, Robin Haynes, Barton F. Shaw, George M. Hahn, Beatrice H. Kappes, John C. TI Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 R5 ENVELOPES; CENTRAL-NERVOUS-SYSTEM; ANTIBODY NEUTRALIZATION; BIOLOGICAL PHENOTYPE; SEXUAL TRANSMISSION; VIRAL DETERMINANTS; LYMPHOID-TISSUES; FUSION INHIBITOR; TROPISM AB Genome sequences of transmitted/founder (T/F) HIV-1 have been inferred by analyzing single genome amplicons of acute infection plasma viral RNA in the context of a mathematical model of random virus evolution; however, few of these T/F sequences have been molecularly cloned and biologically characterized. Here, we describe the derivation and biological analysis of ten infectious molecular clones, each representing a T/F genome responsible for productive HIV-1 clade B clinical infection. Each of the T/F viruses primarily utilized the CCR5 coreceptor for entry and replicated efficiently in primary human CD4(+) T lymphocytes. This result supports the conclusion that single genome amplification-derived sequences from acute infection allow for the inference of T/F viral genomes that are consistently replication competent. Studies with monocyte-derived macrophages (MDM) demonstrated various levels of replication among the T/F viruses. Although all T/F viruses replicated in MDM, the overall replication efficiency was significantly lower compared to prototypic "highly macrophage-tropic" virus strains. This phenotype was transferable by expressing the env genes in an isogenic proviral DNA backbone, indicating that T/F virus macrophage tropism mapped to Env. Furthermore, significantly higher concentrations of soluble CD4 were required to inhibit T/F virus infection compared to prototypic macrophage-tropic virus strains. Our findings suggest that the acquisition of clinical HIV-1 subtype B infection occurs by mucosal exposure to virus that is not highly macrophage tropic and that the generation and initial biological characterization of 10 clade B T/F infectious molecular clones provides new opportunities to probe virus-host interactions involved in HIV-1 transmission. C1 [Ochsenbauer, Christina; Ding, Haitao; Decker, Julie; Salazar, Maria G.; Salazar-Gonzalez, Jesus F.; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Edmonds, Tara G.; Kappes, John C.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL USA. [Keele, Brandon F.] NCI Frederick, SAIC Frederick Inc, Frederick, MD USA. [Shattock, Robin] Univ London Imperial Coll Sci Technol & Med, London, England. [Haynes, Barton F.] Duke Univ, Sch Med, Dept Med, Duke Human Vaccine Inst, Durham, NC 27706 USA. [Haynes, Barton F.] Duke Univ, Sch Med, Dept Immunol, Duke Human Vaccine Inst, Durham, NC USA. [Shaw, George M.; Hahn, Beatrice H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Shaw, George M.; Hahn, Beatrice H.] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. RP Kappes, JC (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. EM kappesjc@uab.edu RI Ghartouchent, malek/B-9088-2012 FU NIH Center for HIV/AIDS Vaccine Immunology (CHAVI) [UO1-AI067854]; Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery/Comprehensive Antibody Vaccine Immune Monitoring Consortium [38619]; Bill and Melinda Gates Foundation [37874]; facilities of the Virology, Biostatistics, and Genetic Sequencing cores of the UAB Center for AIDS Research [P30-AI-27767]; Genetically Defined Microbe and Expression Core of the UAB Mucosal HIV and Immunobiology Center [R24 DK-64400]; Department of Veterans Affairs Medical Center, Research Services; NIH [AI007439] FX This study was supported by the NIH Center for HIV/AIDS Vaccine Immunology (CHAVI; UO1-AI067854); the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery/Comprehensive Antibody Vaccine Immune Monitoring Consortium (grant 38619); a Bill and Melinda Gates Foundation Grand Challenges grant (grant 37874); the facilities of the Virology, Biostatistics, and Genetic Sequencing cores of the UAB Center for AIDS Research (P30-AI-27767); and the Genetically Defined Microbe and Expression Core of the UAB Mucosal HIV and Immunobiology Center (R24 DK-64400). Research was also supported by a Merit Review Award (J.C.K.) and a Research Career Scientist Award (J.C.K.) from the Department of Veterans Affairs Medical Center, Research Services. T.G.E. is supported by NIH training grant AI007439. NR 71 TC 128 Z9 128 U1 2 U2 14 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2012 VL 86 IS 5 BP 2715 EP 2728 DI 10.1128/JVI.06157-11 PG 14 WC Virology SC Virology GA 896AC UT WOS:000300536800029 PM 22190722 ER PT J AU Keyhani, S Falk, R Bishop, T Howell, E Korenstein, D AF Keyhani, Salomeh Falk, Raphael Bishop, Tara Howell, Elizabeth Korenstein, Deborah TI The Relationship Between Geographic Variations and Overuse of Healthcare Services A Systematic Review SO MEDICAL CARE LA English DT Review DE quality of health care; small-area analysis; physicians practice pattern; Delphi Technique; Guidelines and topic; guideline adeherence; health services misuse ID ACUTE MYOCARDIAL-INFARCTION; SMALL-AREA VARIATIONS; REGIONAL-VARIATIONS; OUTCOMES; QUALITY AB Objective: To examine the relationship between overuse of healthcare services and geographic variations in medical care. Design: Systematic Review. Data Sources: Articles published in Medline between 1978, the year of publication of the first framework to measure quality, and January 1, 2009. Study Selection: Four investigators screened 114,830 titles and 2 investigators screened all selected abstracts and articles for possible inclusion and extracted all data. Data Extraction: We extracted data on rates of overuse in different geographic areas. We also extracted data on underuse, if available, for the same population in which overuse was measured. Results: Five papers examined the relationship between geographic variations and overuse of healthcare services. One study in 2008 compared the appropriateness of coronary angiography (CA) for acute myocardial infarction in high-cost areas versus low cost areas in the Medicare population and found largely similar rates of inappropriateness (12.2% vs. 16.2%). A study in 2000 using national data concluded that overuse of CA explained little of the geographic variations in the use of this procedure in the Medicare program. An older study of Medicare patients found similar rates of inappropriate use of CA (15% to 17% vs. 18%), endoscopy (15% vs. 18% 19%), and carotid endarterectomy (29% vs. 30%) in low-use and high-use regions. A small area reanalysis of data from this study of 3 procedures found no evidence of a relationship between inappropriate use of procedures and volume in 23 adjacent counties of California. Another 2008 study found that inappropriate chemotherapy for stage I cancer was less common in low-cost areas compared with high-cost areas (3.1% vs. 6.3%). Conclusions: The limited available evidence does not lend support to the hypothesis that inappropriate use of procedures is a major source of geographic variations in intensity and/or costs of care. More research is needed to improve our understanding of the relationship between geographic variations and the quality of care. C1 [Keyhani, Salomeh] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94121 USA. [Keyhani, Salomeh] San Francisco VA Med Ctr, WHSR & D Res Enhancement Award Program, San Francisco, CA USA. [Falk, Raphael] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94121 USA. [Howell, Elizabeth] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA. [Korenstein, Deborah] Mt Sinai Sch Med, Div Gen Internal Med, Dept Med, New York, NY USA. [Bishop, Tara] Weill Cornell Med Coll, Dept Publ Hlth & Med, New York, NY USA. RP Keyhani, S (reprint author), Univ Calif San Francisco, Div Gen Internal Med, San Francisco VA Med Ctr 4150,Clement 111A1, San Francisco, CA 94121 USA. EM salomeh.keyhani@ucsf.edu FU Commonwealth Fund; VA HSR&D Career Development Award FX Supported by the Commonwealth Fund. Dr Keyhani is also supported by a VA HSR&D Career Development Award. NR 14 TC 20 Z9 20 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAR PY 2012 VL 50 IS 3 BP 257 EP 261 DI 10.1097/MLR.0b013e3182422b0f PG 5 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 896YF UT WOS:000300606600011 PM 22329997 ER PT J AU Burks, DJ Kobus, AM AF Burks, Derek J. Kobus, Amy M. TI The legacy of altruism in health care: the promotion of empathy, prosociality and humanism SO MEDICAL EDUCATION LA English DT Article ID US MEDICAL-STUDENTS; PATIENT-CENTEREDNESS; ACADEMIC MEDICINE; TEACH EMPATHY; BURNOUT; EDUCATION; PHYSICIANS; COMMUNICATION; VIEWPOINT; ATTITUDES AB OBJECTIVES This study aimed to examine concepts of altruism and empathy among medical students and professionals in conjunction with health care initiatives designed to support the maintenance of these qualities. METHODS We searched for the terms ` altruism', ` altruistic', ` helping', ` prosocial behaviour' and ` empathy' in the Englishlanguage literature published from 1980 to the present within the Ovid MEDLINE, PsycInfo and PubMed databases. We used conceptual analysis to examine the relationships among altruism, empathy and related prosocial concepts in health care in order to understand how such factors may relate to emotional and career burnout, cynicism, decreased helping and decreased patient- centredness in care. RESULTS Altruistic ideals and qualities of empathy appear to decrease among some medical students as they progress through their education. During this process, students face increasingly heavy workloads, deal with strenuous demands and become more acquainted with non- humanistic informal practices inherent in the culture of medicine. In combination, these factors increase the likelihood that emotional suppression, detachment from patients, burnout and other negative consequences may result, perhaps as a means of self-preservation. Alternatively, by making a mindful and intentional choice to endeavour for self-care and a healthy work-life balance, medical students can uphold humanistic and prosocial attitudes and behaviours. CONCLUSIONS Promoting altruism in the context of a compensated health care career is contradictory and misguided. Instead, an approach to clinical care that is prosocial and empathic is recommended. Training in mindfulness, self-reflection and emotion skills may help medical students and professionals to recognise, regulate and behaviourally demonstrate empathy within clinical and professional encounters. However, health care initiatives to increase empathy and other humanistic qualities will be limited unless more practical and feasible emotion skills training is offered to and accepted by medical students. Success will be further moderated by the culture of medicine's full acceptance of empathy and humanism into its customs, beliefs, values, interactions and daily practices. C1 [Burks, Derek J.] Portland VA Med Ctr, Dept Mental Hlth & Neurosci, Portland, OR USA. [Burks, Derek J.] VISN 20 Mental Illness Res Educ & Clin Ctr, Portland, OR USA. [Burks, Derek J.] Oregon Hlth & Sci Univ, Sch Med, Dept Clin Res, Portland, OR 97201 USA. [Kobus, Amy M.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA. RP Burks, DJ (reprint author), Natl Ctr Telehlth & Technol, 9933 W Hayes St, Tacoma, WA 98431 USA. EM derekjburks@gmail.com NR 74 TC 24 Z9 25 U1 6 U2 51 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0308-0110 J9 MED EDUC JI Med. Educ. PD MAR PY 2012 VL 46 IS 3 BP 317 EP 325 DI 10.1111/j.1365-2923.2011.04159.x PG 9 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 895NW UT WOS:000300504100011 PM 22324531 ER PT J AU Goldberg, NRS Fields, V Pflibsen, L Salvatore, MF Meshul, CK AF Goldberg, Natalie R. S. Fields, Victoria Pflibsen, Lacey Salvatore, Michael F. Meshul, Charles K. TI Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Dopamine; Striatum; MPTP; Social enrichment; Tyrosine hydroxylase ID VESICULAR MONOAMINE TRANSPORTER; SLEEP BEHAVIOR DISORDER; POTENTIAL EARLY MARKERS; ADULT SUBSTANTIA-NIGRA; DOPAMINE TRANSPORTER; TYROSINE-HYDROXYLASE; STRIATAL DOPAMINE; NEURONAL DEATH; BASAL GANGLIA; MICE LACKING AB Environmental enrichment has been shown to be both neuroprotective and neurorestorative in 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse models of Parkinson's disease (PD). However, whether social interaction or novel physical stimulation is responsible for this recovery is controversial. in the current study, we have investigated the effects of only social enrichment (SocE) in progressively MPTP-lesioned mice. After mice were lesioned using a progressively increased dose (4 mg/kg, 8 mg/kg, 16 mg/kg and 32 mg/kg; each dose daily for 5 days), the MPTP-induced behavioral deficits, after the 32 mg/kg dose, were reversed with acute l-DOPA. This acute behavioral recovery suggests that this progressive MPTP-induced neurodegeneration is an appropriate murine model of PD. Mice were housed four per cage for the first 2 weeks of progressive lesioning or vehicle treatment. After the 8 mg/kg MPTP dose (prior to SocE intervention) mice showed a significant decrease in rearing and foot fault behaviors (FF/BB) compared to the vehicle group. Additionally, there was a 38% decrease in mean number of tyrosine hydroxylase immunoreactive (TH-ir) substantia nigra pars compacta (SNpc) neurons/section, and a 50% decrease in the optical density of TH-ir dorsolateral caudate putamen (CPu) terminals compared to the vehicle group. Mice were then housed either two (socially limited environment; SLE) or twelve (SocE) mice per cage during continued MPTP lesioning for the next 2 weeks at 16 mg/kg and 32 mg/kg MPTP. MPTP treatment was then discontinued, while mice remained in the SLE or SocE cages for an additional week. Rearing behavior was further impaired in SLE-MPTP mice following progressive MPTP, accompanied by additional decreases in the mean number of TH-ir SNpc neurons/section and CPu TH-ir terminals. CPu TH and dopamine transporter (DAT) protein expression, as well as dopamine tissue and TH protein levels was significantly decreased compared to either vehicle group. However, the deficit in rearing behavior in SLE-MPTP mice was reversed with acute I-DOPA following the intervention period. SocE-MPTP mice showed rearing and FF/BB behaviors similar to vehicle levels, although FF/BB was not significantly different from pre-intervention levels. The reversal from pre-intervention rearing deficits was correlated with an attenuated decrease in the mean number of SNpc TH-ir neurons/section and CPu TH and DAT protein, and with a blocked decrease in CPu TH-ir terminals compared to pre-intervention levels. Our findings show that SocE mice not only resist further nigrostriatal lesioning and FF/BB deficit, but rearing behavior is recovered to the level of the vehicle group despite continued MPTP treatment. In contrast, SLE mice showed continued loss of nigrostriatal TH-ir and decline of motor behaviors with progressive MPTP. The data suggest that non-pharmacological intervention that started at an early stage of dopamine loss is effective at slowing or blocking further nigrostriatal degeneration. Published by Elsevier Inc. C1 [Goldberg, Natalie R. S.; Pflibsen, Lacey; Meshul, Charles K.] Portland VA Med Ctr, Portland, OR USA. [Fields, Victoria; Salvatore, Michael F.] Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol Toxicol & Neurosci, Shreveport, LA 71105 USA. [Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci & Pathol, Portland, OR 97201 USA. RP Meshul, CK (reprint author), VA Med Ctr RD 29, 3710 SW Vet Hosp Rd, Portland, OR 97239 USA. EM meshulc@ohsu.edu FU Department of Veterans Affairs; Edward P Stiles Trust - LSUHSC - Shreveport; Biomedical Research Foundation of NW Louisiana FX Support was from the Department of Veterans Affairs Merit Review Program to CKM, and the Edward P Stiles Trust Fund - LSUHSC - Shreveport and Biomedical Research Foundation of NW Louisiana to MFS. We also thank Deborah Finn for consultation regarding statistical analyses. NR 122 TC 14 Z9 14 U1 1 U2 10 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD MAR PY 2012 VL 45 IS 3 BP 1051 EP 1067 DI 10.1016/j.nbd.2011.12.024 PG 17 WC Neurosciences SC Neurosciences & Neurology GA 895TP UT WOS:000300519600023 PM 22198503 ER PT J AU Kahn, R Gorgon, L Jones, K McSherry, F Glover, ED Anthenelli, RM Jackson, T Williams, J Murtaugh, C Montoya, I Yu, E Elkashef, A AF Kahn, Roberta Gorgon, Liza Jones, Karen McSherry, Frances Glover, Elbert D. Anthenelli, Robert M. Jackson, Thomas Williams, Jill Murtaugh, Cristin Montoya, Ivan Yu, Elmer Elkashef, Ahmed TI Selegiline Transdermal System (STS) as an Aid for Smoking Cessation SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID PLACEBO-CONTROLLED TRIAL; MONOAMINE-OXIDASE; CIGARETTE SMOKERS; DOUBLE-BLIND; ABSTINENCE; HYDROCHLORIDE; INHIBITION; DEPRESSION AB Introduction: This study examined the efficacy and safety of selegiline transdermal system (STS) and brief repeated behavioral intervention (BRBI) for smoking cessation in heavy smokers. We hypothesized that the quit rate of subjects who received STS and BRBI would be significantly greater than that of those who received placebo patch and BRBI. Methods: This was a double-blind, placebo-controlled parallel-group study in which 246 men and women were randomized to receive either STS (n = 121) or placebo patch (n = 125) for 9 weeks. Recruitment targeted heavy smokers, defined as individuals with self-reported use of = 15 cigarettes/day in the 30 days prior to enrollment, who had smoked cigarettes for the past 5 years, and had an expired CO level >= 9 ppm during screening. Results: Although STS was well tolerated, the overall results indicated that STS with BRBI was not more effective than placebo plus BRBI for smoking cessation (p = .58). Conclusions: The results are discussed in relation to interventions for heavy smokers. Although 2 trials using oral selegiline both showed trends toward improved abstinence, these results indicate that STS with BRBI was not an effective aid for smoking cessation at the end of treatment (10 weeks), 14, or 26 weeks. C1 [Kahn, Roberta; Gorgon, Liza; Montoya, Ivan; Elkashef, Ahmed] Natl Inst Drug Abuse, Div Pharmacotherapies & Med Consequences Drug Abu, Bethesda, MD 20892 USA. [Jones, Karen; McSherry, Frances; Murtaugh, Cristin] Cooperat Studies Program Coordinating Ctr, Dept Vet Affairs, Perry Point, MD USA. [Glover, Elbert D.] Univ Maryland, Ctr Hlth Behav Res, Dept Publ & Community Hlth, College Pk, MD 20742 USA. [Anthenelli, Robert M.] Univ Cincinnati, Tri State Tobacco & Alcohol Res Ctr, Cincinnati, OH USA. [Anthenelli, Robert M.] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Jackson, Thomas] Univ Wisconsin, UW Ctr Tobacco Res & Intervent, Sch Med & Publ Hlth, Madison, WI USA. [Williams, Jill] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Yu, Elmer] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Kahn, R (reprint author), Natl Inst Drug Abuse, Div Pharmacotherapies & Med Consequences Drug Abu, 6001 Execut Blvd Room 4123,MSC 9551, Bethesda, MD 20892 USA. EM rkan@nida.nih.gov FU National Institutes of Health, National Institute on Drug Abuse through the Department of Veterans Affairs [Y1-DA4006] FX This study was supported by the National Institutes of Health, National Institute on Drug Abuse through the Department of Veterans Affairs Cooperative Studies Program (Interagency Agreement No. Y1-DA4006). NR 21 TC 9 Z9 9 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAR PY 2012 VL 14 IS 3 BP 377 EP 382 DI 10.1093/ntr/ntr143 PG 6 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 898DB UT WOS:000300714500018 PM 21846661 ER PT J AU Katon, J Reiber, G Williams, MA Yanez, D Miller, E AF Katon, Jodie Reiber, Gayle Williams, Michelle A. Yanez, David Miller, Edith TI Hemoglobin A(1c) and Postpartum Abnormal Glucose Tolerance Among Women With Gestational Diabetes Mellitus SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID GLYCATED HEMOGLOBIN; DCA 2000; A1C; MULTICENTER; INTOLERANCE; POPULATION; PREDICTORS; ANTEPARTUM; PREVENTION; ANALYZER AB OBJECTIVE: To analyze the association of hemoglobin A(1c) (HbA(1c)) at gestational diabetes mellitus (GDM) diagnosis with postpartum abnormal glucose in a cohort of women with GDM. METHODS: Women with singleton pregnancies treated for GDM at a large diabetes and pregnancy program located in Charlotte, North Carolina, who completed a postpartum 2-hour oral glucose tolerance test were eligible for inclusion in this retrospective cohort study. Clinical information, including maternal HbA(1c) at diagnosis, was abstracted from medical records. A parametric survival model was used to assess the association of HbA(1c) at GDM diagnosis with postpartum maternal abnormal glucose including impaired fasting glucose, impaired glucose tolerance, and any postpartum abnormal glucose. RESULTS: Of the 277 postpartum women with GDM, 75 (32%) had impaired fasting glucose, 61 (28%) had impaired glucose tolerance, and 15 (9%) were diagnosed with type 2 diabetes mellitus after delivery. After adjustment for clinic, maternal age, parity, prepregnancy body mass index 25 or higher, nonwhite race or ethnicity, and gestational week at first HbA(1c), we detected a trend of increased risk for impaired fasting glucose (P=.01), impaired glucose tolerance (P=.002), and any glucose abnormality (P<.001) associated with increased quartile of HbA1c at GDM diagnosis. CONCLUSION: Hemoglobin A1c measured at GDM diagnosis may be a useful tool for identifying patients with GDM at highest risk of developing postpartum abnormal glucose. LEVEL OF EVIDENCE: II (Obstet Gynecol 2012;119:566-74) DOI: 10.1097/AOG.0b013e3182475ac2 C1 [Katon, Jodie] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Carolinas Med Ctr, Diabet & Pregnancy Program, Charlotte, NC 28203 USA. RP Katon, J (reprint author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA. EM jkaton@u.washington.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health [T32 HD052462]; Seattle chapter of Achievement Rewards for College Scientists; Samuel and Althea Stroum Foundation; University of Washington Department of Epidemiology FX Dr. Katon was supported by grant number T32 HD052462 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health; the Seattle chapter of Achievement Rewards for College Scientists; and the Samuel and Althea Stroum Foundation. This study was also funded by a grant from the University of Washington Department of Epidemiology. NR 35 TC 6 Z9 7 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAR PY 2012 VL 119 IS 3 BP 566 EP 574 DI 10.1097/AOG.0b013e3182475ac2 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 897GY UT WOS:000300637400012 PM 22353955 ER PT J AU Adeseun, GA Bonney, CC Rosas, SE AF Adeseun, Gbemisola A. Bonney, Christine C. Rosas, Sylvia E. TI Health Literacy Associated With Blood Pressre but not Other Cardiovascular Disease Risk Factors Among Dialysis Patients SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; cardiovascular disease; end-stage renal disease; health literacy; hemodialysis; hypertension; peritoneal dialysis ID BODY-MASS INDEX; HEMODIALYSIS-PATIENTS; ALL-CAUSE; MORTALITY; HYPERTENSION; KNOWLEDGE; CKD; PREVALENCE; CHOLESTEROL; SURVIVAL AB BACKGROUND Limited health literacy is prevalent and has been linked to adverse patient outcomes. We examined the relationship between health literacy and cardiovascular disease (CVD) risk factors, including blood pressure (BP) parameters, lipids, waist-to-hip ratio (WHR), body mass index (BMI), and tobacco utilization among dialysis patients. METHODS We conducted a cross-sectional study of 72 participants in a prospective cohort study of vascular calcification in newly initiated dialysis patients. Health literacy was assessed using the Short Test of Functional Health Literacy (S-TOFHLA) in Adults. The study population was dichotomized into those with and without adequate literacy. Linear and logistic regression analyses were used to predict continuous and dichotomous cardiovascular risk factor variables, respectively. RESULTS Twenty-one percent had limited health literacy. Compared to limited health literacy, adequate health literacy was associated with lower BP parameters in multivariable analyses (systolic blood pressure (SBP): beta-16.8, s.e. 6.7, P = 0.01; diastolic blood pressure (DBP):beta-13.8, s.e. 4.1, P = 0.001; mean arterial pressure (MAP):beta-14.8, s.e. 4.6, P = 0.002). Health literacy was not a statistically significant predictor of low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, WHR, BMI, or tobacco utilization. CONCLUSIONS Limited health literacy is common in individuals on dialysis. Individuals with adequate health literacy skills had DBP readings that were on average 13.8 mm Hg lower and MAP that was 14.8 mm Hg lower than those with inadequate health literacy. Prospective studies to elucidate if improvements in health literacy skills will lead to improvement in BP control are needed. C1 [Adeseun, Gbemisola A.; Bonney, Christine C.; Rosas, Sylvia E.] Univ Penn, Dept Med, Div Renal Electrolyte & Hypertens, Philadelphia, PA 19104 USA. [Rosas, Sylvia E.] Philadelphia Vet Adm Med Ctr, Dept Med, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Rosas, SE (reprint author), Univ Penn, Dept Med, Div Renal Electrolyte & Hypertens, Philadelphia, PA 19104 USA. EM sylvia.rosas@uphs.upenn.edu RI Rosas, Sylvia/D-1106-2009 FU NIH [R21 HL 086971]; Veterans Health Administration; National Center for Research Resources [UL1RR024134]; [R01 DK 080033] FX This work was supported by NIH grants R21 HL 086971. Salary support was provided by the Veterans Health Administration and R01 DK 080033 (Dr Rosas). The project described was supported by Grant Number UL1RR024134 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Funding sources had no involvement in study design, data collection, analysis, and interpretation, writing of the report, or decision to submit the paper for publication. NR 38 TC 14 Z9 14 U1 0 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD MAR PY 2012 VL 25 IS 3 BP 348 EP 353 DI 10.1038/ajh.2011.252 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 893VN UT WOS:000300385900013 PM 22237154 ER PT J AU LaVela, SL Gering, J Schectman, G Weaver, FM AF LaVela, Sherri L. Gering, Jeffrey Schectman, Gordon Weaver, Frances M. TI Optimizing Primary Care Telephone Access and Patient Satisfaction SO EVALUATION & THE HEALTH PROFESSIONS LA English DT Article DE access to care; patient satisfaction; patient-centered care; quality improvement; telephone medicine ID CONSULTATION; SERVICES; TRIAGE AB Telephone medicine is often preferred by patients to meet primary care needs and may be associated with high patient satisfaction. This article presents findings about incoming patient calls to primary care for medically based reasons during office hours and reports factors independently associated with telephone encounter satisfaction, considering patient characteristics, call reasons, and staff responsiveness, for a national cohort of primary care users. Interviews were conducted with patients from 18 nationwide primary care clinics during the fall of 2009. Calling for an urgent medical issue was associated with dissatisfaction. Odds of call satisfaction were greater when patients thought staff was friendly (10x), call answer was timely (5x), and needed medical information was provided (7x). These findings can be used for interventions to optimize telephone access and patient satisfaction which is beneficial because satisfactory telephone encounters reduce primary care use and satisfied patients are more likely to be engaged in their health care. C1 [LaVela, Sherri L.; Weaver, Frances M.] US Dept Vet Affairs, Ctr Management Complex Chron Care, Edward Hines Jr VA Hosp, Hines, IL 60141 USA. [LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA. [Gering, Jeffrey] Chillicothe Vet Affairs Med Ctr, Chillicothe, OH 45601 USA. [Gering, Jeffrey] Ohio Univ, Chillicothe, OH USA. [Schectman, Gordon] Vet Affairs Cent Off, Off Patient Care Serv, Washington, DC USA. [Schectman, Gordon] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Program Hlth Serv Res, Maywood, IL 60153 USA. RP LaVela, SL (reprint author), US Dept Vet Affairs, Ctr Management Complex Chron Care, Edward Hines Jr VA Hosp, 5000 S 5th Ave,151-H, Hines, IL 60141 USA. EM sherri.lavela@va.gov FU Office of Systems Redesign of the Department of Veterans Affairs FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This material is based upon work supported by the Office of Systems Redesign of the Department of Veterans Affairs. This paper reflects only the authors' opinions and does not necessarily reflect the official position of the Department of Veterans Affairs. NR 19 TC 8 Z9 8 U1 0 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0163-2787 J9 EVAL HEALTH PROF JI Eval. Health Prof. PD MAR PY 2012 VL 35 IS 1 BP 77 EP 86 DI 10.1177/0163278711411479 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 894HJ UT WOS:000300417400005 PM 21685222 ER PT J AU Palevsky, PM AF Palevsky, Paul M. TI Chronic-on-acute kidney injury SO KIDNEY INTERNATIONAL LA English DT Editorial Material ID ACUTE-RENAL-FAILURE; DIALYSIS; DISEASE AB Although older teaching suggested that patients who survived an episode of acute kidney injury (AKI) had a benign course, recent studies have demonstrated that AKI is strongly associated with increased risk for development of progressive chronic kidney disease (CKD) and longer-term mortality. Much as we understand that CKD predisposes to the development of AKI, we must recognize that the relationship is bidirectional and that our patients with AKI are at risk for chronic-on-acute kidney disease. Kidney International (2012) 81, 430-431. doi:10.1038/ki.2011.435 C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 10 TC 15 Z9 16 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD MAR PY 2012 VL 81 IS 5 BP 430 EP 431 DI 10.1038/ki.2011.435 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 893SY UT WOS:000300377000002 PM 22333743 ER PT J AU Anderson, RM Weindruch, R AF Anderson, Rozalyn M. Weindruch, Richard TI The caloric restriction paradigm: Implications for healthy human aging SO AMERICAN JOURNAL OF HUMAN BIOLOGY LA English DT Article ID GENE-EXPRESSION PROFILE; RANDOMIZED CONTROLLED-TRIAL; TERM DIETARY RESTRICTION; RHESUS-MONKEYS; LIFE-SPAN; ADIPOSE-TISSUE; METABOLIC-DISORDERS; ENERGY-INTAKE; MITOCHONDRIAL BIOGENESIS; SKELETAL-MUSCLE AB Underlying the importance of research on the biology of aging is the fact that many nations face the demographic reality of a rapidly aging populace and the looming healthcare challenges that it brings. This reality is a result of aging itself being the most significant risk factor for a range of the most prevalent diseases, including many cancers, cardiovascular disease, and diabetes. Accordingly, interventions are sorely needed that would be able to delay or prevent diseases and disorders associated with the aging process and thereby increase the period of time that aging individuals are in good health (the health-span). Caloric restriction (CR) has emerged as a model of major interest as it is widely agreed that CR is the most potent environmental intervention that delays the onset of aging and extends life span in diverse experimental organisms. A better understanding of the mechanisms by which CR delays aging will reveal new insights into the aging process and the underlying causes of disease vulnerability with age. These novel insights will allow the development of novel treatments and preventive measures for age-associated diseases and disorders. Am. J. Hum. Biol. 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Anderson, Rozalyn M.; Weindruch, Richard] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Anderson, Rozalyn M.; Weindruch, Richard] William S Middleton Mem Vet Adm Med Ctr, Geriatr Educ Res & Clin Ctr, Madison, WI USA. RP Anderson, RM (reprint author), Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA. EM rmanderson@medicine.wisc.edu FU NIH [NIA P01AG11915, R01AG037000]; NCRR/CTSA [UL1RR025011] FX Contract grant sponsor: NIH; Contract grant numbers: NIA P01AG11915, R01AG037000, and NCRR/CTSA UL1RR025011. NR 66 TC 57 Z9 59 U1 1 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1042-0533 J9 AM J HUM BIOL JI Am. J. Hum. Biol. PD MAR-APR PY 2012 VL 24 IS 2 BP 101 EP 106 DI 10.1002/ajhb.22243 PG 6 WC Anthropology; Biology SC Anthropology; Life Sciences & Biomedicine - Other Topics GA 888IQ UT WOS:000299997500001 PM 22290875 ER PT J AU Larauche, M AF Larauche, M. TI Novel insights in the role of peripheral corticotropin-releasing factor and mast cells in stress-induced visceral hypersensitivity SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE mast cells; peripheral corticotropin releasing factor; stress-induced visceral hypersensitivity ID IRRITABLE-BOWEL-SYNDROME; COLONIC EPITHELIAL BARRIER; FACTOR SIGNALING PATHWAYS; LIGHT-CHAIN KINASE; PSYCHOLOGICAL STRESS; MATERNAL-DEPRIVATION; IBS PATIENTS; GASTROINTESTINAL-TRACT; RECTAL DISTENSION; PROTEASE ACTIVITY AB Visceral hypersensitivity is one of the hallmarks in irritable bowel syndrome (IBS) pathophysiology. Stress is well known to affect visceral sensitivity in humans and rodents, an effect which is associated in part with alterations of intestinal epithelial permeability in rodents. Although the pathophysiology of visceral hypersensitivity is still unclear, two key factors have been identified as playing a major role in its modulation, namely peripheral corticotropin-releasing factor (CRF) and mast cells. In a recent study in Neurogastroenterology and Motility, van den Wijngaard etal. demonstrate that the mast-cell dependent visceral hypersensitivity observed in maternally separated rats after an acute exposure to a psychological stress can be prevented but not reversed by the peripherally restricted CRF receptor antagonist, a-helical CRF941. They further show that the preventive effect of the CRF receptor antagonist is linked to a stabilization of mast cells and maintenance of the epithelial barrier at the colonic level. These data suggest that post stress mast cell activation and subsequent visceral hypersensitivity are not targeted by peripheral CRF receptor antagonists. These novel insights in the role of peripheral CRF in the modulation of stress-induced visceral hypersensitivity add to our growing understanding of the mechanisms that may lie at the origin of visceral pain disturbances following stress and will contribute to enhance the development of drugs that may have potential therapeutic benefits for IBS patients. C1 [Larauche, M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Oppenheimer Family Ctr Neurobiol Stress,Dept Med, Los Angeles, CA 90073 USA. [Larauche, M.] VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA USA. RP Larauche, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Oppenheimer Family Ctr Neurobiol Stress,Dept Med, Los Angeles, CA 90073 USA. EM mlarauche@mednet.ucla.edu OI Larauche, Muriel/0000-0003-3320-3675 NR 53 TC 15 Z9 17 U1 0 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1350-1925 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD MAR PY 2012 VL 24 IS 3 BP 201 EP 205 DI 10.1111/j.1365-2982.2011.01867.x PG 5 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 888JX UT WOS:000300000900006 PM 22316289 ER PT J AU Benson, A Maust, DT Tanh, D Mavandadi, S Streim, JE DiFilippo, S Oslin, D AF Benson, Amy Maust, Donovan T. Tanh, Daniel Mavandadi, Shahrzad Streim, Joel E. DiFilippo, Suzanne Oslin, David TI Self-reported Reasons for New Psychotropic Medications in Asymptomatic Older Adults SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Benson, Amy; Maust, Donovan T.; Tanh, Daniel; Mavandadi, Shahrzad; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Mavandadi, Shahrzad; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA USA. FU Pennsylvania Department of Aging, PACE Program FX This research was funded by: Funded by the Pennsylvania Department of Aging, PACE Program. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA EI 48 BP S95 EP S95 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500098 ER PT J AU Cohen, CI Kasckow, J Vahia, I Jeste, DV AF Cohen, Carl I. Kasckow, John Vahia, Ipsit Jeste, Dilip V. TI NEW RESEARCH ADVANCES IN LATE LIFE SCHIZOPHRENIA SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Cohen, Carl I.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Vahia, Ipsit; Jeste, Dilip V.] Univ Calif San Diego, San Diego, CA USA. FU Astra Zeneca FX John Kasckow, MD, PhD; Research Support: Astra Zeneca NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA 307 BP S31 EP S31 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500031 ER PT J AU Kasckow, J Golshan, S Zisook, S AF Kasckow, John Golshan, Shahrokh Zisook, Sidney TI Subsyndromal Depressive Symptoms in Middle Aged and Older Patients with Schizophrenia: Relationship to Suicidal Ideation SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Golshan, Shahrokh; Zisook, Sidney] Univ Calif San Diego, San Diego, CA 92103 USA. FU VISN 4; 22 MIRECC; [MH6398] FX This research was funded by: Supported by MH6398 (SZ, JWK), the VISN 4 and 22 MIRECC. The contents do not represent the views of the Dept of Veterans Affairs of the US government. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA NR 1 BP S121 EP S121 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500126 ER PT J AU Maust, DT Benson, A Mavandadi, S Streim, JE Glasenberg, J DiFilippo, S Oslin, D AF Maust, Donovan T. Benson, Amy Mavandadi, Shahrzad Streim, Joel E. Glasenberg, Jenna DiFilippo, Suzanne Oslin, David TI Who Gets Prescribed Antipsychotic Monotherapy versus Combination Therapy with an Antidepressant in a Community Sample of Older Persons? SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Maust, Donovan T.; Benson, Amy; Mavandadi, Shahrzad; Streim, Joel E.; Glasenberg, Jenna; DiFilippo, Suzanne; Oslin, David] Univ Penn, Philadelphia, PA 19104 USA. [Mavandadi, Shahrzad; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David] Philadelphia VA Med Ctr, Philadelphia, PA USA. FU PACE Program, Pennsylvania Department of Aging, Harrisburg, PA FX This research was funded by: PACE Program, Pennsylvania Department of Aging, Harrisburg, PA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA EI 49 BP S96 EP S97 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500099 ER PT J AU Mavandadi, S Benson, A Tanh, D DiFilippo, S Streim, JE Oslin, D AF Mavandadi, Shahrzad Benson, Amy Tanh, Daniel DiFilippo, Suzanne Streim, Joel E. Oslin, David TI The Association between Caregiver Burden and Neuropsychiatric Symptom Severity among Community-Dwelling Older Adults with Dementia SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Mavandadi, Shahrzad; DiFilippo, Suzanne; Streim, Joel E.; Oslin, David] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Mavandadi, Shahrzad; Benson, Amy; Tanh, Daniel; DiFilippo, Suzanne; Streim, Joel E.; Oslin, David] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA NR 27 BP S142 EP S143 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500152 ER PT J AU Melrose, RJ Harwood, DG Khoo, T Mandelkern, MA Sultzer, D AF Melrose, Rebecca J. Harwood, Dylan G. Khoo, Theresa Mandelkern, Mark A. Sultzer, David TI The association between regional cerebral metabolism and visuoconstructive skills in probable Alzheimer's Disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Melrose, Rebecca J.; Harwood, Dylan G.; Khoo, Theresa; Sultzer, David] VA Greater Los Angeles Healthcare Syst, Brain Behav & Aging Res Ctr, Los Angeles, CA USA. [Melrose, Rebecca J.; Harwood, Dylan G.; Sultzer, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Nucl Med Serv, Los Angeles, CA USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. FU Dept. of Veterans Affairs FX This research was funded by: Supported by the Dept. of Veterans Affairs (Career Development Award to R. Melrose; Office of R&D Merit Review) NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA EI 39 BP S88 EP S89 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500089 ER PT J AU Metti, AL Cauley, JA Newman, AB Ayonayon, H Barry, LC Kuller, LM Satterfield, S Simonsick, EM Yaffe, K AF Metti, Andrea L. Cauley, Jane A. Newman, Anne B. Ayonayon, Hilsa Barry, Lisa C. Kuller, Lewis M. Satterfield, Suzanne Simonsick, Eleanor M. Yaffe, Kristine TI Plasma Beta Amyloid Level and Depression in Older Adults SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Metti, Andrea L.; Cauley, Jane A.; Newman, Anne B.; Kuller, Lewis M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Ayonayon, Hilsa; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Barry, Lisa C.] Yale Univ, Sch Med, New Haven, CT USA. [Satterfield, Suzanne] Univ Tennessee Memphis, Memphis, TN USA. [Simonsick, Eleanor M.] NIA, Clin Res Branch, Baltimore, MD 21224 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. FU National Institute of Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050, 2T32AG000181]; NINR [R01-NR012459]; Intramural Research Program on the NIH, National Institute of Aging FX This research was funded by: This research was supported by National Institute of Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, and NINR grant R01-NR012459. This research was supported in part by the Intramural Research Program on the NIH, National Institute of Aging. Andrea Metti is supported by NIA Training Grant 2T32AG000181. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA EI 66 BP S109 EP S110 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500114 ER PT J AU Murray, PS Kirkwood, CM Gray, MC Ikonomovic, MD Paljug, WR Abrahamson, EE Hamilton, RL Kofler, JK Klunk, WE Lopez, OL Penzes, P Sweet, RA AF Murray, Patrick S. Kirkwood, Caitlin M. Gray, Megan C. Ikonomovic, Milos D. Paljug, William R. Abrahamson, Eric E. Hamilton, Ronald L. Kofler, Julia K. Klunk, William E. Lopez, Oscar L. Penzes, Peter Sweet, Robert A. TI Increased ratio of beta-amyloid 42/40 and reduced Kalirin expression in prefrontal cortex in Alzheimer disease with psychosis SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Murray, Patrick S.; Ikonomovic, Milos D.; Paljug, William R.; Abrahamson, Eric E.; Hamilton, Ronald L.; Kofler, Julia K.; Klunk, William E.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Kirkwood, Caitlin M.; Gray, Megan C.] Univ Pittsburgh, Pittsburgh, PA USA. [Murray, Patrick S.; Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. FU Veterans Health Administration [5I01BX000452]; National Institute on Aging [5P50AG005133, 5R01AG027224]; National Institute of Mental Health [5T32MH019986] FX This research was funded by: Supported by Grants 5I01BX000452 from the Veterans Health Administration and by 5P50AG005133 and 5R01AG027224 from the National Institute on Aging. Patrick Murray is supported by 5T32MH019986 from the National Institute of Mental Health. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA EI 40 BP S89 EP S90 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500090 ER PT J AU Okereke, O Hoang, T Qiu, W Byers, AL AF Okereke, Olivia Hoang, Tina Qiu, Wendy (Wei Qiao) Byers, Amy L. TI LIFESTYLE FACTORS AND TRAJECTORIES OF LATE-LIFE MENTAL HEALTH SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Okereke, Olivia] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA. [Byers, Amy L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hoang, Tina; Byers, Amy L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Qiu, Wendy (Wei Qiao)] Boston Univ, Sch Med, Boston, MA 02118 USA. [Okereke, Olivia] Harvard Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA 320 BP S39 EP S39 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500042 ER PT J AU Park, M Huang, DL AF Park, Mijung Huang, Deborah L. TI More Variety In Sources of Social Support is Better for Late-Life Depression Outcome SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Park, Mijung; Huang, Deborah L.] Univ Washington, Seattle, WA 98195 USA. [Huang, Deborah L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. FU Geriatric Mental Health Research Fellowship [NIMH 2 T32 MH 73553-6]; VA Advanced Fellowship in Geriatrics, VA Puget Sound Health Care System, Seattle, Washington FX This research was funded by: Dr. Park is supported by Geriatric Mental Health Research Fellowship (NIMH 2 T32 MH 73553-6). Dr. Huang is supported by VA Advanced Fellowship in Geriatrics, VA Puget Sound Health Care System, Seattle, Washington. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA EI 13 BP S68 EP S69 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500063 ER PT J AU Streim, JE DiFilippo, S TenHave, T Mavandadi, S Weintraub, D Oslin, D AF Streim, Joel E. DiFilippo, Suzanne TenHave, Thomas Mavandadi, Shahrzad Weintraub, Daniel Oslin, David TI Antidepressant Discontinuation Associated with Cognitive Decline in Older Adult Residents of Long-term Care Facilities SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Streim, Joel E.; DiFilippo, Suzanne; Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA. [TenHave, Thomas] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Streim, Joel E.; DiFilippo, Suzanne; Mavandadi, Shahrzad; Weintraub, Daniel; Oslin, David] Dept Vet Affairs Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Philadelphia, PA 19104 USA. [Oslin, David] Univ Penn, Dept Psychiat, Perelman Sch Med, Treatment Res Ctr, Philadelphia, PA 19104 USA. FU National Institute for Mental Health [R01 MH051247-13]; Department of Veterans Affairs (VA) VISN 4 Mental Illness Research Education and Clinical Center (MIRECC) FX This research was funded by: This work was supported by the National Institute for Mental Health (grant no. R01 MH051247-13) and partially supported by the Department of Veterans Affairs (VA) VISN 4 Mental Illness Research Education and Clinical Center (MIRECC) NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA NR 34 BP S147 EP S148 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500159 ER PT J AU Sultzer, D Leskin, LS Melrose, RJ Harwood, DG Narvaez, T Ando, T Walston, A Bussel, N Mandelkern, MA AF Sultzer, David Leskin, Lorraine S. Melrose, Rebecca J. Harwood, Dylan G. Narvaez, Theresa Ando, Timothy Walston, Amy Bussel, Natalya Mandelkern, Mark A. TI Delusions, memory, and insight in Alzheimer's disease: clinical associations and relationships with FDG-PET cortical metabolic activity SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract C1 [Sultzer, David; Leskin, Lorraine S.; Melrose, Rebecca J.; Harwood, Dylan G.; Narvaez, Theresa; Ando, Timothy; Walston, Amy; Bussel, Natalya; Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sultzer, David; Melrose, Rebecca J.; Harwood, Dylan G.; Walston, Amy] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA USA. [Mandelkern, Mark A.] UC Irvine, Dept Phys, Irvine, CA USA. FU NIMH; Department of Veterans Affairs FX This research was funded by: Supported in part by the NIMH and the Department of Veterans Affairs NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA NR 25 BP S140 EP S141 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500150 ER PT J AU Valdez, K Brown, GK Johnson, JC Oslin, D AF Valdez, Karen Brown, Gregory K. Johnson, Jerry C. Oslin, David TI Comparison of Two Screening Instruments in the Detection of Suicidal Ideation in Older Primary Care Veterans: Paykel Questionnaire and Patient Health Questionnaire-9 SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Valdez, Karen; Brown, Gregory K.; Oslin, David] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Johnson, Jerry C.] Univ Penn, Dept Geriatr Med, Philadelphia, PA 19104 USA. [Oslin, David] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Oslin, David] VISN 4 Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA. FU Philadelphia Veterans Affairs Medical Center; VISN 4 Mental Illness Research, Education, and Clinical Center (MIRECC) FX This research was funded by: Poster funding by Philadelphia Veterans Affairs Medical Center and the VISN 4 Mental Illness Research, Education, and Clinical Center (MIRECC) NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA EI 16 BP S70 EP S71 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500066 ER PT J AU Wang, S Luo, XD Barnes, D Sano, M Yaffe, K AF Wang, Sophia Luo, Xiaodong Barnes, Deborah Sano, Mary Yaffe, Kristine TI The Effects of Late Life Physical Activity on Cognition over 20 Years in Oldest Old Women SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Wang, Sophia; Sano, Mary] James J Peters VA, Bronx, NY USA. [Wang, Sophia; Luo, Xiaodong; Sano, Mary] Mt Sinai Sch Med, New York, NY USA. [Barnes, Deborah; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Barnes, Deborah; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. FU NIA; Alzheimer's Association; University of California, San Francisco, School of Medicine; NIA [K24 AG 031155]; National Institutes of Health [AG05407, AR35582, AG05394, AR35584, AR35583, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, 2 R01 AG027574-22A1, 5 R01AG026720-04] FX This research was funded by: SW is a VA Neurosciences Research Fellow. XL is supported by a NIA funded ADRC grant. DB is supported by the Alzheimer's Association and the University of California, San Francisco, School of Medicine. MS is supported by a NIA funded ADRC grant and CTSA grant. KY is supported by a NIA grant K24 AG 031155 and an Independent Investigator Award from the Alzheimer's Association. The Study of Osteoporotic Fractures (SOF) and the SOF-WISE are supported by grants AG05407, AR35582, AG05394, AR35584, AR35583, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, 2 R01 AG027574-22A1, and 5 R01AG026720-04 from the National Institutes of Health. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA EI 69 BP S112 EP S112 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500117 ER PT J AU Wu, P Read, S Biscow, M AF Wu, Pauline Read, Stephen Biscow, Mark TI Sustained Cognitive Benefit in Mild Alzheimer's Disease with Pioglitazone - Case Report of a 4.5 Year Treatment Trial SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of American-Association-for-Geriatric-Psychiatry CY MAR 16-19, 2012 CL Washington, DC C1 [Wu, Pauline; Read, Stephen] Univ Calif Los Angeles, Los Angeles, CA USA. [Wu, Pauline; Read, Stephen] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Biscow, Mark] St Johns Hlth Ctr, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2012 VL 20 IS 3 SU 1 MA EI 41 BP S90 EP S90 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA V45WK UT WOS:000209846500091 ER PT J AU Serrano, NA Trenite, GN Yueh, B Farwell, G Futran, ND Mendez, E AF Serrano, Nicholas A. Trenite, Gilean N. Yueh, Bevan Farwell, Gregory Futran, Neal D. Mendez, Eduardo TI Risk Factors Associated With Repair of Orbital and Lateral Skull Defects SO ARCHIVES OF FACIAL PLASTIC SURGERY LA English DT Article ID FREE-FLAP RECONSTRUCTION; MYOCUTANEOUS FREE-FLAP; FREE-TISSUE TRANSFER; MICROVASCULAR RECONSTRUCTION; CLASSIFICATION-SYSTEM; BASE RECONSTRUCTION; MIDFACIAL DEFECTS; EXENTERATION; NECK; HEAD AB Objective: To explore the complications and associated risks factors after orbital exenteration and lateral skull base defect repair. Methods: Patients who had undergone a reconstruction of their orbital cavity and lateral skull base defects were selected from our departmental database. The outcome of interest was postoperative complications. The risks factors were defined as age, sex, history of radiation therapy, and intracranial involvement (with and without dural involvement). Information was collected on the type of reconstruction used after the orbital cavity repair. The chi(2) test and logistic regression were used to analyze associations between postoperative complications and the various risks factors. Results: Of the 32 identified patients, 19 had intracranial involvement (9 with dural involvement). Twenty-four patients underwent reconstruction with free tissue transfer in the same setting. Reconstruction with free tissue transfer was significantly associated with fewer major postoperative complications (P < .053). There was a trend toward more complications with a history of radiation therapy or intracranial involvement. Conclusions: Reconstruction of the orbital cavity and lateral skull base can be challenging, especially if there is a history of radiation therapy and intracranial involvement. Free tissue transfer is a safe and effective method for reconstruction of such defects. C1 [Mendez, Eduardo] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98104 USA. [Mendez, Eduardo] Vet Affairs Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. [Serrano, Nicholas A.] Univ Washington, Sch Med, Seattle, WA USA. [Trenite, Gilean N.] Onze Lieve Vrouw Hosp, Dept Surg, Amsterdam, Netherlands. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. [Farwell, Gregory] Univ Calif Davis, Sacramento, CA 95817 USA. RP Mendez, E (reprint author), Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Dept Otolaryngol Head & Neck Surg, 1959 NE Pacific St,Mailbox 356515, Seattle, WA 98195 USA. EM edmendez@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053 NR 25 TC 4 Z9 4 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1521-2491 J9 ARCH FACIAL PLAST S JI Arch. Facial Plast. Surg. PD MAR-APR PY 2012 VL 14 IS 2 BP 97 EP 103 DI 10.1001/archfacial.2011.1301 PG 7 WC Surgery SC Surgery GA 914LI UT WOS:000301951100005 PM 22183060 ER PT J AU Au, DH Udris, EM Engelberg, RA Diehr, PH Bryson, CL Reinke, LE Curtis, JR AF Au, David H. Udris, Edmunds M. Engelberg, Ruth A. Diehr, Paula H. Bryson, Christopher L. Reinke, Lynn E. Curtis, J. Randall TI A Randomized Trial to Improve Communication About End-of-Life Care Among Patients With COPD SO CHEST LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; ADVANCE DIRECTIVE EDUCATION; LUNG-CANCER; PALLIATIVE CARE; HEALTH; REHABILITATION; EFFICACY; QUALITY; DEATH; QUESTIONNAIRE AB Objective: Patients with COPD consistently express a desire to discuss end-of-life care with clinicians, but these discussions rarely occur. We assessed whether an intervention using patient-specific feedback about preferences for discussing end-of-life care would improve the occurrence and quality of communication between patients with COPD and their clinicians. Methods: We performed a cluster-randomized trial of clinicians and patients from the outpatient clinics at the Veterans Affairs Puget Sound Health Care System. Using self-reported questionnaires, we assessed patients' preferences for communication, life-sustaining therapy, and experiences at the end of life. The intervention clinicians and patients received a one-page patient-specific feedback form, based on questionnaire responses, to stimulate conversations. The control group completed questionnaires but did not receive feedback. Patient-reported occurrence and quality of end-of-life communication (QOC) were assessed within 2 weeks of a targeted visit. Intention-to-treat regression analyses were performed with generalized estimating equations to account for clustering of patients within clinicians. Results: Ninety-two clinicians contributed 376 patients. Patients in the intervention arm reported nearly a threefold higher rate of discussions about end-of-life care (unadjusted, 30% vs 11%; P<.001). Baseline end-of-life communication was poor (intervention group QOC score, 23.3; 95% CI, 19.9-26.8; control QOC score, 19.2; 95% CI, 15.9-22.4). Patients in the intervention arm reported higher-quality end-of-life communication that was statistically significant, although the overall improvement was small (Cohen effect size, 0.21). Conclusions: A one-page patient-specific feedback form about preferences for end-of-life care and communication improved the occurrence and quality of communication from patients' perspectives. Trial Registry: ClinicalTrials.gov; No.: NCT00106080; URL: www.clinicaltrials.gov CHEST 2012; 141(3):726-735 C1 [Au, David H.; Udris, Edmunds M.; Bryson, Christopher L.; Reinke, Lynn E.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Au, David H.; Engelberg, Ruth A.; Bryson, Christopher L.; Curtis, J. Randall] Univ Washington, Dept Med, Seattle, WA USA. [Diehr, Paula H.] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA. [Diehr, Paula H.] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. RP Au, DH (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM David.Au@VA.gov FU Department of Veterans Affairs [IIR-02-292]; Veterans Affairs Health Services Research and Development Career Development Award; National Heart Lung and Blood Institute [K24 HL068593] FX This study was funded by the Department of Veterans Affairs [Grant IIR-02-292]. Dr Au was funded during the trial period by a Veterans Affairs Health Services Research and Development Career Development Award. Dr Curtis was funded by a K24 Award from that National Heart Lung and Blood Institute [Grant K24 HL068593]. NR 29 TC 40 Z9 40 U1 2 U2 8 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD MAR PY 2012 VL 141 IS 3 BP 726 EP 735 DI 10.1378/chest.11-0362 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 120KO UT WOS:000317169400025 PM 21940765 ER PT J AU Dillon, AR Dell'Italia, LJ Tillson, M Killingsworth, C Denney, T Hathcock, J Botzman, L AF Dillon, A. Ray Dell'Italia, Louis J. Tillson, Michael Killingsworth, Cheryl Denney, Thomas Hathcock, John Botzman, Logan TI Left ventricular remodeling in preclinical experimental mitral regurgitation of dogs SO JOURNAL OF VETERINARY CARDIOLOGY LA English DT Review DE Cardiac remodeling; Volume overload; Extracellular matrix AB Dogs with experimental mitral regurgitation (MR) provide insights into the left ventricular remodeling in preclinical MR. The early preclinical left ventricular (LV) changes after mitral regurgitation represent progressive dysfunctional remodeling, in that no compensatory response returns the functional stroke volume (SV) to normal even as total SV increases. The gradual disease progression leads to mitral annulus stretch and enlargement of the regurgitant orifice, further increasing the regurgitant volume. Remodeling with loss of collagen weave and extracellular matrix (ECM) is accompanied by stretching and hypertrophy of the cross-sectional area and length of the cardiomyocyte. Isolated ventricular cardiomyocytes demonstrate dysfunction based on decreased cell shortening and reduced intracellular calcium transients before chamber enlargement or decreases in contractility in the whole heart can be clinically appreciated. The genetic response to increased end-diastolic pressure is down-regulation of genes associated with support of the collagen and ECM and up-regulation of genes associated with matrix remodeling. Experiments have not demonstrated any beneficial effects on remodeling from treatments that decrease afterload via blocking the renin-angiotensin system (RAS). Beta-1 receptor blockade and chymase inhibition have altered the progression of the LV remodeling and have supported cardiomyocyte function. The geometry of the LV during the remodeling provides insight into the importance of regional differences in responses to wall stress. (C) 2012 Elsevier B.V. All rights reserved. C1 [Dillon, A. Ray; Tillson, Michael; Hathcock, John; Botzman, Logan] Auburn Univ, Coll Vet Med, Auburn, AL 36849 USA. [Dell'Italia, Louis J.; Killingsworth, Cheryl] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Dell'Italia, Louis J.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Denney, Thomas] Auburn Univ, Coll Engn, Auburn, AL 36849 USA. [Denney, Thomas] Auburn Univ, MRI Ctr, Auburn, AL 36849 USA. RP Dillon, AR (reprint author), Auburn Univ, Coll Vet Med, Auburn, AL 36849 USA. EM dilloar@auburn.edu NR 43 TC 9 Z9 11 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1760-2734 EI 1875-0834 J9 J VET CARDIOL JI J. Vet. Cardiol. PD MAR PY 2012 VL 14 IS 1 BP 73 EP 92 DI 10.1016/j.jvc.2012.01.012 PG 20 WC Veterinary Sciences SC Veterinary Sciences GA V31VG UT WOS:000208910500008 PM 22386719 ER PT J AU Morone, NE Lynch, CP Losasso, VJ Liebe, K Greco, CM AF Morone, Natalia E. Lynch, Cheryl P. Losasso, Vincent J., III Liebe, Karl Greco, Carol M. TI Mindfulness to Reduce Psychosocial Stress SO MINDFULNESS LA English DT Article DE Psychosocial stress; Mindfulness; Meditation; Qualitative AB While the adverse impact of stress on health states has been established, effective stress reduction programs are largely underused in clinical settings. In an area with little published information, this study identifies themes that describe the process of applying mindfulness methods to cope with psychosocial stressors in participants of the Mindfulness-Based Stress Reduction (MBSR) program. The study design is a qualitative investigation with a phenomenological approach using participant feedback from 11 MBSR 8-week programs. Participants were 74 adults from the greater Pittsburgh area. Content analysis was used to inductively generate thematic categories. Four themes were identified that described the process and results of learning mindfulness to adapt to psychosocial stressors. We categorized participants' feedback into interrelated themes of awareness (subdivided into self-discovery-" step back from my thoughts in order to view them more clearly", and being in the present), coping-" pause, take a breath", serenity-" increased feeling of calm, centeredness", and change in perspective-" different understanding interpersonally and intrapersonally." In addition, a brief section describes specific health benefits identified by participants. Participants found the mindfulness-based approach effective for stress reduction. The learning process allowed them to routinely apply mindfulness strategies that provided multiple benefits. C1 [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Morone, Natalia E.] Univ Pittsburgh, Translat Sci Inst, Pittsburgh, PA 15213 USA. [Morone, Natalia E.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Lynch, Cheryl P.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC USA. [Lynch, Cheryl P.] Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA. [Losasso, Vincent J., III] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Liebe, Karl] HealthSouth Harmarville Rehabil Hosp, Dept Med Phys & Rehabil, Pittsburgh, PA USA. [Greco, Carol M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. RP Morone, NE (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. EM moronene@upmc.edu NR 21 TC 4 Z9 5 U1 0 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1868-8527 EI 1868-8535 J9 MINDFULNESS JI Mindfulness PD MAR PY 2012 VL 3 IS 1 BP 22 EP 29 DI 10.1007/s12671-011-0076-z PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V33HM UT WOS:000209009900004 ER PT J AU Chattergoon, NN Louey, S Giraud, GD Thornburg, KL AF Chattergoon, Natasha N. Louey, Samantha Giraud, George D. Thornburg, Kent L. TI Myocardial Thyroid Hormone Deiodinases Are Regulated by Fetal T-3. SO REPRODUCTIVE SCIENCES LA English DT Meeting Abstract C1 [Chattergoon, Natasha N.; Louey, Samantha; Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97201 USA. [Louey, Samantha; Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Giraud, George D.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 EI 1933-7205 J9 REPROD SCI JI Reprod. Sci. PD MAR PY 2012 VL 19 IS S3 SU 3 BP 252A EP 252A PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 287LP UT WOS:000329543602219 ER PT J AU Oshima, M Deitiker, PR Smith, RG Mosier, D Atassi, MZ AF Oshima, Minako Deitiker, Philip R. Smith, R. Glenn Mosier, Dennis Atassi, M. Zouhair TI T-cell recognition of acetylcholine receptor provides a reliable means for monitoring autoimmunity to acetylcholine receptor in antibody-negative myasthenia gravis patients SO AUTOIMMUNITY LA English DT Article DE Myasthenia gravis; acetylcholine receptor; seronegative; T cells; synthetic peptides ID PERIPHERAL-BLOOD LYMPHOCYTES; HIGH-RESOLUTION; ALPHA-SUBUNIT; IN-VITRO; HLA-DQ; EXTRACELLULAR PART; CHAIN PEPTIDES; UNITED-STATES; ASSOCIATION; DQB1-ASTERISK-0502 AB Myasthenia gravis (MG) is an autoimmune disease usually associated with autoantibodies (auto-Abs) against nicotinic acetylcholine receptor (AChR). Some MG patients appear negative for anti-AChR Abs (seronegative), and a fraction of these have auto-Abs against muscle-specific kinase. The remaining patients, although displaying MG symptoms, show no detectable auto-Abs. We describe here a possible association of a rare human leukocyte antigen (HLA)-DQ type and AChR Ab-negative MG. We also found that the majority of seronegative patients exhibit an anti-AChR autoimmune T lymphocyte response. We investigated the existence of AChR-reactive T cells in peripheral blood lymphocytes from seronegative patients by their proliferative responses against a mixture of 18 overlapping synthetic peptides encompassing the extracellular part of human AChR a-chain. Of the 10 samples, eight exhibited positive T-cell proliferative responses against the peptide mixtures. The proliferative assay was equally efficient using a mixture of eight peptides frequently recognized by MG T cells. This T-cell proliferative assay should provide a reliable method for monitoring seronegative MG patients. C1 [Oshima, Minako; Deitiker, Philip R.; Atassi, M. Zouhair] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA. [Smith, R. Glenn] Univ Texas Med Branch, Dept Neurol, Galveston, TX 77555 USA. [Mosier, Dennis] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Atassi, M. Zouhair] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Mosier, Dennis] ME DeBakey VA Med Ctr, Neurol Serv, Houston, TX 77030 USA. [Mosier, Dennis] ME DeBakey VA Med Ctr, Med Res Serv, Houston, TX 77030 USA. RP Atassi, MZ (reprint author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza,BCM125, Houston, TX 77030 USA. EM matassi@bcm.edu FU Muscular Dystrophy Association; Welch Foundation [Q-0007] FX This study was partly supported by grants from the Muscular Dystrophy Association. The support of the Welch Foundation (Grant Q-0007), due to the award to M.Z. Atassi of the Robert A. Welch Chair of Chemistry, is also gratefully acknowledged. NR 31 TC 6 Z9 9 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0891-6934 J9 AUTOIMMUNITY JI Autoimmunity PD MAR PY 2012 VL 45 IS 2 BP 153 EP 160 DI 10.3109/08916934.2011.611550 PG 8 WC Immunology SC Immunology GA 885AA UT WOS:000299748800005 PM 21985279 ER PT J AU Hardy, DC Ross, JH Schuyler, CA Leite, RS Slate, EH Huang, Y AF Hardy, Douglas C. Ross, Jonathan H. Schuyler, Corinne A. Leite, Renata S. Slate, Elizabeth H. Huang, Yan TI Matrix metalloproteinase-8 expression in periodontal tissues surgically removed from diabetic and non-diabetic patients with periodontal disease SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE diabetes mellitus; gene expression; metalloproteinase-8; periodontal diseases ID GINGIVAL CREVICULAR FLUID; NEUTROPHIL COLLAGENASE ACTIVITY; CHAIR-SIDE TEST; IN-VIVO; MMP-8; INTERLEUKIN-6; LIPOPOLYSACCHARIDE; MELLITUS; OBESITY; CELLS AB Background: Although it is known that periodontal matrix metalloproteinase-8 (MMP-8) expression is associated with periodontal disease, the information concerning the periodontal MMP-8 expression in diabetic patients with periodontal disease is insufficient. Materials and Methods: Periodontal tissue specimens were collected from seven patients without periodontal disease and diabetes (Group 1), 15 patients with periodontal disease alone (Group 2) and 10 patients with both periodontal disease and diabetes (Group 3). The frozen sections were prepared and MMP-8 protein expression was detected using immunohistochemistry and quantified. For in vitro study, human U937 mononuclear cells were pre-exposed to normal or high glucose and then treated with lipopolysaccharide (LPS). Results: The nonparametric Kruskal-Wallis test showed that the difference in MMP-8 protein levels among the three groups were statistically significant (p = 0.003). Nonparametric analysis using Jonckheere-Terpstra test showed a tendency of increase in periodontal MMP-8 levels across Group 1 to Group 2 to Group 3 (p = 0.0002). In vitro studies showed that high glucose and LPS had a synergistic effect on MMP-8 expression. Conclusion: Our current study showed an increasing trend in MMP-8 protein expression levels across patients without both periodontal disease and diabetes, patients with periodontal disease alone and patients with both diseases. C1 [Huang, Yan] Med Univ S Carolina, Dept Med, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. [Hardy, Douglas C.; Ross, Jonathan H.] Med Univ S Carolina, Coll Dent Med, Dept Stomatol, Div Periodont, Charleston, SC 29403 USA. [Leite, Renata S.; Slate, Elizabeth H.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29403 USA. [Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Dept Med, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU NIH [DE016353]; Department of Veterans Affairs FX There is no conflict of interest to declare. This study was supported by NIH grant DE016353 and Merit Review Grant from Department of Veterans Affairs (to Y. H.). NR 40 TC 10 Z9 13 U1 1 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6979 J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD MAR PY 2012 VL 39 IS 3 BP 249 EP 255 DI 10.1111/j.1600-051X.2011.01788.x PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 883LM UT WOS:000299635500005 PM 22092744 ER PT J AU Nordenstedt, H Mattsson, F El-Serag, H Lagergren, J AF Nordenstedt, H. Mattsson, F. El-Serag, H. Lagergren, J. TI Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma SO BRITISH JOURNAL OF CANCER LA English DT Article DE bile duct cancer; biliary tumour; cohort study; gallstones; population-based ID PRIMARY SCLEROSING CHOLANGITIS; UNITED-STATES; BILE-DUCT; INTRAHEPATIC CHOLANGIOCARCINOMA; EPIDEMIOLOGY; CANCER; POPULATION; PANCREAS AB BACKGROUND: Cholangiocarcinomas are highly lethal tumours of the intrahepatic or extrahepatic biliary tract. The aetiology is largely unknown, and the potential roles of gallstones and gall bladder removal (cholecystectomy) need to be addressed in a large study with a long follow-up. METHODS: A population-based nationwide Swedish cohort study was carried out, in which patients hospitalised for gallstone diagnosis with or without gallbladder removal (cholecystectomy) between 1965 and 2008 were identified in the Swedish Patient Registry. The cohort was followed up for cancer in the Swedish Cancer Registry. The observed numbers of intra- and extrahepatic cholangiocarcinomas that developed after one year of follow-up were compared with the expected numbers, calculated from the corresponding background population, and the relative risks were estimated by standardised incidence ratios (SIRs) and 95% confidence intervals (CIs). RESULTS: Among the 192 960 non-cholecystectomised individuals with gallstones, there was a more than two-fold overall increased risk of both intra- and extra-hepatic cholangiocarcinomas, which remained stable over the follow-up period (SIR 2.77, 95% CI 2.17-3.49, and SIR 2.58, 95% CI 2.21-3.00, respectively). In the cholecystectomy cohort, including 345 251 people and 4 854 969 person-years, 325 incident cholangiocarcinomas were identified, of which 98 (30%) were intrahepatic and 227 (70%) were extrahepatic. Initially (1-4 years after surgery), the risk was increased for both intrahepatic cholangiocarcinoma (SIR 1.80, 95% CI 1.19-2.62) and extrahepatic cholangiocarcinoma (SIR 2.29, 95% CI 1.83-2.82), but no increase remained after 10 years of follow-up or more (SIR 1.10, 95% CI 0.79-1.48, and SIR 0.87, 95% CI 0.70-1.07, respectively). INTERPRETATION: Gallstones seem to increase the risk of both intra-and extrahepatic cholangiocarcinoma. However, this risk seems to decline to the level of the background population with time after cholecystectomy. British Journal of Cancer (2012) 106, 1011-1015. doi:10.1038/bjc.2011.607 www.bjcancer.com Published online 12 January 2012 (C) 2012 Cancer Research UK C1 [Nordenstedt, H.; Mattsson, F.; Lagergren, J.] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. [El-Serag, H.] Houston Ctr Qual Care & Utilizat Studies, Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. [El-Serag, H.] Houston Ctr Qual Care & Utilizat Studies, Baylor Coll Med, Houston, TX USA. [Lagergren, J.] Kings Coll London, Div Canc Studies, London WC2R 2LS, England. RP Nordenstedt, H (reprint author), Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. EM helena.nordenstedt@ki.se OI Lagergren, Jesper/0000-0002-5143-5448 FU Swedish Research Council; Swedish Cancer Society FX The study was supported by project grants from the Swedish Research Council and the Swedish Cancer Society. NR 21 TC 24 Z9 25 U1 3 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0007-0920 J9 BRIT J CANCER JI Br. J. Cancer PD FEB 28 PY 2012 VL 106 IS 5 BP 1011 EP 1015 DI 10.1038/bjc.2011.607 PG 5 WC Oncology SC Oncology GA 900NO UT WOS:000300894300031 PM 22240785 ER PT J AU Cornier, MA Melanson, EL Salzberg, AK Bechtell, JL Tregellas, JR AF Cornier, Marc-Andre Melanson, Edward L. Salzberg, Andrea K. Bechtell, Jamie L. Tregellas, Jason R. TI The effects of exercise on the neuronal response to food cues SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE fMRI; Neuroimaging; Physical activity; Food intake; Appetite ID POSITRON-EMISSION-TOMOGRAPHY; MODULATES BRAIN ACTIVITY; PHYSICAL-ACTIVITY; WEIGHT-LOSS; ENERGY-BALANCE; BODY-WEIGHT; INDUCED SUPPRESSION; NEURAL RESPONSES; FUNCTIONAL MRI; APPETITE AB Increased physical activity is associated with successful long-term weight loss maintenance due to mechanisms likely more complex than simply increased energy expenditure. The impact of physical activity on the central regulation of food intake may be an important mechanism of this effect. The objective of this study was to examine the effects of exercise training and acute exercise on the neuronal response to food cues as well as eating behaviors. fMRI was performed in the fasted state at baseline and again after a 6 month progressive exercise intervention (supervised, 5 days/wk) both with and without an acute exercise bout in 12 overweight/obese (5 women, 7 men; BMI 33 +/- 4 kg/m(2)) healthy adults. fMRI data were acquired while subjects were presented with visual stimuli of foods of high hedonic value as compared to neutral control objects. Questionnaires on eating behaviors, ratings of appeal and desire for foods, and ratings of appetite (hunger, satiety, prospective intake) using visual analog scales were also performed at baseline and again after the 6-month exercise intervention. While only a trend was observed for a reduction in body weight (102 +/- 5 to 99 +/- 6 kg, p=0.09), a significant reduction in fat mass was observed (36.4 +/- 2.8 to 33.7 +/- 3.2 kg, p = 0.04), although as expected changes in fat mass were variable (-10.0 to +3.7 kg). Chronic exercise was associated with a reduction in the neuronal response to food, primarily in the posterior attention network and insula. A significant positive correlation between the change in fat/body mass and the change in insula response to food cues with chronic exercise was observed. An acute exercise bout attenuated the effects of chronic exercise. The exercise intervention, however, did not impact any of the measures of appetitive behavior. In summary, despite no effects on behavioral measures of appetite, chronic exercise training was associated with attenuation in the response to visual food cues in brain regions known to be important in food intake regulation. The insula, in particular, appears to play an important role in the potential exercise-induced weight loss and weight loss maintenance. (C) 2011 Elsevier Inc. All rights reserved. C1 [Cornier, Marc-Andre; Melanson, Edward L.; Salzberg, Andrea K.; Bechtell, Jamie L.] Univ Colorado, Div Endocrinol Metab & Diabet, Sch Med, Dept Med, Aurora, CO 80045 USA. [Tregellas, Jason R.] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO 80045 USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA. RP Cornier, MA (reprint author), Univ Colorado, Div Endocrinol Metab & Diabet, Sch Med, Dept Med, Anschutz Med Campus,Mail Stop 8106,12801 E 17th A, Aurora, CO 80045 USA. EM marc.cornier@ucdenver.edu RI Tregellas, Jason/J-3637-2015 FU NIH/NCRR Colorado CTSI [UL1 RR025780]; NIH/NIDDK Clinical Nutrition Research Unit [DK48520]; NIH/NIDDK [R01DK07708, R01DK089095, R01DK072174] FX We acknowledge and thank Debra Singel and Yiping Du for their assistance with the fMRI studies. We also thank the dietary services and metabolic kitchen of the University of Colorado Denver CTRC. This publication was supported by NIH/NCRR Colorado CTSI Grant Number UL1 RR025780, NIH/NIDDK Clinical Nutrition Research Unit Grant Number DK48520, and NIH/NIDDK Grant Numbers R01DK07708, R01DK089095 and R01DK072174. Its contents are the authors' sole responsibility and do not necessarily represent official NIH views. NR 58 TC 42 Z9 43 U1 4 U2 22 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD FEB 28 PY 2012 VL 105 IS 4 BP 1028 EP 1034 DI 10.1016/j.physbeh.2011.11.023 PG 7 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 898MW UT WOS:000300747500017 PM 22155218 ER PT J AU Studenshi, SA AF Studenshi, Stephanie A. TI Gait Speed in Hospitalized Older People SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material ID ELDERLY-PATIENTS; DISABILITY; PREDICTOR; OUTCOMES; MOBILITY C1 [Studenshi, Stephanie A.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Dept Internal Med, Pittsburgh, PA 15090 USA. [Studenshi, Stephanie A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15090 USA. RP Studenshi, SA (reprint author), Univ Pittsburgh, Sch Med, Div Geriatr Med, Dept Internal Med, 3471 5th Ave,Ste 500, Pittsburgh, PA 15090 USA. EM studenskiS@dom.pitt.edu FU NIA NIH HHS [P30 AG024827, AG024827] NR 10 TC 6 Z9 6 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD FEB 27 PY 2012 VL 172 IS 4 BP 358 EP 359 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 898JU UT WOS:000300739500012 PM 22371923 ER PT J AU Raldow, AC Presley, CJ Yu, JB Sharma, R Cramer, LD Soulos, PR Long, JB Makarov, DV Gross, CP AF Raldow, Ann C. Presley, Carolyn J. Yu, James B. Sharma, Richa Cramer, Laura D. Soulos, Pamela R. Long, Jessica B. Makarov, Danil V. Gross, Cary P. TI The Relationship Between Clinical Benefit and Receipt of Curative Therapy for Prostate Cancer SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID RADIATION; OUTCOMES; QUALITY C1 [Presley, Carolyn J.; Soulos, Pamela R.; Long, Jessica B.; Gross, Cary P.] Yale Univ, Sch Med, Gen Internal Med Sect, New Haven, CT 06510 USA. [Raldow, Ann C.; Presley, Carolyn J.; Yu, James B.; Sharma, Richa; Cramer, Laura D.; Soulos, Pamela R.; Long, Jessica B.; Makarov, Danil V.; Gross, Cary P.] Yale Univ, Sch Med, Canc Outcomes Publ Policy & Effectiveness Res COP, Yale Comprehens Canc Ctr, New Haven, CT 06510 USA. [Presley, Carolyn J.; Soulos, Pamela R.; Long, Jessica B.; Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Yu, James B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA. [Raldow, Ann C.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [Makarov, Danil V.] NYU, Sch Med, Dept Urol, New York, NY 10003 USA. [Makarov, Danil V.] US Dept Vet Affairs, Washington, DC USA. RP Gross, CP (reprint author), Yale Univ, Sch Med, Gen Internal Med Sect, 333 Cedar St,POB 208025, New Haven, CT 06510 USA. EM cary.gross@yale.edu FU NCI NIH HHS [R01 CA149045, 5R01CA149045] NR 8 TC 6 Z9 6 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD FEB 27 PY 2012 VL 172 IS 4 BP 362 EP 363 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 898JU UT WOS:000300739500015 PM 22371925 ER PT J AU Myaskovsky, L Doebler, DA Posluszny, DM Dew, MA Unruh, M Fried, LF Switzer, GE Kim, S Chang, CCH Ramkumar, M Shapiro, R AF Myaskovsky, Larissa Doebler, Donna Almario Posluszny, Donna M. Dew, Mary Amanda Unruh, Mark Fried, Linda F. Switzer, Galen E. Kim, Sunghee Chang, Chung-Chou H. Ramkumar, Mohan Shapiro, Ron TI Perceived Discrimination Predicts Longer Time to Be Accepted for Kidney Transplant SO TRANSPLANTATION LA English DT Article DE Kidney transplantation; Disparities; Discrimination ID RENAL-TRANSPLANTATION; AFRICAN-AMERICANS; RACIAL-DIFFERENCES; ORGAN DONATION; DONOR; DISPARITIES; HEALTH; SURVIVAL; ACCESS; RACE AB Background. Although end-stage kidney disease in African Americans (AAs) is four times greater than in whites, AAs are less than one half as likely to undergo kidney transplantation (KT). This racial disparity has been found even after controlling for clinical factors such as comorbid conditions, dialysis vintage and type, and availability of potential living donors. Therefore, studying nonmedical factors is critical to understanding disparities in KT. Methods. We conducted a longitudinal cohort study with 127 AA and white patients with end-stage kidney disease undergoing evaluation for KT (December 2006 to July 2007) to determine whether, after controlling for medical factors, differences in time to acceptance for transplant is explained by patients' cultural factors (e. g., perceived racism and discrimination, medical mistrust, religious objections to living donor KT), psychosocial characteristics (e. g., social support, anxiety, depression), or transplant knowledge. Participants completed two telephone interviews (shortly after initiation of transplant evaluation and after being accepted or found ineligible for transplant). Results. Results indicated that AA patients reported higher levels of the cultural factors than did whites. We found no differences in comorbidity or availability of potential living donors. AAs took significantly longer to get accepted for transplant than did whites (hazard ratio = 1.49, P = 0.005). After adjustment for demographic, psychosocial, and cultural factors, the association of race with longer time for listing was no longer significant. Conclusions. We suggest that interventions to address racial disparities in KT incorporate key nonmedical risk factors in patients. C1 [Myaskovsky, Larissa; Fried, Linda F.; Switzer, Galen E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Myaskovsky, Larissa; Posluszny, Donna M.; Unruh, Mark; Fried, Linda F.; Switzer, Galen E.; Chang, Chung-Chou H.; Ramkumar, Mohan] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Myaskovsky, Larissa; Dew, Mary Amanda; Switzer, Galen E.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Doebler, Donna Almario; Dew, Mary Amanda; Chang, Chung-Chou H.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Fried, Linda F.; Ramkumar, Mohan] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15206 USA. [Kim, Sunghee] Duke Univ, Med Ctr, Duke Clin Res Inst, Pittsburgh, PA USA. [Shapiro, Ron] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. RP Myaskovsky, L (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA. EM larissa.myaskovsky@va.gov FU Veterans Administration (VA) Health Services Research and Development Department (HSRD) [04-409]; VA HSRD Merit Award [IIR 06-220]; VA Center for Health Equity Research and Promotion (CHERP) [LIP 72-023]; VA Veterans Integrated Service Network (VISN) [XVA 72-034]; National Institutes of Diabetes, Digestive, and Kidney Diseases (NIDDK) [R01DK081325]; University of Pittsburgh Center for Social and Urban Research [XNV 72-085] FX This work was supported by the Veterans Administration (VA) Health Services Research and Development Department (HSR&D) Merit Review Entry Program 04-409, VA HSR&D Merit Award IIR 06-220, VA Center for Health Equity Research and Promotion (CHERP) Pilot Fund LIP 72-023, VA Veterans Integrated Service Network (VISN) 4 Competitive Pilot Project Funds XVA 72-034, National Institutes of Diabetes, Digestive, and Kidney Diseases (NIDDK) R01DK081325, and the University of Pittsburgh Center for Social and Urban Research Manners Faculty Development Award XNV 72-085. NR 55 TC 8 Z9 8 U1 1 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD FEB 27 PY 2012 VL 93 IS 4 BP 423 EP 429 DI 10.1097/TP.0b013e318241d0cd PG 7 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 894GT UT WOS:000300415800018 PM 22228417 ER PT J AU Yang, XH Qiao, DH Meyer, K Pier, T Keles, S Friedl, A AF Yang, Xinhai Qiao, Dianhua Meyer, Kristy Pier, Thomas Keles, Sunduz Friedl, Andreas TI Angiogenesis Induced by Signal Transducer and Activator of Transcription 5A (STAT5A) Is Dependent on Autocrine Activity of Proliferin SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MAMMARY EPITHELIAL-CELLS; GENE-EXPRESSION; ENDOTHELIAL-CELLS; MESSENGER-RNA; GROWTH; PROLACTIN; RECEPTOR; PROTEIN; FAMILY; FIBROSARCOMA AB Multiple secreted factors induce the formation of new blood vessels (angiogenesis). The signal transduction events that orchestrate the numerous cellular activities required for angiogenesis remain incompletely understood. We have shown previously that STAT5 plays a pivotal role in angiogenesis induced by FGF2 and FGF8b. To delineate the signaling pathway downstream of STAT5, we expressed constitutively active (CA) or dominant-negative (DN) mutant STAT5A in mouse brain endothelial cells (EC). We found that the conditioned medium from CA-STAT5A but not from dominant-negative STAT5A overexpressing EC is sufficient to induce EC invasion and tube formation, indicating that STAT5A regulates the secretion of autocrine proangiogenic factors. Conversely, CA-STAT5A-induced conditioned medium had no effect on EC proliferation. Using a comparative genome-wide transcription array screen, we identified the prolactin family member proliferin (PLF1 and PLF4) as a candidate autocrine factor. The CA-STAT5A-dependent transcription and secretion of PLF by EC was confirmed by quantitative RT-PCR and Western blotting, respectively. CA-STAT5A binds to the PLF1 promoter region, suggesting a direct transcriptional regulation. Knockdown of PLF expression by shRNA or by blocking of PLF activity with neutralizing antibodies removed the CA-STAT5A-dependent proangiogenic activity from the conditioned medium of EC. Similarly, the ability of concentrated conditioned medium from CA-STAT5A transfected EC to induce angiogenesis in Matrigel plugs in vivo was abolished when PLF was depleted from the medium. These observations demonstrate a FGF/STAT5/PLF signaling cascade in EC and implicate PLF as autocrine regulator of EC invasion and tube formation. C1 [Yang, Xinhai; Qiao, Dianhua; Meyer, Kristy; Pier, Thomas; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53792 USA. [Keles, Sunduz] Univ Wisconsin, Dept Stat & Biostat & Med Informat, Madison, WI 53792 USA. [Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs Med Ctr, Madison, WI 53705 USA. RP Friedl, A (reprint author), WIMR Rm 6051,1111 Highland Ave, Madison, WI 53705 USA. EM afriedl@wisc.edu FU National Institutes of Health [RO1NS048921-01]; Biomedical Laboratory Research and Development Service of the VA Office of Research and Development [I01BX000137] FX This work was supported, in whole or in part, by National Institutes of Health Grant RO1NS048921-01. This work was also based upon work supported in part by Award I01BX000137 from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development. NR 33 TC 7 Z9 7 U1 1 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 24 PY 2012 VL 287 IS 9 BP 6490 EP 6502 DI 10.1074/jbc.M111.254631 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 899CQ UT WOS:000300791800038 PM 22199350 ER PT J AU Wey, MCY Fernandez, E Martinez, PA Sullivan, P Goldstein, DS Strong, R AF Wey, Margaret Chia-Ying Fernandez, Elizabeth Martinez, Paul Anthony Sullivan, Patricia Goldstein, David S. Strong, Randy TI Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's Disease SO PLOS ONE LA English DT Article ID HUMAN ALPHA-SYNUCLEIN; ENDOGENOUS DOPAMINERGIC NEUROTOXIN; AMYOTROPHIC-LATERAL-SCLEROSIS; ONSET ALZHEIMERS-DISEASE; STRIDE LENGTH REGULATION; TREADMILL GAIT ANALYSIS; L-DOPA; HYDROGEN-PEROXIDE; 3,4-DIHYDROXYPHENYLACETALDEHYDE; SEROTONIN AB Previous studies have reported elevated levels of biogenic aldehydes in the brains of patients with Parkinson's disease (PD). In the brain, aldehydes are primarily detoxified by aldehyde dehydrogenases (ALDH). Reduced ALDH1 expression in surviving midbrain dopamine neurons has been reported in brains of patients who died with PD. In addition, impaired complex I activity, which is well documented in PD, reduces the availability of the NAD(+) co-factor required by multiple ALDH isoforms to catalyze the removal of biogenic aldehydes. We hypothesized that chronically decreased function of multiple aldehyde dehydrogenases consequent to exposure to environmental toxins and/or reduced ALDH expression, plays an important role in the pathophysiology of PD. To address this hypothesis, we generated mice null for Aldh1a1 and Aldh2, the two isoforms known to be expressed in substantia nigra dopamine neurons. Aldh1a1(-/-) xAldh2(-/-) mice exhibited age-dependent deficits in motor performance assessed by gait analysis and by performance on an accelerating rotarod. Intraperitoneal administration of L-DOPA plus benserazide alleviated the deficits in motor performance. We observed a significant loss of neurons immunoreactive for tyrosine hydroxylase (TH) in the substantia nigra and a reduction of dopamine and metabolites in the striatum of Aldh1a1(-/-) xAldh2(-/-) mice. We also observed significant increases in biogenic aldehydes reported to be neurotoxic, including 4-hydroxynonenal (4-HNE) and the aldehyde intermediate of dopamine metabolism, 3,4-dihydroxyphenylacetaldehyde (DOPAL). These results support the hypothesis that impaired detoxification of biogenic aldehydes may be important in the pathophysiology of PD and suggest that Aldh1a1(-/-) xAldh2(-/-) mice may be a useful animal model of PD. C1 [Wey, Margaret Chia-Ying; Fernandez, Elizabeth; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Wey, Margaret Chia-Ying; Fernandez, Elizabeth; Martinez, Paul Anthony; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Fernandez, Elizabeth; Strong, Randy] S Texas Vet Hlth Care Network, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. [Sullivan, Patricia; Goldstein, David S.] Natl Inst Neurol Disorders & Stroke, Clin Neurocardiol Sect, Clin Neurosci Program, Div Intramural Res, Bethesda, MD USA. RP Wey, MCY (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. EM FernandezE@uthscsa.edu; Strong@uthscsa.edu FU Veteran Affairs Office of Research Development; National Institute of Aging [T32 AG021890-08] FX This work was supported by grants from the Veteran Affairs Office of Research & Development (to E.F. and R.S.) and the National Institute of Aging predoctoral training grant T32 AG021890-08 (to M.C.W.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 65 TC 47 Z9 47 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 22 PY 2012 VL 7 IS 2 AR e31522 DI 10.1371/journal.pone.0031522 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 926ZZ UT WOS:000302875500023 PM 22384032 ER PT J AU Stetler, RA Gao, YQ Zhang, LL Weng, ZF Zhang, F Hu, XM Wang, SP Vosler, P Cao, GD Sun, DD Graham, SH Chen, J AF Stetler, R. Anne Gao, Yanqin Zhang, Lili Weng, Zhongfang Zhang, Feng Hu, Xiaoming Wang, Suping Vosler, Peter Cao, Guodong Sun, Dandan Graham, Steven H. Chen, Jun TI Phosphorylation of HSP27 by Protein Kinase D Is Essential for Mediating Neuroprotection against Ischemic Neuronal Injury SO JOURNAL OF NEUROSCIENCE LA English DT Article ID HEAT-SHOCK-PROTEIN; CEREBRAL-ISCHEMIA; BRAIN-INJURY; CELL-DEATH; SERINE-82 PHOSPHORYLATION; UP-REGULATION; CYTOCHROME-C; APOPTOSIS; HEAT-SHOCK-PROTEIN-27; ACTIVATION AB Heat shock protein 27 (HSP27) (or HSPB1) exerts cytoprotection against many cellular insults, including cerebral ischemia. We previously identified apoptosis signal-regulating kinase 1 (ASK1) as a critical downstream target of HSP27 conferring the neuroprotective effects of HSP27 against neuronal ischemia. However, the function of HSP27 is highly influenced by posttranslational modification, with differential cellular effects based on phosphorylation at specific serine residues. The role of phosphorylation in neuronal ischemic neuroprotection is currently unknown. We have created transgenic mice and viral vectors containing HSP27 mutated at three critical serine residues (Ser15, Ser78, and Ser82) to either alanine (HSP27-A, nonphosphorylatable) or aspartate (HSP27-D, phosphomimetic) residues. Under both in vitro and in vivo neuronal ischemic settings, overexpression of wild-type HSP27 (HSP27) and HSP27-D, but not HSP27-A, was neuroprotective and inhibited downstream ASK1 signaling pathways. Consistently, overexpressed HSP27 was phosphorylated by endogenous mechanisms when neurons were under ischemic stress, and single-point mutations identified Ser15 and Ser82 as critical for neuroprotection. Using a panel of inhibitors and gene knockdown approaches, we identified the upstream kinase protein kinase D (PKD) as the primary kinase targeting HSP27 directly for phosphorylation. PKD and HSP27 coimmunoprecipitated, and inhibition or knockdown of PKD abrogated the neuroprotective effects of HSP27 as well as the interaction with and inhibition of ASK1 signaling. Together, these data demonstrate that HSP27 requires PKD-mediated phosphorylation for its suppression of ASK1 cell death signaling and neuroprotection against ischemic injury. C1 [Stetler, R. Anne; Gao, Yanqin; Zhang, Lili; Weng, Zhongfang; Zhang, Feng; Hu, Xiaoming; Wang, Suping; Vosler, Peter; Cao, Guodong; Sun, Dandan; Graham, Steven H.; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Stetler, R. Anne; Gao, Yanqin; Zhang, Lili; Weng, Zhongfang; Zhang, Feng; Hu, Xiaoming; Wang, Suping; Vosler, Peter; Cao, Guodong; Sun, Dandan; Graham, Steven H.; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Stetler, R. Anne; Zhang, Lili; Weng, Zhongfang; Zhang, Feng; Hu, Xiaoming; Wang, Suping; Vosler, Peter; Cao, Guodong; Sun, Dandan; Graham, Steven H.; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. [Stetler, R. Anne; Gao, Yanqin; Cao, Guodong; Chen, Jun] Fudan Univ, Sch Med, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Stetler, R. Anne; Gao, Yanqin; Cao, Guodong; Chen, Jun] Fudan Univ, Sch Med, Inst Brain Sci, Shanghai 200032, Peoples R China. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. EM yqgao@shmu.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU NIH-NINDS [NS43802, NS45048, NS36736, NS56118]; Veterans Affairs Merit Review grant; Chinese Natural Science Foundation [30670642, 30870794, 81020108021]; American Heart Association [10SDG2560122, 10POST4150028]; NIH [1F30NS057886] FX This work was supported by NIH-NINDS Grants NS43802, NS45048, NS36736, and NS56118, and Veterans Affairs Merit Review grant (J.C.); and Chinese Natural Science Foundation Grants 30670642, 30870794, and 81020108021 (Y.G.). F.Z. and X. H. were supported American Heart Association Grants 10SDG2560122 and 10POST4150028, respectively. P. V. was supported by NIH National Research Service Award Fellowship 1F30NS057886. We thank Dr. Qiming Wang (University of Pittsburgh, Pittsburgh, PA) for providing the PKD inhibitor and the anti-PKD3 antibody. We thank Carol Culver for editorial assistance and Pat Strickler for secretarial support. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 38 TC 30 Z9 32 U1 1 U2 8 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD FEB 22 PY 2012 VL 32 IS 8 BP 2667 EP 2682 DI 10.1523/JNEUROSCI.5169-11.2012 PG 16 WC Neurosciences SC Neurosciences & Neurology GA 898DT UT WOS:000300716600011 PM 22357851 ER PT J AU Pillai, SK Abdel-Mohsen, M Guatelli, J Skasko, M Monto, A Fujimoto, K Yukl, S Greene, WC Kovari, H Rauch, A Fellay, J Battegay, M Hirschel, B Witteck, A Bernasconi, E Ledergerber, B Gunthard, HF Wong, JK AF Pillai, Satish K. Abdel-Mohsen, Mohamed Guatelli, John Skasko, Mark Monto, Alexander Fujimoto, Katsuya Yukl, Steven Greene, Warner C. Kovari, Helen Rauch, Andri Fellay, Jacques Battegay, Manuel Hirschel, Bernard Witteck, Andrea Bernasconi, Enos Ledergerber, Bruno Guenthard, Huldrych F. Wong, Joseph K. CA Swiss HIV Cohort Study TI Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL ACTIVITY; REVERSE TRANSCRIPTION; CYTIDINE DEAMINATION; ANTIVIRAL PROTEIN; VIF PROTEIN; T-CELLS; C VIRUS; APOBEC3G; HYPERMUTATION AB The antiviral potency of the cytokine IFN-alpha has been long appreciated but remains poorly understood. A number of studies have suggested that induction of the apolipoprotein B mRNA editing enzyme, catalytic polypeptide 3 (APOBEC3) and bone marrow stromal cell antigen 2 (BST-2/tetherin/CD317) retroviral restriction factors underlies the IFN-alpha-mediated suppression of HIV-1 replication in vitro. We sought to characterize the as-yet-undefined relationship between IFN-alpha treatment, retroviral restriction factors, and HIV-1 in vivo. APOBEC3G, APOBEC3F, and BST-2 expression levels were measured in HIV/hepatitis C virus (HCV)-coinfected, antiretroviral therapy-naive individuals before, during, and after pegylated IFN-alpha/ribavirin (IFN-alpha/riba) combination therapy. IFN-alpha/riba therapy decreased HIV-1 viral load by -0.921 (+/- 0.858) log(10) copies/mL in HIV/HCV-coinfected patients. APOBEC3G/3F and BST-2 mRNA expression was significantly elevated during IFN-alpha/riba treatment in patient-derived CD4+ T cells (P < 0.04 and P < 0.008, paired Wilcoxon), and extent of BST-2 induction was correlated with reduction in HIV-1 viral load during treatment (P < 0.05, Pearson's r). APOBEC3 induction during treatment was correlated with degree of viral hypermutation (P < 0.03, Spearman's rho), and evolution of the HIV-1 accessory protein viral protein U (Vpu) during IFN-alpha/riba treatment was suggestive of increased BST-2-mediated selection pressure. These data suggest that host restriction factors play a critical role in the antiretroviral capacity of IFN-alpha in vivo, and warrant investigation into therapeutic strategies that specifically enhance the expression of these intrinsic immune factors in HIV-1-infected individuals. C1 [Pillai, Satish K.; Abdel-Mohsen, Mohamed; Monto, Alexander; Yukl, Steven; Greene, Warner C.; Wong, Joseph K.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Pillai, Satish K.; Monto, Alexander; Fujimoto, Katsuya; Yukl, Steven; Wong, Joseph K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Guatelli, John; Skasko, Mark] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Dept Med, La Jolla, CA 92093 USA. [Greene, Warner C.] Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA. [Kovari, Helen; Ledergerber, Bruno; Guenthard, Huldrych F.] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland. [Rauch, Andri] Univ Bern, Univ Hosp Berne, Div Infect Dis, CH-3010 Bern, Switzerland. [Fellay, Jacques] Univ Lausanne Hosp, Div Infect Dis, CH-1011 Lausanne, Switzerland. [Fellay, Jacques] Univ Lausanne Hosp, Inst Microbiol, CH-1011 Lausanne, Switzerland. [Battegay, Manuel] Univ Basel Hosp, Div Infect Dis, CH-4031 Basel, Switzerland. [Hirschel, Bernard] Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland. [Witteck, Andrea] Cantonal Hosp St Gallen, Div Infect Dis, CH-9007 St Gallen, Switzerland. [Bernasconi, Enos] Reg Hosp Lugano, Div Infect Dis, CH-6903 Lugano, Switzerland. RP Pillai, SK (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM satish.pillai@ucsf.edu RI Infektiologie, USZ/A-6921-2011; gunthard, huldrych/F-1724-2011; Fujimoto, Katsuya/G-2835-2012; SHCS, all/G-4072-2011; SHCS, int. coll. A/G-4083-2011; Fellay, Jacques/A-6681-2009; Ledergerber, Bruno/B-5656-2009 OI gunthard, huldrych/0000-0002-1142-6723; Fellay, Jacques/0000-0002-8240-939X; Ledergerber, Bruno/0000-0002-6881-4401 FU National Institutes of Health [1K01DA024654, AI081668]; American Recovery and Reinvestment Act (ARRA); Swiss HIV Cohort Study Project [594]; Swiss National Science Foundation [324730-130865, R01NS051132, R21MH083573, R56AI91573, 33CSC0-108787]; Swiss HIV Cohort Study Research Foundation FX We thank the patients who participate in the Swiss HIV Cohort Study and the physicians and study nurses for excellent patient care. This study was supported by National Institutes of Health Grant 1K01DA024654 (to S. K. P.), Grant AI081668, and an American Recovery and Reinvestment Act (ARRA) supplement (to J.G.). Additional support was provided by Swiss HIV Cohort Study Project 594; the Veterans Affairs Merit Review (K. F., S.Y., and J.K.W.); and Swiss National Science Foundation Grants 324730-130865 (to H. F. G.), R01NS051132, R21MH083573, and R56AI91573. The Swiss HIV Cohort Study is supported by Swiss National Science Foundation Grant 33CSC0-108787 and the Swiss HIV Cohort Study Research Foundation. NR 56 TC 64 Z9 65 U1 1 U2 15 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 21 PY 2012 VL 109 IS 8 BP 3035 EP 3040 DI 10.1073/pnas.1111573109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 895KM UT WOS:000300495100073 PM 22315404 ER PT J AU Buxbaum, JD Betancur, C Bozdagi, O Dorr, NP Elder, GA Hof, PR AF Buxbaum, Joseph D. Betancur, Catalina Bozdagi, Ozlem Dorr, Nate P. Elder, Gregory A. Hof, Patrick R. TI Optimizing the phenotyping of rodent ASD models: enrichment analysis of mouse and human neurobiological phenotypes associated with high-risk autism genes identifies morphological, electrophysiological, neurological, and behavioral features SO MOLECULAR AUTISM LA English DT Article DE Systems biology; mouse behavior; autism; autism spectrum disorders; genetically modified mice; forward genetics; reverse genetics ID COMPONENTS; PROTEOME AB Background: There is interest in defining mouse neurobiological phenotypes useful for studying autism spectrum disorders (ASD) in both forward and reverse genetic approaches. A recurrent focus has been on high-order behavioral analyses, including learning and memory paradigms and social paradigms. However, well-studied mouse models, including for example Fmr1 knockout mice, do not show dramatic deficits in such high-order phenotypes, raising a question as to what constitutes useful phenotypes in ASD models. Methods: To address this, we made use of a list of 112 disease genes etiologically involved in ASD to survey, on a large scale and with unbiased methods as well as expert review, phenotypes associated with a targeted disruption of these genes in mice, using the Mammalian Phenotype Ontology database. In addition, we compared the results with similar analyses for human phenotypes. Findings: We observed four classes of neurobiological phenotypes associated with disruption of a large proportion of ASD genes, including: (1) Changes in brain and neuronal morphology; (2) electrophysiological changes; (3) neurological changes; and (4) higher-order behavioral changes. Alterations in brain and neuronal morphology represent quantitative measures that can be more widely adopted in models of ASD to understand cellular and network changes. Interestingly, the electrophysiological changes differed across different genes, indicating that excitation/inhibition imbalance hypotheses for ASD would either have to be so non-specific as to be not falsifiable, or, if specific, would not be supported by the data. Finally, it was significant that in analyses of both mouse and human databases, many of the behavioral alterations were neurological changes, encompassing sensory alterations, motor abnormalities, and seizures, as opposed to higher-order behavioral changes in learning and memory and social behavior paradigms. Conclusions: The results indicated that mutations in ASD genes result in defined groups of changes in mouse models and support a broad neurobiological approach to phenotyping rodent models for ASD, with a focus on biochemistry and molecular biology, brain and neuronal morphology, and electrophysiology, as well as both neurological and additional behavioral analyses. Analysis of human phenotypes associated with these genes reinforced these conclusions, supporting face validity for these approaches to phenotyping of ASD models. Such phenotyping is consistent with the successes in Fmr1 knockout mice, in which morphological changes recapitulated human findings and electrophysiological deficits resulted in molecular insights that have since led to clinical trials. We propose both broad domains and, based on expert review of more than 50 publications in each of the four neurobiological domains, specific tests to be applied to rodent models of ASD. C1 [Buxbaum, Joseph D.; Bozdagi, Ozlem] Mt Sinai Sch Med, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA. [Buxbaum, Joseph D.; Bozdagi, Ozlem; Dorr, Nate P.; Elder, Gregory A.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Buxbaum, Joseph D.; Hof, Patrick R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA. [Buxbaum, Joseph D.; Elder, Gregory A.; Hof, Patrick R.] Mt Sinai Sch Med, Friedman Brain Inst, New York, NY 10029 USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Betancur, Catalina] INSERM, U952, F-75005 Paris, France. [Betancur, Catalina] CNRS, UMR 7224, F-75005 Paris, France. [Betancur, Catalina] Univ Paris 06, F-75005 Paris, France. [Elder, Gregory A.] James J Peters VA Med Ctr, Neurol Serv, Bronx, NY 10468 USA. RP Buxbaum, JD (reprint author), Mt Sinai Sch Med, Seaver Autism Ctr Res & Treatment, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM joseph.buxbaum@mssm.edu OI Buxbaum, Joseph/0000-0001-8898-8313; Betancur, Catalina/0000-0002-3327-4804 FU Seaver Foundation; Simons Foundation; NIMH [MH093725]; INSERM FX This work was supported by the Seaver Foundation (JDB, OB, PRH), the Simons Foundation (JDB, OB, PRH), the NIMH (MH093725; JDB, OB, PRH), and INSERM (CB). OB is a Seaver Fellow. JDB is the G Harold and Leila Y Mathers Professor at Mount Sinai. NR 9 TC 14 Z9 14 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2040-2392 J9 MOL AUTISM JI Mol. Autism PD FEB 20 PY 2012 VL 3 AR 1 DI 10.1186/2040-2392-3-1 PG 8 WC Genetics & Heredity; Neurosciences SC Genetics & Heredity; Neurosciences & Neurology GA 254RH UT WOS:000327184000001 PM 22348382 ER PT J AU Qiao, DH Meyer, K Friedl, A AF Qiao, Dianhua Meyer, Kristy Friedl, Andreas TI Glypican-1 Stimulates Skp2 Autoinduction Loop and G(1)/S Transition in Endothelial Cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ANAPHASE PROMOTING COMPLEX/CYCLOSOME; RESTRICTION POINT CONTROL; TGF-BETA; CANCER-CELLS; CYCLIN D1; C-MYC; CDK INHIBITORS; S-PHASE; GROWTH; DEGRADATION AB The heparan sulfate proteoglycan glypican-1 (GPC1) is involved in tumorigenesis and angiogenesis and is overexpressed frequently in tumor and endothelial cells (ECs) in human gliomas. We demonstrated previously that in brain EC, GPC1 regulates mitotic cyclins and securin as well as mitosis and that GPC1 is required for progression through the cell cycle. To characterize the molecular mechanism underlying cell cycle regulation by GPC1, we systematically investigated its effects on key G(1)/S checkpoint regulators and on major signaling pathways reportedly activated by Dally (Division abnormally delayed) the Drosophila GPC1 homologue. We found that elevated GPC1 affected a wide range of G(1)/S checkpoint regulators, leading to inactivation of the G(1)/S checkpoint and increased S phase entry, apparently by activating the mitogen-independent Skp2 autoinduction loop. Specifically, GPC1 suppressed CDK inhibitors (CKIs), including p21, p27, p16, and p19, and the D cyclins, and induced CDK2 and Skp2. GPC1 may trigger the Skp2 autoinduction loop at least partially by suppressing p21 transcription as knockdown of p21 by RNAi can mimic the effect of GPC1 on the cell cycle regulators related to the loop. Moreover, multiple mitogenic signaling pathways, including ERK MAPK, Wnt and BMP signaling, were significantly stimulated by GPC1 as has been reported for Dally in Drosophila. Notably, the c-Myc oncoprotein, which is frequently up-regulated by both ERK and Wnt signaling and functions as a potent transcription repressor for CKIs as well as D cyclins, was also significantly induced by GPC1. These findings provide mechanistic insights into how GPC1 regulates the cell cycle and proliferation. C1 [Qiao, Dianhua; Meyer, Kristy; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA. [Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs Med Ctr, Madison, WI 53705 USA. RP Friedl, A (reprint author), WIMR Room 6051,1111 Highland Ave, Madison, WI 53705 USA. EM afriedl@wisc.edu NR 51 TC 16 Z9 17 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 17 PY 2012 VL 287 IS 8 BP 5898 EP 5909 DI 10.1074/jbc.M111.325282 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 897HE UT WOS:000300638000064 PM 22203671 ER PT J AU He, DG Li, H Yusuf, N Elmets, CA Athar, M Katiyar, SK Xu, H AF He, Donggou Li, Hui Yusuf, Nabiha Elmets, Craig A. Athar, Mohammad Katiyar, Santosh K. Xu, Hui TI IL-17 Mediated Inflammation Promotes Tumor Growth and Progression in the Skin SO PLOS ONE LA English DT Article ID CD8(+) T-CELLS; INTERLEUKIN-17 FAMILY-MEMBERS; MYELOID SUPPRESSOR-CELLS; CHEMICAL CARCINOGENESIS; IMMUNE SUPPRESSION; MOUSE SKIN; CANCER; METASTASIS; MICROENVIRONMENT; TUMORIGENESIS AB The mechanism for inflammation associated tumor development is a central issue for tumor biology and immunology and remains to be fully elucidated. Although IL-17 is implicated in association with inflammation mediated carcinogenesis, mechanisms are largely elusive. In the current studies, we showed that IL-17 receptor-A gene deficient (IL-17R-/-) mice were resistant to chemical carcinogen-induced cutaneous carcinogenesis, a well-established inflammation associated tumor model in the skin. The deficiency in IL-17R increased the infiltration of CD8+ T cells whereas it inhibited the infiltration of CD11b+ myeloid cells and development of myeloid derived suppressor cells. Inflammation induced skin hyperplasia and production of pro-tumor inflammatory molecules were inhibited in IL-17R-/- mice. We found that pre-existing inflammation in the skin increased the susceptibility to tumor growth, which was associated with increased development of tumor specific IL-17 producing T cells. This inflammation induced susceptibility to tumor growth was abrogated in IL-17R-/- mice. Finally, neutralizing IL-17 in mice that had already developed chemical carcinogen induced skin tumors could inhibit inflammation mediated tumor progression at late stages. These results demonstrate that IL-17 mediated inflammation is an important mechanism for inflammation mediated promotion of tumor development. The study has major implications for targeting IL-17 in prevention and treatment of tumors. C1 [He, Donggou; Li, Hui; Yusuf, Nabiha; Elmets, Craig A.; Athar, Mohammad; Katiyar, Santosh K.; Xu, Hui] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Yusuf, Nabiha; Elmets, Craig A.; Athar, Mohammad; Katiyar, Santosh K.; Xu, Hui] Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL USA. [Yusuf, Nabiha; Elmets, Craig A.; Katiyar, Santosh K.; Xu, Hui] Birmingham VA Med Ctr, Birmingham, AL USA. RP He, DG (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. EM xuhui@uab.edu FU United States National Institutes of Health [ES017494, CA138998, AI071041, AR46256] FX This publication was made possible by grants (AI071041 and AR46256 [HX] and ES017494 and CA138998 [MA]) from the United States National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 63 TC 34 Z9 35 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 16 PY 2012 VL 7 IS 2 AR e32126 DI 10.1371/journal.pone.0032126 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 925XS UT WOS:000302796200131 PM 22359662 ER PT J AU Emmendorfer, T Glassman, PA Moore, V Leadholm, TC Good, CB Cunningham, F AF Emmendorfer, Thomas Glassman, Peter A. Moore, Von Leadholm, Thomas C. Good, Chester B. Cunningham, Francesca TI Monitoring adverse drug reactions across a nationwide health care system using information technology SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article DE Databases; Department of Veterans Affairs; Drugs, adverse reactions; Information; Quality assurance; Records; Technology ID AMBULATORY-CARE; EVENTS; VETERANS AB Purpose. The improvement and linkage of two Department of Veterans Affairs (VA) databases for monitoring adverse drug reactions (ADRs) are described, with a discussion of the potential implications for improved medication safety within the VA health care system. Summary. Before 2007, VA had limited capability to track and evaluate ADRs across its nationwide network of health care facilities. Since then, VA has established a standardized monitoring system that has improved the reporting, analysis, and trending of ADRs reported by providers and pharmacists at individual VA facilities. The enhanced system has two components with distinct but complementary functions: the Adverse Reaction Tracking database, which is derived by extracting text-based, patient-specific information entered into the VA electronic medical record system by clinicians at the point of care; and the VA Adverse Drug Event Reporting System (VA ADERS), an external web-based portal that contains aggregated data from 146 VA facilities, with standardized coding of reported events. Both databases allow for ADR reporting at the local, regional, and national levels. The VA ADERS database permits rapid electronic reporting of certain ADRs to the federal MedWatch program. The two databases can be used in tandem for more comprehensive assessments of ADR patterns and reporting rates and to generate a wide range of benchmarking data. Conclusion. In recent years, the refinement of two databases for ADR reporting has increased VA's capability to systematically monitor, track, and report ADRs across its national network of health care facilities. Linking the two databases has further strengthened those capabilities, enhancing medication safety practices and aiding in pharmacovigilance. C1 [Emmendorfer, Thomas; Glassman, Peter A.] VA Pharm Benefits Management Serv, VA Ctr Medicat Safety, Hines, IL 60141 USA. [Glassman, Peter A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Leadholm, Thomas C.] VA PBM Serv, VA ADERS, Tucson, AZ USA. [Leadholm, Thomas C.] Consolidated Mail Outpatient Pharm, Tucson, AZ USA. [Good, Chester B.] VA Pittsburgh Healthcare Syst, Sect Gen Med, Pittsburgh, PA USA. RP Emmendorfer, T (reprint author), VA Pharm Benefits Management Serv, VA Ctr Medicat Safety, 1st Ave,1 Block,N Cermak Rd,Bldg 37,Room 139, Hines, IL 60141 USA. EM thomas.emmendorfer@va.gov NR 13 TC 6 Z9 6 U1 0 U2 7 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD FEB 15 PY 2012 VL 69 IS 4 BP 321 EP 328 DI 10.2146/ajhp110026 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 943LM UT WOS:000304123500011 PM 22302257 ER PT J AU Tobin, MJ AF Tobin, Martin J. TI Extubation and the Myth of "Minimal Ventilator Settings" SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID PRESSURE SUPPORT VENTILATION; MECHANICAL VENTILATION; WEANING PATIENTS; FAILURE; AIRWAY C1 [Tobin, Martin J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA. [Tobin, Martin J.] Loyola Univ Chicago, Stritch Sch Med, Hines, IL USA. RP Tobin, MJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 13 TC 23 Z9 23 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 15 PY 2012 VL 185 IS 4 BP 349 EP 350 DI 10.1164/rccm.201201-0050ED PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 897EY UT WOS:000300629900003 PM 22336673 ER PT J AU Wang, Y Shi, M Chung, KA Zabetian, CP Leverenz, JB Berg, D Srulijes, K Trojanowski, JQ Lee, VMY Siderowf, AD Hurtig, H Litvan, I Schiess, MC Peskind, ER Masuda, M Hasegawa, M Lin, XM Pan, C Galasko, D Goldstein, DS Jensen, PH Yang, H Cain, KC Zhang, J AF Wang, Yu Shi, Min Chung, Kathryn A. Zabetian, Cyrus P. Leverenz, James B. Berg, Daniela Srulijes, Karin Trojanowski, John Q. Lee, Virginia M. -Y. Siderowf, Andrew D. Hurtig, Howard Litvan, Irene Schiess, Mya C. Peskind, Elaine R. Masuda, Masami Hasegawa, Masato Lin, Xiangmin Pan, Catherine Galasko, Douglas Goldstein, David S. Jensen, Poul Henning Yang, Hui Cain, Kevin C. Zhang, Jing TI Phosphorylated alpha-Synuclein in Parkinson's Disease SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID PROGRESSIVE SUPRANUCLEAR PALSY; MULTIPLE-SYSTEM ATROPHY; HUMAN CEREBROSPINAL-FLUID; RICHARDSONS-SYNDROME; CONSENSUS STATEMENT; ALZHEIMERS-DISEASE; PSP-PARKINSONISM; LEWY BODIES; DIAGNOSIS; NEURODEGENERATION AB Phosphorylated alpha-synuclein (PS-129), a protein implicated in the pathogenesis of Parkinson's disease (PD), was identified by mass spectrometry in human cerebrospinal fluid (CSF). A highly sensitive and specific assay was established and used to measure PS-129 together with total alpha-synuclein in the CSF of patients with PD, other parkinsonian disorders such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), and healthy individuals (a total of similar to 600 samples). PS-129 CSF concentrations correlated weakly with PD severity and, when combined with total alpha-synuclein concentrations in CSF, contributed to distinguishing PD from MSA and PSP. Further rigorous validation in independent cohorts of patients, especially those where samples have been collected longitudinally, will determine whether the concentration of PS-129 in CSF will be useful for diagnosing PD and for monitoring PD severity and progression. C1 [Wang, Yu; Shi, Min; Lin, Xiangmin; Pan, Catherine; Yang, Hui; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Wang, Yu] Huazhong Univ Sci & Technol, Dept Neurosurg, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China. [Chung, Kathryn A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Zabetian, Cyrus P.; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA. [Leverenz, James B.; Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA. [Leverenz, James B.; Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Berg, Daniela; Srulijes, Karin] Univ Tubingen, Dept Neurodegenerat, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany. [Berg, Daniela; Srulijes, Karin] Univ Tubingen, German Ctr Neurodegenerat Dis, D-72076 Tubingen, Germany. [Trojanowski, John Q.; Lee, Virginia M. -Y.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Inst Aging,Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Siderowf, Andrew D.; Hurtig, Howard] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19107 USA. [Litvan, Irene] Univ Louisville, Sch Med, Div Movement Disorders, Louisville, KY 40202 USA. [Schiess, Mya C.] Univ Texas Hlth Sci Ctr, Dept Neurol, Houston, TX 77030 USA. [Masuda, Masami; Hasegawa, Masato] Tokyo Metropolitan Inst Med Sci, Dept Neuropathol & Cell Biol, Setagaya Ku, Tokyo 1568585, Japan. [Goldstein, David S.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Goldstein, David S.] NINDS, Clin Neurocardiol Sect, Community Networks Program, Div Intramural Res,NIH, Bethesda, MD 20892 USA. [Jensen, Poul Henning] Aarhus Univ, Dept Med Chem, DK-8000 Aarhus C, Denmark. [Cain, Kevin C.] Univ Washington, Dept Biostat, Seattle, WA 98105 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. EM zhangj@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558; , xiangmin/0000-0001-9128-689X FU NIH [AG025327, AG033398, ES004696-5897, ES007033-6364, NS057567, NS060252, NS062684, NS065070, NS053488]; Lundbeck Foundation; European Community [241791]; Avid Radiopharmaceuticals FX Funding: The investigation was supported by the NIH (grants AG025327, AG033398, ES004696-5897, ES007033-6364, NS057567, and NS060252 to J.Z.; NS062684 to J.Z., C. P.Z., and J.B.L.; NS065070 to C. P.Z.; and NS053488 to J.Q.T., V.M.-Y.L., and A. D. S.), the Lundbeck Foundation, and the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 241791 (to P.H.J.).; Competing interests: A. D. S. serves as a consultant for Teva Neuroscience and has grant support from Avid Radiopharmaceuticals not related to this investigation. J.B.L. serves as a consultant for Bayer, Novartis, and Teva Neuroscience. The other authors declare that they have no competing interests. NR 32 TC 32 Z9 32 U1 2 U2 19 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD FEB 15 PY 2012 VL 4 IS 121 AR 121ra20 DI 10.1126/scitranslmed.3002566 PG 8 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 898HR UT WOS:000300732600004 PM 22344688 ER PT J AU Gore, JL Wright, JL Daratha, KB Roberts, KP Lin, DW Wessells, H Porter, M AF Gore, John L. Wright, Jonathan L. Daratha, Kenn B. Roberts, Kenneth P. Lin, Daniel W. Wessells, Hunter Porter, Michael TI Hospital-level variation in the quality of urologic cancer surgery SO CANCER LA English DT Article DE prostate carcinoma; kidney carcinoma; bladder carcinoma; quality of care ID OUTCOMES ASSESSMENT PROGRAM; RADICAL PROSTATECTOMY; BLADDER-CANCER; KIDNEY-CANCER; OPERATIVE MORTALITY; CYSTECTOMY; VOLUME; CARE; COMPLICATIONS AB BACKGROUND: Unexplained variation in outcomes after common surgeries raises concerns about the quality and appropriateness of surgical care. Understanding variation in surgical outcomes may identify processes that could affect the quality of surgical and postoperative care. The authors of this report examined hospital-level variation in outcomes after inpatient urologic oncology procedures. METHODS: Patients who underwent radical cystectomy, radical nephrectomy, and radical prostatectomy were identified from the Washington State Comprehensive Hospital Abstract Reporting System for the years 2003 through 2007. The postoperative length of stay (LOS) was measured, and LOS that exceeded the 75th percentile was classified as prolonged. The occurrence of Agency for Healthcare Quality patient safety indicators (PSIs), readmissions, and deaths also were measured. Analyses were adjusted for patient age and comorbidity in random effects, multilevel, multivariable models that assessed hospital-level outcomes. RESULTS: The authors identified 853 patients from 37 hospitals who underwent cystectomy, 3018 patients who underwent nephrectomy from 51 hospitals, and 8228 patients who underwent prostatectomy from 51 hospitals. Complications captured by PSIs were rare. Hospital-level variation was most profound for LOS outcomes after nephrectomy and prostatectomy (variance in prolonged LOS, 8.1% and 26.7%, respectively), thromboembolic events after nephrectomy (8% of variance), and mortality after cystectomy (7.1% of variance). CONCLUSIONS: Hospital-level variation confounds the care of urologic cancer patients in the state of Washington. The authors concluded that transparent reporting of surgical outcomes and local quality-improvement initiatives should be considered to ameliorate the observed variation and improve the quality of cystectomy, nephrectomy, and prostatectomy care. Cancer 2012;118:987-96. Published 2011 by the American Cancer Society*. C1 [Gore, John L.; Wright, Jonathan L.; Lin, Daniel W.; Wessells, Hunter; Porter, Michael] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. [Wright, Jonathan L.; Lin, Daniel W.; Porter, Michael] Vet Affairs Puget Sound Hlth Care Syst, Div Urol, Seattle, WA USA. [Daratha, Kenn B.] Washington State Univ, Coll Nursing, Spokane, WA USA. [Roberts, Kenneth P.] Washington State Univ, Washington Wyoming Alaska Montana Idaho WWAMI Med, Spokane, WA USA. RP Gore, JL (reprint author), Univ Washington, Sch Med, Dept Urol, 1959 NE Pacific St,Box 356510, Seattle, WA 98195 USA. EM jlgore@u.washington.edu RI Roberts, Ken/D-5701-2012 OI Gore, John/0000-0002-2847-5062 FU National Center for Research Resources, National Institutes of Health [UL1RR025014]; Veterans Affairs Puget Sound Health Care System, Seattle, Washington FX This work was supported by grant UL1RR025014 from the National Center for Research Resources, National Institutes of Health. This material also is the result of work supported in part by resources from the Veterans Affairs Puget Sound Health Care System, Seattle, Washington. NR 32 TC 11 Z9 11 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD FEB 15 PY 2012 VL 118 IS 4 BP 987 EP 996 DI 10.1002/cncr.26373 PG 10 WC Oncology SC Oncology GA 886EF UT WOS:000299834300016 PM 21792864 ER PT J AU Coon, TA Glasser, JR Mallampalli, RK Chen, BB AF Coon, Tiffany A. Glasser, Jennifer R. Mallampalli, Rama K. Chen, Bill B. TI Novel E3 ligase component FBXL7 ubiquitinates and degrades Aurora A, causing mitotic arrest SO CELL CYCLE LA English DT Article DE F-box protein; centrosome; mitosis; Aurora A ID SPINDLE ASSEMBLY CHECKPOINT; F-BOX PROTEINS; HUMAN-CELLS; REGULATORY ENZYME; B DEGRADATION; IDENTIFICATION; MITOSIS; CANCER; CYTOKINESIS; ANEUPLOIDY AB Aurora family kinases play pivotal roles in several steps during mitosis. Specifically, Aurora A kinase is an important regulator of bipolar mitotic spindle formation and chromosome segregation. Like other members of the Aurora family, Aurora A kinase is also regulated by post-translational modifications. Here, we show that a previously undescribed E3 ligase component belonging to the SCF (Skp-Cullin1-F-box protein) E3 ligase family, SCFFBXL7, impairs cell proliferation by mediating Aurora A polyubiquitination and degradation. Both Aurora A and FBXL7 co-localize within the centrosome during spindle formation. FBXL7 ectopic expression led to G(2)/M phase arrest in transformed epithelia, resulting in the appearance of tetraploidy and mitotic arrest with circular monopolar spindles and multipolar spindle formation. Interestingly, FBXL7 specifically interacts with Aurora A during mitosis but not in interphase, suggesting a regulatory role for FBXL7 in controlling Aurora A abundance during mitosis. C1 [Coon, Tiffany A.; Glasser, Jennifer R.; Mallampalli, Rama K.; Chen, Bill B.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15260 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. RP Chen, BB (reprint author), Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15260 USA. EM chenb@upmc.edu FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; US Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174] FX This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health R01 grants HL096376, HL097376 and HL098174 (to R.K.M.). The contents presented do not represent the views of the Department of Veterans Affairs or the United States Government. NR 40 TC 18 Z9 20 U1 0 U2 3 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4101 J9 CELL CYCLE JI Cell Cycle PD FEB 15 PY 2012 VL 11 IS 4 BP 721 EP 729 DI 10.4161/cc.11.4.19171 PG 9 WC Cell Biology SC Cell Biology GA 897CY UT WOS:000300621400022 PM 22306998 ER PT J AU Corrales-Medina, VF Musher, DM Wells, GA Chirinos, JA Chen, L Fine, MJ AF Corrales-Medina, Vicente F. Musher, Daniel M. Wells, George A. Chirinos, Julio A. Chen, Li Fine, Michael J. TI Cardiac Complications in Patients With Community-Acquired Pneumonia Incidence, Timing, Risk Factors, and Association With Short-Term Mortality SO CIRCULATION LA English DT Article DE pneumonia; complications; heart failure; arrhythmias, cardiac; myocardial infarction ID ACUTE CORONARY SYNDROMES; MYOCARDIAL-INFARCTION; HOSPITALIZED-PATIENTS; CLINICAL-OUTCOMES; ACUTE INFECTION; UNITED-STATES; IMPACT; HEART; SURVIVAL; EVENTS AB Background-Community-acquired pneumonia (CAP) affects > 5 million adults each year in the United States. Although incident cardiac complications occur in patients with community-acquired pneumonia, their incidence, timing, risk factors, and associations with short-term mortality are not well understood. Methods and Results-A total of 1343 inpatients and 944 outpatients with community-acquired pneumonia were followed up prospectively for 30 days after presentation. Incident cardiac complications (new or worsening heart failure, new or worsening arrhythmias, or myocardial infarction) were diagnosed in 358 inpatients (26.7%) and 20 outpatients (2.1%). Although most events (89.1% in inpatients, 75% in outpatients) were diagnosed within the first week, more than half of them were recognized in the first 24 hours. Factors associated with their diagnosis included older age (odds ratio [OR] = 1.03; 95% confidence interval [CI], 1.02-1.04), nursing home residence (OR, 1.8; 95% CI, 1.2-2.9), history of heart failure (OR, 4.3; 95% CI, 3.0-6.3), prior cardiac arrhythmias (OR, 1.8; 95% CI, 1.2-2.7), previously diagnosed coronary artery disease (OR, 1.5; 95% CI, 1.04-2.0), arterial hypertension (OR, 1.5; 95% CI, 1.1-2.1), respiratory rate >= 30 breaths per minute (OR, 1.6; 95% CI, 1.1-2.3), blood pH < 7.35 (OR, 3.2; 95% CI, 1.8 -5.7), blood urea nitrogen >= 30 mg/dL (OR, 1.5; 95% CI, 1.1-2.2), serum sodium < 130 mmol/L (OR, 1.8; 95% CI, 1.02-3.1), hematocrit < 30% (OR, 2.0; 95% CI, 1.3-3.2), pleural effusion on presenting chest x-ray (OR, 1.6; 95% CI, 1.1-2.4), and inpatient care (OR, 4.8; 95% CI, 2.8-8.3). Incident cardiac complications were associated with increased risk of death at 30 days after adjustment for baseline Pneumonia Severity Index score (OR, 1.6; 95% CI, 1.04-2.5). Conclusions-Incident cardiac complications are common in patients with community-acquired pneumonia and are associated with increased short-term mortality. Older age, nursing home residence, preexisting cardiovascular disease, and pneumonia severity are associated with their occurrence. Further studies are required to test risk stratification and prevention and treatment strategies for cardiac complications in this population. (Circulation. 2012; 125: 773-781.) C1 [Wells, George A.] Univ Ottawa, Dept Med, Ottawa, ON, Canada. [Corrales-Medina, Vicente F.; Wells, George A.] Ottawa Hosp, Res Inst, Ottawa, ON, Canada. [Wells, George A.; Chen, Li] Univ Ottawa, Inst Heart, Cardiovasc Res Methods Ctr, Ottawa, ON, Canada. [Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Microbiol, Houston, TX 77030 USA. [Musher, Daniel M.] Michael E DeBakey VA Med Ctr, Med Care Line Infect Dis Sect, Houston, TX USA. [Chirinos, Julio A.] Philadelphia VA Med Ctr, Div Cardiol, Philadelphia, PA USA. [Chirinos, Julio A.] Univ Penn, Philadelphia, PA 19104 USA. [Fine, Michael J.] Univ Pittsburgh, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. RP Corrales-Medina, VF (reprint author), 1053 Carling Ave,CPC 470, Ottawa, ON K1Y 4E9, Canada. EM vcorrales@toh.on.ca OI Corrales-Medina, Vicente/0000-0002-9691-491X FU Agency for Healthcare Research and Quality; Department of Medicine of the Ottawa Hospital; Ottawa Hospital Research Institute FX The PORT study was funded by the Agency for Healthcare Research and Quality. Dr Corrales-Medina is supported by a research priority grant from the Department of Medicine of the Ottawa Hospital and a Junior Investigator Award from the Ottawa Hospital Research Institute. NR 33 TC 104 Z9 109 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD FEB 14 PY 2012 VL 125 IS 6 BP 773 EP U92 DI 10.1161/CIRCULATIONAHA.111.040766 PG 13 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 896XR UT WOS:000300605200015 PM 22219349 ER PT J AU Brennan, JM Dai, D Patel, MR Rao, SV Armstrong, EJ Messenger, JC Curtis, JP Shunk, KA Anstrom, KJ Eisenstein, EL Weintraub, WS Peterson, ED Douglas, PS Hillegass, WB AF Brennan, J. Matthew Dai, David Patel, Manesh R. Rao, Sunil V. Armstrong, Ehrin J. Messenger, John C. Curtis, Jeptha P. Shunk, Kendrick A. Anstrom, Kevin J. Eisenstein, Eric L. Weintraub, William S. Peterson, Eric D. Douglas, Pamela S. Hillegass, William B. TI Characteristics and Long-Term Outcomes of Percutaneous Revascularization of Unprotected Left Main Coronary Artery Stenosis in the United States SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE long-term outcomes; percutaneous revascularization; unprotected left main coronary artery stenosis ID DRUG-ELUTING STENTS; CARDIAC-SURGERY; DISEASE; REGISTRY; INTERVENTION; IMPACT; SAFETY AB Objectives This study sought to assess percutaneous coronary intervention (PCI) for unprotected left main coronary artery (ULMCA) stenosis in routine U. S. clinical practice. Background Percutaneous coronary intervention for ULMCA stenosis is controversial; however, current use and outcomes of ULMCA PCI in routine U. S. clinical practice have not been described. Methods We evaluated 5,627 patients undergoing ULMCA PCI at 693 centers within the National Cardiovascular Data Registry Catheterization Percutaneous Coronary Intervention Registry for temporal trends in PCI use (2004 to 2008), patient characteristics, and in-hospital mortality. Thirty-month mortality and composite major adverse events (death, myocardial infarction, and revascularization) with drug-eluting versus bare-metal stents were compared using inverse probability weighted (IPW) hazard ratios (HRs) in a nonrandomized Medicare-linked (age >= 65 years) patient cohort (n = 2,765). Results ULMCA PCI was performed in 4.3% of patients with ULMCA stenosis. Unadjusted in-hospital mortality rates ranged from 2.9% for elective cases to 45.1% for emergent/salvage cases. By 30 months, 57.9% of the elderly ULMCA PCI population experienced death, myocardial infarction, or revascularization, and 42.7% died. Patients receiving drug-eluting stents (versus bare-metal stents) had a lower 30-month mortality (IPW HR: 0.84, 95% confidence interval [CI]: 0.73 to 0.96), but the composite of major adverse events were similar (IPW HR: 0.95, 95% CI: 0.84 to 1.06). Conclusions In the United States, ULMCA PCI is performed in <5% of patients with ULMCA disease and is generally reserved for those at high procedural risk. Adverse events are common in elderly patients and are related to patient and procedural characteristics, including stent type. (J Am Coll Cardiol 2012;59:648-54) (C) 2012 by the American College of Cardiology Foundation C1 [Brennan, J. Matthew; Dai, David; Patel, Manesh R.; Rao, Sunil V.; Anstrom, Kevin J.; Eisenstein, Eric L.; Peterson, Eric D.; Douglas, Pamela S.] Duke Univ, Med Ctr, Duke Clin Res Inst, Dept Med, Durham, NC 27705 USA. [Armstrong, Ehrin J.] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. [Shunk, Kendrick A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Armstrong, Ehrin J.; Shunk, Kendrick A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Messenger, John C.] Univ Colorado Denver Sch Med, Dept Med, Aurora, CO USA. [Curtis, Jeptha P.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. [Weintraub, William S.] Christiana Care Hosp, Dept Med, Newark, DE USA. [Hillegass, William B.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. RP Brennan, JM (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Dept Med, 2400 Pratt St,Suite 800, Durham, NC 27705 USA. EM brenn009@mc.duke.edu FU Agency for Healthcare Research and Quality, United States Department of Health and Human Services, Rockville, Maryland [ID 24-DKE-3, HHSAA290-2005-0032-TO4-WA2]; Cordis Corporation; Medtronic, Inc.; ACC-NCDR; Abbott Vascular; Alexion; AstraZeneca; Bristol-Myers Squibb; Eli Lilly; Innocoll Pharmaceuticals; Medtronic; PfizerProctor Gamble; Bristol-Myers Squibb/Sanofi-Aventis; Merck; Lilly; Johnson Johnson; Society of Thoracic Surgeons; American College of Cardiology; National Cardiovascular Data Registry, American College of Cardiology, Washington, DC; Siemens Medical Systems; SurgiVision; Revascular Therapeutics FX This project was sponsored by the Agency for Healthcare Research and Quality, United States Department of Health and Human Services, Rockville, Maryland, as part of the Cardiovascular Consortium and funded under Project ID 24-DKE-3 and Work Assignment Number HHSAA290-2005-0032-TO4-WA2 as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program. Dr. Patel is a consultant for Bayer Healthcare, Ortho-McNeil Jansen, and Genzyme. Dr. Rao has received research funding from Cordis Corporation. Dr. Messenger is the site principal investigator for the Resolute and EDUCATE studies; and has received funding from Medtronic, Inc. Dr. Curtis receives salary support from the ACC-NCDR; and has equity holding in Medtronic. Dr. Shunk has received research funding from Abbott Vascular and Siemens Medical Systems and consulting fees from SurgiVision and Revascular Therapeutics. Dr. Anstrom has received research funding and salary support from Alexion, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Innocoll Pharmaceuticals, Medtronic, Pfizer, and Proctor & Gamble; serves on the data safety monitoring boards of Pfizer and Vertex; and receives consulting fees from Abbott Vascular, Ikaria, Pacific Therapeutics, Bristol-Myers Squibb, and AstraZeneca. Mr. Eisenstein has received research funding from Medtronic and Eli Lilly. Dr. Peterson has received research funding from Bristol-Myers Squibb/Sanofi-Aventis, Merck, Lilly, Johnson & Johnson, Society of Thoracic Surgeons, and American College of Cardiology. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or by the United States Department of Health and Human Services. Additional support was obtained from the National Cardiovascular Data Registry, American College of Cardiology, Washington, DC. NR 18 TC 28 Z9 32 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 14 PY 2012 VL 59 IS 7 BP 648 EP 654 DI 10.1016/j.jacc.2011.10.883 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 893YN UT WOS:000300393900004 PM 22322080 ER PT J AU Lee, HJ Mariappan, MM Feliers, D Cavaglieri, RC Sataranatarajan, K Abboud, HE Choudhury, GG Kasinath, BS AF Lee, Hak Joo Mariappan, Meenalakshmi M. Feliers, Denis Cavaglieri, Rita C. Sataranatarajan, Kavithalakshmi Abboud, Hanna E. Choudhury, Goutam Ghosh Kasinath, Balakuntalam S. TI Hydrogen Sulfide Inhibits High Glucose-induced Matrix Protein Synthesis by Activating AMP-activated Protein Kinase in Renal Epithelial Cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MESSENGER-RNA TRANSLATION; CYSTATHIONINE-GAMMA-LYASE; DIABETIC-NEPHROPATHY; MYOCARDIAL-ISCHEMIA; REPERFUSION INJURY; SULFANE SULFUR; KNOCKOUT MICE; HYPERTROPHY; GROWTH; RAT AB Hydrogen sulfide, a signaling gas, affects several cell functions. We hypothesized that hydrogen sulfide modulates high glucose (30 mM) stimulation of matrix protein synthesis in glomerular epithelial cells. High glucose stimulation of global protein synthesis, cellular hypertrophy, and matrix laminin and type IV collagen content was inhibited by sodium hydrosulfide (NaHS), an H2S donor. High glucose activation of mammalian target of rapamycin (mTOR) complex 1 (mTORC1), shown by phosphorylation of p70S6 kinase and 4E-BP1, was inhibited by NaHS. High glucose stimulated mTORC1 to promote key events in the initiation and elongation phases of mRNA translation: binding of eIF4A to eIF4G, reduction in PDCD4 expression and inhibition of its binding to eIF4A, eEF2 kinase phosphorylation, and dephosphorylation of eEF2; these events were inhibited by NaHS. The role of AMP-activated protein kinase (AMPK), an inhibitor of protein synthesis, was examined. NaHS dose-dependently stimulated AMPK phosphorylation and restored AMPK phosphorylation reduced by high glucose. Compound C, an AMPK inhibitor, abolished NaHS modulation of high glucose effect on events in mRNA translation as well as global and matrix protein synthesis. NaHS induction of AMPK phosphorylation was inhibited by siRNA for calmodulin kinase kinase beta, but not LKB1, upstream kinases for AMPK; STO-609, a calmodulin kinase kinase beta inhibitor, had the same effect. Renal cortical content of cystathionine beta-synthase and cystathionine gamma-lyase, hydrogen sulfide-generating enzymes, was significantly reduced in mice with type 1 diabetes or type 2 diabetes, coinciding with renal hypertrophy and matrix accumulation. Hydrogen sulfide is a newly identified modulator of protein synthesis in the kidney, and reduction in its generation may contribute to kidney injury in diabetes. C1 [Lee, Hak Joo; Mariappan, Meenalakshmi M.; Feliers, Denis; Cavaglieri, Rita C.; Sataranatarajan, Kavithalakshmi; Abboud, Hanna E.; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Lee, Hak Joo; Mariappan, Meenalakshmi M.; Sataranatarajan, Kavithalakshmi; Abboud, Hanna E.; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam S.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Kasinath, BS (reprint author), 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kasinath@uthscsa.edu FU National Institutes of Health [DK077295, RC2AG036613, DK050190]; Veterans Affairs Medical Research Service; Juvenile Diabetes Research Foundation [1-2010-141, 1-2008-185]; Veterans Affairs Research Career Scientist Award FX This work was supported, in whole or in part, by National Institutes of Health Grants DK077295 and RC2AG036613 (to B. S. K.) and DK050190 (to G. G. C.). This work was also supported by a grant from the Veterans Affairs Medical Research Service (to B. S. K. and G. G. C.) and Juvenile Diabetes Research Foundation Grants 1-2010-141 (to D. F.) and 1-2008-185 (to G. G. C.).; Recipient of a Veterans Affairs Research Career Scientist Award. NR 65 TC 44 Z9 47 U1 0 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 10 PY 2012 VL 287 IS 7 BP 4451 EP 4461 DI 10.1074/jbc.M111.278325 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 896YX UT WOS:000300608500009 PM 22158625 ER PT J AU Small, AC Tsao, CK Moshier, E Godbold, J Sonpavde, G Oh, WK Galsky, MD AF Small, Alexander C. Tsao, Che-Kai Moshier, Erin Godbold, James Sonpavde, Guru Oh, William K. Galsky, Matt D. TI Prevalence and characteristics of patients with metastatic prostate cancer who receive no anticancer therapy. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA. Texas Oncol, Houston, TX USA. Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 10 PY 2012 VL 30 IS 5 SU S MA 101 PG 1 WC Oncology SC Oncology GA V31OH UT WOS:000208892400102 PM 28143086 ER PT J AU Tadros, NN Farris, PE Shannon, J Beer, TM Garzotto, M AF Tadros, Nicholas N. Farris, Paige E. Shannon, Jackilen Beer, Tomasz M. Garzotto, Mark TI The safety of prostate biopsy procedures in the research setting: A 10-year multicenter experience. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 10 PY 2012 VL 30 IS 5 SU S MA 87 PG 1 WC Oncology SC Oncology GA V31OH UT WOS:000208892400089 PM 28143351 ER PT J AU Tsao, CK Moshier, E Small, AC Sonpavde, G Godbold, J Oh, WK Galsky, MD AF Tsao, Che-Kai Moshier, Erin Small, Alexander C. Sonpavde, Guru Godbold, James Oh, William K. Galsky, Matt D. TI Cytoreductive nephrectomy in the United States: Patterns of care and patient characteristics. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA. Texas Oncol, Houston, TX USA. Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 10 PY 2012 VL 30 IS 5 SU S MA 366 PG 1 WC Oncology SC Oncology GA V31OH UT WOS:000208892400365 PM 28143249 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial SO BMC MEDICINE LA English DT Editorial Material DE Gout; Disparity; Race; treatment; Febuxostat; Allopurinol; randomized; African-American ID ACUTE MYOCARDIAL-INFARCTION; SERUM URATE; INDEPENDENT IMPACT; JOINT ARTHROPLASTY; UNITED-STATES; CARE; HYPERURICEMIA; ALLOPURINOL; POPULATION; PREVALENCE AB There is a disproportionate burden of gout in African-Americans in the U. S. due to a higher disease prevalence and lower likelihood of receiving urate-lowering therapy (ULT), compared to Caucasians. There is an absence of strong data as to whether the response to ULT differs by race/ethnicity. BMC Musculoskeletal Disorders recently published a secondary analyses of the CONFIRMS trial, a large randomized controlled, double-blind trial of 2,269 gout patients. The authors reported that the likelihood of achieving the primary study efficacy end-point of achieving serum urate < 6 mg/dl was similar between African-Americans and Caucasians, for all three treatment arms (Febuxostat 40 mg and 80 mg and allopurinol 300/200 mg). More importantly, rates were similar in subgroups of patients with mild or moderate renal insufficiency. Adverse event rates were similar, as were the rates of gout flares. These findings constitute a convincing evidence to pursue aggressive ULT in gout patients, regardless of race/ethnicity. This approach will likely help to narrow the documented racial disparities in gout care. Please see related article: http://www.biomedcentral.com/1471-2474/13/15 C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Med Serv, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Fac Off Tower 805B, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Med Serv, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 NR 26 TC 3 Z9 3 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD FEB 9 PY 2012 VL 10 AR 15 DI 10.1186/1741-7015-10-15 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 932ZA UT WOS:000303327800001 PM 22316088 ER PT J AU Kachadourian, R Day, BJ Pugazhenti, S Franklin, CC Genoux-Bastide, E Mahaffey, G Gauthier, C Di Pietro, A Boumendjel, A AF Kachadourian, Remy Day, Brian J. Pugazhenti, Subbiah Franklin, Christopher C. Genoux-Bastide, Estelle Mahaffey, Gregory Gauthier, Charlotte Di Pietro, Attilio Boumendjel, Ahcene TI A Synthetic Chalcone as a Potent Inducer of Glutathione Biosynthesis SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID GLUTAMATE-CYSTEINE LIGASE; CANCER RESISTANCE PROTEIN; HEME OXYGENASE-1; IN-VITRO; CELLS; EXPRESSION; KINASE; INHIBITOR; NRF2; 2'-HYDROXYCHALCONE AB Chalcones continue to attract considerable interest due to their anti-inflammatory and antiangiogenic properties. We recently reported the ability of 2',5'-dihydroxychalcone (2',5'-DHC) to induce both breast cancer resistance protein-mediated export of glutathione (GSH) and c-Jun N-terminal kinase-mediated increased intracellular GSH levels. Herein, we report a structure-activity relationship study of a series of 30 synthetic chalcone derivatives with hydroxyl, methoxyl, and halogen (F andCl) substituents and their ability to increase intracellular GSH levels. This effect was drastically improved with one or two electrowithdrawing groups on phenyl ring B and up to three methoxyl and/or hydroxyl groups on phenyl ring A. The optimal structure, 2-chloro-4',6'-dimethoxy-2'-hydroxychalcone, induced both a potent NF-E2-related factor 2-mediated transcriptional response and an increased formation of glutamate cysteine ligase holoenzyme, as shown using a human breast cancer cell line stably expressing a luciferase reporter gene driven by antioxidant response elements. C1 [Kachadourian, Remy; Day, Brian J.; Pugazhenti, Subbiah] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. [Kachadourian, Remy; Day, Brian J.; Pugazhenti, Subbiah] Univ Colorado, Dept Med, Aurora, CO 80045 USA. [Day, Brian J.; Franklin, Christopher C.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Aurora, CO 80045 USA. [Pugazhenti, Subbiah; Mahaffey, Gregory] Denver VA Med Ctr, Denver, CO 80220 USA. [Genoux-Bastide, Estelle; Boumendjel, Ahcene] UJF Grenoble 1, CNRS, Dept Pharmacochim Mol, UMR 5063, F-38041 Grenoble, France. [Gauthier, Charlotte; Di Pietro, Attilio] Univ Lyon 1, Inst Biol & Chim Prot, Equipe Labellisee Ligue 2009, BMSSI,UMR5086, F-69367 Lyon 7, France. RP Kachadourian, R (reprint author), Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. EM remyka@gmail.com FU NIH [HL755223, HL84469, ES015678, ES017582]; VA Merit Review [NEUD-004-07F]; Ligue Nationale Contre le Cancer (Equipe Labelisee Ligue) FX We are grateful to Madeleine Blanc and Chantal Beney for technical assistance in the synthesis of the chalcones. We also thank Dr. Joe M. McCord (University of Colorado, Aurora) for providing the MCF-7/AREc32 cell line generated by Dr. C. Roland Wolf (University of Dundee, United Kingdom). This work was supported by NIH Grants HL755223, HL84469, ES015678, and ES017582 to B.J.D. and VA Merit Review NEUD-004-07F to S.P. C.G. is the recipient of a doctoral fellowship from the Ligue Nationale Contre le Cancer (Equipe Labelisee Ligue 2009). B.J.D. is a consultant for and holds equity in Aeolus Pharmaceuticals that is commercially developing metalloporphyrins as human therapeutic agents. NR 41 TC 20 Z9 20 U1 2 U2 18 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD FEB 9 PY 2012 VL 55 IS 3 BP 1382 EP 1388 DI 10.1021/jm2016073 PG 7 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 888DV UT WOS:000299984900033 PM 22239485 ER PT J AU Donohue, JM Morden, NE Gellad, WF Bynum, JP Zhou, WP Hanlon, JT Skinner, J AF Donohue, Julie M. Morden, Nancy E. Gellad, Walid F. Bynum, Julie P. Zhou, Weiping Hanlon, Joseph T. Skinner, Jonathan TI Sources of Regional Variation in Medicare Part D Drug Spending SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID HEALTH-CARE; GEOGRAPHIC-VARIATION; POTENTIAL SAVINGS; GENERIC DRUGS; BENEFIT; RISK; HYPERTENSION; METAANALYSIS; INHIBITORS; DISEASE AB Background Sources of regional variation in spending for prescription drugs under Medicare Part D are poorly understood, and such variation may reflect differences in health status, use of effective treatments, or selection of branded drugs over lower-cost generics. Methods We analyzed 2008 Medicare data for 4.7 million beneficiaries for prescription-drug use and expenditures overall and in three drug categories: angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), and selective serotonin-reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Differences in per capita expenditures across hospital-referral regions (HRRs) were decomposed into annual prescription volume and cost per prescription. The ratio of prescriptions filled as branded drugs to all prescriptions filled was calculated. We adjusted all measures for demographic, socioeconomic, and health-status differences. Results Mean adjusted per capita pharmaceutical spending ranged from $2,413 in the lowest to $3,008 in the highest quintile of HRRs. Most (75.9%) of that difference was attributable to the cost per prescription ($53 vs. $63). Regional differences in cost per prescription explained 87.5% of expenditure variation for ACE inhibitors and ARBs and 56.3% for statins but only 36.1% for SSRIs and SNRIs. The ratio of branded-drug to total prescriptions, which correlated highly with cost per prescription, ranged across HRRs from 0.24 to 0.45 overall and from 0.24 to 0.55 for ACE inhibitors and ARBs, 0.29 to 0.60 for statins, and 0.15 to 0.51 for SSRIs and SNRIs. Conclusions Regional variation in Medicare Part D spending results largely from differences in the cost of drugs selected rather than prescription volume. A reduction in branded-drug use in some regions through modification of Part D plan benefits might lower costs without reducing quality of care. (Funded by the National Institute on Aging and others.) C1 [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] Univ Pittsburgh, Dept Med Gen Internal Med, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med Geriatr Pharm & Therapeut & Biomed Infor, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Gellad, Walid F.] RAND, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Morden, Nancy E.; Bynum, Julie P.; Zhou, Weiping; Skinner, Jonathan] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA. [Morden, Nancy E.; Skinner, Jonathan] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA. [Skinner, Jonathan] Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA. RP Donohue, JM (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A613, Pittsburgh, PA 15261 USA. EM jdonohue@pitt.edu OI Donohue, Julie/0000-0003-2418-6017 FU National Institute on Aging [P01AG019783, AG-07-001, P30AG024827, T32 AG021885, K07AG033174, K23AG028947, R01AG034056, U01 AG012553, R56AG027017]; Agency for Healthcare Research and Quality [R01HS017695, R01HS018721, K12 HS019461]; National Institute of Nursing Research [R01 NR010135]; National Institute of Mental Health [R34 MH082682]; Robert Wood Johnson Foundation [059491]; Veterans Affairs Health Services Research and Development Service [IIR-06-062, CDA 09-207]; National Institute on Aging and others FX Supported by grants from the National Institute on Aging (P01AG019783, AG-07-001, P30AG024827, T32 AG021885, K07AG033174, K23AG028947, R01AG034056, U01 AG012553, and R56AG027017), the Agency for Healthcare Research and Quality (R01HS017695, R01HS018721, and K12 HS019461), the National Institute of Nursing Research (R01 NR010135), the National Institute of Mental Health (R34 MH082682), the Robert Wood Johnson Foundation (059491), and the Veterans Affairs Health Services Research and Development Service (IIR-06-062 and CDA 09-207).; Funded by the National Institute on Aging and others. NR 39 TC 34 Z9 34 U1 0 U2 7 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 9 PY 2012 VL 366 IS 6 BP 530 EP 538 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 888GH UT WOS:000299991300009 PM 22316446 ER PT J AU Brent, GA AF Brent, Gregory A. TI The Debate over Thyroid-Function Screening in Pregnancy SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID DYSFUNCTION; MANAGEMENT; WOMEN C1 [Brent, Gregory A.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. RP Brent, GA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. NR 11 TC 20 Z9 22 U1 3 U2 6 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 9 PY 2012 VL 366 IS 6 BP 562 EP 563 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 888GH UT WOS:000299991300013 PM 22316450 ER PT J AU Zaman, MS Shahryari, V Deng, GR Thamminana, S Saini, S Majid, S Chang, I Hirata, H Ueno, K Yamamura, S Singh, K Tanaka, Y Tabatabai, ZL Dahiya, R AF Zaman, Mohd Saif Shahryari, Varahram Deng, Guoren Thamminana, Sobha Saini, Sharonjot Majid, Shahana Chang, Inik Hirata, Hiroshi Ueno, Koji Yamamura, Soichiro Singh, Kamaldeep Tanaka, Yuichiro Tabatabai, Z. Laura Dahiya, Rajvir TI Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival SO PLOS ONE LA English DT Article ID RENAL-CELL CARCINOMA; HUMAN BREAST-CANCER; GENE-EXPRESSION; APOPTOSIS; P53; P21(WAF1/CIP1/SDI1); TRANSCRIPTION; PROTEIN; P21; CDK AB Background: MicroRNA-21 is up-regulated in a variety of cancers like, breast, colorectal, lung, head and neck etc. However, the regulation of miR-21 in renal cell carcinoma (RCC) has not yet been studied systematically. Methods and Results: We measured miR-21 levels in 54 pairs of kidney cancers and their normal matched tissues by real-time PCR. The expression level of miR-21 was correlated with 5 year survival and the pathological stage. Functional studies were done after inhibiting miR-21 in RCC cell lines. We studied in vitro and in vivo effects of the chemo preventive agent genistein on miR-21 expression. In 48 cases (90%), miR-21 was increased. All patients with low miR-21 expression survived 5 years, while with high miR-21 expression, only 50% survived. Higher expression of miR-21 is associated with an increase in the stage of renal cancer. Functional studies after inhibiting miRNA-21 in RCC cell lines show cell cycle arrest, induction of apoptosis and reduced invasive and migratory capabilities. Western blot analysis showed an increase in the expression of p21 and p38 MAP kinase genes and a reduction in cyclin E2. Genistein inhibited the expression of miR-21 in A-498 cells and in the tumors formed after injecting genistein treated A-498 cells in nude mice besides inhibiting tumor formation. Conclusions: The current study shows a clear correlation between miR-21 expression and clinical characteristics of renal cancer. Thus we believe that miR-21 can be used as a tumor marker and its inhibition may prove to be useful in controlling cancers with up-regulated miR-21. C1 [Zaman, Mohd Saif] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Zaman, MS (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. EM rdahiya@urology.ucsf.edu FU Veterans Association; National Institutes of Health [RO1CA130860] FX This study was supported by the Veterans Association Merit Review, Veterans Association Research Enhancement Award Program and National Institutes of Health Grant RO1CA130860 (to the principal investigator, Dr. R. Dahiya). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 59 Z9 61 U1 1 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 8 PY 2012 VL 7 IS 2 AR e31060 DI 10.1371/journal.pone.0031060 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 924ZP UT WOS:000302730100036 PM 22347428 ER PT J AU Carnes, M AF Carnes, Molly TI What Would Patsy Mink Think? SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID PREJUDICE; CLIMATE; WOMEN; GAP C1 [Carnes, Molly] Univ Wisconsin Madison, Dept Med, Madison, WI 53706 USA. [Carnes, Molly] Univ Wisconsin Madison, Dept Psychiat, Madison, WI 53706 USA. [Carnes, Molly] Univ Wisconsin Madison, Dept Ind & Syst Engn, Madison, WI USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Carnes, M (reprint author), Univ Wisconsin Madison, Dept Med, Madison, WI 53706 USA. EM mlcarnes@wisc.edu NR 11 TC 2 Z9 2 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 8 PY 2012 VL 307 IS 6 BP 571 EP 572 DI 10.1001/jama.2012.79 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 888GT UT WOS:000299992500020 PM 22318277 ER PT J AU Qaseem, A Humphrey, LL Sweet, DE Starkey, M Shekelle, P AF Qaseem, Amir Humphrey, Linda L. Sweet, Donna E. Starkey, Melissa Shekelle, Paul CA Clinical Guidelines Comm Amer Coll TI Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID DIPEPTIDYL PEPTIDASE-4 INHIBITOR; FIXED-DOSE COMBINATION; RANDOMIZED CONTROLLED-TRIAL; IMPROVED GLYCEMIC CONTROL; SULFONYLUREA PLUS METFORMIN; CONGESTIVE-HEART-FAILURE; ALL-CAUSE MORTALITY; DOUBLE-BLIND; RETROSPECTIVE COHORT; INSULIN SENSITIVITY AB Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medications. Methods: This guideline is based on a systematic evidence review evaluating literature published on this topic from 1966 through April 2010 that was identified by using MEDLINE (updated through December 2010), EMBASE, and the Cochrane Central Register of Controlled Trials. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included all-cause mortality, cardiovascular morbidity and mortality, cerebrovascular morbidity, neuropathy, nephropathy, and retinopathy. This guideline grades the evidence and recommendations by using the American College of Physicians clinical practice guidelines grading system. Recommendation 1: ACP recommends that clinicians add oral pharmacologic therapy in patients diagnosed with type 2 diabetes when lifestyle modifications, including diet, exercise, and weight loss, have failed to adequately improve hyperglycemia (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians prescribe monotherapy with metformin for initial pharmacologic therapy to treat most patients with type 2 diabetes (Grade: strong recommendation; high-quality evidence). Recommendation 3: ACP recommends that clinicians add a second agent to metformin to treat patients with persistent hyperglycemia when lifestyle modifications and monotherapy with metformin fail to control hyperglycemia (Grade: strong recommendation; high-quality evidence). C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Univ Kansas, Sch Med, Wichita, KS 67214 USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU ACP FX Financial support for the development of this guideline comes exclusively from the ACP operating budget. NR 134 TC 123 Z9 127 U1 2 U2 18 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 7 PY 2012 VL 156 IS 3 BP 218 EP U92 DI 10.7326/0003-4819-156-3-201202070-00011 PG 19 WC Medicine, General & Internal SC General & Internal Medicine GA 887XD UT WOS:000299964200006 PM 22312141 ER PT J AU Kerlikowske, K Hubbard, R AF Kerlikowske, Karla Hubbard, Rebecca TI Comparative Effectiveness of Digital Versus Film-Screen Mammography RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Kerlikowske, Karla] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Hubbard, Rebecca] Grp Hlth Res Inst, Seattle, WA 98101 USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. NR 4 TC 0 Z9 0 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 7 PY 2012 VL 156 IS 3 BP 251 EP 251 DI 10.7326/0003-4819-156-3-201202070-00024 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 887XD UT WOS:000299964200018 ER PT J AU Jaber, N Dou, ZX Chen, JS Catanzaro, J Jiang, YP Ballou, LM Selinger, E Ouyang, XS Lin, RZ Zhang, JH Zong, WX AF Jaber, Nadia Dou, Zhixun Chen, Juei-Suei Catanzaro, Joseph Jiang, Ya-Ping Ballou, Lisa M. Selinger, Elzbieta Ouyang, Xiaosen Lin, Richard Z. Zhang, Jianhua Zong, Wei-Xing TI Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE LC3; SQSTM1/p62; 3-MA; epidermal growth factor receptor; transferrin ID PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASES; EARLY ENDOSOMES; SELF-DIGESTION; METABOLISM; PATHWAY; HVPS34; CANCER; MICE; ACTIVATION AB A critical regulator of autophagy is the Class III PI3K Vps34 (also called PIK3C3). Although Vps34 is known to play an essential role in autophagy in yeast, its role in mammals remains elusive. To elucidate the physiological function of Vps34 and to determine its precise role in autophagy, we have generated Vps34(f/f) mice, in which expression of Cre recombinase results in a deletion of exon 4 of Vps34 and a frame shift causing a deletion of 755 of the 887 amino acids of Vps34. Acute ablation of Vps34 in MEFs upon adenoviral Cre infection results in a diminishment of localized generation of phosphatidylinositol 3-phosphate and blockade of both endocytic and autophagic degradation. Starvation-induced autophagosome formation is blocked in both Vps34-null MEFs and liver. Liver-specific Albumin-Cre; Vps34(f/f) mice developed hepatomegaly and hepatic steatosis, and impaired protein turnover. Ablation of Vps34 in the heart of muscle creatine kinase-Cre; Vps34(f/f) mice led to cardiomegaly and decreased contractility. In addition, while amino acid-stimulated mTOR activation was suppressed in the absence of Vps34, the steady-state level of mTOR signaling was not affected in Vps34-null MEFs, liver, or cardiomyocytes. Taken together, our results indicate that Vps34 plays an essential role in regulating functional autophagy and is indispensable for normal liver and heart function. C1 [Zhang, Jianhua] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Jaber, Nadia; Dou, Zhixun; Chen, Juei-Suei; Catanzaro, Joseph; Zong, Wei-Xing] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA. [Jiang, Ya-Ping; Selinger, Elzbieta; Lin, Richard Z.] SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA. [Ballou, Lisa M.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. [Lin, Richard Z.] Northport VA Med Ctr, Northport, NY 11768 USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Zhang, JH (reprint author), Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. EM zhanja@uab.edu; wzong@notes.cc.sunysb.edu RI Lin, Richard/J-1754-2014 OI Lin, Richard/0000-0002-3473-7276; Zhang, Jianhua/0000-0002-2128-9574 FU National Institute of Health [CA129536, DK62722, CA136754, NS064090]; Susan Komen for the Cure [KG081538]; Department of Veterans Affairs; Carol Baldwin Breast Cancer Research Foundation FX We thank Drs. Deborah Brown, Noboru Mizushima, Zhenyu Yue, Qing Zhong, and Hong Chen for reagents and insightful suggestions; Namratha Sheshadri, Shengnan Liu, and Debjani Pal for technical assistance; and Susan van Horn and Edward Philips for assistance on EM. Work was supported by National Institute of Health Grants CA129536 (to W.-X.Z.), DK62722, CA136754 (to R.Z.L.), and NS064090 (to J.Z.), Susan Komen for the Cure Grant KG081538 (to W.-X.Z.), Department of Veterans Affairs merit awards (to R.Z.L. and J.Z.), and the Carol Baldwin Breast Cancer Research Foundation (to W.-X.Z.). NR 42 TC 134 Z9 144 U1 3 U2 30 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 7 PY 2012 VL 109 IS 6 BP 2003 EP 2008 DI 10.1073/pnas.1112848109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 887KC UT WOS:000299925000045 PM 22308354 ER PT J AU Newton, TF De la Garza, R Brown, G Kosten, TR Mahoney, JJ Haile, CN AF Newton, Thomas F. De la Garza, Richard, II Brown, Gregory Kosten, Thomas R. Mahoney, James J., III Haile, Colin N. TI Noradrenergic alpha(1) Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial SO PLOS ONE LA English DT Article ID ABUSE LIABILITY; RHESUS-MONKEYS; D-AMPHETAMINE; LOCOMOTOR; REINSTATEMENT; DOXAZOSIN; DOPAMINE; PRAZOSIN; AGONIST; NOREPINEPHRINE AB Background: Preclinical research implicates dopaminergic and noradrenergic mechanisms in mediating the reinforcing effects of drugs of abuse, including cocaine. The objective of this study was to evaluate the impact of treatment with the noradrenergic alpha(1) receptor antagonist doxazosin on the positive subjective effects of cocaine. Methods: Thirteen non-treatment seeking, cocaine-dependent volunteers completed this single-site, randomized, placebo-controlled, within-subjects study. In one study phase volunteers received placebo and in the other they received doxazosin, with the order counterbalanced across participants. Study medication was masked by over-encapsulating doxazosin tablets and matched placebo lactose served as the control. Study medication treatment was initiated at 1 mg doxazosin or equivalent number of placebo capsules PO/day and increased every three days by 1 mg. After receiving 4 mg doxazosin or equivalent number of placebo capsules participants received masked doses of 20 and 40 mg cocaine IV in that order with placebo saline randomly interspersed to maintain the blind. Results: Doxazosin treatment was well tolerated and doxazosin alone produced minimal changes in heart rate and blood pressure. During treatment with placebo, cocaine produced dose-dependent increases in subjective effect ratings of "high'', "stimulated'', "like cocaine'', "desire cocaine'', "any drug effect'', and "likely to use cocaine if had access'' (p<.001). Doxazosin treatment significantly attenuated the effects of 20 mg cocaine on ratings of "stimulated'', "like cocaine'', and "likely to use cocaine if had access'' (p<.05). There were trends for doxazosin to reduce ratings of "stimulated'', "desire cocaine'', and "likely to use cocaine if had access'' (p<.10). Conclusions: Medications that block noradrenergic alpha(1) receptors, such as doxazosin, may be useful as treatments for cocaine dependence, and should be evaluated further. C1 [Newton, Thomas F.; De la Garza, Richard, II; Brown, Gregory; Kosten, Thomas R.; Mahoney, James J., III; Haile, Colin N.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Newton, TF (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM tnewton@bcm.edu RI De La Garza, Richard/B-2489-2014; Mahoney, James/I-2753-2014 OI De La Garza, Richard/0000-0003-1943-4469; Mahoney, James/0000-0003-0824-1776; Haile, Colin/0000-0001-8293-7291; newton, thomas/0000-0002-3198-5901; Brown, Grant/0000-0002-9002-5003 FU National Institutes of Health [P50 DA18197, M01 RR00188] FX This study was supported by grants from the National Institutes of Health, P50 DA18197 and M01 RR00188. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 21 Z9 22 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 3 PY 2012 VL 7 IS 2 AR e30854 DI 10.1371/journal.pone.0030854 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 917LO UT WOS:000302178400017 PM 22319592 ER PT J AU Das, F Ghosh-Choudhury, N Dey, N Mandal, CC Mahimainathan, L Kasinath, BS Abboud, HE Choudhury, GG AF Das, Falguni Ghosh-Choudhury, Nandini Dey, Nirmalya Mandal, Chandi Charan Mahimainathan, Lenin Kasinath, Balakuntalam S. Abboud, Hanna E. Choudhury, Goutam Ghosh TI Unrestrained Mammalian Target of Rapamycin Complexes 1 and 2 Increase Expression of Phosphatase and Tensin Homolog Deleted on Chromosome 10 to Regulate Phosphorylation of Akt Kinase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TUMOR-SUPPRESSOR GENE; TUBEROUS-SCLEROSIS; SIGNALING PATHWAY; S6 KINASE; INSULIN-RESISTANCE; BINDING PARTNER; MTOR COMPLEX; ACTIVATION; PTEN; TSC2 AB Tuberous sclerosis complex 2 (TSC2) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) function to block growth factor-induced mammalian target of rapamycin (mTOR) signaling and are mutated in autosomal dominant hamartoma syndromes. mTOR binds to a spectrum of common and different proteins to form TOR complex 1 (TORC1) and TORC2, which regulate cell growth, division, and metabolism. TSC2 deficiency induces constitutive activation of mTOR, leading to a state of insulin resistance due to a negative feedback regulation, resulting in reduced Akt phosphorylation. We have recently described an alternative mechanism showing that in TSC2 deficiency, enhanced PTEN expression contributes to reduced Akt phosphorylation. To explore the mechanism of PTEN regulation, we used rapamycin and constitutively active mTOR to show that TORC1 increases the expression of PTEN mRNA and protein. We found that in TSC2(-/-) mouse embryonic fibroblasts expression of a kinase-dead mutant of mTOR, which inhibits both TORC1 and TORC2, decreases the expression of PTEN via transcriptional mechanism. Furthermore, kinase-deadm TOR increased and decreased phosphorylation of Akt at catalytic loop site Thr-308 and hydrophobic motif site Ser-473, respectively. Moreover, inhibition of deregulated TORC1 in TSC2-null mouse embryonic fibroblasts or in 293 cells by down-regulation of raptor decreased the levels of the transcription factor Hif1 alpha and blocked PTEN expression, resulting in enhanced phosphorylation of Akt at Thr-308 and Ser-473. Finally, knockdown of rictor or mSin1 attenuated the expression of Hif1 alpha, which decreased transcription of PTEN. These results unravel a previously unrecognized cell-autonomous function of TORC1 and TORC2 in the up-regulation of PTEN, which prevents phosphorylation of Akt and may shield against the development of malignancy in TSC patients. C1 [Das, Falguni; Dey, Nirmalya; Mahimainathan, Lenin; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Mandal, Chandi Charan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Vet Affairs Res, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu OI /0000-0001-5077-3552 FU National Institutes of Health [RO1 DK50190, RO1 AR 52425, RO1 DK 077295, RC2A 036613]; Veterans Affairs Merit Review; Cancer Therapy and Research Center, San Antonio; Veterans Affairs Senior Research Career Scientist Award; Juvenile Diabetes Research Foundation [1-2008-185] FX This work was supported, in whole or in part, by National Institutes of Health Grants RO1 DK50190 (to G. G. C.), RO1 AR 52425 (to N. G. C.). This work was also supported by Veterans Affairs Merit Review grant (to G. G. C.).; Supported by Veterans Affairs Merit Review grants and a Ronald P. Williams Orthopedic Oncology Developmental Research Award from Cancer Therapy and Research Center, San Antonio.; Supported by NIH RO1 DK 077295, RC2A 036613, and Veterans Affairs Research Service grant.; Recipient of a Veterans Affairs Senior Research Career Scientist Award and supported by Regular Research Grant 1-2008-185 from the Juvenile Diabetes Research Foundation. To whom correspondence should be addressed: Dept. of Medicine, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78229. E-mail: choudhuryg@uthscsa.edu. NR 65 TC 21 Z9 21 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 3 PY 2012 VL 287 IS 6 BP 3808 EP 3822 DI 10.1074/jbc.M111.246397 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 894EX UT WOS:000300410900018 PM 22184110 ER PT J AU Ludvigsson, J Krisky, D Casas, R Battelino, T Castano, L Greening, J Kordonouri, O Otonkoski, T Pozzilli, P Robert, JJ Veeze, HJ Palmer, J AF Ludvigsson, Johnny Krisky, David Casas, Rosaura Battelino, Tadej Castano, Luis Greening, James Kordonouri, Olga Otonkoski, Timo Pozzilli, Paolo Robert, Jean-Jacques Veeze, Henk J. Palmer, Jerry TI GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID BETA-CELL FUNCTION; DOUBLE-BLIND TRIAL; PROTEIN PEPTIDE DIAPEP277; LONG-TERM COMPLICATIONS; RECENT-ONSET; INSULIN-SECRETION; C-PEPTIDE; KETOACIDOSIS; CHILDREN; RECOMMENDATIONS AB Background The 65-kD isoform of glutamic acid decarboxylase (GAD65) is a major autoantigen in type 1 diabetes. We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function in patients with recent-onset type 1 diabetes. Methods We studied 334 patients, 10 to 20 years of age, with type 1 diabetes, fasting C-peptide levels of more than 0.3 ng per milliliter (0.1 nmol per liter), and detectable serum GAD65 autoantibodies. Within 3 months after diagnosis, patients were randomly assigned to receive one of three study treatments: four doses of GAD-alum, two doses of GAD-alum followed by two doses of placebo, or four doses of placebo. The primary outcome was the change in the stimulated serum C-peptide level (after a mixed-meal tolerance test) between the baseline visit and the 15-month visit. Secondary outcomes included the glycated hemoglobin level, mean daily insulin dose, rate of hypoglycemia, and fasting and maximum stimulated C-peptide levels. Results The stimulated C-peptide level declined to a similar degree in all study groups, and the primary outcome at 15 months did not differ significantly between the combined active-drug groups and the placebo group (P=0.10). The use of GAD-alum as compared with placebo did not affect the insulin dose, glycated hemoglobin level, or hypoglycemia rate. Adverse events were infrequent and mild in the three groups, with no significant differences. Conclusions Treatment with GAD-alum did not significantly reduce the loss of stimulated C peptide or improve clinical outcomes over a 15-month period. (Funded by Diamyd Medical and the Swedish Child Diabetes Foundation; ClinicalTrials.gov number, NCT00723411.) C1 [Ludvigsson, Johnny] Linkoping Univ, Dept Clin & Expt Med, Div Pediat, S-58185 Linkoping, Sweden. [Krisky, David] Diamyd Med, Pittsburgh, PA USA. [Battelino, Tadej] Univ Med Ctr Univ Childrens Hosp, Fac Med, Ljubljana, Slovenia. [Castano, Luis] Hosp Cruces Univ Basque Country, Baracaldo, Bizkaia, Spain. [Greening, James] Leicester Royal Infirm, Dept Paediat, Leicester, Leics, England. [Kordonouri, Olga] Kinderkrankenhaus Bult, Diabet Ctr Children & Adolescents, Hannover, Germany. [Otonkoski, Timo] Univ Helsinki, Childrens Hosp, Helsinki, Finland. [Otonkoski, Timo] Helsinki Univ Cent Hosp, Helsinki, Finland. [Pozzilli, Paolo] Univ Campus Biomed, Rome, Italy. [Robert, Jean-Jacques] Univ Paris 05, Hop Necker Enfants Malades, Paris, France. [Veeze, Henk J.] Stichting Diabeter, Rotterdam, Netherlands. [Palmer, Jerry] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Palmer, Jerry] Univ Washington, Seattle, WA 98195 USA. RP Ludvigsson, J (reprint author), Linkoping Univ, Dept Clin & Expt Med, Div Pediat, S-58185 Linkoping, Sweden. EM johnny.ludvigsson@liu.se RI Rica, Itxaso /E-7645-2012; , Ivan/D-6804-2012 OI , Ivan/0000-0002-3108-058X FU Diamyd Medical; Swedish Child Diabetes Foundation (Barndiabetesfonden) FX Supported by Diamyd Medical and the Swedish Child Diabetes Foundation (Barndiabetesfonden). NR 36 TC 121 Z9 129 U1 5 U2 41 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 2 PY 2012 VL 366 IS 5 BP 433 EP 442 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 884QX UT WOS:000299724400008 PM 22296077 ER PT J AU Girgis, M Lin, WY Hou, S Rochefort, M Shen, C Tomlinson, JS AF Girgis, M. Lin, W. Y. Hou, S. Rochefort, M. Shen, C. Tomlinson, J. S. TI MicroPET Evaluation of In Vivo Biorthogonal Click Chemistry Reaction between a Radiolabeled Tetrazine Probe and TCO-modified Nanoparticles SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Girgis, M.; Tomlinson, J. S.] Univ Calif Los Angeles, Div Surg Oncol, Los Angeles, CA USA. [Rochefort, M.] VA Greater Los Angeles, Dept Surg, Los Angeles, CA USA. [Lin, W. Y.; Hou, S.; Shen, C.] Univ Calif Los Angeles, Crump Mol Imaging Inst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S18 EP S19 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700040 ER PT J AU Merkow, RP Kmiecik, TE Bentrem, DJ Chow, WB Cohen, ME Hall, BL Ko, CY Bilimoria, KY AF Merkow, R. P. Kmiecik, T. E. Bentrem, D. J. Chow, W. B. Cohen, M. E. Hall, B. L. Ko, C. Y. Bilimoria, K. Y. TI Do Cancer-specific Variables Improve Risk-adjusted Hospital Quality Comparisons? SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Merkow, R. P.; Kmiecik, T. E.; Bentrem, D. J.; Bilimoria, K. Y.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Chow, W. B.; Ko, C. Y.] Univ Calif Los Angeles, Los Angeles, CA USA. [Chow, W. B.; Ko, C. Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cohen, M. E.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Hall, B. L.] Washington Univ, St Louis, MO USA. [Hall, B. L.] Barnes Jewish Hosp, St Louis, MO 63110 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S6 EP S6 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700002 ER PT J AU Rochefort, MM Girgis, MD Knowles, S Bergara, F Olafsen, T Tomlinson, JS AF Rochefort, M. M. Girgis, M. D. Knowles, S. Bergara, F. Olafsen, T. Tomlinson, J. S. TI An Engineered Chimeric, Fc Mutated, Anti-CA19-9 scFv-Fc for Imaging Pancreas Cancer SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 65th Annual Cancer Symposium of the Society-of-Surgical-Oncology (SSO) CY MAR 21-24, 2012 CL Orlando, FL SP Soc Surg Oncol (SSO) C1 [Rochefort, M. M.; Girgis, M. D.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Knowles, S.; Bergara, F.; Olafsen, T.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Insitute Mol Imaging, Los Angeles, CA 90024 USA. [Tomlinson, J. S.] Vet Affairs Greater Los Angeles, Dept Surg, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 SU 1 BP S44 EP S44 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA 025PE UT WOS:000310202700111 ER PT J AU Reisinger, HS Hunt, SC Burgo-Black, AL Agarwal, MA AF Reisinger, Heather Schacht Hunt, Stephen C. Burgo-Black, A. Lucile Agarwal, Madhulika A. TI A Population Approach to Mitigating the Long-Term Health Effects of Combat Deployments SO PREVENTING CHRONIC DISEASE LA English DT Article ID TRAUMATIC BRAIN-INJURY; RISK-FACTORS; VETERANS; IRAQ; CARE; AFGHANISTAN; WAR; POLYTRAUMA; SOLDIERS; SYSTEM AB A major focus of the mission of the US Department of Veterans Affairs (VA) is to respond to the needs of military personnel returning from war. Given the broad spectrum of the potential effects of combat deployment on the health and well being of service members, VA is increasingly oriented toward comprehensive postcombat support, health promotion, disease prevention, and proactive approaches to caring for combat veterans. This article briefly summarizes the health care needs of service members returning from Afghanistan and Iraq, describes VA's approaches to addressing their needs, and outlines VA's evolving vision for how to apply principles of population health management to ensure prompt and effective response to the postdeployment needs of veterans returning from future conflicts. At the heart of postcombat care will be population-based approaches oriented to health recovery using interdisciplinary, team-based platforms. C1 [Hunt, Stephen C.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Hunt, Stephen C.] Univ Washington, Sch Med, Seattle, WA USA. [Burgo-Black, A. Lucile] VA Connecticut Healthcare Syst, New Haven, CT USA. [Burgo-Black, A. Lucile] Yale Univ, Sch Med, New Haven, CT USA. [Agarwal, Madhulika A.] Off Hlth Policy & Serv, Dept Vet Affairs, Washington, DC USA. RP Reisinger, HS (reprint author), Iowa City VA Healthcare Syst, CADRE, 601 Hwy 6 W, Iowa City, IA 52246 USA. EM heather.reisinger@va.gov FU VA career development award [CD1 08-013-1] FX We thank our interdisciplinary team, Margaret Hammond, Ira Katz, Linda Kinsinger, Larry Mole, Joel Scholten, and Terry Walters, who reviewed this manuscript and provided important feedback. Dr. Reisinger acknowledges the support of her VA career development award (CD1 08-013-1), which focuses on VA outreach to OEF/OIF/OND service members and their families. NR 23 TC 2 Z9 2 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD FEB PY 2012 VL 9 AR 110116 DI 10.5888/pcd9.110116 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 977HC UT WOS:000306646300007 ER PT J AU Sapozhnikova, V Willsey, B Asmis, R Wang, TY Jenkins, JT Mancuso, J Ma, LL Kuranov, R Milner, TE Johnston, K Feldman, MD AF Sapozhnikova, Veronika Willsey, Brian Asmis, Reto Wang, Tianyi Jenkins, James Travis Mancuso, Jacob Ma, Li Leo Kuranov, Roman Milner, Thomas E. Johnston, Keith Feldman, Marc D. TI Use of near-infrared luminescent gold nanoclusters for detection of macrophages SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE nanoparticles; imaging; luminescence spectroscopy; biophotonics ID QUANTUM DOTS; NANOPARTICLES; FLUORESCENCE; SILICA; CANCER; MOUSE; CELLS AB We determined the effect of aggregation and coating thickness of gold on the luminescence of nanoparticles engulfed by macrophages and in gelatin phantoms. Thin gold-coated iron oxide nanoclusters (nanoroses) have been developed to target macrophages to provide contrast enhancement for near-infrared optical imaging applications. We compare the brightness of nanoroses luminescent emissions in response to 635 nm laser excitation to other nanoparticles including nanoshells, nanorods, and Cy5 conjugated iron oxide nanoparticles. Luminescent properties of all these nanoparticles were investigated in monomeric and aggregated form in gelatin phantoms and primary macrophage cell cultures using confocal microscopy. Aggregation of the gold nanoparticles increased luminescence emission and correlated with increased surface mass of gold per nanoparticle (nanoshells 37 +/- 14.30 x 10(-3) brightness with 1.23 x 10(-4) wt of gold (g)/nanoparticle versus original nanorose 1.45 +/- 0.37 x 10(-3) with 2.10 x 10(-16) wt of gold/nanoparticle, p < 0.05). Nanoshells showed greater luminescent intensity than original nanoroses or Cy5 conjugated iron oxide nanoparticles when compared as nanoparticles per macrophage (38 +/- 10 versus 11 +/- 2.8 versus 17 +/- 6.5, p < 0.05, respectively, ANOVA), but showed relatively poor macrophage uptake (1025 +/- 128 versus 7549 +/- 236 versus 96, 000 nanoparticles/cell, p < 0.05, student t-test nanoshel Is versus nanoroses). Enhancement of gold fluorescent emissions by nanoparticles can be achieved by reducing the thickness of the gold coating, by clustering the gold on the surface of the nanoparticles (nanoshells), and by clustering the gold nanoparticles themselves. (C) 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.JBO.17.2.026006] C1 [Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX 78229 USA. [Willsey, Brian; Ma, Li Leo; Johnston, Keith] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA. [Sapozhnikova, Veronika] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Asmis, Reto] Univ Texas Hlth Sci Ctr San Antonio, Dept Clin Lab Sci, San Antonio, TX 78229 USA. [Asmis, Reto] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Wang, Tianyi] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Kuranov, Roman] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Milner, Thomas E.] Univ Texas Austin, Inst Cellular & Mol Biol, Dept Biomed Engn, Austin, TX 78712 USA. RP Feldman, MD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Room 5-642,7703 Floyd Curl Dr, San Antonio, TX 78248 USA. EM feldmanm@uthscsa.edu OI Ma, Li/0000-0002-0959-5616 FU UTHSCSA; NIH-NCI [P30 CA54174]; NIH-NIA [P01AG19316]; Veterans Administration; NIH NRSA [HL07446] FX The authors would like to thank Hunter Barbara for assistance with TEM imaging and cell culture processing. Confocal images were generated in the Core Optical Imaging Facility, which is supported by UTHSCSA, NIH-NCI P30 CA54174 (CTRC at UTHSCSA) and NIH-NIA P01AG19316. The current study was supported by Veterans Administration Merit Grant, and NIH NRSA Grant #HL07446. NR 29 TC 4 Z9 4 U1 3 U2 45 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD FEB PY 2012 VL 17 IS 2 AR 026006 DI 10.1117/1.JBO.17.2.026006 PG 12 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 929AM UT WOS:000303033600022 PM 22463038 ER PT J AU Villemagne, VL Klunk, WE Mathis, CA Rowe, CC Brooks, DJ Hyman, BT Ikonomovic, MD Ishii, K Jack, CR Jagust, WJ Johnson, KA Koeppe, RA Lowe, VJ Masters, CL Montine, TJ Morris, JC Nordberg, A Petersen, RC Reiman, EM Selkoe, DJ Sperling, RA Van Laere, K Weiner, MW Drzezga, A AF Villemagne, Victor L. Klunk, William E. Mathis, Chester A. Rowe, Christopher C. Brooks, David J. Hyman, Bradley T. Ikonomovic, Milos D. Ishii, Kenji Jack, Clifford R. Jagust, William J. Johnson, Keith A. Koeppe, Robert A. Lowe, Val J. Masters, Colin L. Montine, Thomas J. Morris, John C. Nordberg, Agneta Petersen, Ronald C. Reiman, Eric M. Selkoe, Dennis J. Sperling, Reisa A. Van Laere, Koen Weiner, Michael W. Drzezga, Alexander TI A beta Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Editorial Material ID PITTSBURGH COMPOUND-B; POSITRON-EMISSION-TOMOGRAPHY; MILD COGNITIVE IMPAIRMENT; CEREBRAL AMYLOID ANGIOPATHY; C-11-PIB PET; NEUROPATHOLOGIC ASSESSMENT; LEWY BODIES; MOUSE MODEL; HUMAN BRAIN; PIB-PET C1 [Drzezga, Alexander] Tech Univ Munich, Dept Nucl Med, Munich, Germany. [Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Dept Nucl Med, Heidelberg, Vic, Australia. [Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Ctr PET, Heidelberg, Vic, Australia. [Klunk, William E.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Mathis, Chester A.] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA. [Brooks, David J.] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2AZ, England. [Brooks, David J.] GE Healthcare, Med Diagnost, Amersham, Bucks, England. [Johnson, Keith A.; Selkoe, Dennis J.; Sperling, Reisa A.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Ishii, Kenji] Tokyo Metropolitan Inst Gerontol, Positron Med Ctr Clin, Itabashi Ku, Tokyo, Japan. [Jack, Clifford R.; Lowe, Val J.] Mayo Clin, Dept Radiol, Rochester, MN USA. [Jagust, William J.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Johnson, Keith A.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Koeppe, Robert A.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA. [Masters, Colin L.] Univ Melbourne, Mental Hlth Res Inst, Parkville, Vic 3052, Australia. [Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Morris, John C.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA. [Nordberg, Agneta] Karolinska Univ Hosp, Dept Neurobiol Care Sci & Soc, Karolinska Inst, Stockholm, Sweden. [Petersen, Ronald C.] Mayo Clin, Dept Neurol, Coll Med, Rochester, MN USA. [Reiman, Eric M.] Univ Arizona, Banner Alzheimers Inst, Phoenix, AZ USA. [Van Laere, Koen] Katholieke Univ Leuven Hosp, Div Nucl Med, Louvain, Belgium. [Weiner, Michael W.] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Drzezga, A (reprint author), Tech Univ Munich, Dept Nucl Med, Munich, Germany. EM villemagne@petnm.unimelb.edu.au; klunkwe@upmc.edu; mathisca@upmc.edu; christopher.rowe@austin.org.au; david.brooks@csc.mrc.ac.uk; bhyman@partners.org; ikonomovicmd@upmc.edu; ishii@pet.tmig.or.jp; jack.clifford@mayo.edu; jagust@berkeley.edu; kajohnson@partners.org; koeppe@umich.edu; vlowe@mayo.edu; c.masters@unimelb.edu.au; tmontine@uw.edu; morrisj@abraxas.wustl.edu; agneta.k.nordberg@ki.se; peter8@mayo.edu; eric.reiman@bannerhealth.com; dselkoe@rics.bwh.harvard.edu; reisa@rics.bwh.harvard.edu; koen.vanlaere@uzleuven.be; michael.weiner@ucsf.edu; a.drzezga@lrz.tu-muenchen.de RI Jack, Clifford/F-2508-2010; IBL, A/C-8408-2013 OI Jack, Clifford/0000-0001-7916-622X; Klunk, William/0000-0001-5512-0251 FU Medical Research Council [MC_U120036861]; NIA NIH HHS [P30 AG019610, R01 AG006173] NR 90 TC 22 Z9 23 U1 0 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD FEB PY 2012 VL 39 IS 2 BP 209 EP 219 DI 10.1007/s00259-011-2045-0 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 918YC UT WOS:000302286600002 PM 22218879 ER PT J AU Ford, JM Mathalon, DH AF Ford, Judith M. Mathalon, Daniel H. TI Anticipating the future: Automatic prediction failures in schizophrenia SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Review DE Schizophrenia; Efference copy; Corollary discharge; Context; ERPs ID COROLLARY DISCHARGE DYSFUNCTION; PRIMATE AUDITORY-CORTEX; CORTICAL RESPONSIVENESS; STIMULUS SEQUENCE; SPEECH PRODUCTION; EFFERENCE COPY; P300; RESPONSES; DEFICITS; SYMPTOMS AB People with schizophrenia often misperceive sensations and misinterpret experiences, perhaps contributing to psychotic symptoms. These misperceptions and misinterpretations might result from an inability to make valid predictions about expected sensations and experiences. Healthy normal people take advantage of neural mechanisms that allow them to make predictions unconsciously, facilitating processing of expected sensations and distinguishing the expected from the unexpected. In this paper, we focus on two types of automatic, unconscious mechanisms that allow us to predict our perceptions. The first involves predictions made via innate mechanisms basic to all species in the animal kingdom - the efference copy and corollary discharge mechanisms. They accompany our voluntary movements and allow us to suppress sensations resulting from our actions. We study this during talking, and show that auditory cortical response to the speech sounds during talking is reduced compared to when they are played back. This suppression is reduced in schizophrenia, suggesting a failure to predict the sensations resulting from talking. The second mechanism involves implicitly learning what to expect from the current context of events. We study this by observing the brain's response to an unexpected repetition of an event, when a change would have been predicted. That patients have a reduced response suggests they failed to predict that it was time for a change. Both types of predictions should happen automatically and effortlessly, allowing for economic processing of expected events and orientation to unexpected ones. These prediction failures characterize the diagnosis of schizophrenia rather than reflecting specific symptoms. Published by Elsevier B.V. C1 [Ford, Judith M.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv, 116D,4150 Clement St, San Francisco, CA 94121 USA. EM Judith.ford@yale.edu OI Mathalon, Daniel/0000-0001-6090-4974 FU NIMH [R01, K02]; VA (Merit Review); NARSAD FX This work was supported by grants from NIMH (R01, K02) and the VA (Merit Review), which were administered by the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, California. This work was also supported by NARSAD. NR 85 TC 34 Z9 35 U1 2 U2 24 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD FEB PY 2012 VL 83 IS 2 SI SI BP 232 EP 239 DI 10.1016/j.ijpsycho.2011.09.004 PG 8 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 921ZW UT WOS:000302517600013 PM 21959054 ER PT J AU Ribeiro, JD Pease, JL Gutierrez, PM Silva, C Bernert, RA Rudd, MD Joiner, TE AF Ribeiro, Jessica D. Pease, James L. Gutierrez, Peter M. Silva, Caroline Bernert, Rebecca A. Rudd, M. David Joiner, Thomas E., Jr. TI Sleep problems outperform depression and hopelessness as cross-sectional and longitudinal predictors of suicidal ideation and behavior in young adults in the military SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Sleep; Insomnia; Suicide; Suicidal ideation; Depression; Hopelessness ID MENTAL-HEALTH PROBLEMS; MAJOR DEPRESSION; COMPLETED SUICIDE; MODIFIED SCALE; RISK-FACTORS; MCMI-III; DISORDER; INSOMNIA; DISTURBANCE; NIGHTMARES AB Background: Sleep problems appear to represent an underappreciated and important warning sign and risk factor for suicidal behaviors. Given past research indicating that disturbed sleep may confer such risk independent of depressed mood, in the present report we compared self-reported insomnia symptoms to several more traditional, well-established suicide risk factors: depression severity, hopelessness, PTSD diagnosis, as well as anxiety, drug abuse, and alcohol abuse symptoms. Methods: Using multiple regression, we examined the cross-sectional and longitudinal relationships between insomnia symptoms and suicidal ideation and behavior, controlling for depressive symptom severity, hopelessness, PTSD diagnosis, anxiety symptoms, and drug and alcohol abuse symptoms in a sample of military personnel (N = 311). Results: In support of a priori hypotheses, self-reported insomnia symptoms were crosssectionally associated with suicidal ideation, even after accounting for symptoms of depression, hopelessness. PTSD diagnosis, anxiety symptoms and drug and alcohol abuse. Self-reported insomnia symptoms also predicted suicide attempts prospectively at one-month follow up at the level of a non-significant trend, when controlling for baseline self-reported insomnia symptoms, depression, hopelessness, FTSD diagnosis and anxiety, drug and alcohol abuse symptoms. Insomnia symptoms were unique predictors of suicide attempt longitudinally when only baseline self-reported insomnia symptoms, depressive symptoms and hopelessness were controlled. Limitations: The assessment of insomnia symptoms consisted of only three self-report items. Findings may not generalize outside of populations at severe suicide risk. Conclusions: These findings suggest that insomnia symptoms may be an important target for suicide risk assessment and the treatment development of interventions to prevent suicide. (C) 2011 Elsevier B.V. All rights reserved. C1 [Ribeiro, Jessica D.; Silva, Caroline; Joiner, Thomas E., Jr.] Florida State Univ, Tallahassee, FL 32306 USA. [Pease, James L.; Gutierrez, Peter M.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA. [Bernert, Rebecca A.] Stanford Univ, Stanford, CA 94305 USA. [Rudd, M. David] Univ Utah, Salt Lake City, UT 84112 USA. RP Joiner, TE (reprint author), Florida State Univ, Tallahassee, FL 32306 USA. EM joiner@psy.fsu.edu OI Silva, Caroline/0000-0002-7477-1495; Gutierrez, Peter/0000-0001-8981-8404 FU Department of Defense FX This research was supported, in part, by grants awarded to the Denver VA Medical Center and to Florida State University by the Department of Defense. The Department of Defense had no further role in the study design: in the collection, analysis, and interpretation of data: in the writing of the report; and in the decision to submit the paper for publication. The views and opinions expressed do not represent those of the Department of Veterans Affairs, the Department of Defense, or the United States Government. NR 86 TC 70 Z9 74 U1 1 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2012 VL 136 IS 3 BP 743 EP 750 DI 10.1016/j.jad.2011.09.049 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915AT UT WOS:000301996000071 PM 22032872 ER PT J AU Meghani, SH Byun, E Gallagher, RM AF Meghani, Salimah H. Byun, Eeeseung Gallagher, Rollin M. TI Time to Take Stock: A Meta-Analysis and Systematic Review of Analgesic Treatment Disparities for Pain in the United States SO PAIN MEDICINE LA English DT Review DE Pain; DisparitiesuEthnic; DisparitiesuRacial; Pain Management; Pain Treatment; Opioids; Analgesics; The Joint Commission; United States ID LOW-BACK INJURIES; EMERGENCY-DEPARTMENT PATIENTS; ACUTE ABDOMINAL-PAIN; LONG-BONE FRACTURES; ETHNIC DISPARITIES; RACIAL-DIFFERENCES; AFRICAN-AMERICANS; PRIMARY-CARE; POSTOPERATIVE PAIN; EPIDURAL ANALGESIA AB Background. The recent Institute of Medicine Report assessing the state of pain care in the United States acknowledged the lack of consistent data to describe the nature and magnitude of unrelieved pain and identify subpopulations with disproportionate burdens. Objectives. We synthesized 20 years of cumulative evidence on racial/ethnic disparities in analgesic treatment for pain in the United States. Evidence was examined for the 1) magnitude of association between race/ethnicity and analgesic treatment; 2) subgroups at an increased risk; and 3) the effect of moderators ( pain type, setting, study quality, and data collection period) on this association. Methods. United States studies with at least one explicit aim or analysis comparing analgesic treatment for pain between Whites and a minority group were included ( SciVerse Scopus database, 19892011). Results. Blacks/African Americans experienced both a higher number and magnitude of disparities than any other group in the analyses. Opioid treatment disparities were ameliorated for Hispanics/ Latinos for " traumatic/surgical" pain ( P = 0.293) but remained for " non- traumatic/nonsurgical" pain ( odds ratio [OR] = 0.70, 95% confidence interval [CI] = 0.64- 0.77, P = 0.000). For Blacks/African Americans, opioid prescription disparities were present for both types of pain and were starker for " non- traumatic/nonsurgical" pain ( OR = 0.66, 95% CI = 0.59- 0.75, P = 0.000). In subanalyses, opioid treatment disparities for Blacks/African Americans remained consistent across pain types, settings, study quality, and data collection periods. Conclusion. Our study quantifies the magnitude of analgesic treatment disparities in subgroups of minorities. The size of the difference was sufficiently large to raise not only normative but quality and safety concerns. The treatment gap does not appear to be closing with time or existing policy initiatives. A concerted strategy is needed to reduce pain care disparities within the larger quality of care initiatives. C1 [Meghani, Salimah H.; Byun, Eeeseung] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Gallagher, Rollin M.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Meghani, SH (reprint author), Univ Penn, NewCourtland Ctr Transit & Hlth, Dept Biobehav Hlth Sci, Claire M Fagin Hall,418 Curie Blvd,Room 337, Philadelphia, PA 19104 USA. EM meghanis@nursing.upenn.edu FU Pricara, Unit of Ortho-McNeil, Inc. FX This work was supported by an unrestricted educational grant to the Philadelphia Research and Education Foundation, Philadelphia VA Medical Center, from Pricara, Unit of Ortho-McNeil, Inc. administered by Ortho-McNeil Janssen Scientific Affairs. NR 80 TC 35 Z9 35 U1 3 U2 9 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD FEB PY 2012 VL 13 IS 2 BP 150 EP 174 DI 10.1111/j.1526-4637.2011.01310.x PG 25 WC Medicine, General & Internal SC General & Internal Medicine GA 897YZ UT WOS:000300700900003 PM 22239747 ER PT J AU Shega, JW Andrew, M Hemmerich, J Cagney, KA Ersek, M Weiner, DK Dale, W AF Shega, Joseph W. Andrew, Melissa Hemmerich, Josh Cagney, Kathleen A. Ersek, Mary Weiner, Debra K. Dale, William TI The Relationship of Pain and Cognitive Impairment with Social VulnerabilityuAn Analysis of the Canadian Study of Health and Aging SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Cognitively Impaired; Social ID OLDER-ADULTS; PREVALENCE; DEMENTIA; PEOPLE; OSTEOARTHRITIS; INTEGRATION; POPULATION; DECLINE; COHORT; SCALE AB Objective. The objective of this study was to delineate the relationship between noncancer pain and cognitive impairment with social vulnerability. Design. The study was designed as a crosssectional analysis of the Canadian Study of Health and Aging, 1996 wave. Setting. Community-dwelling older adults in Canada. Subjects. 3,776 study participants. Outcome Measures. Pain was categorized as no or very mild pain vs moderate or severe pain. Cognitive impairment was dichotomized from the Modified Mini-Mental State Examination (0-100) to no (> 77) or impairment (77 or <). Social vulnerability (outcome) was operationalized as the accumulation of 39 possible self-report variables related to social circumstance, scores range from 0 to 1, where higher scores indicate greater vulnerability. Additional covariates included demographics, depressed mood, comorbidity, and functional impairment. Bivariate and multivariate relationships between pain and cognitive impairment with social vulnerability were assessed using t-tests and linear regression, respectively. Results. Of 5,703 respondents, 1,927 were missing a component of the social vulnerability index and of these nine were missing a pain response, leaving 3,767 (66.1%) of the original sample. A total of 2,435 (64.6%) reported no/ mild pain and 3,435 (91.2%) were cognitively intact. The mean (standard deviation) social vulnerability index was 9.97 (3.62) with scores ranging from 1.12 to 26.85. Moderate or severe pain 0.44 (95% confidence interval [ CI] 0.21, 0.66, P < 0.01) and cognitive impairment 0.49 (95% CI 0.13, 0.86, P < 0.01) were independently associated with social vulnerability, but the interaction term was not statistically significant, 0.40 (95% CI - 0.32,1.14, P = 0.27). Conclusion. Pain and cognitive impairment are independently associated with social vulnerability. Improvements in pain management might mitigate social vulnerability in a growing number of older adults with either or both conditions. C1 [Shega, Joseph W.; Hemmerich, Josh; Dale, William] Univ Chicago, Sect Geriatr & Palliat Med, Chicago, IL 60637 USA. [Dale, William] Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA. [Cagney, Kathleen A.] Univ Chicago, Dept Hlth Studies & Sociol, Chicago, IL 60637 USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Weiner, Debra K.] Univ Pittsburgh, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Andrew, Melissa] Dalhousie Univ, Div Geriatr Med, Halifax, NS, Canada. RP Shega, JW (reprint author), Sect Geriatr & Palliat Med MC 6098, 5841 S Maryland Ave, Chicago, IL 60637 USA. EM jshega@gmail.com FU National Health Research Development Program [6606-3954-MC[S]]; National Institute on Aging [K23AG029815]; Canadian Institutes of Health Research [MOP-62823]; QEII Research Foundation FX All the data reported here were gathered using public funding from the National Health Research Development Program, which administrated a grant from the Seniors' Independence Research program (6606-3954-MC[S]). Funding for these analyses came from a career development award from the National Institute on Aging K23AG029815 and from the Canadian Institutes of Health Research through an operating grant (MOP-62823). Additional support came from the Dalhousie Medical Research Foundation (career support to KR as Kathryn Allen Weldon Professor of Alzheimer Research) and the Fountain Innovation Fund of the QEII Research Foundation. Funding agencies had no role in the design and conduct of the study; data collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript. NR 28 TC 5 Z9 5 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD FEB PY 2012 VL 13 IS 2 BP 190 EP 197 DI 10.1111/j.1526-4637.2011.01309.x PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 897YZ UT WOS:000300700900006 PM 22239723 ER PT J AU Mathews, CA Perez, VB Delucchi, KL Mathalon, DH AF Mathews, Carol A. Perez, Veronica B. Delucchi, Kevin L. Mathalon, Daniel H. TI Error-related negativity in individuals with obsessive-compulsive symptoms: Toward an understanding of hoarding behaviors SO BIOLOGICAL PSYCHOLOGY LA English DT Article DE Error monitoring; ERN; Obsessive-compulsive disorder (OCD); Hoarding symptoms ID BRAIN ACTIVITY; ANTERIOR CINGULATE; RESPONSE CONFLICT; DECISION-MAKING; ERP COMPONENTS; NEURAL SYSTEM; DISORDER; PERFORMANCE; TASK; FMRI AB The error-related negativity (ERN), an event-related potential component elicited by error responses in cognitive tasks, has been shown to be abnormal in most, but not all, studies of obsessive-compulsive disorder or obsessive-compulsive symptoms (OCD/S); these inconsistencies may be due to task selection, symptom subtype, or both. We used meta-analysis to further characterize the ERN in OCD/S, and pooled data across studies to examine the ERN in OCD/S with hoarding. We found an enhanced ERN in OCD/S relative to controls, as well as heterogeneity across tasks. When stratified, OCD/S showed a significantly enhanced ERN only in response conflict tasks. However, OCD/S + hoarding showed a marginally larger ERN than OCD/S-hoarding, but only for probabilistic learning tasks. These results suggest that abnormal ERN in OCD/S is task-dependent, and that OCD/S + hoarding show different ERN activity from OCD/S - hoarding perhaps suggesting different pathophysiological mechanisms of error monitoring. (C) 2012 Elsevier B.V. All rights reserved. C1 [Mathews, Carol A.; Perez, Veronica B.; Delucchi, Kevin L.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Perez, Veronica B.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Delucchi, Kevin L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Mathews, CA (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM cmathews@lppi.ucsf.edu OI Mathalon, Daniel/0000-0001-6090-4974; Delucchi, Kevin/0000-0003-2195-9627 FU NIMH NIH HHS [R01 MH058262, T32 MH089920, T32 MH089920-01] NR 71 TC 24 Z9 24 U1 4 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-0511 J9 BIOL PSYCHOL JI Biol. Psychol. PD FEB PY 2012 VL 89 IS 2 BP 487 EP 494 DI 10.1016/j.biopsycho.2011.12.018 PG 8 WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental SC Psychology; Behavioral Sciences GA 909JI UT WOS:000301560400025 PM 22227169 ER PT J AU Egloff, AM Davis, AG Shuai, Y Land, S Pilewski, JM Luketich, JD Landreneau, R Miller, YE Grandis, JR Siegfried, JM AF Egloff, Ann Marie Davis, Autumn Gaither Shuai, Yongli Land, Stephanie Pilewski, Joseph M. Luketich, James D. Landreneau, Rodney Miller, York E. Grandis, Jennifer R. Siegfried, Jill M. TI Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study SO RESPIRATORY RESEARCH LA English DT Article DE Gastrin-releasing peptide receptor; lung cancer risk; case-control study; surrogate tissue ID BOMBESIN-LIKE PEPTIDES; AUTOCRINE GROWTH; GENE-EXPRESSION; MESSENGER-RNA; CELLS; RISK; CARCINOMA; SMOKERS; SMOKING; WOMEN AB Background: Normal bronchial tissue expression of GRPR, which encodes the gastrin-releasing peptide receptor, has been previously reported by us to be associated with lung cancer risk in 78 subjects, especially in females. We sought to define the contribution of GRPR expression in bronchial epithelia to lung cancer risk in a larger case-control study where adjustments could be made for tobacco exposure and sex. Methods: We evaluated GRPR mRNA levels in histologically normal bronchial epithelial cells from 224 lung cancer patients and 107 surgical cancer-free controls. Associations with lung cancer were tested using logistic regression models. Results: Bronchial GRPR expression was significantly associated with lung cancer (OR = 4.76; 95% CI = 2.32- 9.77) in a multivariable logistic regression (MLR) model adjusted for age, sex, smoking status and pulmonary function. MLR analysis stratified by smoking status indicated that ORs were higher in never and former smokers (OR = 7.74; 95% CI = 2.96-20.25) compared to active smokers (OR = 1.69; 95% CI = 0.46-6.33). GRPR expression did not differ by subject sex, and lung cancer risk associated with GRPR expression was not modified by sex. Conclusions: GRPR expression in non-cancerous bronchial epithelium was significantly associated with the presence of lung cancer in never and former smokers. The association in never and former smokers was found in males and females. Association with lung cancer did not differ by sex in any smoking group. C1 [Egloff, Ann Marie; Grandis, Jennifer R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. [Davis, Autumn Gaither; Grandis, Jennifer R.; Siegfried, Jill M.] Univ Pittsburgh, Dept Med Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA. [Shuai, Yongli; Land, Stephanie; Landreneau, Rodney] Univ Pittsburgh, Inst Canc, Dept Biostat, Pittsburgh, PA 15260 USA. [Pilewski, Joseph M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Luketich, James D.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA. [Miller, York E.] Univ Colorado, Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80202 USA. RP Egloff, AM (reprint author), Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. EM egloffam@upmc.edu FU SPORE in Lung Cancer [P50-CA090440]; SPORE in Lung Cancer at the Univerity of Colorado [P50-CA058187, K07-CA137140] FX Support:; P50-CA090440 SPORE in Lung Cancer (JMS); P50-CA058187 (SPORE in Lung Cancer at the Univerity of Colorado (YEM) K07-CA137140 (AME) NR 24 TC 4 Z9 4 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-993X J9 RESP RES JI Respir. Res. PD FEB 1 PY 2012 VL 13 AR 9 DI 10.1186/1465-9921-13-9 PG 9 WC Respiratory System SC Respiratory System GA 911KV UT WOS:000301716600002 PM 22296774 ER PT J AU Rodriguez-Jimenez, R Bagney, A Garcia-Navarro, C Aparicio, AI Lopez-Anton, R Moreno-Ortega, M Jimenez-Arriero, MA Santos, JL Lobo, A Kern, RS Green, MF Nuechterlein, KH Palomo, T AF Rodriguez-Jimenez, R. Bagney, A. Garcia-Navarro, C. Aparicio, A. I. Lopez-Anton, R. Moreno-Ortega, M. Jimenez-Arriero, M. A. Santos, J. L. Lobo, A. Kern, R. S. Green, M. F. Nuechterlein, K. H. Palomo, T. TI The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in Spain SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Cognition; MATRICS; MCCB ID MINI-MENTAL STATE; SOCIAL COGNITION; NEUROCOGNITIVE DEFICITS; INDIVIDUAL-DIFFERENCES; MEMORY PERFORMANCE; SEX-DIFFERENCES; LIFE-SPAN; SCHIZOPHRENIA; NEUROSCIENCE; EMOTION AB The MATRICS Consensus Cognitive Battery (MCCB), developed by the National Institute of Mental Health (NIMH) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, has been recommended as the standard battery for clinical trials of cognition-enhancing interventions for schizophrenia. Normative data for the MCCB has been previously obtained in the U.S. Extrapolation of these normative data to different countries may be problematic due to the translation of the different tests, as well as potential cultural influences. We present the process of obtaining normative data for the MCCB in Spain with administration of the battery to a general community standardization sample. In addition, we examine the influence of age, gender, and educational level on test performance. The MCCB was administered to a total sample of 210 healthy volunteers, at three Spanish sites. For each site, recruitment of the sample was stratified according to age, gender, and educational level. Our findings indicate significant age, gender, and education effects on the normative data for the MCCB in Spain, which are comparable to those effects described for the original standardized English version in the U.S. The fact that the normative data are comparable, and that the variables age, gender, and education have a similar influence on performance, supports the robustness of the MCCB for use in different countries. (C) 2011 Elsevier B.V. All rights reserved. C1 [Rodriguez-Jimenez, R.; Bagney, A.; Garcia-Navarro, C.; Moreno-Ortega, M.; Jimenez-Arriero, M. A.; Palomo, T.] Hosp 12 Octubre, Dept Psychiat, Inst Invest, E-28041 Madrid, Spain. [Rodriguez-Jimenez, R.; Bagney, A.; Garcia-Navarro, C.; Lopez-Anton, R.; Jimenez-Arriero, M. A.; Lobo, A.; Palomo, T.] Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain. [Aparicio, A. I.; Santos, J. L.] Hosp Virgen La Luz, Dept Psychiat, Cuenca, Spain. [Lobo, A.] Hosp Clin Univ, Dept Psychiat, Zaragoza, Spain. [Lobo, A.] Univ Zaragoza, Zaragoza, Spain. [Kern, R. S.; Green, M. F.; Nuechterlein, K. H.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Kern, R. S.; Green, M. F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Nuechterlein, K. H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Rodriguez-Jimenez, R (reprint author), Hosp 12 Octubre, Dept Psychiat, Inst Invest, E-28041 Madrid, Spain. EM roberto.rodriguez.jimenez@gmail.com OI Lobo, Antonio/0000-0002-9098-655X; Garcia-Navarro, Cristina/0000-0002-4427-579X FU Fondo de Investigaciones Sanitarias, FIS [PI080514]; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM) of the Instituto de Salud Carlos III FX This research was supported in part by grant PI080514 (Fondo de Investigaciones Sanitarias, FIS) and by the Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM) of the Instituto de Salud Carlos III.; Although not related to this work, Dr. Nuechterlein has consulted for Endo Pharmaceuticals, Johnson and Johnson, Merck, and Wyeth and has an investigator-initiated research grant from Ortho-McNeil Janssen Scientific Affairs.; Dr. Kern receives financial compensation for his role as officer for the non-profit organization, MATRICS Assessment, Inc. NR 51 TC 21 Z9 21 U1 1 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2012 VL 134 IS 2-3 BP 279 EP 284 DI 10.1016/j.schres.2011.11.026 PG 6 WC Psychiatry SC Psychiatry GA 900FE UT WOS:000300871200026 PM 22192501 ER PT J AU Robertson, PA Tsitsopoulos, PP Voronov, LI Havey, RM Patwardhan, AG AF Robertson, Peter A. Tsitsopoulos, Parmenion P. Voronov, Leonard I. Havey, Robert M. Patwardhan, Avinash G. TI Biomechanical investigation of a novel integrated device for intra-articular stabilization of the C1-C2 (atlantoaxial) joint SO SPINE JOURNAL LA English DT Article DE Atlantoaxial; Biomechanics; Fusion device; Stabilization ID TRANSARTICULAR SCREW FIXATION; LATERAL MASS SCREW; INTERLAMINAR CLAMPS; POLYAXIAL SCREW; TECHNICAL NOTE; FUSION; ARTHRODESIS; COMPLEX; PLATE; SUBLUXATION AB BACKGROUND CONTEXT: The anatomy of the atlantoaxial joint makes stabilization at this level challenging. Current techniques that use transarticular screw fixation (Magerl) or segmental screw fixation (Harms) give dramatically improved stability but risk damage to the vertebral artery. A novel integrated device was designed and developed to obtain intra-articular stabilization via primary interference fixation within the C1-C2 lateral mass articulation. PURPOSE: To assess the atlantoaxial stability achieved with a novel integrated device when compared with the intact, destabilized, and stabilized state using the Harms technique. STUDY DESIGN: A biomechanical study of implants in human cadaveric cervical spines. METHODS: Six human cadaveric specimens were used. Biomechanical testing was performed with moment control in flexion-extension, lateral bending, and axial rotation. Range of motion (ROM) was measured in the intact state, after both destabilization by creation of a Type II odontoid peg fracture and sequential stabilization using the integrated device and the Harms technique. RESULTS: Mean flexion-extension ROM of the intact specimens at C1-C2 was 14.1 degrees +/- 62.9 degrees. Destabilization increased the ROM to 31.6 degrees +/- 4.6 degrees. Instrumentation with the Harms technique reduced flexion-extension motion to 4.0 degrees +/- 1.4 degrees (p<.01). The integrated device reduced flexion-extension motion to 3.6 degrees +/- 1.8 degrees (p<.01). In lateral bending, the respective mean angular motions were 1.8 degrees +/- 1.1 degrees, 14.1 degrees +/- 5.8 degrees, 1.4 degrees +/- 0.7 degrees, and 0.4 degrees +/- 0.3 degrees for the intact destabilized Harms technique and integrated device. For axial rotation, the respective mean values were 67.3 degrees +/- 13.8 degrees, 74.2 degrees +/- 16.1 degrees, 1.4 degrees +/- 0.7 degrees and 0.9 degrees +/- 0.7 degrees. Both the Harms technique and integrated device significantly reduced motion compared with the destabilized spine in flexion-extension, lateral bending, and axial rotation (p<.05). Direct comparison of the Harms technique and the integrated device revealed no significant difference (p>.10). CONCLUSIONS: The integrated device resulted in interference fixation at the C1-C2 lateral mass joints with comparable stability to the Harms technique. Perceived advantages with the integrated device include avoidance of fixation below the C2 lateral mass where the vertebral artery is susceptible to injury, and access to the C1 screw entry point through the blade of the integrated device avoiding extended dissection superior to the C2 nerve root and its surrounding venous plexus. (C) 2012 Elsevier Inc. All rights reserved. C1 [Robertson, Peter A.] Mercy Specialist Ctr, Orthopaed Clin, Auckland 1023, New Zealand. [Tsitsopoulos, Parmenion P.; Voronov, Leonard I.; Havey, Robert M.; Patwardhan, Avinash G.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Musculoskeletal Biomech Lab, Hines, IL 60141 USA. [Tsitsopoulos, Parmenion P.; Voronov, Leonard I.; Havey, Robert M.; Patwardhan, Avinash G.] Loyola Univ Chicago, Dept Orthopaed Surg & Rehabil, Maywood, IL 60153 USA. RP Robertson, PA (reprint author), Mercy Specialist Ctr, Orthopaed Clin, 100 Mt Rd, Auckland 1023, New Zealand. EM p.a.robertson@xtra.co.nz FU Medtronic; Back Institute, Auckland, New Zealand; Ortho Kinematics; Axiomed; Spinal Kinetics; Simpirica; Synthes FX PAR: Consulting: Medtronic (F), Johnson and Johnson DePuy (B); Speaking/Teaching Arrangements: Medtronic (Financial); Trips/Travel: Medtronic (Financial); Board of Directors: The Back Institute, Auckland, New Zealand (Financial); Scientific Advisory Board: Medtronic (Financial); Grants: Medtronic (C, Paid directly to institution/employer). PPT: Nothing to disclose. LIV: Nothing to disclose. RMH: Nothing to disclose. AGP: Stock Ownership: Spinal Kinetics (10,000 shares); Consulting: Alphatec (B), Aesculap (B); Speaking/Teaching Arrangements: Aesculap (B); Trips/Travel: Spinal Kinetics (B), Aesculap (A); Scientific Advisory Board: Ortho Kinematics (Financial), Axiomed (Financial), Spinal Kinetics (Financial); Research Support (Staff/Materials): Simpirica (E, Paid directly to institution/employer); Grants: Synthes (E, Paid directly to istitution/employer). NR 42 TC 5 Z9 7 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 J9 SPINE J JI Spine Journal PD FEB PY 2012 VL 12 IS 2 BP 136 EP 142 DI 10.1016/j.spinee.2012.01.004 PG 7 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 906ML UT WOS:000301349200009 PM 22341395 ER PT J AU Garcia-Romero, MT Werth, VP AF Teresa Garcia-Romero, Maria Werth, Victoria P. TI Randomized Controlled Trials Needed for Bullous Pemphigoid Interventions SO ARCHIVES OF DERMATOLOGY LA English DT Editorial Material ID PREDNISOLONE METASULFOBENZOATE; TOPICAL CORTICOSTEROIDS; PLASMA-EXCHANGE; AZATHIOPRINE; METHYLPREDNISOLONE C1 [Teresa Garcia-Romero, Maria; Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Teresa Garcia-Romero, Maria; Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Teresa Garcia-Romero, Maria] Hosp Gen Dr Manuel Gea Gonzalez, Dept Dermatol, Mexico City, DF, Mexico. RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Ste 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU NIAMS NIH HHS [K24 AR002207] NR 13 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD FEB PY 2012 VL 148 IS 2 BP 243 EP 246 PG 4 WC Dermatology SC Dermatology GA 895WF UT WOS:000300526700018 PM 22351828 ER PT J AU Crowell, AL Ryapolova-Webb, ES Ostrem, JL Galifianakis, NB Shimamoto, S Lim, DA Starr, PA AF Crowell, Andrea L. Ryapolova-Webb, Elena S. Ostrem, Jill L. Galifianakis, Nicholas B. Shimamoto, Shoichi Lim, Daniel A. Starr, Philip A. TI Oscillations in sensorimotor cortex in movement disorders: an electrocorticography study SO BRAIN LA English DT Article DE Parkinson's disease; dystonia; essential tremor; electrocorticography; primary motor cortex ID EVENT-RELATED DESYNCHRONIZATION; SELF-PACED MOVEMENT; PARKINSONS-DISEASE; SUBTHALAMIC NUCLEUS; GLOBUS-PALLIDUS; MOTOR CORTEX; BETA OSCILLATIONS; CERVICAL DYSTONIA; NEURONAL-ACTIVITY; SPECTRAL-ANALYSIS AB Movement disorders of basal ganglia origin may arise from abnormalities in synchronized oscillatory activity in a network that includes the basal ganglia, thalamus and motor cortices. In humans, much has been learned from the study of basal ganglia local field potentials recorded from temporarily externalized deep brain stimulator electrodes. These studies have led to the theory that Parkinson's disease has characteristic alterations in the beta frequency band (13-30 Hz) in the basal ganglia-thalamocortical network. However, different disorders have rarely been compared using recordings in the same structure under the same behavioural conditions, limiting straightforward assessment of current hypotheses. To address this, we utilized subdural electrocorticography to study cortical oscillations in the three most common movement disorders: Parkinson's disease, primary dystonia and essential tremor. We recorded local field potentials from the arm area of primary motor and sensory cortices in 31 subjects using strip electrodes placed temporarily during routine surgery for deep brain stimulator placement. We show that: (i) primary motor cortex broadband gamma power is increased in Parkinson's disease compared with the other conditions, both at rest and during a movement task; (ii) primary motor cortex high beta (20-30 Hz) power is increased in Parkinson's disease during the 'stop' phase of a movement task; (iii) the alpha-beta peaks in the motor and sensory cortical power spectra occur at higher frequencies in Parkinson's disease than in the other two disorders; and (iv) patients with dystonia have impaired movement-related beta band desynchronization in primary motor and sensory cortices. The findings support the emerging hypothesis that disease states reflect abnormalities in synchronized oscillatory activity. This is the first study of sensorimotor cortex local field potentials in the three most common movement disorders. C1 [Crowell, Andrea L.] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA. [Ryapolova-Webb, Elena S.; Lim, Daniel A.; Starr, Philip A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Ostrem, Jill L.; Galifianakis, Nicholas B.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Galifianakis, Nicholas B.; Lim, Daniel A.; Starr, Philip A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Care Ctr, San Francisco, CA USA. [Shimamoto, Shoichi] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 533 Parnassus Ave,U-125, San Francisco, CA 94143 USA. EM starrp@neurosurg.ucsf.edu OI Lim, Daniel/0000-0001-7221-3425 FU National Institutes of Health [R01NS069779]; Dystonia Medical Research Foundation; Doris Duke Clinical Research Fellowship FX National Institutes of Health (R01NS069779 to P. A. S.); Dystonia Medical Research Foundation (to P. A. S.); and Doris Duke Clinical Research Fellowship (to A.L.C.). NR 55 TC 48 Z9 48 U1 1 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD FEB PY 2012 VL 135 BP 615 EP 630 DI 10.1093/brain/awr332 PN 2 PG 16 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 895GZ UT WOS:000300485600032 PM 22252995 ER PT J AU Sakamoto, M Perry, W Hilsabeck, RC Barakat, F Hassanein, T AF Sakamoto, Maiko Perry, William Hilsabeck, Robin C. Barakat, Fatma Hassanein, Tarek TI Assessment and Usefulness of Clinical Scales for Semiquantification of Overt Hepatic Encephalopathy SO CLINICS IN LIVER DISEASE LA English DT Article DE Overt hepatic encephalopathy; Clinical scales; Neuropsychological tests; Neurophysiologic tests; Hepatic encephalopathy assessment; HESA; WHC; Cirrhosis ID CRITICAL FLICKER FREQUENCY; PORTAL-SYSTEMIC ENCEPHALOPATHY; CONTINUOUS REACTION-TIMES; INHIBITORY CONTROL TEST; LIVER-TRANSPLANTATION; COGNITIVE IMPAIRMENT; SCORING ALGORITHM; BISPECTRAL INDEX; CIRRHOSIS; DIAGNOSIS AB Hepatic encephalopathy (HE) represents the effects of liver dysfunction on the brain. When HE is clinically obvious (eg, confusion, poor judgment, personality change), it is termed overt HE. The severity of HE is measured by different methods. Assessing the severity of HE is important for determining patient prognosis and effectiveness of therapy. This article discusses the different methods for grading HE, including clinical rating scales, neuropsychological tests, and neurophysiologic measures. C1 [Barakat, Fatma; Hassanein, Tarek] So Calif Liver Ctr, Coronado, CA 92118 USA. [Sakamoto, Maiko; Perry, William] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, Neuropsychol Postdoctoral Residency Program, San Antonio, TX 78229 USA. RP Hassanein, T (reprint author), So Calif Liver Ctr, 230 Prospect Pl,Suite 220, Coronado, CA 92118 USA. EM thassanein@livercenters.com NR 62 TC 2 Z9 2 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1089-3261 J9 CLIN LIVER DIS JI Clin. Liver Dis. PD FEB PY 2012 VL 16 IS 1 BP 27 EP + DI 10.1016/j.cld.2011.12.005 PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 903YJ UT WOS:000301159000004 PM 22321463 ER PT J AU Marcos, PJ Restrepo, MI Verea, H AF Marcos, P. J. Restrepo, M. I. Verea, H. TI Supported home-care schemes: the key to increasing outpatient care? SO EUROPEAN RESPIRATORY JOURNAL LA English DT Letter ID COMMUNITY-ACQUIRED PNEUMONIA C1 [Marcos, P. J.] Complejo Hosp Univ A Coruna, Serv Neumol, Dept Pulm Dis, La Coruna 15006, Spain. [Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78229 USA. [Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. [Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hosp Med, San Antonio, TX 78229 USA. RP Marcos, PJ (reprint author), Complejo Hosp Univ A Coruna, Serv Neumol, Dept Pulm Dis, La Coruna 15006, Spain. EM pedro.jorge.marcos.rodriguez@sergas.es RI Restrepo, Marcos/H-4442-2014; Marcos, Pedro J/K-9965-2015 OI Marcos, Pedro J/0000-0001-9600-3537 FU NHLBI NIH HHS [K23HL096054, K23 HL096054] NR 3 TC 0 Z9 0 U1 0 U2 0 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 J9 EUR RESPIR J JI Eur. Resp. J. PD FEB PY 2012 VL 39 IS 2 BP 509 EP 509 DI 10.1183/09031936.00166811 PG 1 WC Respiratory System SC Respiratory System GA 894FB UT WOS:000300411400044 PM 22298621 ER PT J AU Gellad, WF Donohue, JM Zhao, XH Zhang, YT Banthin, JS AF Gellad, Walid F. Donohue, Julie M. Zhao, Xinhua Zhang, Yuting Banthin, Jessica S. TI The Financial Burden From Prescription Drugs Has Declined Recently For The Nonelderly, Although It Is Still High For Many SO HEALTH AFFAIRS LA English DT Article ID MEDICAID PRIOR-AUTHORIZATION; EXPENDITURE PANEL SURVEY; HEALTH-CARE; TRENDS AB Prescription drug spending and pharmacy benefit design have changed greatly over the past decade. However, little is known about the financial impact these changes have had on consumers. We examined ten years of nationally representative data from the Medical Expenditure Panel Survey and describe trends in two measures of financial burden for prescription drugs: out-of-pocket drug costs as a function of family income and the proportion of all out-of-pocket health care expenses accounted for by drugs. We found that although the percentage of people with high financial burden for prescription drugs increased from 1999 to 2003, it decreased from 2003 to 2007, with a slight increase in 2008. The decline is evidence of the success of strategies to lower drug costs for consumers, including the increased use of generic drugs. However, the financial burden is still high among some groups, notably those with public insurance and those with low incomes. For example, one in four nonelderly people devote more than half of their total out-of-pocket health care spending to prescription drugs. These trends suggest that the affordability of prescription drugs under the future insurance exchanges will need to be monitored, as will efforts by states to increase prescription drug copayments under Medicaid or otherwise restrict drug use to reduce public spending. C1 [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh Vet Affairs VA Med Ctr, Pittsburgh, PA 15260 USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Gellad, Walid F.] RAND, Pittsburgh, PA USA. [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA. [Zhao, Xinhua] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Banthin, Jessica S.] Congress Budget Off, Div Hlth & Human Resources, Washington, DC USA. RP Gellad, WF (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh Vet Affairs VA Med Ctr, Pittsburgh, PA 15260 USA. EM wfg3@pitt.edu OI Donohue, Julie/0000-0003-2418-6017 FU Veterans Affairs Health Services [CDA 09-207]; RAND-University of Pittsburgh Health Institute; Clinical and Translational Science Institute (CTSI); National Center for Research Resources, National Institutes of Health (NIH) [UL1 RR024153]; NIH Roadmap for Medical Research; Agency for Healthcare Research and Quality and National Institute of Mental Health [AHRQ 1R01HS017695, 1R34 MH082682, P30 MH090333]; National Institute of Mental Health [RC1 MH088510]; Agency for Healthcare Research and Quality [R01 HS018657] FX The results of this study were presented at the AcademyHealth Annual Research Meeting in Seattle, Washington, June 13, 2011. The study was supported in part by a Veterans Affairs Health Services Research and Development Career Development Award (CDA 09-207) to Walid Gellad, as well as by the RAND-University of Pittsburgh Health Institute and the Clinical and Translational Science Institute (CTSI) Translating Research into Practice Program. The CTSI is made possible by Grant No. UL1 RR024153 to the University of Pittsburgh from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and by the NIH Roadmap for Medical Research. Julie Donohue was supported by Agency for Healthcare Research and Quality and National Institute of Mental Health grants (Nos. AHRQ 1R01HS017695, 1R34 MH082682, and P30 MH090333). Yuting Zhang was supported by National Institute of Mental Health Grant No. RC1 MH088510 and Agency for Healthcare Research and Quality Grant No. R01 HS018657. This study was conducted while Jessica Banthin was employed by the Agency for Healthcare Research and Quality. This work represents the opinions of the authors alone and does not necessarily represent the views of the Department of Veterans Affairs, the Agency for Healthcare Research and Quality, the Congressional Budget Office, or the US government. NR 28 TC 13 Z9 13 U1 1 U2 4 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD FEB PY 2012 VL 31 IS 2 BP 408 EP 416 DI 10.1377/hlthaff.2011.0469 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 894GE UT WOS:000300414300021 PM 22323172 ER PT J AU Gupta, RS Lau, CH Springston, EE Smith, B Warrier, MR Pongracic, J Holl, J AF Gupta, R. S. Lau, C. H. Springston, E. E. Smith, B. Warrier, M. R. Pongracic, J. Holl, J. TI Diagnosis of childhood food allergy in the United States SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 02-06, 2012 CL Orlando, FL SP Amer Acad Allergy Asthma & Immunol (AAAAI) C1 [Gupta, R. S.; Lau, C. H.; Pongracic, J.] Childrens Mem Hosp, Chicago, IL 60614 USA. [Gupta, R. S.; Springston, E. E.; Holl, J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Smith, B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Smith, B.] Loyola Univ, Maywood, IL 60153 USA. [Warrier, M. R.] Allergy Asthma & Sinus Care, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 SU S BP AB230 EP AB230 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 903QL UT WOS:000301133401035 ER PT J AU Knafl, KA Deatrick, JA Havill, NL AF Knafl, Kathleen A. Deatrick, Janet A. Havill, Nancy L. TI Continued Development of the Family Management Style Framework SO JOURNAL OF FAMILY NURSING LA English DT Article DE Family Management Style Framework; childhood chronic conditions; research review ID DUCHENNE MUSCULAR-DYSTROPHY; DISABLED-CHILDREN; YOUNG-CHILDREN; PARENTAL EXPERIENCES; DISABILITIES; MOTHERS; PERSPECTIVES; STRESS; ASTHMA; BABIES AB Based on a review of 64 published reports, this article addresses the implications of current research for the further development of the Family Management Style Framework (FMSF). Articles are published in 46 different journals, including 13 in nursing and 12 in interdisciplinary outlets. Most studies are based on samples of less than 50 individuals. The review provides continuing support for the 8 dimensions of the framework, with between 8 and 16 reports supporting the relevance of each. Changes to the sociocultural component of the framework are proposed as well as wording changes to reflect the broader applicability of the framework. The family's social network, health care and education professionals, and resources predominate as key influences on family management. C1 [Knafl, Kathleen A.; Havill, Nancy L.] Univ N Carolina, Sch Nursing, PhD Program, Chapel Hill, NC 27516 USA. [Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. RP Knafl, KA (reprint author), Univ N Carolina, Sch Nursing, PhD Program, 406 Brookgreen Dr, Chapel Hill, NC 27516 USA. EM kknafl@email.unc.edu FU National Institute of Nursing Research; National Institutes of Health [R01, NR08048]; Donaghue Medical Research Foundation FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors received support for the development of the Family Management Measure from the National Institute of Nursing Research; National Institutes of Health (R01, NR08048) and the Donaghue Medical Research Foundation. NR 71 TC 34 Z9 36 U1 7 U2 20 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1074-8407 J9 J FAM NURS JI J. Fam. Nurs. PD FEB PY 2012 VL 18 IS 1 SI SI BP 11 EP 34 DI 10.1177/1074840711427294 PG 24 WC Family Studies; Nursing SC Family Studies; Nursing GA 894PZ UT WOS:000300440300003 PM 22223495 ER PT J AU Jacobs, PG Konrad-Martin, D Mcmillan, GP McDermott, D Fausti, SA Kagen, D Wan, EA AF Jacobs, Peter G. Konrad-Martin, Dawn Mcmillan, Garnett P. McDermott, Daniel Fausti, Stephen A. Kagen, David Wan, Eric A. TI Influence of acute hyperglycemia on otoacoustic emissions and the medial olivocochlear reflex SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID OUTER HAIR-CELLS; COCHLEAR MECHANICS; ADENOSINE 5'-TRIPHOSPHATE; AUDITORY-SYSTEM; NOISE; HEARING; SPEECH; SOUND; ATP; HUMANS AB Stimulus-frequency (SF) otoacoustic emission (OAE) amplitude and the amplitude of medial olivocochlear (MOC) inhibition of SF OAEs for ipsilateral, contralateral and bilateral MOC reflex elicitors were recorded in six subjects with type 2 diabetes during a glucose tolerance test (GTT). Five of the six subjects were tested twice for a total of 11 trials and three subjects were tested in a control experiment. During the GTT experiment, the subjects' blood glucose was elevated from a euglycemic level below 150 mg/dL to a hyperglycemic level above 160 mg/dL following the consumption of a bolus of 80 g of sugar. A subset of three subjects were tested in a control experiment during which SF OAE and MOC reflex measurements were made while blood sugar levels remained constant within the euglycemic region. Mean SF OAE amplitudes were elevated following glucose consumption. A statistically significant increase in MOC inhibition amplitude was observed during elevated sugar levels for the 11 GTT trials. Maximum inhibition occurred about an hour after glucose consumption when blood glucose levels peaked. Results indicate that acute hyperglycemia influences efferent control of the cochlea in people with type 2 diabetes. [DOI: 10.1121/1.3676609] C1 [Jacobs, Peter G.; Konrad-Martin, Dawn; Mcmillan, Garnett P.; McDermott, Daniel; Fausti, Stephen A.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. [Kagen, David] Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA. [Wan, Eric A.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA. RP Jacobs, PG (reprint author), Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM peter.jacobs@va.gov FU US National Institute of Diabetes and Digestive and Kidney Diseases [1R21 DK079283-01A1]; VA Rehabilitative Research and Development (RRD) Service [C2759C, C4447K]; VA RR&D National Center for Rehabilitative Auditory Research within Portland VA Medical Center, Portland OR FX This work was funded by the US National Institute of Diabetes and Digestive and Kidney Diseases (1R21 DK079283-01A1), the VA Rehabilitative Research and Development (RR&D) Service (C2759C, C4447K), and the VA RR&D National Center for Rehabilitative Auditory Research within the Portland VA Medical Center, Portland, OR. Thanks to W. Kenneth Ward at Oregon Health & Science University for reviewing an early draft of this paper and providing feedback. NR 56 TC 3 Z9 5 U1 0 U2 1 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD FEB PY 2012 VL 131 IS 2 BP 1296 EP 1306 DI 10.1121/1.3676609 PN 1 PG 11 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA 895ID UT WOS:000300488800048 PM 22352503 ER PT J AU Woodard, LD Landrum, CR Urech, TH Profit, J Virani, SS Petersen, LA AF Woodard, LeChauncy D. Landrum, Cassie R. Urech, Tracy H. Profit, Jochen Virani, Salim S. Petersen, Laura A. TI Treating Chronically Ill People with Diabetes Mellitus with Limited Life Expectancy: Implications for Performance Measurement SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE diabetes mellitus; quality of care; performance measurement; limited life expectancy ID AFFAIRS HEALTH-CARE; QUALITY-OF-CARE; PRACTICE GUIDELINES; GLYCEMIC CONTROL; ELDERLY-PATIENTS; GLUCOSE CONTROL; OLDER PATIENTS; VETERANS; DISEASE; HEART AB OBJECTIVES: To develop an algorithm to identify individuals with limited life expectancy and examine the effect of limited life expectancy on glycemic control and treatment intensification in individuals with diabetes mellitus. DESIGN: Individuals with diabetes mellitus and coexisting congestive heart failure, chronic obstructive pulmonary disease, dementia, end-stage liver disease, and/or primary or metastatic cancer with limited life expectancy were identified. To validate the algorithm, 5-year mortality was assessed in individuals identified as having limited life expectancy. Rates of meeting performance measures for glycemic control between individuals with and without limited life expectancy were compared. In individuals with uncontrolled glycosylated hemoglobin (HbA(1c)) levels, the effect of limited life expectancy on treatment intensification within 90 days was examined. SETTING: One hundred ten Department of Veterans Affairs facilities; October 2006 to September 2007. PARTICIPANTS: Eight hundred eighty-eight thousand six hundred twenty-eight individuals with diabetes mellitus. MEASUREMENTS: HbA(1c); treatment intensification within 90 days of index HbA(1c) reading. RESULTS: Twenty-nine thousand sixteen (3%) participants had limited life expectancy. Adjusting for age, 5-year mortality was five times as high in participants with limited life expectancy than in those without. Participants with limited life expectancy had poorer glycemic control than those without (glycemic control: 77.1% vs 78.1%; odds ratio (OR) = 0.84, 95% confidence interval (CI) = 0.81-0.86) and less-frequent treatment intensification (treatment intensification: 20.9% vs 28.6%; OR = 0.71, 95% CI = 0.67-0.76), even after controlling for patientlevel characteristics. CONCLUSION: Participants with limited life expectancy were less likely than those without to have controlled HbA1c levels and to receive treatment intensification, suggesting that providers treat these individuals less aggressively. Quality measurement and performance-based reimbursement systems should acknowledge the different needs of this population. J Am Geriatr Soc 60: 193-200, 2012. C1 [Woodard, LeChauncy D.; Landrum, Cassie R.; Urech, Tracy H.; Profit, Jochen; Virani, Salim S.; Petersen, Laura A.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy & Qual Program, Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Woodard, LeChauncy D.; Profit, Jochen; Virani, Salim S.; Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Woodard, LD (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy & Qual Program, Hlth Serv Res & Dev Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM woodard.lechauncy@va.gov OI Virani, Salim/0000-0001-9541-6954 FU Department of Veterans Affairs (VA) HSRD [PPO 09-316]; VA HSRD [SHP 08-166]; Houston VA HSR&D Center of Excellence [HFP90-020]; Robert Wood Johnson Foundation Generalist Physician Faculty [045444]; National Institute of Child Health and Human Development [K23 HD056298]; VA HSRD Service [CDA-09-028] FX No author has any conflicts of interest to disclose. This work is supported in part by Department of Veterans Affairs (VA) HSR&D PPO 09-316 (PI LeChauncy D. Woodard, MD, MPH), VA HSR&D SHP 08-166 (PI Laura A. Petersen, MD, MPH), and Houston VA HSR&D Center of Excellence HFP90-020 (PI Laura A. Petersen, MD, MPH). Dr. Petersen was a Robert Wood Johnson Foundation Generalist Physician Faculty Scholar (Grant 045444) at the time this work was conducted. Dr. Profit's contribution is supported by National Institute of Child Health and Human Development Grant K23 HD056298 (PI Jochen Profit). Dr. Virani is supported by a VA HSR&D Service Career Development Award (CDA-09-028). Parts of this manuscript were presented at the Department of Veterans Affairs annual Health Services Research and Development National Meeting, February 2009, Washington, DC, and at the Society of General Internal Medicine annual meeting, May 2009, Miami, Florida. NR 37 TC 9 Z9 9 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2012 VL 60 IS 2 BP 193 EP 201 DI 10.1111/j.1532-5415.2011.03784.x PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 897ST UT WOS:000300677400001 PM 22260627 ER PT J AU Lee, SJ Boyd, CM AF Lee, Sei J. Boyd, Cynthia M. TI Diabetes Mellitus Performance Measures in Individuals with Limited Life Expectancy SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Editorial Material ID PRACTICE GUIDELINES; QUALITY; INSULIN; SULFONYLUREAS; HYPOGLYCEMIA; PITFALLS; RISK; CARE C1 [Lee, Sei J.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Lee, Sei J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Boyd, Cynthia M.] Johns Hopkins Univ, Dept Hlth Policy & Management, Div Geriatr Med & Gerontol, Baltimore, MD 21218 USA. RP Lee, SJ (reprint author), San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. FU NIA NIH HHS [K23 AG040779-01, K23AG040779, K23 AG032910, K23 AG040779, K23AG032910] NR 20 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2012 VL 60 IS 2 BP 361 EP 363 DI 10.1111/j.1532-5415.2011.03783.x PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 897ST UT WOS:000300677400025 PM 22332676 ER PT J AU Schmader, KE Hanlon, JT AF Schmader, Kenneth E. Hanlon, Joseph T. TI Goodbyes, Hellos, and Changes SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Editorial Material C1 [Schmader, Kenneth E.] Duke Univ, Med Ctr, Geriatr Res Educ & Clin Ctr,Dept Med, Ctr Study Aging & Human Dev,Durham VA Med Ctr, Durham, NC 27706 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Med, Div Pharm & Therapeut,Div Geriatr Med, Pittsburgh, PA 15260 USA. [Hanlon, Joseph T.] VA Pittsburgh Healthcare Syst, Geriatr Res & Educ & Clin Ctr, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. RP Schmader, KE (reprint author), Duke Univ, Med Ctr, Geriatr Res Educ & Clin Ctr,Dept Med, Ctr Study Aging & Human Dev,Durham VA Med Ctr, Durham, NC 27706 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2012 VL 10 IS 1 BP 1 EP 1 PG 1 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 900CJ UT WOS:000300863900001 ER PT J AU Thorpe, CT Lassila, HC O'Neil, CK Thorpe, JM Hanlon, JT Maher, RL AF Thorpe, Carolyn T. Lassila, Holly C. O'Neil, Christine K. Thorpe, Joshua M. Hanlon, Joseph T. Maher, Robert L. TI Reconsideration of Key Articles Regarding Medication-Related Problems in Older Adults from 2011 SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Editorial Material ID ADVERSE DRUG EVENTS; OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; FLEETWOOD NORTHERN-IRELAND; POPULATION-BASED COHORT; NURSING-HOME RESIDENTS; D PRESCRIPTION BENEFIT; ELDERLY-PATIENTS; PART-D; CARE HOMES C1 [Thorpe, Carolyn T.; Thorpe, Joshua M.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Thorpe, Carolyn T.; Thorpe, Joshua M.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Hlth Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Lassila, Holly C.; O'Neil, Christine K.; Maher, Robert L.] Duquesne Univ, Sch Pharm, Div Clin Social & Adm Sci, Pittsburgh, PA 15219 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Med Geriatr, 3471 5th Ave,Kaufman Bld,Suite 500, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu RI Thorpe, Joshua/C-1188-2013 FU AHRQ HHS [K12 HS019461, R01 HS017695, R01 HS018721]; NIA NIH HHS [K07 AG033174, K07AG033174, P30 AG024827, P30AG024827, R01 AG034056, R01AG034056, R56 AG027017, R56AG027017, T32 AG021885]; NIDDK NIH HHS [R21 DK090634, R21DK090634]; NINR NIH HHS [R01 NR010135, R01NR010135] NR 132 TC 1 Z9 1 U1 3 U2 14 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD FEB PY 2012 VL 10 IS 1 BP 2 EP 13 DI 10.1016/j.amjopharm.2012.01.004 PG 12 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 900CJ UT WOS:000300863900002 PM 22330099 ER PT J AU Chodosh, J Pearson, ML Connor, KI Vassar, SD Kaisey, M Lee, ML Vickrey, BG AF Chodosh, Joshua Pearson, Marjorie L. Connor, Karen I. Vassar, Stefanie D. Kaisey, Marwa Lee, Martin L. Vickrey, Barbara G. TI A Dementia Care Management Intervention: Which Components Improve Quality? SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID MANAGING ALZHEIMERS-DISEASE; RANDOMIZED CONTROLLED-TRIAL; OF-CARE; COORDINATION; CAREGIVERS; PERCEPTIONS; GUIDELINES; OUTCOMES; ILLNESS AB Objectives: To analyze whether types of providers and frequency of encounters are associated with higher quality of care within a coordinated dementia care management (CM) program for patients and caregivers. Design: Secondary analysis of intervention-arm data from a dementia CM cluster-randomized trial, where intervention participants interacted with healthcare organization care managers (HOCMs), community agency care managers (CACMs), and/or healthcare organization primary care providers (HOPCPs) over 18 months. Methods: Encounters of 238 patient/caregivers (dyads) with HOCMs, CACMs, and HOPCPs were abstracted from care management electronic records. The quality domains of assessment, treatment, education/support, and safety were measured from medical record abstractions and caregiver surveys. Mean percentages of met quality indicators associated with exposures to each provider type and frequency were analyzed using multivariable regression, adjusting for participant characteristics and baseline quality. Results: As anticipated, for all 4 domains, the mean percentage of met dementia quality indicators was 15.510 47.2 percentage points higher for dyads with HOCM-only exposure than for dyads with none (all P < .008); not anticipated were higher mean percentages with increasing combinations of provider-type exposure-up to 73.7 percentage points higher for safety (95% confidence interval 65.2%-82.1%) with exposure to all 3 provider types compared with no exposure. While greater frequency of HOCM-dyad encounters was associated with higher quality (P <=.04) this was not so for other provider types. Conclusions: HOCMs' interactions with dyads was essential for dementia care quality improvement. Additional coordinated interactions with primary care and community agency staff yielded even higher quality. (Am J Manag Care. 2012;18(2)85-94) C1 [Chodosh, Joshua] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. [Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Connor, Karen I.; Vassar, Stefanie D.; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. RAND Hlth, Santa Monica, CA USA. [Connor, Karen I.; Vassar, Stefanie D.; Vickrey, Barbara G.] VA Greater Los Angeles Healthcare Syst, Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA USA. [Kaisey, Marwa] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Lee, Martin L.] VA Greater Los Angeles Healthcare Syst, Sepulveda Ctr Excellence, Hlth Serv Res & Dev Serv, Sepulveda, CA USA. RP Chodosh, J (reprint author), 11301 Wilshire Blvd 11G, Los Angeles, CA 90073 USA. EM jchodosh@mednet.ucla.edu FU California Department of Public Health [07-65800]; State of California Department of Aging [IG-0001-22]; California HealthCare Foundation [99-3020]; State of California Department of Health Services Alzheimer's Disease Education Initiative; State of California Department of Public Health [06-55314] FX This study was supported by the California Department of Public Health (contract 07-65800). The ACCESS project was funded by the State of California Department of Aging (IG-0001-22); the California HealthCare Foundation (contract 99-3020); the State of California Department of Health Services Alzheimer's Disease Education Initiative; and the State of California Department of Public Health (contract 06-55314) for the University of California, Los Angeles Alzheimer's Disease Research Center. NR 29 TC 13 Z9 13 U1 3 U2 7 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD FEB PY 2012 VL 18 IS 2 BP 85 EP 94 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 903BE UT WOS:000301089200002 PM 22435836 ER PT J AU Wecht, JM Rosado-Rivera, D Jegede, A Cirnigliaro, CM Jensen, MA Kirshblum, S Bauman, WA AF Wecht, Jill M. Rosado-Rivera, Dwindally Jegede, Adejoke Cirnigliaro, Christopher M. Jensen, Marley A. Kirshblum, Steve Bauman, William A. TI Systemic and cerebral hemodynamics during cognitive testing SO CLINICAL AUTONOMIC RESEARCH LA English DT Article DE Paraplegia; Tetraplegia; Blood pressures; Transcranial Doppler ultrasound; Cerebral blood flow; Mental stimulation ID SPINAL-CORD-INJURY; BLOOD-FLOW VELOCITY; WHITE-MATTER HYPERINTENSITIES; CLOSED HEAD-INJURY; TRANSCRANIAL DOPPLER; ORTHOSTATIC HYPOTENSION; ARTERIAL STIFFNESS; MENTAL STRESS; OLDER-ADULTS; PERFORMANCE AB Objective Cognitive deficits are reported in 10-60% of individuals with SCI, the primary etiology of these deficits is believed to be concomitant traumatic brain injury (TBI). We recently documented diminished memory and marginally deficient attention and processing speed in individuals with SCI discordant for hypotension but matched for TBI. Methods Twenty-nine individuals participated: 16 non-SCI controls, 6 paraplegic (T2-T10) and 7 tetraplegic (C4-C8). The Stroop test was used to measure cognitive function and transcranial Doppler ultrasound was used to measure cerebral blood flow (CBF) while resting (5 min) and continuously during cognitive testing. Mean arterial pressure (MAP) was calculated from three brachial blood pressures and cerebral vascular resistance index was calculated as: CVRi = MAP/CBF. Results The paraplegia group (54 +/- 6) was marginally older than the non-SCI (42 +/- 15; p = 0.06) and tetraplegic (42 +/- 11; p = 0.09) groups. Compared to non-SCI group, normalized t-score on the Stroop Color (SC) task was significantly lower in the paraplegic group (p < 0.05). In the tetraplegic group, MAP was significantly lower (p < 0.05) than the non-SCI and paraplegic groups, and related to SC t-score (r(2) = 0.873; p < 0.01). In the paraplegic group, CBF was reduced (p < 0.05) and CVRi increased (p < 0.05) compared to the non-SCI group, and CVRi was increased compared to the tetraplegic group (p < 0.05). A significant inverse relationship was noted between change in CVRi and SC t-score in the non-SCI group. Conclusion Asymptomatic hypotension relates to cognitive performance in persons with tetraplegia; therefore, BP normalization should be considered. The inappropriate cerebral vascular response to cognitive testing and poor test performance should be investigated in persons with paraplegia. C1 [Wecht, Jill M.; Rosado-Rivera, Dwindally; Jegede, Adejoke; Cirnigliaro, Christopher M.; Jensen, Marley A.; Bauman, William A.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Wecht, Jill M.; Bauman, William A.] James J Peters VAMC, Med Serv, Bronx, NY USA. [Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Wecht, Jill M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Cirnigliaro, Christopher M.; Jensen, Marley A.; Kirshblum, Steve] Kessler Inst Rehabil, W Orange, NJ USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rm 7A-13,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM jm.wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [A6161W, B3203R, B4162C]; NIH; NHS FX This research was supported by the Veterans Affairs Rehabilitation Research and Development Service (grant no. A6161W, B3203R and B4162C).; We certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on us or on any organization with which we are associated AND, if applicable, we certify that all financial and material support for this research (e. g., NIH or NHS grants) and work are clearly identified in the title page of the manuscript. NR 66 TC 9 Z9 9 U1 1 U2 4 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0959-9851 J9 CLIN AUTON RES JI Clin. Auton. Res. PD FEB PY 2012 VL 22 IS 1 BP 25 EP 33 DI 10.1007/s10286-011-0139-1 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 899XE UT WOS:000300849200004 PM 21792728 ER PT J AU Day, KV Kautz, SA Wu, SS Suter, SP Behrman, AL AF Day, Kristin V. Kautz, Steven A. Wu, Samuel S. Suter, Sarah P. Behrman, Andrea L. TI Foot placement variability as a walking balance mechanism post-spinal cord injury SO CLINICAL BIOMECHANICS LA English DT Article DE Spinal cord injury; Walking; Balance; Margin of stability; Variability ID DYNAMIC STABILITY; RECOVERY; RELIABILITY; VALIDITY; FALLS AB Background: Spinal cord injury affects walking balance control, which necessitates methods to quantify balance ability. The purposes of this study were to 1) examine walking balance through foot placement variability post-injury; 2) assess the relationship between measures of variability and clinical balance assessments; and 3) determine if spatial parameter variability might be used as a clinical correlate for more complex balance measurements. Methods: Ten persons with spinal cord injury walked without devices on a split-belt treadmill at self-selected speeds. Ten healthy controls walked at 03 and 0.6 m/s for comparison. Variability of step width and length, anteroposterior and mediolateral foot placements relative to center-of-mass, and margin-of-stability were calculated. Clinical assessments included Berg Balance Scale and Dynamic Gait Index. Findings: Participants with spinal cord injury demonstrated significantly different variability in all biomechanical measures compared to controls (P <= 0.007). Berg Balance Scale scores were significantly inversely associated with step length as well as anteroposterior and mediolateral foot placement variability (P <= 0.05). Dynamic Gait Index scores were significantly inversely associated with mediolateral foot placement variability (P <= 0.05). Participants with spinal cord injury showed significant correlations between spatial parameter variability and all other measures (P <= 0.005), except between step length and margin-of-stability (P=0.068); controls revealed fewer correlations. Interpretation: Persons post-spinal cord injury exhibit an abnormal amount of stepping variability when challenged to walk without devices, yet preserve the ability to avoid falling. When complex laboratory measures of variability are unavailable clinically, spatial parameter variability or standardized balance assessments may be plausible indicators of walking balance control. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Day, Kristin V.] Cardinal Hill Rehabil Hosp, Lexington, KY 40504 USA. [Day, Kristin V.] Univ Kentucky, Dept Rehabil Sci, Lexington, KY USA. [Day, Kristin V.; Suter, Sarah P.; Behrman, Andrea L.] Univ Florida, Dept Phys Therapy, Gainesville, FL USA. [Day, Kristin V.; Kautz, Steven A.; Suter, Sarah P.; Behrman, Andrea L.] Malcom G Randall VA Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL USA. [Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Kautz, Steven A.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA. [Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Wu, Samuel S.] Univ Florida, Dept Epidemiol & Hlth Policy Res, Gainesville, FL USA. [Wu, Samuel S.] Malcom G Randall VA Med Ctr, Rehabil Outcomes Res Ctr, Gainesville, FL USA. [Suter, Sarah P.] Univ Florida, Shands Hosp, Dept Rehabil Serv, Gainesville, FL USA. [Behrman, Andrea L.] Univ Florida, McKnight Brain Inst, Gainesville, FL USA. RP Day, KV (reprint author), Cardinal Hill Rehabil Hosp, 2050 Versailles Rd, Lexington, KY 40504 USA. EM kvd2@cardinalhill.org; kautz@musc.edu; samwu@biostat.ufl.edu; spstic@phhp.ufl.edu; abehrman@phhp.ufl.edu OI Kautz, Steven/0000-0003-3151-8235 FU Human Motor Performance Laboratory engineering; VA RRD [B40241]; NIH [R01HD46820, 132 HD043730]; Florida Department of Health Brain and Spinal Cord Injury; Rehabilitation Research & Development Service of the VA FX The authors would like to thank members of the Locomotor Training Research and Recovery Team for assistance with data collection as well as the Human Motor Performance Laboratory engineering support for assistance with data processing. We would also like to acknowledge Yunfeng Dai, MS, for assistance with statistical analysis programming. The following grant funding mechanisms supported production of this work: VA RR&D B40241, NIH R01HD46820, NIH 132 HD043730, the Florida Department of Health Brain and Spinal Cord Injury Program ECRRA, and the Rehabilitation Research & Development Service of the VA. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, NICHD, Department of VA, or U.S. Government. NR 25 TC 11 Z9 11 U1 3 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0268-0033 J9 CLIN BIOMECH JI Clin. Biomech. PD FEB PY 2012 VL 27 IS 2 BP 145 EP 150 DI 10.1016/j.clinbiomech.2011.09.001 PG 6 WC Engineering, Biomedical; Orthopedics; Sport Sciences SC Engineering; Orthopedics; Sport Sciences GA 899IW UT WOS:000300810600007 PM 22000699 ER PT J AU Schenker, Y White, DB Asch, DA Kahn, JM AF Schenker, Yael White, Douglas B. Asch, David A. Kahn, Jeremy M. TI Health-care system distrust in the intensive care unit SO JOURNAL OF CRITICAL CARE LA English DT Article DE Health-care system; Distrust; Critical care; Surrogate ID END-OF-LIFE; RACIAL-DIFFERENCES; TRUST; PHYSICIAN; SCALE; ATTITUDES; FAMILY; STATES AB Purpose: To examine the performance and properties of the Revised Health Care System Distrust Scale among surrogates in the intensive care unit (ICU). Materials and Methods: Pilot, prospective cohort study of 50 surrogates of adult, mechanically ventilated patients surveyed on days 1, 3, and 7 of ICU admission. Results: Responses on the Health Care System Distrust Scale on day 1 ranged from 9 to 34 (possible range 9-45, with higher scores indicating more distrust), with a mean and SD of 20.3 +/- 6.9. Factor analysis demonstrated a 2-factor structure, corresponding to the domains of values and competence. Cronbach alpha for the overall scale was .83, for the competence subscale, .76, and for the values subscale, .74. Health-care system distrust was inversely correlated with trust in ICU physicians (Pearson coefficient - .63). When evaluated over the course of each patient's ICU stay, health-care system distrust ratings decreased by 0.31 per patient-day (95% CI 0.55-0.06, P = .015). Correlation between health-care system distrust and trust in ICU physicians decreased slightly over time. Conclusions: Among surrogates in the ICU, the Health Care System Distrust Scale has high internal consistency and convergent validity. There was substantial variability in surrogates' trust in the healthcare system. (C) 2012 Elsevier Inc. All rights reserved. C1 [Schenker, Yael] Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, Pittsburgh, PA 15260 USA. [White, Douglas B.; Kahn, Jeremy M.] Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA 15260 USA. [Asch, David A.] Univ Penn, Ctr Hlth Equity Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Pittsburgh, Leonard Davis Inst Hlth Econ, Pittsburgh, PA 15260 USA. RP Schenker, Y (reprint author), Univ Pittsburgh, Div Gen Internal Med, Sect Palliat Care & Med Eth, Pittsburgh, PA 15260 USA. EM schenkery@upmc.edu OI Asch, David/0000-0002-7970-286X FU National Palliative Care Research Center; Greenwall Foundation; National Institutes of Health [AG032875, HL082650] FX Dr Schenker was supported by a Junior Faculty Career Development Award from the National Palliative Care Research Center. Dr White is supported by a Greenwall Foundation Faculty Scholars Award and a Paul Beeson Award in Aging Research from the National Institutes of Health (AG032875). Dr Kahn is supported by a career development award from the National Institutes of Health (HL082650). NR 37 TC 6 Z9 6 U1 5 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0883-9441 J9 J CRIT CARE JI J. Crit. Care PD FEB PY 2012 VL 27 IS 1 BP 3 EP 10 DI 10.1016/j.jcrc.2011.04.006 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA 898VX UT WOS:000300771600002 PM 21715134 ER PT J AU Taecharvongphairoj, V Goldberg, J Walling, A Rosenfeld, K Lorenz, K AF Taecharvongphairoj, Veeravat Goldberg, Jaime Walling, Anne Rosenfeld, Kenneth Lorenz, Karl TI Prognostic Tools for Congestive Heart Failure SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Taecharvongphairoj, Veeravat; Goldberg, Jaime; Rosenfeld, Kenneth; Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Walling, Anne] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 345 EP 345 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900038 ER PT J AU Baggs, J Schmitt, M Prendergast, T Norton, S Sellers, C Quinn, J AF Baggs, Judith Schmitt, Madeline Prendergast, Thomas Norton, Sally Sellers, Craig Quinn, Jill TI Who Is Attending? End-of-Life Decision Making in the ICU SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Baggs, Judith] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Schmitt, Madeline; Norton, Sally; Sellers, Craig; Quinn, Jill] Univ Rochester, Rochester, NY USA. [Prendergast, Thomas] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 352 EP 352 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900048 ER PT J AU Goebel, J Ahluwalia, S Chong, K Lorenz, KA Walling, A AF Goebel, Joy Ahluwalia, Sangeeta Chong, Kelly Lorenz, Karl A. Walling, Anne TI Why, How, What, and "So What!" Developing Clinical Informatics Tools for Determined Skeptics SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Goebel, Joy] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Ahluwalia, Sangeeta; Chong, Kelly; Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Walling, Anne] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 403 EP 403 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900131 ER PT J AU Wittich, A Williams, B Woodby, L Bailey, FA Burgio, K AF Wittich, Angelina Williams, Beverly Woodby, Lesa Bailey, F. Amos Burgio, Kathryn TI "He Got His Last Wishes"-Next-of-Kin Ways of Knowing Patient's End of Life Preferences and Affirming Clinical Conformity SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Wittich, Angelina] Birmingham Vet Adm Med Ctr, Birmingham, AL USA. [Williams, Beverly] VA Med Ctr, Birmingham, AL USA. [Woodby, Lesa; Bailey, F. Amos] BHM VAMC, Birmingham, AL USA. [Burgio, Kathryn] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 434 EP 435 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900184 ER PT J AU Goldman, B Sanchez-Reilly, S Ross, J Lee, S AF Goldman, Babak Sanchez-Reilly, Sandra Ross, Jeanette Lee, Shuko TI Evaluating an Interdisciplinary, Multicultural, Innovative, and Required Palliative Care Medical Student Course SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Goldman, Babak; Sanchez-Reilly, Sandra; Ross, Jeanette] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra; Lee, Shuko] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 447 EP 448 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900205 ER PT J AU Healy, J El Ahdab, S Lee, S Ross, J Sanchez-Reilly, S AF Healy, Jennifer El Ahdab, Samih Lee, Shuko Ross, Jeanette Sanchez-Reilly, Sandra TI Bereaved Family Members as Teachers: Educating Medical Students in What Matters Most SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Healy, Jennifer] UTHSCSA, HPM, San Antonio, TX USA. [Lee, Shuko; Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 451 EP 451 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900210 ER PT J AU Alshehabi, M Nguyen, G Lee, S Sanchez-Reilly, S AF Alshehabi, Muna Nguyen, George Lee, Shuko Sanchez-Reilly, Sandra TI Is PEG Tube Really the Way To Go: A Comparison of Symptoms Among Subjects With Head and Neck Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Alshehabi, Muna; Nguyen, George; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko; Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 455 EP 456 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900218 ER PT J AU Carleton, J Madhusudanannair, V Lee, S Sanchez-Reilly, S AF Carleton, Johelen Madhusudanannair, Vinu Lee, Shuko Sanchez-Reilly, Sandra TI The Impact of Deferolimus On Survival and Quality of Life in Advanced Cancer Subjects SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Associations CY MAR 07-10, 2012 CL Denver, CO SP Amer Acad Hospice & Palliative Med, Hospice & Palliative Nurses Assoc C1 [Carleton, Johelen] Univ Texas San Antonio, San Antonio, TX USA. [Madhusudanannair, Vinu] UTHSCH San Antonio, San Antonio, TX USA. [Lee, Shuko; Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2012 VL 43 IS 2 BP 463 EP 464 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 889DY UT WOS:000300054900230 ER PT J AU Beason, DP Connizzo, BK Dourte, LM Mauck, RL Soslowsky, LJ Steinberg, DR Bernstein, J AF Beason, David P. Connizzo, Brianne K. Dourte, LeAnn M. Mauck, Robert L. Soslowsky, Louis J. Steinberg, David R. Bernstein, Joseph TI Fiber-aligned polymer scaffolds for rotator cuff repair in a rat model SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article DE Rotator cuff; scaffold; tendon; biomechanics; injury; animal model; tissue engineering; shoulder ID BIOARTIFICIAL TENDONS; OVINE MODEL; AUGMENTATION; SUBMUCOSA; MATRIX AB Background: Repair techniques of rotator cuff tendon tears have improved in recent years; nonetheless, the failure rate remains high. Despite the availability of various graft materials for repair augmentation, there has yet to be a biomechanical study using fiber-aligned scaffolds in vivo. The objective of this study was to evaluate the efficacy of fiber-aligned nanofibrous polymer scaffolds as a potential treatment-delivery vehicle in a rat rotator cuff injury model. Materials and methods: Scaffolds with and without sacrificial fibers were fabricated via electrospinning and implanted to augment supraspinatus repair in rats. Repairs without scaffold augmentation were also performed to serve as controls. Rats were sacrificed at 4 and 8 weeks postoperatively, and repairs were evaluated histologically and biomechanically. Results: Both scaffold formulations remained in place, with more noticeable cellular infiltration and colonization at 4 and 8 weeks after injury and repair for scaffolds lacking sacrificial fibers. Specimens with scaffolds were larger in cross-sectional area compared with controls. Biomechanical testing revealed no significant differences in structural properties between the groups. Some apparent material properties were significantly reduced in the scaffold groups. These reductions were due to increases in cross-sectional area, most likely caused by the extra thickness of the implanted scaffold material. No differences were observed between the 2 scaffold groups. Conclusions: No adverse effect of surgical implantation of overlaid fiber-aligned scaffolds on structural properties of supraspinatus tendons in rat rotator cuff repair was demonstrated, validating this model as a platform for targeted delivery. Level of evidence: Review Article. (C) 2012 Journal of Shoulder and Elbow Surgery Board of Trustees. C1 [Steinberg, David R.; Bernstein, Joseph] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Beason, David P.; Connizzo, Brianne K.; Dourte, LeAnn M.; Mauck, Robert L.; Soslowsky, Louis J.] Univ Penn, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. RP Bernstein, J (reprint author), Philadelphia Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM joseph.bernstein@uphs.upenn.edu FU Philadelphia Veterans Affairs Medical Center Institutional Animal Care and Use Committee [01036, 0003]; Veterans Administration MERIT program [RRD 85071R] FX This study was approved by the Philadelphia Veterans Affairs Medical Center Institutional Animal Care and Use Committee (ID#: 01036, Prom#: 0003).; This study was funded by the Veterans Administration MERIT program (Grant VA No. RR&D 85071R), awarded to Dr. Bernstein. These funds were used in the conducting of experiments and collecting of data. NR 23 TC 28 Z9 29 U1 2 U2 38 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD FEB PY 2012 VL 21 IS 2 BP 245 EP 250 DI 10.1016/j.jse.2011.10.021 PG 6 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 898WJ UT WOS:000300772800017 PM 22244068 ER PT J AU Skibitsky, M Edelen, MO Martin, JL Harker, J Alessi, C Saliba, D AF Skibitsky, Megan Edelen, Maria Orlando Martin, Jennifer L. Harker, Judith Alessi, Cathy Saliba, Debra TI Can Standardized Sleep Questionnaires be Used to Identify Excessive Daytime Sleeping in Older Post-Acute Rehabilitation Patients? SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Sleep; postacute care; rehabilitation; screen ID NURSING-HOME RESIDENTS; PRACTICE PARAMETERS; CIRCADIAN-RHYTHMS; WAKEFULNESS TEST; ELDERLY PERSONS; LATENCY TEST; CLINICAL-USE; POPULATION; COMPLAINTS; MORTALITY AB Objectives: Excessive daytime sleeping is associated with poorer functional outcomes in rehabilitation populations and may be improved with targeted interventions. The purpose of this study was to test simple methods of screening for excessive daytime sleeping among older adults admitted for postacute rehabilitation. Design: Secondary analysis of data from 2 clinical samples. Setting: Two postacute rehabilitation (PAR) units in southern California. Participants: Two hundred twenty-six patients older than 65 years with Mini-Mental State Examination (MMSE) score higher than 11 undergoing rehabilitation. Measurements: The primary outcome was excessive daytime sleeping, defined as greater than 15% (1.8 hours) of daytime hours (8 AM to 8 PM) sleeping as measured by actigraphy. Results: Participants spent, on average, 16.2% (SD12.5%) of daytimehours sleeping as measured by actigraphy. Thirty-nine percent of participants had excessive daytime sleeping. The Pittsburgh Sleep Quality Index (PSQI) was significantly associated with actigraphically measured daytime sleeping (P=.0038), but the Epworth Sleepiness Scale (ESS) was not (P=.49). Neither the ESS nor the PSQI achieved sufficient sensitivity and specificity to be used as a screening tool for excessive daytime sleeping. Two additional models using items from these questionnaires were not significantly associated with the outcome. Conclusions: In an older PAR population, self-report items from existing sleep questionnaires do not identify excessive daytime sleeping. Therefore we recommend objective measures for the evaluation of excessive daytime sleeping as well as further research to identify new self-report items that may be more applicable in PAR populations. Copyright (C) 2012 - American Medical Directors Association, Inc. C1 [Edelen, Maria Orlando; Saliba, Debra] RAND Corp, Santa Monica, CA 90401 USA. [Skibitsky, Megan; Martin, Jennifer L.; Alessi, Cathy; Saliba, Debra] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, Jennifer L.; Harker, Judith; Alessi, Cathy; Saliba, Debra] Vet Adm Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Alessi, Cathy; Saliba, Debra] Los Angeles Jewish Homes Borun Ctr Gerontol Res, Los Angeles, CA USA. RP Saliba, D (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM megan.skibitsky@hsc.utah.edu FU Veterans Administration Health Services Research and Development [SDR 03-217, IIR 01-053-1, AIA 03-047]; NIH/NIA [K23 AG028452]; VA Greater Los Angeles Healthcare System Geriatric Research, Education, and Clinical Center (GRECC); AFAR FX Research was supported by the Veterans Administration Health Services Research and Development (SDR 03-217, D.S.; IIR 01-053-1, C.A.; and AIA 03-047, J.L.M.), NIH/NIA K23 AG028452 (J.L.M.), and the VA Greater Los Angeles Healthcare System Geriatric Research, Education, and Clinical Center (GRECC), and the AFAR Medical Student Summer Research Training in Aging Program. NR 33 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD FEB PY 2012 VL 13 IS 2 BP 127 EP 135 DI 10.1016/j.jamda.2010.05.004 PG 9 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 898HX UT WOS:000300733600010 PM 21450184 ER PT J AU Shacka, J Davidson, K Evonuk, K Feng, WG Jaimes, E Warnock, D AF Shacka, John Davidson, Kathryn Evonuk, Kirsten Feng Wenguang Jaimes, Edgar Warnock, David TI CNS Neuropathology in a Mouse Model of Fabry Disease Indicates Alterations in the Autophagy-Lysosome Pathway SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 8th Anuual Research Meeting of the WORLD Symposium on Lysosomal Disease Networks CY FEB 07-10, 2012 CL San Diego, CA C1 [Shacka, John; Davidson, Kathryn; Evonuk, Kirsten] Birmingham VA Med Ctr, UAB Dept Pathol, Birmingham, AL USA. [Feng Wenguang; Jaimes, Edgar; Warnock, David] UAB Dept Med Nephrol, Birmingham, AL USA. OI Evonuk, Kirsten/0000-0002-2750-0289 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2012 VL 105 IS 2 BP S57 EP S57 DI 10.1016/j.ymgme.2011.11.148 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 885DI UT WOS:000299758300159 ER PT J AU McHale, MJ Sarwar, ZU Cardenas, DP Porter, L Salinas, AS Michalek, JE McManus, LM Shireman, PK AF McHale, Matthew J. Sarwar, Zaheer U. Cardenas, Damon P. Porter, Laurel Salinas, Anna S. Michalek, Joel E. McManus, Linda M. Shireman, Paula K. TI Increased fat deposition in injured skeletal muscle is regulated by sex-specific hormones SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE hormones; injury; adipocyte; ovariectomy; castration ID INFLUENCE POSTEXERCISE INDEXES; POINT-COUNTERPOINT ESTROGEN; GENDER DIFFERENCES; TRAUMA-HEMORRHAGE; OXIDATIVE STRESS; MALE RATS; ALTERED INFLAMMATION; SATELLITE CELLS; BONE-DENSITY; CCR2-/-MICE AB McHale MJ, Sarwar ZU, Cardenas DP, Porter L, Salinas AS, Michalek JE, McManus LM, Shireman PK. Increased fat deposition in injured skeletal muscle is regulated by sex-specific hormones. Am J Physiol Regul Integr Comp Physiol 302: R331-R339, 2012. First published November 23, 2011; doi:10.1152/ajpregu.00427.2011.-Sex differences in skeletal muscle regeneration are controversial; comparisons of regenerative events between sexes have not been rigorously defined in severe injury models. We comprehensively quantified inflammation and muscle regeneration between sexes and manipulated sex-specific hormones to determine effects on regeneration. Cardiotoxin injury was induced in intact, castrated and ovariectomized female and male mice; ovariectomized mice were replaced with low-or high-dose 17-beta estradiol (E-2) or progesterone (P4). Extent of injury was comparable between intact mice, but females were more efficient in removal of necrotic debris, despite similar tissue levels of inflammatory cells and chemokines. Myofiber size during regeneration was equivalent between intact mice and after castration or ovariectomy (OVX) but was decreased (P < 0.001) in ovariectomized mice with high-dose E-2 replacement. Intermuscular adipocytes were absent in uninjured muscle, whereas adipocyte area was increased among regenerated myofibers in all groups. Interestingly, intermuscular fat was greater (P = 0.03) in intact females at day 14 compared with intact males. Furthermore, castration increased (P = 0.01) and OVX decreased adipocyte accumulation. After OVX, E-2, but not P4, replacement decreased (P <= 0.03) fat accumulation. In conclusion, sex-dependent differences in regeneration consisted of more efficient removal of necrosis and increased fat deposition in females with similar injury, inflammation, and regenerated myofiber size; high-dose E-2 decreased myofiber size and fat deposition. Adipocyte accumulation in regenerating muscle was influenced by sex-specific hormones. Recovery following muscle injury was different between males and females, and sex-specific hormones contributed to these differences, suggesting that sex-specific treatments could be beneficial after injury. C1 [McHale, Matthew J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, Div Vasc Surg, San Antonio, TX 78229 USA. [Michalek, Joel E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. [McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Shireman, Paula K.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, Div Vasc Surg, 7703 Floyd Curl Dr,MSC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU United States Air Force; National Institutes of Health [R01-HL074236]; Veterans Administration; UTHSCSA; NIH-NCI [P30 CA054174] FX These studies were supported, in part, by the United States Air Force and by grants from the National Institutes of Health R01-HL074236 and Veterans Administration Merit Review. Data were generated in the Core Flow Cytometry Facility, which is supported by the UTHSCSA and NIH-NCI P30 CA054174 (Cancer Therapy & Research Center). NR 71 TC 7 Z9 7 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD FEB PY 2012 VL 302 IS 3 BP R331 EP R339 DI 10.1152/ajpregu.00427.2011 PG 9 WC Physiology SC Physiology GA 896ZB UT WOS:000300609000003 PM 22116509 ER PT J AU Tolliver, BK DeSantis, SM Brown, DG Prisciandaro, JJ Brady, KT AF Tolliver, Bryan K. DeSantis, Stacia M. Brown, Delisa G. Prisciandaro, James J. Brady, Kathleen T. TI A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report SO BIPOLAR DISORDERS LA English DT Article DE acamprosate; addiction; alcohol; bipolar disorder; craving; depression; glutamate; mania ID NATIONAL EPIDEMIOLOGIC SURVEY; SUBSTANCE USE DISORDERS; PSYCHIATRIC-DISORDERS; COMORBIDITY SURVEY; ATTEMPTED-SUICIDE; ACUTE MANIA; DSM-IV; ABUSE; PREVALENCE; NALTREXONE AB Background: Alcohol use disorders commonly co-occur with bipolar disorder and are associated with a more severe course of bipolar illness, yet treatment research in this important clinical population is scarce. The current study assessed the effects of acamprosate on alcohol use and mood symptoms in subjects with co-occurring bipolar disorder and active alcohol dependence. Methods: Thirty-three adults meeting criteria for bipolar I or bipolar II disorder and current alcohol dependence were randomized to receive add-on acamprosate (1998 mg/day) or placebo while concurrently maintained on mood stabilizing medications. Participants were assessed weekly for frequency and quantity of alcohol consumption and general clinical severity for eight weeks. Depressive symptoms, manic symptoms, and alcohol craving were assessed biweekly. Biomarkers of alcohol use were assessed at study baseline and endpoint. Results: Of the 33 subjects randomized, 23 (69.7%) completed all active phase visits. Over the trial as a whole, no statistically significant treatment differences were detected in drinking outcomes. Post-hoc analysis revealed lower Clinical Global Impression scores of substance use severity in acamprosate-treated participants in weeks 7-8 of the trial. No significant differences in depressive symptoms, manic symptoms, or adverse events were observed between groups. Conclusions: Acamprosate was well-tolerated, with no worsening of depressive or manic symptoms, and appeared to confer some clinical benefit in study completers in the last two weeks of the trial. Larger studies of longer duration are required to fully explore the utility of acamprosate in this population. C1 [Tolliver, Bryan K.; Brown, Delisa G.; Prisciandaro, James J.; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC 29425 USA. [DeSantis, Stacia M.] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Brady, Kathleen T.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Tolliver, BK (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 67 President St, Charleston, SC 29425 USA. EM tollive@musc.edu FU Forest Laboratories FX This study was supported by an investigator-initiated research grant from Forest Laboratories. The authors report no other commercial associations that might pose a conflict of interest in connection with this manuscript. NR 48 TC 24 Z9 25 U1 6 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 EI 1399-5618 J9 BIPOLAR DISORD JI Bipolar Disord. PD FEB PY 2012 VL 14 IS 1 BP 54 EP 63 DI 10.1111/j.1399-5618.2011.00973.x PG 10 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 894SU UT WOS:000300448000006 PM 22329472 ER PT J AU Su, KG Savino, C Marracci, G Chaudhary, P Yu, XL Morris, B Galipeau, D Giorgio, M Forte, M Bourdette, D AF Su, Kimmy G. Savino, Costanza Marracci, Gail Chaudhary, Priya Yu, Xiaolin Morris, Brooke Galipeau, Danielle Giorgio, Marco Forte, Michael Bourdette, Dennis TI Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE EAE; mitochondria; multiple sclerosis; neurodegeneration; neuroprotective; p66 isoform of ShcA ID MITOCHONDRIAL PERMEABILITY TRANSITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CYCLOPHILIN-D; LIFE-SPAN; OXIDATIVE STRESS; SPINAL-CORD; CELL-DEATH; AXONAL DEGENERATION; REDOX ENZYME; ANIMAL-MODEL AB Although multiple sclerosis (MS) has traditionally been considered to be an inflammatory disease, recent evidence has brought neurodegeneration into the spotlight, suggesting that accumulated damage and loss of axons is critical to disease progression and the associated irreversible disability. Proposed mechanisms of axonal degeneration in MS posit cytosolic and subsequent mitochondrial Ca2+ overload, accumulation of pathologic reactive oxygen species (ROS), and mitochondrial dysfunction leading to cell death. In this context, the role of the p66 isoform of ShcA protein (p66) may be significant. The ShcA isoform is uniquely targeted to the mitochondrial intermembrane space in response to elevated oxidative stress, and serves as a redox enzyme amplifying ROS generation in a positive feedforward loop that eventually mediates cell death by activation of the mitochondrial permeability transition pore. Consequently, we tested the hypothesis that genetic inactivation of p66 would reduce axonal injury in a murine model of MS, experimental autoimmune encephalomyelitis (EAE). As predicted, the p66-knockout (p66-KO) mice developed typical signs of EAE, but had less severe clinical impairment and paralysis than wild-type (WT) mice. Histologic examination of spinal cords and optic nerves showed significant axonal protection in the p66-KO tissue, despite similar levels of inflammation. Furthermore, cultured p66-KO neurons treated with agents implicated in MS neurodegenerative pathways showed greater viability than WT neurons. These results confirm the critical role of ROS-mediated mitochondrial dysfunction in the axonal loss that accompanies EAE, and identify p66 as a new pharmacologic target for MS neuroprotective therapeutics. C1 [Su, Kimmy G.; Marracci, Gail; Chaudhary, Priya; Yu, Xiaolin; Morris, Brooke; Galipeau, Danielle; Forte, Michael; Bourdette, Dennis] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Savino, Costanza; Giorgio, Marco] Portland VA Med Ctr, Portland, OR 97239 USA. [Marracci, Gail; Bourdette, Dennis] European Inst Oncol, I-20141 Milan, Italy. RP Forte, M (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM forte@ohsu.edu; bourdett@ohsu.edu RI Giorgio, Marco/I-9425-2012 OI Giorgio, Marco/0000-0002-5842-6042 FU National Institutes of Health [P30-NS0693464, GM-069883, NS-057433, F30-NS704792]; National MS Society; Tartar Trust; OHSU Brain Institute; Laura Fund for Innovation in Multiple Sclerosis; Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development; Biomedical Laboratory Research and Development FX We thank the members of the Forte and Bourdette laboratories for their excellent technical assistance. This work was supported by grants from the National Institutes of Health (P30-NS0693464, GM-069883, NS-057433, and F30-NS704792), the National MS Society, the Tartar Trust, the OHSU Brain Institute, the Laura Fund for Innovation in Multiple Sclerosis, and the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the US government. NR 34 TC 17 Z9 19 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD FEB PY 2012 VL 35 IS 4 BP 562 EP 571 DI 10.1111/j.1460-9568.2011.07972.x PG 10 WC Neurosciences SC Neurosciences & Neurology GA 895MC UT WOS:000300499300007 PM 22277070 ER PT J AU Aubin, PM Whittaker, E Ledoux, WR AF Aubin, Patrick M. Whittaker, Eric Ledoux, William R. TI A Robotic Cadaveric Gait Simulator With Fuzzy Logic Vertical Ground Reaction Force Control SO IEEE TRANSACTIONS ON ROBOTICS LA English DT Article DE Force control; gait simulation; medical robots and systems; neural and fuzzy control; parallel robotics ID IN-VITRO SIMULATION; STANCE PHASE GAIT; MODEL; MUSCLE; WALKING; JOINT AB Lower limb dynamic cadaveric gait simulators are useful to investigate the biomechanics of the foot and ankle, but many systems have several common limitations, which include simplified tendon forces, nonphysiologic tibial kinematics, greatly reduced velocities, scaled body weight (BW), and, most importantly, trial-and-error vertical ground reaction force (vGRF) control. This paper presents the design, development, and validation of the robotic gait simulator (RGS), which addresses these limitations. A 6-degrees-of-freedom (6-DOF) parallel robot was utilized as part of the RGS to recreate the relative tibia to ground motion. A custom-designed nine-axis proportional-integral-derivative (PID) force-control tendon actuation system provided force to the extrinsic tendons of the cadaveric lower limb. A fuzzy logic vGRF controller was developed, which altered tendon forces in real time and iteratively adjusted the robotic trajectory in order to track a target vGRF. The RGS was able to accurately reproduce 6-DOF tibial kinematics, tendon forces, and vGRF with a cadaveric lower limb. The fuzzy logic vGRF controller was able to track the target in vivo vGRF with an average root-mean-square error of only 5.6% BW during a biomechanically realistic 3/4 BW, 2.7-s stance phase simulation. C1 [Aubin, Patrick M.] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. [Aubin, Patrick M.; Whittaker, Eric; Ledoux, William R.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA 98108 USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. RP Aubin, PM (reprint author), Vilnius Gediminas Tech Univ, Dept Biomech, LT-01134 Vilnius, Lithuania. EM patrickmarkaubin@gmail.com; whittaker.eric@gmail.com; wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU VA Rehabilitation Research and Development Service [A2661C, A3923R, A4843C, A6669R] FX Manuscript received June 24, 2010; revised May 4, 2011; accepted August 3, 2011. Date of publication September 29, 2011; date of current version February 9, 2012. This paper was recommended for publication by Associate Editor E. Guglielmelli and Editor J.-P. Laumond upon evaluation of the reviewers' comments. This work was supported by the VA Rehabilitation Research and Development Service under Grant A2661C, Grant A3923R, Grant A4843C, and Grant A6669R. NR 26 TC 11 Z9 13 U1 3 U2 23 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1552-3098 J9 IEEE T ROBOT JI IEEE Trans. Robot. PD FEB PY 2012 VL 28 IS 1 BP 246 EP 255 DI 10.1109/TRO.2011.2164958 PG 10 WC Robotics SC Robotics GA 891AJ UT WOS:000300188300020 ER PT J AU Thompson, GR Patterson, TF AF Thompson, George R., III Patterson, Thomas F. TI Fungal disease of the nose and paranasal sinuses SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Fungal colonization; fungus balls; allergic fungal rhinosinusitis; chronic rhinosinusitis; granulomatous fungal sinusitis; acute fulminant fungal rhinosinusitis ID CHRONIC HYPERTROPHIC RHINOSINUSITIS; FOLLOW-UP; ANTIFUNGAL AGENTS; AMPHOTERICIN-B; DOUBLE-BLIND; SINUSITIS; DIAGNOSIS; IMMUNOTHERAPY; BALLS AB Fungal infections of the nose and paranasal sinuses represent a spectrum of diseases ranging from colonization to invasive rhinosinusitis. Clinical manifestations are largely dependent on the immune status of the host, and given the ubiquitous nature of these organisms, exposure is unavoidable. Noninvasive disease includes asymptomatic fungal colonization, fungus balls, and allergic fungal rhinosinusitis. Invasive disease includes indolent chronic rhinosinusitis, granulomatous fungal sinusitis, and acute fulminant fungal rhinosinusitis. A differentiation of these somewhat overlapping syndromes and the disparate treatment regimens required for effective management are the focus of this review. (J Allergy Clin Immunol 2012;129:321-6.) C1 [Thompson, George R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, Coccidioidomycosis Serol Lab,Dept Med Microbiol &, Davis, CA 95616 USA. [Thompson, George R., III] Univ Calif Davis Med Ctr, Dept Internal Med, Div Infect Dis, Sacramento, CA 95817 USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Thompson, GR (reprint author), Univ Calif Davis, Dept Internal Med, Div Infect Dis, Coccidioidomycosis Serol Lab,Dept Med Microbiol &, 1 Shields Ave,Tupper Hall,Rm 3146, Davis, CA 95616 USA. EM grthompson@ucdavis.edu FU Pfizer; Astellas Pharma US; Merck FX G. R. Thompson has received research support from Pfizer. T. F. Patterson has consultant arrangements with Pfizer, Viamet Pharmaceuticals, Toyama, Merck, and Astellas Pharma US and has received research support from Astellas Pharma US, Merck, and Pfizer. NR 39 TC 33 Z9 33 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2012 VL 129 IS 2 BP 321 EP 326 DI 10.1016/j.jaci.2011.11.039 PG 6 WC Allergy; Immunology SC Allergy; Immunology GA 887TC UT WOS:000299951700004 PM 22206776 ER PT J AU Rosendorff, C AF Rosendorff, Clive TI ss-Blockade: Benefits Beyond Blood Pressure Reduction? SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material ID BETA-BLOCKERS C1 [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Rosendorff, Clive] Mt Sinai Sch Med, New York, NY USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD FEB PY 2012 VL 14 IS 2 BP 69 EP 70 DI 10.1111/j.1751-7176.2011.00562.x PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 882FR UT WOS:000299549100001 PM 22277137 ER PT J AU Ellingson, LD Shields, MR Stegner, AJ Cook, DB AF Ellingson, Laura D. Shields, Morgan R. Stegner, Aaron J. Cook, Dane B. TI Physical Activity, Sustained Sedentary Behavior, and Pain Modulation in Women With Fibromyalgia SO JOURNAL OF PAIN LA English DT Article DE Fibromyalgia; pain modulation; physical activity; fMRI; sedentary behavior ID BRAIN RESPONSES; TEMPORAL SUMMATION; AMERICAN-COLLEGE; HEALTH; PERCEPTION; HUMANS; STIMULATION; MECHANISMS; DEPRESSION; SCIENCE AB Fibromyalgia (FM) has been conceptualized as a disorder of the central nervous system, characterized by augmented sensory processing and an inability to effectively modulate pain. We previously reported that physical activity is related to brain processing of pain, providing evidence for a potential mechanism of pain management. The purpose of this study was to extend our work by manipulating pain modulation and determining relationships to both physical activity and sustained sedentary behavior. Eleven women with FM completed accelerometer measures of physical activity and underwent functional magnetic resonance imaging of painful heat, administered alone and during distracting cognitive tasks. Results showed that physical activity was significantly (P < .005) and positively related to brain responses during distraction from pain in regions implicated in pain modulation including the dorsolateral prefrontal cortex (DLPFC), the dorsal posterior cingulate, and the periaqueductal grey. A significant negative relationship occurred in the left anterior insula. For sedentary time, significant negative relationships were observed in areas involved in both pain modulation and the sensory-discriminative aspects of pain including the DLPFC, thalamus, and superior frontal and pre- and post-central gyri. These results suggest that physical activity and sedentary behaviors are related to central nervous system regulation of pain in FM. Perspective: Our results support a promising benefit of physical activity and highlight the potentially deleterious effects of sustained sedentary behavior for pain regulation in FM. Studies aimed at increasing physical activity or reducing sedentary behavior and determining the impact of these on pain regulation are warranted. Published by Elsevier Inc. on behalf of the American Pain Society C1 [Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, Unit Gymnasium Natatorium 2, Madison, WI 53706 USA. [Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Cook, DB (reprint author), Univ Wisconsin, Dept Kinesiol, Unit Gymnasium Natatorium 2, 2000 Observ Dr, Madison, WI 53706 USA. EM dcook@education.wisc.edu FU National Institutes of Health [ROI 5R01AR050969]; National Institute of Arthritis and Musculoskeletal and Skin Disorders (NIAMS) FX Supported by National Institutes of Health grant ROI 5R01AR050969, and the National Institute of Arthritis and Musculoskeletal and Skin Disorders (NIAMS). NR 47 TC 38 Z9 38 U1 3 U2 18 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD FEB PY 2012 VL 13 IS 2 BP 195 EP 206 DI 10.1016/j.jpain.2011.11.001 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 896TL UT WOS:000300594200011 PM 22245361 ER PT J AU Green, JA Mor, MK Shields, AM Sevik, MA Palevsky, PM Fine, MJ Arnold, RM Weisbord, SD AF Green, Jamie A. Mor, Maria K. Shields, Anne Marie Sevik, Mary Ann Palevsky, Paul M. Fine, Michael J. Arnold, Robert M. Weisbord, Steven D. TI Renal Provider Perceptions and Practice Patterns Regarding the Management of Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID QUALITY-OF-LIFE; CHRONIC DIALYSIS PATIENTS; PRIMARY-CARE PROVIDERS; STAGE KIDNEY-DISEASE; ERECTILE DYSFUNCTION; SYMPTOM BURDEN; HEALTH-CARE; PREVALENCE; NEPHROLOGISTS; SILDENAFIL AB Background: Although pain, sexual dysfunction, and depression are common in patients receiving chronic hemodialysis, these symptoms frequently remain untreated. We sought to characterize renal provider perceptions and practice patterns regarding the treatment of these symptoms. Methods: We surveyed renal providers whose patients were participating in a clinical trial of symptom management at nine hemodialysis units in southwestern Pennsylvania. We used Spearman's correlation to assess the association of provider characteristics with the reported frequency of providing treatment. Results: Overall, 27 of 35 (77%) providers completed the survey. While 21 (78%) believed symptom management to be "very" important and 23 (85%) reported spending a "moderate" to "a lot" of time managing symptoms, <50% reported treating pain and <20% reported treating sexual dysfunction or depression "most" or "all" of the time. Most providers believed it was nonrenal providers' responsibility to treat these symptoms. A greater reported comfort level managing symptoms was associated with a higher reported frequency of treating pain (r = 0.6; p < 0.01), sexual dysfunction (r = 0.67; p < 0.01), and depression (r = 0.43; p < 0.03). Providers who believed it was nonrenal providers' responsibility to treat these symptoms reported treating pain (r = -0.62; p < 0.01) and depression (r = -0.48; p = 0.02) less frequently. Conclusions: Despite reporting considerable importance and substantial time managing symptoms in general, renal providers commonly describe not treating pain, sexual dysfunction, and depression in hemodialysis patients. Given renal providers' beliefs that nonrenal clinicians are primarily responsible for treating these symptoms, multidisciplinary approaches to symptom management in these patients are needed. C1 [Green, Jamie A.; Weisbord, Steven D.] Univ Pittsburgh, Grad Sch Publ Hlth, Renal Electrolyte Div, Pittsburgh, PA 15261 USA. [Sevik, Mary Ann; Fine, Michael J.; Arnold, Robert M.] Univ Pittsburgh, Grad Sch Publ Hlth, Div Gen Internal Med, Pittsburgh, PA 15261 USA. [Arnold, Robert M.] Univ Pittsburgh, Grad Sch Publ Hlth, Sect Palliat Care, Pittsburgh, PA 15261 USA. [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Mor, Maria K.; Shields, Anne Marie; Sevik, Mary Ann; Fine, Michael J.; Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Palevsky, Paul M.; Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Green, JA (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Renal Electrolyte Div, A915 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM greenja@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU Department of Veterans Affairs Health Services Research and Development Service [Weisbord HSRD IIR 07-190]; American Kidney Fund Clinical Scientist in Nephrology Program FX This study was funded by a grant from the Department of Veterans Affairs Health Services Research and Development Service (Weisbord HSR&D IIR 07-190). Dr. Green is supported by a grant from the American Kidney Fund Clinical Scientist in Nephrology Program. NR 29 TC 10 Z9 11 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2012 VL 15 IS 2 BP 163 EP 167 DI 10.1089/jpm.2011.0284 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 897FL UT WOS:000300631700005 PM 22339326 ER PT J AU Anderson, WG Goldstein, NE AF Anderson, Wendy G. Goldstein, Nathan E. TI Update in Hospice and Palliative Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; DEMENTIA; CANCER; VIDEO C1 [Anderson, Wendy G.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Anderson, Wendy G.] Univ Calif San Francisco, Palliat Care Program, San Francisco, CA 94143 USA. [Goldstein, Nathan E.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, Bronx, NY USA. RP Anderson, WG (reprint author), Univ Calif San Francisco, Div Hosp Med, 521 Parnassus Ave,Box 0903, San Francisco, CA 94143 USA. EM Wendy.Anderson@ucsf.edu FU University of California San Francisco Clinical and Translational Science Institute; National Institutes of Health (NIH) [5KL2 RR024130-04]; National Institute of Aging (NIA) [K23 AG025933] FX Dr. Anderson was supported by the University of California San Francisco Clinical and Translational Science Institute Career Development Program, supported by National Institutes of Health (NIH) grant number 5KL2 RR024130-04. Dr. Goldstein was supported by a Mentored Patient-Oriented Research Career Development Award from the National Institute of Aging (NIA), number K23 AG025933. Drs. Anderson and Goldstein presented these articles for the State of the Science Plenary Session at the Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association on February 19, 2011, in Vancouver, British Columbia, Canada. NR 11 TC 1 Z9 1 U1 1 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2012 VL 15 IS 2 BP 236 EP 241 DI 10.1089/jpm.2011.0449 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 897FL UT WOS:000300631700016 PM 22339328 ER PT J AU Tangri, N Inker, LA Tighiouart, H Sorensen, E Menon, V Beck, G Shlipak, M Coresh, J Levey, AS Sarnak, MJ AF Tangri, Navdeep Inker, Lesley A. Tighiouart, Hocine Sorensen, Eric Menon, Vandana Beck, Gerald Shlipak, Michael Coresh, Josef Levey, Andrew S. Sarnak, Mark J. TI Filtration Markers May Have Prognostic Value Independent of Glomerular Filtration Rate SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID BETA-TRACE-PROTEIN; CHRONIC KIDNEY-DISEASE; SERUM CYSTATIN-C; PROSTAGLANDIN-D SYNTHASE; ESTIMATING GFR; RISK-FACTOR; CARDIOVASCULAR EVENTS; HEART-FAILURE; CREATININE; OUTCOMES AB Serum levels of creatinine, cystatin C, or beta trace protein allow estimation of GFR, but whether these markers contribute additional prognostic information beyond that reflected in GFR is unknown. Here, we analyzed data from the Modification of Diet in Renal Disease study, which provided baseline levels of these markers for 816 participants with a median follow-up of 16.6 years. We examined associations between the reciprocals of these filtration markers and I-125 iothalamate GFR, expressed per SD, with kidney failure and mortality. In univariate analysis, lower GFR and higher levels of each filtration marker associated with a higher risk for all outcomes. After adjustment for GFR in a Cox proportional hazards model, higher creatinine associated with a higher risk for kidney failure but a lower risk for all-cause mortality. Higher cystatin C and beta trace protein associated with a higher risk for both kidney failure and all-cause mortality. In models including either cystatin C or beta trace protein, the association of GFR with all-cause mortality was no longer significant after the addition of the filtration marker, suggesting the possibility of multicollinearity. In summary, after adjustment for GFR, levels of creatinine, cystatin C, and beta trace protein, each remained directly associated with kidney failure but differed with respect to their associations with mortality. These differences may be a result of non-GFR related associations of filtration markers, residual confounding by GFR, or collinearity between the filtration markers and GFR. beta trace protein and cystatin C seem to provide more consistent prognostic information than creatinine. C1 [Tangri, Navdeep; Inker, Lesley A.; Sorensen, Eric; Levey, Andrew S.; Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Dept Med, Boston, MA 02111 USA. [Tighiouart, Hocine; Menon, Vandana] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA. [Beck, Gerald] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA. [Menon, Vandana] Outcome Sci, Cambridge, MA USA. [Shlipak, Michael] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Shlipak, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Coresh, Josef] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Sarnak, MJ (reprint author), Tufts Med Ctr, Div Nephrol, Dept Med, Box 391, Boston, MA 02111 USA. EM msarnak@tuftsmedicalcenter.org OI Tangri, Navdeep/0000-0002-5075-6370 FU CKD-EPI [UO1 DK 053869, UO1 DK 067651, UO1 DK 35073]; KRESCENT; Kidney Foundation of Canada; Canadian Institute of Health Research; Canadian Society of Nephrology; [K24 DK078204]; [K23DK081017] FX This work was supported by Grants K24 DK078204 (M.J.S.), CKD-EPI UO1 DK 053869, UO1 DK 067651, and UO1 DK 35073 (A.S.L. and L.A.I.), as well as K23DK081017 (L.A.I.). N.T. is supported by a KRESCENT postdoctoral fellowship, a joint initiative of the Kidney Foundation of Canada, the Canadian Institute of Health Research, and the Canadian Society of Nephrology. NR 42 TC 38 Z9 38 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD FEB PY 2012 VL 23 IS 2 BP 351 EP 359 DI 10.1681/ASN.2011070663 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 895XX UT WOS:000300531100021 PM 22173699 ER PT J AU Maguen, S Madden, E Lau, KM Seal, K AF Maguen, Shira Madden, Erin Lau, Karen M. Seal, Karen TI The impact of head injury mechanism on mental health symptoms in veterans: Do number and type of exposures matter? SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-CONSUMPTION; AUDIT-C; IRAQ; AFGHANISTAN; DEPLOYMENT AB This study examined the association between screening results for mental health problems and the number and type of head injuries in 1,082 Iraq and Afghanistan War veterans who received population-based screening for traumatic brain injury at a Veterans Administration health care facility. Nearly one third of all veterans reported multiple types of head injuries (median = 1 among those with any head injury, range = 16 types of head injury). Veterans reporting multiple head injury mechanisms had 6 times the odds of screening positive for posttraumatic stress disorder (PTSD), adjusted odds ratio (OR) = 6.15, 95% confidence interval (CI) [4.4, 8.7], p < .001, over 4 times the odds of screening positive for depression, adjusted OR = 4.09, 95% CI [2.8, 5.9], p < .001, and about twice the odds of screening positive for alcohol misuse, adjusted OR = 1.64, 95% CI [1.19, 2.3], p = .003, compared to those without head injuries. Veterans reporting a blast plus another head injury mechanism had higher odds of screening positive for all mental health outcomes than any other group (e.g., compared to no head injury group): PTSD, adjusted OR = 6.52, 95% CI [4.6, 9.3], p < .001; depression, adjusted OR = 4.42, 95% CI [3.0, 6.4], p < .001; alcohol misuse, adjusted OR =1.59, 95% CI [1.14, 2.2], p = .006. Given their association with a variety of mental health outcomes, number and type of head injury mechanism should be considered as part of any postdeployment evaluation. C1 [Maguen, Shira; Madden, Erin; Lau, Karen M.; Seal, Karen] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Seal, Karen] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov RI Schueter, nicos/A-3625-2014 NR 19 TC 5 Z9 5 U1 2 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2012 VL 25 IS 1 BP 3 EP 9 DI 10.1002/jts.21669 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 897VA UT WOS:000300685800002 PM 22354503 ER PT J AU Joseph, AM McFall, M Saxon, AJ Chow, BK Leskela, J Dieperink, ME Carmody, TP Beckham, JC AF Joseph, Anne M. McFall, Miles Saxon, Andrew J. Chow, Bruce K. Leskela, Jennie Dieperink, Michael E. Carmody, Timothy P. Beckham, Jean C. TI Smoking intensity and severity of specific symptom clusters in posttraumatic stress disorder SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID ADMINISTERED PTSD SCALE; RECRUITED DAILY SMOKERS; CIGARETTE CONSUMPTION; NICOTINE DEPENDENCE; VETERANS; AFGHANISTAN; CESSATION; IRAQ AB Smoking prevalence among patients with posttraumatic stress disorder (PTSD) is over 40%. Baseline data from the VA Cooperative Studies Program trial of integrated versus usual care for smoking cessation in veterans with PTSD (N = 863) were used in multivariate analyses of PTSD and depression severity, and 4 measures of smoking intensity: cigarettes per day (CPD), Fagerstrom Test for Nicotine Dependence (FTND), time to first cigarette, and expired carbon monoxide. Multivariate regression analysis showed the following significant associations: CPD with race (B = -7.16), age (B = 0.11), and emotional numbing (B =0 .16); FTND with race (B = -0.94), education (B = -0.34), emotional numbing (B = 0.04), significant distress (B = -0.12), and PHQ-9 (B = 0.04); time to first cigarette with education (B = 0.41), emotional numbing (B = -0.03), significant distress (B = 0.09), and PHQ-9 (B = -0.03); and expired carbon monoxide with race (B = -9.40). Findings suggest that among veterans with PTSD, White race and emotional numbing were most consistently related to increased smoking intensity and had more explanatory power than total PTSD symptom score. Results suggest specific PTSD symptom clusters are important to understanding smoking behavior in patients with PTSD. C1 [Joseph, Anne M.] Univ Minnesota, Dept Med, Minneapolis, MN 55414 USA. [McFall, Miles; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Chow, Bruce K.] VA Palo Alto Hlth Care Syst, Vet Affairs Cooperat Studies Program, Palo Alto, CA USA. [Leskela, Jennie; Dieperink, Michael E.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55414 USA. [Carmody, Timothy P.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Carmody, Timothy P.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Beckham, Jean C.] Duke Univ, Durham VA Med Ctr, Chapel Hill, NC USA. [Beckham, Jean C.] Duke Univ, Dept Psychiat & Behav Sci, Chapel Hill, NC USA. RP Joseph, AM (reprint author), Univ Minnesota, Dept Med, 717 Delaware St SE,Suite 166, Minneapolis, MN 55414 USA. EM amjoseph@umn.edu RI Schueter, nicos/A-3625-2014 NR 32 TC 11 Z9 11 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2012 VL 25 IS 1 BP 10 EP 16 DI 10.1002/jts.21670 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 897VA UT WOS:000300685800003 PM 22328334 ER PT J AU Chang, S Phan, RT Moatamed, NA Apple, SK AF Chang, S. Phan, R. T. Moatamed, N. A. Apple, S. K. TI Utility of BRAF Gene Testing on Thyroid Nodules Diagnosed as Follicular Lesion of Undetermined Significance (FLUS) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol (USCAP) C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2012 VL 92 SU 1 MA 345 BP 85A EP 85A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 885SA UT WOS:000299799900346 ER PT J AU Weintraub, D Mamikonyan, E Papay, K Shea, JA Xie, SX Siderowf, A AF Weintraub, Daniel Mamikonyan, Eugenia Papay, Kimberly Shea, Judith A. Xie, Sharon X. Siderowf, Andrew TI Questionnaire for impulsive-compulsive disorders in Parkinson's Disease-Rating Scale SO MOVEMENT DISORDERS LA English DT Article DE dopamine agonists; impulse control disorder; Parkinson's disease ID BEHAVIORS; DYSREGULATION AB Impulse control disorders and related disorders (hobbyism-punding and dopamine dysregulation syndrome) occur in 15% to 20% of Parkinson's disease (PD) patients. We assessed the validity and reliability of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's DiseaseRating Scale (QUIP-RS), a rating scale designed to measure severity of symptoms and support a diagnosis of impulse control disorders and related disorders in PD. A convenience sample of PD patients at a movement disorders clinic self-completed the QUIP-RS and were administered a semistructured diagnostic interview by a blinded trained rater to assess discriminant validity for impulse control disorders (n = 104) and related disorders (n = 77). Subsets of patients were assessed to determine interrater reliability (n = 104), retest reliability (n = 63), and responsiveness to change (n = 29). Adequate cutoff points (both sensitivity and specificity values >80% plus acceptable likelihood ratios) were established for each impulse control disorder and hobbyism-punding. Interrater and retest reliability (intraclass correlation coefficient r) were >0.60 for all disorders. Participants in an impulse control disorder treatment study who experienced full (t = 3.65, P = .004) or partial (t = 2.98, P = .01) response demonstrated significant improvement on the rating scale over time, while nonresponders did not (t = 0.12, P = .91). The QUIP-RS appears to be valid and reliable as a rating scale for impulse control disorders and related disorders in PD. Preliminary results suggest that it can be used to support a diagnosis of these disorders, as well as to monitor changes in symptom severity over time. (C) 2011 Movement Disorder Society C1 [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel; Siderowf, Andrew] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA. [Shea, Judith A.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Shea, Judith A.] Philadelphia Vet Affairs Med Ctr, CHERP, Philadelphia, PA USA. [Xie, Sharon X.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU Michael J. Fox Foundation. FX Michael J. Fox Foundation. NR 20 TC 51 Z9 51 U1 4 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2012 VL 27 IS 2 BP 242 EP 247 DI 10.1002/mds.24023 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 894LW UT WOS:000300429200014 PM 22134954 ER PT J AU Munoz, A Somogyi, G Boone, T Ford, A Smith, C AF Munoz, Alvaro Somogyi, George Boone, Timothy Ford, Anthony Smith, Christopher TI BLADDER SENSORY SIGNALS ARE POSITIVELY MODULATED BY UROTHELIAL P2 X 3 AND P2 X 2/3 PURINERGIC RECEPTORS IN SPINAL CORD INJURED RATS SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-for-Urodynamics-and-Female-Urology (SUFU) CY FEB 28-MAR 03, 2012 CL New Orleans, LA SP Soc Urodynam & Female Urol (SUFU) C1 [Munoz, Alvaro; Somogyi, George; Smith, Christopher] Baylor Coll Med, Houston, TX 77030 USA. [Boone, Timothy] Methodist Hosp, Houston, TX 77030 USA. [Boone, Timothy; Smith, Christopher] VA Med Ctr, Houston, TX USA. [Ford, Anthony] Afferent Pharmaceut, San Mateo, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2012 VL 31 IS 2 BP 241 EP 241 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 895NG UT WOS:000300502400072 ER PT J AU Wilmot, B Voruganti, VS Chang, YPC Fu, Y Chen, Z Taylor, HA Wilson, JG Gipson, T Shah, VO Umans, JG Flessner, MF Hitzemann, R Shuldiner, AR Comuzzie, AG McWeeney, S Zager, PG MacCluer, JW Cole, SA Cohen, DM AF Wilmot, Beth Voruganti, V. Saroja Chang, Yen-Pei C. Fu, Yi Chen, Zhan Taylor, Hrman A. Wilson, James G. Gipson, Teresa Shah, Vallabh O. Umans, Jason G. Flessner, Michael F. Hitzemann, Robert Shuldiner, Alan R. Comuzzie, Anthony G. McWeeney, Shannon Zager, Philip G. MacCluer, Jean W. Cole, Shelley A. Cohen, David M. TI Heritability of serum sodium concentration: evidence for sex- and ethnic-specific effects SO PHYSIOLOGICAL GENOMICS LA English DT Article DE hyponatremia; hypernatremia; osmoregulation; water balance ID NEPHROGENIC DIABETES-INSIPIDUS; CORONARY-HEART-DISEASE; INAPPROPRIATE ANTIDIURESIS; INDUCED HYPONATREMIA; RECEPTOR GENE; CARDIOVASCULAR-DISEASE; PROGNOSTIC IMPORTANCE; AMERICAN-INDIANS; LINKAGE ANALYSIS; CHANNEL AB Wilmot B, Voruganti VS, Chang YP, Fu Y, Chen Z, Taylor HA, Wilson JG, Gipson T, Shah VO, Umans JG, Flessner MF, Hitzemann R, Shuldiner AR, Comuzzie AG, McWeeney S, Zager PG, MacCluer JW, Cole SA, Cohen DM. Heritability of serum sodium concentration: evidence for sex- and ethnic-specific effects. Physiol Genomics 44: 220-228, 2012. First published December 20, 2011; doi:10.1152/physiolgenomics.00153.2011.-Serum sodium concentration is the clinical index of systemic water balance. Although disordered water balance is common and morbid, little is known about genetic effects on serum sodium concentration at the population level. Prior studies addressed only participants of European descent and either failed to demonstrate significant heritability or showed only modest effect. We investigated heritability of serum sodium concentration in large cohorts reflecting a range of races/ethnicities, including the Framingham Heart Study (FHS, non-Hispanic Caucasian), the Heredity and Phenotype Intervention Heart Study (HAPI, Amish Caucasian), the Jackson Heart Study (JHS, African American), the Strong Heart Family Study (SHFS, American Indian), and the Genetics of Kidney Disease in Zuni Indians Study (GKDZI, American Indian). Serum sodium was transformed for the osmotic effect of glucose, and participants with markedly elevated glucose or reduced estimated glomerular filtration rate (eGFR) were excluded. Using a standard variance components method, incorporating covariates of age, glucose, and eGFR, we found heritability to be high in African American and American Indian populations and much more modest in non-Hispanic Caucasian populations. Estimates among females increased after stratification on sex and were suggestive among female participants in FHS (0.18 +/- 0.12, P = 0.057) and male participants in JHS (0.24 +/- 0.16, P = 0.067) and statistically significant among female participants in JHS (0.44 +/- 0.09, P = 1 x 10(-7)), SHFS (0.59 +/- 0.05, P = 9.4 x 10(-46)), and GKDZI (0.46 +/- 0.15, P = 1.7 x 10(-4)), and male participants in HAPI (0.18 +/- 0.12, P = 0.03) and SHFS (0.67 +/- 0.07, P = 5.4 x 10(-26)). Exclusion of diuretic users increased heritability among females and was significant in all cohorts where data were available. In aggregate, these data strongly support the heritability of systemic water balance and underscore sex and ethnicity-specific effects. C1 [Fu, Yi; Chen, Zhan; Cohen, David M.] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Wilmot, Beth; McWeeney, Shannon] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Hitzemann, Robert] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Gipson, Teresa] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97239 USA. [Fu, Yi; Chen, Zhan; Cohen, David M.] Portland VA Med Ctr, Portland, OR USA. [Voruganti, V. Saroja; Comuzzie, Anthony G.; MacCluer, Jean W.; Cole, Shelley A.] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA. [Taylor, Hrman A.; Wilson, James G.; Flessner, Michael F.] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Taylor, Hrman A.; Wilson, James G.; Flessner, Michael F.] GV Sonny Montgomery Vet Affairs Med Ctr, Jackson, MS USA. [Chang, Yen-Pei C.; Shuldiner, Alan R.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Umans, Jason G.] Medstar Res Inst, Washington, DC USA. [Zager, Philip G.] Univ New Mexico, Sch Med, Dept Med, Albuquerque, NM 87131 USA. [Shah, Vallabh O.] Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA. RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Mailcode L463V,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM cohend@ohsu.edu OI Shuldiner, Alan/0000-0001-9921-4305 FU National Institutes of Health; Department of Veterans Affairs; American Heart Association; National Heart, Lung, and Blood Institute's (NHLBI) FHS [N01-HC-25195]; NHLBI in collaboration with Boston University; NHLBI [U01 HL-041654, U01 HL-041642, U01 HL-041652, U01 HL-065520, U01 HL-065521]; National Institute of Diabetes and Digestive and Kidney Diseases [DK-066660-03, DK-57300-05]; University of New Mexico Clinical Research Center [5M01RR-00997]; National Institute of Environmental Health Sciences [P30 ES-012072]; Dialysis Clinic; National Center on Minority Health and Health Disparities FX This work was supported by grants from the National Institutes of Health, the Department of Veterans Affairs, and the American Heart Association (to D. M. Cohen). A portion of this work was supported by the National Heart, Lung, and Blood Institute's (NHLBI) FHS (contract no. N01-HC-25195). The FHS is conducted and supported by the NHLBI in collaboration with Boston University. The HAPI Heart Study is supported by NHLBI Grant HL-72515-01. The SHS is supported by the following NHLBI grants: U01 HL-041654, U01 HL-041642, U01 HL-041652, U01 HL-065520, and U01 HL-065521. GKDZI receives funding from National Institute of Diabetes and Digestive and Kidney Diseases (DK-066660-03; DK-57300-05), University of New Mexico Clinical Research Center (5M01RR-00997), National Institute of Environmental Health Sciences (P30 ES-012072), and Dialysis Clinic. The JHS is supported by the NHLBI and the National Center on Minority Health and Health Disparities. NR 69 TC 4 Z9 4 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 EI 1531-2267 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD FEB PY 2012 VL 44 IS 3 BP 220 EP 228 DI 10.1152/physiolgenomics.00153.2011 PG 9 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 896XN UT WOS:000300604800002 PM 22186255 ER PT J AU Yuen, EK Goetter, EM Herbert, JD Forman, EM AF Yuen, Erica K. Goetter, Elizabeth M. Herbert, James D. Forman, Evan M. TI Challenges and Opportunities in Internet-Mediated Telemental Health SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE telemental health; remote treatment; distance treatment; technology; Internet ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; POSTTRAUMATIC-STRESS-DISORDER; FACE-TO-FACE; OBSESSIVE-COMPULSIVE DISORDER; SMOKING-CESSATION PROGRAM; PANIC DISORDER; SOCIAL PHOBIA; SELF-HELP; WEIGHT-LOSS AB The use of technology to provide remote psychological assessment and intervention services is growing rapidly. Remote assessment, treatment, training, and consultation options, particularly those provided via the Internet (e.g., videoconferencing, self-help Web sites, handheld devices), have the potential to increase access to high-quality psychological services. Despite the promise of these technologies, a variety of clinical, ethical, and logistical challenges accompany the remote delivery of such services. Among these challenges are issues involving security, competence, the therapeutic alliance, usability, and technical difficulties. We elucidate some of the challenges posed by these technologies and suggest preliminary recommendations for psychologists considering their use. C1 [Herbert, James D.] Drexel Univ, Dept Psychol, Coll Arts & Sci, Philadelphia, PA 19102 USA. [Forman, Evan M.] Drexel Univ, Doctoral Program Clin Psychol, Philadelphia, PA 19102 USA. [Yuen, Erica K.] Med Univ S Carolina, Charleston, SC 29425 USA. [Yuen, Erica K.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Herbert, JD (reprint author), Drexel Univ, Dept Psychol, Coll Arts & Sci, 245 N 15th St,Mail Stop 988, Philadelphia, PA 19102 USA. EM james.herbert@drexel.edu RI Forman, Evan/I-1042-2012 NR 71 TC 24 Z9 24 U1 1 U2 6 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD FEB PY 2012 VL 43 IS 1 BP 1 EP 8 DI 10.1037/a0025524 PG 8 WC Psychology, Multidisciplinary SC Psychology GA 895GE UT WOS:000300483400001 ER PT J AU Meyer, EC Zimering, R Daly, E Knight, J Kamholz, BW Gulliver, SB AF Meyer, Eric C. Zimering, Rose Daly, Erin Knight, Jeffrey Kamholz, Barbara W. Gulliver, Suzy Bird TI Predictors of Posttraumatic Stress Disorder and Other Psychological Symptoms in Trauma-Exposed Firefighters SO PSYCHOLOGICAL SERVICES LA English DT Article DE PTSD; firefighters; depression; alcohol abuse; social support ID ADMINISTERED PTSD SCALE; SOCIAL SUPPORT; PSYCHOMETRIC PROPERTIES; PROFESSIONAL FIREFIGHTERS; VOLUNTEER FIREFIGHTERS; CAGE QUESTIONNAIRE; RESCUE WORKERS; PREVALENCE; INVENTORY; METAANALYSIS AB Firefighters are exposed to a range of potentially traumatic stressors, yet studies examining the impact of this exposure are equivocal. Although some studies suggest increased risk for mental health problems, others suggest unusual resilience. Type of assessment methodology may contribute to the lack of consistent findings. We assessed 142 trauma-exposed, professional firefighters utilizing a standardized clinical interview and self-report measures and found low rates of posttraumatic stress disorder (PTSD) diagnoses (4.2%), and depressive, anxiety, and alcohol-abuse symptoms. Frequency of trauma exposure did not predict psychological symptoms. Perceived social support, occupational stress, coping, as well as the interaction between perceived social support and self-blame were significant predictors of symptoms. Firefighters reporting low-perceived social support and high self-blame demonstrated the highest levels of clinically significant symptoms. These findings may inform education, treatment, and resilience training for emergency personnel. C1 [Meyer, Eric C.; Gulliver, Suzy Bird] Cent Texas Vet Hlth Care Syst 151C, US Dept Vet Affairs, VISN 17, Ctr Excellence Res Returning War Vet, Waco, TX 76711 USA. [Zimering, Rose; Daly, Erin; Knight, Jeffrey; Kamholz, Barbara W.] US Dept Vet Affairs, Boston, MA USA. [Zimering, Rose; Knight, Jeffrey; Kamholz, Barbara W.] Boston Univ, Sch Med, Boston, MA 02215 USA. RP Meyer, EC (reprint author), Cent Texas Vet Hlth Care Syst 151C, US Dept Vet Affairs, VISN 17, Ctr Excellence Res Returning War Vet, 4800 Mem Dr, Waco, TX 76711 USA. EM Eric.Meyer2@va.gov NR 60 TC 29 Z9 34 U1 9 U2 41 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2012 VL 9 IS 1 BP 1 EP 15 DI 10.1037/a0026414 PG 15 WC Psychology, Clinical SC Psychology GA 896BW UT WOS:000300541400001 PM 22449083 ER PT J AU Yoder, M Tuerk, PW Price, M Grubaugh, AL Strachan, M Myrick, H Acierno, R AF Yoder, Matthew Tuerk, Peter W. Price, Matthew Grubaugh, Anouk L. Strachan, Martha Myrick, Hugh Acierno, Ron TI Prolonged Exposure Therapy for Combat-Related Posttraumatic Stress Disorder: Comparing Outcomes for Veterans of Different Wars SO PSYCHOLOGICAL SERVICES LA English DT Article DE posttraumatic stress disorder; veterans; prolonged exposure; treatment effectiveness; exposure therapy ID PTSD; AFGHANISTAN; IRAQ AB There is significant support for exposure therapy as an effective treatment for posttraumatic stress disorder (PTSD) across a variety of populations, including veterans; however, there is little empirical information regarding how veterans of different war theaters respond to exposure therapy. Accordingly, questions remain regarding therapy effectiveness for treatment of PTSD for veterans of different eras. Such questions have important implications for the dissemination of evidence based treatments, treatment development, and policy. The current study compared treatment outcomes across 112 veterans of the Vietnam War, the first Persian Gulf War, and the wars in Afghanistan and Iraq. All subjects were diagnosed with PTSD and enrolled in Prolonged Exposure (PE) treatment. Veterans from all three groups showed significant improvement in PTSD symptoms, with veterans from Vietnam and Afghanistan/Iraq responding similarly to treatment. Persian Gulf veterans did not respond to treatment at the same rate or to the same degree as veterans from the other two eras. Questions and issues regarding the effectiveness of evidence based treatment for veterans from different eras are discussed. C1 [Yoder, Matthew; Tuerk, Peter W.; Price, Matthew; Grubaugh, Anouk L.; Strachan, Martha; Myrick, Hugh; Acierno, Ron] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Yoder, Matthew; Tuerk, Peter W.; Price, Matthew; Grubaugh, Anouk L.; Strachan, Martha; Myrick, Hugh; Acierno, Ron] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Yoder, M (reprint author), Ralph H Johnson Med Ctr, Dept Vet Affairs, 109 Bee St, Charleston, SC 29401 USA. EM yoderm@musc.edu RI Schueter, nicos/A-3625-2014 FU NIMH NIH HHS [T32 MH018869] NR 25 TC 25 Z9 25 U1 1 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2012 VL 9 IS 1 BP 16 EP 25 DI 10.1037/a0026279 PG 10 WC Psychology, Clinical SC Psychology GA 896BW UT WOS:000300541400002 PM 22449084 ER PT J AU Harper, JD Spencer, ES Porter, MP Gore, JL AF Harper, Jonathan D. Spencer, E. Sophie Porter, Michael P. Gore, John L. TI Adoption of Laparoscopic Radical Nephrectomy in the State of Washington SO UROLOGY LA English DT Article ID DONOR NEPHRECTOMY; KIDNEY-CANCER; DIFFUSION; REGIONALIZATION AB OBJECTIVE To examine state-wide trends in adoption of laparoscopic radical nephrectomy (LRN). Open radical nephrectomy and LRN confer equivalent long-term oncological outcomes, yet LRN usage has not increased analogous to diffusion of laparoscopy in other fields. MATERIAL AND METHODS From the Washington State Comprehensive Hospital Abstract Reporting System, we identified patients who underwent ORN and LRN from 1998 to 2007. Number of LRNs was examined for each hospital state-wide. Length of stay outcomes were examined, and multivariate models were created to examine characteristics of LRN patients and of patients who received care at high-volume LRN hospitals (HiLap). RESULTS The proportion of nephrectomies performed laparoscopically increased 27%. In 1998, 7 hospitals (12%) performed >= 1 LRN compared with 36 hospitals (61%) in 2007. Four HiLap hospitals accounted for 61% of the increase in LRN from 1998-2002, and 36% of the increase overall. Women (OR 1.15, 95% CI 1.00-1.33) and healthier patients (OR 1.52, 95% CI 1.28-1.82 for patients with Charlson 0 vs >= 2) were more likely to undergo LRN. Mean length of stay for nephrectomies was shorter at HiLap hospitals (P = .04 for 1998-2002, P < .001 for 2003-2007). CONCLUSIONS Uptake of LRN in Washington state parallels national trends; however, the proportion of LRN is lower than expected. A handful of hospitals account for the majority of the increase in LRN. The quality of nephrectomy care may be better at these centers. Barriers exist that prevent LRN adoption even after a trial case. Dissemination of the processes or personnel associated with use of LRN may increase the proportion of patients undergoing LRN. UROLOGY 79: 326-331, 2012. (C) 2012 Elsevier Inc. All rights reserved. C1 Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA USA. RP Harper, JD (reprint author), UW Urol, 1959 NE Pacific,Box 356510, Seattle, WA 98195 USA. EM jdharper@uw.edu OI Gore, John/0000-0002-2847-5062 FU VA Puget Sound Health Care System, Seattle, Washington FX This material is the result of work supported in part by resources from the VA Puget Sound Health Care System, Seattle, Washington. NR 18 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD FEB PY 2012 VL 79 IS 2 BP 326 EP 331 DI 10.1016/j.urology.2011.10.029 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 894DM UT WOS:000300407200034 PM 22310748 ER PT J AU Zhuang, LY Duty, BD Conlin, MJ Daneshmand, S AF Zhuang, Liyan Duty, Brian D. Conlin, Michael J. Daneshmand, Siamak TI Colocalycostomy for Repair of Ureterojejunal Fistula SO UROLOGY LA English DT Editorial Material AB Calycostomy is a procedure used for an inaccessible renal pelvis during pyeloplasty. We report the first case of using an anterior calycostomy to repair a ureterojejeunal fistula in a transverse colon conduit in which the ureter and pelvis were not accessible because of intense fibrosis. UROLOGY 79: e12-e14, 2012. (C) 2012 Elsevier Inc. C1 [Daneshmand, Siamak] USC Norris Comprehens Canc Ctr, Inst Urol, USC Keck Sch Med, Los Angeles, CA 90089 USA. Oregon Hlth & Sci Univ, Dept Surg, Div Urol & Renal Transplantat, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. RP Daneshmand, S (reprint author), USC Norris Comprehens Canc Ctr, Inst Urol, USC Keck Sch Med, 1441 Eastlake Ave,Suite 7416, Los Angeles, CA 90089 USA. EM siadaneshmand@yahoo.com OI Conlin, Michael/0000-0002-3128-3731; Daneshmand, Siamak/0000-0001-6224-9598 NR 1 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD FEB PY 2012 VL 79 IS 2 BP E12 EP E14 DI 10.1016/j.urology.2011.04.040 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 894DM UT WOS:000300407200006 PM 21705047 ER PT J AU Grenon, SM Hughes-Fulford, M Rapp, J Conte, MS AF Grenon, S. Marlene Hughes-Fulford, Millie Rapp, Joseph Conte, Michael S. TI Polyunsaturated fatty acids and peripheral artery disease SO VASCULAR MEDICINE LA English DT Review DE lipids; nutrition; peripheral arterial disease; peripheral vascular diseases; review ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; FISH-OIL SUPPLEMENTATION; TUMOR-NECROSIS-FACTOR; ALPHA-LINOLENIC ACID; NF-KAPPA-B; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; HUMAN ENDOTHELIAL-CELLS; SMOOTH-MUSCLE-CELLS AB There is substantial evidence that polyunsaturated fatty acids (PUFAs) such as n-3 and n-6 fatty acids (FAs) play an important role in prevention of atherosclerosis. In vitro and in vivo studies focusing on the interactions between monocytes and endothelial cells have explored the molecular effects of FAs on these interactions. Epidemiological surveys, followed by large, randomized, control trials have demonstrated a reduction in major cardiovascular events with supplementation of n-3 FAs in secondary prevention settings. The evidence of beneficial effects specific to patients with peripheral artery disease (PAD) remains elusive, and is the focus of this review. C1 [Grenon, S. Marlene] Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco Vet Affairs Med Ctr, Surg Serv, San Francisco, CA 94121 USA. [Hughes-Fulford, Millie] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [Hughes-Fulford, Millie] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94121 USA. RP Grenon, SM (reprint author), Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco Vet Affairs Med Ctr, Surg Serv, Mail Code 112 G, San Francisco, CA 94121 USA. EM marlene.grenon@ucsfmedctr.org FU Department of Surgery, University of California, San Francisco; Northern California Institute for Research and Education; National Center for Research Resources [KL2RR024130] FX This work was supported by funds from the Department of Surgery, University of California, San Francisco and the Northern California Institute for Research and Education. The project described was supported by Award Number KL2RR024130 from the National Center for Research Resources. NR 121 TC 14 Z9 14 U1 1 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1358-863X EI 1477-0377 J9 VASC MED JI Vasc. Med. PD FEB PY 2012 VL 17 IS 1 BP 51 EP 63 DI 10.1177/1358863X11429175 PG 13 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 896HY UT WOS:000300557500007 PM 22363018 ER PT J AU Ford, JM Perez, VB Mathalon, DH AF Ford, Judith M. Perez, Veronica B. Mathalon, Daniel H. TI Neurophysiology of a possible fundamental deficit in schizophrenia SO WORLD PSYCHIATRY LA English DT Editorial Material ID COROLLARY DISCHARGE DYSFUNCTION; AUDITORY HALLUCINATIONS; SYNCH C1 [Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. [Ford, Judith M.; Perez, Veronica B.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. OI Mathalon, Daniel/0000-0001-6090-4974 FU NIMH NIH HHS [R01 MH076989, T32 MH089920, K02 MH067967, R01 MH058262] NR 10 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER MASSON PI MILANO PA VIA PALEOCAPA 7, 20121 MILANO, ITALY SN 1723-8617 J9 WORLD PSYCHIATRY JI World Psychiatry PD FEB PY 2012 VL 11 IS 1 BP 58 EP 60 PG 3 WC Psychiatry SC Psychiatry GA 894XI UT WOS:000300460400018 PM 22295012 ER PT J AU Huddle, TS AF Huddle, Thomas S. TI Regarding Physician Advocacy Reply SO ACADEMIC MEDICINE LA English DT Letter C1 [Huddle, Thomas S.] Univ Alabama Birmingham Sch Med, Div Gen Internal Med, Dept Med, Birmingham, AL 35294 USA. [Huddle, Thomas S.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Huddle, TS (reprint author), Univ Alabama Birmingham Sch Med, Div Gen Internal Med, Dept Med, Birmingham, AL 35294 USA. EM thuddle@uab.edu NR 0 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD FEB PY 2012 VL 87 IS 2 BP 132 EP 132 DI 10.1097/ACM.0b013e318241ade6 PG 1 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 894BN UT WOS:000300402100003 ER PT J AU Ponikowski, P Metra, M Teerlink, JR Unemori, E Felker, GM Voors, AA Filippatos, G Greenberg, B Teichman, SL Severin, T Mueller-Velten, G Cotter, G Davison, BA AF Ponikowski, Piotr Metra, Marco Teerlink, John R. Unemori, Elaine Felker, G. Michael Voors, Adriaan A. Filippatos, Gerasimos Greenberg, Barry Teichman, Sam L. Severin, Thomas Mueller-Velten, Guenther Cotter, Gad Davison, Beth A. TI Design of the RELAXin in Acute Heart Failure Study SO AMERICAN HEART JOURNAL LA English DT Article ID RANDOMIZED CONTROLLED-TRIALS; IN-HOSPITAL MORTALITY; CLINICAL-TRIALS; TASK-FORCE; PHASE-III; NESIRITIDE; ASSOCIATION; ANTAGONIST; OUTCOMES; DYSPNEA AB Background Acute heart failure (AHF) remains a major public health burden with a high prevalence and poor prognosis. Relaxin is a naturally occurring peptide hormone that increases cardiac output, arterial compliance, and renal blood flow during pregnancy. The RELAX-AHF-1 study will evaluate the effect of RLX030 (recombinant form of human relaxin 2) on symptom relief and clinical outcomes in patients with AHF. Methods The protocol includes a completed phase 2 234-patient dose-finding study (Pre-RELAX-AHF) and an ongoing phase 3 1,160-patient trial (RELAX-AHF-1). Patients with AHF and systolic blood pressure >125 mm Hg are randomized within 16 hours of presentation to a 48-hour IV infusion of RLX030 or placebo. The 30 mu g/kg per day dose of RLX030 was chosen for RELAX-AHF-1 based on effects on dyspnea, clinical outcomes, and safety observed in Pre-RELAX-AHF. Primary efficacy end points in RELAX-AHF-1 are (1) the area under the curve of change of the dyspnea Visual Analog Scale from baseline through day 5 and (2) whether the patient reports moderately to markedly better dyspnea at 6, 12, and 24 hours. Secondary efficacy end points include days alive and out of the hospital through day 60 and cardiovascular death or rehospitalization for heart failure or renal failure through day 60. Patients will be followed up through day 180 for mortality. As of September 19, 2011, 978 patients have been enrolled. Conclusions Pre-RELAX-AHF results suggested that infusion of RLX030 may accelerate dyspnea relief and improve prognosis in patients hospitalized with AHF. RELAX-AHF-1 will further evaluate these effects. (Am Heart J 2012;163:149-155.e1.) C1 [Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC 27707 USA. [Ponikowski, Piotr] Med Univ, Mil Hosp, Dept Heart Dis, Wroclaw, Poland. [Metra, Marco] Univ Brescia, Dept Expt & Appl Med, Brescia, Italy. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Sect Cardiol, San Francisco, CA 94143 USA. [Unemori, Elaine; Teichman, Sam L.] Corthera Inc, San Mateo, CA USA. [Felker, G. Michael] Duke Univ, Duke Clin Res Inst, Durham, NC USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 AV Groningen, Netherlands. [Filippatos, Gerasimos] Athens Univ Hosp Attikon, Heart Failure Unit, Athens, Greece. [Greenberg, Barry] Univ Calif San Diego, Adv Heart Failure Program, San Diego, CA 92103 USA. [Severin, Thomas; Mueller-Velten, Guenther] Novartis Pharma AG, Basel, Switzerland. RP Davison, BA (reprint author), Momentum Res Inc, 3100 Tower Blvd,Suite 802, Durham, NC 27707 USA. EM bethdavison@momentum-research.com RI Teerlink, John/D-2986-2012; Lainscak, Mitja/F-3237-2015; Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568; Davison, Beth/0000-0003-2374-6449 NR 40 TC 28 Z9 28 U1 1 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD FEB PY 2012 VL 163 IS 2 BP 149 EP U234 DI 10.1016/j.ahj.2011.10.009 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 891ON UT WOS:000300226600004 PM 22305830 ER PT J AU Dubin, R Li, YM Ix, JH Shlipak, MG Whooley, M Peralta, CA AF Dubin, Ruth Li, Yongmei Ix, Joachim H. Shlipak, Michael G. Whooley, Mary Peralta, Carmen A. TI Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: Data from the Heart and Soul Study SO AMERICAN HEART JOURNAL LA English DT Article ID CHRONIC KIDNEY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; SERUM CYSTATIN-C; DEPRESSIVE SYMPTOMS; ELDERLY PERSONS; RENAL-FUNCTION; PTX3; HEALTH; RISK; ATHEROSCLEROSIS AB Background Pentraxin-3 (PTX3) is an inflammatory marker thought to be more specific to vascular inflammation than C-reactive protein (CRP). Whether PTX3 is independently associated with adverse events among persons with stable coronary heart disease (CHD), independently of CRP, and whether kidney dysfunction influences these associations are not known. Methods We evaluated the associations of baseline PTX3 levels with all-cause mortality, cardiovascular (CV) events (myocardial infarction, stroke, or CHD death), and incident heart failure (HF) during 37 months among ambulatory persons with stable CHD participating in the Heart and Soul Study. Cox proportional hazards models were adjusted for age, sex, race, hypertension, diabetes, smoking, and CRP. Results Among 986 persons with stable CHD, each 1 unit increase in log PTX3 at baseline was associated with an 80% increased risk of all-cause mortality (hazard ratio [HR] 1.8, 95% CI 1.5-2.1), a 50% increased risk of CV events (HR 1.5, 95% CI, 1.2-1.9), and an 80% greater risk of incident HF (HR 1.8, 95% CI, 1.3-2.5). Further adjustment for estimated glomerular filtration rate (eGFR) attenuated these associations to 1.6 (1.3-1.9) for mortality, 1.3 (1.0-1.6) for CV events and 1.5 (1.1-2.1) for incident HF. Stratification by eGFR >60 mL/min per 1.73m(2) or <60 mL/min per 1.73m(2) did not affect these associations (P interaction > .3 for all outcomes). Conclusions Among persons with stable CHD, higher PTX3 concentrations were associated with increased risk for all-cause mortality, CV events, and incident HF independently of systemic inflammation. Adjustment for eGFR modestly attenuated these associations, suggesting that future studies of PTX3 should adjust for kidney function. (Am Heart J 2012;163:274-9.) C1 [Dubin, Ruth] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Li, Yongmei; Shlipak, Michael G.; Whooley, Mary; Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ix, Joachim H.] Univ Calif San Diego, La Jolla, CA 92093 USA. RP Dubin, R (reprint author), Univ Calif San Francisco, Div Nephrol, 521 Parnassus Ave,C443, San Francisco, CA 94143 USA. EM ruth.dubin@ucsf.edu FU NHLBI NIH HHS [R01 HL079235]; NIDDK NIH HHS [K23 DK082793, K23 DK082793-01, T32 DK007219] NR 27 TC 44 Z9 45 U1 2 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD FEB PY 2012 VL 163 IS 2 BP 274 EP 279 DI 10.1016/j.ahj.2011.11.007 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 891ON UT WOS:000300226600021 PM 22305847 ER PT J AU Burns, AC Petersen, NJ Garza, A Arya, M Patterson, JE Naik, AD Trautner, BW AF Burns, Allison C. Petersen, Nancy J. Garza, Armandina Arya, Monisha Patterson, Jan E. Naik, Aanand D. Trautner, Barbara W. TI Accuracy of a urinary catheter surveillance protocol SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Catheter-associated urinary tract infection; Infection control; Chart review; Infection; Infection control ID INFECTIOUS-DISEASES-SOCIETY; HOME-ASSOCIATED INFECTIONS; CARE-ASSOCIATED INFECTIONS; TRACT-INFECTION; GUIDELINES; MEDICARE; PREVENTION; DIAGNOSIS; AMERICA; ADULTS AB Background: Many hospitals are increasing surveillance for catheter-associated urinary tract infections, which requires documentation of urinary catheter device-days. However, device-days are usually obtained by chart review or nursing reports. The aim of this study was to demonstrate that chart review can provide accurate urinary catheter data compared with physical inspection of the urinary catheter at the bedside. Methods: We compared 2 methods for collecting urinary catheter data over a 6-month period on 10 wards at our VA hospital. For the chart reviews, we created a daily bed-occupancy roster from the electronic medical record. Catheter data were extracted from the daily progress notes for each patient using a standardized review process. Bedside reviews were conducted by visiting the ward and verifying the presence and type of urinary catheters. Agreement between the 2 methods was calculated. Results: We obtained urinary catheter data by both methods in 621 cases. The presence or type of urinary catheter differed between chart and bedside review in only 10 cases (1.6%). Chart review had a sensitivity of 100%, a specificity of 97.7%, raw agreement of 98.4%, and a kappa value of 0.96. Conclusions: Individual chart review in the electronic medical record provided very accurate data on urinary catheter use. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Burns, Allison C.; Petersen, Nancy J.; Garza, Armandina; Arya, Monisha; Naik, Aanand D.; Trautner, Barbara W.] Michael E DeBakey VA Med Ctr, VA Hlth Serv Res & Dev Houston Ctr Excellence, Houston, TX USA. [Arya, Monisha; Trautner, Barbara W.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. [Patterson, Jan E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Infect Dis, San Antonio, TX 78229 USA. [Patterson, Jan E.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Naik, Aanand D.; Trautner, Barbara W.] Baylor Coll Med, Dept Med, Sect Geriatr, Houston, TX 77030 USA. [Trautner, Barbara W.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Trautner, BW (reprint author), MEDVAMC HSR & D CoE 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM barbara.trautner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 09-104]; VA HSR&D Houston Center of Excellence [HFP90-020]; RRD [B4623]; National Institute of Aging [K23AG027144]; Doris Duke Charitable Foundation FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service IIR 09-104. Also partly supported by the VA HSR&D Houston Center of Excellence (HFP90-020). The views expressed are those of the authors and do not necessarily represent those of the Department of Veterans Affairs/Baylor College of Medicine. B.W.T. is a physician investigator at the Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, Texas. She is also supported by a VA Career Development Award from RR&D (B4623). A.D.N. is supported by the National Institute of Aging (K23AG027144) and the Doris Duke Charitable Foundation. NR 20 TC 9 Z9 9 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB PY 2012 VL 40 IS 1 BP 55 EP 58 DI 10.1016/j.ajic.2011.04.006 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 891CW UT WOS:000300195000012 PM 21813209 ER PT J AU Vinnard, C Lee, I Linkin, D AF Vinnard, Christopher Lee, Ingi Linkin, Darren TI Successful control of a norovirus outbreak among attendees of a hospital teaching conference SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Infection control; Health care; Gastroenteritis ID VIRUS AB We report an outbreak of norovirus gastroenteritis after a hospital teaching conference, and describe the specific measures instituted by the infection control team. No secondary cases of norovirus infection were identified among hospital staff or patients. In a case-control study, we identified multiple food source contamination as the source of the outbreak. Our report highlights the potential success of a multifaceted infection control strategy in preventing the transmission of norovirus in health care settings. Copyright (C) 2012 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Vinnard, Christopher; Lee, Ingi; Linkin, Darren] Univ Penn, Dept Med, Div Infect Dis, Sch Med, Philadelphia, PA 19104 USA. [Linkin, Darren] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Vinnard, C (reprint author), Univ Penn, Dept Med, Div Infect Dis, Sch Med, 502 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA. EM christopher.vinnard@uphs.upenn.edu OI Linkin, Darren R./0000-0002-2408-0987 FU National Institutes of Health [T32] FX C.V. received salary support through a National Institutes of Health Institutional Research Training Grant (T32). NR 8 TC 4 Z9 4 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB PY 2012 VL 40 IS 1 BP 73 EP 74 DI 10.1016/j.ajic.2011.03.033 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 891CW UT WOS:000300195000017 PM 21816511 ER PT J AU Kinkel, RP Dontchev, M Kollman, C Skaramagas, TT O'Connor, PW Simon, JH AF Kinkel, R. Philip Dontchev, Mariya Kollman, Craig Skaramagas, Thomai T. O'Connor, Paul W. Simon, Jack H. CA Controlled High-Risk Avonex Multip TI Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes A 10-Year Follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance SO ARCHIVES OF NEUROLOGY LA English DT Article ID DEFINITE MULTIPLE-SCLEROSIS; 1ST DEMYELINATING EVENT; MS; CONVERSION; DISABILITY; THERAPY AB Objective: To determine whether immediate initiation of treatment at the time of a clinically isolated syndrome in patients at high risk for clinically definite multiple sclerosis alters disease course over 10 years. Design: Prospective follow-up study. Setting: Twenty-four Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) sites in the United States and Canada. Participants: A total of 81 patients originally randomly assigned to receive intramuscular interferon beta-1a (the immediate-treatment group) and 74 patients originally randomly assigned to receive placebo (the delayed-treatment group). All patients were from CHAMPS. Intervention: For the immediate-treatment group, treatment was initiated within a month after the onset of a clinically isolated syndrome, and for the delayed-treatment group, treatment was initiated a median of 30 months (interquartile range, 24-35 months) after CHAMPS randomization. Main Outcome Measures: Rate of developing clinically definite multiple sclerosis, annualized relapse rate, disease course classification, disability measures, and magnetic resonance imaging measures. Results: The immediate-treatment group showed a lower 10-year rate of clinically definite multiple sclerosis (unadjusted hazard ratio, 0.64 [95% CI, 0.48-0.87]; P=.004) and a lower annualized relapse rate between years 5 and 10 (P=.03). There was no differential effect on disability, magnetic resonance imaging T2-weighted lesions, or the proportion of patients developing progressive disease at 10 years. Few patients reached the Expanded Disability Status Scale milestone scores of 4.0 or greater (9% of patients) or 6.0 or greater (6% of patients). Conclusions: Immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome in high-risk patients reduces relapse rates over 10 years but does not improve disability outcomes compared with a control group that also initiated therapy relatively early in the disease course. C1 [Kinkel, R. Philip] Harvard Univ, Beth Israel Deaconess Med Ctr, Multiple Sclerosis Ctr, Sch Med, Boston, MA 02215 USA. [Dontchev, Mariya; Kollman, Craig] Jaeb Ctr Hlth Res, Tampa, FL USA. [Skaramagas, Thomai T.] Cleveland Clin Fdn, Cleveland, OH USA. [O'Connor, Paul W.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Simon, Jack H.] Portland VA Med Ctr, Portland, OR USA. RP Kinkel, RP (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Multiple Sclerosis Ctr, Sch Med, 330 Brookline Ave,KS 211, Boston, MA 02215 USA. EM rkinkel@bidmc.harvard.edu FU National MS Society; MS Society of Canada; Direct-MS FX Dr Kinkel has received either personal compensation or financial support from his institution for activities in collaboration with pharmaceutical companies (including Acorda, Avanir, Biogen Idec, and Teva) that develop products for MS. He has also received grant support from the National MS Society as well as support as section editor of Reviews in Neurological Diseases. Dr O'Connor has received either personal compensation or financial support from his institution for activities in collaboration with pharmaceutical companies (including Actelion, Biogen Idec, Celgene, sanofi-aventis, EMD Serono, Abbott, Teva, Bayer, BioMS Technology Corp, Genentech, Lilly, Roche, and Novartis) that develop products for MS. He has received grant support from the MS Society of Canada and Direct-MS. Dr Simon has received either personal compensation or financial support from his institution for activities related to pharmaceutical companies (including Genzyme, Protein Design Labs, Pfizer, Genentech, Bristol-Myers Squibb, Artielle Immunotherapeutics, BioMS Technology Corp, and Biogen Idec) that develop products for MS. NR 16 TC 43 Z9 43 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD FEB PY 2012 VL 69 IS 2 BP 183 EP 190 DI 10.1001/archneurol.2011.1426 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 891NV UT WOS:000300224800005 PM 21987393 ER PT J AU Krause, JS Terza, JV Erten, M Focht, KL Dismuke, CE AF Krause, James S. Terza, Joseph V. Erten, Mujde Focht, Kendrea L. Dismuke, Clara E. TI Prediction of Postinjury Employment and Percentage of Time Worked After Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Employment; Occupations; Rehabilitation; Spinal cord injuries; Work ID EARNINGS AB Krause JS, Terza JV, Erten M, Focht KL, Dismuke CE. Prediction of postinjury employment and percentage of time worked after spinal cord injury. Arch Phys Med Rehabil 2012;93:373-5. Objective: To use a 2-part model to identify biographic, injury, educational, and vocational predictors of postinjury employment and the percentage of time employed after spinal cord injury (SCI) onset. Design: Survey. Setting: Data were collected at 3 hospitals in the Southeastern and Midwestern United States. Participants: Participants were adults with traumatic SCI of at least 1 year duration, all under 65 years at the time of SCI onset. A total of 1329 observations were used in the analysis. Interventions: Not applicable. Main Outcome Measures: Postinjury employment, defined by whether the individual had ever been employed after SCI and percentage of time employed after SCI onset. Results: Almost 52% of participants worked at some point in time postinjury. Among those who had worked postinjury, the mean portion of time spent working was 0.56. Several factors were significantly related to postinjury employment and portion of time worked postinjury. The probability of postinjury employment increased with successively less severe injury. However, only ambulatory participants were found to have a significantly greater portion of time postinjury among those who became employed. Having obtained either a 4-year or graduate degree after injury was associated with a greater likelihood of postinjury employment. Conversely, among those who worked postinjury, having obtained those degrees prior to injury was associated with a greater portion of time employed. Being white, a man, having completed a 4-year degree or a graduate degree, and having worked in the service industry prior to SCI onset were all associated with a greater portion of time working among those who had worked. Conclusions: The factors precipitating PE are not identical to those associated with a greater portion of time employed after SCI onset. C1 [Krause, James S.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA. [Terza, Joseph V.] Univ N Carolina, Bryan Sch Business & Econ, Greensboro, NC 27412 USA. [Erten, Mujde] Univ Maryland, Sch Pharm, Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA. [Dismuke, Clara E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC 29403 USA. RP Krause, JS (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Suite C101,MSC 700, Charleston, SC 29425 USA. EM krause@musc.edu FU Department of Education, National Institute on Disability and Rehabilitation Research [H133G060126, H133B090005] FX Supported by the Department of Education, National Institute on Disability and Rehabilitation Research (grant nos. H133G060126 and H133B090005). The content of this article does not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government. NR 10 TC 8 Z9 9 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2012 VL 93 IS 2 BP 373 EP 375 DI 10.1016/j.apmr.2011.09.006 PG 3 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 893ER UT WOS:000300338900029 PM 22289252 ER PT J AU Mullen, TD Hannun, YA Obeid, LM AF Mullen, Thomas D. Hannun, Yusuf A. Obeid, Lina M. TI Ceramide synthases at the centre of sphingolipid metabolism and biology SO BIOCHEMICAL JOURNAL LA English DT Review DE ceramide; ceramide synthase (CerS); de novo sphingolipid synthesis; salvage pathway; sphingolipid; sphingosine ID SPHINGANINE N-ACYLTRANSFERASE; RADIATION-INDUCED APOPTOSIS; LONGEVITY ASSURANCE GENE-1; COLON-CANCER CELLS; ACTIVATED PROTEIN-KINASE; MYELOID-LEUKEMIA CELLS; DE-NOVO; SERINE PALMITOYLTRANSFERASE; (DIHYDRO)CERAMIDE SYNTHASE; ENZYMATIC-HYDROLYSIS AB Sphingolipid metabolism in metazoan cells consists of a complex interconnected web of numerous enzymes, metabolites and modes of regulation. At the centre of sphingolipid metabolism reside CerSs (ceramide synthases), a group of enzymes that catalyse the formation of ceramides from sphingoid base and acyl-CoA substrates. From a metabolic perspective, these enzymes occupy a unique niche in that they simultaneously regulate de novo sphingolipid synthesis and the recycling of free sphingosine produced from the degradation of pre-formed sphingolipids (salvage pathway). Six mammalian CerSs (CerS1-CerS6) have been identified. Unique characteristics have been described for each of these enzymes, but perhaps the most notable is the ability of individual CerS isoforms to produce ceramides with characteristic acyl-chain distributions. Through this control of acyl-chain length and perhaps in a compartment-specific manner, CerSs appear to regulate multiple aspects of sphingolipid-mediated cell and organismal biology. In the present review, we discuss the function of CerSs as critical regulators of sphingolipid metabolism, highlight their unique characteristics and explore the emerging roles of CerSs in regulating programmed cell death, cancer and many other aspects of biology. C1 [Hannun, Yusuf A.; Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Mullen, Thomas D.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Hannun, YA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM hannun@musc.edu; obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS) [5T32ES012878]; Ruth L. Kirschstein National Research Service (NIH/NIEHS) [1 F30 ES016975-01]; NIH [R01AG016583, R01GM062887]; Office of Research and Development; Department of Veterans Affairs; Ralph H. Johnson Veterans Affairs Medical Center; NIH/National Cancer Institute (NCI) [P01 CA097132] FX This work is supported by the MUSC Department of Pharmaceutical Sciences Training Program in Environmental Stress Signaling [National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS)] [grant number 5T32ES012878] and a Ruth L. Kirschstein National Research Service Award (NIH/NIEHS) [grant number 1 F30 ES016975-01] (to T.D.M.), and was supported in part by the NIH [grant numbers R01AG016583, R01GM062887] and a MERIT Award by the Office of Research and Development, Department of Veterans Affairs, Ralph H. Johnson Veterans Affairs Medical Center (to L.M.O.), and by the NIH/National Cancer Institute (NCI) [grant number P01 CA097132 (to Y.A.H.)). NR 131 TC 120 Z9 124 U1 5 U2 34 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD FEB 1 PY 2012 VL 441 BP 789 EP 802 DI 10.1042/BJ20111626 PN 3 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 886MY UT WOS:000299859700002 PM 22248339 ER PT J AU Sher, L Braquehais, MD Casas, M AF Sher, Leo Dolores Braquehais, Maria Casas, Miquel TI Posttraumatic stress disorder, depression, and suicide in veterans SO CLEVELAND CLINIC JOURNAL OF MEDICINE LA English DT Review ID NATIONAL COMORBIDITY SURVEY; AFGHANISTAN WAR VETERANS; VIETNAM COMBAT VETERANS; RISK-FACTORS; PSYCHIATRIC OUTPATIENTS; EVENTUAL SUICIDE; IDEATION; BEHAVIOR; HOPELESSNESS; PREVALENCE AB Suicidal behavior is a critical problem in war veterans. Combat veterans are not only more likely to have suicidal ideation, often associated with posttraumatic stress disorder (PTSD) and depression, but they are more likely to act on a suicidal plan. Especially since veterans may be less likely to seek help from a mental health professional, non-mental-health physicians are in a key position to screen for PTSD, depression, and suicidal ideation in these patients. The authors discuss the association of PTSD, depression, and suicide in veterans, keys to assessment of suicide risk, and interventions. C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Dolores Braquehais, Maria; Casas, Miquel] Univ Autonoma Barcelona, Dept Psychiat & Legal Med, Vall dHebron Univ Hosp, CIBERSAM, Barcelona, Spain. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu RI Schueter, nicos/A-3625-2014 NR 67 TC 11 Z9 11 U1 2 U2 15 PU CLEVELAND CLINIC PI CLEVELAND PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA SN 0891-1150 J9 CLEV CLIN J MED JI Clevel. Clin. J. Med. PD FEB PY 2012 VL 79 IS 2 BP 92 EP 97 DI 10.3949/ccjm.79a.11069 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 893CB UT WOS:000300332100002 PM 22301558 ER PT J AU Primack, BA Kim, KH Shensa, AS Sidani, J Barnett, T Switzer, GE AF Primack, Brian A. Kim, Kevin H. Shensa, Ariel S. Sidani, Jaime Barnett, Tracey Switzer, Galen E. TI TOBACCO, MARIJUANA, AND ALCOHOL USE IN UNIVERSITY STUDENTS: A CLUSTER ANALYSIS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Primack, Brian A.; Kim, Kevin H.; Shensa, Ariel S.; Sidani, Jaime] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Barnett, Tracey] Univ Florida, Gainesville, FL 32611 USA. [Switzer, Galen E.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2012 VL 50 IS 2 SU S BP S74 EP S75 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 891UV UT WOS:000300243000156 ER PT J AU Chang, S Phan, RT Moatamed, NA Apple, SK AF Chang, S. Phan, R. T. Moatamed, N. A. Apple, S. K. TI Utility of BRAF Gene Testing on Thyroid Nodules Diagnosed as Follicular Lesion of Undetermined Significance (FLUS) SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 101st Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 17-23, 2012 CL Vancouver, CANADA SP US & Canadian Acad Pathol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2012 VL 25 SU 2 MA 345 BP 85A EP 85A PG 1 WC Pathology SC Pathology GA 888EP UT WOS:000299986900346 ER PT J AU Baldwin, KJ Zivkovic, SA Lieberman, FS AF Baldwin, Kelly Jo Zivkovic, Sasa A. Lieberman, Frank S. TI Neurologic Emergencies in Patients Who Have Cancer: Diagnosis and Management SO NEUROLOGIC CLINICS LA English DT Article DE Leptomeningeal carcinomatosis; Cerebral edema; Seizure; Metastasis; Compressive myelopathy; Hydrocephalus; Stroke; Paraneoplastic ID SPINAL-CORD COMPRESSION; NONCONVULSIVE STATUS EPILEPTICUS; CLINICAL-PRACTICE GUIDELINE; PARANEOPLASTIC LIMBIC ENCEPHALITIS; NMDA-RECEPTOR ENCEPHALITIS; DURAL SINUS THROMBOSIS; NERVOUS-SYSTEM INFECTIONS; BRAIN METASTASES; EPIDURAL METASTASIS; CEREBROVASCULAR COMPLICATIONS AB The nervous system can be significantly affected by cancer. Neurologic symptoms are present in 30% to 50% of oncologic patients presenting to the emergency department or in neurologic consultation at teaching hospitals. Evaluation and treatment require collaborative effort between specialties. The causes of neurologic emergencies in patients with cancer are mostly related to effects of cancer, toxicities of treatments, infections, and paraneoplastic syndromes. These complications cause significant morbidity and mortality and require prompt and accurate diagnostic and treatment measures. This article reviews the common neurologic emergencies affecting patients with cancer and discusses epidemiology, clinical presentation, diagnosis, and treatment modalities. C1 [Zivkovic, Sasa A.] Univ Pittsburgh, Med Ctr, VA Pittsburgh Healthcare Syst, Dept Neurol,MSSL Neurol, Pittsburgh, PA 15240 USA. [Baldwin, Kelly Jo] Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15213 USA. [Lieberman, Frank S.] Univ Pittsburgh, Med Ctr, Pittsburgh Canc Inst, Adult Neurooncol Program,Dept Neurol, Pittsburgh, PA 15232 USA. RP Zivkovic, SA (reprint author), Univ Pittsburgh, Med Ctr, VA Pittsburgh Healthcare Syst, Dept Neurol,MSSL Neurol, Univ Dr C,10E Room 133, Pittsburgh, PA 15240 USA. EM zivksx@upmc.edu NR 119 TC 3 Z9 5 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8619 J9 NEUROL CLIN JI Neurol. Clin. PD FEB PY 2012 VL 30 IS 1 BP 101 EP + DI 10.1016/j.ncl.2011.09.004 PG 29 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 894ZC UT WOS:000300465000007 PM 22284057 ER PT J AU Cunningham, ET Pasadhika, S Suhler, EB Zierhut, M AF Cunningham, Emmett T., Jr. Pasadhika, Sirichai Suhler, Eric B. Zierhut, Manfred TI Drug-induced Inflammation in Patients on TNF alpha Inhibitors SO OCULAR IMMUNOLOGY AND INFLAMMATION LA English DT Editorial Material DE drug-induced uveitis; sarcoidosis; granulomatous; inflixamab; etanercept; adalimumab ID OF-THE-LITERATURE; UVEITIS-LIKE SYNDROME; IRIS TRANSILLUMINATION; ORAL MOXIFLOXACIN; IFN-ALPHA; THERAPY; SARCOIDOSIS; DISEASE; DISORDERS; FUTURE C1 [Cunningham, Emmett T., Jr.] Calif Pacific Med Ctr, San Francisco, CA USA. [Cunningham, Emmett T., Jr.] Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA. [Pasadhika, Sirichai] Univ Arizona, Coll Med, Dept Ophthalmol & Vis Sci, Tucson, AZ USA. [Suhler, Eric B.] Portland VA Med Ctr, Dept Ophthalmol, Portland, OR USA. [Suhler, Eric B.] Oregon Hlth & Sci Univ, Casey Eye Inst, Uveitis Div, Portland, OR 97201 USA. [Zierhut, Manfred] Univ Tubingen, Ctr Ophthalmol, Tubingen, Germany. RP Cunningham, ET (reprint author), W Coast Retina Med Grp, 185 Berry St,Lobby 2,Suite 130, San Francisco, CA 94107 USA. EM emmett_cunningham@yahoo.com NR 47 TC 3 Z9 3 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0927-3948 J9 OCUL IMMUNOL INFLAMM JI Ocul. Immunol. Inflamm. PD FEB PY 2012 VL 20 IS 1 BP 2 EP 5 DI 10.3109/09273948.2011.644383 PG 4 WC Ophthalmology SC Ophthalmology GA 892AO UT WOS:000300259000002 PM 22324894 ER PT J AU Shahani, L Hartman, C Troisi, C Kapadia, A Giordano, TP AF Shahani, Lokesh Hartman, Christine Troisi, Cathy Kapadia, Asha Giordano, Thomas P. TI Causes of Hospitalization and Perceived Access to Care Among Persons Newly Diagnosed with HIV Infection: Implications for HIV Testing Programs SO AIDS PATIENT CARE AND STDS LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; UNITED-STATES; MEDICAL-CARE; SERVICES UTILIZATION; ADULTS; PREVALENCE; COHORT; SETTINGS; PATTERNS AB There has been little research on the causes of hospitalization when patients are first diagnosed with HIV in the hospital. Reduced access to care could partially explain inpatient diagnosis. We sought to determine if the patients diagnosed as inpatients are hospitalized due to a HIV-related cause versus some other causes, to compare access to care of patients diagnosed with HIV in hospital and outpatient settings, and to determine factors associated with access to care. Participants were newly diagnosed with HIV and recruited between January 2006 and August 2007. The reason for hospitalization was classified as HIV-related, other infectious cause, noninfectious cause, or miscellaneous cause. Access to care was self-reported using a six-item scale and scores were compared with the t test. Multivariate linear regression determined factors associated with improved access to care. Of 185 participants in the study, 78 were diagnosed in hospital and 107 in outpatient settings. Thirty-two percent of participants were female, 90% were racial/ethnic minority, 45% had no high school diploma, and 85% were uninsured. HIV-related conditions accounted for 60% of admissions, followed by non-infectious causes (20%) and other infectious causes (17%). Inpatients did not report less access to care than patients diagnosed while outpatients. Multivariate analysis demonstrated improvement in access to care with better health insurance (p = 0.01) and greater education (p = 0.08). HIV-related preventable conditions account for many hospitalizations when patients are first diagnosed with HIV. While socioeconomic factors are associated with perceived access to care, persons diagnosed in the inpatient setting do not report lower perceived access to care than persons diagnosed as outpatients, suggesting other barriers to earlier diagnosis. C1 [Shahani, Lokesh; Troisi, Cathy; Kapadia, Asha] Univ Texas Hlth Sci Ctr Houston Sch Publ Hlth, Houston, TX USA. [Hartman, Christine; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Hartman, Christine; Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA. [Troisi, Cathy] City Houston, Dept Hlth & Human Serv, Houston, TX USA. RP Giordano, TP (reprint author), Michael E DeBakey VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM tpg@bcm.tmc.edu FU National Institutes of Mental Health [R34MH074360]; Baylor/UTHouston Center for AIDS Research [P30AI036211] FX Supported by National Institutes of Mental Health grant R34MH074360, the Baylor/UTHouston Center for AIDS Research grant P30AI036211, and the facilities and resources of the Harris County Hospital District and the Michael E. DeBakey VA Medical Center. Dr. Giordano is a researcher at the Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, Texas. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 32 TC 4 Z9 4 U1 3 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD FEB PY 2012 VL 26 IS 2 BP 81 EP 86 DI 10.1089/apc.2011.0040 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 888KX UT WOS:000300003500003 PM 22149765 ER PT J AU Roy, B Desai, RV Mujib, M Epstein, AE Zhang, Y Guichard, J Jones, LG Feller, MA Ahmed, MI Aban, IB Love, TE Levesque, R White, M Aronow, WS Fonarow, GC Ahmed, A AF Roy, Brita Desai, Ravi V. Mujib, Marjan Epstein, Andrew E. Zhang, Yan Guichard, Jason Jones, Linda G. Feller, Margaret A. Ahmed, Mustafa I. Aban, Inmaculada B. Love, Thomas E. Levesque, Raynald White, Michel Aronow, Wilbert S. Fonarow, Gregg C. Ahmed, Ali TI Effect of Warfarin on Outcomes in Septuagenarian Patients With Atrial Fibrillation SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CHRONIC HEART-FAILURE; CHRONIC KIDNEY-DISEASE; FOLLOW-UP; RHYTHM MANAGEMENT; PROPENSITY SCORE; OLDER-ADULTS; STROKE; HOSPITALIZATION; ASSOCIATION; MORTALITY AB Anticoagulation has been shown to decrease ischemic stroke in atrial fibrillation (AF). However, concerns remain regarding their safety and efficacy in those <= 70 years of age who constitute most patients with AF. Of the 4,060 patients (mean age 65 years, range 49 to 80) in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, 2,248 (55% of 4,060) were 70 to 80 years of age, 1,901 of whom were receiving warfarin. Propensity score for warfarin use, estimated for each of the 2,248 patients, was used to match 227 of the 347 patients not on warfarin (in 1:1, 1:2, or 1:3 sets) to 616 patients on warfarin who were balanced in 45 baseline characteristics. All-cause mortality occurred in 18% and 33% of matched patients receiving and not receiving warfarin, respectively, during up to 6 years (mean 3.4) of follow-up (hazard ratio [HR] when warfarin use was compared to its nonuse 0.58, 95% confidence interval [CI] 0.43 to 0.77, p <0.001). All-cause hospitalization occurred in 64% and 67% of matched patients receiving and not receiving warfarin, respectively (HR associated with warfarin use 0.93, 95% CI 0.77 to 1.12, p = 0.423). Ischemic stroke occurred in 4% and 8% of matched patients receiving and not receiving warfarin, respectively (HR associated with warfarin use 0.57, 95% CI 0.31 to 1.04, p = 0.068). Major bleeding occurred in 7% and 10% of matched patients receiving and not receiving warfarin, respectively (HR associated with warfarin use 0.73, 95% CI 0.44 to 1.22, p = 0.229). In conclusion, warfarin use was associated with decreased mortality in septuagenarian patients with AF but had no association with hospitalization or major bleeding. Published by Elsevier Inc. (Am J Cardiol 2012;109:370-377) C1 [Roy, Brita; Mujib, Marjan; Zhang, Yan; Guichard, Jason; Jones, Linda G.; Feller, Margaret A.; Ahmed, Mustafa I.; Aban, Inmaculada B.; Ahmed, Ali] Univ Alabama Birmingham, Birmingham, AL 35229 USA. [Desai, Ravi V.] Lehigh Valley Hosp, Allentown, PA USA. [Epstein, Andrew E.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Epstein, Andrew E.] Univ Penn, Philadelphia, PA 19104 USA. [Jones, Linda G.; Ahmed, Ali] Vet Affairs Med Ctr, Birmingham, AL USA. [Love, Thomas E.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [White, Michel] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Aronow, Wilbert S.] New York Med Coll, Valhalla, NY 10595 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Ahmed, A (reprint author), Univ Alabama Birmingham, Birmingham, AL 35229 USA. EM aahmed@uab.eclu RI Mujib, Marjan/J-2709-2013 OI Mujib, Marjan/0000-0002-3261-8599 FU National Institutes of Health from National Heart, Lung, and Blood Institute, Bethesda, Maryland [R01-HL085561, R01-HL085561-S, R01-HL097047] FX Dr. Ahmed is supported by the National Institutes of Health through Grants R01-HL085561, R01-HL085561-S and R01-HL097047 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland and a generous gift from Ms. Jean B. Morris of Birmingham, Alabama. NR 30 TC 8 Z9 8 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD FEB 1 PY 2012 VL 109 IS 3 BP 370 EP 377 DI 10.1016/j.amjcard.2011.09.023 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 888UP UT WOS:000300030400011 PM 22118824 ER PT J AU Acierno, R Rheingold, A Amstadter, A Kurent, J Amella, E Resnick, H Muzzy, W Lejuez, C AF Acierno, Ron Rheingold, Alyssa Amstadter, Ananda Kurent, Jerome Amella, Elaine Resnick, Heidi Muzzy, Wendy Lejuez, Carl TI Behavioral Activation and Therapeutic Exposure for Bereavement in Older Adults SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE complicated bereavement; behavioral activation; therapeutic exposure; major depression; posttraumatic stress disorder; older adults ID BECK DEPRESSION INVENTORY; COMPLICATED GRIEF; CONJUGAL BEREAVEMENT; DISORDER DISTINCT; TRAUMATIC GRIEF; HEALTH; REPLICATION; ANXIETY; SYMPTOMATOLOGY; INTERVENTION AB The development and clinical trial of a 5-session behavioral intervention for complicated bereavement (CB) is presented. We conceptualized CB in terms of Major Depression (MDD) and Post-traumatic Stress Disorder (PTSD) and consequently applied treatment components of Behavioral Activation and Therapeutic Exposure (BA-TE). In order to assure standardization of treatment, control costs, and engage patients, a multi-media, multi-context format was adopted to address avoidance and withdrawal behaviors conceptualized as central pathogenic responses in CB. Participants (N = 26) were assessed before and after BA-TE treatment via structured clinical interview and standardized questionnaires in terms of PTSD, MDD, CB, and health concerns. The number of days since the death of the loved one was widely variable and served as a covariate for all outcome analyses. ANCOVAS revealed statistically significant improvement, irrespective of how many days since death had elapsed prior to initiation of intervention, on structured interviews and self-report measures for most outcome variables. C1 [Acierno, Ron; Rheingold, Alyssa; Kurent, Jerome; Amella, Elaine; Resnick, Heidi; Muzzy, Wendy] Med Univ S Carolina, Charleston, SC 29425 USA. [Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Amstadter, Ananda] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA. [Lejuez, Carl] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. RP Acierno, R (reprint author), Med Univ S Carolina, 67 President St,MSC861, Charleston, SC 29425 USA. EM acierno@musc.edu OI Amella, Elaine/0000-0003-4114-429X FU National Institute on Aging [R21-AG023495-01A2] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by a grant from the National Institute on Aging (R21-AG023495-01A2) made to the first author. NR 46 TC 17 Z9 17 U1 0 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD FEB PY 2012 VL 29 IS 1 BP 13 EP 25 DI 10.1177/1049909111411471 PG 13 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 887MT UT WOS:000299932500004 PM 21685428 ER PT J AU Baird, GS Nelson, SK Keeney, TR Stewart, A Williams, S Kraemer, S Peskind, ER Montine, TJ AF Baird, Geoffrey S. Nelson, Sally K. Keeney, Tracy R. Stewart, Alex Williams, Stephen Kraemer, Stephan Peskind, Elaine R. Montine, Thomas J. TI Age-Dependent Changes in the Cerebrospinal Fluid Proteome by Slow Off-Rate Modified Aptamer Array SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID HEPATOCYTE GROWTH-FACTOR; ALZHEIMERS-DISEASE; MASS-SPECTROMETRY; LUMBAR PUNCTURE; BRAIN; IDENTIFICATION; MENINGITIS; BIOMARKERS; CHEMOKINES; SIGNATURE AB An important precondition for the successful development of diagnostic assays of cerebrospinal fluid (CSF) biomarkers of age-related neurodegenerative diseases is an understanding of the dynamic nature of the CSF proteome during the normal aging process. In this study, a novel proteomic technology was used to quantify hundreds of proteins simultaneously in the CSF from 90 cognitively normal adults 21 to 85 years of age. SomaLogic's highly multiplexed proteomic platform can measure more than 800 proteins simultaneously from small volumes of biological fluids using novel slow off-rate modified aptamer (SOMAmer) protein affinity reagents with sensitivity, specificity, and dynamic ranges that meet or exceed those of enzyme-linked immunosorbent assays. In the first application of this technology to CSF, we detected 248 proteins that possessed signals greater than twofold over background. Several novel correlations between detected protein concentrations and age were discovered that indicate that both inflammation and response to injury in the central nervous system may increase with age. Applying this powerful proteomic approach to CSF provides potential new insight into the aging of the human central nervous system that may have utility in discovering new disease-related changes in the CSF proteome. (Am J Pathol 2012, 180:446-454. DOI: 10.1016/j.ajpath.2011.10.024) C1 [Baird, Geoffrey S.] Univ Washington, Harborview Med Ctr, Dept Lab Med, Seattle, WA 98105 USA. [Baird, Geoffrey S.; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98105 USA. [Nelson, Sally K.; Keeney, Tracy R.; Stewart, Alex; Williams, Stephen; Kraemer, Stephan] SomaLogic Inc, Boulder, CO USA. [Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, VA NW Network Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA. RP Baird, GS (reprint author), Univ Washington, Harborview Med Ctr, Dept Lab Med, Box 359743,325 9th Ave, Seattle, WA 98105 USA. EM gbaird@u.washington.edu FU SomaLogic, Inc.; Nancy and Buster Alvord Endowment; Department of Veterans Affairs; NIH [AG05136] FX Supported by funding from SomaLogic, Inc., the Nancy and Buster Alvord Endowment, the Department of Veterans Affairs, an anonymous foundation, and NIH grant AG05136. NR 46 TC 22 Z9 24 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD FEB PY 2012 VL 180 IS 2 BP 446 EP 456 DI 10.1016/j.ajpath.2011.10.024 PG 11 WC Pathology SC Pathology GA 887HZ UT WOS:000299918800003 PM 22122984 ER PT J AU Maalouf, RM Eid, AA Gorin, YC Block, K Escobar, GP Bailey, S Abboud, HE AF Maalouf, Rita M. Eid, Assaad A. Gorin, Yves C. Block, Karen Escobar, Gladys Patricia Bailey, Steven Abboud, Hanna E. TI Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE cardiac injury; oxidative stress; NADPH oxidases ID NADPH OXIDASE 4; NAD(P)H OXIDASE; MESANGIAL CELLS; FAILING HEART; NOX FAMILY; EXPRESSION; ACTIVATION; APOPTOSIS; REVEALS; MYOFIBROBLASTS AB Maalouf RM, Eid AA, Gorin YC, Block K, Escobar GP, Bailey S, Abboud HE. Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes. Am J Physiol Cell Physiol 302: C597-C604, 2012. First published October 26, 2011; doi: 10.1152/ajpcell.00331.2011.-Oxidative stress contributes to diabetic cardiomyopathy. This study explored the role of the NADPH oxidase Nox4 as a source of reactive oxygen species (ROS) involved in the development of diabetic cardiomyopathy. Phosphorothioated antisense (AS) or sense (S) oligonucleotides for Nox4 were administered for 2 wk to rats made diabetic by streptozotocin. NADPH oxidase activity, ROS generation, and the expression of Nox4, but Nox1 or Nox2, were increased in left ventricular tissue of the diabetic rats. Expression of molecular markers of hypertrophy and myofibrosis including fibronectin, collagen, alpha-smooth muscle actin, and beta-myosin heavy chain were also increased. These parameters were attenuated by the administration of AS but not S Nox4. Moreover, the impairment of contractility observed in diabetic rats was prevented in AS- but not S-treated animals. Exposure of cultured cardiac myocytes to 25 mM glucose [high glucose (HG)] increased NADPH oxidase activity, the expression of Nox4, and molecular markers of cardiac injury. These effects of HG were prevented in cells infected with adenoviral vector containing a dominant negative form of Nox4. This study provides strong evidence that Nox4 is an important source of ROS in the left ventricle and that Nox4-derived ROS contribute to cardiomyopathy at early stages of type 1 diabetes. C1 [Maalouf, Rita M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, San Antonio, TX 78229 USA. [Block, Karen; Abboud, Hanna E.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Maalouf, Rita M.] Notre Dame Univ, Fac Nat & Appl Sci, Louaize, Lebanon. [Eid, Assaad A.] Amer Univ Beirut, Dept Anat Cell Biol & Physiol, Fac Med, Beirut, Lebanon. RP Maalouf, RM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, M1501,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM rita.maalouf@ndu.edu.lb OI Gorin, Yves/0000-0003-4048-6925 FU Juvenile Diabetes Research Foundation FX Support for these studies was provided by the following sources: Juvenile Diabetes Research Foundation multiproject research grant (to H. E. Abboud, Y. C. Gorin, and K. Block), Advanced Postdoctoral Fellowship from the Juvenile Diabetes Research Foundation (to A. A. Eid). We thank Dr. Mauli Agrawal for help with the final version of the manuscript. NR 37 TC 54 Z9 54 U1 0 U2 10 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD FEB PY 2012 VL 302 IS 3 BP C597 EP C604 DI 10.1152/ajpcell.00331.2011 PG 8 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 885OC UT WOS:000299787300012 PM 22031600 ER PT J AU Sher, L AF Sher, Leo TI What should we tell medical students and residents about euthanasia and assisted suicide? SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; VOLUNTARY EUTHANASIA; MYOCARDIAL-INFARCTION; ACTIVE EUTHANASIA; CANCER-PATIENTS; PHYSICIANS; ATTITUDES; PERSPECTIVE; HEALTH; ILL C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA. [Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu NR 48 TC 4 Z9 4 U1 1 U2 10 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0004-8674 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD FEB PY 2012 VL 46 IS 2 BP 87 EP 91 DI 10.1177/0004867411433894 PG 5 WC Psychiatry SC Psychiatry GA 887BX UT WOS:000299901500004 PM 22311524 ER PT J AU Hudish, TM Opincariu, LI Mozer, AB Johnson, MS Cleaver, TG Malkoski, SP Merrick, DT Keith, RL AF Hudish, Tyler M. Opincariu, Laura I. Mozer, Anthony B. Johnson, Micah S. Cleaver, Timothy G. Malkoski, Stephen P. Merrick, Daniel T. Keith, Robert L. TI N-nitroso-tris-chloroethylurea Induces Premalignant Squamous Dysplasia in Mice SO CANCER PREVENTION RESEARCH LA English DT Article ID INDUCED LUNG CARCINOGENESIS; CHEMICALLY-INDUCED MODEL; TRANSCRIPTION FACTOR-I; CELL CARCINOMA; K-RAS; TUMORS; CANCER; NEOPLASMS; ADENOCARCINOMAS; EXPRESSION AB Squamous cell carcinoma (SCC) and premalignant endobronchial lesions have been difficult to study in murine models. In this study, we evaluate the topical N-nitroso-tris-chloroethylurea (NTCU) murine SCC model, determine the extent to which resulting premalignant airway dysplasia develops, discuss clinicopathologic grading criteria in lesion progression, and confirm that immunohistochemical (IHC) staining patterns are consistent with those observed in human endobronchial dysplasia and SCC. Male and female FVB mice were treated biweekly with topical NTCU (4, 8, or 40 mmol/L) or vehicle for 32 weeks. Following sacrifice, squamous cell lesions were enumerated and categorized into the following groups: flat atypia, low-grade dysplasia, high-grade dysplasia, and invasive SCC. The 40 mmol/L NTCU concentration produced the entire spectrum of premalignant dysplasias and squamous cell carcinomas, but was associated with poor survival. Concentrations of 4 and 8 mmol/L NTCU were better tolerated and produced only significant levels of flat atypia. Squamous origin of the range of observed lesions was confirmed with IHC staining for cytokeratin 5/6, p63, thyroid transcription factor-1 (TTF-1), and Napsin-A. This study shows that topical application of high-dose NTCU produces endobronchial premalignant lesions with classic squamous characteristics and should allow for improved preclinical evaluation of potential chemopreventive agents. Cancer Prev Res; 5(2); 283-9. (C) 2011 AACR. C1 [Hudish, Tyler M.; Opincariu, Laura I.; Mozer, Anthony B.; Johnson, Micah S.; Merrick, Daniel T.; Keith, Robert L.] Denver VA Med Ctr, Dept Med, Denver, CO 80220 USA. [Cleaver, Timothy G.; Malkoski, Stephen P.; Keith, Robert L.] Univ Colorado Denver, Dept Med, Aurora, CO USA. RP Keith, RL (reprint author), Denver VA Med Ctr, Dept Med, 1055 Clermont St,Box 151, Denver, CO 80220 USA. EM robert.keith@va.gov FU Department of Veterans Affairs; NCI [K08-CA131483] FX This work was supported by Department of Veterans Affairs Merit Review Program (R.L. Keith) and NCI Grant K08-CA131483 (S.P. Malkoski). NR 34 TC 7 Z9 7 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 J9 CANCER PREV RES JI Cancer Prev. Res. PD FEB PY 2012 VL 5 IS 2 BP 283 EP 289 DI 10.1158/1940-6207.CAPR-11-0257 PG 7 WC Oncology SC Oncology GA 888ZO UT WOS:000300043500015 PM 22086679 ER PT J AU Chang, I Liu, J Majid, S Saini, S Zaman, MS Yamamura, S Shahryari, V Chiyomaru, T Deng, GR Dahiya, R Tanaka, Y AF Chang, Inik Liu, Jan Majid, Shahana Saini, Sharanjot Zaman, Mohd S. Yamamura, Soichiro Shahryari, Varahram Chiyomaru, Takeshi Deng, Guoren Dahiya, Rajvir Tanaka, Yuichiro TI Catechol-O-methyltransferase-mediated metabolism of 4-hydroxyestradiol inhibits the growth of human renal cancer cells through the apoptotic pathway SO CARCINOGENESIS LA English DT Article ID ESTRADIOL-INDUCED TUMORIGENESIS; HAMSTER-KIDNEY; OXIDATIVE STRESS; EPITHELIAL-CELLS; DOWN-REGULATION; MESSENGER-RNA; EXPRESSION; ESTROGENS; GENE; MEN AB Long-term exposure to estrogen and its metabolites may play an important role in renal cell carcinogenesis. Catechol-O-methyltransferase (COMT) participates in the estrogen metabolism pathway by neutralizing toxic substances. Although reduced COMT activity has been suggested to be a risk factor for estrogen-associated cancers, no studies have investigated the biological significance of COMT in the pathogenesis of human renal cell cancers (RCCs). We initially found that COMT levels are significantly decreased in human RCC tissues and cells suggesting it plays a suppressive role in tumor development. However, transient overexpression of COMT has no functional effect on RCC cell lines. In contrast, when cells overexpressing COMT are treated with its substrate 4-hydroxyestradiol (4-OHE2), growth is inhibited by apoptotic cell death. We also found that COMT overexpression combined with 4-OHE2 induces upregulation of growth arrest- and DNA damage-inducible protein alpha (GADD45 alpha). We further show that downregulation of GADD45 alpha by a small interfering RNA-mediated approach inhibits cell death, indicating the essential role of GADD45 alpha in the underlying mechanism of COMT action in response to 4-OHE2. Finally, 4-methoxyestradiol fully reproduces the antiproliferative function of COMT with 4-OHE2 by promoting GADD45 alpha induction. Together, these findings show that COMT in the presence of 4-OHE2 prevents RCC cell proliferation by enhancing apoptosis and that GADD45 alpha plays a critical role in the COMT-mediated inhibition of RCC. C1 [Tanaka, Yuichiro] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94121 USA. RP Tanaka, Y (reprint author), San Francisco VA Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA. EM yuichiro.tanaka@ucsf.edu FU Veterans Affairs Merit Review grant FX This study was supported by the Veterans Affairs Merit Review grant. NR 39 TC 5 Z9 5 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD FEB PY 2012 VL 33 IS 2 BP 420 EP 426 DI 10.1093/carcin/bgr294 PG 7 WC Oncology SC Oncology GA 888YF UT WOS:000300039800025 PM 22159223 ER PT J AU Shapiro, S Traiger, GL Turner, M McGoon, MD Wason, P Barst, RJ AF Shapiro, Shelley Traiger, Glenna L. Turner, Michelle McGoon, Michael D. Wason, Prieya Barst, Robyn J. TI Sex Differences in the Diagnosis, Treatment, and Outcome of Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management SO CHEST LA English DT Article ID CLINICAL CLASSIFICATION; REVEAL REGISTRY; SURVIVAL AB Background: Pulmonary arterial hypertension (PAH) is a life-threatening disease that affects more women than men. The reasons for the female preponderance are unclear, and there are limited data available for men with PAH. Methods: Data from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) were analyzed to explore sex differences among patients with PAH with regard to 2-year survival from enrollment and 5-year survival from time of diagnosis. Results: The data set included 2,318 women and 651 men. More women had PAH associated with connective tissue disease (P < .001), and more men had portopulmonary hypertension (P <.001) and HIV-associated PAH (P < .001). More women had congenital heart disease-associated PAH (P = .017), thyroid disease (P < .001), and depression reported (P <= .001). At diagnosis, men had higher mean pulmonary artery pressure (53 +/- 14 vs 51 +/- 14.3 mm Fig; P = .013) and mean right atrial pressure (10 6 vs 9 6 mm Hg; P = .031). Women had better survival estimates for 2 years from enrollment and for 5 years from diagnosis. Stratifying by age showed that survival from enrollment was similar between men and women aged <60 years at enrollment, whereas men aged >= 60 years have lower survival rates compared with women aged >= 60 years. Conclusions: Our findings highlight similarities and differences between men and women with PAH, raising questions for future exploration regarding the role of hormones and sex in causation and survival in PAH. C1 [Shapiro, Shelley; Traiger, Glenna L.] Univ Calif Los Angeles, VA Greater LA Healthcare Syst, Los Angeles, CA 90073 USA. David Geffen Univ Calif, Los Angeles Sch Med, Los Angeles, CA USA. [Turner, Michelle] ICON Late Phase & Outcomes Res, San Francisco, CA USA. [McGoon, Michael D.] Mayo Clin, Rochester, MN USA. [Wason, Prieya] Actel Pharmaceut US Inc, San Francisco, CA USA. [Barst, Robyn J.] Columbia Univ, Coll Phys & Surg, New York, NY USA. RP Shapiro, S (reprint author), Univ Calif Los Angeles, VA Greater LA Healthcare Syst, 11301 Wilshire Blvd,Cardiol Sect 111E, Los Angeles, CA 90073 USA. EM sshapiro@ucla.edu FU Actelion Pharmaceuticals US, Inc.; Actelion; Pfizer; Gilead; United Therapeutics; Bayer; Medtronic; Eli Lilly Co.; NIH/NHLBI; Novartis FX Funding for the REVEAL Registry is provided by Actelion Pharmaceuticals US, Inc.; The authors have reported to CHEST the following conflicts of interest: Dr Shapiro has received research grants from Actelion, Pfizer, Gilead, United Therapeutics, and Bayer. Dr Shapiro has served as a consultant for Gilead and United Therapeutics and as a speaker for Actelion, United Therapeutics, and Gilead. Ms Traiger serves as a consultant and is on the speakers' bureau for Actelion, United Therapeutics, and Gilead. Ms Turner is employed by ICON Late Phase & Outcomes Research, a company that receives research support from Actelion and other pharmaceutical companies. Dr McGoon serves as a consultant for Actelion, Gilead, Lung Rx, and Medtronic. Dr McCoon has received grants from Gilead and Medtronic. Dr McGoon has received honoraria for his service on the REVEAL Steering Committee, which is supported by Actelion. Ms Wason is employed by Actelion Pharmaceuticals US, Inc. Dr Barst serves as a consultant for and has received honoraria from Actelion, Bayer, GlaxoSmithKline, Gilead, Eli Lilly & Co., Merck, Novartis, and Pfizer. Dr Barst has received grants from Actelion, Gilead, Eli Lilly & Co., NIH/NHLBI, Novartis, and Pfizer. Dr Barst has received honoraria for her service on the REVEAL Steering Committee, which is supported by Actelion. NR 17 TC 40 Z9 42 U1 1 U2 11 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2012 VL 141 IS 2 BP 363 EP 373 DI 10.1378/chest.10-3114 PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 887HQ UT WOS:000299917900013 PM 21757572 ER PT J AU Negi, SI Steinberg, L Polsani, VR Gowani, SA Nambi, V Kumar, V Marinescu, V Jones, PH Petersen, LA Ballantyne, CM Virani, SS AF Negi, Smita I. Steinberg, Lynne Polsani, Venkateshwar R. Gowani, Saqib A. Nambi, Vijay Kumar, Varinder Marinescu, Victor Jones, Peter H. Petersen, Laura A. Ballantyne, Christie M. Virani, Salim S. TI Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training SO JOURNAL OF CLINICAL LIPIDOLOGY LA English DT Article DE Adult Treatment Panel guidelines; Non-HDL-C calculation; Non-HDL-C goals; Physicians-in-training ID SYSTEMATIC REVIEWS; IMPROVE; RISK; INTERVENTIONS; DISEASE; APOLIPOPROTEINS; ASSOCIATION; PERFORMANCE; ATTAINMENT; GUIDELINES AB BACKGROUND: Non-high density lipoprotein cholesterol (non-HDL-C) goal attainment per Adult Treatment Panel III (ATP III) guidelines remains low. OBJECTIVE: To understand gaps in knowledge and practices of physicians-in-training (internal medicine, family medicine, cardiology, endocrinology) towards non-HDL-C. METHODS: A survey based on a conceptual model to assess the trainee's knowledge, attitudes, and practice regarding non-HDL-C was developed and administered to physicians-in-training (n = 655) at 26 training programs in the United States. Responses of those in internal medicine and family medicine (residents-in-training; n = 418) were compared with those in cardiology and endocrinology (fellows-in-training; n = 124). RESULTS: Response rate was 83.7%. Fifty-three percent of residents and 31% of fellows-in-training had not read the ATP III guidelines (P < .001). Thirty-three percent of the residents and 35% fellows-in-training could not calculate non-HDL-C from a standard lipid panel (P = .7). Sixty-seven percent of the residents and 52% of fellows were not aware of treatment goals for non-HDL-C (P = .004 for comparison between residents and fellows). Both residents and fellows reported infrequent calculation of non-HDL-C levels in patients with elevated triglycerides (>= 200 mg/dL; 32.5% vs 35.4%, respectively, P = .6). Lack of familiarity with ATP 111 guidelines, lack of knowledge regarding importance of non-HDL-C, lack of institutional mandate to calculate non-HDL-C, and lack of emphasis on non-HDL-C by teaching staff were reported as barriers to non-HDL-C use in routine clinical practice. CONCLUSIONS: At least one-third of physicians-in-training could not calculate non-HDL-C from a standard lipid panel, and a large number were not aware of ATP III treatment goals pertaining to non-HDL-C. This area represents one for improvement if non-HDL-C is to be retained as a treatment target in the forthcoming ATP-IV guidelines. Published by Elsevier Inc on behalf of National Lipid Association. C1 [Negi, Smita I.; Nambi, Vijay; Jones, Peter H.; Ballantyne, Christie M.; Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Atherosclerosis & Vasc Med, Houston, TX 77030 USA. [Negi, Smita I.; Nambi, Vijay; Jones, Peter H.; Ballantyne, Christie M.; Virani, Salim S.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX USA. [Steinberg, Lynne] Univ Houston, Houston, TX USA. [Polsani, Venkateshwar R.] Tulane Heart & Vasc Ctr, New Orleans, LA USA. [Gowani, Saqib A.] Univ Connecticut, Farmington, CT USA. [Kumar, Varinder] Univ Vermont, Burlington, VT USA. [Marinescu, Victor] William Beaumont Hosp, Detroit, MI USA. [Petersen, Laura A.; Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res, Houston, TX 77030 USA. [Petersen, Laura A.; Virani, Salim S.] Baylor Coll Med, Dev Ctr Excellence, Sect Hlth Serv, Dept Med, Houston, TX 77030 USA. RP Virani, SS (reprint author), Baylor Coll Med, Dept Med, Sect Atherosclerosis & Vasc Med, Houston, TX 77030 USA. EM virani@bcm.edu OI Steinberg, Lynne/0000-0002-3265-1778; Virani, Salim/0000-0001-9541-6954 FU Merck and Co, Inc [II SP 37267]; Department of Veterans Affairs Health Services Research and Development Service [CDA 09-028]; NIH [K23 HL096893]; Abbott; AstraZeneca; Bristol-Myers Squibb; diaDexus; GlaxoSmithKline; Kowa; Merck; Novartis; Roche; Sanofi-Synthelabo; Takeda; National Football League Medical Charities FX This work was supported by Investigator Initiated Research funding by Merck and Co, Inc (II SP 37267). Dr. Virani is supported by a Department of Veterans Affairs Health Services Research and Development Service Career Development Award (CDA 09-028). Dr. Nambi is supported by a NIH-Career Development Grant (K23 HL096893). Vijay Nambi, MD, has served on the virtual advisory board or Abbott Laboratories. Peter H. Jones, MD, is on the advisory board/consultant of Abbott, Merck, Roche/Genentech and Atherotech. Speakers Bureau for Abbott. Merck, and AstraZeneca. Christie M. Ballantyne, MD, has received grant/research support (all paid to the institution, not individual) from Abbott, AstraZeneca, Bristol-Myers Squibb, diaDexus, GlaxoSmithKline, Kowa, Merck, Novartis, Roche, Sanofi-Synthelabo, Takeda, the National Institutes of Health, American Diabetes Association, and the American Heart Association; is a consultant for Abbott, Adnexus, Amyl in. AstraZeneca, Bristol-Myers Squibb, Esperion, Genentech, GlaxoSmithKline, Idera Pharma, Kowa, Merck, Novartis, Omthera, Resverlogix, Roche, Sanofi-Synthelabo, and Takeda; on the speakers bureau for Abbott, AstraZeneca, GlaxoSmithKline, and Merck; and has received honoraria from Abbott, AstraZeneca, GlaxoSmithKline, Merck, Sanofi-Synthelabo, and Takeda. Salim S. Virani, MD, received research support (all grants to the institution and not individual) from Merck and Co, Inc., and National Football League Medical Charities and was on the speakers bureau at Abbott (discontinued 11/2010). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 27 TC 9 Z9 10 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-2874 EI 1876-4789 J9 J CLIN LIPIDOL JI J. Clin. Lipidol. PD FEB PY 2012 VL 6 IS 1 BP 50 EP 57 DI 10.1016/j.jacl.2011.10.020 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 886KB UT WOS:000299852200007 PM 22264574 ER PT J AU Romano, PS Volpp, K AF Romano, Patrick S. Volpp, Kevin TI The ACGME's 2011 Changes to Resident Duty Hours: Are They an Unfunded Mandate on Teaching Hospitals? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID WORK HOURS; MORTALITY; CARE; EDUCATION; IMPACT; SLEEP C1 [Romano, Patrick S.] UC Davis, Div Gen Med, Sacramento, CA 95817 USA. [Romano, Patrick S.] UC Davis, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA. [Volpp, Kevin] Univ Penn, Philadelphia Vet Affairs Med Ctr, Leonard Davis Inst Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. RP Romano, PS (reprint author), UC Davis, Div Gen Med, 4150V St,PSSB Suite 2400, Sacramento, CA 95817 USA. EM psromano@ucdavis.edu RI Romano, Patrick/N-4225-2014 OI Romano, Patrick/0000-0001-6749-3979 NR 17 TC 6 Z9 6 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2012 VL 27 IS 2 BP 136 EP 138 DI 10.1007/s11606-011-1936-x PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 889HS UT WOS:000300064900002 PM 22127799 ER PT J AU Ahalt, C Binswanger, IA Steinman, M Tulsky, J Williams, BA AF Ahalt, Cyrus Binswanger, Ingrid A. Steinman, Michael Tulsky, Jacqueline Williams, Brie A. TI Confined to Ignorance: The Absence of Prisoner Information from Nationally Representative Health Data Sets SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE incarceration; prisoner; data; health; disparities ID RISK; CARE; INCARCERATION; INMATES; DEATH; POPULATIONS; DISPARITIES; RELEASE; SYSTEM AB Incarceration is associated with poor health and high costs. Given the dramatic growth in the criminal justice system's population and associated expenses, inclusion of questions related to incarceration in national health data sets could provide essential data to researchers, clinicians and policy-makers. To evaluate a representative sample of publically available national health data sets for their ability to be used to study the health of currently or formerly incarcerated persons and to identify opportunities to improve criminal justice questions in health data sets. We reviewed the 36 data sets from the Society of General Internal Medicine Dataset Compendium related to individual health. Through content analysis using incarceration-related keywords, we identified data sets that could be used to study currently or formerly incarcerated persons, and we identified opportunities to improve the availability of relevant data. While 12 (33%) data sets returned keyword matches, none could be used to study incarcerated persons. Three (8%) could be used to study the health of formerly incarcerated individuals, but only one data set included multiple questions such as length of incarceration and age at incarceration. Missed opportunities included: (1) data sets that included current prisoners but did not record their status (10, 28%); (2) data sets that asked questions related to incarceration but did not specifically record a subject's status as formerly incarcerated (8, 22%); and (3) longitudinal studies that dropped and/or failed to record persons who became incarcerated during the study (8, 22%). Few health data sets can be used to evaluate the association between incarceration and health. Three types of changes to existing national health data sets could substantially expand the available data, including: recording incarceration status for study participants who are incarcerated; recording subjects' history of incarceration when this data is already being collected; and expanding incarceration-related questions in studies that already record incarceration history. C1 [Ahalt, Cyrus; Steinman, Michael; Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Ahalt, Cyrus; Steinman, Michael; Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Binswanger, Ingrid A.] Univ Colorado, Denver Sch Med, Div Gen Internal Med, Denver, CO USA. [Tulsky, Jacqueline; Williams, Brie A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. EM brie.williams@ucsf.edu OI Binswanger, Ingrid/0000-0001-8862-8078 FU National Institute of Aging [K23AG033102]; UCSF Hartford Center of Excellence; Langeloth Foundation; Robert Wood Johnson Physician Faculty Scholars Program FX Dr. Williams is supported by the National Institute of Aging (K23AG033102), the UCSF Hartford Center of Excellence, and the Langeloth Foundation. Dr. Binswanger is supported by the Robert Wood Johnson Physician Faculty Scholars Program. These funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Mr. Ahalt, Dr. Williams, and Dr. Steinman are employees of the Department of Veterans Affairs. The opinions expressed in this manuscript may not represent those of the VA. NR 39 TC 17 Z9 17 U1 3 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2012 VL 27 IS 2 BP 160 EP 166 DI 10.1007/s11606-011-1858-7 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 889HS UT WOS:000300064900009 PM 21922160 ER PT J AU Newsom, J Estrada, CA Panisko, D Willett, L AF Newsom, Jeremiah Estrada, Carlos A. Panisko, Danny Willett, Lisa TI Selecting the Best Clinical Vignettes for Academic Meetings: Should the Scoring Tool Criteria be Modified? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE professional competence; internship and residency; education medical/methods; educational measurement/methods/standards; congresses as topic; reproducibility of results ID INTERRATER AGREEMENT; STRUCTURED METHOD; ABSTRACTS; REVIEWERS; MEDICINE; AUTHORS AB The performance of scoring tools to select clinical vignettes for presentation at academic meetings has never been assessed. To measure the psychometric properties of two scoring tools used to select clinical vignettes and to determine which elements are most helpful. Prospective observational study. Participants submitting clinical vignette abstracts, Society of General Internal Medicine annual meetings (2006-2007). The 2006 scoring tool had three criteria (clarity, significance, and relevance) with brief general descriptors. The 2007 modified tool had five criteria (clarity, significance, relevance, teaching value, and overall assessment) with more detailed descriptors. A total of 938 clinical vignette abstracts were submitted (484 in 2006; 454 in 2007); 59.5% (n = 288) were accepted for presentation. Cronbach's alpha was 0.81 for the 2006 three-item tool and 0.95 for the 2007 modified five-item tool. Simplifying the five-item 2007 tool to three items (relevance, teaching value, overall assessment) yielded a Cronbach's alpha of 0.95. The agreement between the number of clinical vignettes accepted for presentation (2007) using the average score of the five items with the number that would have been accepted using the simplified three items (relevance, teaching value, overall assessment) was almost perfect, with kappa 0.89 (95% confidence interval, 0.85 to 0.93). Both scoring tools performed well, but a simplified tool with three items (relevance, teaching value, and overall assessment) and detailed descriptors was optimal; the simplified tool could improve the reviewer efficiency and quality of clinical vignettes presented at national meetings. C1 [Newsom, Jeremiah; Estrada, Carlos A.; Willett, Lisa] Univ Alabama, Birmingham, AL USA. [Newsom, Jeremiah; Estrada, Carlos A.] Vet Affairs Natl Qual Scholars Program, Birmingham VA Med Ctr, Birmingham, AL USA. [Panisko, Danny] Univ Toronto, Toronto, ON, Canada. RP Willett, L (reprint author), BDB 341,1530 3rd Ave S, Birmingham, AL 35294 USA. EM lwillett@uab.edu NR 33 TC 2 Z9 2 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2012 VL 27 IS 2 BP 202 EP 206 DI 10.1007/s11606-011-1879-2 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 889HS UT WOS:000300064900016 PM 21927965 ER PT J AU Prabaker, KK Tran, TPH Pratummas, T Goetz, MB Graber, CJ AF Prabaker, Kavitha K. Tran, Thuong P. -H. Pratummas, Tamara Goetz, Matthew Bidwell Graber, Christopher J. TI Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article DE contrast; nephrotoxicity; reversible; vancomycin ID RESISTANT STAPHYLOCOCCUS-AUREUS; INDUCED NEPHROPATHY; N-ACETYLCYSTEINE; THERAPY; AMINOGLYCOSIDE; BACTEREMIA; TOXICITY; INFECTIONS; PATHOGENESIS; COMBINATION AB BACKGROUND: Vancomycin troughs of 15-20 mg/L are recommended in the treatment of invasive staphylococcal disease, higher levels than previously recommended. OBJECTIVE/SETTING: We sought to determine if there was an association between vancomycin trough and nephrotoxicity, defined as 0.5 mg/L or 50% increase in serum creatinine, at a large Veterans Affairs medical center. PATIENTS AND METHODS: We reviewed records of 348 inpatients at our institution who received >= 5 days of vancomycin during 2 time periods when vancomycin dosing protocols differed (May 2005-April 2006 and January 2007December 2007). Potential risk factors for nephrotoxicity were collected prior to nephrotoxicity onset, and all patients with nephrotoxicity events occurring within 5 days of starting vancomycin were excluded. RESULTS: Overall incidence of nephrotoxicity was 31/348 patients (8.9%). A similar percentage of patients experienced nephrotoxicity in 2005-2006 versus 2007 (16/201 vs 15/147, respectively; P = 0.57), despite a rise in mean (9.7 mg/L in 2005-2006 vs 13.2 mg/L in 2007; P < 0.0001) and highest (11.8 mg/L in 2005-2006 vs 15.7 mg/L in 2007; P < 0.0001) vancomycin trough levels achieved. In a multivariate logistic regression model, only receipt of intravenous contrast dye was significantly associated with nephrotoxicity (OR 4.01, P < 0.001), though there was a trend toward an association between maximum vancomycin trough >= 15 mg/L and nephrotoxicity (OR 2.05, P = 0.082). Overall reversibility of nephrotoxicity either prior to or within 72 hours of vancomycin discontinuation was 77.8%. CONCLUSIONS: We conclude that nephrotoxicity, with higher trough levels occurring at >= 5 days of vancomycin therapy, was uncommon at our institution and typically reversible. Journal of Hospital Medicine 2012; 7: 91-97. (C) 2011 Society of Hospital Medicine C1 [Tran, Thuong P. -H.; Goetz, Matthew Bidwell; Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA 90073 USA. [Prabaker, Kavitha K.; Goetz, Matthew Bidwell; Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. [Prabaker, Kavitha K.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Tran, Thuong P. -H.; Pratummas, Tamara] VA Greater Los Angeles Healthcare Syst, Serv Pharm, Los Angeles, CA 90073 USA. [Goetz, Matthew Bidwell; Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Graber, CJ (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA. EM cgraber@ucla.edu OI Goetz, Matthew/0000-0003-4542-992X FU Ortho-McNeil-Janssen; Merck FX All authors report no conflicts of interest relevant to the content of the article, though C.J.G. has received an unrestricted educational grant from Ortho-McNeil-Janssen, grant support for an unrelated project from Merck, and has served on an advisory board for Pfizer. This project was not supported by extramural funding. NR 41 TC 14 Z9 15 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD FEB PY 2012 VL 7 IS 2 BP 91 EP 97 DI 10.1002/jhm.946 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 887SC UT WOS:000299948800005 PM 22086511 ER PT J AU Perkins, HS Cortez, JD Hazuda, HP AF Perkins, Henry S. Cortez, Josie D. Hazuda, Helen P. TI Patients' diverse beliefs about what happens at the time of death SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID LIFE DECISION-MAKING; MEDICAL PROCEDURES; CULTURAL ISSUES; CANCER-PATIENTS; END; CARE; INFORMATION; STRATEGIES AB BACKGROUND: Beliefs about what happens at the time of death surely affect a patient's whole dying experience and could help guide end-of-life care. Yet virtually no research describes those beliefs. This exploratory study begins the descriptive process. METHODS: Assuming culture is key, we interviewed 26 Mexican-American (MA), 18 Euro-American (EA), and 14 African-American (AA) inpatients about their beliefs concerning what happens at the time of death. RESULTS: One belief, that death separates the dead from the living, was widespread. Majorities of all 3 ethnic group samples and of 5 of the 6 gender subsamples expressed this belief, saying the dead "go" or "leave" from this life. Other beliefs differed by ethnic group or gender. For example, more EAs (50%) than others said death is a momentary event, and more MAs (35%) than others said death involves "being taken" by an external force (always God or Jesus). Furthermore, considerably more EA women (45%) than others said some senses persist after death. In contrast, the physiologic signs that participants cited as defining the exact time of death varied from individual to individual with no ethnic or gender pattern, and no one sign predominated. CONCLUSIONS: A few beliefs about what happens at the time of death may characterize Americans in general; many other beliefs may characterize only certain ethnic groups, genders, or individuals. To identify such beliefs and to use them to guide end-of-life care, hospitalists and other health professionals may have to elicit them directly from patients or survivors. Journal of Hospital Medicine 2012; 7: 110-116. (C) 2011 Society of Hospital Medicine C1 [Perkins, Henry S.; Hazuda, Helen P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Cortez, Josie D.] Intercultural Dev Res Assoc, San Antonio, TX USA. [Hazuda, Helen P.] Audie L Murphy Mem Vet Adm Med Ctr, Dept Vet Affairs, San Antonio, TX 78284 USA. RP Perkins, HS (reprint author), Univ Texas Hlth Sci Ctr, Dept Med, Div Gen Med, POB 1696, Dearborn, MI 48121 USA. EM perkins@uthscsa.edu FU Audie L. Murphy Veterans Administration Medical Center, San Antonio, Texas; Department of Veterans Affairs; John A. Hartford Foundation; American Federation on Aging Research; Mexican-American Medical Treatment Effectiveness Research Center; Aging Research and Education Center; Medical Dean's Office; University of Texas Health Science Center at San Antonio FX This work was supported with resources from the Audie L. Murphy Veterans Administration Medical Center, San Antonio, Texas, but the views expressed here do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government.; The following institutions helped fund the research either directly or indirectly: The Department of Veterans Affairs; The John A. Hartford Foundation; the American Federation on Aging Research; and the Mexican-American Medical Treatment Effectiveness Research Center, the Aging Research and Education Center, and the Medical Dean's Office, all at The University of Texas Health Science Center at San Antonio. Funders played no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, and approval of the manuscript. The authors have no financial conflict of interests. NR 28 TC 1 Z9 1 U1 2 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD FEB PY 2012 VL 7 IS 2 BP 110 EP 116 DI 10.1002/jhm.947 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 887SC UT WOS:000299948800008 PM 22125098 ER PT J AU Kansagara, D Ramsay, RS Labby, D Saha, S AF Kansagara, Devan Ramsay, Rebecca S. Labby, David Saha, Somnath TI Post-discharge intervention in vulnerable, chronically ill patients SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article DE communication; continuity of care; quality improvement; transition and discharge planning ID CONGESTIVE-HEART-FAILURE; RANDOMIZED CONTROLLED-TRIAL; TYPE-2 DIABETES-MELLITUS; HOME-BASED INTERVENTION; PRIMARY-CARE; SELF-MANAGEMENT; HOSPITAL DISCHARGE; CHRONIC ILLNESS; FOLLOW-UP; ELDERLY-PATIENTS AB BACKGROUND: Studies suggest that the inpatient to outpatient transition of care is a vulnerable period for patients, and socioeconomically disadvantaged populations may be particularly susceptible. OBJECTIVE: In this prospective cohort study, clustered by hospital, we sought to determine the feasibility and utility of a simple, post-discharge intervention in reducing hospital readmissions. METHODS: Chronically ill Medicaid managed care members were consecutively identified from the discharge records of 10 area hospitals. For patients from the 7 intervention hospitals, trained medical assistants performed a brief telephone needs assessment, within 1 week of discharge, in which issues requiring near-term resolution were identified and addressed. Patients with more complicated care needs were identified according to a 4domain care needs framework and enrolled in more intensive care management. Patients discharged from the 3 control hospitals received usual care. We used a generalized estimating equation model, which adjusts for clustering by hospital, to evaluate the primary outcome of hospital readmission within 60 days. RESULTS: There were 97 intervention and 130 control patients. Intervention patients were slightly younger and had higher adjusted clinical group (ACG) scores. In unadjusted analysis, the intervention group had lower, but statistically similar, 60-day rehospitalization rates (23.7% vs 29.2%, P =0.35). This difference became significant after controlling for ACG score, prior inpatient utilization, and age: adjusted odds ratio (OR) [95% confidence interval (CI)] 0.49 [0.24-1.00]. CONCLUSIONS: A simple post-discharge intervention and needs assessment may be associated with reduced recurrent hospitalization rates in a cohort of chronically ill Medicaid managed care patients with diverse care needs. Journal of Hospital Medicine 2012; 7: 124-130. (C) 2011 Society of Hospital Medicine C1 [Kansagara, Devan] Oregon Hlth & Sci Univ, Med P3, Portland VA Med Ctr, Portland, OR 97239 USA. [Ramsay, Rebecca S.; Labby, David] CareOregon, Portland, OR USA. RP Kansagara, D (reprint author), Oregon Hlth & Sci Univ, Med P3, Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM kansagar@ohsu.edu FU Medical Research Foundation; Oregon Health and Science University; United States Department of Veterans Affairs FX This work was supported by a grant from the Medical Research Foundation and with help from the Human Investigations Program at Oregon Health and Science University. Drs Kansagara and Saha were additionally supported by the United States Department of Veterans Affairs. The sponsors played no role in study design; collection, analysis, and interpretation of data; writing of the report; or the decision to submit the paper for publication. None of the authors has a relevant conflict of interest. NR 41 TC 9 Z9 9 U1 3 U2 13 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD FEB PY 2012 VL 7 IS 2 BP 124 EP 130 DI 10.1002/jhm.941 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 887SC UT WOS:000299948800010 PM 22086871 ER PT J AU Schmid, DA Yang, T Ogier, M Adams, I Mirakhur, Y Wang, QF Massa, SM Longo, FM Katz, DM AF Schmid, Danielle A. Yang, Tao Ogier, Michael Adams, Ian Mirakhur, Yatin Wang, Qifang Massa, Stephen M. Longo, Frank M. Katz, David M. TI A TrkB Small Molecule Partial Agonist Rescues TrkB Phosphorylation Deficits and Improves Respiratory Function in a Mouse Model of Rett Syndrome SO JOURNAL OF NEUROSCIENCE LA English DT Article ID POTENT NEUROTROPHIC ACTIVITIES; CPG-BINDING PROTEIN-2; KOLLIKER-FUSE NUCLEUS; FACTOR EXPRESSION; MECP2-NULL MICE; LIFE-SPAN; RECEPTORS; DISORDERS; DYSFUNCTION; NEURONS AB Rett syndrome (RTT) results from loss-of-function mutations in the gene encoding the methyl-CpG-binding protein 2 (MeCP2) and is characterized by abnormal motor, respiratory and autonomic control, cognitive impairment, autistic-like behaviors and increased risk of seizures. RTT patients and Mecp2-null mice exhibit reduced expression of brain-derived neurotrophic factor (BDNF), which has been linked in mice to increased respiratory frequency, a hallmark of RTT. The present study was undertaken to test the hypotheses that BDNF deficits in Mecp2 mutants are associated with reduced activation of the BDNF receptor, TrkB, and that pharmacologic activation of TrkB would improve respiratory function. We characterized BDNF protein expression, TrkB activation and respiration in heterozygous female Mecp2 mutant mice (Het), a model that recapitulates the somatic mosaicism for mutant MECP2 found in typical RTT patients, and evaluated the ability of a small molecule TrkB agonist, LM22A-4, to ameliorate biochemical and functional abnormalities in these animals. We found that Het mice exhibit (1) reduced BDNF expression and TrkB activation in the medulla and pons and (2) breathing dysfunction, characterized by increased frequency due to periods of tachypnea, and increased apneas, as in RTT patients. Treatment of Het mice with LM22A-4 for 4 weeks rescued wild-type levels of TrkB phosphorylation in the medulla and pons and restored wild-type breathing frequency. These data provide new insight into the role of BDNF signaling deficits in the pathophysiology of RTT and highlight TrkB as a possible therapeutic target in this disease. C1 [Schmid, Danielle A.; Ogier, Michael; Adams, Ian; Mirakhur, Yatin; Wang, Qifang; Katz, David M.] Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA. [Yang, Tao; Longo, Frank M.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Massa, Stephen M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA. [Massa, Stephen M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Lab Computat Neurochem & Drug Discovery, San Francisco, CA 94121 USA. [Massa, Stephen M.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA. RP Katz, DM (reprint author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA. EM david.katz@case.edu FU National Institute of Neurological Disorders and Stroke; American Recovery and Reinvestment Act; International Rett Syndrome Foundation; Jean Perkins Foundation; Taube Philanthropies; Koret Foundation; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory RD FX This work was supported by the National Institute of Neurological Disorders and Stroke, including funding from the American Recovery and Reinvestment Act (D.M.K.), the International Rett Syndrome Foundation (D.M.K.), the Jean Perkins Foundation (F.M.L.), Taube Philanthropies (F.M.L.), the Koret Foundation (F.M.L.), the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory R&D (S.M.M.). We thank James Howell, and Elizabeth Shick for outstanding technical assistance, Dr. David Baekey (University of Florida) for validating the selection of quiet breathing periods used for analysis of the plethysmographic results, and Drs. Sharyl Fyffe-Maricich and Steve Maricich for their thoughtful comments on an earlier version of the manuscript. NR 40 TC 53 Z9 53 U1 0 U2 4 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD FEB 1 PY 2012 VL 32 IS 5 BP 1803 EP 1810 DI 10.1523/JNEUROSCI.0865-11.2012 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 888AW UT WOS:000299977200026 PM 22302819 ER PT J AU Koepsell, TD Littman, AJ Forsberg, CW AF Koepsell, Thomas D. Littman, Alyson J. Forsberg, Christopher W. TI Obesity, Overweight, and Their Life Course Trajectories in Veterans and Non-Veterans SO OBESITY LA English DT Article ID BODY-MASS INDEX; WAIST CIRCUMFERENCE; PHYSICAL-ACTIVITY; RISK-FACTORS; WEIGHT; HEIGHT; RATIO; RECRUITS; SAMPLE; FAT AB Veterans comprise a large and growing segment of the US population. Results from national telephone surveys suggest higher prevalence of overweight among Veterans compared with demographically similar non-Veterans, based on self-reported height and weight. Using 1999-2008 data from the National Health and Nutrition Examination Survey (NHANES), we compared 3,768 Veterans and 21,974 non-Veterans on: (i) several measures of adiposity based on direct anthropometry; (ii) life-course of self-reported BMI; and (iii) behaviors related to weight loss or maintenance. Whether Veterans were more likely than demographically similar non-Veterans to be obese or overweight depended on the adiposity measure employed. On BMI, Veterans were about equally likely to be obese (30+ kg/m(2)), but more likely to be overweight (25-29.9 kg/m(2)) by both self-report and by direct measurement (significantly so only by self-report). On waist-stature ratio, a roughly similar pattern was observed. On waist circumference, Veterans tended to have larger values than demographically similar non-Veterans, with more Veterans in the largest two categories. But on dual-photon X-ray absorptiometry, Veterans were less likely to have 35+% body fat than non-Veterans of similar age, gender, and race/ethnicity. Life-course trends in self-reported BMI suggested a possible burst of weight gain after military discharge. These results suggest that Veterans may, on average, have less excess body fat than non-Veterans-a pattern not revealed by standard anthropometric measures. C1 [Koepsell, Thomas D.; Littman, Alyson J.; Forsberg, Christopher W.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. [Koepsell, Thomas D.; Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Koepsell, Thomas D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Koepsell, TD (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. EM koepsell@u.washington.edu FU Office of Research and Development; Department of Veterans Affairs; VA Puget Sound Health Care System; Cooperative Studies Program FX This manuscript is based upon work supported by the Office of Research and Development, Cooperative Studies Program, Department of Veterans Affairs and the VA Puget Sound Health Care System. The contents do not necessarily represent the views of the Department of Veterans Affairs or the US Government. NR 20 TC 24 Z9 24 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD FEB PY 2012 VL 20 IS 2 BP 434 EP 439 DI 10.1038/oby.2011.2 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 883AD UT WOS:000299604100026 PM 21293452 ER PT J AU Sohn, MW Budiman-Mak, E Oh, EH Park, MS Stuck, RM Stone, NJ Pearce, WB AF Sohn, Min-Woong Budiman-Mak, Elly Oh, Elissa H. Park, Michael S. Stuck, Rodney M. Stone, Neil J. Pearce, William B. TI Obesity Paradox in Amputation Risk Among Nonelderly Diabetic Men SO OBESITY LA English DT Article ID VASCULAR COMPLICATIONS; OVERWEIGHT AB The association between BMI and amputation risk is not currently well known. We used data for a cohort of diabetic patients treated in the US Department of Veterans Affairs Healthcare System in 2003. Men aged <65 years at the end of follow-up were examined for their amputation risk and amputation-free survival during the next 5 years (2004-2008). Compared to overweight individuals (BMI 25-29.9 kg/m(2)), the risks of amputation and treatment failure (amputation or death) were higher for patients with BMI <25 kg/m(2) and were lower for those with BMI >= 30kg/m(2). Individuals with BMI kg/m(2) were only half as likely to experience any (hazard ratios (HR) = 0.49; 95% confidence interval (Cl), 0.30-0.80) and major amputations (HR = 0.53; 95% CI, 0.39-0.73) during follow-up as overweight individuals. While the amputation risk continued to decrease for higher BMI, amputation-free survival showed a slight upturn at BMI >40 kg/m(2). The association between obesity and amputation risk in our data shows a pattern consistent with "obesity paradox" observed in many health conditions. More research is needed to better understand pathophysiological mechanisms that may explain the paradoxical association between obesity and lower-extremity amputation (LEA) risk. C1 [Sohn, Min-Woong; Budiman-Mak, Elly] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Sohn, Min-Woong; Oh, Elissa H.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA. [Budiman-Mak, Elly] Loyola Univ, Stritch Sch Med, Dept Med, Maywood, IL 60153 USA. [Park, Michael S.; Pearce, William B.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Stuck, Rodney M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Surg Serv, Hines, IL 60141 USA. [Stuck, Rodney M.] Loyola Univ, Stritch Sch Med, Dept Orthoped Surg, Maywood, IL 60153 USA. [Stone, Neil J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. RP Sohn, MW (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. EM Min-Woong.Sohn@va.gov RI Sohn, Min-Woong/C-3560-2015 OI Sohn, Min-Woong/0000-0002-9474-2907 FU Center for Management of Complex Chronic Care, Hines VA Hospital, Hines, IL [LIP 42-099] FX The authors gratefully acknowledge the financial support from the Center for Management of Complex Chronic Care, Hines VA Hospital, Hines, IL (LIP 42-099; E.B-M., MD, Principal Investigator). The paper presents the findings and conclusions of the authors; it does not necessarily represent the Department of Veterans Affairs or Health Services Research and Development Service. The corresponding author had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 13 TC 7 Z9 8 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD FEB PY 2012 VL 20 IS 2 BP 460 EP 462 DI 10.1038/oby.2011.301 PG 3 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 883AD UT WOS:000299604100031 PM 21996669 ER PT J AU New, AS AF New, Antonia S. TI Commentary on Schizoid personality disorder-the peculiarities of their interpersonal relationships and existential roles' by Nirestean, et al. SO PERSONALITY AND MENTAL HEALTH LA English DT Editorial Material C1 [New, Antonia S.] Mt Sinai Sch Med, New York, NY 10029 USA. [New, Antonia S.] James J Peters VAMC, Mental Illness Res Educ & Clin Care Ctr, Bronx, NY USA. RP New, AS (reprint author), Mt Sinai Sch Med, New York, NY 10029 USA. EM Antonia.new@mssm.edu NR 2 TC 0 Z9 0 U1 2 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1932-8621 J9 PERSONAL MENT HEALTH JI Personal. Ment. Health PD FEB PY 2012 VL 6 IS 1 BP 83 EP 85 DI 10.1002/pmh.1180 PG 3 WC Psychiatry; Psychology, Social SC Psychiatry; Psychology GA 887RM UT WOS:000299946800010 ER PT J AU Reitmair, A Sachs, G Bin Im, W Wheeler, L AF Reitmair, Armin Sachs, George Bin Im, Wha Wheeler, Larry TI C6orf176: a novel possible regulator of cAMP-mediated gene expression SO PHYSIOLOGICAL GENOMICS LA English DT Article DE cAMP signaling; gene expression; intraocular pressure; prostaglandins PGE2 ID ELEMENT-BINDING PROTEIN; BETA-CELL SURVIVAL; NONCODING RNAS; HUMAN GENOME; KINASE-A; PHOSPHORYLATION; ANTISENSE; CREB; TRANSCRIPTION AB Reitmair A, Sachs G, Im WB, Wheeler L. C6orf176: a novel possible regulator of cAMP-mediated gene expression. Physiol Genomics 44: 152-161, 2012. First published November 22, 2011; doi:10.1152/physiolgenomics.00089.2011.-cAMP mediates diverse cellular signals including prostaglandin (PG) E-2-mediated intraocular pressure (IOP)-lowering activity in human ocular ciliary smooth muscle cells (hCSM). We have identified gene regulatory networks and key genes upon activation of the cAMP pathway in hCSM, using novel agonists highly selective for PGE(2) receptor subtypes EP2 or EP4, which are G protein-coupled receptors well known to activate cAMP signaling. Here we describe a novel, EP2/EP4-induced, primate-specific gene of hitherto unknown function, also known as C6orf176 (chromosome 6 open reading frame 176) and recently reclassified as noncoding RNA in NCBI's database. Its expression, as determined by quantitative real-time RT-PCR (qRT-PCR), is dramatically upregulated (>2,000-fold) subsequent to transduction of EP2/EP4/Gs/cAMP signaling not only in hCSM, but also in HEK cells overexpressing the recombinant receptors. Moreover, activation of other IOP lowering, Gs-coupled prostanoid receptors, such as DP1 and IP, as well as a direct activator of adenylyl cyclase, forskolin, also substantially upregulated C6orf176 in hCSM, while FP and TP, which are Gq-coupled prostanoid receptor subtypes, did not. Novel transcript variants carrying open reading frames, derived from an at least 67 kb genomic locus on chromosome 6q27 with putative alternative transcription start sites, were identified. Transcriptional upregulation of transcript variants as well as of two genes expressed in antisense orientation that partially overlap the transcribed C6orf176 region was observed, to varying degrees, subsequent to induction of cAMP signaling using various agonists. Small interfering RNA-mediated C6orf176 gene silencing experiments showed modulation of several cAMP-responsive genes. These transcriptional activities identify C6orf176 as a potential biomarker and/or therapeutic target in context with diseases linked to deregulated cAMP signaling. Also, the cAMP-inducible C6orf176 gene locus could be useful as a model system for studying transcriptional regulation by chromatin and RNA polymerase II. C1 [Reitmair, Armin; Bin Im, Wha; Wheeler, Larry] Allergan Pharmaceut Inc, Dept Biol Sci, Irvine, CA 92612 USA. [Sachs, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. [Sachs, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Sachs, George] W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Los Angeles, CA 90073 USA. RP Reitmair, A (reprint author), Allergan Pharmaceut Inc, Dept Biol Sci, RD3,2525 Dupont Dr, Irvine, CA 92612 USA. EM reitmair_armin@allergan.com NR 29 TC 8 Z9 11 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD FEB PY 2012 VL 44 IS 2 BP 152 EP 161 DI 10.1152/physiolgenomics.00089.2011 PG 10 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 889BO UT WOS:000300048700005 PM 22108211 ER PT J AU Siegel, JM AF Siegel, Jerome M. TI REM sleep must have an adaptive value REPLY SO SLEEP MEDICINE REVIEWS LA English DT Letter C1 [Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Siegel, Jerome M.] Vet Adm Greater Los Angeles Healthcare Syst, Neurobiol Res 151A3, North Hills, CA 91343 USA. [Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. EM jsiegel@ucla.edu NR 3 TC 0 Z9 0 U1 2 U2 7 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1087-0792 J9 SLEEP MED REV JI Sleep Med. Rev. PD FEB PY 2012 VL 16 IS 1 BP 111 EP 111 DI 10.1016/j.smrv.2011.11.003 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 886JO UT WOS:000299850900011 ER PT J AU Thrift, AG Vickrey, BG AF Thrift, Amanda G. Vickrey, Barbara G. TI Advances in Health Policy and Outcome 2010-2011 SO STROKE LA English DT Editorial Material DE health care; health policy; outcomes ID ISCHEMIC-STROKE; COST-EFFECTIVENESS; PREVENTION; BURDEN C1 [Thrift, Amanda G.] Monash Univ, Epidemiol & Prevent Unit, Stroke & Ageing Res Ctr STARC, Dept Med,Monash Med Ctr,So Clin Sch, Melbourne, Vic 3004, Australia. [Thrift, Amanda G.] Natl Stroke Res Inst, Heidelberg, Vic, Australia. [Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Vickrey, Barbara G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Thrift, AG (reprint author), Monash Univ, Epidemiol & Prevent Unit, Stroke & Ageing Res Ctr STARC, Dept Med,Monash Med Ctr,So Clin Sch, Level 1-43-51 Kanooka Grove, Clayton, Vic 3168, Australia. EM amanda.thrift@monash.edu RI Thrift, Amanda/I-6251-2012 OI Thrift, Amanda/0000-0001-8533-4170 NR 21 TC 1 Z9 1 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD FEB PY 2012 VL 43 IS 2 BP 300 EP 301 DI 10.1161/STROKEAHA.111.642637 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 885RK UT WOS:000299798300005 PM 22267821 ER PT J AU Tetrault, JM Tate, JP McGinnis, KA Goulet, JL Sullivan, LE Bryant, K Justice, AC Fiellin, DA AF Tetrault, Jeanette M. Tate, Janet P. McGinnis, Kathleen A. Goulet, Joseph L. Sullivan, Lynn E. Bryant, Kendall Justice, Amy C. Fiellin, David A. CA Vet Aging Cohort Study Team TI Hepatic Safety and Antiretroviral Effectiveness in HIV-Infected Patients Receiving Naltrexone SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE HIV; Naltrexone; Alcoholism; Opioid-Related Disorders ID HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; HIGH-DOSE NALTREXONE; ILLICIT DRUG-USE; ALCOHOL DEPENDENCE; MEDICATION ADHERENCE; RELEASE NALTREXONE; OPIOID DEPENDENCE; THERAPY; DRINKING AB Background: We sought to determine the impact of naltrexone on hepatic enzymes and HIV biomarkers in HIV-infected patients. Methods: We used data from the Veterans Aging Cohort Study-Virtual Cohort, an electronic database of administrative, pharmacy, and laboratory data. We restricted our sample to HIV-infected patients who received an initial oral naltrexone prescription of at least 7 days duration. We examined aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and HIV biomarker (CD4 and HIV RNA) values for the 365 days prior to, during, and for the 365 days post-naltrexone prescription. We also examined cases of liver enzyme elevation (LEE; defined as > 5 times baseline ALT or AST or > 3.5 times baseline if baseline ALT or AST was > 40 IU/l). Results: Of 114 HIV-infected individuals, 97% were men, 45% white, 57% Hepatitis C co-infected; median age was 49 years; 89% of the sample had a history of alcohol dependence and 32% had opioid dependence. Median duration of naltrexone prescription was 49 (interquartile range 30 to 83) days, representing 9,525 person-days of naltrexone use. Mean ALT and AST levels remained below the upper limit of normal. Two cases of LEE occurred. Mean CD4 count remained stable and mean HIV RNA decreased after naltrexone prescription. Conclusions: In HIV-infected patients, oral naltrexone is rarely associated with clinically significant ALT or AST changes and does not have a negative impact on biologic parameters. Therefore, HIV-infected patients with alcohol or opioid dependence can be treated with naltrexone. C1 [Tetrault, Jeanette M.; Goulet, Joseph L.; Sullivan, Lynn E.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Tate, Janet P.; McGinnis, Kathleen A.; Goulet, Joseph L.; Justice, Amy C.; Fiellin, David A.] Vet Aging Cohort Study, West Haven, CT USA. [Tate, Janet P.; Goulet, Joseph L.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [McGinnis, Kathleen A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Bryant, Kendall] NIAAA, Rockville, MD 20852 USA. RP Tetrault, JM (reprint author), 367 Cedar St,4th Floor, New Haven, CT 06510 USA. EM jeanette.tetrault@yale.edu OI Fiellin, David/0000-0002-4006-010X; Goulet, Joseph/0000-0002-0842-804X FU National Institute on Alcohol Abuse and Alcoholism [U10 AA 13566]; VHA Public Health Strategic Health Core Group; National Institute on Alcohol and Alcohol Abuse [U01 AA 13566]; National Institute on Drug Abuse (NIDA) [R01 DA019511-03, R01 DA025991, R01 DA020576-01A1, K23 DA024050-02] FX The Veterans Aging Cohort Study is funded by the National Institute on Alcohol Abuse and Alcoholism (U10 AA 13566) and the VHA Public Health Strategic Health Core Group. The material presented in this study is based upon work supported in part by funding from the National Institute on Alcohol and Alcohol Abuse (U01 AA 13566) and the National Institute on Drug Abuse (NIDA R01 DA019511-03, R01 DA025991, R01 DA020576-01A1, K23 DA024050-02). NR 46 TC 11 Z9 11 U1 2 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD FEB PY 2012 VL 36 IS 2 BP 318 EP 324 DI 10.1111/j.1530-0277.2011.01601.x PG 7 WC Substance Abuse SC Substance Abuse GA 883DS UT WOS:000299614700018 PM 21797892 ER PT J AU Merkow, RP Bilimoria, KY McCarter, MD Chow, WB Ko, CY Bentrem, DJ AF Merkow, Ryan P. Bilimoria, Karl Y. McCarter, Martin D. Chow, Warren B. Ko, Clifford Y. Bentrem, David J. TI Use of Multimodality Neoadjuvant Therapy for Esophageal Cancer in the United States: Assessment of 987 Hospitals SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article ID PHASE-III TRIAL; PREOPERATIVE CHEMORADIOTHERAPY; PERIOPERATIVE CHEMOTHERAPY; RESECTABLE CANCER; SURGERY; METAANALYSIS; CARCINOMA; CHEMORADIATION; ADENOCARCINOMA; CISPLATIN AB Consensus guidelines recommend neoadjuvant therapy in locally advanced esophageal cancer; however, whether this recommendation has been widely adopted is unknown. Therefore, we evaluated the utilization of neoadjuvant therapy in esophageal cancer and its association with outcomes in the United States. From the National Cancer Data Base all patients with middle and lower third clinical stage I-III esophageal cancers who underwent surgical resection were identified (1998-2007). Multivariable regression models were developed to identify predictors of neoadjuvant therapy use and associated outcomes. We identified 8562 patients who underwent surgical resection for esophageal cancer. In nonmetastatic locally advanced tumors, neoadjuvant therapy use increased (stage II 47.9% to 72.5%; stage III 51.0% to 90.1%; P < 0.001). On multivariable analysis, factors associated with the decreased use of neoadjuvant therapy for stage II and III disease were age a parts per thousand yen75 years, Medicare insurance coverage, Charlson score a parts per thousand yen2, stage II (vs. III) disease, and geographic region. Patients with stage II and III disease who underwent neoadjuvant therapy had a lower risk of positive lymph nodes (odds ratio [OR] 0.45, 95% confidence interval [CI] 0.35-0.55) and positive surgical margins (OR 0.51, 95% CI 0.38-0.69). Thirty-day postoperative mortality rates were not significantly affected by neoadjuvant therapy (OR 0.90, 95% CI 0.66-1.24). A pathologic complete response was observed in 10.8% of patients. The only factor that was predictive of pathologic complete response was squamous cell tumor histology (OR 2.14, 95% CI 1.52-3.02). In surgically treated patients, the use of neoadjuvant trimodal therapy has increased in the past decade; however, opportunities exist to improve adherence to national guidelines. C1 [Merkow, Ryan P.; Bentrem, David J.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Merkow, Ryan P.; McCarter, Martin D.] Univ Colorado, Sch Med, Dept Surg, Aurora, CO USA. [Bilimoria, Karl Y.] Univ Texas MD Anderson Canc Ctr, Dept Surg, Houston, TX 77030 USA. [Chow, Warren B.; Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Chow, Warren B.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bentrem, David J.] Jesse Brown VA Med Ctr, Dept Surg, Chicago, IL USA. RP Merkow, RP (reprint author), Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. EM dbentrem@nmff.org FU Health Services Research Division, Department of Veterans Affairs FX D.J.B. is supported by a Career Development Award from the Health Services Research Division, Department of Veterans Affairs. NR 40 TC 22 Z9 23 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2012 VL 19 IS 2 BP 357 EP 364 DI 10.1245/s10434-011-1945-3 PG 8 WC Oncology; Surgery SC Oncology; Surgery GA 881KO UT WOS:000299483200004 PM 21769460 ER PT J AU Ikonomidis, JS Ruddy, JM Benton, SM Arroyo, J Brinsa, TA Stroud, RE Zeeshan, A Bavaria, JE Gorman, JH Gorman, RC Spinale, FG Jones, JA AF Ikonomidis, John S. Ruddy, Jean Marie Benton, Stewart M., Jr. Arroyo, Jazmine Brinsa, Theresa A. Stroud, Robert E. Zeeshan, Ahmed Bavaria, Joseph E. Gorman, Joseph H., III Gorman, Robert C. Spinale, Francis G. Jones, Jeffrey A. TI Aortic Dilatation With Bicuspid Aortic Valves: Cusp Fusion Correlates to Matrix Metalloproteinases and Inhibitors INVITED COMMENTARY SO ANNALS OF THORACIC SURGERY LA English DT Article ID ASCENDING AORTA; NEUTROPHIL COLLAGENASE; PROTEIN EXPRESSION; TISSUE INHIBITORS; ANEURYSMS; PATTERNS; DISSECTIONS; PROTEOLYSIS AB Background. Congenital bicuspid aortic valves (BAVs) result from fusion of 2 valve cusps, resulting in left-noncoronary (L-N), right-left (R-L), and right-noncoronary (R-N) morphologic presentations. BAVs predispose to ascending thoracic aortic aneurysms (ATAAs). This study hypothesized that ATAAs with each BAV morphologic group possess unique signatures of matrix metalloproteinases (MMPs) and endogenous tissue inhibitors of metalloproteinases (TIMPs). Methods. Ascending thoracic aortic aneurysm tissue from 46 patients with BAVs was examined for MMP/TIMP abundance, and global MMP activity was compared with normal aortic specimens (n = 15). Proteolytic balance was calculated as the ratio of MMP abundance to a composite TIMP score. Results were stratified by valve morphologic group (L-N [n = 6], R-L [n = 31], and R-N [n = 9]). Results. The BAV specimens (p < 0.05 versus normal aorta, 100%) displayed elevated global MMP activity (273% +/- 63%), MMP-9 (263% +/- 47%), and decreased MMP-7 (56% +/- 10%), MMP-8 (58% +/- 11%), TIMP-1 (63% +/- 7%), and TIMP-4 (38% +/- 3%). The R-L group showed increased global MMP activity (286% +/- 89%) and MMP-9 (267% +/- 55%) with reduced MMP-7 (45% +/- 7%), MMP-8 (68% +/- 15%), TIMP-1 (58% +/- 7%), and TIMP-4 (35% +/- 3%). The L-N group showed elevated global MMP activity (284% +/- 71%) and decreased MMP-8 (37% +/- 17%) and TIMP-4 (48% +/- 14) activity. In the R-N group, MMP-7 (46% +/- 13%) and MMP-8 (36% +/- 17%) and TIMP-1 (59% +/- 10%) and TIMP-4 (42% +/- 5%) were decreased. The R-L group demonstrated an increased proteolytic balance for MMP-1, MMP-9, and MMP-12 relative to L-N and R-N. Conclusions. Each BAV morphologic group possesses a unique signature of MMPs and TIMPs. MMP/TIMP score ratios suggest that the R-L group may be more aggressive, justifying earlier surgical intervention. (Ann Thorac Surg 2012;93:457-64) (C) 2012 by The Society of Thoracic Surgeons C1 [Ikonomidis, John S.] Med Univ S Carolina, Div Cardiothorac Surg, S Carolina Heart Valve Ctr, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. Univ Penn, Div Cardiothorac Surg, Philadelphia, PA 19104 USA. RP Ikonomidis, JS (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, S Carolina Heart Valve Ctr, 25 Courtenay Dr,Ste 7030, Charleston, SC 29425 USA. EM ctsxresearch@musc.edu FU NIH/NHLBI [R21 HL089170] FX This study was supported by NIH/NHLBI grant R21 HL089170. NR 37 TC 29 Z9 30 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD FEB PY 2012 VL 93 IS 2 BP 457 EP 464 DI 10.1016/j.athoracsur.2011.09.057 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 882CX UT WOS:000299540200025 PM 22206960 ER PT J AU Rosenbaum, JT Davey, MP AF Rosenbaum, James T. Davey, Michael P. TI The intestinal microbiome in ankylosing spondylitis: comment on the article by Rosenbaum and Davey Reply SO ARTHRITIS AND RHEUMATISM LA English DT Letter C1 [Rosenbaum, James T.; Davey, Michael P.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Davey, Michael P.] Portland VA Med Ctr, Portland, OR USA. RP Rosenbaum, JT (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD FEB PY 2012 VL 64 IS 2 BP 598 EP 598 DI 10.1002/art.33405 PG 1 WC Rheumatology SC Rheumatology GA 883HU UT WOS:000299625700041 ER PT J AU Freytes, CO Toro, JJ Yeh, RF Stadtmauer, EA Ratanatharathorn, V Akpek, G Sahovic, E Tricot, GJ Shaughnessy, PJ White, DJ Rodriguez, TE Solomon, SR Yu, L Patil, S Sun, Y Armstrong, E Elekes, A Kato, K Reece, DE AF Freytes, C. O. Toro, J. J. Yeh, R. F. Stadtmauer, E. A. Ratanatharathorn, V Akpek, G. Sahovic, E. Tricot, G. J. Shaughnessy, P. J. White, D. J. Rodriguez, T. E. Solomon, S. R. Yu, L. Patil, S. Sun, Y. Armstrong, E. Elekes, A. Kato, K. Reece, D. E. TI PHARMACOKINETICS AND SAFETY OF ONCE-DAILY INTRAVENOUS BUSULFAN WITH BORTEZOMIB IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA UNDERGOING A SECOND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meeting CY FEB 01-05, 2012 CL San Diego, CA C1 [Freytes, C. O.; Toro, J. J.] Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, C. O.; Toro, J. J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Yeh, R. F.; Yu, L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Stadtmauer, E. A.] Univ Penn, Philadelphia, PA 19104 USA. [Ratanatharathorn, V] Karmanos Canc Inst, Detroit, MI USA. [Akpek, G.] Univ Maryland, Baltimore, MD 21201 USA. [Sahovic, E.] Western Penn Hosp, Pittsburgh, PA 15224 USA. [Tricot, G. J.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Shaughnessy, P. J.] Texas Transplant Inst, San Antonio, TX USA. [White, D. J.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. [Rodriguez, T. E.] Loyola Univ Chicago Med Ctr, Maywood, IL USA. [Solomon, S. R.] Northside Hosp, Atlanta, GA USA. [Patil, S.; Sun, Y.; Armstrong, E.; Elekes, A.; Kato, K.] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA. [Reece, D. E.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2012 VL 18 IS 2 SU 2 MA 132 BP S253 EP S253 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 880HQ UT WOS:000299398600133 ER PT J AU Khera, N Storer, BE Chapko, MK Lee, SJ AF Khera, N. Storer, B. E. Chapko, M. K. Lee, S. J. TI CLINICAL OUTCOMES AND COSTS OF SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meeting CY FEB 01-05, 2012 CL San Diego, CA C1 [Khera, N.; Storer, B. E.; Lee, S. J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Chapko, M. K.] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2012 VL 18 IS 2 SU 2 MA 372 BP S341 EP S342 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 880HQ UT WOS:000299398600371 ER PT J AU Kornblit, B Storer, B Storb, RF Hari, P Vucinic, V Maziarz, RT Chauncey, T Pulsipher, MA Bruno, B Petersen, FB Bethge, WA Hubel, K Storek, J Maloney, DG Sandmaier, BM AF Kornblit, B. Storer, B. Storb, R. F. Hari, P. Vucinic, V. Maziarz, R. T. Chauncey, T. Pulsipher, M. A. Bruno, B. Petersen, F. B. Bethge, W. A. Hubel, K. Storek, J. Maloney, D. G. Sandmaier, B. M. TI A RANDOMIZED PHASE III TRIAL INVESTIGATING 2 Gy TBI VS. Flu/2 Gy TBI CONDITIONING FOR HLA-MATCHED RELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION (HCT): TEMPO OF CD3 AND NK CELL ENGRAFTMENT DETERMINES RELAPSE AND PROGRESSION FREE SURVIVAL IN PATIENTS WITH HEMATOLOGIC SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meeting CY FEB 01-05, 2012 CL San Diego, CA C1 [Kornblit, B.; Storer, B.; Storb, R. F.; Chauncey, T.; Maloney, D. G.; Sandmaier, B. M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Kornblit, B.; Storer, B.; Storb, R. F.; Chauncey, T.; Maloney, D. G.; Sandmaier, B. M.] Univ Washington, Seattle, WA 98195 USA. [Hari, P.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Vucinic, V.] Univ Leipzig, Leipzig, Germany. [Maziarz, R. T.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA. [Chauncey, T.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Pulsipher, M. A.] Univ Utah, Med Ctr, Salt Lake City, UT USA. [Bruno, B.] Univ Turin, Sch Med, Turin, Italy. [Petersen, F. B.] LDS Hosp, Salt Lake City, UT USA. [Bethge, W. A.] Univ Tubingen, Med Ctr, Tubingen, Germany. [Hubel, K.] Univ Cologne, D-50931 Cologne, Germany. [Storek, J.] Univ Calgary, Calgary, AB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2012 VL 18 IS 2 SU 2 MA 31 BP S214 EP S214 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 880HQ UT WOS:000299398600032 ER PT J AU Lill, M Lim, S Yeh, RF Waller, E Costa, LJ Shore, T Craig, M Freytes, CO Shea, TC Mineishi, S Rondelli, D Horwitz, ME Braunschweig, I Fay, JW Mason, JR Yu, LH Patil, S Sun, Y Armstrong, E Elekes, A Kato, K Vaughan, WP AF Lill, M. Lim, S. Yeh, R. F. Waller, E. Costa, L. J. Shore, T. Craig, M. Freytes, C. O. Shea, T. C. Mineishi, S. Rondelli, D. Horwitz, M. E. Braunschweig, I. Fay, J. W. Mason, J. R. Yu, L. H. Patil, S. Sun, Y. Armstrong, E. Elekes, A. Kato, K. Vaughan, W. P. TI DOSE PRECISION USING A PRETRANSPLANT TEST PK OF INTRAVENOUS BUSULFAN PRIOR TO BuCyVP-16 PREPARATIVE REGIMEN IN LYMPHOMA SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meeting CY FEB 01-05, 2012 CL San Diego, CA C1 [Lill, M.; Lim, S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Yeh, R. F.; Yu, L. H.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98104 USA. [Waller, E.] Emory Univ, Atlanta, GA 30322 USA. [Costa, L. J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Shore, T.] Cornell Univ, Weil Med Coll, New York, NY 10021 USA. [Shore, T.] New York Presbyterian Hosp, New York, NY USA. [Craig, M.] W Virginia Univ, Morgantown, WV 26506 USA. [Freytes, C. O.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. [Freytes, C. O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Shea, T. C.] Univ N Carolina, Chapel Hill, NC USA. [Mineishi, S.] Univ Michigan, Ann Arbor, MI 48109 USA. [Rondelli, D.] Univ Illinois, Ctr Canc, Chicago, IL USA. [Horwitz, M. E.] Duke Univ, Med Ctr, Durham, NC USA. [Braunschweig, I.] Montefiore Med Ctr, Bronx, NY 10467 USA. [Fay, J. W.] Baylor Univ, Med Ctr, Dallas, TX USA. [Mason, J. R.] Scripps Clin, La Jolla, CA 92037 USA. [Patil, S.; Sun, Y.; Armstrong, E.; Elekes, A.; Kato, K.] Otruka Pharmaceutical Dev & Commercializat Inc, Princeton, NJ USA. [Vaughan, W. P.] Univ Alabaman, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2012 VL 18 IS 2 SU 2 MA 114 BP S246 EP S246 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 880HQ UT WOS:000299398600115 ER PT J AU Newell, LF Leeborg, N Dong, ZM Avraham, GP Deans, R Chauncey, TR Maziarz, RT AF Newell, L. F. Leeborg, N. Dong, Z. M. Avraham, Perets G. Deans, R. Chauncey, T. R. Maziarz, R. T. TI MULTIPOTENT ADULT PROGENITOR CELLS (MULTISTEM (R)) ENHANCE BONE MARROW RECOVERY AFTER ABLATIVE ALLOGENEIC STEM CELL TRANSPLANT SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meeting CY FEB 01-05, 2012 CL San Diego, CA C1 [Newell, L. F.; Leeborg, N.; Avraham, Perets G.; Maziarz, R. T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Dong, Z. M.; Chauncey, T. R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Deans, R.] Athersys Inc, Cleveland, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2012 VL 18 IS 2 SU 2 MA 164 BP S264 EP S264 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 880HQ UT WOS:000299398600165 ER PT J AU Toro, JJ Haile, DJ Lee, S Jewell, PS Freytes, CO AF Toro, J. J. Haile, D. J. Lee, S. Jewell, P. S. Freytes, C. O. TI USE OF THE VETERANS AFFAIRS NUTRITIONAL STATUS CLASSIFICATION SCHEME IN THE EVALUATION OF SURVIVAL AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meeting CY FEB 01-05, 2012 CL San Diego, CA C1 [Toro, J. J.; Haile, D. J.; Lee, S.; Jewell, P. S.; Freytes, C. O.] Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. [Toro, J. J.; Freytes, C. O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2012 VL 18 IS 2 SU 2 MA 306 BP S319 EP S320 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 880HQ UT WOS:000299398600307 ER PT J AU Casaburi, R Porszasz, J Hecht, A Tiep, B Albert, RK Anthonisen, NR Bailey, WC Connett, JE Cooper, JA Criner, GJ Curtis, J Dransfield, M Lazarus, SC Make, B Martinez, FJ McEvoy, C Niewoehner, DE Reilly, JJ Scanlon, P Scharf, SM Sciurba, FC Woodruff, P AF Casaburi, Richard Porszasz, Janos Hecht, Ariel Tiep, Brian Albert, Richard K. Anthonisen, Nicholas R. Bailey, William C. Connett, John E. Cooper, J. Allen, Jr. Criner, Gerard J. Curtis, Jeffrey Dransfield, Mark Lazarus, Stephen C. Make, Barry Martinez, Fernando J. McEvoy, Charlene Niewoehner, Dennis E. Reilly, John J. Scanlon, Paul Scharf, Steven M. Sciurba, Frank C. Woodruff, Prescott CA COPD Clinical Res Network TI Influence of Lightweight Ambulatory Oxygen on Oxygen Use and Activity Patterns of COPD Patients Receiving Long-Term Oxygen Therapy SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE adherence; long-term oxygen therapy; activity monitoring; tri-axial accelerometer ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED-TRIAL; STANDARDIZATION; HOME; PRESCRIPTION; POPULATION; SURVIVAL; LUNG AB Lightweight ambulatory oxygen devices are provided on the assumptions that they enhance compliance and increase activity, but data to support these assumptions are lacking. We studied 22 patients with severe chronic obstructive pulmonary disease receiving long-term oxygen therapy (14 men, average age = 66.9 y, FEV1 = 33.6% pred, PaO2 at rest = 51.7 torr) who were using E-cylinders as their portable oxygen. Subjects were recruited at 5 sites and studied over a 2-week baseline period and for 6 months after randomizing them to either continuing to use 22-lb E-cylinders towed on a cart or to carrying 3.6-lb aluminum cylinders. Utilizing novel electronic devices, ambulatory and stationary oxygen use was monitored continuously over the 2 weeks prior to and the 6 months following randomization. Subjects wore tri-axial accelerometers to monitor physical activity during waking hours for 2-3 weeks prior to, and at 3 and 6 months after, randomization. Seventeen subjects completed the study. At baseline, subjects used 17.2 hours of stationary and 2.5 hours of ambulatory oxygen daily. At 6 months, ambulatory oxygen use was 1.4 +/- 1.0 hrs in those randomized to E-cylinders and 1.9 +/- 2.4 hrs in those using lightweight oxygen (P = NS). Activity monitoring revealed low activity levels prior to randomization and no significant increase over time in either group. In this group of severe chronic obstructive pulmonary disease patients, providing lightweight ambulatory oxygen did not increase either oxygen use or activity. Future efforts might focus on strategies to encourage oxygen use and enhance activity in this patient group. This trial is registered at ClinicalTrials.gov (NCT003257540). C1 [Casaburi, Richard; Porszasz, Janos; Hecht, Ariel] Univ Calif Los Angeles, Los Angeles Biomed Res Inst, Med Ctr, Rehabil Clin Trials Ctr, Torrance, CA 90502 USA. [Tiep, Brian] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Albert, Richard K.] Denver Hlth, Dept Med, Denver, CO USA. [Albert, Richard K.] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA. [Anthonisen, Nicholas R.] Univ Manitoba, Winnipeg, MB, Canada. [Bailey, William C.; Cooper, J. Allen, Jr.; Dransfield, Mark] Univ Alabama, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Connett, John E.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA. [Cooper, J. Allen, Jr.; Dransfield, Mark] Birmingham VAMC, Pulm Sect, Birmingham, AL USA. [Criner, Gerard J.] Temple Univ, Div Pulm & Crit Care Med, Philadelphia, PA 19122 USA. [Curtis, Jeffrey; Martinez, Fernando J.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA. [Lazarus, Stephen C.; Woodruff, Prescott] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA. [Lazarus, Stephen C.; Woodruff, Prescott] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Make, Barry] Natl Jewish Hlth, Denver, CO USA. [McEvoy, Charlene] HealthPartners Res Fdn, Minneapolis, MN USA. [Niewoehner, Dennis E.] Univ Minnesota, VA Med Ctr, Pulm Sect, Minneapolis, MN USA. [Reilly, John J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Scanlon, Paul] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA. [Scharf, Steven M.] Univ Maryland, Div Pulm & Crit Care Med, Baltimore, MD 21201 USA. [Sciurba, Frank C.] Univ Pittsburgh, Div Pulm & Crit Care Med, Pittsburgh, PA USA. RP Casaburi, R (reprint author), Univ Calif Los Angeles, Los Angeles Biomed Res Inst, Med Ctr, Rehabil Clin Trials Ctr, Bldg J4,1124 W Carson St, Torrance, CA 90502 USA. EM casaburi@ucla.edu RI Reilly, John/H-8755-2012 OI Porszasz, Janos/0000-0002-5823-0031; Curtis, Jeffrey/0000-0001-5191-4847 FU COPD Clinical Research Network; National Heart, Lung, and Blood Institute [1U10]; National Center for Research Resources; Brigham and Women's Hospital [HL074428, RR02635]; Denver Health Medical Center [L074409, RR00051]; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center [HL074407, RR00425]; Temple University [HL074408]; University of Alabama at Birmingham [HL074418]; University of California, San Francisco [HL074431]; University of Maryland, Baltimore [HL074441, RR16500]; University of Michigan [HL074422]; University of Pittsburgh [HL074439, RR00056]; Minnesota Veterans Research Institute, Minneapolis [HL074416]; University of Minnesota (Data Coordinating Center) [HL074424]; Data and Safety Monitoring Board FX This study was funded by the COPD Clinical Research Network a w10-site network supported by a Cooperative Agreement (1U10 mechanism) from the National Heart, Lung, and Blood Institute; no funds from commercial sources were utilized. At some sites General Clinical Research Centers (GCRC) were utilized; their M01 grants from the National Center for Research Resources are listed. Members of this Network, with their personnel and grant support are: Brigham and Women's Hospital - J.J. Reilly, Jr. (PI), G. Washko, (Investigator), S. Peterson, C. Mayo (Coordinator), Grant HL074428, GCRC Grant RR02635; Denver Health Medical Center - R. K. Albert (PI), B. Make (Co-PI), C. Welsh (Investigators), M. Gilmartin, C. Verano (Coordinators), Grant HL074409, GCRC Grant RR00051; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - R. Casaburi (PI), J. Porszasz (Investigator), R. D. Love (Coordinator), Grant HL074407, GCRC Grant RR00425; Temple University - G. J. Criner (PI); W. Chatila, N. Marchetti, V. Kim, G D'Alonzo, S. Krachman, F. Cordova, K. Brennan, N. Patel, J. Mamary (Investigator), C. Grabianowski, N. Krayger, H. Criner (Coordinators), Grant HL074408; University of Alabama at Birmingham - W. C. Bailey, J. A. D. Cooper (Co-PIs), M. T. Dransfield, L. B Gerald, P. O'Reilly (Investigators), S. Tidwell (Coordinator), Grant HL074418; University of California, San Francisco - S. C. Lazarus (PI), H. A. Boushey, P. G. Woodruff (Investigators), R. Sakurai, C. Nguyen (Coordinators), Grant HL074431; University of Maryland, Baltimore - S. M. Scharf (PI), M. Alattar, P. Amelung, M. Cowan, J. Hanson, J. Hasday, A. Iacono, C. Shanholtz, N. Todd, A. Verceles (Investigators), W. Bell-Farrell, T. Fitzgerald, P. Wood (Coordinators), Grant HL074441, GCRC Grant RR16500; University of Michigan, Ann Arbor - F. J. Martinez (PI), J. Curtis, M. K. Han, P. Christensen (Investigators), K. Baptist, C. Flaherty, C. Getty, C. Jett, L. McCloskey, D. Thompson, D. White (Coordinators), Grant HL074422; University of Pittsburgh - F. Sciurba, (PI), R. Folger, D. Filippino (Coordinators), Grant HL074439, GCRC Grant RR00056; Minnesota Veterans Research Institute, Minneapolis - D. E. Niewoehner (PI), C. McEvoy, P. D. Scanlon, K. R. Rice (Co-PIs), C. B. Bourassa, P. Neuenfeldt (Coordinators), Grant HL074416. University of Minnesota (Data Coordinating Center) - J. E. Connett (PI), N. R. Anthonisen (Steering Committee Chair), C. Wendt (Co-PI), W. Patrek, H. Voelker, M. Skeans (Coordinators), Grant HL074424. Data and Safety Monitoring Board - B. B. Bender, S. F. Kelsey, J. R. Landis, B. Phillips, G. M. Turino, R. Veatch, A. Waldo, A. Wanner. Protocol Review Committee H. W. Kelly, J. Maurer, A. J. McSweeny, R. M. Senior, E. A. Thom, P. D. Wagner, R. L. ZuWallack. NHLBI - G. Weinmann (Deputy Director, Division of Lung Diseases), T. Croxton (Director, Airway Biology & Disease Program), A. Punturieri, (Program Officer), M. P. Stylianou (Bio-statistician). NR 27 TC 19 Z9 19 U1 1 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1541-2555 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PD FEB PY 2012 VL 9 IS 1 BP 3 EP 11 DI 10.3109/15412555.2012.630048 PG 9 WC Respiratory System SC Respiratory System GA 884XY UT WOS:000299743400002 PM 22292592 ER PT J AU McNeely, MJ Shofer, JB Leonetti, DL Fujimoto, WY Boyko, EJ AF McNeely, Marguerite J. Shofer, Jane B. Leonetti, Donna L. Fujimoto, Wilfred Y. Boyko, Edward J. TI Associations Among Visceral Fat, All-Cause Mortality, and Obesity-Related Mortality in Japanese Americans SO DIABETES CARE LA English DT Article ID DIABETES-MELLITUS; MEN; DIAGNOSIS; CHOICE AB OBJECTIVE-The study objective was to examine the associations among visceral fat (VF), all-cause mortality, and obesity-related mortality. RESEARCH DESIGN AND METHODS-A total of 733 Japanese Americans were followed for 16.9 years. Hazard ratios (HRs) per interquartile range increase in VF were calculated using time-dependent Cox proportional hazard models censored at age 82 years, with age as the time axis adjusted for sex and smoking. RESULTS-Higher VF was associated with all-cause mortality (HR 1.39 [95% CI 1.11-1.75] 107 deaths) and obesity-related mortality (1.39 [1.04-1.85], 68 deaths from cardiovascular disease, diabetes, or obesity-related cancer). After further adjustment for waist circumference, VF remained significantly associated with all-cause mortality (1.41 [1.04-1.92]) but not with obesity-related mortality. The associations between mortality and VF were not independent of BMI. CONCLUSIONS-VF was associated with all-cause mortality and obesity-related mortality in Japanese Americans. VF did not significantly improve mortality risk assessment beyond that of BMI. C1 [McNeely, Marguerite J.; Fujimoto, Wilfred Y.; Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Shofer, Jane B.] Univ Washington, Ctr Studies Demog & Ecol, Seattle, WA 98195 USA. [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP McNeely, MJ (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. EM mcneely@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU National Institutes of Health [DK-77745, DK-31170, HL-49293, DK-02654]; King County Japanese-American Community FX This work was supported by the National Institutes of Health (grants DK-77745, DK-31170, HL-49293, and DK-02654) and by facilities and services provided by the Diabetes and Endocrinology Research Center (DK-17047), Clinical Nutrition Research Unit (DK-35816), and General Clinical Research Center (RR-00037) at the University of Washington. VA Puget Sound provided support for Dr. Boyko's involvement in this research.; The authors thank the King County Japanese-American Community for support and cooperation. NR 13 TC 15 Z9 15 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2012 VL 35 IS 2 BP 296 EP 298 DI 10.2337/dc11-1193 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 886LN UT WOS:000299856000020 PM 22190675 ER PT J AU Foster, RG Golden-Mason, L Rutebemberwa, A Rosen, HR AF Foster, Richard G. Golden-Mason, Lucy Rutebemberwa, Alleluiah Rosen, Hugo R. TI Interleukin (IL)-17/IL-22-Producing T cells Enriched Within the Liver of Patients with Chronic Hepatitis C Viral (HCV) Infection SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE HCV; Liver; Th17; IL22; Fibrosis ID INNATE IMMUNITY; TH17 CELLS; EXPRESSION; DISEASE AB Effector CD4+ helper T cells have historically been classified into T helper 1 (Th1) and Th2 based on the production of signature cytokines. The recently identified interleukin (IL)-17 cytokine family plays important roles in host immunity against intracellular pathogens and in chronic inflammatory conditions; data have implicated IL-17 in autoimmune and viral liver disease. This study used three patient groups with HCV infection: acute HCV who either cleared spontaneously or became chronically infected (n = 12), endstage liver disease from whom both peripheral and intrahepatic lymphocytes were studied directly ex vivo (n = 11), and 134 patients with different stages of HCV-related fibrosis from whom serum was collected concurrently with liver biopsy. Normal healthy subjects (n = 41) served as controls. Acute HCV was not associated with expansion of either CD4+ or CD8+ T cells producing IL-17 (Th17, Tc17) or IL-22, and frequencies did not differ in the blood of patients who cleared versus became persistently infected. The hepatic compartment of chronic HCV patients demonstrated statistically more CD4+ and CD8+ that produced IL-17, IL-22 or both as compared to peripheral blood. These T cells displayed a distinct phenotypic profile, high expression of the homing receptor CD161 and low levels of inhibitory receptors, mucin-domain-containing-molecule-3 (Tim-3) and programmed-death 1. Using a sensitive ELISA, we found no significant differences in serum levels of IL-17 according to HCV-related fibrosis. In chronic HCV, T cells producing IL-17/IL-22 may home to the liver; however, circulating levels of IL-17 do not correlate with fibrosis. C1 [Foster, Richard G.; Golden-Mason, Lucy; Rutebemberwa, Alleluiah; Rosen, Hugo R.] Univ Colorado Denver, Dept Med, Hepatitis Ctr C, Div Gastroenterol & Hepatol, Aurora, CO 80045 USA. [Foster, Richard G.; Golden-Mason, Lucy; Rutebemberwa, Alleluiah; Rosen, Hugo R.] Natl Jewish Hosp, Aurora, CO 80045 USA. [Golden-Mason, Lucy; Rosen, Hugo R.] Univ Colorado, Integrated Program Immunol, Denver, CO 80202 USA. [Golden-Mason, Lucy; Rosen, Hugo R.] Natl Jewish Hosp, Denver, CO USA. [Golden-Mason, Lucy; Rosen, Hugo R.] Eastern Colorado VA, Denver, CO USA. [Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA. RP Rosen, HR (reprint author), Univ Colorado Denver, Dept Med, Hepatitis Ctr C, Div Gastroenterol & Hepatol, B-158,Acad Off Bldg 1,12631 E 17th Ave,Rm 7614,PO, Aurora, CO 80045 USA. EM hugo.rosen@ucdenver.edu FU HCV center [U19 A 1066328-01]; VA Merit Review grant FX This research is supported by a VA Merit Review grant and U19 A 1066328-01 (HCV center grant) to H.R.R. NR 19 TC 24 Z9 26 U1 0 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD FEB PY 2012 VL 57 IS 2 BP 381 EP 389 DI 10.1007/s10620-011-1997-z PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 881LS UT WOS:000299487500017 PM 22183819 ER PT J AU Nitsche, C Edderkaoui, M Moore, RM Eibl, G Kasahara, N Treger, J Grippo, PJ Mayerle, J Lerch, MM Gukovskaya, AS AF Nitsche, Claudia Edderkaoui, Mouad Moore, Ryan M. Eibl, Guido Kasahara, Noriyuki Treger, Janet Grippo, Paul J. Mayerle, Julia Lerch, Markus M. Gukovskaya, Anna S. TI The Phosphatase PHLPP1 Regulates Akt2, Promotes Pancreatic Cancer Cell Death, and Inhibits Tumor Formation SO GASTROENTEROLOGY LA English DT Article DE ROS; NADPH Oxidase; Apoptosis; Tumor Progression ID KINASE-B ACTIVATION; TYROSINE PHOSPHATASES; DUCTAL ADENOCARCINOMA; SIGNALING PATHWAY; NADPH OXIDASE; K-RAS; APOPTOSIS; PROTEIN; GROWTH; EXPRESSION AB BACKGROUND & AIMS: The kinase Akt mediates resistance of pancreatic cancer (PaCa) cells to death and is constitutively active (phosphorylated) in cancer cells. Whereas the kinases that activate Akt are well characterized, less is known about phosphatases that dephosporylate and thereby inactivate it. We investigated regulation of Akt activity and cell death by the phosphatases PHLPP1 and PHLPP2 in PaCa cells, mouse models of PaCa, and human pancreatic ductal adenocarcinoma (PDAC). METHODS: We measured the effects of PHLPP overexpression or knockdown with small interfering RNAs on Akt activation and cell death. We examined regulation of PHLPPs by growth factors and reactive oxygen species, as well as associations between PHLPPs and tumorigenesis. RESULTS: PHLPP overexpression inactivated Akt, whereas PHLPP knockdown increased phosphorylation of Akt in PaCa cells. Levels of PHLPPs were greatly reduced in human PDAC and in mouse genetic and xenograft models of PaCa. PHLPP activities in PaCa cells were down-regulated by growth factors and Nox4 reduced nicotinamide adenine dinucleotide phosphate oxidase. PHLPP1 selectively dephosphorylated Akt2, whereas PHLPP2 selectively dephosphorylated Akt1. Akt2, but not Akt1, was up-regulated in PDAC, and Akt2 levels correlated with mortality. Consistent with these results, high levels of PHLPP1, which dephosphorylates Akt2 (but not PHLPP2, which dephosphorylates Akt1), correlated with longer survival times of patients with PDAC. In mice, xenograft tumors derived from PaCa cells that overexpress PHLPP1 (but not PHLPP2) had inactivated Akt, greater extent of apoptosis, and smaller size. CONCLUSIONS: PHLPP1 has tumor suppressive activity and might represent a therapeutic or diagnostic tool for PDAC. C1 [Nitsche, Claudia; Edderkaoui, Mouad; Moore, Ryan M.; Gukovskaya, Anna S.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Nitsche, Claudia; Edderkaoui, Mouad; Moore, Ryan M.; Kasahara, Noriyuki; Treger, Janet; Gukovskaya, Anna S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Eibl, Guido] Univ Calif Los Angeles, Dept Surg, Hirshberg Lab Translat Pancreat Canc Res, Los Angeles, CA 90024 USA. [Nitsche, Claudia; Mayerle, Julia; Lerch, Markus M.] Ernst Moritz Arndt Univ Greifswald, Dept Internal Med A, Greifswald, Germany. [Grippo, Paul J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. RP Gukovskaya, AS (reprint author), UCLA VA Greater Los Angeles, Pancreat Res Grp, W Los Angeles VA Healthcare Ctr, 11308 Wilshire Blvd,Bldg 258,Room 340, Los Angeles, CA USA. EM agukovsk@ucla.edu RI Lerch, Markus M./E-2206-2016 OI Lerch, Markus M./0000-0002-9643-8263 FU National Cancer Institute [R01CA119025]; Department of Veterans Affairs Merit Review; Alfried Krupp von Bohlen und Halbach Stiftung grant FX Supported by National Cancer Institute grant R01CA119025 and the Department of Veterans Affairs Merit Review (to A. S. G.) and the Alfried Krupp von Bohlen und Halbach Stiftung grant (to C.N.). NR 34 TC 33 Z9 34 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2012 VL 142 IS 2 BP 377 EP U296 DI 10.1053/j.gastro.2011.10.026 PG 16 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 882CV UT WOS:000299540000044 PM 22044669 ER PT J AU Castillo, JG Telem, D Heimann, TM AF Castillo, Javier G. Telem, Dana Heimann, Tomas M. TI An Extremely Unusual and Large Cause of Anemia SO GASTROENTEROLOGY LA English DT Editorial Material ID ANGIOSARCOMA C1 [Castillo, Javier G.] James J Peters VA Med Ctr, Dept Thorac Surg, Bronx, NY USA. [Telem, Dana; Heimann, Tomas M.] James J Peters VA Med Ctr, Dept Gen Surg, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. RP Castillo, JG (reprint author), James J Peters VA Med Ctr, Dept Thorac Surg, Bronx, NY USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2012 VL 142 IS 2 BP E23 EP E24 DI 10.1053/j.gastro.2011.03.067 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 882CV UT WOS:000299540000011 PM 22197165 ER PT J AU Jensen, DM AF Jensen, Dennis M. TI The ins and outs of diverticular bleeding SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID SEVERE HEMATOCHEZIA; URGENT COLONOSCOPY; HEMORRHAGE; DIAGNOSIS C1 [Jensen, Dennis M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Jensen, Dennis M.] Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA USA. [Jensen, Dennis M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Jensen, Dennis M.] CURE Digest Dis Res Ctr, Los Angeles, CA USA. RP Jensen, DM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. FU NIADDK NIH HHS [AM 41301] NR 10 TC 5 Z9 5 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD FEB PY 2012 VL 75 IS 2 BP 388 EP 391 DI 10.1016/j.gie.2011.09.004 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 885BF UT WOS:000299752800022 PM 22248606 ER PT J AU Elvington, A Atkinson, C Kulik, L Zhu, H Yu, J Kindy, MS Holers, VM Tomlinson, S AF Elvington, Andrew Atkinson, Carl Kulik, Liudmila Zhu, Hong Yu, Jin Kindy, Mark S. Holers, V. Michael Tomlinson, Stephen TI Pathogenic Natural Antibodies Propagate Cerebral Injury Following Ischemic Stroke in Mice SO JOURNAL OF IMMUNOLOGY LA English DT Article ID MANNOSE-BINDING LECTIN; ANNEXIN-IV EXPRESSION; REPERFUSION INJURY; SKELETAL-MUSCLE; ISCHEMIA/REPERFUSION INJURY; APOPTOTIC CELLS; COMPLEMENT; IGM; PHOSPHORYLCHOLINE; PROTECTION AB Self-reactive natural Abs initiate injury following ischemia and reperfusion of certain tissues, but their role in ischemic stroke is unknown. We investigated neoepitope expression in the postischemic brain and the role of natural Abs in recognizing these epitopes and mediating complement-dependent injury. A novel IgM mAb recognizing a subset of phospholipids (C2) and a previously characterized anti-annexin IV mAb (B4) were used to reconstitute and characterize injury in Ab-deficient Rag1(-/-) mice after 60 min of middle cerebral artery occlusion and reperfusion. Reconstitution with C2 or B4 mAb in otherwise protected Rag1(-/-) mice restored injury to that seen in wild-type (wt) mice, as demonstrated by infarct volume, demyelination, and neurologic scoring. IgM deposition was demonstrated in both wt mice and reconstituted Rag1(-/-) mice, and IgM colocalized with the complement activation fragment C3d following B4 mAb reconstitution. Further, recombinant annexin IV significantly reduced infarct volumes in wt mice and in Rag1(-/-) mice administered normal mouse serum, demonstrating that a single Ab reactivity is sufficient to develop cerebral ischemia reperfusion injury in the context of an entire natural Ab repertoire. Finally, C2 and B4 mAbs bound to hypoxic, but not normoxic, human endothelial cells in vitro. Thus, the binding of pathogenic natural IgM to postischemic neoepitopes initiates complement-dependent injury following murine cerebral ischemia and reperfusion, and, based also on previous data investigating IgM reactivity in human serum, there appears to be a similar recognition system in both mouse and man. The Journal of Immunology, 2012, 188: 1460-1468. C1 [Elvington, Andrew; Atkinson, Carl; Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Childrens Res Inst, Charleston, SC 29401 USA. [Kulik, Liudmila; Holers, V. Michael] Univ Colorado Denver, Dept Med & Immunol, Aurora, CO 80045 USA. [Zhu, Hong; Yu, Jin; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Neurosci Inst, Charleston, SC 29425 USA. [Kindy, Mark S.; Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave,BSB 201, Charleston, SC 29425 USA. EM tomlinss@musc.edu FU National Institutes of Health [HL082485, HL86576, AI31105]; Department of Veterans Affairs [NURC-001218A, NURC-051010F] FX This work was supported by grants from the National Institutes of Health (HL082485, HL86576, and AI31105) and the Department of Veterans Affairs (Merit Awards NURC-001218A and NURC-051010F). NR 47 TC 23 Z9 23 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD FEB 1 PY 2012 VL 188 IS 3 BP 1460 EP 1468 DI 10.4049/jimmunol.1102132 PG 9 WC Immunology SC Immunology GA 884FL UT WOS:000299690200061 PM 22198950 ER PT J AU Zoghbi, GJ Iskandrian, AE AF Zoghbi, Gilbert J. Iskandrian, Ami E. TI Selective adenosine agonists and myocardial perfusion imaging SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE Myocardial perfusion imaging; selective adenosine agonists; regadenoson; binodenoson; apadenoson ID A(2A) RECEPTOR AGONIST; INITIAL CLINICAL-EXPERIENCE; PLACEBO-CONTROLLED TRIAL; BLOOD-FLOW-VELOCITY; HEART-RATE RESPONSE; PHARMACOLOGICAL STRESS; CORONARY VASODILATION; CONSCIOUS DOGS; DOUBLE-BLIND; REGADENOSON AB Selective adenosine receptor agonists have several advantages for use as stress agents in conjunction with myocardial perfusion imaging compared to the non selective agents such as adenosine and dipyridamole. This review will summarize the pre-clinical and clinical data on the selective adenosine agonist stress agents regadenoson (Lexiscan(A (R))), binodenoson (CorVue (TM)) and apadenoson (Stedivaze (TM)) that have been studied so far with focus on regadenoson that has the most clinical data published so far. The article will review the adenosine receptor types and properties. It will also review the various attributes of the selective adenosine agonists including their pharmacology, pharmacokinetics and pharmacodynamics, their coronary vasodilatory and hemodynamic effects, their safety and side effects, their interactions with other drugs and their use with myocardial perfusion imaging. The landmark trials of the selective adenosine agonists will be reviewed as well as their use in special patient populations undergoing stress myocardial perfusion imaging. C1 [Zoghbi, Gilbert J.; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Zoghbi, Gilbert J.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Zoghbi, GJ (reprint author), Univ Alabama, Div Cardiovasc Dis, FOT 920,1960 6th Ave S, Birmingham, AL 35294 USA. EM gzoghbi@uab.edu NR 42 TC 25 Z9 25 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2012 VL 19 IS 1 BP 126 EP 141 DI 10.1007/s12350-011-9474-9 PG 16 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 881XC UT WOS:000299524100017 PM 22130964 ER PT J AU Olfson, M Huang, C Gerhard, T Winterstein, AG Crystal, S Allison, PD Marcus, SC AF Olfson, Mark Huang, Cecilia Gerhard, Tobias Winterstein, Almut G. Crystal, Stephen Allison, Paul D. Marcus, Steven C. TI Stimulants and Cardiovascular Events in Youth With Attention-Deficit/Hyperactivity Disorder SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE attention-deficit/hyperactivity disorder; stimulants; cardiovascular events; drug safety; pharmacoepidemiology ID DEFICIT-HYPERACTIVITY DISORDER; ACUTE MYOCARDIAL-INFARCTION; TACHYCARDIA-INDUCED CARDIOMYOPATHY; POSITIVE PREDICTIVE-VALUE; BLOOD-PRESSURE; CHILDREN; DISEASE; ADHD; ADOLESCENTS; STROKE AB Objective: This study examined associations between stimulant use and risk of cardiovascular events and symptoms in youth with attention-deficit/hyperactivity disorder and compared the risks associated with methylphenidate and amphetamines. Method: Claims were reviewed of privately insured young people 6 to 21 years old without known cardiovascular risk factors (n = 171,126). A day-level cohort analysis evaluated the risk of cardiovascular events after a diagnosis of attention-deficit/hyperactivity disorder in relation to stimulant exposures. Based on filled stimulant prescriptions, follow-up days were classified as current, past, and no stimulant use. Endpoints included an emergency department or inpatient diagnosis of angina pectoris, cardiac dysrhythmia, or transient cerebral ischemia (cardiac events) or tachycardia, palpitations, or syncope (cardiac symptoms). Results: There were 0.92 new cardiac events and 3.08 new cardiac symptoms per 1,000,000 days of current stimulant use. Compared with no stimulant use (reference group), the adjusted odds ratios of cardiac events were 0.69 (95% confidence interval 0.42-1.12) during current stimulant use and 1.18 (95% CI 0.83-1.66) during past stimulant use. The corresponding adjusted odds ratios for cardiac symptoms were 1.18 (95% CI 0.89-1.59) for current and 0.93 (95% CI 0.71-1.21) for past stimulant use. No significant differences were observed in risks of cardiovascular events (2.14, 95% CI 0.82-5.63) or symptoms (1.08, 95% CI 0.66-1.79) for current methylphenidate use compared with amphetamine use (reference group). Conclusions: Clinical diagnoses of cardiovascular events and symptoms were rare and not associated with stimulant use. The results help to allay concerns over the cardiovascular safety of stimulant treatment for attention-deficit/hyperactivity disorder in young people without known pre-existing risk factors. J. Am. Acad. Child Adolesc. Psychiatry, 2012;51(2):147-156. C1 [Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Olfson, Mark] Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA. [Huang, Cecilia; Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, Piscataway, NJ 08855 USA. [Gerhard, Tobias] Rutgers State Univ, Ernest Mario Sch Pharm, Piscataway, NJ 08855 USA. [Winterstein, Almut G.] Univ Florida, Coll Pharm, Gainesville, FL USA. [Winterstein, Almut G.] Univ Florida, Coll Med & Publ Hlth, Gainesville, FL USA. [Winterstein, Almut G.] Univ Florida, Coll Hlth Profess, Gainesville, FL USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Olfson, M (reprint author), New York State Psychiat Inst & Hosp, 1051 Riverside Dr, New York, NY 10032 USA. EM mo49@columbia.edu RI Allison, Paul/A-1345-2007; winterstein, Almut/A-3017-2014 OI Allison, Paul/0000-0002-0646-5242; winterstein, Almut/0000-0002-6518-5961 FU National Institute of Mental Health [R21 MH079905]; Agency for Healthcare Research and Quality [U18 HS016097]; Center for Education and Research on Mental Health Therapeutics; Eli Lilly and Co.; Bristol-Myers Squibb; Ortho-McNeil Janssen FX This study was supported by National Institute of Mental Health grant R21 MH079905, Agency for Healthcare Research and Quality award U18 HS016097, and the Center for Education and Research on Mental Health Therapeutics.; Dr. Olfson has received research grants to Columbia University from Eli Lilly and Co. and Bristol-Myers Squibb. Dr. Marcus has received grant support from Ortho-McNeil Janssen and has served as a consultant to AstraZeneca. Drs. Huang, Gerhard, Winterstein, Crystal, and Allison report no biomedical financial interests or potential conflicts of interest. NR 61 TC 30 Z9 30 U1 1 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD FEB PY 2012 VL 51 IS 2 BP 147 EP 156 DI 10.1016/j.jaac.2011.11.008 PG 10 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 882YD UT WOS:000299598900006 PM 22265361 ER PT J AU Bridge, JA Marcus, SC Olfson, M AF Bridge, Jeffrey A. Marcus, Steven C. Olfson, Mark TI Outpatient Care of Young People After Emergency Treatment of Deliberate Self-Harm SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE deliberate self-harm; emergency care; outpatient mental health care; young people; suicide ID MENTAL-HEALTH-SERVICES; ADOLESCENT SUICIDE; INJURY; ATTEMPTERS; ACCIDENT AB Objective: Little is known about the mental health care received by young people after an episode of deliberate self-harm. This study examined predictors of emergency department (ED) discharge, mental health assessments in the ED, and follow-up outpatient mental health care for Medicaid-covered youth with deliberate self-harm. Method: A retrospective longitudinal cohort analysis was conducted of national 2006 Medicaid claims data supplemented with the Area Resource File and a Substance Abuse and Mental Health Services Administration Medicaid policy survey of state policy characteristics focusing on ED treatment episodes by youth 10 to 19 years old for deliberate self-harm (n = 3,241). Rates and adjusted risk ratios (ARR) of discharge to the community, mental health assessments in the ED, and outpatient visits during the 30 days after the ED visit were assessed. Results: Most patients (72.9%) were discharged to the community. Discharge was inversely related to recent psychiatric hospitalization (ARR 0.75, 99% confidence interval [CI] 0.63-0.90). Thirty-nine percent of discharged patients received a mental health assessment in the ED and a roughly similar percentage (43.0%) received follow-up outpatient mental health care. Follow-up mental health care was directly related to recent outpatient (ARR 2.58, 99% CI 2.27-2.94) and inpatient (ARR 1.33, 99% CI 1.14-1.56) mental health care and inversely related to Hispanic ethnicity (ARR 0.78, 99% CI 0.64-0.95) and residence in a county with medium-to-high poverty rates (ARR 0.84, 99% CI 0.73 0.97). Conclusions: A substantial proportion of young Medicaid beneficiaries who present to EDs with deliberate self-harm are discharged to the community and do not receive emergency mental health assessments or follow-up outpatient mental health care. J. Am. Acad. Child Adolesc. Psychiatry, 2012;51(2):213-222. C1 [Olfson, Mark] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA. [Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Bridge, Jeffrey A.] Ohio State Univ, Ctr Innovat Pediat Practice, Nationwide Childrens Hosp, Res Inst, Columbus, OH 43210 USA. [Marcus, Steven C.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Olfson, M (reprint author), Columbia Univ, Coll Phys & Surg, Dept Psychiat, 1051 Riverside Dr, New York, NY 10032 USA. EM mo49@columbia.edu FU American Foundation for Suicide Prevention; Eli Lilly and Co.; Bristol-Myers Squibb; Ortho-McNeil Janssen FX This research was funded by a grant to Columbia University from the American Foundation for Suicide Prevention (MO).; Dr. Olfson has received research grants to Columbia University from Eli Lilly and Co. and Bristol-Myers Squibb. Dr. Marcus has received grant support from Ortho-McNeil Janssen and has served as a consultant to AstraZeneca. Dr. Bridge reports no biomedical financial interests or potential conflicts of interest. NR 36 TC 21 Z9 21 U1 4 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD FEB PY 2012 VL 51 IS 2 BP 213 EP 222 DI 10.1016/j.jaac.2011.11.002 PG 10 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 882YD UT WOS:000299598900012 PM 22265367 ER PT J AU Covington, MD Schnellmann, RG AF Covington, Marisa D. Schnellmann, Rick G. TI Chronic high glucose downregulates mitochondrial calpain 10 and contributes to renal cell death and diabetes-induced renal injury SO KIDNEY INTERNATIONAL LA English DT Article DE acute kidney injury; apoptosis; diabetic nephropathy; hyperglycemia; mitochondria ID INSULIN-SECRETION; KIDNEY; NEPHROPATHY; EXPRESSION; APOPTOSIS; SIRNA; RAT; TRANSLOCATION; ACTIVATION; CULTURE AB Whereas most calpains are cytosolic proteases, calpain 10 is resident in mitochondria and is important in mitochondria! homeostasis. Because calpain 10 has been implicated in type 2 diabetes, we studied its possible role in diabetes-induced renal dysfunction. We treated renal proximal tubular cells with high glucose (17 mmol/l) and found decreased mitochondrial calpain 10 mRNA and protein at 96h compared with cells incubated with 0 or 5 mmol/l glucose or 17 mmol/l D-mannitol. High glucose increased mitochondrial calpain 10 substrates (NDUFB8 and ATP synthase p), decreased basal and uncoupled respiration, and initiated cell apoptosis as indicated by cleaved caspase 3 and nuclear condensation. Renal calpain 10 protein and mRNA were specifically decreased in streptozotocin-induced diabetic rats with kidney dysfunction, and in diabetic ob/ob mice. In agreement with our in vitro data, the kidneys of streptozotocin-induced diabetic rats had elevated calpain 10 substrates and cleaved caspase 3. Finally, specific siRNA-induced knockdown of calpain 10 in the proximal tubules of control rats resulted in decreased renal function as evidenced by increased serum creatinine, and increased caspase 3 cleavage compared with rats receiving scrambled siRNA. Thus, the glucose-induced loss of calpain 10 in vivo results in renal cell apoptosis and organ failure through accumulation of mitochondrial calpain 10 substrates and mitochondrial dysfunction. Whether this is a major cause of the decreased renal function in diabetic nephropathy will require further studies. Kidney International (2012) 81, 391-400; doi:10.1038/ki.2011.356; published online 19 October 2011 C1 [Covington, Marisa D.; Schnellmann, Rick G.] Med Univ S Carolina, Ctr Cell Death Injury & Regenerat, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Ctr Cell Death Injury & Regenerat, Dept Pharmaceut & Biomed Sci, 280 Calhoun St,POB 250140, Charleston, SC 29425 USA. EM schnell@musc.edu FU NIEHS [ES-012239]; NIGMS [GM-084147]; Biomedical Laboratory of the Department of Veterans Affairs; National Institutes of Health [T32 HL007260, C06 RR-015455] FX This research was supported by NIEHS grant ES-012239 (to RGS) and NIGMS grant GM-084147 (to RGS), and by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. MDC was supported by the National Institutes of Health Training grant T32 HL007260. Animal facilities were funded by NIH grant C06 RR-015455. NR 35 TC 21 Z9 25 U1 1 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD FEB PY 2012 VL 81 IS 4 BP 391 EP 400 DI 10.1038/ki.2011.356 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 886JJ UT WOS:000299850400009 PM 22012129 ER PT J AU Tosun, D Rosen, H Miller, BL Weiner, MW Schuff, N AF Tosun, Duygu Rosen, Howard Miller, Bruce L. Weiner, Michael W. Schuff, Norbert TI MRI patterns of atrophy and hypoperfusion associations across brain regions in frontotemporal dementia SO NEUROIMAGE LA English DT Article DE Brain atrophy; Brain hypoperfusion; Dementia; Neurodegenerative diseases; Joint ICA; Multimodality MRI ID MILD COGNITIVE IMPAIRMENT; CEREBRAL-BLOOD-FLOW; ALZHEIMERS-DISEASE; LOBAR DEGENERATION; SEMANTIC DEMENTIA; CORTICOBASAL DEGENERATION; SUPRANUCLEAR PALSY; GLUCOSE-METABOLISM; PERFUSION MRI; IMAGING DATA AB Magnetic Resonance Imaging (MRI) provides various imaging modes to study the brain. We tested the benefits of a joint analysis of multimodality MRI data in combination with a large-scale analysis that involved simultaneously all image voxels using joint independent components analysis (jICA) and compared the outcome to results using conventional voxel-by-voxel unimodality tests. Specifically, we designed a jICA to decompose multimodality MRI data into independent components that explain joint variations between the image modalities as well as variations across brain regions. We tested the jICA design on structural and perfusion-weighted MRI data from 12 patients diagnosed with behavioral variant frontotemporal dementia (bvFTD) and 12 cognitively normal elderly individuals. While unimodality analyses showed widespread brain atrophy and hypoperfusion in the patients, jICA further revealed two significant joint components of variations between atrophy and hypoperfusion across brain regions. The 1st joint component revealed associated brain atrophy and hypoperfusion predominantly in the right brain hemisphere in behavioral variant frontotemporal dementia, and the 2nd joint component revealed greater atrophy relative to hypoperfusion affecting predominantly the left hemisphere in behavioral variant frontotemporal dementia. The patterns are consistent with the clinical symptoms of behavioral variant frontotemporal dementia that relate to asymmetric compromises of the left and right brain hemispheres. The joint components also revealed that that structural alterations can be associated with physiological alterations in spatially separated but potentially connected brain regions. Finally, jICA outperformed voxel-by-voxel unimodal tests significantly in terms of an effect size, separating the behavioral variant frontotemporal dementia patients from the controls. Taken together, the results demonstrate the benefit of multimodality MRI in conjunction with jICA for mapping neurodegeneration, which may lead ultimately to an improved diagnosis of behavioral variant frontotemporal dementia and other forms of neurodegenerative diseases. (C) 2011 Elsevier Inc. All rights reserved. C1 [Tosun, Duygu; Weiner, Michael W.; Schuff, Norbert] Vet Affairs Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Rosen, Howard; Miller, Bruce L.] Univ Calif San Francisco, Memory & Aging Ctr, San Francisco, CA 94143 USA. [Rosen, Howard; Miller, Bruce L.; Weiner, Michael W.; Schuff, Norbert] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Tosun, Duygu; Weiner, Michael W.; Schuff, Norbert] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. RP Tosun, D (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Bldg 13,114M, San Francisco, CA 94121 USA. EM duygu.tosun@ucsf.edu FU National Institutes of Health [P41 RR23953, P01 AG019724]; Department of Defense [W81XWH-05-2-0094] FX This work was supported by the National Institutes of Health grant P41 RR23953 and P01 AG019724, and the Department of Defense grant W81XWH-05-2-0094. This work has also been made possible by use of research facilities at the Veteran Affairs Medical Center in San Francisco. NR 57 TC 9 Z9 10 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD FEB 1 PY 2012 VL 59 IS 3 BP 2098 EP 2109 DI 10.1016/j.neuroimage.2011.10.031 PG 12 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 881NS UT WOS:000299494000013 PM 22036676 ER PT J AU Jonker, MA Hermsen, JL Sano, Y Heneghan, AF Lan, JG Kudsk, KA AF Jonker, Mark A. Hermsen, Joshua L. Sano, Yoshifumi Heneghan, Aaron F. Lan, Jinggang Kudsk, Kenneth A. TI Small intestine mucosal immune system response to injury and the impact of parenteral nutrition SO SURGERY LA English DT Article ID POLYMERIC IMMUNOGLOBULIN RECEPTOR; VENTILATOR-ASSOCIATED PNEUMONIA; ENTERAL NUTRITION; SECRETORY IGA; BACTERIAL TRANSLOCATION; SEPTIC MORBIDITY; ABDOMINAL-TRAUMA; LYMPHOID-TISSUE; RISK-FACTORS; ILL PATIENTS AB Background. Both humans and mice increase airway immunoglobulin A (IgA) after injury. This protective response is associated with TNF-alpha, IL-1 beta, and IL-6 airway increases and in mice is dependent upon these cytokines as well as enteral feeding. Parenteral nutrition (PN) with decreased enteral stimulation (DES) alters gut barrier function, decreases intestinal IgA, and decreases the principal IgA transport protein pIgR. We investigated the small intestine (SI) IgA response to injury and the role of TNT-alpha, IL-1 beta, IL-6, and PN/DES. Methods. Expt 1: Murine kinetics of SI washing fluid (SIWF) IgA; SI, SIWF and serum TNT-alpha, IL-1 beta, and IL-6, was determined by ELISA from 0 to 8 hours after a limited surgical stress injury (laparotomy and neck incisions). Expt 2: Mice received chow or PN/DES before injury and SIWF IgA and SI pIgR levels were determined at 0 and 8 hours. Expt 3: Mice received PBS, TNT-alpha antibody, or IL-1 beta antibody 30 minutes before injury to measure effects on the SIWF IgA response. Expt 4: Mice received injury or exogenous TNF-alpha, IL-1 beta, and IL-6 to measure effects on the SIWF IgA response. Results. Expt 1: SIWF IgA levels increased significantly by 2 hours after injury without associated increases in TNT-alpha or IL-1 beta whereas IL-6 was only increased at 1 hour after injury. Expt 2: PN/DES significantly reduced baseline SIWF IgA and SI pIgR and eliminated their increase after injury seen in Chow mice. Expt 3: TNT-alpha and IL-1 beta blockade did not affect the SIWF IgA increase after injury. Expt 4: Exogenous TNT-alpha, IL-1 beta, and IL-6 increased SIWF IgA similarly to injury. Conclusion. The SI mucosal immune responds to injury or exogenous TNF-alpha, IL-1 beta, and IL-6 with an increase in lumen IgA, although it does not rely on local SI increases in TNT-alpha or IL-1 beta as it does in the lung. Similar to the lung, the IgA response is eliminated with.PN/DES. (Surgery 2012;151:278-86.) C1 [Sano, Yoshifumi; Heneghan, Aaron F.; Lan, Jinggang; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI USA. [Sano, Yoshifumi; Heneghan, Aaron F.; Lan, Jinggang; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Dept Surg, Madison, WI USA. [Jonker, Mark A.; Hermsen, Joshua L.; Sano, Yoshifumi; Heneghan, Aaron F.; Lan, Jinggang; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU National Institutes of Health [R01 GM53439] FX Supported by National Institutes of Health Grant R01 GM53439 and also based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Service. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 44 TC 12 Z9 15 U1 0 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD FEB PY 2012 VL 151 IS 2 BP 278 EP 286 DI 10.1016/j.surg.2010.10.013 PG 9 WC Surgery SC Surgery GA 883BO UT WOS:000299607800017 PM 21145571 ER PT J AU Garvey, WT Ryan, DH Look, M Gadde, KM Allison, DB Peterson, CA Schwiers, M Day, WW Bowden, CH AF Garvey, W. Timothy Ryan, Donna H. Look, Michelle Gadde, Kishore M. Allison, David B. Peterson, Craig A. Schwiers, Michael Day, Wesley W. Bowden, Charles H. TI Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID CARDIOVASCULAR RISK-FACTORS; IMPAIRED GLUCOSE-TOLERANCE; DOUBLE-BLIND; LIFE-STYLE; TOPIRAMATE; EFFICACY; SAFETY; COMBINATION; PREVENTION; MANAGEMENT AB Background: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with >= 2 weight-related comorbidities. Objective: This study evaluated the long-term efficacy and safety of PHEN/TPM CR in overweight and obese subjects with cardiometabolic disease. Design: This was a placebo-controlled, double-blind, 52-wk extension study; volunteers at selected sites continued with original randomly assigned treatment [placebo, 7.5 mg phentermine/46 mg controlled-release topiramate (7.5/46), or 15 mg phentermine/92 mg controlled-release topiramate (15/92)] to complete a total of 108 wk. All subjects participated in a lifestyle-modification program. Results: Of 866 eligible subjects, 676 (78%) elected to continue in the extension. Overall, 84.0% of subjects completed the study, with similar completion rates between treatment groups. At week 108, PHEN/TPM CR was associated with significant, sustained weight loss (intent-to-treat with last observation carried forward; P < 0.0001 compared with placebo); least-squares mean percentage changes from baseline in body weight were -1.8%, -9.3%, and -10.5% for placebo, 7.5/46, and 15/92, respectively. Significantly more PHEN/TPM CR-treated subjects at each close achieved >= 5%, >= 10%, >= 15%, and >= 20% weight loss compared with placebo (P < 0.001). PHEN/TPM CR improved cardiovascular and metabolic variables and decreased rates of incident diabetes in comparison with placebo. PHEN/TPM CR was well tolerated over 108 wk, with reduced rates of adverse events occurring between weeks 56 and 108 compared with rates between weeks 0 and 56. Conclusion: PHEN/TPM CR in conjunction with lifestyle modification may provide a well-tolerated and effective option for the sustained treatment of obesity complicated by cardiometabolic disease. This trial was registered at clinicaltrials.gov as NCT00796367. Am J Clin Nutr 2012;95:297-308. C1 [Garvey, W. Timothy] Univ Alabama, Dept Nutr Sci, UAB Diabet Res & Training Ctr, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Univ Alabama, Dept Med, UAB Diabet Res & Training Ctr, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. [Ryan, Donna H.] Pennington Biomed Res Ctr, Baton Rouge, LA USA. [Look, Michelle] San Diego Sports Med, San Diego, CA USA. [Gadde, Kishore M.] Duke Univ, Med Ctr, Obes Clin Trials Program, Durham, NC USA. [Allison, David B.] Univ Alabama, Dept Biostat, UAB Nutr & Obes Res Ctr, Birmingham, AL 35294 USA. [Peterson, Craig A.; Day, Wesley W.; Bowden, Charles H.] Vivus Inc, Mountain View, CA USA. [Schwiers, Michael] Medpace, Cincinnati, OH USA. RP Garvey, WT (reprint author), Univ Alabama, Dept Nutr Sci, UAB Diabet Res & Training Ctr, Webb 232,1675 Univ Blvd, Birmingham, AL 35294 USA. EM garveyt@uab.edu OI Allison, David/0000-0003-3566-9399 FU Vivus Inc; Forest Laboratories; National Institute of Diabetes and Digestive and Kidney Diseases FX Vivus Inc provided funding and essential materials for this study.; The authors' responsibilities were as follows-KMG, DBA, DHR, MS, CAP, WWD, and CHB: designed the research; WTG, KMG, and ML: conducted the research; WTG, KMG, DBA, DHR, CAP, MS, WWD, and CHB: analyzed and interpreted data; WTG, DHR, ML, KMG, DBA, CAP, MS, WWD, and CHB: drafted and edited the manuscript; and MS: had primary responsibility for final content and is the guarantor of the manuscript, having had full access to all of the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. The external authors as well as those employed by the funding sponsor participated in protocol design, data analyses, interpretation, and preparation of the manuscript. WTG participated in clinical trials with Merck & Co, Inc; Amylin Pharmaceuticals; Vivus Inc; Abbott; and Daiichi-Sankyo. He has served as an advisor, consultant, and/or speaker for Abbott Nutrition, Daiichi-Sankyo, Johnson & Johnson, LipoScience, Tethys, and Vivus Inc. He is a scientific advisory board member for Daiichi-Sankyo and Tethys, and he holds stock in Bristol-Myers Squibb; Isis/Genzyme; Merck & Co, Inc; Pfizer Inc; Novartis Pharmaceuticals Corp; and Vivus Inc. DHR served as a consultant for Vivus but did not receive any payment for service. ML is a scientific advisory board member for Vivus Inc. KMG received research support from Forest Laboratories, the National Institute of Diabetes and Digestive and Kidney Diseases, and Vivus Inc and owns stock in Orexigen Therapeutics. DBA received grants, honoraria, donations, and consulting fees from numerous food, beverage, and pharmaceutical companies, as well as other commercial and nonprofit entities with interests in obesity, including but not limited to Arena Pharmaceuticals, Jason Pharmaceuticals Inc, Pfizer Inc, and Vivus Inc. He served as a board member for the Pfizer Inc VPO program. WWD, CHB, and CAP are employees of Vivus Inc. MS was employed as the lead statistician for Medpace Inc, the study Contract Research Organization, throughout the study design, execution, and analysis; he had no additional conflicts to disclose. NR 34 TC 186 Z9 188 U1 1 U2 23 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD FEB PY 2012 VL 95 IS 2 BP 297 EP 308 DI 10.3945/ajcn.111.024927 PG 12 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 883QC UT WOS:000299647800007 PM 22158731 ER PT J AU Spellberg, B Lipsky, BA AF Spellberg, Brad Lipsky, Benjamin A. TI Systemic Antibiotic Therapy for Chronic Osteomyelitis in Adults SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; GRAM-NEGATIVE BACILLI; INFECTED ORTHOPEDIC IMPLANTS; MULTIPLE-DOSE PHARMACOKINETICS; PROSTHETIC JOINT INFECTIONS; ORAL CIPROFLOXACIN THERAPY; DIABETIC FOOT INFECTIONS; SOFT-TISSUE INFECTIONS; TRIMETHOPRIM-SULFAMETHOXAZOLE; PSEUDOMONAS-AERUGINOSA AB The standard recommendation for treating chronic osteomyelitis is 6 weeks of parenteral antibiotic therapy. However, oral antibiotics are available that achieve adequate levels in bone, and there are now more published studies of oral than parenteral antibiotic therapy for patients with chronic osteomyelitis. Oral and parenteral therapies achieve similar cure rates; however, oral therapy avoids risks associated with intravenous catheters and is generally less expensive, making it a reasonable choice for osteomyelitis caused by susceptible organisms. Addition of adjunctive rifampin to other antibiotics may improve cure rates. The optimal duration of therapy for chronic osteomyelitis remains uncertain. There is no evidence that antibiotic therapy for >4-6 weeks improves outcomes compared with shorter regimens. In view of concerns about encouraging antibiotic resistance to unnecessarily prolonged treatment, defining the optimal route and duration of antibiotic therapy and the role of surgical debridement in treating chronic osteomyelitis are important, unmet needs. C1 [Spellberg, Brad] Harbor UCLA Med Ctr, Div Gen Internal Med, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA. [Spellberg, Brad] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Lipsky, Benjamin A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Lipsky, Benjamin A.] Univ Washington, Seattle, WA 98195 USA. RP Spellberg, B (reprint author), Harbor UCLA Med Ctr, Div Gen Internal Med, Los Angeles Biomed Res Inst, 1124 W Carson St,Liu Vaccine Bldg, Torrance, CA 90502 USA. EM bspellberg@labiomed.org OI Lipsky, Benjamin A./0000-0001-9886-5114 FU Gilead; Astellas; Novartis; Cubist; GlaxoSmithKline; Pfizer; Basilea; Medicines Company; Achaogen; Eisai; Meiji; Polymedix FX B. S. has received clinical trial grant/contract support from Gilead, Astellas, Novartis, and Cubist and consulting fees from GlaxoSmithKline, Pfizer, Basilea, The Medicines Company, Achaogen, Eisai, Meiji, and Polymedix. B. A. L. has received grant support or provided consultation to the following: Pfizer, Merck, Cubist, and Johnson & Johnson. NR 172 TC 66 Z9 72 U1 4 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2012 VL 54 IS 3 BP 393 EP 407 DI 10.1093/cid/cir842 PG 15 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 876SM UT WOS:000299128000021 PM 22157324 ER PT J AU Wiederhold, NP Najvar, LK Bocanegra, R Kirkpatrick, WR Patterson, TF AF Wiederhold, N. P. Najvar, L. K. Bocanegra, R. Kirkpatrick, W. R. Patterson, T. F. TI Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Article DE Anidulafungin; Candida albicans; candidiasis; fluconazole; neutropenia ID MURINE DISSEMINATED CANDIDIASIS; IMMUNE-SYSTEM; CASPOFUNGIN; ASPERGILLUS; ANTIFUNGAL; LY303366; ALBICANS; MICE AB We compared the rate and extent of anidulafungins and fluconazoles activity in neutropenic and non-neutropenic mice with Candida albicans invasive candidiasis. In immunocompetent mice, anidulafungin significantly improved survival vs. controls and fluconazole, and significant reductions in (1 -> 3)-beta-D-glucan and fungal burden were observed. In neutropenic animals, the highest doses of anidulafungin (5 mg/kg) and fluconazole (10 mg/kg) also improved survival and reduced fungal burden. However, there were no differences in survival between these antifungals as anidulafungins activity was attenuated in this model. These results demonstrate that the extent of anidulafungin in vivo efficacy may be dependent on host immune status. C1 [Wiederhold, N. P.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Wiederhold, N. P.; Najvar, L. K.; Bocanegra, R.; Kirkpatrick, W. R.; Patterson, T. F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Najvar, L. K.; Bocanegra, R.; Kirkpatrick, W. R.; Patterson, T. F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Wiederhold, NP (reprint author), UTHSCSA, PERC MSC 6220,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM wiederholdn@uthscsa.edu OI Wiederhold, Nathan/0000-0002-2225-5122 FU Pfizer, Inc.; Pfizer; Schering-Plough; Merck; Basilea; Astellas FX Funding for this study was provided by Pfizer, Inc. NPW has received research support from Pfizer, Schering-Plough, Merck, Basilea and Astellas, and travel support from Viamet. He has also served as a consultant for Merck, Astellas and Viamet. TFP has received research support from Basilea, Astellas, Merck, Pfizer and Schering-Plough, and has served as a consultant for Basilea, Astellas, Merck, Pfizer, Toyama and Viamet. NR 17 TC 4 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1198-743X EI 1469-0691 J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD FEB PY 2012 VL 18 IS 2 BP E20 EP E23 DI 10.1111/j.1469-0691.2011.03712.x PG 4 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 879MW UT WOS:000299335000002 PM 22128831 ER PT J AU Peters, EJG Lipsky, BA Berendt, AR Embil, JM Lavery, LA Senneville, E Urbancic-Rovan, V Bakker, K Jeffcoate, WJ AF Peters, E. J. G. Lipsky, B. A. Berendt, A. R. Embil, J. M. Lavery, L. A. Senneville, E. Urbancic-Rovan, V. Bakker, K. Jeffcoate, W. J. TI A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Article; Proceedings Paper CT 6th International Symposium on the Diabetic Foot CY MAY 10-14, 2011 CL Noordwijkerhout, NETHERLANDS DE diabetes mellitus; diabetic foot; infection; osteomyelitis; antibiotics; surgery; systematic review ID COLONY-STIMULATING FACTOR; SKIN-STRUCTURE INFECTIONS; RANDOMIZED-CONTROLLED-TRIAL; HYPERBARIC-OXYGEN THERAPY; SOFT-TISSUE INFECTIONS; OPEN-LABEL TRIAL; COMPLICATED SKIN; PIPERACILLIN-TAZOBACTAM; ANTIBIOTIC-THERAPY; MULTICENTER TRIAL AB The International Working Group on the Diabetic Foot expert panel on infection conducted a systematic review of the published evidence relating to treatment of foot infection in diabetes. Our search of the literature published prior to August 2010 identified 7517 articles, 29 of which fulfilled predefined criteria for detailed data extraction. Four additional eligible papers were identified from other sources. Of the total of 33 studies, 29 were randomized controlled trials, and four were cohort studies. Among 12 studies comparing different antibiotic regimens in the management of skin and soft-tissue infection, none reported a better responsewith any particular regimen. Of seven studies that compared antibiotic regimens in patients with infection involving both soft tissue and bone, one reported a better clinical outcome in those treated with cefoxitin compared with ampicillin/ sulbactam, but the others reported no differences between treatment regimens. In two health economic analyses, there was a small saving using one regimen versus another. No published data support the superiority of any particular route of delivery of systemic antibiotics or clarify the optimal duration of antibiotic therapy in either soft-tissue infection or osteomyelitis. In one non-randomized cohort study, the outcome of treatment of osteomyelitis was better when the antibiotic choice was based on culture of bone specimens as opposed to wound swabs, but this study was not randomized, and the results may have been affected by confounding factors. Results from two studies suggested that early surgical intervention was associated with a significant reduction in major amputation, but the methodological quality of both was low. In two studies, the use of superoxidized water was associated with a better outcome than soap or povidone iodine, but both had a high risk of bias. Studies using granulocyte-colony stimulating factor reported mixed results. There was no improvement in infection outcomes associated with hyperbaric oxygen therapy. No benefit has been reported with any other intervention, and, overall, there are currently no trial data to justify the adoption of any particular therapeutic approach in diabetic patients with infection of either soft tissue or bone of the foot. Copyright (C) 2012 John Wiley & Sons, Ltd. C1 [Peters, E. J. G.] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, NL-1007 MB Amsterdam, Netherlands. [Lipsky, B. A.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Berendt, A. R.] Oxford Univ Hosp NHS Trust, Oxford, England. [Embil, J. M.] Univ Manitoba, Winnipeg, MB, Canada. [Lavery, L. A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Lavery, L. A.] Parkland Hosp, Dallas, TX USA. [Senneville, E.] Gustave Dron Hosp, Tourcoing, France. [Urbancic-Rovan, V.] Univ Med Ctr, Ljubljana, Slovenia. [Bakker, K.] IWGDF, Heemstede, Netherlands. [Jeffcoate, W. J.] Nottingham Univ Hosp Trust, Nottingham, England. RP Peters, EJG (reprint author), Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, Room ZH-4A35,POB 7057, NL-1007 MB Amsterdam, Netherlands. EM e.peters@vumc.nl RI Peters, Edgar /B-7790-2014 OI Lipsky, Benjamin A./0000-0001-9886-5114; Lavery, Lawrence/0000-0002-7920-9952 NR 43 TC 37 Z9 38 U1 0 U2 25 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1520-7552 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD FEB PY 2012 VL 28 SU 1 BP 142 EP 162 DI 10.1002/dmrr.2247 PG 21 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 880AY UT WOS:000299377700025 PM 22271738 ER PT J AU Lipsky, BA Peters, EJG Senneville, E Berendt, AR Embil, JM Lavery, LA Urbancic-Rovan, V Jeffcoate, WJ AF Lipsky, B. A. Peters, E. J. G. Senneville, E. Berendt, A. R. Embil, J. M. Lavery, L. A. Urbancic-Rovan, V. Jeffcoate, W. J. TI Expert opinion on the management of infections in the diabetic foot SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Article; Proceedings Paper CT 6th International Symposium on the Diabetic Foot CY MAY 10-14, 2011 CL Noordwijkerhout, NETHERLANDS DE diabetes mellitus; diabetic foot; infection; osteomyelitis; antibiotics; surgery; systematic review ID RESISTANT STAPHYLOCOCCUS-AUREUS; TO-BONE TEST; SOFT-TISSUE INFECTIONS; CLASSIFICATION-SYSTEM; SURGICAL-TREATMENT; NUCLEAR-MEDICINE; LOWER-EXTREMITY; RISK-FACTORS; UNSUSPECTED OSTEOMYELITIS; CONSERVATIVE MANAGEMENT AB This update of the International Working Group on the Diabetic Foot incorporates some information from a related review of diabetic foot osteomyelitis (DFO) and a systematic review of the management of infection of the diabetic foot. The pathophysiology of these infections is now well understood, and there is a validated system for classifying the severity of infections based on their clinical findings. Diagnosing osteomyelitis remains difficult, but several recent publications have clarified the role of clinical, laboratory and imaging tests. Magnetic resonance imaging has emerged as the most accurate means of diagnosing bone infection, but bone biopsy for culture and histopathology remains the criterion standard. Determining the organisms responsible for a diabetic foot infection via culture of appropriately collected tissue specimens enables clinicians to make optimal antibiotic choices based on culture and sensitivity results. In addition to culture-directed antibiotic therapy, most infections require some surgical intervention, ranging from minor debridement to major resection, amputation or revascularization. Clinicians must also provide proper wound care to ensure healing of the wound. Various adjunctive therapies may benefit some patients, but the data supporting them are weak. If properly treated, most diabetic foot infections can be cured. Providers practising in developing countries, and their patients, face especially challenging situations. Copyright (C) 2012 John Wiley & Sons, Ltd. C1 [Lipsky, B. A.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Peters, E. J. G.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands. [Senneville, E.] Gustave Dron Hosp, Tourcoing, France. [Berendt, A. R.] Oxford Univ Hosp NHS Trust, Bone Infect Unit, Nuffield Orthopaed Ctr, Oxford, England. [Embil, J. M.] Univ Manitoba, Winnipeg, MB, Canada. [Lavery, L. A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Lavery, L. A.] Parkland Hosp, Dallas, TX USA. [Urbancic-Rovan, V.] Univ Med Ctr, Ljubljana, Slovenia. [Jeffcoate, W. J.] Nottingham Univ Hosp Trust, Nottingham, England. RP Lipsky, BA (reprint author), Univ Washington, Director Primary Care Clin, VA Puget Sound, VA Puget Sound Syst, 1660 S Columbian Way S-123-GMS, Seattle, WA 98108 USA. EM dblipsky@hotmail.com RI Peters, Edgar /B-7790-2014 OI Lipsky, Benjamin A./0000-0001-9886-5114; Lavery, Lawrence/0000-0002-7920-9952 NR 160 TC 78 Z9 79 U1 0 U2 22 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1520-7552 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD FEB PY 2012 VL 28 SU 1 BP 163 EP 178 DI 10.1002/dmrr.2248 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 880AY UT WOS:000299377700026 PM 22271739 ER PT J AU Lipsky, BA Peters, EJG Berendt, AR Senneville, E Bakker, K Embil, JM Lavery, LA Urbancic-Rovan, V Jeffcoate, WJ AF Lipsky, B. A. Peters, E. J. G. Berendt, A. R. Senneville, E. Bakker, K. Embil, J. M. Lavery, L. A. Urbancic-Rovan, V. Jeffcoate, W. J. TI Specific guidelines for the treatment of diabetic foot infections 2011 SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Editorial Material DE diabetes mellitus; diabetic foot; infection; osteomyelitis; antibiotics; surgery; systematic review C1 [Lipsky, B. A.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Peters, E. J. G.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands. [Berendt, A. R.] Nuffield Orthopaed Ctr, Oxford OX3 7LD, England. [Senneville, E.] Gustave Dron Hosp, Tourcoing, France. [Bakker, K.; Embil, J. M.] IWGDF, Heemstede, Netherlands. [Lavery, L. A.] Univ Manitoba, Winnipeg, MB, Canada. [Urbancic-Rovan, V.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Urbancic-Rovan, V.] Parkland Hosp, Dallas, TX USA. [Jeffcoate, W. J.] Univ Med Ctr, Ljubljana, Slovenia. [Jeffcoate, W. J.] Nottingham Univ Hosp NHS Trust, Nottingham, England. RP Lipsky, BA (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way S-123 GMS, Seattle, WA 98108 USA. EM dblipsky@hotmail.com RI Peters, Edgar /B-7790-2014 OI Lipsky, Benjamin A./0000-0001-9886-5114; Lavery, Lawrence/0000-0002-7920-9952 NR 0 TC 28 Z9 30 U1 0 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1520-7552 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD FEB PY 2012 VL 28 SU 1 BP 234 EP 235 DI 10.1002/dmrr.2251 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 880AY UT WOS:000299377700031 PM 22271744 ER PT J AU Hershcovici, T Poh, CH Fass, OZ Ashpole, N Akiba, Y Guillen-Rodriguez, JM Kaunitz, JD Fass, R AF Hershcovici, Tiberiu Poh, Choo H. Fass, Ofer Z. Ashpole, Nicole Akiba, Yasutada Guillen-Rodriguez, Jose M. Kaunitz, Jonathan D. Fass, Ronnie TI Oesophageal sensation in response to high PCO2 and acidic solutions in nonerosive reflux disease SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION LA English DT Article DE Acid perfusion; heartburn; high PCO2 solution; nonerosive reflux disease ID PROTON PUMP INHIBITOR; HEALTH SURVEY QUESTIONNAIRE; TRPV1 GENE-EXPRESSION; CARBONIC-ANHYDRASE; BICARBONATE SECRETION; GASTRIC-JUICE; RAT ESOPHAGUS; EPITHELIUM; IMPEDANCE; SYMPTOMS AB Background Heartburn is commonly associated with the presence of acid in the oesophageal lumen. However, in patients with nonerosive reflux disease (NERD), the mechanism by which acid traverses the mucosa is not clear. We hypothesized that the luminal acid signal traverses the oesophageal epithelium in the form of the highly permeant gas CO2, which then is reconverted to H+ in the submucosa. Materials and methods Ten patients with heartburn, normal upper endoscopy and increased oesophageal acid exposure (NERD patients) and 10 healthy subjects were enrolled. Perceptual responses to intraoesophageal acid (0.1 N HCl solution) and a high PCO2 solution were determined using a randomized cross over design. Stimulusresponse functions to perfusions were quantified by three parameters: lag time to symptom perception, intensity rating and perfusion sensitivity score. Results In NERD patients, the difference in lag time to typical symptom perception, intensity rating and perfusion sensitivity score between high PCO2 and acid perfusions was statistically significant (P = 0.02, 0.01 and 0.02, respectively). However, the difference in the same perfusion parameters between acid and high PCO2 perfusions was nonsignificant in healthy controls. When NERD and controls were compared, the difference between the different perfusion variables was nonsignificant (adjusted to age). Conclusions In NERD subjects, acid perfusion reliably evoked heartburn symptoms of greater intensity than in healthy controls. Nevertheless, a high PCO2 perfusion failed to produce symptoms in either group. C1 [Hershcovici, Tiberiu; Poh, Choo H.; Fass, Ofer Z.; Ashpole, Nicole; Fass, Ronnie] Univ Arizona, Hlth Sci Ctr, Tucson, AZ 85723 USA. [Hershcovici, Tiberiu; Poh, Choo H.; Fass, Ofer Z.; Ashpole, Nicole; Fass, Ronnie] So Arizona VA Hlth Care Syst, Neuroenter Clin Res Grp, Gastroenterol Sect, Tucson, AZ 85723 USA. [Akiba, Yasutada; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Med, Greater Los Angles Vet Affairs Healthcare Syst, Los Angeles, CA 90024 USA. [Akiba, Yasutada; Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA USA. [Guillen-Rodriguez, Jose M.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA. RP Fass, R (reprint author), Univ Arizona, Hlth Sci Ctr, 601 S 6th Ave,1-111-GI, Tucson, AZ 85723 USA. EM ronnie.fass@va.gov FU NIDDK NIH HHS [R01 DK054221] NR 44 TC 2 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2972 J9 EUR J CLIN INVEST JI Eur. J. Clin. Invest. PD FEB PY 2012 VL 42 IS 2 BP 195 EP 202 DI 10.1111/j.1365-2362.2011.02560.x PG 8 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 873JC UT WOS:000298877500011 PM 21679182 ER PT J AU Konrad-Martin, D Reavis, KM McMillan, GP Dille, MF AF Konrad-Martin, Dawn Reavis, Kelly M. McMillan, Garnett P. Dille, Marilyn F. TI Multivariate DPOAE metrics for identifying changes in hearing: Perspectives from ototoxicity monitoring SO INTERNATIONAL JOURNAL OF AUDIOLOGY LA English DT Article DE Otoacoustic emission; noise-induced hearing loss; ototoxicity monitoring ID PRODUCT OTOACOUSTIC EMISSIONS; FAST FOURIER-TRANSFORMS; SENSORY CELL LOSS; OUTER HAIR-CELLS; DISTORTION-PRODUCT; NOISE EXPOSURE; SUPPRESSION EXPERIMENTS; IMPAIRED SUBJECTS; BASILAR-MEMBRANE; TEST-PERFORMANCE AB Distortion-product otoacoustic emissions (DPOAEs) provide a window into real-time cochlear mechanical function. Yet, relationships between the changes in DPOAE metrics and auditory sensitivity are still poorly understood. Explicating these relationships might support the use of DPOAEs in hearing conservation programs (HCPs) for detecting early damage leading to noise-induced hearing loss (NIHL) so that mitigating steps might be taken to limit any lasting damage. This report describes the development of DPOAE-based statistical models to assess the risk of hearing loss from cisplatin treatment among cancer patients. Ototoxicity risk assessment (ORA) models were constructed using a machine learning paradigm in which partial least squares and leave-one-out cross-validation were applied, yielding optimal screening algorithms from a set of known risk factors for ototoxicity and DPOAE changes from pre-exposure baseline measures. Single DPOAE metrics alone were poorer indicators of the risk of ototoxic hearing shifts than the best performing multivariate models. This finding suggests that multivariate approaches applied to the use of DPOAEs in a HCP, will improve the ability of DPOAE measures to identify ears with noise-induced mechanical damage and/or hearing loss at each monitoring interval. This prediction must be empirically assessed in noise-exposed subjects. C1 [Konrad-Martin, Dawn; Reavis, Kelly M.; McMillan, Garnett P.; Dille, Marilyn F.] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res NCRAR, Portland, OR 97239 USA. [Konrad-Martin, Dawn; Dille, Marilyn F.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [McMillan, Garnett P.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. RP Konrad-Martin, D (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res NCRAR, 3710 US Vet Hosp Rd,P5 NCRAR, Portland, OR 97239 USA. EM dawn.martin@va.gov OI Reavis, Kelly/0000-0002-4906-1010 FU National Center for Rehabilitative Auditory Research; Office of Rehabilitation Research and Development Service, Department of Veterans Affairs [C2113R, C7223R, C7113N] FX We thank Colleen Le Prell, Lynne Marshall, and an anonymous reviewer for their comments on an earlier version of this manuscript. Work was supported by the National Center for Rehabilitative Auditory Research, and the Office of Rehabilitation Research and Development Service, Department of Veterans Affairs (Grants awarded to the first and last authors, C2113R, C7223R, and C7113N). This work was presented at the National Hearing Conservation Association 2011 Annual Conference in Mesa, USA. NR 68 TC 5 Z9 5 U1 1 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1499-2027 J9 INT J AUDIOL JI Int. J. Audiol. PD FEB PY 2012 VL 51 SU 1 BP S51 EP S62 DI 10.3109/14992027.2011.635713 PG 12 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 880DL UT WOS:000299384800007 PM 22264063 ER PT J AU Dang, BN Giordano, TP Kim, JH AF Dang, Bich N. Giordano, Thomas P. Kim, Jennifer H. TI Sociocultural and Structural Barriers to Care Among Undocumented Latino Immigrants with HIV Infection SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE HIV; AIDS; Illegal immigrant; Undocumented; Latino; Hispanic; Qualitative research ID UNITED-STATES; MEN; COUNTRIES; STIGMA AB Timely entry into HIV care is critical for early initiation of therapy, immunologic recovery and improved survival. However, undocumented Latinos are more likely to enter HIV care late in the disease course and with concurrent AIDS. We conducted a qualitative study to examine the circumstantial, situational and social factors that uniquely affect entry and retention in care for this population. Between June and August 2006, we conducted semi-structured, in-depth, individual interviews with 22 undocumented Latino immigrants living with HIV infection. The interviews were audiotaped, transcribed and reviewed for accuracy. Data was analyzed using a grounded theory approach. Word content was coded and sorted by themes using AnSWR software. Emergent themes related to health care barriers include (1) the challenges of dealing with HIV stigma and rejection from family and community; and (2) the experienced and perceived structural barriers of accessing care as an undocumented individual. Societal intolerance of HIV and stigma-related experiences result in feelings of secrecy and shame. In addition, the undocumented state complicates the situation even further. These unique barriers include fear of deportation, work restrictions, inadequate translation services and difficulties meeting paperwork requirements. This study offers insight into the unique sociocultural and structural barriers faced by undocumented Latinos with HIV infection. Understanding and addressing these barriers will prove vital in the development and implementation of strategies to promote early entry into HIV care. C1 [Dang, Bich N.; Giordano, Thomas P.] Michael E DeBakey VA Med Ctr 152, VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA. [Dang, Bich N.; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Dang, Bich N.; Giordano, Thomas P.] Harris Cty Hosp Dist, Houston, TX USA. [Kim, Jennifer H.] Houston Ryan White Planning Council, Houston, TX USA. RP Dang, BN (reprint author), Michael E DeBakey VA Med Ctr 152, VA Hlth Serv Res & Dev Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM bndang@bcm.edu NR 20 TC 28 Z9 28 U1 0 U2 26 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD FEB PY 2012 VL 14 IS 1 BP 124 EP 131 DI 10.1007/s10903-011-9542-x PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 876QR UT WOS:000299123200014 PM 22012476 ER PT J AU Coca, SG Jammalamadaka, D Sint, K Philbrook, HT Shlipak, MG Zappitelli, M Devarajan, P Hashim, S Garg, AX Parikh, CR AF Coca, Steven G. Jammalamadaka, Divakar Sint, Kyaw Philbrook, Heather Thiessen Shlipak, Michael G. Zappitelli, Michael Devarajan, Prasad Hashim, Sabet Garg, Amit X. Parikh, Chirag R. CA Translational Res Invest Biomarker TI Preoperative proteinuria predicts acute kidney injury in patients undergoing cardiac surgery SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; ACUTE-RENAL-FAILURE; RISK-FACTORS; DISEASE; COHORT; SCORE; STRATIFICATION; ALBUMINURIA; MORTALITY; OUTCOMES AB Objective: The study objective was to examine the utility of using proteinuria in preoperative risk stratification for acute kidney injury. Acute kidney injury is a common and important complication for patients undergoing cardiac surgery. Proteinuria, which reflects structural damage to the glomeruli or renal tubules, may aid the prediction of acute kidney injury. Methods: The urine albumin to creatinine ratio and dipstick proteinuria concentration were prospectively measured in 1159 patients undergoing cardiac surgery. The cohort was organized into 4 clinical risk categories based on the preoperative urine albumin to creatinine ratio: 10 mg/g or less (<= 1.1 mg/mmol), 11 to 29 mg/g (1.2-3.3 mg/mmol), 30 to 299 mg/g (3.4-33.8 mg/mmol), and 300 mg/g or greater (>= 33.9 mg/mmol). The primary outcome was postoperative acute kidney injury, defined by the Acute Kidney Injury Network stage I criterion (serum creatinine increase >= 50% or >= 0.3 mg/dL; 26.5 mu mol/L). Results: An increase in the incidence of acute kidney injury was noted across the urine albumin to creatinine ratio categories. Adding the urine albumin to creatinine ratio to the clinical model to predict acute kidney injury improved the area under the curve from 0.67 to 0.70 (P < .001), and the continuous net reclassification improvement was 29% (P < .001). The urine albumin to creatinine ratio was also independently associated with the risk of in-hospital dialysis and intensive care unit and hospital lengths of stay. Surgery status and preoperative glomerular filtration rate were effect modifiers; the association was stronger among those undergoing elective surgery and those with an estimated glomerular filtration rate of 45 mL/min/1.73 m(2) or greater. Conclusions: Preoperative proteinuria provides graded stratification risk for acute kidney injury and is an independent predictor of other outcomes in patients undergoing cardiac surgery. (J Thorac Cardiovasc Surg 2012;143:495-502) C1 [Parikh, Chirag R.] Yale Univ, Nephrol Sect, Dept Internal Med, Sch Med, West Haven, CT 06516 USA. [Coca, Steven G.; Sint, Kyaw; Parikh, Chirag R.] VA Connecticut, Clin Epidemiol Res Ctr, West Haven, CT USA. [Philbrook, Heather Thiessen; Garg, Amit X.] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Zappitelli, Michael] McGill Univ, Montreal Childrens Hosp, Dept Pediat, Div Nephrol,Hlth Ctr, Montreal, PQ H3H 1P3, Canada. [Devarajan, Prasad] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Hashim, Sabet] Yale Univ, Dept Surg, Sch Med, West Haven, CT 06516 USA. RP Parikh, CR (reprint author), Yale Univ, Nephrol Sect, Dept Internal Med, Sch Med, 950 Campbell Ave,Mail Code 151B,Bldg 35 A,Room 21, West Haven, CT 06516 USA. EM chirag.parikh@yale.edu FU American Heart Association; National Heart, Lung, and Blood Institute [R01HL-085757]; CTSA from National Center for Research Resources [UL1 RR024139] FX The research reported in this article was supported by the American Heart Association Clinical Development award; Grant R01HL-085757 from the National Heart, Lung, and Blood Institute; and CTSA Grant UL1 RR024139 from the National Center for Research Resources. NR 23 TC 32 Z9 35 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD FEB PY 2012 VL 143 IS 2 BP 495 EP 502 DI 10.1016/j.jtcvs.2011.09.023 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 879GP UT WOS:000299318000040 PM 22050987 ER PT J AU Merchant, RM Yang, L Becker, LB Berg, RA Nadkarni, V Nichol, G Carr, BG Mitra, N Bradley, SM Abella, BS Groeneveld, PW AF Merchant, Raina M. Yang, Lin Becker, Lance B. Berg, Robert A. Nadkarni, Vinay Nichol, Graham Carr, Brendan G. Mitra, Nandita Bradley, Steven M. Abella, Benjamin S. Groeneveld, Peter W. CA Amer Heart Assoc Get TI Variability in Case-mix Adjusted In-hospital Cardiac Arrest Rates SO MEDICAL CARE LA English DT Article DE cardiopulmonary resuscitation; heart arrest; resuscitation ID CARDIOPULMONARY-RESUSCITATION; RACIAL VARIATION; CARE; QUALITY; MORTALITY; SURVIVAL; OUTCOMES; TEAMS AB Background: It is unknown how in-hospital cardiac arrest (IHCA) rates vary across hospitals and predictors of variability. Objectives: Measure variability in IHCA across hospitals and determine if hospital-level factors predict differences in case-mix adjusted event rates. Research Design: Get with the Guidelines Resuscitation (GWTG-R) (n = 433 hospitals) was used to identify IHCA events between 2003 and 2007. The American Hospital Association survey, Medicare, and US Census were used to obtain detailed information about GWTG-R hospitals. Participants: Adult patients with IHCA. Measures: Case-mix-adjusted predicted IHCA rates were calculated for each hospital and variability across hospitals was compared. A regression model was used to predict case-mix adjusted event rates using hospital measures of volume, nurse-to-bed ratio, percent intensive care unit beds, palliative care services, urban designation, volume of black patients, income, trauma designation, academic designation, cardiac surgery capability, and a patient risk score. Results: We evaluated 103,117 adult IHCAs at 433 US hospitals. The case-mix adjusted IHCA event rate was highly variable across hospitals, median 1/1000 bed days (interquartile range: 0.7 to 1.3 events/1000 bed days). In a multivariable regression model, case-mix adjusted IHCA event rates were highest in urban hospitals [rate ratio (RR), 1.1; 95% confidence interval (CI), 1.0-1.3; P = 0.03] and hospitals with higher proportions of black patients (RR, 1.2; 95% CI, 1.0-1.3; P = 0.01) and lower in larger hospitals (RR, 0.54; 95% CI, 0.45-0.66; P < 0.0001). Conclusions: Case-mix adjusted IHCA event rates varied considerably across hospitals. Several hospital factors associated with higher IHCA event rates were consistent with factors often linked with lower hospital quality of care. C1 [Merchant, Raina M.; Becker, Lance B.; Carr, Brendan G.; Abella, Benjamin S.] Univ Penn, Dept Emergency Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Yang, Lin; Groeneveld, Peter W.] Univ Penn, Div Gen Internal Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Berg, Robert A.; Nadkarni, Vinay] Univ Penn, Dept Anesthesiol & Crit Care Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Bradley, Steven M.] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. [Merchant, Raina M.; Mitra, Nandita] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Merchant, RM (reprint author), Univ Penn, Dept Biostat & Epidemiol, 423 Guardian St,1022 Blockley Hall, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu OI Abella, Benjamin/0000-0003-2521-0891 FU Robert Wood Johnson Foundation at the University of Pennsylvania; Institute for Health Technology Studies (Washington, DC) from the National Heart, Lung, and Blood Institute [1-R01-HL086919]; Pennsylvania Department of Health; Department of Veterans Affairs' Health Services Research and Development Service; Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, Washington; Laerdal Foundation for Acute Care Medicine, Stavanger, Norway; AHRQ, Bethesda, MD; Resuscitation Outcomes Consortium [NIH U01 HL077863-05]; NHLBI [R21 HL093641-01A1, R01 HL089554-03]; Resynchronization/Defibrillation for Advanced Heart Failure Trial (RAFT) [200211UCT-110607, 1RC2HL101759-01]; Medtronic Foundation; Laerdal Medical Corp, Stavanger, Norway FX Supported by funding from the Robert Wood Johnson Foundation Clinical Scholars program at the University of Pennsylvania (Merchant). This study was also supported by an unrestricted grant from the Institute for Health Technology Studies (Washington, DC) and Grant 1-R01-HL086919 from the National Heart, Lung, and Blood Institute. This study was also funded, in part, under a grant from the Pennsylvania Department of Health, which specifically disclaims responsibility for any analyses, interpretations, or conclusions. Dr Groeneveld was additionally supported by a Research Career Development Award from the Department of Veterans Affairs' Health Services Research and Development Service. None of the above funding sources were involved in the design or conduct of the study, collection, management, analysis, or interpretation of the data, or preparation, review, or approval of the article.; R. M. M., L. Y., S. B. has no conflicts of interest to disclose; L. B.: Speaker honoraria/consultant fees: Philips Healthcare, Seattle, WA. Institutional grant/research support: Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, Washington; R. B.: Institutional grant/research support: NIH, Bethesda, MD; V. N.: Institutional grant/research support: Laerdal Foundation for Acute Care Medicine, Stavanger, Norway; NIH, Bethesda, MD; AHRQ, Bethesda, MD. G. N.: Institutional grant/research support: Resuscitation Outcomes Consortium (NIH U01 HL077863-05) 2004 to 2015; Co-PI, Evaluation of Video Self-Instruction in Compressions-Only CPR (Asmund S. Laerdal Foundation for Acute Medicine) 2007 to 2010; PI, Randomized Trial of Hemofiltration After Resuscitation from Cardiac Arrest (NHLBI R21 HL093641-01A1) 2009 to 2011; PI, Randomized Field Trial of Cold Saline IV After Resuscitation from Cardiac Arrest (NHLBI R01 HL089554-03) 2007 to 2012; Co-I, Resynchronization/Defibrillation for Advanced Heart Failure Trial (RAFT) (200211UCT-110607) 2003 to 2010; Co-I, Novel Methods of Measuring Health Disparities (1RC2HL101759-01) 2009 to 2011; Co-I, Cascade Cardiac Resuscitation System (Medtronic Foundation) 2010 to 2015; PI, Research Collaborator: Gambro Renal Inc., Lakewood, CO, Sotera Wireless, San Diego, CA, Lifebridge Medizintechnik AG, Ampfing, Germany, Other: Chair, AHA Executive Database Steering Committee; Chair, Mission: Lifeline EMS Task Force, Co-Chair, AHA Resuscitation Science Symposium Planning Committee; Member, AHA Advanced Cardiac Life Support Subcommittee; Member, AHA Epidemiology and Statistics Committee; Member, Pacific Mountain Affiliate Board of Directors, American Heart Association, Received travel reimbursement, AHA. B. C.: Institutional grant/research support: NIH, AHRQ. B. A.: Speaker honoraria/consultant fees: Philips Healthcare, Seattle, WA; Medivance Corporation, Louisville, CO. Institutional grant/research support: Philips Healthcare, Andover, MA; Doris Duke Foundation, New York City, NY; American Heart Association, Dallas, TX; NIH, Bethesda, MD. In-kind research support: Laerdal Medical Corp, Stavanger, Norway. P. G.: Federal employee. NR 33 TC 20 Z9 20 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2012 VL 50 IS 2 BP 124 EP 130 DI 10.1097/MLR.0b013e31822d5d17 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 879FR UT WOS:000299315600003 PM 22249921 ER PT J AU Lapham, GT Achtmeyer, CE Williams, EC Hawkins, EJ Kivlahan, DR Bradley, KA AF Lapham, Gwen T. Achtmeyer, Carol E. Williams, Emily C. Hawkins, Eric J. Kivlahan, Daniel R. Bradley, Katharine A. TI Increased Documented Brief Alcohol Interventions With a Performance Measure and Electronic Decision Support SO MEDICAL CARE LA English DT Article DE alcoholism and addictive behaviors; performance measurement; veterans; preventive care; implementation research ID PRIMARY-HEALTH-CARE; BEHAVIORAL-COUNSELING INTERVENTIONS; COMPUTERIZED CLINICAL REMINDERS; BRIEF PHYSICIAN ADVICE; GENERAL-PRACTITIONERS; PREVENTIVE-SERVICES; COST-EFFECTIVENESS; PUBLIC-HEALTH; VETERANS; PATIENT AB Background: Alcohol screening and brief interventions (BIs) are ranked the third highest US prevention priority, but effective methods of implementing BI into routine care have not been described. Objectives: This study evaluated the prevalence of documented BI among Veterans Affairs (VA) outpatients with alcohol misuse before, during, and after implementation of a national performance measure (PM) linked to incentives and dissemination of an electronic clinical reminder (CR) for BI. Methods: VA outpatients were included in this study if they were randomly sampled for national medical record reviews and screened positive for alcohol misuse (Alcohol Use Disorders Identification Test-Consumption score >= 5) between July 2006 and September 2008 (N = 6788). Consistent with the PM, BI was defined as documented advice to reduce or abstain from drinking plus feedback linking drinking to health. The prevalence of BI was evaluated among outpatients who screened positive for alcohol misuse during 4 successive phases of BI implementation: baseline year (n = 3504), after announcement (n = 753) and implementation (n = 697) of the PM, and after CR dissemination (n = 1834), unadjusted and adjusted for patient characteristics. Results: Among patients with alcohol misuse, the adjusted prevalence of BI increased significantly over successive phases of BI implementation, from 5.5% (95% CI 4.1%-7.5%), 7.6% (5.6%-10.3%), 19.1% (15.4%-23.7%), to 29.0% (25.0%-33.4%) during the baseline year, after PM announcement, PM implementation, and CR dissemination, respectively (test for trend P < 0.001). Conclusions: A national PM supported by dissemination of an electronic CR for BI was associated with meaningful increases in the prevalence of documented brief alcohol interventions. C1 [Lapham, Gwen T.; Achtmeyer, Carol E.; Williams, Emily C.; Hawkins, Eric J.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA 98101 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Bradley, Katharine A.] Univ Washington, Hlth Serv, Seattle, WA 98195 USA. RP Lapham, GT (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way, Seattle, WA 98101 USA. EM Gwendolyn.Lapham@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service; Veterans Affairs Substance Use Disorders Quality Enhancement Research Initiative [SUB 98-000] FX Supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service. The article was specifically produced with support from the Veterans Affairs Substance Use Disorders Quality Enhancement Research Initiative (SUB 98-000). NR 50 TC 52 Z9 52 U1 5 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2012 VL 50 IS 2 BP 179 EP 187 DI 10.1097/MLR.0b013e3181e35743 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 879FR UT WOS:000299315600010 PM 20881876 ER PT J AU Taff, HT Nett, JE Andes, DR AF Taff, Heather T. Nett, Jeniel E. Andes, David R. TI Comparative analysis of Candida biofilm quantitation assays SO MEDICAL MYCOLOGY LA English DT Article DE Candida; biofilm; assay ID IN-VITRO; ALBICANS; QUANTIFICATION; INFECTION; GROWTH; SURFACES; VIVO AB Candida grows on devices producing treatment resistant biofilms. A key tool for the study of biofilms includes an accurate assessment of viable cell growth. This study systematically tested seven techniques, among which the XTT assay provided the most reproducible, accurate, and efficient method for the quantitative estimation of C. albicans biofilms. C1 [Taff, Heather T.; Nett, Jeniel E.; Andes, David R.] Univ Wisconsin, Dept Microbiol, Madison, WI 53706 USA. [Taff, Heather T.; Nett, Jeniel E.; Andes, David R.] Univ Wisconsin, Dept Immunol, Madison, WI 53706 USA. [Andes, David R.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Nett, Jeniel E.; Andes, David R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Andes, DR (reprint author), 5211 UW Med Fdn Centennial Bldg,1685 Highland Ave, Madison, WI 53705 USA. EM dra@medicine.wisc.edu FU National Institutes of Health [RO1 AI073289-01] FX The authors would like to thank A. Mitchell and C. Nobile for the strains. This work was supported by the National Institutes of Health (RO1 AI073289-01). NR 25 TC 26 Z9 26 U1 0 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD FEB PY 2012 VL 50 IS 2 BP 214 EP 218 DI 10.3109/13693786.2011.580016 PG 5 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 876FS UT WOS:000299093600014 PM 21539503 ER PT J AU Deo, AJ Cahill, ME Li, SY Goldszer, I Henteleff, R VanLeeuwen, JE Rafalovich, I Gao, RQ Stachowski, EK Sampson, AR Lewis, DA Penzes, P Sweet, RA AF Deo, Anthony J. Cahill, Michael E. Li, Siyu Goldszer, Isaac Henteleff, Ruth VanLeeuwen, Jon-Eric Rafalovich, Igor Gao, Ruoqi Stachowski, Erin K. Sampson, Allan R. Lewis, David A. Penzes, Peter Sweet, Robert A. TI Increased expression of Kalirin-9 in the auditory cortex of schizophrenia subjects: Its role in dendritic pathology SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Endophenotypes; Kalirin; Schizophrenia; Schizoaffective; Auditory cortex; Dendrite ID GDP/GTP EXCHANGE FACTOR; PYRAMIDAL NEURONS; PREFRONTAL CORTEX; POSTSYNAPTIC DENSITY; SPINE MORPHOGENESIS; PLANUM TEMPORALE; HESCHL GYRUS; DBL FAMILY; MECHANISMS; REDUCTION AB Reductions in dendritic arbor length and complexity are among the most consistently replicated changes in neuronal structure in post mortem studies of cerebral cortical samples from subjects with schizophrenia, however, the underlying molecular mechanisms have not been identified. This study is the first to identify an alteration in a regulatory protein which is known to promote both dendritic length and arborization in developing neurons, Kalirin-9. We found Kalirin-9 expression to be paradoxically increased in schizophrenia. We followed up this observation by overexpressing Kalirin-9 in mature primary neuronal cultures, causing reduced dendritic length and complexity. Kalirin-9 overexpression represents a potential mechanism for dendritic changes seen in schizophrenia. Published by Elsevier Inc. C1 [Deo, Anthony J.; Goldszer, Isaac; Henteleff, Ruth; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA 15213 USA. [Deo, Anthony J.] Univ Pittsburgh, Sch Med, Phys Scientist Training Program, Pittsburgh, PA 15213 USA. [Cahill, Michael E.; VanLeeuwen, Jon-Eric; Rafalovich, Igor; Gao, Ruoqi; Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA. [Li, Siyu; Sampson, Allan R.] Univ Pittsburgh, Dept Stat, Pittsburgh, PA 15213 USA. [Stachowski, Erin K.; Lewis, David A.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15213 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Educ & Clin Ctr, VISN Mental Illness Res 4, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu RI Lewis, David/G-4053-2014; Penzes, Peter/L-3987-2016 OI Lewis, David/0000-0002-3225-6778; Penzes, Peter/0000-0001-5449-1640 FU NIH [MH071533, MH084053, MH071316, F31AG031621-01A2, 1F31MH087043]; Doris Duke Charitable Foundation; BMS Foundation; Bristol-Myers Squibb; Curridium Ltd; Pfizer FX This work was supported by the NIH grants MH071533, MH084053 and MH071316. Anthony Deo was supported by a Clinical Research Fellow grant from the Doris Duke Charitable Foundation to the University of Pittsburgh School of Medicine. Michael Cahill is supported by NIH F31AG031621-01A2; Jon VanLeeuwen is supported by NIH 1F31MH087043. Allan R. Sampson is a statistical consultant to Johnson & Johnson Pharmaceutical Research and Development. Dr. Lewis currently receives investigator-initiated research support from the BMS Foundation, Bristol-Myers Squibb, Curridium Ltd and Pfizer and in 2007-2010 served as a consultant in the areas of target identification and validation and new compound development to AstraZeneca, BioLine RX, Bristol-Myers Squibb, Hoffman-Roche, Lilly, Merck, Neurogen, and SK Life Science. The authors thank Josephine Asafu-Adjei for statistical assistance. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs or the United States Government. NR 48 TC 17 Z9 17 U1 0 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD FEB PY 2012 VL 45 IS 2 BP 796 EP 803 DI 10.1016/j.nbd.2011.11.003 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 881QC UT WOS:000299500200014 PM 22120753 ER PT J AU van Walraven, SM Ball, LM Koopman, HM Switzer, GE Ropes-de Jong, CMH de Jong, A Bredius, RGM Egeler, RM AF van Walraven, S. M. Ball, L. M. Koopman, H. M. Switzer, G. E. Ropes-de Jong, C. M. H. de Jong, A. Bredius, R. G. M. Egeler, R. M. TI Managing a dual roleuexperiences and coping strategies of parents donating haploidentical G-CSF mobilized peripheral blood stem cells to their children SO PSYCHO-ONCOLOGY LA English DT Article DE childhood cancer; parent donor; experience; coping mechanisms; oncology; haploidentical stem cell transplantation ID BONE-MARROW-TRANSPLANTATION; ACUTE-LEUKEMIA; FOLLOW-UP; DONORS; DISTRESS; CONSENT; PATTERNS; NEEDS AB Hematopoietic stem cell transplantation is an effective therapy for life-threatening hematological diseases. Parents may be asked to donate hematopoietic stem cells for their child when no compatible related or unrelated donor is available. Objective: Parents donating G-CSF mobilized peripheral blood stem cells simultaneously and uniquely fulfill the dual role of donor and caregiver for their ill child. The experiences of both sibling and unrelated stem cell donors have been extensively reported but not those of parental donors. Methods: We therefore undertook a study specifically to investigate the experiences and coping strategies of parental stem cell donors. In-depth qualitative interviews were conducted with 13 parental donors, which were subsequently transcribed and subjected to thematic analysis. In addition, parental coping was assessed utilizing the Utrecht Coping List. Results: Qualitative analyses revealed four main thematic categories describing the way parental stem cell donation was experienced, namely 'Hope and Fear', 'Need for Information', 'Do Anything for your Child' and 'Transplant Outcome' In addition parents noted similar difficulties which were unrelated to their specific role as a donor, for example they felt socially isolated. Conclusions: Individual information for the parents needs to address not only the transplantation procedure but particularly those aspects related to the donation process. We feel there is a need for a protocol specifically designed to support and coach parental donors. Copyright (C) 2010 John Wiley & Sons, Ltd. C1 [van Walraven, S. M.; Ball, L. M.; Ropes-de Jong, C. M. H.; Bredius, R. G. M.; Egeler, R. M.] Leiden Univ, Med Ctr, Dept Pediat, NL-2333 ZA Leiden, Netherlands. [Koopman, H. M.] Leiden Univ, Med Ctr, Dept Med Psychol, NL-2333 ZA Leiden, Netherlands. [Switzer, G. E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Switzer, G. E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Switzer, G. E.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA. [Switzer, G. E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ & Promot, Pittsburgh, PA USA. [de Jong, A.] Hgsk Utrecht, Utrecht, Netherlands. RP van Walraven, SM (reprint author), Leiden Univ, Med Ctr, Dept Pediat, Albinusdreef 2,J6-S-221, NL-2333 ZA Leiden, Netherlands. EM s.m.van_walraven@lumc.nl NR 39 TC 6 Z9 6 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2012 VL 21 IS 2 BP 168 EP 175 DI 10.1002/pon.1885 PG 8 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA 880NX UT WOS:000299415200008 PM 22271537 ER PT J AU Bowling, CB O'Hare, AM AF Bowling, C. Barrett O'Hare, Ann M. TI Managing Older Adults With CKD: Individualized Versus Disease-Based Approaches SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Elderly; disease oriented; individualized; patient centered; kidney disease ID CHRONIC KIDNEY-DISEASE; RANDOMIZED CONTROLLED-TRIALS; MULTIPLE CHRONIC CONDITIONS; GLOMERULAR-FILTRATION-RATE; MORTALITY RISK; COGNITIVE IMPAIRMENT; PRACTICE GUIDELINES; STARTING DIALYSIS; ELDERLY PERSONS; UNITED-STATES AB The last decade has seen the evolution and ongoing refinement of a disease-oriented approach to chronic kidney disease (CKD). Disease-oriented models of care assume a direct causal association between observed signs and symptoms and underlying disease pathophysiologic processes. Treatment plans target underlying disease mechanisms with the goal of improving disease-related outcomes. Because average glomerular filtrate rates tend to decrease with age, CKD becomes increasingly prevalent with advancing age and those who meet criteria for CKD are disproportionately elderly. However, several features of geriatric populations may limit the utility of disease-oriented models of care. In older adults, complex comorbid conditions and geriatric syndromes are common; signs and symptoms often do not reflect a single underlying pathophysiologic process; there can be substantial heterogeneity in life expectancy, functional status, and health priorities; and information about the safety and efficacy of recommended interventions often is lacking. For all these reasons, geriatricians have tended to favor an individualized patient-centered model of care over more traditional disease-based approaches. An individualized approach prioritizes patient preferences and embraces the notion that observed signs and symptoms often do not reflect a single unifying disease process and instead reflect the complex interplay between many different factors. This approach emphasizes modifiable outcomes that matter to the patient. Prognostic information related to these and other outcomes generally is used to shape rather than dictate treatment decisions. We argue that an individualized patient-centered approach to care may have more to offer than a traditional disease-based approach to CKD in many older adults. Am J Kidney Dis. 59(2):293-302. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Bowling, C. Barrett] Univ Alabama, Med Ctr, Dept Vet Affairs, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL 35294 USA. [Bowling, C. Barrett] Univ Alabama, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [O'Hare, Ann M.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA USA. RP O'Hare, AM (reprint author), 1160 S Columbian Way,111J RDU, Seattle, WA 98108 USA. EM ann.ohare@va.gov FU National Institute on Aging; Birmingham/Atlanta Geriatric Research Education and Clinical Center; John A. Hartford Foundation/Southeast Center of Excellence in Geriatric Medicine FX Support was through a Beeson Career Development Award from the National Institute on Aging to Dr O'Hare and the Birmingham/Atlanta Geriatric Research Education and Clinical Center Special Fellowship in Advanced Geriatrics and John A. Hartford Foundation/Southeast Center of Excellence in Geriatric Medicine to Dr Bowling. NR 55 TC 44 Z9 47 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD FEB PY 2012 VL 59 IS 2 BP 293 EP 302 DI 10.1053/j.ajkd.2011.08.039 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 879GK UT WOS:000299317500021 PM 22189037 ER PT J AU Stineman, MG Henry-Sanchez, JT Kurichi, JE Pan, Q Xie, DW Saliba, D Zhang, Z Streim, JE AF Stineman, Margaret G. Henry-Sanchez, John T. Kurichi, Jibby E. Pan, Qiang Xie, Dawei Saliba, Debra Zhang, Zi Streim, Joel E. TI Staging Activity Limitation and Participation Restriction in Elderly Community-Dwelling Persons According to Difficulties in Self-Care and Domestic Life Functioning SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Independent Living; Aging; Daily Living Activities; ICF ID HOME ACCESSIBILITY FEATURES; SKILLED NURSING FACILITIES; PHYSICAL INDEPENDENCE; OLDER PERSONS; DISABILITY; REHABILITATION; VALIDITY; PATIENT; HEALTH; ICF AB Stineman MG, Henry-Sanchez JT, Kurichi JE, Pan Q, Xie D, Saliba D, Zhang Z, Streim JE: Staging activity limitation and participation restriction in elderly community-dwelling persons according to difficulties in self-care and domestic life functioning. Am J Phys Med Rehabil 2012; 91: 126-140. Objective: This study aimed to describe the conceptual foundation and development of an activity limitation and participation restriction staging system for community-dwelling people 70 yrs or older according to the severity and types of self-care (activities of daily living [ADLs]) and domestic life (instrumental ADLs (IADLs)) limitations experienced. Design: Data from the second Longitudinal Study of Aging (N = 9447) were used to develop IADL stages through the analyses of self- and proxy-reported difficulties in performing IADLs. An analysis of activity limitation profiles identified hierarchical thresholds of difficulty that defined each stage. IADL stages are combined with ADL stages to profile status for independent living. Results: IADL stages define five ordered thresholds of increasing activity limitations and a "not relevant'' stage for those who normally have someone else do those activities. Approximately 42% of the population experience IADL limitations. To achieve a stage, a person must meet or exceed stage-specific thresholds of retained functioning defined for each activity. Combined ADL and IADL stages define 29 patterns of activity limitations expressing the individual's potential for participating in life situations pertinent to self- care and independent community life. Conclusions: ADL and IADL stages can serve to distinguish between groups of people according to both severity and the types of limitations experienced during home or outpatient assessments, in population surveillance, and in research. C1 [Stineman, Margaret G.; Kurichi, Jibby E.; Pan, Qiang; Xie, Dawei; Zhang, Zi] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Stineman, Margaret G.; Henry-Sanchez, John T.] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA. [Saliba, Debra] Univ Calif Los Angeles, Greater Los Angeles VA GRECC, Jewish Home Borun Ctr Gerontol Res, RAND, Los Angeles, CA USA. [Streim, Joel E.] Univ Penn, Geriatr Psychiat Sect, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Streim, Joel E.] Philadelphia Vet Affairs Med Ctr, VISN MIRECC 4, Philadelphia, PA USA. RP Stineman, MG (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Dept Biostat & Epidemiol, 423 Guardian Dr,904 Blockley Hall, Philadelphia, PA 19104 USA. FU technical panel from the grant Impairment Activity Staging [AG032420-01A1] FX We thank the members of the technical panel from the grant Impairment Activity Staging (AG032420-01A1). NR 51 TC 13 Z9 13 U1 6 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD FEB PY 2012 VL 91 IS 2 BP 126 EP 140 DI 10.1097/PHM.0b013e318241200d PG 15 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 879HX UT WOS:000299321400006 PM 22248806 ER PT J AU Singh, H Giardina, TD Forjuoh, SN Reis, MD Kosmach, S Khan, MM Thomas, EJ AF Singh, Hardeep Giardina, Traber Davis Forjuoh, Samuel N. Reis, Michael D. Kosmach, Steven Khan, Myrna M. Thomas, Eric J. TI Electronic health record-based surveillance of diagnostic errors in primary care SO BMJ QUALITY & SAFETY LA English DT Article ID ADVERSE DRUG EVENTS; MALPRACTICE CLAIMS; CANCER-DIAGNOSIS; PATIENT SAFETY; MISSED OPPORTUNITIES; GENERAL-PRACTICE; MEDICAL-RECORD; UNITED-STATES; CLASSIFICATION; STRATEGIES AB Background: Diagnostic errors in primary care are harmful but difficult to detect. The authors tested an electronic health record (EHR)-based method to detect diagnostic errors in routine primary care practice. Methods: The authors conducted a retrospective study of primary care visit records 'triggered' through electronic queries for possible evidence of diagnostic errors: Trigger 1: A primary care index visit followed by unplanned hospitalisation within 14 days and Trigger 2: A primary care index visit followed by >= 1 unscheduled visit(s) within 14 days. Control visits met neither criterion. Electronic trigger queries were applied to EHR repositories at two large healthcare systems between 1 October 2006 and 30 September 2007. Blinded physician-reviewers independently determined presence or absence of diagnostic errors in selected triggered and control visits. An error was defined as a missed opportunity to make or pursue the correct diagnosis when adequate data were available at the index visit. Disagreements were resolved by an independent third reviewer. Results: Queries were applied to 212 165 visits. On record review, the authors found diagnostic errors in 141 of 674 Trigger 1-positive records (positive predictive value (PPV)=20.9%, 95% CI 17.9% to 24.0%) and 36 of 669 Trigger 2-positive records (PPV=5.4%, 95% CI 3.7% to 7.1%). The control PPV of 2.1% (95% CI 0.1% to 3.3%) was significantly lower than that of both triggers (p <= 0.002). Inter-reviewer reliability was modest, though higher than in comparable previous studies (K=0.37 (95% CI 0.31 to 0.44)). Conclusions: While physician agreement on diagnostic error remains low, an EHR-facilitated surveillance methodology could be useful for gaining insight into the origin of these errors. C1 [Singh, Hardeep; Giardina, Traber Davis; Khan, Myrna M.] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep; Giardina, Traber Davis; Khan, Myrna M.] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. [Forjuoh, Samuel N.; Reis, Michael D.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Family & Community Med, Scott & White Healthcare, Temple, TX USA. [Kosmach, Steven] Univ Texas Hlth Sci Ctr Houston, Div Biostat, Sch Publ Hlth, Houston, TX USA. [Thomas, Eric J.] Univ Texas Houston, Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. [Thomas, Eric J.] Univ Texas Med Sch Houston, Div Gen Med, Dept Med, Houston, TX USA. RP Singh, H (reprint author), Baylor Coll Med, VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu OI Davis Giardina, Traber/0000-0002-9184-6524 FU NIH [K23CA125585]; Agency for Health Care Research and Quality Health Services [R18HS17244-02]; Houston VA HSR&D Center of Excellence [HFP90-020] FX The study was supported by an NIH K23 career development award (K23CA125585) to HS, Agency for Health Care Research and Quality Health Services Research Demonstration and Dissemination Grant (R18HS17244-02) to EJT and in part by the Houston VA HSR&D Center of Excellence (HFP90-020). These sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. NR 48 TC 29 Z9 29 U1 4 U2 14 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD FEB PY 2012 VL 21 IS 2 BP 93 EP 100 DI 10.1136/bmjqs-2011-000304 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 879JF UT WOS:000299324800002 PM 21997348 ER PT J AU Kerlikowske, K AF Kerlikowske, Karla TI Screening mammography in women less than age 50 years SO CURRENT OPINION IN OBSTETRICS & GYNECOLOGY LA English DT Review DE benefits and harms; digital mammography; risk-based screening; screening mammography ID CARCINOMA IN-SITU; SERVICES TASK-FORCE; BREAST-CANCER RISK; FALSE-POSITIVE MAMMOGRAMS; COST-EFFECTIVENESS; SURVEILLANCE CONSORTIUM; ABNORMAL MAMMOGRAMS; AMERICAN-COLLEGE; FILM MAMMOGRAPHY; UNITED-STATES AB Purpose of review For women aged 40-49 years, to describe the benefits and harms of performing screening mammography, accuracy of digital mammography, and new evidence on the effectiveness of risk-based screening. Recent findings New data support a 15% reduction in breast cancer mortality for women aged 40-49 years after 10 years of screening; however, the absolute benefit is small and not outweighed by important harms. Digital mammography is more sensitive, but less specific than film mammography in women aged 40-49 years. Risk-based screening that identifies and screens women aged 40-49 years with breast cancer risk similar to an average-risk woman aged 50-59 years results in similar benefits and harms of screening these high-risk women as screening average-risk 50-year-old women. Summary Practitioners should discuss with women aged 40-49 years the benefits and harms of undergoing screening mammography before offering them screening. If women elect to undergo screening mammography, they should undergo biennial screening with digital mammography. Targeting screening for those women aged 40-49 years with risk factors that substantially increase the risk of breast cancer, such as high breast density, family history of breast cancer, and history of benign breast biopsy, could maximize the benefits and minimizes the harms of screening this age group. C1 [Kerlikowske, Karla] Univ Calif San Francisco, Gen Internal Med Sect, Dept Vet Affairs, San Francisco, CA 94143 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM Karla.Kerlikowske@ucsf.edu NR 46 TC 6 Z9 6 U1 2 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-872X J9 CURR OPIN OBSTET GYN JI Curr. Opin. Obstet. Gynecol. PD FEB PY 2012 VL 24 IS 1 BP 38 EP 43 DI 10.1097/GCO.0b013e32834da49a PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 876PD UT WOS:000299118800007 PM 22037165 ER PT J AU Egede, LE Dismuke, CE AF Egede, Leonard E. Dismuke, Clara E. TI Serious Psychological Distress and Diabetes: A Review of the Literature SO CURRENT PSYCHIATRY REPORTS LA English DT Review DE Kessler; Psychological distress; Serious psychological distress; Diabetes; Depression; Schizophrenia; Post-traumatic stress disorder; PTSD; Diabetes distress; Anxiety ID CORONARY-HEART-DISEASE; MAJOR DEPRESSION; GLYCEMIC CONTROL; MEDICATION ADHERENCE; COMORBID DEPRESSION; GENERAL-POPULATION; PROSPECTIVE COHORT; MENTAL-ILLNESS; HEALTH-CARE; LOW-INCOME AB With the development of a measure of serious psychological distress (SPD) in 2002, more attention is being paid to the association of SPD with diabetes outcomes and processes of care. We review the literature on the relationship between SPD and diabetes processes of care and outcomes, as well as the literature on the relationship between specific mental health diagnoses and diabetes processes of care and outcomes during the 2010 to 2011 period. There is an extensive literature on the association of mental health diagnoses with diabetes outcomes, especially for depression. Because the Kessler scale measures a much broader range of mental health issues than any specific DSM-IV/Structured Clinical Interview for DSM Disorders diagnosis and is designed to assess SPD at the population level, additional research needs to be conducted both in clinical settings and using large administrative datasets to examine the association between SPD and diabetes outcomes and processes of care. C1 [Egede, Leonard E.; Dismuke, Clara E.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC 29425 USA. [Egede, Leonard E.; Dismuke, Clara E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU Center for Disease Prevention and Health Interventions for Diverse Populations HSRD [REA 08-261] FX The authors acknowledge and appreciate the resources provided by the Center for Disease Prevention and Health Interventions for Diverse Populations HSR&D program (grant REA 08-261) and the Ralph H. Johnson Veterans Affairs Medical Center. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 65 TC 37 Z9 37 U1 10 U2 31 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD FEB PY 2012 VL 14 IS 1 BP 15 EP 22 DI 10.1007/s11920-011-0240-0 PG 8 WC Psychiatry SC Psychiatry GA 876FJ UT WOS:000299092700003 PM 22002804 ER PT J AU Hazlett, EA Goldstein, KE Kolaitis, JC AF Hazlett, Erin A. Goldstein, Kim E. Kolaitis, Jeanine C. TI A Review of Structural MRI and Diffusion Tensor Imaging in Schizotypal Personality Disorder SO CURRENT PSYCHIATRY REPORTS LA English DT Review DE Schizotypal personality disorder; Schizotypy; MRI; Diffusion tensor; Diffusion tensor imaging; Fractional anisotropy; DTI; White matter; Gray matter; Morphometry; Schizophrenia; Schizophrenia spectrum; Brain volume; Frontal lobe; Temporal lobe; Superior temporal gyrus; Cingulate; Cingulum ID SUPERIOR TEMPORAL GYRUS; WHITE-MATTER INTEGRITY; LOBE GRAY-MATTER; ANTERIOR CINGULATE; SCHIZOPHRENIA SPECTRUM; INTERNAL CAPSULE; ONSET SCHIZOPHRENIA; UNCINATE FASCICULUS; HUMAN BRAIN; VOLUME AB Individuals with schizotypal personality disorder (SPD) share genetic, phenomenologic, and cognitive abnormalities with people diagnosed with schizophrenia. To date, 15 structural MRI studies of the brain have examined size, and 3 diffusion tensor imaging studies have examined white matter connectivity in SPD. Overall, both types of structural neuroimaging modalities have shown temporal lobe abnormalities similar to those observed in schizophrenia, while frontal lobe regions appear to show more sparing. This intriguing pattern suggests that frontal lobe sparing may suppress psychosis, which is consistent with the idea of a possible neuroprotective factor. In this paper, we review these 18 studies and discuss whether individuals with SPD who both resemble and differ from schizophrenia patients in their phenomenology, share some or all of the structural brain imaging characteristics of schizophrenia. We attempt to group the MRI abnormalities in SPD into three patterns: 1) a spectrum of severity-abnormalities are similar to those observed in schizophrenia but not so severe; 2) a spectrum of region-abnormalities affecting some, but not all, brain regions affected in schizophrenia; and 3) a spectrum of compensation-abnormalities reflecting greater-than-normal white matter volume, possibly serving as a buffer or compensatory mechanism protecting the individual with SPD from the frank psychosis observed in schizophrenia. C1 [Hazlett, Erin A.; Kolaitis, Jeanine C.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN3, Bronx, NY 10468 USA. [Hazlett, Erin A.; Kolaitis, Jeanine C.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Goldstein, Kim E.] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA. RP Hazlett, EA (reprint author), James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN3, 130 W Kingsbridge Rd,Room 6A-45, Bronx, NY 10468 USA. EM erin.hazlett@mssm.edu FU VA MERIT [I01 CX000261] FX Support for this work came from VA MERIT I01 CX000261 (to Dr. Hazlett). NR 70 TC 25 Z9 26 U1 2 U2 20 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD FEB PY 2012 VL 14 IS 1 BP 70 EP 78 DI 10.1007/s11920-011-0241-z PG 9 WC Psychiatry SC Psychiatry GA 876FJ UT WOS:000299092700010 PM 22006127 ER PT J AU Grudzen, CR Richardson, LD Koenig, WJ Hoffman, JR Lorenz, KA Asch, SM AF Grudzen, Corita R. Richardson, Lynne D. Koenig, William J. Hoffman, Jerome R. Lorenz, Karl A. Asch, Steven M. TI Translation of Evidence-Based Clinical Standards into a New Prehospital Resuscitation Policy in Los Angeles County SO HEALTH SERVICES RESEARCH LA English DT Article DE End-of-life; health policy; clinical practice guidelines; Emergency Medical Services ID INTENSIVE-CARE-UNIT; POSTTRAUMATIC STRESS; FAMILY-MEMBERS; CARDIAC-ARREST; INFORMATION; INDICATORS; SYMPTOMS; MAKERS AB Objective. To translate a set of evidence-based clinical standards designed to allow paramedics to forgo unnecessary and potentially harmful resuscitation attempts into a feasible new policy. Data Sources/Setting. Policy documents, meeting minutes, and personal communications between a large urban Emergency Medical Services (EMS) agency serving all of Los Angeles County (LAC) and a research group were reviewed over 12 months. Study Design. LAC EMS and University of California, Los Angeles (UCLA) formed a partnership (the EMS-UCLA Collaborative) to develop and translate the standards into new EMS protocols. Clinical indicators considered appropriate and feasible by an expert panel were submitted to the agency for inclusion in the new policy. Findings. The Collaborative submitted the results to the LAC EMS Commission and a physician advisory group for review. Of the 41 indicators approved by the expert panel, 22 would have resulted in changes to the current policy. All six involved asking family members about or honoring written and verbal Do Not Attempt Resuscitate requests, but only 4 of the 16 indicators based on clinical characteristics were included in the new policy. Ultimately, 10 of the 22 indicators that would have changed policy were approved and implemented. Conclusions. By collaboration, a large EMS agency and a research team were able to develop and implement a revised resuscitation policy within 1 year. C1 [Grudzen, Corita R.; Richardson, Lynne D.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA. [Grudzen, Corita R.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Koenig, William J.] Los Angeles Cty Emergency Med Agcy, Los Angeles, CA USA. [Hoffman, Jerome R.] Univ Calif Los Angeles, Dept Emergency Med, Los Angeles, CA USA. [Hoffman, Jerome R.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Lorenz, Karl A.] VA Greater Angeles, Los Angeles, CA USA. [Asch, Steven M.] VA Palo Alto, Palo Alto, CA USA. RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, Box 1620,1 Gustave L Levy Pl, New York, NY 10029 USA. EM corita.grudzen@mssm.edu OI Grudzen, Corita/0000-0003-3039-8497 FU California Health Care Foundation; Robert Wood Johnson Clinical Scholars Program FX This work was supported by the California Health Care Foundation and the Robert Wood Johnson Clinical Scholars Program. NR 21 TC 1 Z9 1 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2012 VL 47 IS 1 BP 363 EP 379 DI 10.1111/j.1475-6773.2011.01341.x PN 2 PG 17 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 875OU UT WOS:000299041600004 PM 22091960 ER PT J AU Kullgren, JT McLaughlin, CG Mitra, N Armstrong, K AF Kullgren, Jeffrey T. McLaughlin, Catherine G. Mitra, Nandita Armstrong, Katrina TI Nonfinancial Barriers and Access to Care for U.S. Adults SO HEALTH SERVICES RESEARCH LA English DT Article DE Access to care; nonfinancial barriers; health reform ID SHARED MEDICAL APPOINTMENTS; HEALTH-CARE; VETERANS; SERVICES; SATISFACTION; CHILDREN; MODEL; TELEMEDICINE; PHYSICIANS; COVERAGE AB Objective. To identify prevalences and predictors of nonfinancial barriers that lead to unmet need or delayed care among U.S. adults. Data Source. 2007 Health Tracking Household Survey. Study Design. Reasons for unmet need or delayed care in the previous 12 months were assigned to one of five dimensions in the Penchansky and Thomas model of access to care. Prevalences of barriers in each nonfinancial dimension were estimated for all adults and for adults with affordability barriers. Multivariable logistic regression models were used to estimate associations between individual, household, and insurance characteristics and barriers in each access dimension. Principal Findings. Eighteen percent of U.S. adults experienced affordability barriers and 21 percent experienced nonfinancial barriers that led to unmet need or delayed care. Two-thirds of adults with affordability barriers also reported nonfinancial barriers. Young adults, women, individuals with lower incomes, parents, and persons with at least one chronic illness had higher adjusted prevalences of nonfinancial barriers. Conclusions. Nonfinancial barriers are common reasons for unmet need or delayed care among U.S. adults and frequently coincide with affordability barriers. Failure to address nonfinancial barriers may limit the impact of policies that seek to expand access by improving the affordability of health care. C1 [Kullgren, Jeffrey T.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA. [Kullgren, Jeffrey T.; Armstrong, Katrina] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [McLaughlin, Catherine G.] Mathematica Policy Res Inc, Ann Arbor, MI USA. [McLaughlin, Catherine G.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA. [Mitra, Nandita] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Armstrong, Katrina] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Armstrong, Katrina] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Kullgren, JT (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Robert Wood Johnson Fdn Clin Scholars, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kullgren@mail.med.upenn.edu FU Brigham and Women's Hospital Department of Medicine FX These contents do not represent the views of the Department of Veterans Affairs or the United States Government. This work was supported in part by a grant from the Brigham and Women's Hospital Department of Medicine Martin Solomon Medical Education Fund. Abstracts from this study were presented at the Society of General Internal Medicine Mid-Atlantic Regional Meeting in Baltimore, MD, on March 18, 2011 and the Society of General Internal Medicine 34th Annual Meeting in Phoenix, AZ, on May 6, 2011. An abstract from this study was also presented at the Academy Health Annual Research Meeting in Seattle, WA, on June 14, 2011. No other disclosures. NR 58 TC 26 Z9 26 U1 5 U2 24 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2012 VL 47 IS 1 BP 462 EP 485 DI 10.1111/j.1475-6773.2011.01308.x PN 2 PG 24 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 875OU UT WOS:000299041600010 PM 22092449 ER PT J AU D'Mello, S Trauernicht, A Ryan, A Bonkowski, E Willson, T Trapnell, BC Frank, SJ Kugasathan, S Denson, LA AF D'Mello, Sharon Trauernicht, Anna Ryan, Anne Bonkowski, Erin Willson, Tara Trapnell, Bruce C. Frank, Stuart J. Kugasathan, Subra Denson, Lee A. TI Innate dysfunction promotes linear growth failure in pediatric Crohn's disease and growth hormone resistance in murine ileitis SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE granulocyte-macrophage colony stimulating factor; pediatric Crohn's disease; linear growth; caspase recruitment domain family member 15; nucleotide-binding oligomerization domain containing 2 ID INFLAMMATORY-BOWEL-DISEASE; BINDING-PROTEIN; ADULT HEIGHT; CHILDREN; RETARDATION; RECEPTOR; AUTOANTIBODIES; SEVERITY; COLITIS; ONSET AB Background: Growth failure remains a common complication of pediatric Crohn's disease (CD) and has been associated with small bowel involvement and need for surgery. We have reported that patients with elevated (=1.6 mu g/mL) granulocyte macrophage colony stimulating factor autoantibodies (GM-CSF Ab) are more likely to experience complicated ileal disease requiring surgery. We hypothesized that concurrent GM-CSF Ab and CARD15 risk allele carriage (C15(+)GMAb(+)) would be associated with growth failure in CD and growth hormone (GH) resistance in murine ileitis. Methods: We enrolled 229 pediatric CD patients at two sites and determined CARD15 genotype, serum GM-CSF Ab, and GH binding protein (GHBP), and height (HTz) and weight (WTz) z-scores at diagnosis. Ileitis was induced in card15-deficient mice by GM-CSF neutralization and nonsteroidal antiinflammatory drug (NSAID) exposure. Hepatic GH receptor (GHR) abundance and GH-dependent Stat5 activation were determined by western blot and Igf-I mRNA expression by real-time polymerase chain reaction (PCR). Results: Mean (95% confidence interval [CI]) HTz at diagnosis was reduced to -0.48 (-4.2, 2.3) in C15(+)GMAb(+) patients, compared to -0.07 (-4.9, 3.4) in disease controls (P <= 0.05). Circulating GHBP, as a marker for tissue GHR abundance, was reduced in C15(+)GMAb(+) patients. Hepatic GHR abundance, GH induction of Stat5 tyrosine phosphorylation, and Igf-I mRNA expression were reduced in male card15-deficient mice with ileitis due to GM-CSF neutralization and NSAID exposure. Conclusions: Innate dysfunction due to concurrent genetic variation in CARD15 and neutralizing GM-CSF Ab is associated with linear growth failure in pediatric CD, and hepatic GH resistance in murine ileitis. C1 [D'Mello, Sharon; Trauernicht, Anna; Ryan, Anne; Bonkowski, Erin; Willson, Tara; Trapnell, Bruce C.; Denson, Lee A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [D'Mello, Sharon; Trauernicht, Anna; Ryan, Anne; Bonkowski, Erin; Willson, Tara; Trapnell, Bruce C.; Denson, Lee A.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Willson, Tara; Denson, Lee A.] Univ Cincinnati, Dept Canc & Cell Biol, Cincinnati, OH USA. [Frank, Stuart J.] Univ Alabama, Dept Med, Med Sch Birmingham, Birmingham, AL 35294 USA. [Frank, Stuart J.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Kugasathan, Subra] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. RP Denson, LA (reprint author), MLC 2010,3333 Burnet Ave, Cincinnati, OH 45229 USA. EM lee.denson@cchmc.org FU Crohn's & Colitis Foundation of America; Broad Medical Research Program; Integrative Morphology core of the National Institutes of Health (NIH) [1P30DK078392-01]; NIH [R01 DK078683, DK068164, T32 DK007727]; VA Merit Review grant FX Supported by the Crohn's & Colitis Foundation of America through a generous gift from the Litwin Foundation, the Broad Medical Research Program, the Integrative Morphology core of the National Institutes of Health (NIH)-supported Cincinnati Children's Hospital Research Foundation Digestive Health Center (1P30DK078392-01), NIH grants R01 DK078683 (to LD.), DK068164 (to L. D.), and T32 DK007727 (to S. D., A. T.), and a VA Merit Review grant (to S.F.). NR 25 TC 9 Z9 9 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD FEB PY 2012 VL 18 IS 2 BP 236 EP 245 DI 10.1002/ibd.21689 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 874LD UT WOS:000298957800007 PM 21337672 ER PT J AU Townsend, K Corry, JM Quigley, BH George, M AF Townsend, Kristen Corry, James M. Quigley, Beth Hogan George, Maureen TI A Feasibility Study of Q-sort to Determine Recall of Skin Test Results and Environmental Remediation Education SO JOURNAL OF ASTHMA LA English DT Article; Proceedings Paper CT Meeting on Excerpts from the Occupational and Environmental CY NOV, 2010 CL Tel Aviv Univ, Tel Aviv, ISRAEL HO Tel Aviv Univ DE African American; allergies; asthma; Q-sort; self-management; triggers; urban ID ASTHMA MANAGEMENT; ACCURACY; INTERVENTION AB Objective. Allergic asthma is common in urban minority children and evidence suggests that remediation tailored to the child's allergic profile is the most effective management strategy. The purpose of this pilot study therefore was to examine the caregiver's recall of their child's skin test results and the accuracy of planned remediation similar to 4 months after testing. Methods. Caregivers were asked to recall their child's skin test results similar to 4 months after their skin testing but before any follow-up visit. A Q-sort was then used to determine the knowledge of the recommended remediation. In this Q-sort, caregivers placed 52 cards, each representing one intervention for an indoor allergen, on a response board that prioritized the interventions. At the conclusion of the Q-sort, caregivers received feedback on the accuracy of their recall and prioritization. Results. African American caregivers (5 females; mean age 33.6) of 5 children (4 males; mean age 7.8) were enrolled. No caregiver's recall of skin test results was concordant with the actual results for type or number of allergens. Caregiver's accuracy in prioritizing strategies was 33-100% for cat dander, 40-70% for molds, 70-87% for dust mite allergens, and 100% for the one dog allergic child. Subjects preferred Q-sort to traditional methods of receiving remediation education. Conclusions. Caregivers do not accurately recall skin test results and this may, in part, impede their ability to implement appropriate interventions. A low-literacy game-style approach is a novel strategy to provide complex teaching that warrants further investigation. C1 [Quigley, Beth Hogan; George, Maureen] Univ Penn, Dept Family & Community Hlth, Sch Nursing, Philadelphia, PA 19104 USA. [Corry, James M.] Childrens Hosp Philadelphia, Div Allergy, Philadelphia, PA 19104 USA. [George, Maureen] Univ Penn, Ctr Hlth Equ Res, Sch Nursing, Philadelphia, PA 19104 USA. RP George, M (reprint author), Univ Penn, Dept Family & Community Hlth, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA. EM mgeorge@nursing.upenn.edu NR 23 TC 2 Z9 2 U1 3 U2 8 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PD FEB PY 2012 VL 49 IS 1 BP 83 EP 89 DI 10.3109/02770903.2011.635832 PG 7 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 875SD UT WOS:000299054100016 PM 22124168 ER PT J AU Tavakoli-Tabasi, S Bagree, A AF Tavakoli-Tabasi, Shahriar Bagree, Ameena TI A Longitudinal Cohort Study of Mucocutaneous Drug Eruptions During Interferon and Ribavirin Treatment of Hepatitis C SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE drug rash; interferon; ribavirin; eczema; hepatitis C ID NUMMULAR ECZEMA SECONDARY; PLUS RIBAVIRIN; VIRUS-INFECTION; PEGINTERFERON ALPHA-2B; COMBINATION THERAPY; CUTANEOUS REACTIONS; INITIAL TREATMENT; HYPERPIGMENTATION; PREVALENCE; PATIENT AB Goals: To describe dermatologic side effects encountered during treatment of patients with chronic hepatitis C, and analyze factors predisposing to such reactions. Background: Treatment of hepatitis C virus (HCV) infection with interferon (IFN) and ribavirin is associated with a number of mucocutaneous adverse reactions that have not been adequately studied. Study: A retrospective cohort study design was used to longitudinally describe mucocutaneous drug eruptions during IFN and ribavirin therapy in HCV-infected patients. Factors predictive of mucocutaneous eruptions were analyzed by the use of Kaplan-Meier curves and Cox proportional hazard model. Results: A total of 286 HCV-infected consecutive patients were treated with one of the IFN alpha formulations plus ribavirin. The mean age was 51.1 years (SD 5.6). There were 6 female patients. There were 5 patients who were also infected with human immunodeficiency virus (HIV). Fifty-six percent of the patients were white, 37% were African American, and 14% were Hispanic. Twenty-one percent of all study patients developed mucocutaneous drug eruptions. The most common drug eruptions were eczematous drug eruptions (48%), seborrheic dermatitis (11%), and xerosis (8%). Dermatologic eruptions were a contributing factor in the decision to discontinue antiviral treatment in 10% of cases. Use of Pegylated IFN formulations (hazard ratio = 1.86; 95% confidence interval, 1.04-3.34) and presence of HIV coinfection (hazard ratio = 4.46; 95% confidence interval, 1.61-12.92) were associated with increased rate of skin reactions. Conclusions: Mucocutaneous reactions during IFN and ribavirin treatment of hepatitis C are common and are associated with HIV infection and use of Pegylated IFN. C1 [Tavakoli-Tabasi, Shahriar] Michael E DeBakey Vet Adm Med Ctr, Houston, TX 77030 USA. [Tavakoli-Tabasi, Shahriar] Baylor Coll Med, Houston, TX 77030 USA. [Bagree, Ameena] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA. RP Tavakoli-Tabasi, S (reprint author), Michael E DeBakey Vet Adm Med Ctr, 2002 Holcombe Blvd,111PC, Houston, TX 77030 USA. EM shahriar@bcm.edu FU Michael E DeBakey VA Medical Center, Houston, TX FX This work was conducted at, and was supported by the Michael E DeBakey VA Medical Center, Houston, TX. NR 24 TC 5 Z9 6 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD FEB PY 2012 VL 46 IS 2 BP 162 EP 167 DI 10.1097/MCG.0b013e318228b5f6 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 876OZ UT WOS:000299118400013 PM 21814144 ER PT J AU Kirchner, JE Parker, LE Bonner, LM Fickel, JJ Yano, EM Ritchie, MJ AF Kirchner, JoAnn E. Parker, Louise E. Bonner, Laura M. Fickel, Jacqueline J. Yano, Elizabeth M. Ritchie, Mona J. TI Roles of managers, frontline staff and local champions, in implementing quality improvement: stakeholders' perspectives SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE LA English DT Article DE champions; frontline providers; implementation; managers; primary care; mental health; quality improvement ID PRACTICE GUIDELINES; OPINION LEADERS; HEALTH-CARE; CONCEPTUAL-FRAMEWORK; PARTICIPATION; SATISFACTION; KNOWLEDGE; TAXONOMY; SYSTEMS; WORK AB Background Translating promising research findings into routine clinical care has proven difficult to achieve; even highly efficacious programmes remain unadopted. Critical to changing care is an understanding of the context within which the improvement effort occurs, including the climate or culture. Health care systems are multicultural due to the wide variety of professionals, subgroups, divisions and teams within them. Yet, little work describes and compares different stakeholders' views on their and others' roles in promoting successful quality improvement implementation. C1 [Kirchner, JoAnn E.; Parker, Louise E.; Ritchie, Mona J.] HSR&D Ctr Mental Healthcare & Outcomes Res, N Little Rock, AR 72114 USA. [Kirchner, JoAnn E.; Parker, Louise E.; Ritchie, Mona J.] Mental Hlth Qual Enhancement Res Initiat, N Little Rock, AR USA. [Kirchner, JoAnn E.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Bonner, Laura M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Bonner, Laura M.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Fickel, Jacqueline J.; Yano, Elizabeth M.] Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Kirchner, JE (reprint author), HSR&D Ctr Mental Healthcare & Outcomes Res, 2200 Ft Roots Dr,Bldg 58, N Little Rock, AR 72114 USA. EM kirchnerjoanne@uams.edu FU Cost and Value of Evidenced-Based Solutions for Depression Study (COVES) [MNT 02-209]; VA HSR&D Research Career Scientist award [05-195] FX Work on this manuscript was supported by the Cost and Value of Evidenced-Based Solutions for Depression Study (COVES) MNT 02-209. Dr Yano's time is supported by VA HSR&D Research Career Scientist award (Project #05-195). We would like to thank Lisa Rubenstein, MD, MPH, and Edmund Chaney, PhD, for their leadership on TIDES Implementation, Geoffrey Curran, PhD, for his review, Penny White for her administrative support, and Valorie Shue for her assistance with editing the manuscript. NR 43 TC 14 Z9 14 U1 1 U2 21 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1356-1294 J9 J EVAL CLIN PRACT JI J. Eval. Clin. Pract. PD FEB PY 2012 VL 18 IS 1 BP 63 EP 69 DI 10.1111/j.1365-2753.2010.01518.x PG 7 WC Health Care Sciences & Services; Medical Informatics; Medicine, General & Internal SC Health Care Sciences & Services; Medical Informatics; General & Internal Medicine GA 872XL UT WOS:000298844600011 PM 20738467 ER PT J AU Agudelo, JF Flierl, MA Smith, WR Moore, EE Williams, AE Eckels, PC Morgan, SJ Stahel, PF AF Agudelo, Juan F. Flierl, Michael A. Smith, Wade R. Moore, Ernest E. Williams, Allison E. Eckels, Philip C. Morgan, Steven J. Stahel, Philip F. TI Influence of Preoperative 7.5% Hypertonic Saline on Neutrophil Activation After Reamed Intramedullary Nailing of Femur Shaft Fractures: A Prospective Randomized Pilot Study SO JOURNAL OF ORTHOPAEDIC TRAUMA LA English DT Article DE hypertonic saline; intramedullary nailing; femur shaft fracture; neutrophil ID MULTIPLE ORGAN FAILURE; RESPIRATORY-DISTRESS-SYNDROME; INFLAMMATORY RESPONSE SYNDROME; TRAUMATIC HEMORRHAGIC-SHOCK; CONTROL ORTHOPEDIC-SURGERY; L-SELECTIN; DAMAGE CONTROL; CYTOTOXIC RESPONSE; FEMORAL FRACTURES; HYPOVOLEMIC SHOCK AB Objectives: Femoral reaming and intramedullary nailing (IMN) primes polymorphonuclear leukocytes (PMNL) and thereby increases the posttraumatic systemic inflammatory response. Resuscitation with hypertonic saline (HTS) attenuates PMNL activation after trauma-hemorrhage. We hypothesized that preoperative administration of 7.5% HTS attenuates PMNL priming after IMN of unilateral femur shaft fractures compared with 0.9% normal saline. Design: Prospective, randomized, double-blind study. Setting: Level I trauma center. Patients: Twenty patients between 18 and 80 years of age with an Injury Severity Score less than 25 and a unilateral femur shaft fracture amenable to IMN fixation within 24 hours after injury. Intervention: Patients were allocated to equally sized HTS or normal saline treatment groups (n = 10) before surgery. Solutions were administered in a blinded bag as a single bolus of 4 mL/kg body weight immediately before surgery. Whole blood samples were collected directly before saline application (t(0)) and at 6, 12, and 24 hours after surgery. Main Outcome Measurements: PMNL surface expression of CD11b and CD62L, as determined by flow cytometry analysis. Results: Demographic characteristics of both treatment groups were comparable. Baseline expression of CD11b and CD62L cell markers was in a similar range in the two cohorts. The expression levels of CD11b were comparable between the two groups throughout the observation time, whereas CD62L levels were significantly higher in the HTS group at 6 and 24 hours after surgery. Conclusion and Significance: Preoperative infusion of HTS appears to exert an anti-inflammatory effect by attenuating the extent of postoperative PMNL activation after reamed IMN for femoral shaft fractures. C1 [Stahel, Philip F.] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg,Dept Neurosurg, Denver, CO 80204 USA. [Smith, Wade R.] Geisinger Med Ctr, Dept Orthopaed Surg, Danville, PA 17822 USA. [Williams, Allison E.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Stahel, PF (reprint author), Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg,Dept Neurosurg, 777 Bannock St, Denver, CO 80204 USA. EM philip.stahel@dhha.org FU Orthopaedic Trauma Association (OTA) FX This study was supported by a grant from the Orthopaedic Trauma Association (OTA). NR 67 TC 4 Z9 4 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-5339 J9 J ORTHOP TRAUMA JI J. Orthop. Trauma PD FEB PY 2012 VL 26 IS 2 BP 86 EP 91 DI 10.1097/BOT.0b013e31821cfd2a PG 6 WC Orthopedics; Sport Sciences SC Orthopedics; Sport Sciences GA 877RQ UT WOS:000299200000010 PM 21904224 ER PT J AU Xie, PX Kranzler, HR Zhang, HP Oslin, D Anton, RF Farrer, LA Gelernter, J AF Xie, Pingxing Kranzler, Henry R. Zhang, Huiping Oslin, David Anton, Raymond F. Farrer, Lindsay A. Gelernter, Joel TI Childhood Adversity Increases Risk for Nicotine Dependence and Interacts with alpha 5 Nicotinic Acetylcholine Receptor Genotype Specifically in Males SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE CHRNA5; childhood adversity; gene-environment interaction; nicotine dependence; Fagerstrom test for nicotine dependence score ID GENOMEWIDE LINKAGE SCAN; SEMISTRUCTURED ASSESSMENT; EPIGENETIC REGULATION; POSTTRAUMATIC-STRESS; ALCOHOLISM SSADDA; OPIOID DEPENDENCE; SMOKING-BEHAVIOR; DRUG-DEPENDENCE; SEX-DIFFERENCES; ABUSE AB The relative importance of specific genetic and environmental factors in regulating nicotine dependence (ND) risk, including the effects on specific forms of childhood adversity on smoking risk, have been understudied. Genome-wide association studies and rodent models have demonstrated that the alpha 5 nicotinic acetylcholine receptor gene (CHRNA5) is important in regulating nicotine intake. Childhood adversity increases the methylation level of the CHRNA5 promoter region in European Americans (EAs), an effect that was observed only in males (Zhang et al, submitted for publication). In view of this potential sex difference in the effects of early life experience on smoking, we investigated the presence of a sex-specific gene-by-environment effect of this marker on ND risk. A nonsynonymous SNP in CHRNA5 previously associated to ND and several related traits, rs16969968, was genotyped in 2206 EAs (1301 men and 905 women). The main and interactive effects of childhood adversity and rs16969968 genotype on diagnosis of ND and ND defined by dichotomized Fagerstrom test for ND (FTND) scores were explored. Men and women were analyzed separately to test for sex differences. Childhood adversity significantly increased ND risk in both sexes, and the effect in women was twice than that in men. Significant interactive effects of childhood adversity and rs16969968 genotype were observed in men (ND: OR = 1.80, 95% CI = 1.18-2.73, P = 0.0044; FTND: OR = 1.79, 95% CI = 1.11-2.88, P = 0.012). No interaction was found in women. This study provides evidence of a sex-specific gene x environment effect of CHRNA5 and childhood adversity on the risk for ND. Neuropsychopharmacology (2012) 37, 669-676; doi: 10.1038/npp.2011.240; published online 19 October 2011 C1 [Xie, Pingxing; Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Xie, Pingxing; Zhang, Huiping; Gelernter, Joel] VA CT Healthcare Ctr, West Haven, CT USA. [Kranzler, Henry R.; Oslin, David] Univ Penn, Dept Psychiat, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Zhang, Huiping; Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Anton, Raymond F.] Med Univ S Carolina, Dept Psychiat, Ctr Alcohol & Drug Programs, Charleston, SC 29425 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Med, Boston, MA USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Genet & Genom, Boston, MA USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. RP Gelernter, J (reprint author), Yale Univ, Sch Med, Dept Psychiat, Div Human Genet Psychiat,VA CT Healthcare Ctr 116, 950 Campbell Ave, West Haven, CT 06516 USA. EM joel.gelernter@yale.edu FU NIH [R01 DA12690, R01 DA12849, R01 AA11330]; Alkermes; GlaxoSmithKline; Gilead; Lundbeck; Merck; Eli Lilly; Janssen; Schering Plough; Abbott; Johnson Johnson; ACTIVE FX We thank the individuals and families participating in this work and the interviewers at all the participating sites for collecting the data. This study was supported by NIH Grants R01 DA12690, R01 DA12849, and R01 AA11330.; Dr Kranzler has received consulting fees from Alkermes, GlaxoSmithKline, Gilead, and Lundbeck and research support from Merck. Dr Anton reports for the last 2 years, being a consultant for Eli Lilly, GlaxoSmithKline, and Alkermes. Drs Kranzler and Anton also report associations with Eli Lilly, Merck, Janssen, Schering Plough, Lundbeck, Alkermes, GlaxoSmithKline, Abbott, and Johnson & Johnson, as these companies provide support to the ACNP Alcohol Clinical Trials Initiative (ACTIVE) and they receive support from ACTIVE. Dr Gelernter reports that he has received compensation for professional services in the previous 3 years from the following entities: Yale University School of Medicine, Veterans Affairs Healthcare System (VA), and the National Institutes of Health (NIAAA, NIDA, and NIMH), and related to academic lectures and editorial functions in various scientific venues (including the ACNP). The other authors declared no conflict of interest. NR 45 TC 18 Z9 18 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD FEB PY 2012 VL 37 IS 3 BP 669 EP 676 DI 10.1038/npp.2011.240 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 876OV UT WOS:000299117900009 PM 22012472 ER PT J AU Langdale, LA AF Langdale, Lorrie A. TI WHAT'S NEW IN SHOCK, FEBRUARY 2012? SO SHOCK LA English DT Editorial Material C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Langdale, LA (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 16 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PD FEB PY 2012 VL 37 IS 2 BP 127 EP 130 DI 10.1097/SHK.0b013e31824255b3 PG 4 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 879FS UT WOS:000299315700001 PM 22249217 ER PT J AU Schwartz, GG AF Schwartz, Gregory G. TI New Horizons for Cholesterol Ester Transfer Protein Inhibitors SO CURRENT ATHEROSCLEROSIS REPORTS LA English DT Article DE Cholesterol ester transfer protein; High density lipoprotein; Torcetrapib; Anacetrapib; Dalcetrapib ID DENSITY-LIPOPROTEIN CHOLESTEROL; TYPE-2 DIABETES-MELLITUS; RANDOMIZED CONTROLLED-TRIAL; LIPID-LEVEL MANAGEMENT; CORONARY-HEART-DISEASE; CETP INHIBITOR; ENDOTHELIAL FUNCTION; HEALTHY-SUBJECTS; HDL CHOLESTEROL; CLINICAL-TRIAL AB High-density lipoprotein (HDL) cholesterol levels bear an inverse relationship to cardiovascular risk. To date, however, no intervention specifically targeting HDL has been demonstrated to reduce cardiovascular risk. Cholesterol ester transfer protein (CETP) mediates transfer of cholesterol ester from HDL to apolipoprotein B-containing particles. Most, but not all observational cohort studies indicate that genetic polymorphisms of CETP associated with reduced activity and higher HDL cholesterol levels are also associated with reduced cardiovascular risk. Some, but not all studies indicate that CETP inhibition in rabbits retards atherosclerosis, whereas transgenic CETP expression in mice promotes atherosclerosis. Torcetrapib, the first CETP inhibitor to reach phase III clinical development, was abandoned due to excess mortality associated with increases in aldosterone and blood pressure. Two other CETP inhibitors have entered phase III clinical development. Anacetrapib is a potent inhibitor of CETP that produces very large increases in HDL cholesterol and large reductions in low-density lipoprotein (LDL) cholesterol, beyond those achieved with statins. Dalcetrapib is a less potent CETP inhibitor that produces smaller increases in HDL cholesterol with minimal effect on LDL cholesterol. Both agents appear to allow efflux of cholesterol from macrophages to HDL in vitro, and neither agent affects blood pressure or aldosterone in vivo. Two large cardiovascular outcomes trials, one with anacetrapib and one with dalcetrapib, should provide a conclusive test of the hypothesis that inhibition of CETP decreases cardiovascular risk. C1 [Schwartz, Gregory G.] Denver VA Med Ctr, Denver, CO 80220 USA. [Schwartz, Gregory G.] Univ Colorado, Denver, CO 80202 USA. [Schwartz, Gregory G.] VA Med Ctr, Denver, CO USA. RP Schwartz, GG (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM Gregory.Schwartz@va.gov FU Roche Laboratories FX G.G. Schwartz has received research grants from Roche Laboratories. NR 45 TC 11 Z9 11 U1 0 U2 1 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1523-3804 J9 CURR ATHEROSCLER REP JI Curr. Atherosclerol. Rep. PD FEB PY 2012 VL 14 IS 1 BP 41 EP 48 DI 10.1007/s11883-011-0217-9 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 874YW UT WOS:000298995900006 PM 22083134 ER PT J AU Parmelee, PA Harralson, TL McPherron, JA DeCoster, J Schumacher, HR AF Parmelee, Patricia A. Harralson, Tina L. McPherron, Jesse A. DeCoster, Jamie Schumacher, H. Ralph TI Pain, Disability, and Depression in Osteoarthritis: Effects of Race and Sex SO JOURNAL OF AGING AND HEALTH LA English DT Article DE osteoarthritis; depression; disability; sex differences; ethnicity ID OLDER-ADULTS; KNEE OSTEOARTHRITIS; PHYSICAL-DISABILITY; RHEUMATOID-ARTHRITIS; ACTIVITY LIMITATIONS; ETHNIC-DIFFERENCES; RACIAL-DIFFERENCES; PRIMARY-CARE; WOMEN; SYMPTOMS AB Objectives: A cross-sectional study examined how race and sex affect associations among osteoarthritis (OA) pain, disability, and depression in 363 older adults with diagnosed knee OA. Method: African American (Black; N = 94) and non-Hispanic White (White; N = 269) men and women self-reported pain, disability, depressive symptoms, arthritis history, general health, and demographic information. Results: Women experienced greater pain and marginally greater disability than men; African Americans reported greater disability and marginally greater pain than non-Hispanic Whites. These effects varied with education, health, and arthritis history. In ordinary least squares regression analyses, race and pain independently predicted depression. Significant interactions of race, sex, and disability were driven by a lack of relationship between depression and disability among African American men. Discussion: Race and sex influence affective response to OA pain and disability in complex ways, with African American men showing paradoxical effects. Further research is needed to elucidate mechanisms of this moderation effect. C1 [Parmelee, Patricia A.] Univ Alabama, Ctr Mental Hlth & Aging, Tuscaloosa, AL 35487 USA. [Harralson, Tina L.] Polaris Hlth Direct, Langhorne, PA USA. [Schumacher, H. Ralph] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Schumacher, H. Ralph] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Parmelee, PA (reprint author), Univ Alabama, Ctr Mental Hlth & Aging, 207 Osband,Box 870315, Tuscaloosa, AL 35487 USA. EM pparmelee@ua.edu FU NIMH NIH HHS [1-R01-MH51800] NR 45 TC 15 Z9 15 U1 0 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 J9 J AGING HEALTH JI J. Aging Health PD FEB PY 2012 VL 24 IS 1 BP 168 EP 187 DI 10.1177/0898264311410425 PG 20 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA 868YP UT WOS:000298562800008 PM 21693669 ER PT J AU Shaughnessy, M Michael, K Resnick, B AF Shaughnessy, Marianne Michael, Kathleen Resnick, Barbara TI Impact of Treadmill Exercise on Efficacy Expectations, Physical Activity, and Stroke Recovery SO JOURNAL OF NEUROSCIENCE NURSING LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; SELF-EFFICACY; OLDER-ADULTS; INSULIN SENSITIVITY; PERFORMANCE; SURVIVORS; QUESTIONNAIRES; PERSPECTIVES; RELIABILITY; VALIDITY AB Stroke survivors are at high risk for cardiovascular mortality which can be in part mitigated by increasing physical activity. Self-efficacy for exercise is known to play a role in adoption of exercise behaviors. This study examines self-reported psychological outcomes in a group of 64 stroke survivors randomized to either a 6-month treadmill training program or a stretching program. Results indicated that, regardless of group, all study participants experienced increased self-efficacy (F = 2.95, p = .09) and outcome expectations for exercise (F = 13.23, p < 0.001) and improvements in activities of daily living as reported on the Stroke Impact Scale (F = 10.97, p = .002). No statistically significant between-group differences were noted, possibly because of the fact that specific interventions designed to enhance efficacy beliefs were not part of the study. Theoretically based interventions should be tested to clarify the role of motivation and potential influence on exercise and physical activity in the stroke survivor population. C1 [Shaughnessy, Marianne] US Dept Vet Affairs, Baltimore, MD USA. [Shaughnessy, Marianne] Baltimore Geriatr Res Educ & Clin Ctr, Vet Affairs Med Ctr, Baltimore, MD USA. [Shaughnessy, Marianne; Michael, Kathleen; Resnick, Barbara] Univ Maryland, Baltimore Sch Nursing, Baltimore, MD USA. RP Shaughnessy, M (reprint author), US Dept Vet Affairs, Baltimore, MD USA. EM mshaughn@grecc.umaryland.edu FU Department of Veterans Affairs and Veterans Affairs Medical Center Baltimore Geriatric Research, Education and Clinical Cente; University of Maryland School of Medicine Division of Gerontology and Geriatric Medicine; National Institute on Aging Claude D. Pepper Older Americans Independence Center [P30-AG028747]; Maryland Exercise and Robotics Center of Excellence FX This work was supported by the Department of Veterans Affairs and Veterans Affairs Medical Center Baltimore Geriatric Research, Education and Clinical Center; the University of Maryland School of Medicine Division of Gerontology and Geriatric Medicine; the National Institute on Aging Claude D. Pepper Older Americans Independence Center (P30-AG028747); and Maryland Exercise and Robotics Center of Excellence. NR 38 TC 10 Z9 10 U1 0 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0888-0395 J9 J NEUROSCI NURS JI J. Neurosci. Nurs. PD FEB PY 2012 VL 44 IS 1 BP 27 EP 35 DI 10.1097/JNN.0b013e31823ae4b5 PG 9 WC Clinical Neurology; Nursing SC Neurosciences & Neurology; Nursing GA 869YS UT WOS:000298636900005 PM 22210302 ER PT J AU Cheng, T Maddox, NC Wong, AW Rahnama, R Kuo, AC AF Cheng, Tiffany Maddox, Nicole C. Wong, Andrew W. Rahnama, Ruyan Kuo, Alfred C. TI Comparison of gene expression patterns in articular cartilage and dedifferentiated articular chondrocytes SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE articular cartilage; dedifferentiation; gene expression ID MESENCHYMAL STEM-CELLS; MOUSE LIMB; CHONDROGENIC DIFFERENTIATION; SUPERFICIAL ZONE; PROGENITOR CELLS; BONE-MARROW; MARKERS; PHENOTYPE; PROTEIN; EXPANSION AB During monolayer culture, articular chondrocytes dedifferentiate into fibroblast-like cells. The mechanisms underlying this process are poorly understood. We sought to further characterize dedifferentiation by identifying an extended panel of genes that distinguish articular cartilage from dedifferentiated chondrocytes. Thirty-nine candidate marker-genes were identified from previous studies on articular-cartilage gene-expression. Real-time PCR was used to evaluate the mRNA levels for these candidates in calf articular cartilage and dedifferentiated articular chondrocytes. Twenty-two of the candidate marker genes exhibited at least a two-fold difference in gene expression in the two cell types. Twelve of these genes had at least a ten-fold difference in gene expression. Tenascin C (TNC), type I collagen (COL1A1), and hypoxia-inducible factor 1 alpha (HIF1a) showed the highest relative expression levels in dedifferentiated chonodrocytes. Type II collagen (COL2A1), type XI collagen (COL11A2), and superficial zone protein (SZP) showed the highest relative expression levels in articular cartilage. In contrast to previous findings, fibromodulin mRNA, and protein levels were higher in dedifferentiated chondrocytes. Compared to smaller subsets of markers, this panel of 12 highly differentially expressed genes may more precisely distinguish articular cartilage from dedifferentiated chondrocytes. Since many of the genes up-regulated in dedifferentiated chondrocytes are also expressed during cartilage development, dedifferentiated chondrocytes may possess features of cartilage precursor cells. (C) 2011 Orthopaedic Research Society Published by Wiley Periodicals, Inc. J Orthop Res 30:234245, 2012 C1 [Kuo, Alfred C.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Kuo, AC (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. EM kuoac@orthosurg.ucsf.edu FU UCSF Department of Orthopaedic Surgery; Northern California Institute for Research and Education; Veterans Affairs Medical Center, San Francisco, California FX This work was supported by the UCSF Department of Orthopaedic Surgery and the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, California. The authors have no competing professional or financial affiliations. NR 49 TC 24 Z9 25 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD FEB PY 2012 VL 30 IS 2 BP 234 EP 245 DI 10.1002/jor.21503 PG 12 WC Orthopedics SC Orthopedics GA 869FB UT WOS:000298581200011 PM 21809379 ER PT J AU Bauman, WA Cirnigliaro, CM La Fountaine, MF Jensen, AM Wecht, JM Kirshblum, SC Spungen, AM AF Bauman, W. A. Cirnigliaro, C. M. La Fountaine, M. F. Jensen, A. M. Wecht, J. M. Kirshblum, S. C. Spungen, A. M. TI Re: A Small-Scale Clinical Trial to Determine the Safety and Efficacy of Testosterone Replacement Therapy in Hypogonadal Men With Spinal Cord Injury Editorial Comment SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 [Bauman, W. A.; Cirnigliaro, C. M.; La Fountaine, M. F.; Jensen, A. M.; Wecht, J. M.; Kirshblum, S. C.; Spungen, A. M.] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA. RP Bauman, WA (reprint author), James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD FEB PY 2012 VL 187 IS 2 BP 558 EP 558 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 875YC UT WOS:000299070400068 ER PT J AU Cai, GQ Atzmon, G Naj, AC Beecham, GW Barzilai, N Haines, JL Sano, M Pericak-Vance, M Buxbaum, JD AF Cai, Guiqing Atzmon, Gil Naj, Adam C. Beecham, Gary W. Barzilai, Nir Haines, Jonathan L. Sano, Mary Pericak-Vance, Margaret Buxbaum, Joseph D. TI Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer Disease SO NEUROBIOLOGY OF AGING LA English DT Article DE Association; Genetics; Mutation; Rare variation ID ASSOCIATION; GENOTYPE AB The Alzheimer amyloid protein precursor (APP) is subject to proteolysis by ADAM10 and ADAM17, precluding the formation of A beta. Recently, coding variations in ADAM10 resulting in altered function have been reported in familial Alzheimer disease (AD). The authors carried out a large-scale (n = 576: Controls, 271; AD, 305) resequencing study of ADAM10 in sporadic AD. The results do not support a significant role for ADAM10 mutations in AD. The results also make it clear that the careful examination of ancestry required in any case-control comparison is especially true with rare variations, where even a very small number of variations might form the basis of scientific conclusions. (C) 2012 Elsevier Inc. All rights reserved. C1 [Cai, Guiqing; Sano, Mary; Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Buxbaum, Joseph D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA. [Atzmon, Gil; Barzilai, Nir] Albert Einstein Coll Med, Dept Med & Genet, Bronx, NY 10467 USA. [Naj, Adam C.; Beecham, Gary W.; Pericak-Vance, Margaret] Univ Miami, Hussman Inst Human Genom, Miami, FL USA. [Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Buxbaum, JD (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM joseph.buxbaum@mssm.edu RI Haines, Jonathan/C-3374-2012 OI Buxbaum, Joseph/0000-0001-8898-8313 FU National Institute on Aging of the National Institutes of Health [AG010491, AG002219, AG005138]; Glenn Foundation [AG027734, AG018728, RR012248, DK020541] FX This work was supported by grants from the National Institute on Aging of the National Institutes of Health (AG010491 and AG002219, as well as pilot award to GC from the Mount Sinai Alzheimer disease Research Center/AG005138). The longevity study was supported by AG027734, AG018728, RR012248, DK020541, and RR012248 and a grant from the Glenn Foundation. JDB is the G. Harold and Leila Y. Mathers Professor of Geriatrics and Adult Development. NR 9 TC 10 Z9 10 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD FEB PY 2012 VL 33 IS 2 BP 416 EP U719 DI 10.1016/j.neurobiolaging.2010.03.003 PG 5 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 863NR UT WOS:000298171800020 PM 20381196 ER PT J AU Chen, LJ Yoo, SE Na, R Liu, YH Ran, QT AF Chen, Liuji Yoo, Si-Eun Na, Ren Liu, Yuhong Ran, Qitao TI Cognitive impairment and increased A beta levels induced by paraquat exposure are attenuated by enhanced removal of mitochondrial H2O2 SO NEUROBIOLOGY OF AGING LA English DT Article DE Pesticide exposure; Alzheimer's disease; Mitochondria; Oxidative stress; Beta-amyloid; Peroxiredoxin 3; Mitochondrial H2O2; Aging ID APP TRANSGENIC MICE; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; SUPEROXIDE-PRODUCTION; AMYLOID HYPOTHESIS; PARKINSONS-DISEASE; OXIDATIVE STRESS; MOUSE-BRAIN; MEMORY; LIFE AB Pesticide exposure is a risk factor of Alzheimer's disease (AD). However, little is known about how pesticide exposure may promote AD pathogenesis. In this study, we investigated the effects of paraquat pesticide exposure on beta-amyloid (A beta) levels and cognition using wild-type (WT) mice and beta-amyloid precursor protein (APP) transgenic mice. Our results showed that wild-type mice and APP transgenic mice after paraquat exposure had increased oxidative damage specifically in mitochondria of cerebral cortex and exhibited mitochondrial dysfunction. Moreover, the elevated mitochondrial damage was directly correlated with impaired associative learning and memory and increased A beta levels in APP transgenic mice exposed to paraquat. Furthermore, overexpression of peroxiredoxin 3, a mitochondrial antioxidant defense enzyme important for H2O2 removal, protected against paraquat-induced mitochondrial damage and concomitantly improved cognition and decreased A beta levels in APP transgenic mice. Therefore, our results demonstrate that mitochondrial damage is a key mechanism underlying cognitive impairment and elevated amyloidogenesis induced by paraquat and that enhanced removal of mitochondrial H2O2 could be an effective strategy to ameliorate AD pathogenesis induced by pesticide exposure. Published by Elsevier Inc. C1 [Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, CSB Dept, Barshop Inst, San Antonio, TX 78245 USA. [Chen, Liuji; Yoo, Si-Eun; Na, Ren; Liu, Yuhong; Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Yoo, Si-Eun] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA. [Ran, Qitao] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Ran, QT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, CSB Dept, Barshop Inst, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM ran@uthscsa.edu FU Department of Veteran Affairs FX The study was supported by a Merit Award (QR) from the Department of Veteran Affairs. NR 34 TC 4 Z9 5 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD FEB PY 2012 VL 33 IS 2 AR 432.e15 DI 10.1016/j.neurobiolaging.2011.01.008 PG 12 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 863NR UT WOS:000298171800052 PM 21429624 ER PT J AU Ritter, BP Angelo, GW Durner, M Rossy-Fullana, E Carrion-Baralt, J Silverman, JM Bespalova, IN AF Ritter, Benjamin P. Angelo, Gary W. Durner, Martina Rossy-Fullana, Enrique Carrion-Baralt, Jose Silverman, Jeremy M. Bespalova, Irina N. TI Mutation screening of PDZD2, GOLPH3, and MTMR12 genes in patients with schizophrenia SO PSYCHIATRIC GENETICS LA English DT Editorial Material ID DISORDERS; RECEPTOR; LOCUS C1 [Ritter, Benjamin P.; Angelo, Gary W.; Durner, Martina; Silverman, Jeremy M.; Bespalova, Irina N.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Ritter, Benjamin P.; Angelo, Gary W.; Durner, Martina; Silverman, Jeremy M.; Bespalova, Irina N.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Rossy-Fullana, Enrique] San Juan Vet Affairs Med Ctr, San Juan, PR USA. [Carrion-Baralt, Jose] Univ Puerto Rico, San Juan, PR 00936 USA. RP Bespalova, IN (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave Levy Pl,POB 1230, New York, NY 10029 USA. EM irina.bespalova@mssm.edu FU NIMH NIH HHS [R03MH082134] NR 6 TC 2 Z9 2 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0955-8829 J9 PSYCHIAT GENET JI Psychiatr. Genet. PD FEB PY 2012 VL 22 IS 1 BP 51 EP 52 DI 10.1097/YPG.0b013e3283463dd7 PG 2 WC Genetics & Heredity; Neurosciences SC Genetics & Heredity; Neurosciences & Neurology GA 866JN UT WOS:000298376800008 PM 21451436 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Competing Influences in the Management of Gastrointestinal Bleeding SO CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY LA English DT Article AB OBJECTIVES: Management of gastrointestinal (GI) bleeding centers on the issues of location, type of mucosal lesion, effects of anticoagulation, diagnosis, and therapy. Each one of these five individual factors is affected by multiple interactions with the other coexisting factors. The aim of the present study is to analyze which set of factors ultimately exerts the largest and most lasting influence on the disease process. METHODS: The interactions among the five contributing factors are analyzed using a transposed Markov chain model. RESULTS: The analysis reveals that, in declining order, location, anticoagulation, and type of lesion exert the largest influence on the disease process. Under steady state conditions, their magnitudes of influence are 50, 33, and 17%, respectively. The other two factors, diagnosis and therapy, result as a consequence of the aforementioned three primary factors, but do not exert any major influence themselves. The outcome of the analysis remains robust to multiple wide-ranging variations in the assumptions underlying the model. CONCLUSIONS: The model of a transposed Markov chain translates an initially bewildering array of interacting influences into a coherent and transparent model of gastrointestinal bleeding. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Dept Gastroenterol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Dept Gastroenterol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 7 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2155-384X J9 CLIN TRANSL GASTROEN JI Clin. Transl. Gastroenterol. PD FEB PY 2012 VL 3 AR e8 DI 10.1038/ctg.2012.3 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA V42QA UT WOS:000209627100001 PM 23238133 ER PT J AU Halpern, SD Asch, DA Volpp, KG AF Halpern, Scott D. Asch, David A. Volpp, Kevin G. TI Commitment contracts as a way to health SO BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID SELF-CONTROL C1 [Halpern, Scott D.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Halpern, Scott D.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Halpern, Scott D.; Asch, David A.] Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. [Halpern, Scott D.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. RP Halpern, SD (reprint author), Univ Penn, Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, 423 Guardian Dr, Philadelphia, PA 19104 USA. EM shalpern@exchange.upenn.edu OI Asch, David/0000-0002-7970-286X FU NCI NIH HHS [R01 CA159932]; NIA NIH HHS [RC2 AG036592] NR 11 TC 14 Z9 14 U1 1 U2 6 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD JAN 30 PY 2012 VL 344 AR e522 DI 10.1136/bmj.e522 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 889QD UT WOS:000300087400004 PM 22290100 ER PT J AU Fitzgerald, JP Nayak, B Shanmugasundaram, K Friedrichs, W Sudarshan, S Eid, AA DeNapoli, T Parekh, DJ Gorin, Y Block, K AF Fitzgerald, John P. Nayak, Bijaya Shanmugasundaram, Karthigayan Friedrichs, William Sudarshan, Sunil Eid, Assaad A. DeNapoli, Thomas Parekh, Dipen J. Gorin, Yves Block, Karen TI Nox4 Mediates Renal Cell Carcinoma Cell Invasion through Hypoxia-Induced Interleukin 6-and 8-Production SO PLOS ONE LA English DT Article ID NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; OXIDASE SUBUNIT NOX4; INDUCIBLE FACTOR-I; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; NAD(P)H OXIDASE; ACTIVATION; EXPRESSION; INFLAMMATION AB Background: Inflammatory cytokines are detected in the plasma of patients with renal cell carcinoma (RCC) and are associated with poor prognosis. However, the primary cell type involved in producing inflammatory cytokines and the biological significance in RCC remain unknown. Inflammation is associated with oxidative stress, upregulation of hypoxia inducible factor 1-alpha, and production of pro-inflammatory gene products. Solid tumors are often heterogeneous in oxygen tension together suggesting that hypoxia may play a role in inflammatory processes in RCC. Epithelial cells have been implicated in cytokine release, although the stimuli to release and molecular mechanisms by which they are released remain unclear. AMP-activated protein kinase (AMPK) is a highly conserved sensor of cellular energy status and a role for AMPK in the regulation of cell inflammatory processes has recently been demonstrated. Methods and Principal Findings: We have identified for the first time that interleukin-6 and interleukin-8 (IL-6 and IL-8) are secreted solely from RCC cells exposed to hypoxia. Furthermore, we demonstrate that the NADPH oxidase isoform, Nox4, play a key role in hypoxia-induced IL-6 and IL-8 production in RCC. Finally, we have characterized that enhanced levels of IL-6 and IL-8 result in RCC cell invasion and that activation of AMPK reduces Nox4 expression, IL-6 and IL-8 production, and RCC cell invasion. Conclusions/Significance: Together, our data identify novel mechanisms by which AMPK and Nox4 may be linked to inflammation-induced RCC metastasis and that pharmacological activation of AMPK and/or antioxidants targeting Nox4 may represent a relevant therapeutic intervention to reduce IL-6- and IL-8-induced inflammation and cell invasion in RCC. C1 [Fitzgerald, John P.; Shanmugasundaram, Karthigayan; Sudarshan, Sunil; Parekh, Dipen J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [Block, Karen] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX 78229 USA. [Nayak, Bijaya; Eid, Assaad A.; Gorin, Yves; Block, Karen] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [DeNapoli, Thomas] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Fitzgerald, JP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. EM block@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU Veterans Administration Research Service; National Institutes of Health, National Cancer Institute (NCI) [R01:CA131272, K08:CA138774]; Cancer Center Support Grant, National Cancer Institute [5 P30 CA054174-18] FX This work was supported by the Veterans Administration Research Service, Career Scientist Award (KB) and the National Institutes of Health, National Cancer Institute (NCI) grants R01:CA131272 (KB) and K08:CA138774 (SS). This work was also supported in part by the Cancer Center Support Grant, National Cancer Institute, 5 P30 CA054174-18 (DJP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 32 TC 35 Z9 36 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 27 PY 2012 VL 7 IS 1 AR e30712 DI 10.1371/journal.pone.0030712 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 911GB UT WOS:000301704200030 PM 22303451 ER PT J AU Sun, Q Prasad, R Rosenthal, E Katiyar, SK AF Sun, Qian Prasad, Ram Rosenthal, Eben Katiyar, Santosh K. TI Grape Seed Proanthocyanidins Inhibit the Invasiveness of Human HNSCC Cells by Targeting EGFR and Reversing the Epithelial-To-Mesenchymal Transition SO PLOS ONE LA English DT Article ID NF-KAPPA-B; FACTOR BINDING PROTEIN-3; GROWTH-FACTOR RECEPTOR; NECK-CANCER; MOUSE SKIN; E-CADHERIN; CARCINOMA; HEAD; SURVIVAL; FLUOROURACIL AB Head and neck squamous cell carcinoma (HNSCC) is responsible for approximately 20,000 deaths per year in the United States. Most of the deaths are due to the metastases. To develop more effective strategies for the prevention of metastasis of HNSCC cells, we have determined the effect of grape seed proanthocyanidins (GSPs) on the invasive potential of HNSCC cell and the mechanisms underlying these effects using OSC19 cells as an in vitro model. Using cell invasion assays, we established that treatment of the OSC19 cells with GSPs resulted in a dose-dependent inhibition of cell invasion. EGFR is over-expressed in 90% of HNSCCs and the EGFR inhibitors, erlotinib and gefitinib, are being explored as therapies for this disease. We found that GSPs treatment reduced the levels of expression of EGFR in the OSC19 cells as well as reducing the activation of NF-kappa B/p65, a downstream target of EGFR, and the expression of NF-kappa B-responsive proteins. GSPs treatment also reduced the activity of ERK1/2, an upstream regulator of NF-kappa B and treatment of the cells with caffeic acid phenethyl ester, an inhibitor of NF-kappa B, inhibited cell invasion. Overexpression of EGFR and high NF-kappa B activity play a key role in the epithelial-to-mesenchymal transition, which is of critical importance in the processes underlying metastasis, and we found treatment with GSPs enhanced the levels of epithelial (E-cadherin, cytokeratins and desmoglein-2) and reduced the levels of mesenchymal (vimentin, fibronectin, N-cadherin and Slug) biomarkers in the OSC19 cells. These results indicate that GSPs have the ability to inhibit HNSCC cell invasion, and do so by targeting the expression of EGFR and activation of NF-kappa B as well as inhibiting the epithelial-to-mesenchymal transition. C1 [Sun, Qian; Prasad, Ram; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Rosenthal, Eben] Univ Alabama, Dept Surg Otolaryngol, Birmingham, AL USA. [Rosenthal, Eben; Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. RP Sun, Q (reprint author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration FX This work was supported by funds from the Veterans Administration Merit Review Award (SKK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 13 Z9 17 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 27 PY 2012 VL 7 IS 1 AR e31093 DI 10.1371/journal.pone.0031093 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 911GB UT WOS:000301704200059 PM 22299051 ER PT J AU Kogai, T Liu, YY Mody, K Shamsian, DV Brent, GA AF Kogai, Takahiko Liu, Yan-Yun Mody, Kaizeen Shamsian, Deborah V. Brent, Gregory A. TI Regulation of Sodium Iodide Symporter Gene Expression by Rac1/p38 beta Mitogen-activated Protein Kinase Signaling Pathway in MCF-7 Breast Cancer Cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID THYROID-STIMULATING HORMONE; TRANS-RETINOIC ACID; SODIUM/IODIDE SYMPORTER; SELECTIVE ACTIVATION; RADIOIODIDE UPTAKE; NIS; RADIOVIROTHERAPY; TRANSPORTER; INHIBITION; ISOFORMS AB Activation of p38 MAPK is a key pathway for cell proliferation and differentiation in breast cancer and thyroid cells. The sodium/iodide symporter (NIS) concentrates iodide in the thyroid and lactating breast. All-trans-retinoic acid (tRA) markedly induces NIS activity in some breast cancer cell lines and promotes uptake of beta-emitting radioiodide I-131 sufficient for targeted cytotoxicity. To identify a signal transduction pathway that selectively stimulates NIS expression, we investigated regulation by the Rac1-p38 signaling pathway in MCF-7 breast cancer cells and compared it with regulation in FRTL-5 rat thyroid cells. Loss of function experiments with pharmacologic inhibitors and small interfering RNA, as well as RT-PCR analysis of p38 isoforms, demonstrated the requirement of Rac1, MAPK kinase 3B, and p38 beta for the full expression of NIS in MCF-7 cells. In contrast, p38 alpha was critical for NIS expression in FRTL-5 cells. Treatment with tRA or overexpression of Rac1 induced the phosphorylation of p38 isoforms, including p38 beta. A dominant negative mutant of Rac1 abolished tRA-induced phosphorylation in MCF-7 cells. Overexpression of p38 beta or Rac1 significantly enhanced (1.9- and 3.9-fold, respectively), the tRA-stimulated NIS expression in MCF-7 cells. This study demonstrates differential regulation of NIS by distinct p38 isoforms in breast cancer cells and thyroid cells. Targeting isoform-selective activation of p38 may enhance NIS induction, resulting in higher efficacy of I-131 concentration and treatment of breast cancer. C1 [Kogai, Takahiko; Brent, Gregory A.] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. RP Kogai, T (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM tkogai@ucla.edu; gbrent@ucla.edu FU National Institutes of Health [RO1 CA089364]; Veterans Affairs Merit Review Funds FX This work was supported, in whole or in part, by National Institutes of Health Grant RO1 CA089364 (to G. A. B.). This work was also supported by Veterans Affairs Merit Review Funds. NR 37 TC 6 Z9 6 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 27 PY 2012 VL 287 IS 5 BP 3292 EP 3300 DI 10.1074/jbc.M111.315523 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 892OI UT WOS:000300295100035 PM 22157753 ER PT J AU Wei, R Bhattacharya, A Chintalaramulu, N Jernigan, AL Liu, YH Van Remmen, H Chaudhuri, AR AF Wei, Rochelle Bhattacharya, Arunabh Chintalaramulu, Naveen Jernigan, Amanda L. Liu, Yuhong Van Remmen, Holly Chaudhuri, Asish R. TI Protein misfolding, mitochondrial dysfunction and muscle loss are not directly dependent on soluble and aggregation state of mSOD1 protein in skeletal muscle of ALS SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Protein misfolding; Mitochondria; Reactive oxygen species; G93A; ALS ID AMYOTROPHIC-LATERAL-SCLEROSIS; OXIDATIVE STRESS; SOD1; RESISTANCE; TARGET AB Mutant superoxide dismutase 1 (mSOD1) is often found as aggregates at the outer-membrane of mitochondria in motor neurons of various mouse models and familial amyotrophic lateral sclerosis (f-ALS) patients. It has been postulated that disruption of mitochondrial function by physical association of misfolded mSOD1 aggregates may actually be the trigger for initiation of degeneration of motor neurons in ALS. However, it was not clear if the same mechanism is involved in muscle degeneration and mitochondrial dysfunction in skeletal muscles of ALS. Recent study from our laboratory show that two skeletal muscle proteins, namely creatine kinase (CK) and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) undergo major conformational and functional changes in the f-ALS mouse model of ALS (G93A). In this paper, we report two intriguing observations which are as follows:(i) G93A protein does not form aggregates in skeletal muscle at any stages of disease process probably due to high chymotrypsin-like activity of proteasome and thus G93A protein aggregates have no direct effects on progressive loss of muscle mass and global changes in protein conformation in ALS, and (ii) the soluble G93A protein does not have direct effects on mitochondrial dysfunction as determined by quantifying the release of reactive oxygen species (ROS) in skeletal muscle mitochondria; instead, the proteins affected by G93A possibly affect mitochondrial ROS release. These data strongly suggest for the first time that unlike in motor neurons, the soluble and aggregation states of the G93A protein do not have direct effects on protein misfolding and mitochondrial dysfunction in skeletal muscle during ALS. Published by Elsevier Inc. C1 [Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Bhattacharya, Arunabh; Jernigan, Amanda L.; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Wei, Rochelle; Bhattacharya, Arunabh; Chintalaramulu, Naveen; Liu, Yuhong; Van Remmen, Holly; Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Van Remmen, Holly; Chaudhuri, Asish R.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Chaudhuri, AR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA. EM chaudhuria@uthscsa.edu FU Veteran Affair Merit Grant Award FX This work was supported by the Veteran Affair Merit Grant Award (AC). NR 23 TC 12 Z9 12 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD JAN 27 PY 2012 VL 417 IS 4 BP 1275 EP 1279 DI 10.1016/j.bbrc.2011.12.126 PG 5 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 891DG UT WOS:000300196100029 PM 22234310 ER PT J AU Pearson, ML Selby, JV Katz, KA Cantrell, V Braden, CR Parise, ME Paddock, CD Lewin-Smith, MR Kalasinsky, VF Goldstein, FC Hightower, AW Papier, A Lewis, B Motipara, S Eberhard, ML AF Pearson, Michele L. Selby, Joseph V. Katz, Kenneth A. Cantrell, Virginia Braden, Christopher R. Parise, Monica E. Paddock, Christopher D. Lewin-Smith, Michael R. Kalasinsky, Victor F. Goldstein, Felicia C. Hightower, Allen W. Papier, Arthur Lewis, Brian Motipara, Sarita Eberhard, Mark L. CA Unexplained Dermopathy Study Team TI Clinical, Epidemiologic, Histopathologic and Molecular Features of an Unexplained Dermopathy SO PLOS ONE LA English DT Article ID STREPTOCOCCUS-PNEUMONIAE; BRACHIORADIAL PRURITUS; MEDICAL OUTCOMES; PARASITOSIS; DELUSIONS; DIAGNOSIS; CULTURE; TISSUE; PCR AB Background: Morgellons is a poorly characterized constellation of symptoms, with the primary manifestations involving the skin. We conducted an investigation of this unexplained dermopathy to characterize the clinical and epidemiologic features and explore potential etiologies. Methods: A descriptive study was conducted among persons at least 13 years of age and enrolled in Kaiser Permanente Northern California (KPNC) during 2006-2008. A case was defined as the self-reported emergence of fibers or materials from the skin accompanied by skin lesions and/or disturbing skin sensations. We collected detailed epidemiologic data, performed clinical evaluations and geospatial analyses and analyzed materials collected from participants' skin. Results: We identified 115 case-patients. The prevalence was 3.65 (95% CI = 2.98, 4.40) cases per 100,000 enrollees. There was no clustering of cases within the 13-county KPNC catchment area (p = .113). Case-patients had a median age of 52 years (range: 17-93) and were primarily female (77%) and Caucasian (77%). Multi-system complaints were common; 70% reported chronic fatigue and 54% rated their overall health as fair or poor with mean Physical Component Scores and Mental Component Scores of 36.63 (SD = 12.9) and 35.45 (SD = 12.89), respectively. Cognitive deficits were detected in 59% of case-patients and 63% had evidence of clinically significant somatic complaints; 50% had drugs detected in hair samples and 78% reported exposure to solvents. Solar elastosis was the most common histopathologic abnormality (51% of biopsies); skin lesions were most consistent with arthropod bites or chronic excoriations. No parasites or mycobacteria were detected. Most materials collected from participants' skin were composed of cellulose, likely of cotton origin. Conclusions: This unexplained dermopathy was rare among this population of Northern California residents, but associated with significantly reduced health-related quality of life. No common underlying medical condition or infectious source was identified, similar to more commonly recognized conditions such as delusional infestation. C1 [Pearson, Michele L.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Selby, Joseph V.; Cantrell, Virginia; Motipara, Sarita] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Katz, Kenneth A.] Hlth & Human Serv Agcy, HIV STD & Hepatitis Branch, San Diego, CA USA. [Braden, Christopher R.] Ctr Dis Control & Prevent, Div Food Waterborne & Environm Dis, Atlanta, GA USA. [Parise, Monica E.; Hightower, Allen W.; Eberhard, Mark L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Paddock, Christopher D.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Lewin-Smith, Michael R.] Joint Pathol Ctr, Silver Spring, MD USA. [Kalasinsky, Victor F.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA. [Goldstein, Felicia C.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Papier, Arthur] Univ Rochester, Sch Med, Dept Dermatol, Rochester, NY USA. [Lewis, Brian] Agcy Tox Subst & Dis Registry, Div Hlth Studies, Atlanta, GA USA. RP Pearson, ML (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. EM mle1@cdc.gov FU Centers for Disease Control (CDC) and Prevention FX Funding for this study was provided by the Centers for Disease Control (CDC) and Prevention. Epidemiologists from the CDC participated in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. NR 31 TC 28 Z9 28 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 25 PY 2012 VL 7 IS 1 AR e29908 DI 10.1371/journal.pone.0029908 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 910ME UT WOS:000301640600015 PM 22295070 ER PT J AU Kangovi, S Grande, D AF Kangovi, Shreya Grande, David TI Hospital Readmissions and Measures of Quality Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Kangovi, Shreya] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Grande, David] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Kangovi, S (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. EM kangovi@mail.med.upenn.edu NR 4 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 25 PY 2012 VL 307 IS 4 BP 361 EP 362 DI 10.1001/jama.2012.12 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 881EP UT WOS:000299464000014 ER PT J AU Atashband, A Ramasubbu, K AF Atashband, Armita Ramasubbu, Kumudha TI A Case of a Double Valve SO CIRCULATION LA English DT Editorial Material C1 [Ramasubbu, Kumudha] Baylor Coll Med, Sect Cardiol 3C 330, Michael E DeBakey Med Ctr, Houston, TX 77030 USA. RP Ramasubbu, K (reprint author), Baylor Coll Med, Sect Cardiol 3C 330, Michael E DeBakey Med Ctr, MEDVAMC 111-B,2002 Holcombe Blvd, Houston, TX 77030 USA. EM kumudhar@bcm.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JAN 24 PY 2012 VL 125 IS 3 BP E272 EP E273 DI 10.1161/CIRCULATIONAHA.111.057240 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 891YL UT WOS:000300252800003 PM 22271851 ER PT J AU Larauche, M Mulak, A Yuan, PQ Kanauchi, O Tache, Y AF Larauche, Muriel Mulak, Agata Yuan, Pu-Qing Kanauchi, Osamu Tache, Yvette TI Stress-induced visceral analgesia assessed non-invasively in rats is enhanced by prebiotic diet SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Stress-related visceral analgesia; Water avoidance stress; Colorectal distension; Enzyme-treated rice fiber prebiotic; Short chain fatty acids; Defecation; Rat; Solid-state manometry ID IRRITABLE-BOWEL-SYNDROME; CORTICOTROPIN-RELEASING-FACTOR; CHAIN FATTY-ACIDS; EPITHELIAL BARRIER DYSFUNCTION; CHRONIC PSYCHOLOGICAL STRESS; WATER-AVOIDANCE STRESS; COLORECTAL DISTENSION; COLONIC HYPERSENSITIVITY; BACTERIAL TRANSLOCATION; RECEPTORS MEDIATE AB AIM: To investigate the influence of repeated water avoidance stress (rWAS) on the visceromotor response (VMR) to colorectal distension (CRD) and the modulation of the response by a prebiotic diet in rats using a novel surgery-free method of solid-state manometry. METHODS: Male Wistar rats fed a standard diet with or without 4% enzyme-treated rice fiber (ERF) for 5 wk were subjected to rWAS (1 h daily x 10 d) or no stress. The VMR to graded phasic CRD was assessed by intraluminal colonic pressure recording on days 0 (baseline), 1 and 10 (45 min) and 11 (24 h) after rWAS and expressed as percentage change from baseline. Cecal content of short chain fatty acids and distal colonic histology were assessed on day 11. RESULTS: WAS on day 1 reduced the VMR to CRD at 40 and 60 mmHg similarly by 28.9% +/- 6.6% in both diet groups. On day 10, rWAS-induced reduction of VMR occurred only at 40 mmHg in the standard diet group (36.2% +/- 17.8%) while in the ERF group VMR was lowered at 20, 40 and 60 mmHg by 64.9% +/- 20.9%, 49.3% +/- 11.6% and 38.9% +/- 7.3% respectively. The visceral analgesia was still observed on day 11 in ERF- but not in standard diet-fed rats. By contrast the non-stressed groups (standard or ERF duet) exhibited no changes in VMR to CRD. In standard diet-fed rats, rWAS induced mild colonic histological changes that were absent in ERF-fed rats exposed to stress compared to non-stressed rats. The reduction of cecal content of isobutyrate and total butyrate, but not butyrate alone, was correlated with lower visceral pain response. Additionally, ERF diet increased rWAS-induced defecation by 26% and 75% during the first 0-15 min and last 15-60 min, respectively, compared to standard diet, and reduced rats' body weight gain by 1.3 fold independently of their stress status. CONCLUSION: These data provide the first evidence of psychological stress-related visceral analgesia in rats that was enhanced by chronic intake of ERF prebiotic. (C) 2012 Baishideng. All rights reserved. C1 [Larauche, Muriel; Yuan, Pu-Qing; Tache, Yvette] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. [Larauche, Muriel; Yuan, Pu-Qing; Tache, Yvette] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Oppenheimer Family Ctr Neurobiol Stress, Dept Med,Digest Dis Div, Los Angeles, CA 90073 USA. [Mulak, Agata] Wroclaw Med Univ, Dept Gastroenterol & Hepatol, PL-50556 Wroclaw, Poland. [Kanauchi, Osamu] Shiga Univ Med Sci, Shiga, Japan. [Kanauchi, Osamu] Kirin Holdings Co Ltd, Cent Labs Frontier Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan. RP Larauche, M (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, 11301 Wilshire Blvd,CURE Bldg 115,Room 111, Los Angeles, CA 90073 USA. EM mlarauche@mednet.ucla.edu OI Larauche, Muriel/0000-0003-3320-3675 FU Central Labs for Frontier Technology Kirin Holdings Co., Ltd Japan; National Institute of Health [P50 DK-64539, DK-41301, R01 DK-33061]; Veterans Administration FX Supported by Central Labs for Frontier Technology Kirin Holdings Co., Ltd Japan and the National Institute of Health grants, P50 DK-64539 (to Tache Y and Larauche M), Center Grant DK-41301 (Animal Core, to Yvette Tache), R01 DK-33061 (to Yvette Tache); and Veterans Administration Research Career Scientist Award NR 67 TC 11 Z9 11 U1 0 U2 3 PU BAISHIDENG PUBL GRP CO LTD PI BEIJING PA RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU, BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA SN 1007-9327 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD JAN 21 PY 2012 VL 18 IS 3 BP 225 EP 236 DI 10.3748/wjg.v18.i3.225 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 887XK UT WOS:000299965000004 PM 22294825 ER PT J AU Barnett, BE Ciocca, ML Goenka, R Barnett, LG Wu, JM Laufer, TM Burkhardt, JK Cancro, MP Reiner, SL AF Barnett, Burton E. Ciocca, Maria L. Goenka, Radhika Barnett, Lisa G. Wu, Junmin Laufer, Terri M. Burkhardt, Janis K. Cancro, Michael P. Reiner, Steven L. TI Asymmetric B Cell Division in the Germinal Center Reaction SO SCIENCE LA English DT Article ID T-LYMPHOCYTE DIVISION; BCL-6; ANTIGEN; DIFFERENTIATION; INFLAMMATION; EXPRESSION; RESPONSES AB Lifelong antibody responses to vaccination require reorganization of lymphoid tissue and dynamic intercellular communication called the germinal center reaction. B lymphocytes undergo cellular polarization during antigen stimulation, acquisition, and presentation, which are critical steps for initiating humoral immunity. Here, we show that germinal center B lymphocytes asymmetrically segregate the transcriptional regulator Bcl6, the receptor for interleukin-21, and the ancestral polarity protein atypical protein kinase C to one side of the plane of division, generating unequal inheritance of fate-altering molecules by daughter cells. Germinal center B lymphocytes from mice with a defect in leukocyte adhesion fail to divide asymmetrically. These results suggest that motile cells lacking constitutive attachment can receive provisional polarity cues from the microenvironment to generate daughter cell diversity and self-renewal. C1 [Barnett, Burton E.; Ciocca, Maria L.; Wu, Junmin; Reiner, Steven L.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA. [Goenka, Radhika; Burkhardt, Janis K.; Cancro, Michael P.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Barnett, Burton E.; Ciocca, Maria L.; Barnett, Lisa G.; Wu, Junmin; Laufer, Terri M.; Reiner, Steven L.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Burkhardt, Janis K.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. RP Reiner, SL (reprint author), Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA. EM sreiner@columbia.edu FU NIH [AI042370, AI076458, T32GM07229, T32HD007516, 3T32GM007170-36S1, T32AI055428, AI065644]; U.S. Department of Defense [W81WWXWH1010185]; Veterans Administration [BX000435]; Abramson family FX We thank J. Chaix, S. Gordon, M. Paley, and L. Rupp for assistance. We are grateful for funding from the NIH (grants AI042370 and AI076458 to S. L. R., T32GM07229 to B. E. B., T32HD007516 and 3T32GM007170-36S1 to M. L. C., T32AI055428 to R. G., and AI065644 to J.K.B.), the U.S. Department of Defense (grant W81WWXWH1010185 to M. P. C.), Veterans Administration (grant BX000435 to T. M. L.), and the Abramson family (to S. L. R.). The data reported in this paper are tabulated in the main paper and in the supporting online material. The authors declare no conflicts of interest. NR 19 TC 37 Z9 38 U1 0 U2 6 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD JAN 20 PY 2012 VL 335 IS 6066 BP 342 EP 344 DI 10.1126/science.1213495 PG 3 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 878RE UT WOS:000299273400049 PM 22174128 ER PT J AU Jackevicius, CA Chou, MM Ross, JS Shah, ND Krumholz, HM AF Jackevicius, Cynthia A. Chou, Mindy M. Ross, Joseph S. Shah, Nilay D. Krumholz, Harlan M. TI Generic Atorvastatin and Health Care Costs SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Pomona, CA 91766 USA. [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Toronto, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chou, Mindy M.] Indian Hlth Serv, San Fidel, NM USA. [Ross, Joseph S.; Krumholz, Harlan M.] Yale Univ, Sch Med, New Haven, CT USA. [Ross, Joseph S.; Krumholz, Harlan M.] Yale New Haven Med Ctr, New Haven, CT 06504 USA. [Shah, Nilay D.] Mayo Clin, Rochester, MN USA. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Pomona, CA 91766 USA. FU NHLBI NIH HHS [U01 HL105270]; NIA NIH HHS [K08 AG032886, K08 AG032886-04] NR 5 TC 34 Z9 35 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 19 PY 2012 VL 366 IS 3 BP 201 EP 204 DI 10.1056/NEJMp1113112 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 877RZ UT WOS:000299201400004 PM 22149736 ER PT J AU Folmer, RL AF Folmer, Robert L. TI rTMS for tinnitus SO FRONTIERS IN HUMAN NEUROSCIENCE LA English DT Editorial Material C1 Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA. RP Folmer, RL (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA. EM folmerr@ohsu.edu NR 3 TC 2 Z9 2 U1 0 U2 2 PU FRONTIERS RES FOUND PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-5161 J9 FRONT HUM NEUROSCI JI Front. Hum. Neurosci. PD JAN 18 PY 2012 VL 6 AR 1 DI 10.3389/fnhum.2012.00001 PG 1 WC Neurosciences; Psychology SC Neurosciences & Neurology; Psychology GA 882LM UT WOS:000299565200001 PM 22279433 ER PT J AU Lim, MA Selak, MA Xiang, Z Krainc, D Neve, RL Kraemer, BC Watts, JL Kalb, RG AF Lim, M. A. Selak, M. A. Xiang, Z. Krainc, D. Neve, R. L. Kraemer, B. C. Watts, J. L. Kalb, R. G. TI Reduced Activity of AMP-Activated Protein Kinase Protects against Genetic Models of Motor Neuron Disease SO JOURNAL OF NEUROSCIENCE LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODEL; HUNTINGTONS-DISEASE; SKELETAL-MUSCLE; CAENORHABDITIS-ELEGANS; CALORIC RESTRICTION; C-ELEGANS; LIFE-SPAN; IN-VIVO; MITOCHONDRIAL DYSFUNCTION AB A growing body of research indicates that amyotrophic lateral sclerosis (ALS) patients and mouse models of ALS exhibit metabolic dysfunction. A subpopulation of ALS patients possesses higher levels of resting energy expenditure and lower fat-free mass compared to healthy controls. Similarly, two mutant copper zinc superoxide dismutase 1 (mSOD1) mouse models of familial ALS possess a hypermetabolic phenotype. The pathophysiological relevance of the bioenergetic defects observed in ALS remains largely elusive. AMP-activated protein kinase (AMPK) is a key sensor of cellular energy status and thus might be activated in various models of ALS. Here, we report that AMPK activity is increased in spinal cord cultures expressing mSOD1, as well as in spinal cord lysates from mSOD1 mice. Reducing AMPK activity either pharmacologically or genetically prevents mSOD1-induced motor neuron death in vitro. To investigate the role of AMPK in vivo, we used Caenorhabditis elegans models of motor neuron disease. C. elegans engineered to express human mSOD1(G85R) in neurons develops locomotor dysfunction and severe fecundity defects when compared to transgenic worms expressing human wild-type SOD1. Genetic reduction of aak-2, the ortholog of the AMPK alpha 2 catalytic subunit in nematodes, improved locomotor behavior and fecundity in G85R animals. Similar observations were made with nematodes engineered to express mutant tat-activating regulatory (TAR) DNA-binding protein of 43 kDa molecular weight. Altogether, these data suggest that bioenergetic abnormalities are likely to be pathophysiologically relevant to motor neuron disease. C1 [Lim, M. A.; Kalb, R. G.] Childrens Hosp Philadelphia, Dept Pediat, Div Neurol, Abramson Res Ctr, Philadelphia, PA 19104 USA. [Kalb, R. G.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Lim, M. A.; Kalb, R. G.] Univ Penn, Neurosci Grad Grp, Philadelphia, PA 19104 USA. [Selak, M. A.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA. [Xiang, Z.; Krainc, D.] MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA. [Neve, R. L.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Kraemer, B. C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Fdn, Seattle, WA 98108 USA. [Kraemer, B. C.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Clin, Seattle, WA 98108 USA. [Watts, J. L.] Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA. RP Kalb, RG (reprint author), Childrens Hosp Philadelphia, Dept Pediat, Div Neurol, Abramson Res Ctr, Philadelphia, PA 19104 USA. EM kalb@email.chop.edu FU National Institutes of Health [F31NS06816502, R21NS060754, RO1NS052325]; Department of Veterans Affairs; ALS Association FX This work was supported by National Institutes of Health Grants F31NS06816502 (M. A. L.), R21NS060754, and RO1NS052325 (R. G. K.), the Department of Veterans Affairs (B. C. K.), and the ALS Association. We thank the generosity of Dr. Morris Birnbaum (University of Pennsylvania, Philadelphia, PA) for the AMPK wild-type and dominant negative plasmids; Dr. David Borchelt (University of Florida, Gainesville, FL) for the wild-type and mutant SOD1 plasmids; Drs. Arthur Horwich (Yale University, New Haven, CT) and Jiou Wang(Johns Hopkins University, Baltimore, MD) for the WT SOD1, G85R mSOD1, and G85R(line 18) worm strains; Dr. Hyeon-Sook Koo (Yonsei University, Seoul, South Korea) for the AAK2::GFP translational reporter strain; Drs. Martin Chalfie, Irini Topalidou, and Xiaoyin Chen (Columbia University, New York, NY) for the sid-1 mutant strains; Dr. Yishi Jin (University of California at San Diego, La Jolla, CA) for the CZ1200 strain; Dr. Miriam Goodman (Stanford University, Palo Alto, CA) for sharing the Parallel Worm Tracker program; and Drs. Gary Ruvkun (Harvard University, Cambridge, MA) and Todd Lamitina (University of Pennsylvania, Philadelphia, PA) for sharing RNAi clones. We acknowledge the Gene Knockout Consortium at Oklahoma Medical Research Center, which provided several of the C. elegans knock-out strains used in our experiments. We also acknowledge Jelena Mojsilovic-Petrovic, Heather Pratt, Peter Krumbhaar, and Daniel Helbig for their excellent technical assistance. Finally, we thank the C. elegans laboratories at the University of Pennsylvania (Christopher Fang-Yen, Todd Lamitina, John Murray, David Raizen, and Meera Sundaram) for their advice and suggestions. NR 97 TC 41 Z9 43 U1 0 U2 9 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JAN 18 PY 2012 VL 32 IS 3 BP 1123 EP 1141 DI 10.1523/JNEUROSCI.6554-10.2012 PG 19 WC Neurosciences SC Neurosciences & Neurology GA 879JG UT WOS:000299324900036 PM 22262909 ER PT J AU Cannuscio, CC AF Cannuscio, Carolyn C. TI Lessons in Elder Care SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia VA Med Ctr,Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Cannuscio, CC (reprint author), Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia VA Med Ctr,Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. EM carolyncannu@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 18 PY 2012 VL 307 IS 3 BP 263 EP 264 DI 10.1001/jama.2011.2004 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 877EY UT WOS:000299161200021 PM 22253392 ER PT J AU Leitch, JM Li, CX Baron, JA Matthews, LM Cao, XH Hart, PJ Culotta, VC AF Leitch, Jeffry M. Li, Cissy X. Baron, J. Allen Matthews, Lauren M. Cao, Xiaohang Hart, P. John Culotta, Valeria C. TI Post-Translational Modification of Cu/Zn Superoxide Dismutase under Anaerobic Conditions SO BIOCHEMISTRY LA English DT Article ID COPPER CHAPERONE CCS; AMYOTROPHIC-LATERAL-SCLEROSIS; SACCHAROMYCES-CEREVISIAE; CU,ZN-SUPEROXIDE DISMUTASE; CAENORHABDITIS-ELEGANS; OXYGEN; YEAST; ACTIVATION; METAL; PATHWAY AB In eukaryotic organisms, the largely cytosolic copper- and zinc-containing superoxide dismutase (Cu/Zn SOD) enzyme represents a key defense against reactive oxygen toxicity. Although much is known about the biology of this enzyme under aerobic conditions, less is understood regarding the effects of low oxygen levels on Cu/Zn SOD enzymes from diverse organisms. We show here that like bakers' yeast (Saccharomyces cerevisiae), adaptation of the multicellular Caenorhabditis elegans to growth at low oxygen levels involves strong downregulation of its Cu/Zn SOD. Much of this regulation occurs at the post-translational level where CCS-independent activation of Cu/Zn SOD is inhibited. Hypoxia inactivates the endogenous Cu/Zn SOD of C. elegans Cu/Zn SOD as well as a P144 mutant of S. cerevisiae Cu/Zn SOD (herein denoted Sod1p) that is independent of CCS. In our studies of S. cerevisiae Sod1p, we noted a posttranslational modification to the inactive enzyme during hypoxia. Analysis of this modification by mass spectrometry revealed phosphorylation at serine 38. Serine 38 represents a putative proline-directed kinase target site located on a solvent-exposed loop that is positioned at one end of the Sod1p beta-barrel, a region immediately adjacent to residues previously shown to influence CCS-dependent activation. Although phosphorylation of serine 38 is minimal when the Sod1p is abundantly active (e.g., high oxygen level), up to 50% of Sod1p can be phosphorylated when CCS activation of the enzyme is blocked, e.g., by hypoxia or low-copper conditions. Serine 38 phosphorylation can be a marker for inactive pools of Sod1p. C1 [Leitch, Jeffry M.; Li, Cissy X.; Baron, J. Allen; Matthews, Lauren M.; Culotta, Valeria C.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA. [Cao, Xiaohang; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Culotta, VC (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA. EM vculotta@jhsph.edu FU Johns Hopkins University National Institute of Environmental Health Sciences Center, National Institutes of Health (NIH) [GM 50016, NS 39112]; NIH [F32 GM 087904, ES 07141, T32 CA009110]; Judith and Jean Pape Adams Charitable Foundation FX This work was supported by the Johns Hopkins University National Institute of Environmental Health Sciences Center, National Institutes of Health (NIH) Grants GM 50016 (V.C.C.) and NS 39112 (P.J.H.), NIH Postdoctoral Fellowship F32 GM 087904 (J.M.L.), and NIH Training Grants ES 07141 (C.X.L.) and T32 CA009110 X.C. was supported in part by a grant by the Judith and Jean Pape Adams Charitable Foundation. NR 42 TC 7 Z9 7 U1 0 U2 14 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD JAN 17 PY 2012 VL 51 IS 2 BP 677 EP 685 DI 10.1021/bi201353y PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 876VJ UT WOS:000299135500011 PM 22148750 ER PT J AU Virani, SS Brautbar, A Davis, BC Nambi, V Hoogeveen, RC Sharrett, AR Coresh, J Mosley, TH Morrisett, JD Catellier, DJ Folsom, AR Boerwinkle, E Ballantyne, CM AF Virani, Salim S. Brautbar, Ariel Davis, Brian C. Nambi, Vijay Hoogeveen, Ron C. Sharrett, A. Richey Coresh, Josef Mosley, Thomas H. Morrisett, Joel D. Catellier, Diane J. Folsom, Aaron R. Boerwinkle, Eric Ballantyne, Christie M. TI Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects The Atherosclerosis Risk in Communities (ARIC) Study SO CIRCULATION LA English DT Article DE cardiovascular diseases; ethnic groups; lipoproteins; race; risk factors ID CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I; PLASMA LIPOPROTEIN(A); MYOCARDIAL-INFARCTION; LP(A) LIPOPROTEIN; ARTERY-DISEASE; ELEVATED LIPOPROTEIN(A); CAROTID ATHEROSCLEROSIS; SERUM-LIPOPROTEIN; CHOLESTEROL AB Background-On the basis of studies with limited statistical power, lipoprotein(a) [Lp(a)] is not considered a risk factor for cardiovascular disease (CVD) in blacks. We evaluated associations between Lp(a) and incident CVD events in blacks and whites in the Atherosclerosis Risk in Communities (ARIC) study. Methods and Results-Plasma Lp(a) was measured in blacks (n = 3467) and whites (n = 9851). Hazards ratios (HRs) for incident CVD events (coronary heart disease and ischemic strokes) were calculated. Lp(a) levels were higher with wider interindividual variation in blacks (median [interquartile range], 12.8 [7.1-21.7] mg/dL) than whites (4.3 [1.7-9.5] mg/dL; P < 0.0001). At 20 years of follow-up, 676 CVD events occurred in blacks, and 1821 events occurred in whites. Adjusted HRs (95% confidence interval) per race-specific 1-SD-greater log-transformed Lp(a) were 1.13 (1.04-1.23) for incident CVD, 1.11 (1.00-1.22) for incident coronary heart disease, and 1.21 (1.06-1.39) for ischemic strokes in blacks. For whites, the respective HRs (95% confidence intervals) were 1.09 (1.04-1.15), 1.10 (1.05-1.16), and 1.07 (0.97-1.19). Quintile analyses showed that risk for incident CVD was graded but statistically significant only for the highest compared with the lowest quintile (HR [95% confidence interval], 1.35 [1.06-1.74] for blacks and 1.27 [1.10-1.47] for whites). Similar results were obtained with the use of Lp(a) cutoffs of <= 10 mg/dL, >10 to <= 20 mg/dL, >20 to <= 30 mg/dL, and >30 mg/dL. Conclusions-Lp(a) levels were positively associated with CVD events. Associations were at least as strong, with a larger range of Lp(a) concentrations, in blacks compared with whites. (Circulation. 2012;125:241-249.) C1 [Virani, Salim S.; Brautbar, Ariel; Nambi, Vijay; Hoogeveen, Ron C.; Morrisett, Joel D.; Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA. [Virani, Salim S.; Brautbar, Ariel; Nambi, Vijay; Hoogeveen, Ron C.; Morrisett, Joel D.; Ballantyne, Christie M.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX USA. [Virani, Salim S.] Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Davis, Brian C.; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr, Houston, TX USA. [Sharrett, A. Richey; Coresh, Josef] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Mosley, Thomas H.] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS USA. [Catellier, Diane J.] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA. [Folsom, Aaron R.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. RP Ballantyne, CM (reprint author), Baylor Coll Med, Dept Med, Sect Cardiovasc Res, 6565 Fannin,MS A-601,Suite A656, Houston, TX 77030 USA. EM cmb@bcm.tmc.edu OI Virani, Salim/0000-0001-9541-6954 FU National Heart, Lung, and Blood Institute [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C]; Department of Veterans Affairs [CDA-09-028]; National Institutes of Health [5K23HL096893-02]; Merck; National Football League Charities; Gillson Longenbaugh Foundation; Gulf Coast Regional Foundation; Abbott; AstraZeneca; Bristol-Myers Squibb; diaDexus; GlaxoSmithKline; Kowa; Novartis; Roche; Sanofi-Synthelabo; Takeda; National Institutes of Health; American Diabetes Association; American Heart Association FX The ARIC study is performed as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Dr Virani is supported by a Department of Veterans Affairs Health Services Research and Development Service Career Development Award (CDA-09-028). Dr Nambi is supported by a National Institutes of Health grant (5K23HL096893-02).; The authors report the following disclosures: Salim Virani: research support from Merck and National Football League Charities (all grants to the institution and not individual); speakers bureau for Abbott (discontinued November 2010). Vijay Nambi: research grants from Gillson Longenbaugh Foundation and Gulf Coast Regional Foundation; consultant/virtual advisory board for Roche; speakers bureau for the American Heart Association; research collaboration with GE, Tomtec, Medipattern (no financial support); editor for Vascular Ultrasound Today; and officer for the American Society of Echocardiology. Christie M. Ballantyne: grant/research support (all paid to institution, not individual) from Abbott, AstraZeneca, Bristol-Myers Squibb, diaDexus, GlaxoSmithKline, Kowa, Merck, Novartis, Roche, Sanofi-Synthelabo, Takeda, National Institutes of Health, American Diabetes Association, American Heart Association; consultant for Abbott, Adnexus, Amylin, AstraZeneca, Bristol-Myers Squibb, Esperion, Genentech, GlaxoSmithKline, Idera Pharma, Kowa, Merck, Novartis, Omthera, Resverlogix, Roche, Sanofi-Synthelabo, Takeda; speakers bureau for Abbott, GlaxoSmithKline, Merck; honoraria from Abbott, AstraZeneca, GlaxoSmithKline, Merck, Sanofi-Synthelabo, Takeda. NR 41 TC 65 Z9 68 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD JAN 17 PY 2012 VL 125 IS 2 BP 241 EP U154 DI 10.1161/CIRCULATIONAHA.111.045120 PG 16 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 879HZ UT WOS:000299321600013 PM 22128224 ER PT J AU Melancon, BJ Lamers, AP Bridges, TM Sulikowski, GA Utley, TJ Sheffler, DJ Noetzel, MJ Morrison, RD Daniels, JS Niswender, CM Jones, CK Conn, PJ Lindsley, CW Wood, MR AF Melancon, Bruce J. Lamers, Alexander P. Bridges, Thomas M. Sulikowski, Gary A. Utley, Thomas J. Sheffler, Douglas J. Noetzel, Meredith J. Morrison, Ryan D. Daniels, J. Scott Niswender, Colleen M. Jones, Carrie K. Conn, P. Jeffrey Lindsley, Craig W. Wood, Michael R. TI Development of a more highly selective M-1 antagonist from the continued optimization of the MLPCN Probe ML012 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS LA English DT Article DE Muscarinic acetylcholine receptor 1; M-1; Antagonist; ML012; VU0415248 ID MUSCARINIC ACETYLCHOLINE-RECEPTORS; XANOMELINE; MODULATORS; AGONIST; GENES; MICE AB This Letter describes the continued optimization of an MLPCN probe molecule (ML012) through an iterative parallel synthesis approach. After exploring extensive modifications throughout the parent structure, we arrived at a more highly M-1-selective antagonist, compound 13I (VU0415248). Muscarinic subtype selectivity across all five human and rat receptors for 13I, along with rat selectivity for the lead compound (ML012), is presented. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Melancon, Bruce J.; Bridges, Thomas M.; Utley, Thomas J.; Sheffler, Douglas J.; Noetzel, Meredith J.; Morrison, Ryan D.; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Wood, Michael R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. [Melancon, Bruce J.; Lamers, Alexander P.; Sulikowski, Gary A.; Lindsley, Craig W.; Wood, Michael R.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA. [Melancon, Bruce J.; Bridges, Thomas M.; Utley, Thomas J.; Sheffler, Douglas J.; Noetzel, Meredith J.; Morrison, Ryan D.; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Wood, Michael R.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA. [Melancon, Bruce J.; Lamers, Alexander P.; Bridges, Thomas M.; Sulikowski, Gary A.; Utley, Thomas J.; Noetzel, Meredith J.; Morrison, Ryan D.; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Wood, Michael R.] Vanderbilt Specialized Chem Ctr Probe Dev MLPCN, Nashville, TN 37232 USA. [Jones, Carrie K.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37232 USA. RP Wood, MR (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. EM michael.r.wood@vanderbilt.edu RI Conn, Peter/D-7848-2012 FU Seaside Therapeutics; NIMH [RO1MH082867]; NIH [U54MH084659]; NINDS [P50NS071669] FX The authors thank Seaside Therapeutics, NIMH (RO1MH082867), NIH (U54MH084659) and NINDS (P50NS071669) for support of our Program in the development of subtype selective mAChR antagonists. NR 18 TC 3 Z9 3 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-894X J9 BIOORG MED CHEM LETT JI Bioorg. Med. Chem. Lett. PD JAN 15 PY 2012 VL 22 IS 2 BP 1044 EP 1048 DI 10.1016/j.bmcl.2011.11.110 PG 5 WC Chemistry, Medicinal; Chemistry, Organic SC Pharmacology & Pharmacy; Chemistry GA 883RY UT WOS:000299653500056 PM 22197142 ER PT J AU Lancioni, C Nyendak, M Kiguli, S Zalwango, S Mori, T Mayanja-Kizza, H Balyejusa, S Null, M Baseke, J Mulindwa, D Byrd, L Swarbrick, G Scott, C Johnson, DF Malone, L Mudido-Musoke, P Boom, WH Lewinsohn, DM Lewinsohn, DA AF Lancioni, Christina Nyendak, Melissa Kiguli, Sarah Zalwango, Sarah Mori, Tomi Mayanja-Kizza, Harriet Balyejusa, Stephen Null, Megan Baseke, Joy Mulindwa, Deo Byrd, Laura Swarbrick, Gwendolyn Scott, Christine Johnson, Denise F. Malone, LaShaunda Mudido-Musoke, Philipa Boom, W. Henry Lewinsohn, David M. Lewinsohn, Deborah A. CA TB Res Unit TI CD8(+) T Cells Provide an Immunologic Signature of Tuberculosis in Young Children SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE Mycobacterium tuberculosis; infant; child; CD8-positive T lymphocytes; enzyme-linked immunosorbent spot ID CHILDHOOD PULMONARY TUBERCULOSIS; CALMETTE-GUERIN VACCINATION; GAMMA RELEASE ASSAYS; PRE-CHEMOTHERAPY ERA; MYCOBACTERIUM-TUBERCULOSIS; INTRATHORACIC TUBERCULOSIS; HOUSEHOLD CONTACTS; HIV-1 INFECTION; INDUCED SPUTUM; SKIN-TEST AB Rationale: The immunologic events surrounding primary Mycobacterium tuberculosis infection and development of tuberculosis remain controversial. Young children who develop tuberculosis do so quickly after first exposure, thus permitting study of immune response to primary infection and disease. We hypothesized that M. tuberculosis-specific CD8(+) T cells are generated in response to high bacillary loads occurring during tuberculosis. Objectives: To determine if M. tuberculosis-specific T cells are generated among healthy children exposed to M. tuberculosis and children with tuberculosis. Methods: Enzyme-linked immunosorbent spot assays were used to measure IFN-gamma production in response to M. tuberculosis-specific proteins ESAT-6/CFP-10 by peripheral blood mononuclear cells and CD8(+) T cells isolated from Ugandan children hospitalized with tuberculosis (n = 96) or healthy tuberculosis contacts (n = 62). Measurements and Main Results: The proportion of positive CD8(+) T-cell assays and magnitude of CD8(+) T-cell responses were significantly greater among young (<5 yr) tuberculosis cases compared with young contacts (P = 0.02, Fisher exact test, P = 0.01, Wilcoxon rank-sum, respectively). M. tuberculosis-specific T-cell responses measured in peripheral blood mononuclear cells were equivalent between groups. Conclusions: Among young children, M. tuberculosis-specific CD8(+) T cells develop in response to high bacillary loads, as occurs during tuberculosis, and are unlikely to be found after M. tuberculosis exposure. T-cell responses measured in peripheral blood mononuclear cells are generated after M. tuberculosis exposure alone, and thus cannot distinguish exposure from disease. In young children, IFN-gamma-producing M. tuberculosis-specific CD8(+) T cells provide an immunologic signature of primary M. tuberculosis infection resulting in disease. C1 [Lancioni, Christina] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA. [Lancioni, Christina; Zalwango, Sarah; Mayanja-Kizza, Harriet; Baseke, Joy; Mulindwa, Deo; Scott, Christine; Johnson, Denise F.; Malone, LaShaunda; Boom, W. Henry; Lewinsohn, David M.; Lewinsohn, Deborah A.] Case Western Reserve Univ, TB Res Unit, Cleveland, OH 44106 USA. [Nyendak, Melissa] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Mori, Tomi] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Null, Megan; Byrd, Laura; Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA. [Kiguli, Sarah; Balyejusa, Stephen; Mudido-Musoke, Philipa] Makerere Univ, Coll Hlth Sci, Dept Pediat, Kampala, Uganda. [Mayanja-Kizza, Harriet] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda. [Zalwango, Sarah; Mayanja-Kizza, Harriet; Baseke, Joy; Mulindwa, Deo; Boom, W. Henry] Uganda CWRU Res Collaborat, Kampala, Uganda. [Swarbrick, Gwendolyn; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland VA Med Ctr, Portland, OR 97201 USA. RP Lancioni, C (reprint author), CDRC P, OHSU, Dept Pediat, 707 SW Gaines St, Portland, OR 97239 USA. EM lancioni@ohsu.edu RI Yankovyi, Oleksandr/C-2020-2015; Вардеванян, Вардан/S-8597-2016; Prisentsov, Anton /G-6173-2017; Piskunov, Roman/N-1772-2015; Lewinsohn, David/I-4936-2013; Vinnikova, Lydmila/P-5860-2015; Salnikov, Sergey/F-5727-2010; Petrov, Vladimir/K-6193-2015; Doroshenko, Alexander/N-7175-2015; Asach, Aleksei/N-2968-2016 OI Yankovyi, Oleksandr/0000-0003-2413-855X; Вардеванян, Вардан/0000-0002-3642-6164; Prisentsov, Anton /0000-0002-8173-4019; Piskunov, Roman/0000-0001-6133-9233; Mayanja-Kizza, Harriet/0000-0002-9297-6208; Lewinsohn, David/0000-0001-9906-9494; Vinnikova, Lydmila/0000-0002-6106-1785; Salnikov, Sergey/0000-0001-7952-4496; Petrov, Vladimir/0000-0002-7733-1030; Doroshenko, Alexander/0000-0003-3693-3876; Asach, Aleksei/0000-0001-9509-2048 FU Tuberculosis Research Unit (TBRU); NIH [AI079847, HHSN266200400081C/NO1-A1-400081, AI48090, AI054474]; National Center For Research Resources [KL2RR024141]; VA Merit Review Grant; Portland VA Medical Center; ALA; Rainbow Babies and Children's Hospital; US NIAID [HHSN266200700022C/N01-AI-70022]; Uganda National Tuberculosis and Leprosy Program FX Supported in part by the Tuberculosis Research Unit (TBRU), established with Federal funds from US NIAID, under contract HHSN266200700022C/N01-AI-70022. This work was also supported by the following agencies and institutes: NIH grants AI079847, HHSN266200400081C/NO1-A1-400081, AI48090, and AI054474; The National Center For Research Resources KL2RR024141; VA Merit Review Grant and the Portland VA Medical Center; ALA Career Investigator Award; and the Rainbow Babies and Children's Hospital Fellowship Research Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors acknowledge the invaluable contribution made by the study medical officers, health visitors, and laboratory and data personnel: Dr. Lorna Nshuti, Dr. Roy Mugerwa, Dr. Christina Hirsch, Allan Chiunda, Brenda Okware, Mark Breda, Dennis Dobbs, Hussein Kisingo, Albert Muganda, Richard Bamuhimbisa, Yusuf Mulumba, Deborah Nsamba, Barbara Kyeyune, Faith Kintu, Mary Nsereko, Gladys Mpalanyi, Janet Mukose, Grace Tumusiime, Pierre Peters, Alphonse Okwera, Keith Chervenak, Karen Morgan, Moses Joloba, Alfred Etwom, Micheal Angel Mugerwa, and Lisa Kucharski. They also acknowledge and thank Dr. Francis Adatu Engwau, Head of the Uganda National Tuberculosis and Leprosy Program, for his support of this project. They acknowledge the medical officers, nurses, and counselors at the National Tuberculosis Treatment Centre, Mulago Hospital, the Ugandan National Tuberculosis and Leprosy Program, and the Uganda Tuberculosis Investigation Bacteriological Unit, Wandegeya, for their contributions to this study. This study would not be possible without the generous participation of the Ugandan patients and families. Finally, they acknowledge Dr. Shannon McWeeney for advice on statistical methods. NR 49 TC 21 Z9 21 U1 0 U2 8 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JAN 15 PY 2012 VL 185 IS 2 BP 206 EP 212 DI 10.1164/rccm.201107-1355OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 879EC UT WOS:000299311500014 PM 22071329 ER PT J AU Zhang, W Benmohamed, R Arvanites, AC Morimoto, RI Ferrante, RJ Kirsch, DR Silverman, RB AF Zhang, Wei Benmohamed, Radhia Arvanites, Anthony C. Morimoto, Richard I. Ferrante, Robert J. Kirsch, Donald R. Silverman, Richard B. TI Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells SO BIOORGANIC & MEDICINAL CHEMISTRY LA English DT Article DE Cyclohexane-1,3-dione; Amyotrophic lateral sclerosis; Mutant G93A SOD1; Blood-brain barrier penetration ID AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; MOUSE MODEL; MICE; ALS AB Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. Currently, there is only one FDA-approved treatment for ALS (riluzole), and that drug only extends life, on average, by 2-3 months. Mutations in Cu/Zn superoxide dismutase (SOD1) are found in familial forms of the disease and have played an important role in the study of ALS pathophysiology. On the basis of their activity in a PC12-G93A-YFP high-throughput screening assay, several bioactive compounds have been identified and classified as cyclohexane-1,3-dione (CHD) derivatives. A concise and efficient synthetic route has been developed to provide diverse CHD analogs. The structural modification of the CHD scaffold led to the discovery of a more potent analog (26) with an EC(50) of 700 nM having good pharmacokinetic properties, such as high solubility, low human and mouse metabolic potential, and relatively good plasma stability. It was also found to efficiently penetrate the blood-brain barrier. However, compound 26 did not exhibit any significant life span extension in the ALS mouse model. It was found that, although 26 was active in PC12 cells, it had poor activity in other cell types, including primary cortical neurons, indicating that it can penetrate into the brain, but is not active in neuronal cells, potentially due to poor selective cell penetration. Further structural modification of the CHD scaffold was aimed at improving global cell activity as well as maintaining potency. Two new analogs (71 and 73) were synthesized, which had significantly enhanced cortical neuronal cell permeability, as well as similar potency to that of 26 in the PC12-G93A assay. These CHD analogs are being investigated further as novel therapeutic candidates for ALS. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Zhang, Wei; Silverman, Richard B.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA. [Benmohamed, Radhia; Arvanites, Anthony C.; Kirsch, Donald R.] Cambria Pharmaceut, Cambridge, MA 02142 USA. [Morimoto, Richard I.] Northwestern Univ, Rice Inst Biomed Res, Dept Mol Biosci, Evanston, IL 60208 USA. [Ferrante, Robert J.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA. [Ferrante, Robert J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA. [Ferrante, Robert J.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Ferrante, Robert J.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr GR H 00, Pittsburgh, PA 15206 USA. [Silverman, Richard B.] Northwestern Univ, Ctr Mol Innovat & Drug Discovery, Chem Life Proc Inst, Dept Mol Biosci, Evanston, IL 60208 USA. RP Silverman, RB (reprint author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA. EM Agman@chem.northwestern.edu FU National Institutes of Health [1R43NS057849]; ALS Association; Department of Defense [AL093052]; Veterans Administration Pittsburgh Healthcare System, Highland Drive, Pittsburgh, PA FX We thank the National Institutes of Health [1R43NS057849], the ALS Association (TREAT program), the Department of Defense [AL093052], and the Veterans Administration Pittsburgh Healthcare System, 7180 Highland Drive, Pittsburgh, PA for their generous support of the research project. The authors are grateful to Biogen Idec, Inc. for carrying out the in vivo rat PK profiling tests, in vitro P450 reversible inhibition study, the plasma binding affinity assay, the hERG inhibition assay, and for funding to MDS Pharma Service (now Ricerca Biosciences, LLC), who carried out the LeadProfilingScreen of 26. NR 15 TC 8 Z9 8 U1 1 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0968-0896 J9 BIOORGAN MED CHEM JI Bioorg. Med. Chem. PD JAN 15 PY 2012 VL 20 IS 2 SI SI BP 1029 EP 1045 DI 10.1016/j.bmc.2011.11.039 PG 17 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry GA 881ON UT WOS:000299496100056 PM 22189273 ER PT J AU Chaiswing, L Zhong, WX Liang, YL Jones, DP Oberley, TD AF Chaiswing, Luksana Zhong, Weixiong Liang, Yongliang Jones, Dean P. Oberley, Terry D. TI Regulation of prostate cancer cell invasion by modulation of extra- and intracellular redox balance SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE Cysteine; Cystine; Prostate cancer; Invasion; Growth; Free radicals ID MATRIX METALLOPROTEINASES; HUMAN PLASMA; IN-VITRO; STATE; GLUTATHIONE; PROLIFERATION; EXPRESSION; OXIDATION; GROWTH; DAMAGE AB Recent metabolic profiles of human prostate cancer tissues showed a significant increase in cysteine (Cys) and a significant decrease in reduced glutathione (GSH) during cancer progression from low- to high-grade Gleason scores. Cys is primarily localized extracellularly, whereas GSH is present mostly inside the cell. We hypothesized that extra-or intracellular redox state alterations differentially regulate cell invasion in PO prostate carcinoma cells versus PrEC normal prostate epithelial cells. Cells were exposed to media with calculated Cys/CySS redox potentials (E(h)CySS) ranging from -60 to -180 mV. After 3 h exposure to a reducing extracellular redox state (E(h)CySS = -180 mV), matrix metalloprotease (MMP), gelatinase, and NADPH oxidase activities increased, correlating with increases in cell invasion, cell migration, and extracellular hydrogen peroxide levels in PO cells but not PrECs. Knockdown of NADPH oxidase or MMP with silencing RNAs during cultivation with E(h)CySS = -180 mV medium significantly decreased PO cell invasion. Modulation of extra- and intracellular redox states by exposure of PC3 cells to Cys/CySS-free medium (approx E(h)CySS = -87 mV) containing 500 mu M N-acetylcysteine resulted in a more reducing intracellular redox state and a significant decrease in cell invasive ability. The decrease in PC3 cell invasion induced by these conditions correlated with a decrease in MMP activity. Our studies demonstrated that an extracellular redox state that was more reducing than a physiologic microenvironment redox state increased PC3 cancer cell invasive ability, whereas an intracellular redox environmental that was more reducing than an intracellular physiologic redox state inhibited PC3 cell invasive ability. Published by Elsevier Inc. C1 [Chaiswing, Luksana; Zhong, Weixiong; Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA. [Zhong, Weixiong; Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. [Liang, Yongliang; Jones, Dean P.] Emory Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA 30322 USA. RP Oberley, TD (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA. EM toberley@wisc.edu FU University of Wisconsin; Department of Pathology Research and Development Committee; University of Wisconsin-Madison Graduate School; Society for Free Radical Biology Medicine; National Cancer Institute; University of Wisconsin Carbone Cancer Center [P30 CA014520]; NIH [RO1 CA07359902, RO1 CA09485301] FX The contents do not represent the views of the U.S. Department of Veterans Affairs. This work was supported in part by funds from the University of Wisconsin, Department of Pathology Research and Development Committee, University of Wisconsin-Madison Graduate School, a 2010 minifellowship award from the Society for Free Radical Biology & Medicine and from the National Cancer Institute, University of Wisconsin Carbone Cancer Center (NIH Grant P30 CA014520), NIH Grants RO1 CA07359902 and RO1 CA09485301 (T.D.O.; Co-I), and resources and facilities at the William S. Middleton Memorial Veterans Hospital (Madison, WI, USA). The authors thank Dr. Young-Mi Go, Department of Medicine, Emory University (Atlanta, GA), for technical training of the Trx1 redox Western blot technique. NR 32 TC 15 Z9 15 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JAN 15 PY 2012 VL 52 IS 2 BP 452 EP 461 DI 10.1016/j.freeradbiomed.2011.10.489 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 878IB UT WOS:000299247600023 PM 22120495 ER PT J AU Smith, MA Schnellmann, RG AF Smith, Matthew A. Schnellmann, Rick G. TI Mitochondrial calpain 10 is degraded by Lon protease after oxidant injury SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE Calpain 10; Lon; Renal proximal tubular cells; Degradation; Toxicant; Inhibitors ID PROXIMAL TUBULE CELLS; OXIDATIVE STRESS; QUALITY CONTROL; RENAL-CELLS; INHIBITION; ACTIVATION; DEGRADATION; EXPRESSION; LOCALIZATION; CLEAVAGE AB Calpain 10 is ubiquitously expressed and is one of four mitochondrial matrix proteases. We determined that over-expression or knock-down of mitochondrial calpain 10 results in cell death, demonstrating that mitochondrial calpain 10 is required for viability. Thus, we studied calpain 10 degradation in isolated mitochondrial matrix, mitochondria and in renal proximal tubular cells (RPTC) under control and toxic conditions. Using isolated renal cortical mitochondria and mitochondrial matrix, calpain 10 underwent rapid degradation at 37 degrees C that was blocked with Lon inhibitors but not by calpain or proteasome inhibitors. While exogenous Ca(2+) addition, Ca(2+) chelation or exogenous ATP addition had no effect on calpain 10 degradation, the oxidants tert-butyl hydroperoxide (TBHP) or H(2)O(2) increased the rate of degradation. Using RPTC, mitochondrial and cytosolic calpain 10 increased in the presence of MG132 (Lon/proteasome inhibitor) but only cytosolic calpain 10 increased in the presence of epoxomicin (proteasome inhibitor). Furthermore, TBHP and H(2)O(2) oxidized mitochondrial calpain 10, decreased mitochondrial, but not cytosolic calpain 10, and pretreatment with MG132 blocked TBHP-induced degradation of calpain 10. In summary, mitochondrial calpain 10 is selectively degraded by Lon protease under basal conditions and is enhanced under and oxidizing conditions, while cytosolic calpain 10 is degraded by the proteasome. Published by Elsevier Inc. C1 [Smith, Matthew A.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, 280 Calhoun St,MSC140, Charleston, SC 29425 USA. EM schnell@musc.edu FU NIH [GM 084147, C06 RR-015455]; NIH/NIEHS [T32ES012878-05]; Department of Veterans Affairs FX This study was supported by NIH Grant [GM 084147], the NIH/NIEHS Training Program in Environmental Stress Signaling [T32ES012878-05], and by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. Animal facilities were funded by NIH grant [C06 RR-015455]. NR 43 TC 7 Z9 8 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD JAN 15 PY 2012 VL 517 IS 2 BP 144 EP 152 DI 10.1016/j.abb.2011.11.023 PG 9 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 876ZJ UT WOS:000299146000008 PM 22179018 ER PT J AU Lee, J Giordano, S Zhang, JH AF Lee, Jisun Giordano, Samantha Zhang, Jianhua TI Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling SO BIOCHEMICAL JOURNAL LA English DT Review DE autophagy; mitochondrion; neurodegeneration; nitrative stress; oxidative stress; redox signalling ID AMYOTROPHIC-LATERAL-SCLEROSIS; MANGANESE SUPEROXIDE-DISMUTASE; ANTIOXIDANT RESPONSIVE ELEMENTS; COMPLEX-I DEFICIENCY; LIPOFUSCINOSES BATTEN-DISEASE; CHAPERONE-MEDIATED AUTOPHAGY; PATHOGENIC DJ-1 MUTATIONS; MOTOR-NEURON DEGENERATION; HYPOXIA-INDUCED AUTOPHAGY; SMOOTH-MUSCLE-CELLS AB Reactive oxygen and nitrogen species change cellular responses through diverse mechanisms that are now being defined. At low levels, they are signalling molecules, and at high levels, they damage organelles, particularly the mitochondria. Oxidative damage and the associated mitochondrial dysfunction may result in energy depletion, accumulation of cytotoxic mediators and cell death. Understanding the interface between stress adaptation and cell death then is important for understanding redox biology and disease pathogenesis. Recent studies have found that one major sensor of redox signalling at this switch in cellular responses is autophagy. Autophagic activities are mediated by a complex molecular machinery including more than 30 Atg (AuTophaGy-related) proteins and 50 lysosomal hydrolases. Autophagosomes form membrane structures, sequester damaged, oxidized or dysfunctional intracellular components and organelles, and direct them to the lysosomes for degradation. This autophagic process is the sole known mechanism for mitochondrial turnover. It has been speculated that dysfunction of autophagy may result in abnormal mitochondrial function and oxidative or nitrative stress. Emerging investigations have provided new understanding of how autophagy of mitochondria (also known as mitophagy) is controlled, and the impact of autophagic dysfunction on cellular oxidative stress. The present review highlights recent studies on redox signalling in the regulation of autophagy, in the context of the basic mechanisms of mitophagy. Furthermore, we discuss the impact of autophagy on mitochondrial function and accumulation of reactive species. This is particularly relevant to degenerative diseases in which oxidative stress occurs over time, and dysfunction in both the mitochondrial and autophagic pathways play a role. C1 [Lee, Jisun; Giordano, Samantha; Zhang, Jianhua] Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Lee, Jisun; Giordano, Samantha; Zhang, Jianhua] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35233 USA. RP Zhang, JH (reprint author), Univ Alabama, Ctr Free Rad Biol, 901 19th St S, Birmingham, AL 35294 USA. EM zhanja@uab.edu RI Carraro, Fabio/N-2613-2013 OI Carraro, Fabio/0000-0003-0771-042X; Zhang, Jianhua/0000-0002-2128-9574 FU National Institutes of Health [NIHR01-NS064090] FX This work was supported by the National Institutes of Health [grant number NIHR01-NS064090] and a Veterans Affairs merit award (to J.Z.). NR 290 TC 426 Z9 461 U1 29 U2 162 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD JAN 15 PY 2012 VL 441 BP 523 EP 540 DI 10.1042/BJ20111451 PN 2 PG 18 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 874RV UT WOS:000298976700001 PM 22187934 ER PT J AU Fennelly, KP Radonovich, L AF Fennelly, Kevin P. Radonovich, Lewis TI Transocular Infection With Influenza and Efficacy of Barrier Methods SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID VIRUS C1 [Fennelly, Kevin P.; Radonovich, Lewis] US Dept Vet Affairs, Natl Ctr Occupat Hlth & Infect Control COHIC, Off Publ Hlth, Gainesville, FL 32608 USA. RP Fennelly, KP (reprint author), US Dept Vet Affairs, Natl Ctr Occupat Hlth & Infect Control COHIC, Off Publ Hlth, 1601 SW Archer Rd,151B, Gainesville, FL 32608 USA. EM kevin.fennelly@va.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JAN 15 PY 2012 VL 205 IS 2 BP 349 EP 349 DI 10.1093/infdis/jir738 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 866NN UT WOS:000298387900027 PM 22124135 ER PT J AU Singh, N AF Singh, Nina TI How I Treat Cryptococcosis in Organ Transplant Recipients SO TRANSPLANTATION LA English DT Article DE Fungal infection; Cryptococcus; Transplant ID RECONSTITUTION INFLAMMATORY SYNDROME; VERSUS-HOST-DISEASE; AMPHOTERICIN-B; NEOFORMANS INFECTION; SOLID-ORGAN; PULMONARY CRYPTOCOCCOSIS; FUNGAL-INFECTIONS; ANTIFUNGAL AGENTS; RENAL-ALLOGRAFT; INTESTINAL TRANSPLANTATION AB Cryptococcosis is a significant opportunistic mycoses in organ transplant recipients. Topical developments in the field in the past few years have highlighted important issues and at the same time raised new questions regarding the management of this yeast. These include, for example, management of pretransplant cryptococcosis during transplant candidacy and timing of transplant in these instances; potential for donor transmission of cryptococcosis in light of recent fatal transmissions; and prevention and treatment of Cryptococcus-associated immune reconstitution syndrome. Discussed herein are challenges posed by these issues and evidence-based data to optimize the management of posttransplant cryptococcosis. C1 [Singh, Nina] VA Pittsburgh Healthcare Syst, Dept Med, Div Infect Dis, Pittsburgh, PA USA. [Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. RP Singh, N (reprint author), Vet Adm Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu FU VA Pittsburgh Health Care System, Pittsburgh, PA FX This work was supported by resources and the use of facilities at the VA Pittsburgh Health Care System, Pittsburgh, PA. NR 66 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD JAN 15 PY 2012 VL 93 IS 1 BP 17 EP 21 DI 10.1097/TP.0b013e318236cd1a PG 5 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 870HU UT WOS:000298660800003 PM 22015465 ER PT J AU Chen, T Benmohamed, R Kim, J Smith, K Amante, D Morimoto, RI Kirsch, DR Ferrante, RJ Silverman, RB AF Chen, Tian Benmohamed, Radhia Kim, Jinho Smith, Karen Amante, Daniel Morimoto, Richard I. Kirsch, Donald R. Ferrante, Robert J. Silverman, Richard B. TI ADME-Guided Design and Synthesis of Aryloxanyl Pyrazolone Derivatives To Block Mutant Superoxide Dismutase 1 (SOD1) Cytotoxicity and Protein Aggregation: Potential Application for the Treatment of Amyotrophic Lateral Sclerosis SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID MOTOR-NEURON DEGENERATION; GULF-WAR VETERANS; ALS; MUTATIONS; RILUZOLE; DISEASE; MICE; GENE; CYTOCHROME-P450; SULFOXIDATION AB Amyotrophic lateral sclerosis (ALS) is an orphan neurodegenerative disease currently without a cure: The arylsulfanyl pyrazolone (ASP) scaffold was one of the active scaffolds identified in a cell-based high throughput screening assay targeting mutant Cu/Zn superoxide dismutase 1 (SOD 1) induced toxicity and aggregation as a marker for ALS. The initial ASP hit compounds were potent and had favorable ADME properties but had poor microsomal and plasma stability. Here, we identify the microsomal metabolite and describe synthesized analogues of these ASP compounds to address the rapid metabolism. Both in vitro potency and pharmacological properties of the ASP scaffold have been dramatically improved via chemical modification to the corresponding sulfone and ether derivatives. One of the ether analogues (13), with superior potency and in vitro pharmacokinetic properties, was tested in vivo for its pharmacokinetic profile, brain penetration, and efficacy in an ALS mouse model. The analogue showed sustained blood and brain levels in vivo and significant activity in the mouse model of ALS, thus validating the new aryloxanyl pyrazolone scaffold as an important novel therapeutic lead for the treatment of this neurodegenerative disorder. C1 [Chen, Tian; Silverman, Richard B.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA. [Benmohamed, Radhia; Kirsch, Donald R.] Cambria Pharmaceut, Cambridge, MA 02142 USA. [Kim, Jinho; Amante, Daniel; Ferrante, Robert J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA. [Kim, Jinho; Amante, Daniel; Ferrante, Robert J.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Kim, Jinho; Amante, Daniel; Ferrante, Robert J.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA. [Kim, Jinho; Amante, Daniel; Ferrante, Robert J.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr GR H 00, Pittsburgh, PA 15206 USA. [Smith, Karen] Bedford VA Med Ctr, Bedford, MA 01730 USA. [Morimoto, Richard I.] Northwestern Univ, Rice Inst Biomed Res, Dept Mol Biosci, Evanston, IL 60208 USA. [Silverman, Richard B.] Northwestern Univ, Ctr Mol Innovat & Drug Discovery, Chem Life Proc Inst, Dept Mol Biosci, Evanston, IL 60208 USA. RP Silverman, RB (reprint author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA. EM Agman@chem.northwestern.edu FU National Institutes of Health [1R43NS057849]; ALS Association (TREAT); Department of Defense [AL093052]; Center for ALS Research at the Univesity of Pittsburgh, PA FX We thank the National Institutes of Health (Grant 1R43NS057849), the ALS Association (TREAT program), the Department of Defense (Grant AL093052), and the Center for ALS Research at the Univesity of Pittsburgh, PA, for their generous support of the research project. The authors are grateful to Biogen Idec Inc. for carrying out the in vivo rat PK profiling tests, in vitro P450 reversible inhibition study, the plasma binding affinity assay, and the hERG inhibition assays; and MDS Pharma Service (now Ricerca Biosciences, LLC) for carrying out the LeadProfilingScreen of 13. NR 50 TC 19 Z9 19 U1 3 U2 18 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD JAN 12 PY 2012 VL 55 IS 1 BP 515 EP 527 DI 10.1021/jm2014277 PG 13 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 874SQ UT WOS:000298978800040 PM 22191331 ER PT J AU Yourman, LC Lee, SJ Schonberg, MA Widera, EW Smith, AK AF Yourman, Lindsey C. Lee, Sei J. Schonberg, Mara A. Widera, Eric W. Smith, Alexander K. TI Prognostic Indices for Older Adults A Systematic Review SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID NURSING-HOME RESIDENTS; MORTALITY-RELATED FACTORS; ADMINISTRATIVE DATA; BREAST-CANCER; MEDICAL LITERATURE; 1-YEAR MORTALITY; ELDERLY-PATIENTS; DECISION-MAKING; AORTIC-ANEURYSM; USERS GUIDES AB Context To better target services to those who may benefit, many guidelines recommend incorporating life expectancy into clinical decisions. Objective To assess the quality and limitations of prognostic indices for mortality in older adults through systematic review. Data Sources We searched MEDLINE, EMBASE, Cochrane, and Google Scholar from their inception through November 2011. Study Selection We included indices if they were validated and predicted absolute risk of mortality in patients whose average age was 60 years or older. We excluded indices that estimated intensive care unit, disease-specific, or in-hospital mortality. Data Extraction For each prognostic index, we extracted data on clinical setting, potential for bias, generalizability, and accuracy. Results We reviewed 21 593 titles to identify 16 indices that predict risk of mortality from 6 months to 5 years for older adults in a variety of clinical settings: the community (6 indices), nursing home (2 indices), and hospital (8 indices). At least 1 measure of transportability (the index is accurate in more than 1 population) was tested for all but 3 indices. By our measures, no study was free from potential bias. Although 13 indices had C statistics of 0.70 or greater, none of the indices had C statistics of 0.90 or greater. Only 2 indices were independently validated by investigators who were not involved in the index's development. Conclusion We identified several indices for predicting overall mortality in different patient groups; future studies need to independently test their accuracy in heterogeneous populations and their ability to improve clinical outcomes before their widespread use can be recommended. JAMA. 2012; 307(2):182-192 www.jama.com C1 [Yourman, Lindsey C.; Lee, Sei J.; Widera, Eric W.; Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94121 USA. [Lee, Sei J.; Widera, Eric W.; Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Schonberg, Mara A.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Div Geriatr, Dept Med, 4150 Clement St 181G, San Francisco, CA 94121 USA. EM aksmith@ucsf.edu FU National Institute on Aging [5T32AG000212]; Greenwall Foundation; National Center for Research Resources [UL1 RR024131] FX Dr Yourman was supported by a National Institute on Aging T32 predoctoral fellowship position (5T32AG000212). Dr Smith was supported by career development grants from the Greenwall Foundation and the National Center for Research Resources to the Clinical and Translational Science Institute-University of California, San Francisco (UL1 RR024131). NR 74 TC 219 Z9 220 U1 5 U2 39 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 11 PY 2012 VL 307 IS 2 BP 182 EP 192 DI 10.1001/jama.2011.1966 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 875NP UT WOS:000299038300030 PM 22235089 ER PT J AU Wu, ZW Zhang, XY Wang, HH Tang, W Xia, Y Zhang, FX Liu, JH Fu, Y Hu, JJ Chen, YL Liu, LJ Chen, DC Xiu, MH Kosten, TR He, JC AF Wu, Zhiwei Zhang, Xiang Yang Wang, Huanhuan Tang, Wei Xia, Yu Zhang, FeiXue Liu, Jiahong Fu, Ye Hu, Jianjun Chen, Yuanling Liu, Linjing Chen, Da Chun Xiu, Mei Hong Kosten, Thomas R. He, Jincai TI Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY LA English DT Review DE Free radical; Oxidative stress; Psychopathology; Schizophrenia; Superoxide dismutase ID ANTIOXIDANT DEFENSE SYSTEM; ACID REACTIVE SUBSTANCES; FREE-RADICAL PATHOLOGY; TARDIVE-DYSKINESIA; LIPID-PEROXIDATION; OXIDATIVE STRESS; ENZYME-ACTIVITIES; THERAPEUTIC IMPLICATIONS; ATYPICAL ANTIPSYCHOTICS; GLUTATHIONE-PEROXIDASE AB Excessive free radical production or oxidative stress may be involved in the pathophysiology of schizophrenia as evidenced by increased superoxide dismutase (SOD) activities, a critical enzyme in the detoxification of superoxide radicals. This study compared plasma SOD activities in 78 never-medicated first-episode and 100 medicated chronic schizophrenia patients to 100 healthy control subjects and correlated these SOD activities with the Positive and Negative Syndrome Scale (PANSS) among the schizophrenic patients. We found that both first-episode and chronic patients had significantly increased plasma SOD activities compared to controls, and that chronic schizophrenic patients on antipsychotic medication had significantly higher SOD activities than first episode schizophrenic patients. Plasma SOD activities were also negatively correlated with positive symptoms of schizophrenia, but only in first-episode patients. Thus, oxidative stress appears to be greater in first episode schizophrenic patients with fewer positive symptoms and may become greater as schizophrenia becomes more chronic, although we cannot exclude the possibility that chronic antipsychotic treatment may increase SOD activities and presumed oxidative stress in schizophrenia. (C) 2011 Elsevier Inc. All rights reserved. C1 [He, Jincai] Wenzhou Med Coll, Affiliated Hosp 1, Sleep Ctr, Wenzhou 325000, Peoples R China. [Zhang, Xiang Yang; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang; Chen, Da Chun; Xiu, Mei Hong] Beijing Huilongguan Hosp, Ctr Psychiat Res, Beijing, Peoples R China. [Wu, Zhiwei; Tang, Wei; Zhang, FeiXue; Liu, Jiahong; Chen, Yuanling; Liu, Linjing] Kangning Hosp, Dept Psychiat, Wenzhou, Peoples R China. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 110,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu; kosten@bcm.edu; hjc@wzmc.edu.cn FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of Veterans Affairs; VISN 16; Mental Illness Research Education and Clinical Center (MIRECC); United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX Funding for this study was provided by grants from the Stanley Medical Research Institute (03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental Illness Research Education and Clinical Center (MIRECC), United States National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639. NR 52 TC 17 Z9 18 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0278-5846 EI 1878-4216 J9 PROG NEURO-PSYCHOPH JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry PD JAN 10 PY 2012 VL 36 IS 1 BP 34 EP 38 DI 10.1016/j.pnpbp.2011.08.018 PG 5 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 889KQ UT WOS:000300073000007 PM 21896300 ER PT J AU Pai, S Ledoux, WR AF Pai, Shruti Ledoux, William R. TI The shear mechanical properties of diabetic and non-diabetic plantar soft tissue SO JOURNAL OF BIOMECHANICS LA English DT Article DE Foot; Diabetes; Subcutaneous; Ulceration; Viscoelastic ID BRAIN-TISSUE; VISCOELASTIC PROPERTIES; LARGE-DEFORMATION; HEEL-PAD; FAT PADS; FOOT; MELLITUS; CARTILAGE; STIFFNESS; PRESSURE AB Changes in the plantar soft tissue shear properties may contribute to ulceration in diabetic patients, however, little is known about these shear parameters. This study examines the elastic and viscoelastic shear behavior of both diabetic and non-diabetic plantar tissue. Previously compression tested plantar tissue specimens (n=54) at six relevant plantar locations (hallux, first, third, and fifth metatarsal heads, lateral midfoot, and calcaneus) from four cadaveric diabetic feet and five non-diabetic feet were utilized. Per in vivo data (i.e., combined deformation patterns of compression followed by shear), an initial static compressive strain (36-38%) was applied to the tissue followed by target shear strains of 50% and 85% of initial thickness. Triangle waves were used to quantify elastic parameters at both strain levels and a stress relaxation test (0.25 s ramp and 300 s hold) was used to quantify the viscoelastic parameters at the upper strain level. Several differences were found between test groups including a 52-62% increase in peak shear stress, a 63% increase in toe shear modulus, a 47% increase in final shear modulus, and a 67% increase in middle slope magnitude (sharper drop in relaxation) in the diabetic tissue. Beyond a 54% greater peak compressive stress in the third metatarsal compared to the lateral midfoot, there were no differences in shear properties between plantar locations. Notably, this study demonstrates that plantar soft tissue with diabetes is stiffer than healthy tissue, thereby compromising its ability to dissipate shear stresses borne by the foot that may increase ulceration risk. Published by Elsevier Ltd. C1 [Pai, Shruti; Ledoux, William R.] VA Puget Sound, VA RR&D Ctr Excellence Limb Loss Prevent & Prosth, Seattle, WA 98108 USA. [Pai, Shruti; Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, VA RR&D Ctr Excellence Limb Loss Prevent & Prosth, MS 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU National Institutes of Health [1R01 DK75633-03]; Department of Veterans Affairs, RRD Service [A4843C] FX This study was supported by the National Institutes of Health grant 1R01 DK75633-03 and the Department of Veterans Affairs, RR&D Service grant A4843C. The authors would also like to thank Jane Shofer for the statistical analysis, Michael Fassbind for equipment design, and Paul Vawter for assisting with data analysis. NR 39 TC 14 Z9 14 U1 3 U2 18 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 J9 J BIOMECH JI J. Biomech. PD JAN 10 PY 2012 VL 45 IS 2 BP 364 EP 370 DI 10.1016/j.jbiomech.2011.10.021 PG 7 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 885BX UT WOS:000299754600023 PM 22079385 ER PT J AU Wang, TY Masoudi, FA Messenger, JC Shunk, KA Boyle, A Brennan, JM Anderson, HV Anstrom, KJ Dai, D Peterson, ED Douglas, PS Rumsfeld, JS AF Wang, Tracy Y. Masoudi, Frederick A. Messenger, John C. Shunk, Kendrick A. Boyle, Andrew Brennan, J. Matthew Anderson, H. Vernon Anstrom, Kevin J. Dai, David Peterson, Eric D. Douglas, Pamela S. Rumsfeld, John S. TI Percutaneous Coronary Intervention and Drug-Eluting Stent Use Among Patients >= 85 Years of Age in the United States SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE aging; coronary artery disease; myocardial infarction; stent ID PREDICTS COGNITIVE DECLINE; LONGER HOSPITAL STAY; BARE-METAL STENTS; ELDERLY-PATIENTS; CARDIAC-SURGERY; OUTCOMES; REGISTRY; TRIALS AB Objectives This study assessed the comparative effectiveness of drug-eluting stents (DES) versus bare-metal stents (BMS) among patients >= 85 years of age. Background Despite an aging population, little is known about the comparative effectiveness of DES versus BMS among patients age >= 85 years undergoing percutaneous coronary intervention (PCI). Methods We examined 471,006 PCI patients age >= 65 years at 947 hospitals in the National Cardiovascular Data Registry between 2004 and 2008 and linked to Medicare claims data. Long-term outcomes (median follow-up 640.8 +/- 423.5 days) were compared between users of DES and BMS. Results Patients age >= 85 years comprise an increasing proportion of PCIs performed among elderly subjects, yet rates of DES use declined the most in this age group. Compared with BMS, use of DES was associated with lower mortality: age >85 years, 29% versus 38% (adjusted hazard ratio [HR]: 0.80 [95% confidence interval (CI): 0.77 to 0.83]); age 75 to 84 years, 17% versus 25% (HR: 0.77 [95% CI: 0.75 to 0.79]); and age 65 to 74 years, 10% versus 16% (HR: 0.73 [95% CI: 0.71 to 0.75]). However, the adjusted mortality difference narrowed with increasing age (p(interaction) <0.001). In contrast, the adjusted HR for myocardial infarction rehospitalization associated with DES use was significantly lower with increasing age: age >= 85 years, 9% versus 12% (HR: 0.77 [95% CI: 0.71 to 0.83]); age 75 to 84 years, 7% versus 9% (HR: 0.81 [95% CI: 0.77 to 0.84]); and age 65 to 74 years, 7% versus 8% (HR: 0.84 [95% CI: 0.80 to 0.88]) (p(interaction) <0.001). Conclusions In this national study of older patients undergoing PCI, declines in DES use were most pronounced among those aged >= 85 years, yet lower adverse-event rates associated with DES versus BMS use were observed. (J Am Coll Cardiol 2012; 59: 105-12) (C) 2012 by the American College of Cardiology Foundation C1 [Wang, Tracy Y.; Brennan, J. Matthew; Anstrom, Kevin J.; Dai, David; Peterson, Eric D.; Douglas, Pamela S.] Duke Clin Res Inst, Durham, NC 27705 USA. [Masoudi, Frederick A.; Messenger, John C.] Univ Colorado, Aurora, CO USA. [Shunk, Kendrick A.; Boyle, Andrew] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Anderson, H. Vernon] Univ Texas Hlth Sci Ctr, Houston, TX USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. RP Wang, TY (reprint author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA. EM tracy.wang@duke.edu OI Boyle, Andrew/0000-0002-3919-5269 FU Agency for Healthcare Research and Quality; U.S. Department of Health and Human Services [24-EHC-1, HHSAA290-2005-0032-TO4-WA1]; Bristol-Myers Squibb/Sanofi Aventis; Schering-Plough/Merck Co., Inc.; Medicines Company; Heartscape Technologies, Inc.; Canyon Pharmaceuticals; Eli Lilly and Company/Daiichi Sankyo alliance; American College of Cardiology; Alexion Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Innocoll Pharmaceuticals; Medtronic; Pfizer Inc.; Proctor & Gamble (modest); Merck Co., Inc.; Johnson Johnson FX This project was sponsored by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, as part of the Cardiovascular Consortium (Project ID: 24-EHC-1, Work Assignment Number: HHSAA290-2005-0032-TO4-WA1, Developing Evidence to Inform Decisions about Effectiveness program). The authors of this paper are responsible for its content, and statements in the paper should not be construed as endorsement by the Agency for Healthcare Research and Quality or the Department of Health and Human Services. Additional support was obtained from the American College of Cardiology National Cardiovascular Data Registry. Dr. Wang has received research grants (to the Duke Clinical Research Institute) from Bristol-Myers Squibb/Sanofi Aventis Partnership, Schering-Plough/Merck & Co., Inc., The Medicines Company, Heartscape Technologies, Inc., Canyon Pharmaceuticals, and Eli Lilly and Company/Daiichi Sankyo alliance; and consulting or honoraria from Medco Health Solutions, Inc., and AstraZeneca. Dr. Masoudi has received salary support from the American College of Cardiology; is senior medical officer for the National Cardiovascular Data Registry (significant); and is a consultant for the Oklahoma Foundation for Medical Quality. Dr. Anstrom has received research and salary support from Alexion Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Innocoll Pharmaceuticals, Medtronic, Pfizer Inc., and Proctor & Gamble (modest); serves on the data safety monitoring boards of Pfizer Inc. and Vertex Pharmaceuticals (modest); and provides consulting services to Pacific Therapeutics Ltd., Bristol-Myers Squibb, and AstraZeneca (modest). Dr. Peterson has received research support from Bristol-Myers Squibb/Sanofi Aventis Partnership, Merck & Co., Inc., Johnson & Johnson, and Eli Lilly and Company (all significant). Dr. Rumsfeld is the chief science officer for the National Cardiovascular Data Registry. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 16 TC 22 Z9 23 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JAN 10 PY 2012 VL 59 IS 2 BP 105 EP 112 DI 10.1016/j.jacc.2011.10.853 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 872GH UT WOS:000298796600003 PM 22222072 ER PT J AU Jacob, CO Eisenstein, M Dinauer, MC Ming, WY Liu, Q John, S Quismorio, FP Reiff, A Myones, BL Kaufman, KM McCurdy, D Harley, JB Silverman, E Kimberly, RP Vyse, TJ Gaffney, PM Moser, KL Klein-Gitelman, M Wagner-Weiner, L Langefeld, CD Armstrong, DL Zidovetzki, R AF Jacob, Chaim O. Eisenstein, Miriam Dinauer, Mary C. Ming, Wenyu Liu, Qiang John, Sutha Quismorio, Francesco P., Jr. Reiff, Andreas Myones, Barry L. Kaufman, Kenneth M. McCurdy, Deborah Harley, John B. Silverman, Earl Kimberly, Robert P. Vyse, Timothy J. Gaffney, Patrick M. Moser, Kathy L. Klein-Gitelman, Marisa Wagner-Weiner, Linda Langefeld, Carl D. Armstrong, Don L. Zidovetzki, Raphael TI Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE autoimmunity; NOX2 ID CHRONIC GRANULOMATOUS-DISEASE; PROTEIN-PROTEIN DOCKING; GENOME-WIDE ASSOCIATION; CONTROLS PHAGOSOMAL PH; AUTOIMMUNE-DISEASE; OXIDATIVE BURST; DENDRITIC CELLS; ERYTHEMATOSUS; SUSCEPTIBILITY; GENE AB Systemic lupus erythematosus (SLE), the prototypic systemic autoimmune disease, is a debilitating multisystem autoimmune disorder characterized by chronic inflammation and extensive immune dysregulation in multiple organ systems, resulting in significant morbidity and mortality. Here, we present a multidisciplinary approach resulting in the identification of neutrophil cytosolic factor 2 (NCF2) as an important risk factor for SLE and the detailed characterization of its causal variant. We show that NCF2 is strongly associated with increased SLE risk in two independent populations: childhood-onset SLE and adult-onset SLE. The association between NCF2 and SLE can be attributed to a single nonsynonymous coding mutation in exon 12, the effect of which is the substitution of histidine-389 with glutamine (H389Q) in the PB1 domain of the NCF2 protein, with glutamine being the risk allele. Computational modeling suggests that the NCF2 H389Q mutation reduces the binding efficiency of NCF2 with the guanine nucleotide exchange factor Vav1. The model predicts that NCF2/H389 residue interacts with Vav1 residues E509, N510, E556, and G559 in the ZF domain of Vav1. Furthermore, replacing H389 with Q results in 1.5 kcal/mol weaker binding. To examine the effect of the NCF2 H389Q mutation on NADPH oxidase function, site-specific mutations at the 389 position in NCF2 were tested. Results show that an H389Q mutation causes a twofold decrease in reactive oxygen species production induced by the activation of the Vav-dependent Fc. receptor-elicited NADPH oxidase activity. Our study completes the chain of evidence from genetic association to specific molecular function. C1 [Jacob, Chaim O.; Quismorio, Francesco P., Jr.; Reiff, Andreas; Zidovetzki, Raphael] Univ So Calif, Dept Med, Lupus Genet Grp, Los Angeles, CA 90089 USA. [Eisenstein, Miriam] Weizmann Inst Sci, Dept Chem Res Support, IL-76100 Rehovot, Israel. [Dinauer, Mary C.; Liu, Qiang] Washington Univ, St Louis Childrens Hosp, Sch Med, St Louis, MO 63110 USA. [Ming, Wenyu; John, Sutha] Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA. [Reiff, Andreas] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Myones, Barry L.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA. [Kaufman, Kenneth M.; Gaffney, Patrick M.; Moser, Kathy L.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [McCurdy, Deborah] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA. [Harley, John B.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH 45229 USA. [Silverman, Earl] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Kimberly, Robert P.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Vyse, Timothy J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London W12 0NN, England. [Klein-Gitelman, Marisa] Childrens Mem Hosp, Chicago, IL 60614 USA. [Klein-Gitelman, Marisa] Northwestern Univ, Chicago, IL 60614 USA. [Wagner-Weiner, Linda] LaRabida Hosp, Chicago, IL 60649 USA. [Wagner-Weiner, Linda] Univ Chicago, Chicago, IL 60649 USA. [Langefeld, Carl D.] Wake Forest Univ Hlth Sci, Winston Salem, NC 27157 USA. [Armstrong, Don L.; Zidovetzki, Raphael] Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA. RP Jacob, CO (reprint author), Univ So Calif, Dept Med, Lupus Genet Grp, Los Angeles, CA 90089 USA. EM jacob@usc.edu; raphael.zidovetzki@ucr.edu OI Armstrong, Don/0000-0002-4904-638X; Kimberly, Robert/0000-0002-5330-3086 FU National Institutes of Health [AR043815, HL45635, AR62277, AI08394, AI024717, AR042460, AR049084, AR33062, RR020143, AI063274] FX We thank Y.X. Wu for technical assistance, C. Marchal and M. Stefanovic for assistance with generating some of the NCF2 expression constructs, J. Matute and X. Li for generating the transgenic K562 cell line, and Dr. XingPing Cui for fruitful discussions. Support for this study was provided by National Institutes of Health Grants AR043815 (to C.O.J.); HL45635 (to M.C.D.); AR62277 (to K.L.M.); AI08394, AI024717, AR042460 (to J.B.H.); AR049084 and AR33062 (to R.P.K.); and RR020143 and AI063274 (to P.M.G.). Additional support was provided by the Alliance for Lupus Research (C.O.J., J.B.H., and R.Z.), Riley Children's Foundation (M.C.D.), Children's Discovery Institute (M.C.D.), and US Department of Veterans Affairs Medical Center, Cincinnati (J.B.H.). NR 49 TC 54 Z9 54 U1 0 U2 7 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JAN 10 PY 2012 VL 109 IS 2 BP E59 EP E67 DI 10.1073/pnas.1113251108 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 874IS UT WOS:000298950200006 PM 22203994 ER PT J AU Lin, E Bhusal, Y Horwitz, D Shelburne, SA Trautner, BW AF Lin, Eugene Bhusal, Yogesh Horwitz, Deborah Shelburne, Samuel A., III Trautner, Barbara W. TI Overtreatment of Enterococcal Bacteriuria SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID URINARY-TRACT-INFECTIONS; VANCOMYCIN-RESISTANT ENTEROCOCCI; CLINICAL-PRACTICE GUIDELINES; CARE-ASSOCIATED INFECTIONS; ASYMPTOMATIC BACTERIURIA; RISK-FACTORS; INAPPROPRIATE TREATMENT; DISEASES-SOCIETY; ADULTS; BACTEREMIA AB Background: The purposes of this study were to investigate the clinical outcomes of enterococcal bacteriuria and to determine whether current management is adherent to Infectious Diseases Society of America guidelines. Methods: We conducted a retrospective medical record review of patients from 2 academic teaching hospitals for 3 months (September 1 through November 30, 2009). Patients were classified as having urinary tract infection (UTI) or asymptomatic bacteriuria (ABU) by applying the guidelines. Antibiotic use was deemed appropriate in patients with UTI and inappropriate in ABU. Medical records were reviewed for Enterococcus cultured from another sterile site within 30 days. Results: A total of 375 urine cultures growing Enterococcus were reviewed, with 339 cultures meeting inclusion criteria. Of these 339 episodes, 183 (54.0%) were classified as ABU and 156 (46.0%) as UTI. In 289 episodes accompanied by urinalysis, pyuria was associated with UTI in 98 of 140 episodes (70.0%) compared with 63 of 149 episodes of ABU (42.3%) (odds ratio, 3.19; 95% CI, 1.96-5.18). Providers inappropriately treated 60 of 183 episodes of ABU (32.8%) with antibiotics. In multivariate analysis, only pyuria was associated with the inappropriate use of antibiotics (odds ratio, 3.27; 95% CI, 1.49-7.18). Only 7 subsequent infections with Enterococcus occurred in the 339 episodes of bacteriuria overall (2.1%), with 2 of the 183 cases of ABU (1.1%) having distant infection. Conclusions: Providers often overtreat enterococcal ABU with antibiotics, particularly in patients with pyuria. Given the low incidence of infectious complications, efforts should be made to optimize the use of antibiotics in enterococcal bacteriuria. C1 [Lin, Eugene; Bhusal, Yogesh; Horwitz, Deborah; Trautner, Barbara W.] Baylor Coll Med, Houston Vet Affairs Hlth Serv Res & Dev Ctr Excel, Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect,Dept Med, Houston, TX 77030 USA. [Trautner, Barbara W.] Baylor Coll Med, Houston Vet Affairs Hlth Serv Res & Dev Ctr Excel, Michael E DeBakey Vet Affairs Med Ctr, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Shelburne, Samuel A., III] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA. RP Trautner, BW (reprint author), Baylor Coll Med, Houston Vet Affairs Hlth Serv Res & Dev Ctr Excel, Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect,Dept Med, Mail Stop 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM trautner@bcm.edu FU Veterans Affairs Career Development Award [B4623]; Health Services Research & Development Service [IIR 09-104]; Houston Veterans Affairs Health Services Research & Development Service Center of Excellence [HFP90-020] FX Dr Trautner's work was supported by a Veterans Affairs Career Development Award (B4623) and by Health Services Research & Development Service IIR 09-104. This work was supported in part by the Houston Veterans Affairs Health Services Research & Development Service Center of Excellence (HFP90-020). NR 33 TC 31 Z9 32 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JAN 9 PY 2012 VL 172 IS 1 BP 33 EP 38 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 874LM UT WOS:000298958900006 PM 22232145 ER PT J AU Peralta, CA Norris, KC Li, SY Chang, TI Tamura, MK Jolly, SE Bakris, G McCullough, PA Shlipak, M AF Peralta, Carmen A. Norris, Keith C. Li, Suying Chang, Tara I. Tamura, Manjula K. Jolly, Stacey E. Bakris, George McCullough, Peter A. Shlipak, Michael CA KEEP Investigators TI Blood Pressure Components and End-stage Renal Disease in Persons With Chronic Kidney Disease The Kidney Early Evaluation Program (KEEP) SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID DIABETIC-NEPHROPATHY; AFRICAN-AMERICAN; FOLLOW-UP; PROGRESSION; RISK; HYPERTENSION; PROTEINURIA; MICROALBUMINURIA; POPULATION; TARGET AB Background: Treatment of hypertension is difficult in chronic kidney disease (CKD), and blood pressure goals remain controversial. The association between each blood pressure component and end-stage renal disease (ESRD) risk is less well known. Methods: We studied associations of systolic and diastolic blood pressure (SBP and DBP, respectively) and pulse pressure (PP) with ESRD risk among 16 129 Kidney Early Evaluation Program (KEEP) participants with an estimated glomerular filtration rate of 60 mL/min/1.73 m(2) using Cox proportional hazards. We estimated the prevalence and characteristics associated with uncontrolled hypertension (SBP >= 150 or DBP >= 90 mm Hg). Results: The mean (SD) age of participants was 69 (12) years; 25% were black, 6% were Hispanic, and 43% had diabetes mellitus. Over 2.87 years, there were 320 ESRD events. Higher SBP was associated with higher ESRD risk, starting at SBP of 140 mm Hg or higher. After sex and age adjustment, compared with SBP lower than 130 mm Hg, hazard ratios (HRs) were 1.08 (95% CI, 0.74-1.59) for SBP of 130 to 139 mm Hg, 1.72 (95% CI, 1.21-2.45) for SBP of 140 to 149 mm Hg, and 3.36 (95% CI, 2.51-4.49) for SBP of 150 mm Hg or greater. After full adjustment, HRs for ESRD were 1.27 (95% CI, 0.88-1.83) for SBP of 140 to 149 mm Hg and 1.36 (95% CI, 1.02-1.85) for SBP of 150 mm Hg or higher. Persons with DBP of 90 mm Hg or higher were at higher risk for ESRD compared with persons with DBP of 60 to 74 mm Hg (HR, 1.81; 95% CI, 1.33-2.45). Higher PP was also associated with higher ESRD risk (HR, 1.44 [95% CI, 1.00-2.07] for PP >= 80 mm Hg compared with PP < 50 mm Hg). Adjustment for SBP attenuated this association. More than 33% of participants had uncontrolled hypertension (SBP >= 150 mm Hg or DBP >= 90 mm Hg), mostly due to isolated systolic hypertension (54%). Conclusions: In this large, diverse, community-based sample, we found that high SBP seemed to account for most of the risk of progression to ESRD. This risk started at SBP of 140 mm Hg rather than the currently recommended goal of less than 130 mm Hg, and it was highest among those with SBP of at least 150 mm Hg. Treatment strategies that preferentially lower SBP may be required to improve BP control in CKD. C1 [Peralta, Carmen A.; Shlipak, Michael] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [Peralta, Carmen A.; Shlipak, Michael] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Norris, Keith C.] Charles Drew Univ Med & Sci, Dept Internal Med, Los Angeles, CA USA. [Li, Suying] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN USA. [Chang, Tara I.; Tamura, Manjula K.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA. [Jolly, Stacey E.] Cleveland Clin, Dept Gen Internal Med, Inst Med, Cleveland, OH 44106 USA. [Bakris, George] Univ Chicago, Pritzker Sch Med, Hypertens Dis Unit, Chicago, IL 60637 USA. [McCullough, Peter A.] Providence Pk Heart Inst, Dept Med, St John Providence Hlth Syst, Novi, MI USA. RP Peralta, CA (reprint author), Univ Calif San Francisco, Dept Med, 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu RI Kurella Tamura, Manjula/C-8284-2014 OI Kurella Tamura, Manjula/0000-0001-5227-2479 FU National Institute of Diabetes and Digestive and Kidney Diseases [1K23SK082793]; Robert Wood Johnson Harold Amos award; National Institutes of Health [MD00148, 1U54RR026138]; Amgen; Abbott; Novartis; Siemens; Genentech; Genzyme; Nephroceuticals; Pfizer; LifeScan; Suplena FX Dr Peralta is funded by National Institute of Diabetes and Digestive and Kidney Diseases grant 1K23SK082793 and a Robert Wood Johnson Harold Amos award. Dr Norris is supported by National Institutes of Health grants MD00148 and 1U54RR026138. KEEP is a program of the National Kidney Foundation and is supported by Amgen, Abbott, Novartis, Siemens, Genentech, Genzyme, Nephroceuticals, Pfizer, LifeScan, and Suplena. NR 29 TC 55 Z9 58 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JAN 9 PY 2012 VL 172 IS 1 BP 41 EP 47 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 874LM UT WOS:000298958900008 PM 22232147 ER PT J AU Navarrett, S Collier, L Cardozo, C Dracheva, S AF Navarrett, Scott Collier, Lauren Cardozo, Christopher Dracheva, Stella TI Alterations of serotonin 2C and 2A receptors in response to T10 spinal cord transection in rats SO NEUROSCIENCE LETTERS LA English DT Article DE Rat; SCI; 5-HT2(A)R; 5-HT2(c)R; mRNA editing ID PRE-MESSENGER-RNA; G-PROTEIN; CONSTITUTIVE ACTIVITY; PREFRONTAL CORTEX; SUICIDE; NEURONS; INJURY; BRAIN AB Recent studies reported that a recovery of motoneurons after spinal cord transection at the sacrocaudal level may depend on adaptive alterations of the serotonin 2C (5-HT2cR) and 2A (5-HT2cR) receptor function via changes in mRNA editing or protein expression, respectively. It has been suggested that depletion of serotonergic input may drive these adaptations. Here, mRNA editing and/or expression of 5-HT2cR and 5-HT2AR was evaluated in rats that sustained a complete transection at the thoracic (T10) level. While 5-HT2AR mRNA expression was upregulated below the site of spinal cord injury (SCI), no changes in 5-HT2cR mRNA editing or expression were detected. These findings argue against the hypothesis that 5-HT2cR editing is regulated by extracellular serotonin levels. Rather, it appears that the editing process is just one of the ways in which excitability of motor neurons can be restored following SCI. To this end, the influence of excitatory locomotor circuits on motor neurons in the thoracic spinal cord of rats requires further exploration. Published by Elsevier Ireland Ltd. C1 [Cardozo, Christopher; Dracheva, Stella] James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Dracheva, Stella] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Dracheva, S (reprint author), James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences SCI, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Stella.Dracheva@mssm.edu FU Department of Veterans Affairs Office of Research and Development; VISN3 Mental Illness Research and Education Clinical Center; VA FX This work was supported by Department of Veterans Affairs Office of Research and Development and VISN3 Mental Illness Research and Education Clinical Center (SD) and by a VA Merit Award (SD). NR 31 TC 17 Z9 17 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD JAN 6 PY 2012 VL 506 IS 1 BP 74 EP 78 DI 10.1016/j.neulet.2011.10.052 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 891GK UT WOS:000300205000015 PM 22056918 ER PT J AU Li, ZP Heber, D AF Li, Zhaoping Heber, David TI Overeating and Overweight Extra Calories Increase Fat Mass While Protein Increases Lean Mass SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID OBESITY C1 [Heber, David] VA Greater Los Angeles Hlth Care Syst, Ctr Human Nutr, Los Angeles, CA 90095 USA. [Li, Zhaoping; Heber, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Heber, D (reprint author), VA Greater Los Angeles Hlth Care Syst, Ctr Human Nutr, 900 Vet Ave, Los Angeles, CA 90095 USA. EM dheber@mednet.ucla.edu NR 19 TC 6 Z9 6 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 4 PY 2012 VL 307 IS 1 BP 86 EP 87 DI 10.1001/jama.2011.1959 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 872ET UT WOS:000298792300026 PM 22215169 ER PT J AU Shen, KZ Johnson, SW AF Shen, Ke-Zhong Johnson, Steven W. TI Gamma-aminobutyric acid(B) receptor activation suppresses stimulus-evoked burst firing in rat substantia nigra reticulata neurons SO NEUROREPORT LA English DT Article DE baclofen; brain slice; burst firing; complex excitatory postsynaptic currents; gamma-aminobutyric acid(B); substantia nigra reticulata; subthalamic nucleus ID SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE; BASAL GANGLIA; COMPLEX EPSCS; GABA-B; STIMULATION; TRANSMISSION; APOMORPHINE; LESIONS AB Previous whole-cell patch-pipette studies showed that focal electrical stimulation of the subthalamic nucleus (STN) evokes a long-lasting complex excitatory postsynaptic currents (EPSC) and synaptically evoked bursts of action potentials in substantia nigra pars reticulata (SNR) neurons. Although synaptically evoked bursting may play a role in normal physiology, excessive burst firing correlates with symptoms of Parkinson's disease. We used patch-pipette recordings in rat brain slices to study the effects of baclofen on complex EPSCs and STN-induced burst firing in SNR neurons. Baclofen (1 mu M) caused a reversible, 73% reduction in complex EPSCs, and this effect was blocked by the gamma-aminobutyric acid(B) antagonist CGP35348 (100 mu M). Using the loose-patch method to record extracellular potentials, a lower concentration of baclofen (100 nM) inhibited STN-evoked bursts, while leaving spontaneous firing of action potentials less affected. We suggest that strategies that selectively inhibit burst firing in the SNR might have therapeutic potential in the treatment of Parkinson's disease. NeuroReport 23:40-44 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Shen, Ke-Zhong; Johnson, Steven W.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Johnson, Steven W.] Portland VA Med Ctr, Portland, OR USA. RP Johnson, SW (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. EM johnsost@ohsu.edu FU United States Public Health Service [NS38715, NS060662]; Portland Veterans Affairs Parkinson's Disease Research, Education, and Clinical Center FX this work was supported by United States Public Health Service Grants NS38715 and NS060662, and the Portland Veterans Affairs Parkinson's Disease Research, Education, and Clinical Center. NR 25 TC 1 Z9 1 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD JAN 4 PY 2012 VL 23 IS 1 BP 40 EP 44 DI 10.1097/WNR.0b013e32834e4899 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 862ZM UT WOS:000298132600009 PM 22127013 ER PT J AU Greenstein, RJ Su, LY Brown, ST AF Greenstein, Robert J. Su, Liya Brown, Sheldon T. TI Vitamins A & D Inhibit the Growth of Mycobacteria in Radiometric Culture SO PLOS ONE LA English DT Article ID AVIUM SUBSPECIES PARATUBERCULOSIS; CROHNS-DISEASE; IN-VITRO; TUBERCULOSIS; DRUGS; SUSCEPTIBILITY; 6-MERCAPTOPURINE; CYCLOSPORINE; RESISTANCE; INFECTION AB Background: The role of vitamins in the combat of disease is usually conceptualized as acting by modulating the immune response of an infected, eukaryotic host. We hypothesized that some vitamins may directly influence the growth of prokaryotes, particularly mycobacteria. Methods: The effect of four fat-soluble vitamins was studied in radiometric Bactec (R) culture. The vitamins were A (including a precursor and three metabolites,) D, E and K. We evaluated eight strains of three mycobacterial species (four of M. avium subspecies paratuberculosis (MAP), two of M. avium and two of M. tb. complex). Principal Findings: Vitamins A and D cause dose-dependent inhibition of all three mycobacterial species studied. Vitamin A is consistently more inhibitory than vitamin D. The vitamin A precursor, beta-carotene, is not inhibitory, whereas three vitamin A metabolites cause inhibition. Vitamin K has no effect. Vitamin E causes negligible inhibition in a single strain. Significance: We show that vitamin A, its metabolites Retinyl acetate, Retinoic acid and 13-cis Retinoic acid and vitamin D directly inhibit mycobacterial growth in culture. These data are compatible with the hypothesis that complementing the immune response of multicellular organisms, vitamins A and D may have heretofore unproven, unrecognized, independent and probable synergistic, direct antimycobacterial inhibitory activity. C1 [Greenstein, Robert J.] James J Peters Vet Affairs Med Ctr, Dept Surg, Bronx, NY USA. [Greenstein, Robert J.; Su, Liya] James J Peters Vet Affairs Med Ctr, Lab Mol Surg Res, Bronx, NY USA. [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Dept Med, Bronx, NY USA. [Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA. RP Greenstein, RJ (reprint author), James J Peters Vet Affairs Med Ctr, Dept Surg, Bronx, NY USA. EM BGAxis@aol.com FU Becton-Dickinson FX This project was extramurally funded by Becton-Dickinson, whose sole contribution was to provide the authors with the culture medium used in these experiments. Intramural funds were from the Bronx Veterans Medical Research Foundation, Inc. a charity at the James J. Peters VAMC Bronx NY. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 8 Z9 8 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 3 PY 2012 VL 7 IS 1 AR e29631 DI 10.1371/journal.pone.0029631 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 903NK UT WOS:000301123400076 PM 22235314 ER PT J AU Mao, PZ Meshul, CK Thuillier, P Goldberg, NRS Reddy, PH AF Mao, Peizhong Meshul, Charles K. Thuillier, Philippe Goldberg, Natalie R. S. Reddy, P. Hemachandra TI CART Peptide Is a Potential Endogenous Antioxidant and Preferentially Localized in Mitochondria SO PLOS ONE LA English DT Article ID AMPHETAMINE-REGULATED TRANSCRIPT; PARKINSONS-DISEASE; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; BODY-WEIGHT; MESOLIMBIC DOPAMINE; NUCLEUS-ACCUMBENS; MESSENGER-RNA; DNA-DAMAGE; COCAINE AB The multifunctional neuropeptide Cocaine and Amphetamine Regulated Transcript (CART) is secreted from hypothalamus, pituitary, adrenal gland and pancreas. It also can be found in circulatory system. This feature suggests a general role for CART in different cells. In the present study, we demonstrate that CART protects mitochondrial DNA (mtDNA), cellular proteins and lipids against the oxidative action of hydrogen peroxide, a widely used oxidant. Using cis-parinaric acid as a sensitive reporting probe for peroxidation in membranes, and a lipid-soluble azo initiator of peroxyl radicals, 2,2'-Azobis(2,4-dimethylvaleronitrile) we found that CART is an antioxidant. Furthermore, we found that CART localized to mitochondria in cultured cells and mouse brain neuronal cells. More importantly, pretreatment with CART by systemic injection protects against a mouse oxidative stress model, which mimics the main features of Parkinson's disease. Given the unique molecular structure and biological features of CART, we conclude that CART is an antioxidant peptide (or antioxidant hormone). We further propose that it may have strong therapeutic properties for human diseases in which oxidative stress is strongly involved such as Parkinson's disease. C1 [Mao, Peizhong; Reddy, P. Hemachandra] Oregon Hlth & Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, Beaverton, OR USA. [Mao, Peizhong; Thuillier, Philippe] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Mao, Peizhong; Thuillier, Philippe] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Meshul, Charles K.; Goldberg, Natalie R. S.] Portland VA Med Ctr, Res Serv, Portland, OR USA. [Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Reddy, P. Hemachandra] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. RP Mao, PZ (reprint author), Oregon Hlth & Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, Beaverton, OR USA. EM maop@ohsu.edu FU American Heart Association [0565527Z]; Department of Veterns Affairs; National Institutes of Health [CA112083-01, AG028072, AG026051, RR000163] FX These studies were supported by the American Heart Association (Beginning Grant-in-Aid 0565527Z) to PM, the Department of Veterns Affairs Merit Review Program to CK, and the National Institutes of Health to PT (CA112083-01) and to PHR (AG028072, AG026051), and to ONPRC (RR000163). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 74 TC 18 Z9 18 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 3 PY 2012 VL 7 IS 1 AR e29343 DI 10.1371/journal.pone.0029343 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 903NK UT WOS:000301123400048 PM 22235287 ER PT J AU Yamamura, S Saini, S Majid, S Hirata, H Ueno, K Deng, G Dahiya, R AF Yamamura, Soichiro Saini, Sharanjot Majid, Shahana Hirata, Hiroshi Ueno, Koji Deng, Guoren Dahiya, Rajvir TI MicroRNA-34a Modulates c-Myc Transcriptional Complexes to Suppress Malignancy in Human Prostate Cancer Cells SO PLOS ONE LA English DT Article ID HEPATOCYTE GROWTH-FACTOR; RECRUITS P-TEFB; RHO-GTPASES; TUMOR-SUPPRESSOR; GENE-EXPRESSION; DNA-REPLICATION; DOWN-REGULATION; CAD PROMOTER; MET RECEPTOR; IN-VIVO AB MicroRNA-34a (miR-34a), a potent mediator of tumor suppressor p53, has been reported to function as a tumor suppressor and miR-34a was found to be downregulated in prostate cancer tissues. We studied the functional effects of miR-34a on c-Myc transcriptional complexes in PC-3 prostate cancer cells. Transfection of miR-34a into PC-3 cells strongly inhibited in vitro cell proliferation, cell invasion and promoted apoptosis. Transfection of miR-34a into PC-3 cells also significantly inhibited in vivo xenograft tumor growth in nude mice. miR-34a downregulated expression of c-Myc oncogene by targeting its 39 UTR as shown by luciferase reporter assays. miR-34a was found to repress RhoA, a regulator of cell migration and invasion, by suppressing c-Myc-Skp2-Miz1 transcriptional complex that activates RhoA. Overexpression of c-Myc reversed miR-34a suppression of RhoA expression, suggesting that miR-34a inhibits invasion by suppressing RhoA through c-Myc. miR-34a was also found to repress c-Myc-pTEFB transcription elongation complex, indicating one of the mechanisms by which miR-34a has profound effects on cellular function. This is the first report to document that miR-34a suppresses assembly and function of the c-Myc-Skp2-Miz1 complex that activates RhoA and the c-Myc-pTEFB complex that elongates transcription of various genes, suggesting a novel role of miR-34a in the regulation of transcription by c-Myc complex. C1 [Yamamura, Soichiro] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Yamamura, S (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. EM rdahiya@urology.ucsf.edu FU NIH [R01CA138642, T32DK007790] FX This study was supported by Grants R01CA138642, T32DK007790 (NIH), VA Research Enhancement Award Program (REAP) and Merit Review grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 60 Z9 64 U1 3 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 3 PY 2012 VL 7 IS 1 AR e29722 DI 10.1371/journal.pone.0029722 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 903NK UT WOS:000301123400094 PM 22235332 ER PT J AU Qaseem, A Wilt, TJ Shekelle, P AF Qaseem, Amir Wilt, Timothy J. Shekelle, Paul TI A Clinical Practice Guideline Update on the Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. [Wilt, Timothy J.] Minneapolis Vet Affairs Ctr Chron Dis Outcomes Re, Minneapolis, MN 55417 USA. [Shekelle, Paul] RAND Corp, Greater Los Angeles Vet Affairs Hlth Ctr, Santa Monica, CA 90401 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, Philadelphia, PA 19106 USA. NR 5 TC 1 Z9 1 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 3 PY 2012 VL 156 IS 1 BP 69 EP 69 DI 10.7326/0003-4819-156-1-201201030-00022 PN 1 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 872VK UT WOS:000298837600015 ER PT J AU Hung, WW Morrison, RS AF Hung, William W. Morrison, R. Sean TI Hip Fracture: A Complex Illness Among Complex Patients RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Hung, William W.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Morrison, R. Sean] Mt Sinai Sch Med, New York, NY 10029 USA. RP Hung, WW (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 3 PY 2012 VL 156 IS 1 BP 71 EP 71 DI 10.7326/0003-4819-156-1-201201030-00028 PN 1 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 872VK UT WOS:000298837600021 ER PT J AU Foland-Ross, LC Bookheimer, SY Lieberman, MD Sugar, CA Townsend, JD Fischer, J Torrisi, S Penfold, C Madsen, SK Thompson, PM Altshuler, LL AF Foland-Ross, Lara C. Bookheimer, Susan Y. Lieberman, Matthew D. Sugar, Catherine A. Townsend, Jennifer D. Fischer, Jeffrey Torrisi, Salvatore Penfold, Conor Madsen, Sarah K. Thompson, Paul M. Altshuler, Lori L. TI Normal amygdala activation but deficient ventrolateral prefrontal activation in adults with bipolar disorder during euthymia SO NEUROIMAGE LA English DT Article DE Bipolar disorder; Amygdala; Prefrontal cortex; fMRI; Emotion ID MOTOR RESPONSE-INHIBITION; ORBITOFRONTAL CORTEX; AFFECTIVE STIMULI; BRAIN ACTIVATION; RATING-SCALE; MANIA; FMRI; TASK; ABNORMALITIES; OPTIMIZATION AB Functional neuroimaging studies have implicated the involvement of the amygdala and ventrolateral prefrontal cortex (vIPFC) in the pathophysiology of bipolar disorder. Hyperactivity in the amygdala and hypoactivity in the vIPFC have been reported in manic bipolar patients scanned during the performance of an affective faces task. Whether this pattern of dysfunction persists during euthymia is unclear. Using functional magnetic resonance imaging (fMRI), 24 euthymic bipolar and 26 demographically matched healthy control subjects were scanned while performing an affective task paradigm involving the matching and labeling of emotional facial expressions. Neuroimaging results showed that, while amygdala activation did not differ significantly between groups, euthymic patients showed a significant decrease in activation of the right vIPFC (BA47) compared to healthy controls during emotion labeling. Additionally, significant decreases in activation of the right insula, putamen, thalamus and lingual gyrus were observed in euthymic bipolar relative to healthy control subjects during the emotion labeling condition. These data, taken in context with prior studies of bipolar mania using the same emotion recognition task, could suggest that amygdala dysfunction may be a state-related abnormality in bipolar disorder, whereas vIPFC dysfunction may represent a trait-related abnormality of the illness. Characterizing these patterns of activation is likely to help in understanding the neural changes related to the different mood states in bipolar disorder, as well as changes that represent more sustained abnormalities. Future studies that assess mood-state related changes in brain activation in longitudinal bipolar samples would be of interest. Published by Elsevier Inc. C1 [Altshuler, Lori L.] Univ Calif Los Angeles, Mood Disorders Res Program, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Foland-Ross, Lara C.; Madsen, Sarah K.; Thompson, Paul M.] Univ Calif Los Angeles, Lab NeuroImaging, Dept Neurol, Sch Med, Los Angeles, CA 90095 USA. [Lieberman, Matthew D.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Altshuler, Lori L.] W Los Angeles Healthcare Ctr, Los Angeles, CA USA. RP Altshuler, LL (reprint author), Univ Calif Los Angeles, Mood Disorders Res Program, Dept Psychiat & Biobehav Sci, 300 Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA. EM laltshuler@mednet.ucla.edu FU National Institute of Mental Health [MH078556, MH075944, MH01848]; National Institute on Aging (NIA); National Institute of Biomedical Imaging and Bioengineering (NIBIB); National Center for Research Resources (NCRR) [AG016570, EB01651, RR019771, RR12169, RR13642, RR00865] FX This work was supported by grants from the National Institute of Mental Health (MH078556 to LCFR, and MH075944 and MH01848 to LLA). Additional support for algorithm development was provided by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and the National Center for Research Resources (NCRR; AG016570, EB01651, RR019771 to PT). For their generous support, the authors also thank the National Association for Research on Schizophrenia and Affective Disorders (NARSAD), Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson-Lovelace Foundation, The Ahmanson Foundation, William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family and Northstar Fund. The project was also supported by grant numbers RR12169, RR13642 and RR00865 from the NCRR. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH. NR 42 TC 38 Z9 40 U1 2 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD JAN 2 PY 2012 VL 59 IS 1 SI SI BP 738 EP 744 DI 10.1016/j.neuroimage.2011.07.054 PG 7 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 838CX UT WOS:000296265500073 PM 21854858 ER PT J AU Shacka, JJ AF Shacka, John J. BE Yue, Z Chu, CT TI LYSOSOME STORAGE DISORDERS ON THE BRAIN: THE AUTOPHAGY LYSOSOME PATHWAY CONTRIBUTES TO DISEASE PATHOPHYSIOLOGY AND MAY BE UTILIZED FOR THERAPEUTIC BENEFIT SO AUTOPHAGY OF THE NERVOUS SYSTEM: CELLULAR SELF-DIGESTION IN NEURONS AND NEUROLOGICAL DISEASES LA English DT Article; Book Chapter ID MUCOLIPIDOSIS TYPE-IV; NEURONAL CEROID-LIPOFUSCINOSES; CATHEPSIN-D DEFICIENCY; NEURONOPATHIC GAUCHER-DISEASE; CHAPERONE-MEDIATED AUTOPHAGY; SAPOSIN C DEFICIENCY; NIEMANN-PICK-DISEASE; CELL-DEATH PATHWAYS; POMPE-DISEASE; BATTEN-DISEASE AB Lysosome storage disorders (LSDs) are defined by genetic mutations that either directly or indirectly compromise lysosome function, many of which exhibit documented CNS pathophysiology. As lysosome dysfunction is a principal contributing factor to the onset and progression of LSDs, it is not surprising to learn of several reports documenting inherent abnormalities in the autophagy-lysosome pathway (ALP), as the ALP requires itntact lysosome function for its proper clearance of substrates and homeostatic maintenance of energy balance. In addition, accumulating evidence suggests that alterations in ALP signaling contribute to the onset and progression of adult onset neurodegenerative disease. Thus the study of LSD mutations and their effects on the ALP has aided in our understanding of ALP-associated contributions to diseases such as Alzheimer's and Parkinson's. Herein we will review LSDs with known CNS pathophysiology and will discuss the often heterogeneous ALP abnormalities amongst these diseases. LSD-specific therapies will also be discussed and how the ALP may be a direct or indirect target of such therapies. Finally, the function of the ALP in LSDs will be discussed relative to its putative role in adult onset neurodegenerative disease. C1 [Shacka, John J.] Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA. [Shacka, John J.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Shacka, JJ (reprint author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA. EM shacka@uab.edu RI di Ronza, Alberto/H-7674-2016 OI di Ronza, Alberto/0000-0002-9813-5143 NR 82 TC 0 Z9 0 U1 0 U2 1 PU WORLD SCIENTIFIC PUBL CO PTE LTD PI SINGAPORE PA PO BOX 128 FARRER RD, SINGAPORE 9128, SINGAPORE BN 978-981-4350-44-0 PY 2012 BP 331 EP 354 D2 10.1142/8150 PG 24 WC Neurosciences SC Neurosciences & Neurology GA BHZ39 UT WOS:000327076800015 ER PT B AU Miller, JD Seyedali, M Hahn, ME AF Miller, Jason D. Seyedali, Mahyo Hahn, Michael E. GP ASME TI WALKING MODE CLASSIFICATION FROM MYOELECTRIC AND INERTIAL FUSION SO PROCEEDINGS OF THE ASME SUMMER BIOENGINEERING CONFERENCE, PTS A AND B LA English DT Proceedings Paper CT ASME Summer Bioengineering Conference (SBC) CY JUN 20-23, 2012 CL Fajardo, PR C1 [Miller, Jason D.; Seyedali, Mahyo; Hahn, Michael E.] VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence, Seattle, WA 98108 USA. RP Miller, JD (reprint author), VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence, Seattle, WA 98108 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MECHANICAL ENGINEERS PI NEW YORK PA THREE PARK AVENUE, NEW YORK, NY 10016-5990 USA BN 978-0-7918-4480-9 PY 2012 BP 797 EP 798 PG 2 WC Engineering, Biomedical; Engineering, Mechanical SC Engineering GA BHD11 UT WOS:000325036600398 ER PT B AU Peterson, TJ Roland, M Adamczyk, P Hahn, ME AF Peterson, Travis J. Roland, Michelle Adamczyk, Peter Hahn, Michael E. GP ASME TI THE EFFECT OF PROSTHETIC FOOT COMPONENT STIFFNESS ON GAIT INITIATION AND TERMINATION OF TRANSTIBIAL AMPUTEES SO PROCEEDINGS OF THE ASME SUMMER BIOENGINEERING CONFERENCE, PTS A AND B LA English DT Proceedings Paper CT ASME Summer Bioengineering Conference (SBC) CY JUN 20-23, 2012 CL Fajardo, PR ID LOWER-LIMB AMPUTEES C1 [Peterson, Travis J.; Roland, Michelle; Hahn, Michael E.] VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence, Seattle, WA 98105 USA. RP Peterson, TJ (reprint author), VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence, Seattle, WA 98105 USA. RI Adamczyk, Peter/P-5928-2014 OI Adamczyk, Peter/0000-0001-5374-7691 NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MECHANICAL ENGINEERS PI NEW YORK PA THREE PARK AVENUE, NEW YORK, NY 10016-5990 USA BN 978-0-7918-4480-9 PY 2012 BP 803 EP 804 PG 2 WC Engineering, Biomedical; Engineering, Mechanical SC Engineering GA BHD11 UT WOS:000325036600401 ER PT J AU Vassar, SD Bordelon, YM Hays, RD Diaz, N Rausch, R Mao, C Vickrey, BG AF Vassar, Stefanie D. Bordelon, Yvette M. Hays, Ron D. Diaz, Natalie Rausch, Rebecca Mao, Cherry Vickrey, Barbara G. TI Confirmatory Factor Analysis of the Motor Unified Parkinson's Disease Rating Scale SO PARKINSONS DISEASE LA English DT Article ID MDS-UPDRS; SECTION; FIT AB The motor examination section of the unified Parkinson's disease rating scale (UPDRS) is widely used in research but few studies have examined whether subscales exist that tap relatively distinct motor abnormalities. We analyzed data from 193 persons enrolled in a population-based study in Central California. Patients were examined after overnight PD medication washout ("OFF" state) and approximately one hour after taking medication ("ON" state). We performed confirmatory factor analysis of the UPDRS for OFF and ON state examinations; correlations, reliability, and relative validity of resulting subscales were evaluated. A model with five factors (gait/posture, tremor, rigidity, bradykinesia affecting the left extremities, bradykinesia affecting the right extremities) fit the data well, with similar results for OFF and ON states. Internal consistency reliability coefficients were 0.90 or higher for all subscales. The gait/posture subscale most strongly discriminated across levels of patient reported PD symptom severity and of how PD affects them on a daily basis. Compared to the right sided bradykinesia subscale, the left sided bradykinesia subscale had higher discrimination across levels of self-reported PD symptom severity and functional impairment. This supports motor UPDRS containing multiple subscales that can be analyzed separately and provide information distinct from the total score that may be useful in clinical studies. C1 [Vassar, Stefanie D.; Bordelon, Yvette M.; Rausch, Rebecca; Mao, Cherry; Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Vassar, Stefanie D.; Vickrey, Barbara G.] VA Greater Los Angeles Healthcare Syst, Parkinsons Dis Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Hays, Ron D.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Dept Med, Los Angeles, CA 90095 USA. [Hays, Ron D.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA. [Hays, Ron D.] RAND Corp, Santa Monica, CA 90407 USA. [Diaz, Natalie] Harbor UCLA Med Ctr, Dept Neurol, Torrance, CA 90502 USA. RP Vickrey, BG (reprint author), Univ Calif Los Angeles, Dept Neurol, Box 951769,C109 RNRC, Los Angeles, CA 90095 USA. EM bvickrey@ucla.edu FU National Institutes of Health/National Institute of Neurological Disorders and Stroke [NS038367]; Veterans Administration through its Southwest Parkinson's Disease Research, Education, and Clinical Center (PADRECC); NIA [P30-AG021684]; NIMHD [2P20MD000182] FX The research presented here was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke for the University of California Los Angeles UDALL Parkinson's Disease Center of Excellence (NS038367), and by the Veterans Administration through its Southwest Parkinson's Disease Research, Education, and Clinical Center (PADRECC). R. H. Hays was also supported in part by Grants from the NIA (P30-AG021684) and the NIMHD (2P20MD000182). The authors thank Jeff Bronstein, MD, PhD for assisting in UPDRS data collection and Aaron Cook, MPH, for technical assistance in paper preparation. NR 27 TC 0 Z9 0 U1 0 U2 1 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2090-8083 J9 PARKINSONS DIS-US JI Parkinsons Dis. PY 2012 AR UNSP 719167 DI 10.1155/2012/719167 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 214MK UT WOS:000324137400001 ER PT J AU Rutten, MJ Janes, MA Chang, IR Gregory, CR Gregory, KW AF Rutten, Michael J. Janes, Michael Ann Chang, Ivy R. Gregory, Cynthia R. Gregory, Kenton W. TI Development of a Functional Schwann Cell Phenotype from Autologous Porcine Bone Marrow Mononuclear Cells for Nerve Repair SO STEM CELLS INTERNATIONAL LA English DT Article ID MESENCHYMAL STEM-CELLS; INCREASES INTRACELLULAR CALCIUM; LARGE-ANIMAL-MODELS; IN-VITRO; STROMAL CELLS; PURINERGIC RECEPTORS; RAT VIBRISSAE; AXON FUNCTION; SPINAL-CORD; DIFFERENTIATION AB Adult bone marrow mononuclear cells (BM-MNCs) are a potential resource for making Schwann cells to repair damaged peripheral nerves. However, many methods of producing Schwann-like cells can be laborious with the cells lacking a functional phenotype. The objective of this study was to develop a simple and rapid method using autologous BM-MNCs to produce a phenotypic and functional Schwann-like cell. Adult porcine bone marrow was collected and enriched for BM-MNCs using a SEPAX device, then cells cultured in Neurobasal media, 4 mM L-glutamine and 20% serum. After 6-8 days, the cultures expressed Schwann cell markers, S-100, O4, GFAP, were FluoroMyelin positive, but had low p75(NGF) expression. Addition of neuregulin (1-25 nM) increased p75(NGF) levels at 24-48 hrs. We found ATP dose-dependently increased intracellular calcium [Ca2+](i), with nucleotide potency being UTP = ATP > ADP > AMP > adenosine. Suramin blocked the ATP-induced [Ca2+](i) but alpha,beta,-methylene-ATP had little effect suggesting an ATP purinergic P2Y2 G-protein-coupled receptor is present. Both the Schwann cell markers and ATP-induced [Ca2+](i) sensitivity decreased in cells passaged >20 times. Our studies indicate that autologous BM-MNCs can be induced to form a phenotypic and functional Schwann-like cell which could be used for peripheral nerve repair. C1 [Rutten, Michael J.; Janes, Michael Ann; Chang, Ivy R.; Gregory, Kenton W.] Providence Hlth & Serv, Portland, OR 97225 USA. [Rutten, Michael J.; Gregory, Cynthia R.; Gregory, Kenton W.] Oregon Hlth & Sci Univ, OHSU Ctr Regenerat Med, Portland, OR 97239 USA. [Gregory, Cynthia R.] Oregon Biomed Engn Inst, Wilsonville, OR 97070 USA. [Gregory, Cynthia R.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Rutten, MJ (reprint author), Providence Hlth & Serv, 9555 SW Barnes Rd, Portland, OR 97225 USA. EM ruttenm@ohsu.edu FU Department of the Army [W81XWH-05-1-0586, W81XWH-09-1-0688]; Inskeep and Loacker philanthropic FX They would like to thank Rebecca Sarao, Ping-Cheng Wu, and Jeffrey Teach for the collection of the bone marrow samples, and Lian Wang and Ann Romer for assistance with the SEPAX bone marrow mononuclear cell purification. They would also like to thank Dr. Daniel Beacham (Molecular Probes/Invitrogen) with advice in the early part of these studies on ATP receptors and intracellular calcium regulation in Schwann cells. The Department of the Army Grants no. W81XWH-05-1-0586, W81XWH-09-1-0688, and Inskeep and Loacker philanthropic donations funded this work. The content of the information does not necessarily reflect the position of the Federal Government and no official endorsement should be inferred. NR 75 TC 1 Z9 1 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-966X EI 1687-9678 J9 STEM CELLS INT JI Stem Cells Int. PY 2012 AR UNSP 738484 DI 10.1155/2012/738484 PG 15 WC Cell & Tissue Engineering SC Cell Biology GA 209RL UT WOS:000323777400001 ER PT J AU Bird, TD AF Bird, Thomas D. BE Wood, NW TI The future of neurogenetics SO NEUROGENETICS: A GUIDE FOR CLINICIANS LA English DT Article; Book Chapter C1 [Bird, Thomas D.] Univ Washington, Dept Neurol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Bird, Thomas D.] Univ Washington, Dept Med Genet, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Bird, TD (reprint author), Univ Washington, Dept Neurol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-54372-9 PY 2012 BP 229 EP 233 D2 10.1017/CBO9781139087711 PG 5 WC Genetics & Heredity; Clinical Neurology SC Genetics & Heredity; Neurosciences & Neurology GA BFZ95 UT WOS:000322012800015 ER PT S AU Lim, K McNeil, M Dickey, M Doyle, P Hula, W AF Lim, K. McNeil, M. Dickey, M. Doyle, P. Hula, W. BE Miozzo, M TI Conflict Resolution and Goal Maintenance Components of Executive Attention are Impaired in Persons With Aphasia: Evidence from the Picture-Word Interference Task SO 50TH ACADEMY OF APHASIA MEETING SE Procedia Social and Behavioral Sciences LA English DT Proceedings Paper CT 50th Academy-of-Aphasia Meeting CY OCT 28-30, 2012 CL San Francisco, CA SP Acad Aphasia C1 [Lim, K.; Doyle, P.; Hula, W.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM limky21@gmail.com OI Dickey, Michael Walsh/0000-0002-9068-3313 NR 2 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1877-0428 J9 PROCD SOC BEHV PY 2012 VL 61 BP 181 EP 182 DI 10.1016/j.sbspro.2012.10.137 PG 2 WC Audiology & Speech-Language Pathology; Clinical Neurology; Rehabilitation SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Rehabilitation GA BFV52 UT WOS:000321555700089 ER PT S AU Cohen, AD Rabinovici, GD Mathis, CA Jagust, WJ Klunk, WE Ikonomovic, MD AF Cohen, Ann D. Rabinovici, Gil D. Mathis, Chester A. Jagust, William J. Klunk, William E. Ikonomovic, Milos D. BE Michaelis, EK Michaelis, ML TI Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta SO CURRENT STATE OF ALZHEIMER'S DISEASE RESEARCH AND THERAPEUTICS SE Advances in Pharmacology LA English DT Article; Book Chapter ID MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; ALZHEIMERS ASSOCIATION WORKGROUPS; FRONTOTEMPORAL LOBAR DEGENERATION; PRIMARY-PROGRESSIVE-APHASIA; APOLIPOPROTEIN-E GENOTYPE; LEWY BODY DEMENTIA; PARKINSONS-DISEASE DEMENTIA; CEREBROSPINAL-FLUID MARKERS; CEREBRAL GLUCOSE-METABOLISM AB The development of A beta-PET imaging agents has allowed for detection of fibrillar A beta deposition in vivo and marks a major advancement in understanding the role of A beta in Alzheimer's disease (AD). Imaging A beta thus has many potential clinical benefits: early or perhaps preclinical detection of disease and accurately distinguishing AD from dementias of other non-A beta causes in patients presenting with mild or atypical symptoms or confounding comorbidities (in which the distinction is difficult to make clinically). From a research perspective, imaging A beta allows us to study relationships between amyloid pathology and changes in cognition, brain structure, and function across the continuum from normal aging to mild cognitive impairment (MCI) to AD; and to monitor the effectiveness of anti-A beta drugs and relate them to neurodegeneration and clinical symptoms. Here, we will discuss the application of one of the most broadly studied and widely used A beta imaging agents, Pittsburgh Compound-B (PiB). C1 [Cohen, Ann D.; Klunk, William E.; Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Rabinovici, Gil D.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA. [Mathis, Chester A.] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA. [Jagust, William J.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Jagust, William J.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Klunk, William E.; Ikonomovic, Milos D.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Cohen, AD (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. OI Klunk, William/0000-0001-5512-0251 FU NIA NIH HHS [P01 AG014449, AG014449, AG034570, K01 AG037562, K23 AG031861, P01 AG025204, P50 AG005133, R01 AG018402, R01 AG034570, R01 AG18402, R37 AG025516, RF1 AG025516] NR 278 TC 32 Z9 33 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1054-3589 BN 978-0-12-394845-8 J9 ADV PHARMACOL JI Adv. Pharmacol. PY 2012 VL 64 BP 27 EP 81 DI 10.1016/B978-0-12-394816-8.00002-7 PG 55 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA BFX20 UT WOS:000321744100002 PM 22840744 ER PT J AU Brady, ST Siegel, GJ Albers, RW Price, D Benjamins, J Fisher, S Hall, A Bazan, N Coyle, J Sisodia, S AF Brady, Scott T. Siegel, George J. Albers, R. Wayne Price, Donald Benjamins, Joyce Fisher, Stephen Hall, Alison Bazan, Nicolas Coyle, Joseph Sisodia, Sangram BE Brady, ST Siegel, GJ Albers, RW Price, DL TI Eighth Edition Acknowledgments and History SO BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION LA English DT Editorial Material; Book Chapter C1 [Brady, Scott T.] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA. [Siegel, George J.] Loyola Univ, Chicago Stritch Sch Med, Dept Neurol & Cell Biol, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Chicago Stritch Sch Med, Dept Neurobiol, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Chicago Stritch Sch Med, Dept Anat, Maywood, IL 60153 USA. [Siegel, George J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA. [Albers, R. Wayne] NINDS, Sect Enzymes, Neurochem Lab, NIH, Bethesda, MD 20892 USA. [Price, Donald] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA. [Price, Donald] Johns Hopkins Univ, Sch Med, Dept Neurol, Div Neuropathol, Baltimore, MD 21205 USA. [Price, Donald] Johns Hopkins Univ, Sch Med, Dept Neurosci, Div Neuropathol, Baltimore, MD 21205 USA. [Benjamins, Joyce] Wayne State Univ, Dept Neurol, Detroit Med Ctr, Univ Hlth Ctr, Detroit, MI 48201 USA. [Fisher, Stephen] Univ Michigan, Ann Arbor, MI 48109 USA. [Fisher, Stephen] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA. [Hall, Alison] Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA. [Hall, Alison] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. [Bazan, Nicolas] Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA. [Coyle, Joseph] Harvard Univ, Sch Med, McLean Hosp, Belmont, MA 02478 USA. RP Brady, ST (reprint author), Univ Illinois, Dept Anat & Cell Biol, 808 S Wood St,Room 578,M-C 512, Chicago, IL 60612 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-095901-6 PY 2012 BP XXI EP XXI PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BFN78 UT WOS:000320652300001 ER PT J AU Brady, ST Siegel, GJ AF Brady, Scott T. Siegel, George J. BE Brady, ST Siegel, GJ Albers, RW Price, DL TI BASIC NEUROCHEMISTRY PRINCIPLES OF MOLECULAR, CELLULAR AND MEDICAL NEUROBIOLOGY EIGHTH EDITION Preface SO BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION LA English DT Editorial Material; Book Chapter C1 [Brady, Scott T.] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA. [Siegel, George J.] Loyola Univ, Chicago Stritch Sch Med, Dept Neurol & Cell Biol, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Chicago Stritch Sch Med, Dept Neurobiol, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Chicago Stritch Sch Med, Dept Anat, Maywood, IL 60153 USA. [Siegel, George J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA. RP Brady, ST (reprint author), Univ Illinois, Dept Anat & Cell Biol, 808 S Wood St,Room 578,M-C 512, Chicago, IL 60612 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-095901-6 PY 2012 BP XXIII EP XXIV PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BFN78 UT WOS:000320652300002 ER PT B AU Siegel, GJ AF Siegel, George J. BE Brady, ST Siegel, GJ Albers, RW Price, DL TI SPECTRIN AND LIPID RAFT MEMBRANE COMPONENTS PARTICIPATE IN THE PATHOLOGY OF BRAIN INJURY SO BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION LA English DT Editorial Material; Book Chapter C1 [Siegel, George J.] Loyola Univ, Dept Neurol & Cell Biol, Chicago Stritch Sch Med, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Dept Neurobiol, Chicago Stritch Sch Med, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Dept Anat, Chicago Stritch Sch Med, Maywood, IL 60153 USA. [Siegel, George J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA. RP Siegel, GJ (reprint author), Loyola Univ, Dept Neurol & Cell Biol, Chicago Stritch Sch Med, 2160 S 1st Ave, Maywood, IL 60153 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-095901-6 PY 2012 BP 37 EP 37 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BFN78 UT WOS:000320652300006 ER PT J AU Siegel, GJ AF Siegel, George J. BE Brady, ST Siegel, GJ Albers, RW Price, DL TI THERAPY OF BRAIN EDEMA: POTENTIAL PHARMACOLOGIC REGULATION OF AQUAPORIN 4 SO BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION LA English DT Editorial Material; Book Chapter C1 [Siegel, George J.] Loyola Univ, Dept Neurol & Cell Biol, Chicago Stritch Sch Med, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Dept Neurobiol, Chicago Stritch Sch Med, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Dept Anat, Chicago Stritch Sch Med, Maywood, IL 60153 USA. [Siegel, George J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA. RP Siegel, GJ (reprint author), Loyola Univ, Dept Neurol & Cell Biol, Chicago Stritch Sch Med, 2160 S 1st Ave, Maywood, IL 60153 USA. NR 8 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-095901-6 PY 2012 BP 59 EP 60 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BFN78 UT WOS:000320652300008 ER PT J AU Siegel, GJ AF Siegel, George J. BE Brady, ST Siegel, GJ Albers, RW Price, DL TI GLYCINERGIC NEUROTRANSMISSION AND NEUROLOGIC DISEASE SO BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION LA English DT Editorial Material; Book Chapter ID MICE IN-VIVO; DENTATE GYRUS; BETA-SUBUNIT; RECEPTOR; HYPEREKPLEXIA; GEPHYRIN; COLLYBISTIN; MUTATIONS; SYNAPSES; EXCITABILITY C1 [Siegel, George J.] Loyola Univ, Dept Neurol & Cell Biol, Chicago Stritch Sch Med, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Dept Neurobiol, Chicago Stritch Sch Med, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Dept Anat, Chicago Stritch Sch Med, Maywood, IL 60153 USA. [Siegel, George J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA. RP Siegel, GJ (reprint author), Loyola Univ, Dept Neurol & Cell Biol, Chicago Stritch Sch Med, 2160 S 1st Ave, Maywood, IL 60153 USA. NR 37 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-095901-6 PY 2012 BP 250 EP 255 PG 6 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BFN78 UT WOS:000320652300022 ER PT B AU Siegel, GJ AF Siegel, George J. BE Brady, ST Siegel, GJ Albers, RW Price, DL TI EPIGENETIC MODIFICATIONS AND NEUROLOGIC DISEASE SO BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION LA English DT Editorial Material; Book Chapter ID EMERGING ROLE; INHIBITORS; DISORDERS C1 [Siegel, George J.] Loyola Univ, Chicago Stritch Sch Med, Dept Neurol & Cell Biol, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Chicago Stritch Sch Med, Dept Neurobiol, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ, Chicago Stritch Sch Med, Dept Anat, Maywood, IL 60153 USA. [Siegel, George J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA. RP Siegel, GJ (reprint author), Loyola Univ, Chicago Stritch Sch Med, Dept Neurol & Cell Biol, 2160 S 1st Ave, Maywood, IL 60153 USA. NR 19 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-095901-6 PY 2012 BP 731 EP 733 PG 3 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BFN78 UT WOS:000320652300065 ER PT B AU Siegel, GJ AF Siegel, George J. BE Brady, ST Siegel, GJ Albers, RW Price, DL TI INHIBITION OF TRANSGLUTAMINASE AS A POTENTIAL THERAPY IN POLYGLUTAMINE REPEAT DISEASES SO BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION LA English DT Editorial Material; Book Chapter ID HUNTINGTONS-DISEASE; NEURONAL DEATH C1 [Siegel, George J.] Loyola Univ Chicago, Stritch Sch Med, Dept Neurol, Maywood, IL 60153 USA. [Siegel, George J.] Loyola Univ Chicago, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA. [Siegel, George J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Neurol Serv, Hines, IL 60141 USA. RP Siegel, GJ (reprint author), Loyola Univ Chicago, Stritch Sch Med, Dept Neurol, Maywood, IL 60153 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-095901-6 PY 2012 BP 852 EP 853 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BFN78 UT WOS:000320652300078 ER PT J AU Scremin, OU Holschneider, DP AF Scremin, Oscar U. Holschneider, Daniel P. BE Watson, C Paxinos, G Puelles, L TI Vascular Supply SO MOUSE NERVOUS SYSTEM LA English DT Article; Book Chapter ID CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MOUSE-BRAIN; STATISTICAL-ANALYSIS; RAT-BRAIN; COMPUTED-TOMOGRAPHY; ANESTHETIZED MOUSE; HYDROGEN CLEARANCE; GLUCOSE-METABOLISM C1 [Scremin, Oscar U.] VA Greater Los Angeles Healthcare Syst, Res Dept, Los Angeles, CA USA. [Scremin, Oscar U.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Holschneider, Daniel P.] Univ So Calif, Keck Sch Med, Dept Psychiat, Los Angeles, CA 90033 USA. [Holschneider, Daniel P.] Univ So Calif, Keck Sch Med, Dept Behav Sci Neurol Cell & Neurobiol, Los Angeles, CA 90033 USA. [Holschneider, Daniel P.] Viterbi Sch Engn, Dept Biomed Engn, Los Angeles, CA USA. RP Scremin, OU (reprint author), VA Greater Los Angeles Healthcare Syst, Res Dept, Los Angeles, CA USA. NR 80 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-091918-8 PY 2012 BP 459 EP 472 DI 10.1016/B978-0-12-369497-3.10014-7 PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BFP24 UT WOS:000320856100015 ER PT J AU Resnik, L Bradford, DW Glynn, SM Jette, AM Hernandez, CJ Wills, S AF Resnik, Linda Bradford, Daniel W. Glynn, Shirley M. Jette, Alan M. Hernandez, Caitlin Johnson Wills, Sharon TI Issues in defining and measuring veteran community reintegration: Proceedings of the Working Group on Community Reintegration, VA Rehabilitation Outcomes Conference, Miami, Florida SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE community integration; community reintegration; disability evaluation; International Classification of Health, Disability, and Functioning; measurement; OIF/OEF; outcome assessment; role functioning; social functioning; veteran ID DEVELOPING CORE SETS; POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; INTERNATIONAL CLASSIFICATION; BIPOLAR DISORDER; MEASURING PARTICIPATION; ENVIRONMENTAL-FACTORS; MULTIPLE-SCLEROSIS; PHYSICAL-THERAPY AB In January 2010, the Department of Veterans Affairs (VA) Rehabilitation Research and Development Service convened a State of the Art (SOTA) conference to advance the field of outcome measurement for rehabilitation-related studies. This article reports on the proceedings of the SOTA Working Group on Community Reintegration. We explored the use of the International Classification of Health, Disability, and Functioning as a theoretical framework for measuring community reintegration; identified key dimensions of community reintegration that could and/or should be measured; discussed challenges in measuring community reintegration; suggested steps to enhance community reintegration measurement; proposed future research that focuses on outcomes measures for community reintegration and the study of community reintegration outcomes; and made policy recommendations that would facilitate community reintegration research within the VA. C1 [Resnik, Linda] Providence Dept Vet Affairs VA Med Ctr, Providence, RI USA. [Resnik, Linda] Brown Univ, Dept Community Hlth, Publ Hlth Program, Providence, RI 02912 USA. [Bradford, Daniel W.] Durham VA Med Ctr, Psychosocial Rehabil & Recovery Ctr, Durham, NC USA. [Bradford, Daniel W.] Duke Univ Hosp, Durham, NC USA. [Glynn, Shirley M.] VA Greater Angeles Healthcare Syst, West Los Angeles Med Ctr, Los Angeles, CA USA. [Glynn, Shirley M.] Univ Calif Los Angeles Hlth Syst, Sch Med, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Jette, Alan M.] Boston Univ, Sch Publ Hlth, Hlth & Disabil Res Inst, Boston, MA USA. [Hernandez, Caitlin Johnson] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA. [Wills, Sharon] Cent Texas Vet Hlth Care Syst, Ctr Trauma Recovery, Posttraumat Stress Disorder Clin Team, Austin Outpatient Clin, Austin, TX USA. [Wills, Sharon] Texas A&M Hlth Sci Ctr, Sch Med, Bryan, TX USA. RP Resnik, L (reprint author), Providence VA Med Ctr, 830 Chalkstone Ave, Providence, RI 02908 USA. EM Linda.Resnik@va.gov OI Jette, Alan/0000-0002-2117-9973 FU VA RRD FX This material is the result of work supported by VA RR&D. NR 63 TC 23 Z9 23 U1 2 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 1 BP 87 EP 100 DI 10.1682/JRRD.2010.06.0107 PG 14 WC Rehabilitation SC Rehabilitation GA 149ES UT WOS:000319302400010 PM 22492341 ER PT J AU Stiers, W Carlozzi, N Cernich, A Velozo, C Pape, T Hart, T Gulliver, S Rogers, M Villarreal, E Gordon, S Gordon, W Whiteneck, G AF Stiers, William Carlozzi, Noelle Cernich, Alison Velozo, Craig Pape, Theresa Hart, Tessa Gulliver, Suzy Rogers, Margaret Villarreal, Edgar Gordon, Shalanda Gordon, Wayne Whiteneck, Gale TI Measurement of social participation outcomes in rehabilitation of veterans with traumatic brain injury SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE clinical practice; measurement; outcomes; participation; rehabilitation; research; social participation; traumatic brain injury; VA; veterans ID COMMUNITY INTEGRATION QUESTIONNAIRE; PORTLAND ADAPTABILITY INVENTORY; QUALITY-OF-LIFE; POSTCONCUSSION SYNDROME; PSYCHOMETRIC EVALUATION; SYMPTOMS; INDIVIDUALS; DISABILITY; SAMPLE; DEPRESSION AB Traumatic brain injury (TBI) is a significant concern in the veteran population, and the Department of Veteran Affairs (VA) has devoted substantial healthcare resources to the rehabilitation of veterans with TBI. Evaluating the outcomes of these rehabilitation activities requires measuring whether they meaningfully improve veterans' lives, especially with regard to community and vocational participation, which are strongly linked to perceived quality of life. In January 2010, the VA Rehabilitation Research and Development Service convened an invitational conference focused on outcome measurement in rehabilitation with a specific focus on veterans' community and vocational participation. This article reports on the working group, addressing the issues of conceptualizing and operationalizing such participation outcome measures for veterans with TBI; we discuss conceptual models of participation, review participation subdomains and their instruments of measurement, and identify current research issues and needs. Two avenues are identified for advancing participation measurement in veterans with TBI. First, we describe suggestions to facilitate the immediate implementation of participation measurement into TBI clinical practice and rehabilitation (cont) research within the VA healthcare system. Second, we describe recommendations for future VA research funding initiatives specific to improving the measurement of participatiOn in veterans with TBI. C1 [Stiers, William] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21239 USA. [Carlozzi, Noelle] Kessler Fdn, Res Ctr, W Orange, NJ USA. [Carlozzi, Noelle] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. [Cernich, Alison] Dept Vet Affairs VA Maryland Hlth Care Syst, Baltimore, MD USA. [Cernich, Alison] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. [Cernich, Alison] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA. [Velozo, Craig] North Florida South Georgia Vet Hlth Syst, Gainesville, FL USA. [Velozo, Craig] Univ Florida, Dept Occupat Therapy, Gainesville, FL USA. [Pape, Theresa] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Pape, Theresa] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA. [Hart, Tessa] Einstein Healthcare Network, Dept Psychiat, Einstein Med Ctr, Philadelphia, PA USA. [Gulliver, Suzy] Cent Texas Vet Hlth Care Syst, Waco VA Med Ctr, Ctr Excellence Res Returning War Vet, Waco, TX USA. [Gulliver, Suzy] Texas A&M Hlth Sci Ctr, Coll Med, Bryan, TX USA. [Rogers, Margaret] Amer Speech Language Hearing Assoc, Rockville, MD USA. [Villarreal, Edgar] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Gordon, Shalanda] Cent Texas Vet Hlth Care Syst, Austin Outpatient Clin, Austin, TX USA. [Gordon, Shalanda] St Phillips Coll, San Antonio, TX USA. [Gordon, Wayne] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Whiteneck, Gale] Craig Hosp, Englewood, CO USA. RP Stiers, W (reprint author), Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, 5601 Loch Raven Blvd,Suite 406, Baltimore, MD 21239 USA. EM wstiers1@jhmi.edu OI Pape, Theresa/0000-0001-7738-5963; Stiers, William/0000-0002-1826-8350 FU State of the Art Conference on Outcome Measures in Rehabilitation; VA Office of Research and Development FX This material was based on work supported by the State of the Art Conference on Outcome Measures in Rehabilitation, VA Office of Research and Development. NR 76 TC 6 Z9 7 U1 4 U2 11 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 1 BP 139 EP 153 DI 10.1682/JRRD.2010.070131 PG 15 WC Rehabilitation SC Rehabilitation GA 149ES UT WOS:000319302400013 PM 22492344 ER PT J AU Ullrich, PM Spungen, AM Atkinson, D Bombardier, CH Chen, YY Erosa, NA Groer, S Ottomanelli, L Tulsky, DS AF Ullrich, Philip M. Spungen, Ann M. Atkinson, Darryn Bombardier, Charles H. Chen, Yuying Erosa, Norma A. Groer, Shirley Ottomanelli, Lisa Tulsky, David S. TI Activity and participation after spinal cord injury: State-of-the-art report SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE activity; disability; employment; functioning; measurement; outcomes; participation; quality of life; rehabilitation; spinal cord injury ID FUNCTIONAL INDEPENDENCE MEASURE; POSTACUTE REHABILITATION; WALKING INDEX; PSYCHOMETRIC PROPERTIES; AUTONOMY QUESTIONNAIRE; WHEELCHAIR PROPULSION; ENVIRONMENTAL-FACTORS; MEASURING DEPRESSION; PHYSICAL-ACTIVITY; BALANCE SCALE AB The importance of activities and community participation for persons with spinal cord injury (SCI) has been recognized for decades and yet theoretical and empirical advances have been limited. This report summarizes the recommendations for researchers on the topic of measuring activity and participation among persons with SCI formulated by the Spinal Cord Injury workgroup at the State-of-the-Art Conference on Outcome Measures in Rehabilitation held in January 2010. Activity and participation were defined as independent constructs ideally measured in reference to personal values and environmental influences. Measures of activity, participation, and factors influencing activity and participation are reviewed and critiqued. Gaps in available measures are described, measures in development are discussed, and suggestions for future research are made. C1 [Ullrich, Philip M.] Dept Vet Affairs VA Puget Sound Healthcare Syst, Spinal Cord Injury & Disorders Serv, Seattle, WA USA. [Ullrich, Philip M.; Bombardier, Charles H.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Spungen, Ann M.] James J Peters VA Med Ctr, VA Rehabil Res & Dev, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY USA. [Atkinson, Darryn] Inst Rehabil, Houston, TX USA. [Atkinson, Darryn] Res Mem Hermann, Houston, TX USA. [Chen, Yuying] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA. [Erosa, Norma A.] Texas A&M Univ, College Stn, TX USA. [Groer, Shirley; Ottomanelli, Lisa] James A Haley Vet Hosp, VA Hlth Serv Res & Dev, Ctr Excellence Maximizing Rehabil Outcomes, Tampa, FL 33612 USA. [Tulsky, David S.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. RP Ullrich, PM (reprint author), SCI D Serv, 128NAT,1660 S Columbian Way, Seattle, WA 98108 USA. EM philip.ullrich@va.gov NR 101 TC 11 Z9 12 U1 7 U2 16 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 1 BP 155 EP 173 DI 10.1682/JRRD.2010.06.0108 PG 19 WC Rehabilitation SC Rehabilitation GA 149ES UT WOS:000319302400014 PM 22492345 ER PT J AU Saunders, GH Echt, KV AF Saunders, Gabrielle H. Echt, Katharina V. TI Blast exposure and dual sensory impairment: An evidence review and integrated rehabilitation approach SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE auditory training; blast exposure; blast injury; central auditory processing disorder; dual sensory impairment; rehabilitation; traumatic brain injury; veteran; visual processing disorder; visual training ID TRAUMATIC BRAIN-INJURY; AUDITORY-VISUAL INTEGRATION; POLYTRAUMA NETWORK SITE; OLDER-ADULTS; MULTISENSORY INTEGRATION; CONSONANT RECOGNITION; PROCESSING DEFICITS; SPEECH RECOGNITION; ALZHEIMERS-DISEASE; HEARING IMPAIRMENT AB Combat exposures to blast can result in both peripheral damage to the ears and eyes and central damage to the auditory and visual processing areas in the brain. The functional effects of the latter include visual, auditory, and cognitive processing difficulties that manifest as deficits in attention, memory, and problem solving symptoms similar to those seen in individuals with visual and auditory processing disorders. Coexisting damage to the auditory and visual system is referred to as dual sensory impairment (DSI). The number of Operation Iraqi Freedom/Operation Enduring Freedom Veterans with DSI is vast; yet currently no established models or guidelines exist for assessment, rehabilitation, or service-delivery practice. In this article, we review the current state of knowledge regarding blast exposure and DSI and outline the many unknowns in this area. Further, we propose a model for clinical assessment and rehabilitation of blast-related DSI that includes development of a coordinated team-based approach to target activity limitations and participation restrictions in order to enhance reintegration, recovery, and quality of life. C1 [Saunders, Gabrielle H.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Dept Vet Affairs VA Rehabil Res & Dev Serv, Portland, OR USA. [Saunders, Gabrielle H.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Echt, Katharina V.] Atlanta VA Med Ctr, Rehabil Res & Dev Ctr Excellence & Geriatr Res, Educ & Clin Ctr, Decatur, GA USA. [Echt, Katharina V.] Emory Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Atlanta, GA USA. RP Saunders, GH (reprint author), Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM gabrielle.saunders@va.gov FU VA Rehabilitation Research and Development Service [4844C, C4850C] FX This material is based on work supported by the VA Rehabilitation Research and Development Service (grants 4844C and C4850C). NR 104 TC 6 Z9 7 U1 1 U2 9 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 7 BP 1043 EP 1058 DI 10.1682/JRRD.2010.08.0157 PG 16 WC Rehabilitation SC Rehabilitation GA 149EZ UT WOS:000319303100008 PM 23341278 ER PT J AU Gallun, FJ Lewis, MS Folmer, RL Diedesch, AC Kubli, LR McDermott, DJ Walden, TC Fausti, SA Lew, HL Leek, MR AF Gallun, Frederick J. Lewis, M. Samantha Folmer, Robert L. Diedesch, Anna C. Kubli, Lina R. McDermott, Daniel J. Walden, Therese C. Fausti, Stephen A. Lew, Henry L. Leek, Marjorie R. TI Implications of blast exposure for central auditory function: A review SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE auditory dysfunction; auditory processing disorder; blast; central auditory dysfunction; central auditory processing; central auditory system; hearing loss; rehabilitation; traumatic brain injury; veteran ID TRAUMATIC BRAIN-INJURY; HEARING-LOSS; SPEECH IDENTIFICATION; PROCESSING DISORDER; SPATIAL SEPARATION; RECEPTIVE-FIELDS; GLOBAL WAR; CORTEX; REHABILITATION; DYSFUNCTION AB Auditory system functions, from peripheral sensitivity to central processing capacities, are all at risk from a blast event. Accurate encoding of auditory patterns in time, frequency, and space are required for a clear understanding of speech and accurate localization of sound sources in environments with background noise, multiple sound sources, and/or reverberation. Further work is needed to refine the battery of clinical tests sensitive to the sorts of central auditory dysfunction observed in individuals with blast exposure. Treatment options include low-gain hearing aids, remote-microphone technology, and auditory-training regimens, but clinical evidence does not yet exist for recommending one or more of these options. As this population ages, the natural aging process and other potential brain injuries (such as stroke and blunt trauma) may combine with blast-related brain changes to produce a population for which the current clinical diagnostic and treatment tools may prove inadequate. It is important to maintain an updated understanding of the scope of the issues present in this population and to continue to identify those solutions that can provide measurable improvements in the lives of Veterans who have been exposed to high-intensity blasts during the course of their military service. C1 [Gallun, Frederick J.; Lewis, M. Samantha; Folmer, Robert L.; Diedesch, Anna C.; McDermott, Daniel J.; Fausti, Stephen A.; Leek, Marjorie R.] Portland VA Med Ctr, Dept Vet Affairs VA Rehabil Res & Dev Natl Ctr Re, Portland, OR USA. [Gallun, Frederick J.; Lewis, M. Samantha; Folmer, Robert L.; Fausti, Stephen A.; Leek, Marjorie R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kubli, Lina R.; Walden, Therese C.] WRNMMC, Audiol & Speech Ctr, Bethesda, MD USA. [Lew, Henry L.] DVBIC, Richmond, VA USA. RP Gallun, FJ (reprint author), VA RR&D Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Frederick.Gallun@va.gov RI Gallun, Frederick/G-3792-2012 OI Gallun, Frederick/0000-0002-4145-2199 FU VA RR&D Merit Review Award [01807]; VA RR&D Career Development II Awards [C4963-W, C7067-W]; VA RR&D Senior Research Career Scientist Award [C4042-L]; VA RR&D National Center for Rehabilitative Auditory Research FX This material was based on work supported by VA RR&D Merit Review Award (grant 01807: PIs Leek, Fausti), VA RR&D Career Development II Awards (grant C4963-W: PI Gallun; and grant C7067-W: PI Lewis), VA RR&D Senior Research Career Scientist Award (grant C4042-L: PI Leek), and the VA RR&D National Center for Rehabilitative Auditory Research. NR 76 TC 6 Z9 7 U1 0 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 7 BP 1059 EP 1074 DI 10.1682/JRRD.2010.09.0166 PG 16 WC Rehabilitation SC Rehabilitation GA 149EZ UT WOS:000319303100009 PM 23341279 ER PT J AU Maguen, S Lau, KM Madden, E Seal, K AF Maguen, Shira Lau, Karen M. Madden, Erin Seal, Karen TI Relationship of screen-based symptoms for mild traumatic brain injury and mental health problems in Iraq and Afghanistan veterans: Distinct or overlapping symptoms? SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE depression; factor analysis; hypervigilance; insomnia; mental health; OIF/OEF; posttraumatic stress disorder; screen; traumatic brain injury; veteran ID POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; WAR VETERANS; CARE; CONFLICTS; VALIDITY AB This study used factor analytic techniques to differentiate distinct from overlapping screen-based symptoms of traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), and depression in Iraq and Afghanistan veterans. These symptoms were derived from screen results of 1,549 veterans undergoing Department of Veterans Affairs postdeployment screening between April 2007 and January 2010. Veterans with positive TBI screens were approximately twice as likely to also screen positive for depression and PTSD (adjusted relative risks = 1.9 and 2.1, respectively). Irritability was a shared symptom between TBI and PTSD, and emotional numbing was a shared symptom between PTSD and depression. Symptoms unique to TBI included dizziness, headaches, memory problems, and light sensitivity. Four separate constructs emerged: TBI, PTSD, depression, and a fourth construct consisting of hypervigilance and sleep problems. These findings illuminate areas of overlap between TBI and common postdeployment mental health problems. Discriminating symptoms of TBI from mental health problems may facilitate diagnosis, triage to specialty care, and targeted symptom management. The emergence of a fourth factor consisting of sleep problems and hypervigilance highlights the need to attend to specific symptoms in the postdeployment screening process. C1 [Maguen, Shira; Lau, Karen M.; Madden, Erin; Seal, Karen] San Francisco Dept Vet Affairs VA Med Ctr, San Francisco, CA USA. [Maguen, Shira; Seal, Karen] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Maguen, Shira; Seal, Karen] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov RI Schueter, nicos/A-3625-2014 FU Department of Defense Psychological Health and Traumatic Brain Injury Research Program; VA Health Sciences Research and Development Service Career Development Award FX This material was based on work supported by the Department of Defense Psychological Health and Traumatic Brain Injury Research Program and a VA Health Sciences Research and Development Service Career Development Award to Dr. Maguen. NR 27 TC 15 Z9 15 U1 2 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 7 BP 1115 EP 1125 DI 10.1682/JRRD.2011.02.0015 PG 11 WC Rehabilitation SC Rehabilitation GA 149EZ UT WOS:000319303100013 PM 23341283 ER PT J AU Littman, AJ Koepsell, TD Forsberg, CW Haselkorn, JK Boyko, EJ AF Littman, Alyson J. Koepsell, Thomas D. Forsberg, Christopher W. Haselkorn, Jodie K. Boyko, Edward J. TI Preventive services in veterans in relation to disability SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE cervical cancer screening; colon cancer screening; Department of Veterans Affairs; disability; prevention; preventive medicine; primary prevention; vaccination; Veterans; women's health ID PNEUMOCOCCAL VACCINATION STATUS; HEALTH INTERVIEW SURVEY; QUALITY-OF-CARE; AMBULATORY-CARE; MEDICAL-CENTERS; FEMALE VETERANS; MANAGED CARE; LOSE WEIGHT; HIGH-RISK; ADULTS AB Veterans with disabilities are at an increased risk of secondary impairments and may have difficulty accessing preventive services; accessibility may differ between Veterans who do and do not receive care at Department of Veterans Affairs (VA) facilities. We used data from the 2003 and 2004 Behavioral Risk Factor Surveillance System surveys to evaluate associations between disability and receipt of preventive services in Veterans. Veterans with a disability were more likely to have received influenza vaccinations (VA users and nonusers), pneumococcal vaccinations (VA nonusers: p < 0.001; VA users: p = 0.073), weight management counseling (VA nonusers: p < 0.001; male VA users: p < 0.001), lower gastrointestinal (GI) endoscopy (VA nonusers: 50-64 yr, p = 0.03; VA users: >= 65 yr, p = 0.085), mammography (VA users: p = 0.097), and serum cholesterol screening (VA nonusers: p < 0.001). Receipt was similar by disability status for fecal occult blood test (FOBT), lower GI endoscopy (VA users: 50-64 yr), human immunodeficiency virus testing, and cervical cancer screening. For no measure was there significantly lower receipt in those with versus without a disability, although there was marginal evidence in VA nonusers for overall colorectal cancer screening (i.e., lower GI endoscopy or FOBT: p = 0.063). Among Veterans, having a disability did not appear to be a barrier to receiving appropriate preventive care. C1 [Littman, Alyson J.; Koepsell, Thomas D.; Forsberg, Christopher W.; Boyko, Edward J.] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Littman, Alyson J.; Koepsell, Thomas D.; Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Koepsell, Thomas D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] VA Puget Sound Hlth Care Syst, Multiple Sclerosis Ctr Excellence West, Seattle, WA USA. RP Littman, AJ (reprint author), VA Puget Sound Med Ctr, Epidemiol Res & Informat Ctr, 1100 Olive Way,Metropolitan Pk West,Suite 1400, Seattle, WA 98101 USA. EM alyson@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU VA Office of Research and Development Cooperative Studies; Rehabilitation Research and Development Programs; VA Rehabilitation Research and Development Service Career Development Award [6982] FX This material is based on work supported in part by the VA Office of Research and Development Cooperative Studies and Rehabilitation Research and Development Programs. Dr. Littman was supported by a VA Rehabilitation Research and Development Service Career Development Award (grant 6982). NR 55 TC 4 Z9 4 U1 3 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 3 BP 339 EP 350 DI 10.1682/JRRD.2010.12.0229 PG 12 WC Rehabilitation SC Rehabilitation GA 149EU UT WOS:000319302600003 PM 22773194 ER PT J AU Foecking, EM Fargo, KN Coughlin, LM Kim, JT Marzo, SJ Jones, KJ AF Foecking, Eileen M. Fargo, Keith N. Coughlin, Lisa M. Kim, James T. Marzo, Sam J. Jones, Kathryn J. TI Single session of brief electrical stimulation immediately following crush injury enhances functional recovery of rat facial nerve SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE electrical stimulation; facial nerve; facial paralysis; functional recovery; injury; motoneuron; peripheral nerve; regeneration; repair; therapy ID FEMORAL MOTONEURONS; GONADAL-STEROIDS; REGENERATION; ACCELERATION; TESTOSTERONE; EXPRESSION; FIELDS AB Peripheral nerve injuries lead to a variety of pathological conditions, including paresis or paralysis when the injury involves motor axons. We have been studying ways to enhance the regeneration of peripheral nerves using daily electrical stimulation (ES) following a facial nerve crush injury In our previous studies, ES was not initiated until 24 h after injury The current experiment tested whether ES administered immediately following the crush injury would further decrease the time for complete recovery from facial paralysis. Rats received a unilateral facial nerve crush injury and an electrode was positioned on the nerve proximal to the crush site. Animals received daily 30 min sessions of ES for 1 d (day of injury only), 2 d, 4 d, 7 d, or daily until complete functional recovery. Untreated animals received no ES. Animals were observed daily for the return of facial function. Our fmdings demonstrated that one session of ES was as effective as daily stimulation at enhancing the recovery of most functional parameters. Therefore, the use of a single 30 min session of ES as a possible treatment strategy should be studied in human patients with paralysis as a result of acute nerve injuries. C1 [Foecking, Eileen M.; Marzo, Sam J.; Jones, Kathryn J.] Loyola Univ Chicago, Stritch Sch Med, Dept Otolaryngol Head & Neck Surg, Maywood, IL USA. [Foecking, Eileen M.; Fargo, Keith N.; Coughlin, Lisa M.; Jones, Kathryn J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Hines, IL 60141 USA. [Fargo, Keith N.] Loyola Univ Chicago, Dept Mol Pharmacol & Therapeut, Maywood, IL USA. [Kim, James T.] Loyola Univ Chicago, Neurosci Program, Maywood, IL USA. [Jones, Kathryn J.] Loyola Univ Chicago, Dept Microbiol & Immunol, Stritch Sch Med, Maywood, IL USA. RP Foecking, EM (reprint author), Edward Hines Jr VA Hosp, Res & Dev Serv, 5000 S 1st Ave,Bldg 1,Rm A241,Mail 151, Hines, IL 60141 USA. EM Eileen.Foecking@va.gov FU Research Funding Committee at Loyola University [200374]; Department of Veterans Affairs Rehabilitation Research and Development Service [CDA-2 RRD B6598W] FX This material was based on work supported by the Research Funding Committee at Loyola University (grant LU# 200374) and the Department of Veterans Affairs Rehabilitation Research and Development Service (grant CDA-2 RR&D B6598W). NR 16 TC 15 Z9 15 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 3 BP 451 EP 458 DI 10.1682/JRRD.2011.03.0033 PG 8 WC Rehabilitation SC Rehabilitation GA 149EU UT WOS:000319302600012 PM 22773203 ER PT J AU Zeiss, AM Batten, SV AF Zeiss, Antonette M. Batten, Sonja V. TI Treatment for PTSD: Clinical Practice Guidelines and steps toward further knowledge SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material C1 [Zeiss, Antonette M.; Batten, Sonja V.] US Dept Vet Affairs, Off Mental Hlth Serv, Cent Off, Washington, DC USA. RP Zeiss, AM (reprint author), US Dept Vet Affairs, Off Mental Hlth Serv, Cent Off, Washington, DC USA. EM Antonette.Zeiss@va.gov RI Schueter, nicos/A-3625-2014 NR 4 TC 0 Z9 0 U1 0 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 5 BP IX EP XII DI 10.1682/JRRD.2012.01.0015 PG 4 WC Rehabilitation SC Rehabilitation GA 149EW UT WOS:000319302800002 PM 23015587 ER PT J AU Bickel, CS Gregory, CM Azuero, A AF Bickel, C. Scott Gregory, Chris M. Azuero, Andres TI Matching initial torque with different stimulation parameters influences skeletal muscle fatigue SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE electrical stimulation; fatigue; frequency; NMES; pulse duration; rehabilitation; skeletal muscle; stimulation parameters; torque; voltage ID NEUROMUSCULAR ELECTRICAL-STIMULATION; FORCE-FREQUENCY-RELATIONSHIP; SPINAL-CORD-INJURY; QUADRICEPS FEMORIS; PULSE DURATION; CONTRACTIONS; DAMAGE; VOLUNTARY; MODULATION; TRAINS AB A fundamental barrier to using electrical stimulation in the clinical setting is an inability to maintain torque production secondary to muscle fatigue. Electrical stimulation parameters are manipulated to influence muscle torque production, and they may also influence fatigability during repetitive stimulation. Our purpose was to determine the response of the quadriceps femoris to three different fatigue protocols using the same initial torque obtained by altering stimulator parameter settings. Participants underwent fatigue protocols in which either pulse frequency (lowHz), pulse duration (lowPD), or voltage (lowV) was manipulated to obtain an initial torque that equaled 25% of maximum voluntary isometric contraction. Muscle soreness was reported on a visual analog scale 48 h after each fatigue test. The lowHz protocol resulted in the least fatigue (25% +/- 14%); the lowPD (50% +/- 13%) and lowV (48% +/- 14%) protocols had similar levels of fatigue. The lowHz protocol resulted in significantly less muscle soreness than the higher frequency protocols. Stimulation protocols that use a lower frequency coupled with long pulse durations and high voltages result in lesser amounts of muscle fatigue and perceived soreness. The identification of optimal stimulation patterns to maximize muscle performance will reduce the effect of muscle fatigue and potentially improve clinical efficacy. C1 [Bickel, C. Scott] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL 35294 USA. [Gregory, Chris M.] Med Univ S Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Gregory, Chris M.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Azuero, Andres] Univ Alabama Birmingham, Sch Nursing, Dept Community Hlth Outcomes & Syst, Birmingham, AL 35294 USA. RP Bickel, CS (reprint author), Univ Alabama Birmingham, Dept Phys Therapy, SHPB 387,1530 3rd Ave S, Birmingham, AL 35294 USA. EM bickel@uab.edu FU Rehabilitation Research and Development Service of the Department of Veterans Affairs (VA) [HD055929]; VA Career Development Award [B6341W]; Brain Rehabilitation Research Center of Excellence [F2182C]; VA Office of Research and Development; Malcom Randall VA Medical Center, Gainesville, Florida FX This material was based on work supported by the Rehabilitation Research and Development Service of the Department of Veterans Affairs (VA) (grant HD055929 to C. M. Gregory), a VA Career Development Award (grant B6341W to C. M. Gregory), and the Brain Rehabilitation Research Center of Excellence (grant F2182C). This work was partially supported by the VA Office of Research and Development and the Malcom Randall VA Medical Center, Gainesville, Florida. NR 29 TC 5 Z9 5 U1 0 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 2 BP 323 EP 331 DI 10.1682/JRRD.2011.02.0030 PG 9 WC Rehabilitation SC Rehabilitation GA 149ET UT WOS:000319302500012 PM 22773532 ER PT J AU Jeffreys, M Capehart, B Friedman, MJ AF Jeffreys, Matthew Capehart, Bruce Friedman, Matthew J. TI Pharmacotherapy for posttraumatic stress disorder: Review with clinical applications SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE best practices; guidelines; health services; medications; mental health; patient care; pharmacotherapy; PTSD; treatment; veterans ID OF-VETERANS-AFFAIRS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; TRAUMATIC BRAIN-INJURY; PRIMARY-CARE; DOUBLE-BLIND; ANXIETY DISORDERS; ADJUNCTIVE RISPERIDONE; DEPRESSIVE DISORDER; ALCOHOL DEPENDENCE AB Posttraumatic stress disorder (PTSD) is a prevalent psychiatric diagnosis among veterans and has high comorbidity with other medical and psychiatric conditions. This article reviews the pharmacotherapy recommendations from the 2010 revised Department of Veterans Affairs/Department of Defense Clinical Practice Guideline (CPG) for PTSD and provides practical PTSD treatment recommendations for clinicians. While evidence-based, trauma-focused psychotherapy is the preferred treatment for PTSD, pharmacotherapy is also an important treatment option. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors and the selective serotonin-norepinephrine reuptake inhibitor venlafaxine. Second-line agents have less evidence for their usefulness in PTSD and carry a potentially greater side effect burden. They include nefazodone, mirtazapine, tricyclic antidepressants, and monoamine oxidase inhibitors. Prazosin is beneficial for nightmares. Benzodiazepines and antipsychotics, either as mono-therapy or used adjunctively, are not recommended in the treatment of PTSD. Treating co-occurring disorders, such as major depressive disorder, substance use disorders, and traumatic brain injury, is essential in maximizing treatment outcomes in PTSD. The CPG provides evidence-based treatment recommendations for treating PTSD with and without such co-occurring disorders. C1 [Jeffreys, Matthew] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Jeffreys, Matthew] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Capehart, Bruce] Durham Dept Vet Affairs Med Ctr VAMC, Durham, NC USA. [Capehart, Bruce] Duke Univ, Durham, NC USA. [Friedman, Matthew J.] Natl Ctr PTSD, White River Jct, VT USA. [Friedman, Matthew J.] White River Junction VAMC, White River Jct, VT USA. [Friedman, Matthew J.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA. RP Jeffreys, M (reprint author), South Texas Vet Hlth Care Syst Psychiat, 5788 Eckhert Rd, San Antonio, TX 78240 USA. EM Matthew.Jeffreys@va.gov RI Schueter, nicos/A-3625-2014 NR 85 TC 24 Z9 26 U1 1 U2 17 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 5 BP 703 EP 715 DI 10.1682/JRRD.2011.09.0183 PG 13 WC Rehabilitation SC Rehabilitation GA 149EW UT WOS:000319302800010 PM 23015581 ER PT J AU Raja, B Neptune, RR Kautz, SA AF Raja, Bhavana Neptune, Richard R. Kautz, Steven A. TI Quantifiable patterns of limb loading and unloading during hemiparetic gait: Relation to kinetic and kinematic parameters SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE gait; hemiparesis; knee angle; leg angle; loading magnitude; pattern; stroke; timing; unloading; vertical ground reaction forces ID WEIGHT-BEARING; STROKE PATIENTS; INDIVIDUALS; HEMIPLEGIA; ADULTS; BONE; CLASSIFICATION; STABILITY; INCREASE; FRACTURE AB Persons with poststroke hemiparesis are characterized by asymmetry in limb loading (LL) and limb unloading (LU), which has been reported in static and quasi-static tasks but has not been quantified during walking. The purpose of this study was to determine the asymmetry in magnitude and duration of LL and LU in individuals with hemiparesis and its relationship with functional walking status and specific kinematic and kinetic variables during walking. Forty-four participants with chronic hemiparesis walked at their self-selected speeds and eighteen nondisabled control subjects of similar ages walked at predetermined matched speeds while three-dimensional ground reaction forces and body-segment kinematics were recorded. Magnitude of paretic LL was reduced, while duration was increased compared with the nonparetic leg and nondisabled controls walking at matched speeds. The paretic LL and LU was significantly correlated with average leg angle, while the nonparetic leg significantly correlated with average knee angle. Three different patterns of LL and LU were identified (concave, convex, and linear). Individuals with hemiparesis make several biomechanical adjustments that minimize LL of the paretic leg. LL deviations were more pronounced with increased lateral placement of the paretic foot and with decreased functional gait speed. Characterization of these deviations may inspire new strategies for rehabilitation. C1 [Raja, Bhavana] Univ Florida, Rehabil Sci Doctoral Program, Gainesville, FL USA. [Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. [Kautz, Steven A.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Kautz, Steven A.] Med Univ S Carolina, Coll Hlth Profess, Div Phys Therapy, Charleston, SC 29425 USA. RP Kautz, SA (reprint author), 77 President St,MSC 700, Charleston, SC 29425 USA. EM kautz@musc.edu OI Kautz, Steven/0000-0003-3151-8235 FU National Institutes of Health [RO1 HD46820]; VA Rehabilitation Research and Development Service FX This material was based on work supported by the National Institutes of Health (grant RO1 HD46820) and the VA Rehabilitation Research and Development Service. NR 32 TC 7 Z9 7 U1 1 U2 5 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 9 BP 1293 EP 1304 DI 10.1682/JRRD.2011.02.0018 PG 12 WC Rehabilitation SC Rehabilitation GA 149FB UT WOS:000319303300002 PM 23408212 ER PT J AU Hind, J Divyak, E Zielinski, J Taylor, A Hartman, M Gangnon, R Robbins, J AF Hind, Jacqueline Divyak, Elizabeth Zielinski, Jill Taylor, Andrew Hartman, Michael Gangnon, Ronald Robbins, JoAnne TI Comparison of standardized bariums with varying rheological parameters on swallowing kinematics in males SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE aspiration; barium; deglutition; dysphagia; fluids; geriatrics; radiology; residue; swallowing; videofluoroscopy ID PENETRATION-ASPIRATION SCALE; INTERVENTIONS; MANAGEMENT; DYSPHAGIA; DEMENTIA; LIQUIDS AB This study measured dose-response of a range of commercially available liquid barium materials designed for use in videofluoroscopic oropharyngeal swallowing assessments, particularly as they relate to the necessity of adding a thickening agent for swallow safety. A group of 25 adult males representing various medical diagnoses consented to participate, with 16 qualifying to complete a videofluoroscopic swallowing assessment with liquid barium materials of three viscosities (nectar: 300 cP, thin honey: 1,500 cP, thick honey: 3,000 cP). Outcome measures included airway invasion (Penetration-Aspiration score), postswallow residue, and patient preference. Penetration-Aspiration and residue scores did not significantly differ between thin honey and thick honey bariums. Significantly more severe airway invasion was observed with nectar boluses than with two levels of honey boluses (p < 0.001). Significantly more residue was observed in the oral cavity (p < 0.002) and valleculae (p < 0.001) with thin and thick honey bariums than with nectar barium. Thin honey was rated as "easy" or "average" to drink by 67% of subjects, compared with 54% for thick honey. This study supports the use of thin honey barium over thick honey barium during videofluoroscopic swallowing assessments because the two honey bariurns were comparable in terms of airway protection and postswallow residue in the oropharynx and the thin honey was preferred by patients. C1 [Hind, Jacqueline; Divyak, Elizabeth; Zielinski, Jill; Hartman, Michael; Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Hind, Jacqueline; Taylor, Andrew; Hartman, Michael; Gangnon, Ronald; Robbins, JoAnne] Univ Wisconsin, Madison, WI USA. RP Hind, J (reprint author), VAMC GRECC 11G,2500 Overlook Terrace, Madison, WI 53705 USA. EM jahind@wisc.edu FU VA Veterans Health Administration; Office of Research and Development; Rehabilitation Research and Development Service [RRP 07-314]; Geriatric Research Education and Clinical Center Manuscript FX This material was based on work supported by the VA Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service (grant RRP 07-314). This is Geriatric Research Education and Clinical Center Manuscript 2011-02. NR 15 TC 9 Z9 9 U1 0 U2 5 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 9 BP 1399 EP 1404 DI 10.1682/JRRD.2011.09.0180 PG 6 WC Rehabilitation SC Rehabilitation GA 149FB UT WOS:000319303300010 PM 23408220 ER PT J AU Sawers, A Hahn, ME Kelly, VE Czerniecki, JM Kartin, D AF Sawers, Andrew Hahn, Michael E. Kelly, Valerie E. Czerniecki, Joseph M. Kartin, Deborah TI Beyond componentry: How principles of motor learning can enhance locomotor rehabilitation of individuals with lower limb loss-A review SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE amputee; artificial limb; gait; learning; limb loss; locomotion; practice; prosthesis; rehabilitation; training ID TRAINING COMPLEX SKILLS; TRANS-FEMORAL AMPUTEES; EXTERNAL-FOCUS; MENTAL PRACTICE; CONTEXTUAL INTERFERENCE; DYADIC PROTOCOL; ACQUISITION; AMPUTATION; FEEDBACK; KNOWLEDGE AB Relatively little attention has been given to the use of well-established motor learning strategies to enable individuals with lower limb loss to effectively and safely learn to walk with their prostheses in the home and community. Traditionally, such outcomes have been pursued by focusing on the design and function of a patient's prosthesis, rather than on how he or she should learn to use it. The use of motor learning strategies may enhance physical rehabilitation outcomes among individuals with lower limb loss. This review explores these motor learning strategies and ways in which they can be applied to the physical rehabilitation of individuals with lower limb loss and highlights some of the challenges to their implementation, as well as unanswered research questions. C1 [Sawers, Andrew; Hahn, Michael E.; Czerniecki, Joseph M.] VA Puget Sound, Dept Vet Affairs VA, Rehabil Res & Dev Ctr Excellence Limb Loss Preven, Seattle, WA USA. [Sawers, Andrew; Kelly, Valerie E.; Czerniecki, Joseph M.; Kartin, Deborah] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Hahn, Michael E.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. RP Sawers, A (reprint author), Emory Univ, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA. EM andrew.b.sawers@emory.edu OI Kelly, Valerie E./0000-0002-0099-9219 FU Center of Excellence grant from the Department of Veterans Affairs, Rehabilitation Research and Development [A4883C] FX This material was based on work supported by a Center of Excellence grant (A4883C) from the Department of Veterans Affairs, Rehabilitation Research and Development. NR 92 TC 6 Z9 7 U1 4 U2 25 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2012 VL 49 IS 10 BP 1431 EP 1441 DI 10.1682/JRRD.2011.12.0235 PG 11 WC Rehabilitation SC Rehabilitation GA 149FD UT WOS:000319303500002 PM 23516048 ER PT S AU Couig, MP AF Couig, Mary Pat BE Couig, MP Kelley, PW TI Willingness, Ability, and Intentions of Health Care Workers to Respond SO ANNUAL REVIEW OF NURSING RESEARCH, VOL 30: DISASTERS AND HUMANITARIAN ASSISTANCE SE Annual Review of Nursing Research-Series LA English DT Article; Book Chapter ID NURSES; EMERGENCY; PREPAREDNESS; PERCEPTIONS; INCIDENTS; STUDENTS; DUTY AB Health care workers (HCWs) are a critical component of the emergency management cycle (prevention, mitigation, preparation, response, and recovery). The potential for large numbers of injured from either a man-made or natural disaster has resulted in the development of surge capacity plans and attempts to predict how many HCWs will be available to respond. Since 1991 (with the majority of the research published in 2002 and later), researchers have been conducting studies to learn about the willingness, ability, and intentions of HCWs to respond to disasters. Potential and real barriers to disaster response are being explored as well. This chapter focuses on research authored or coauthored by nurses. Nurse-authored research is just a portion of the growing body of knowledge in this area; however, the findings are consistent with other published works. HCWs are more likely to be willing and able to respond to natural disasters and less likely to be willing and able during infectious outbreaks or incidents with potential exposure to harmful agents (biological, chemical, nuclear, or radiological). HCW concerns include safety of self and family, availability of protective equipment, medicines and vaccines, and caretaking responsibilities (children, elders, and pets). C1 US Dept Vet Affairs, Off Nursing Serv, Vet Hlth Adm, Washington, DC USA. RP Couig, MP (reprint author), US Dept Vet Affairs, Off Nursing Serv, Vet Hlth Adm, Washington, DC USA. NR 44 TC 1 Z9 1 U1 1 U2 6 PU SPRINGER PUBLISHING CO PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA SN 0739-6686 BN 978-0-8261-1030-5 J9 ANNU REV NURS RES-SE PY 2012 VL 30 BP 193 EP 208 DI 10.1891/0739-6686.30.193 PG 16 WC Nursing SC Nursing GA BEV16 UT WOS:000318254200010 PM 24894058 ER PT B AU Liu, XH Laron, D Feeley, BT AF Liu, Xuhui Laron, Dominique Feeley, Brian T. BE Ma, CB Feeley, BT TI MUSCLE DEGENERATION IN ROTATOR CUFF TEARS SO BASIC PRINCIPLES AND OPERATIVE MANAGEMENT OF THE ROTATOR CUFF LA English DT Article; Book Chapter ID SKELETAL-MUSCLE; PPAR-GAMMA; KAPPA-B; SUPRASCAPULAR NERVE; ANTIFIBROSIS AGENT; SIGNALING PATHWAY; AKT/MTOR PATHWAY; TENDON RELEASE; STEM-CELLS; LONG-TERM C1 [Liu, Xuhui] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Orthoped Surg, San Francisco, CA 94143 USA. [Laron, Dominique] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Orthoped Surg, Ctr Sports Med, San Francisco, CA 94143 USA. [Feeley, Brian T.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Feeley, Brian T.] Hosp Special Surg, New York, NY 10021 USA. [Feeley, Brian T.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Liu, XH (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Orthoped Surg, San Francisco, CA 94143 USA. NR 67 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-004-7 PY 2012 BP 49 EP 59 PG 11 WC Surgery SC Surgery GA BEI55 UT WOS:000316713000006 ER PT J AU Kollef, MH Chastre, J Clavel, M Restrepo, MI Michiels, B Kaniga, K Cirillo, I Kimko, H Redman, R AF Kollef, Marin H. Chastre, Jean Clavel, Marc Restrepo, Marcos I. Michiels, Bart Kaniga, Kone Cirillo, Iolanda Kimko, Holly Redman, Rebecca TI A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia SO CRITICAL CARE LA English DT Article ID CRITICALLY-ILL PATIENTS; HOSPITAL-ACQUIRED PNEUMONIA; INTENSIVE-CARE UNITS; ANTIBIOTIC-THERAPY; MULTICENTER; EXPOSURE; EFFICACY; SAFETY; PROCALCITONIN; PREVALENCE AB Introduction: The aim of this study was to compare a 7-day course of doripenem to a 10-day course of imipenem-cilastatin for ventilator-associated pneumonia (VAP) due to Gram-negative bacteria. Methods: This was a prospective, double-blinded, randomized trial comparing a fixed 7-day course of doripenem one gram as a four-hour infusion every eight hours with a fixed 10-day course of imipenem-cilastatin one gram as a one-hour infusion every eight hours (April 2008 through June 2011). Results: The study was stopped prematurely at the recommendation of the Independent Data Monitoring Committee that was blinded to treatment arm assignment and performed a scheduled review of data which showed signals that were close to the pre-specified stopping limits. The final analyses included 274 randomized patients. The clinical cure rate at the end of therapy (EOT) in the microbiological intent-to-treat (MITT) population was numerically lower for patients in the doripenem arm compared to the imipenem-cilastatin arm (45.6% versus 56.8%; 95% CI, -26.3% to 3.8%). Similarly, the clinical cure rate at EOT was numerically lower for patients with Pseudomonas aeruginosa VAP, the most common Gram-negative pathogen, in the doripenem arm compared to the imipenem-cilastatin arm (41.2% versus 60.0%; 95% CI, -57.2 to 19.5). All cause 28-day mortality in the MITT group was numerically greater for patients in the doripenem arm compared to the imipenem-cilastatin arm (21.5% versus 14.8%; 95% CI, -5.0 to 18.5) and for patients with P. aeruginosa VAP (35.3% versus 0.0%; 95% CI, 12.6 to 58.0). Conclusions: Among patients with microbiologically confirmed late-onset VAP, a fixed 7-day course of doripenem was found to have non-significant higher rates of clinical failure and mortality compared to a fixed 10-day course of imipenem-cilastatin. Consideration should be given to treating patients with VAP for more than seven days to optimize clinical outcome. C1 [Kollef, Marin H.] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA. [Chastre, Jean] Grp Hosp Pitie Salpetriere, Inst Cardiol, Serv Reanimat Med, F-75651 Paris 13, France. [Clavel, Marc] Ctr Hosp Limoges, F-87000 Limoges, France. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Crit Care Med, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm Crit Care Med, San Antonio, TX 78229 USA. [Michiels, Bart] Janssen Res & Dev, B-2340 Beerse, Belgium. [Kaniga, Kone; Cirillo, Iolanda; Kimko, Holly; Redman, Rebecca] Janssen Pharmaceut Res & Dev, Raritan, NJ 08869 USA. RP Kollef, MH (reprint author), Washington Univ, Sch Med, Div Pulm & Crit Care Med, 660 South Euclid Ave,Campus Box 8052, St Louis, MO 63110 USA. EM mkollef@dom.wustl.edu FU Janssen Pharmaceutical Research and Development; Barnes-Jewish Hospital Foundation; Janssen; National Heart, Lung, and Blood Institute [K23HL096054] FX This study was funded by Janssen Pharmaceutical Research and Development. Dr. Kollef's effort was supported by the Barnes-Jewish Hospital Foundation and Dr. Kollef has received consulting fees from Janssen. Dr. Restrepo's time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health." The funding agencies had no role in the preparation, review or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs, nor the University of Texas Health Science Center at San Antonio. The remaining authors have no competing interests to declare. NR 33 TC 65 Z9 69 U1 1 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PY 2012 VL 16 IS 6 AR R218 DI 10.1186/cc11862 PG 17 WC Critical Care Medicine SC General & Internal Medicine GA 125UI UT WOS:000317566500004 PM 23148736 ER PT J AU Laxmisan, A McCoy, AB Wright, A Sittig, DF AF Laxmisan, A. McCoy, A. B. Wright, A. Sittig, D. F. TI Clinical Summarization Capabilities of Commercially-available and Internally-developed Electronic Health Records SO APPLIED CLINICAL INFORMATICS LA English DT Article DE Electronic health records; clinical summarization; user interface ID CARE; INFORMATION; TIME; CONSEQUENCES; PHYSICIANS; HANDOFFS; ADOPTION; SUPPORT AB Objective: Clinical summarization, the process by which relevant patient information is electronically summarized and presented at the point of care, is of increasing importance given the increasing volume of clinical data in electronic health record systems (EHRs). There is a paucity of research on electronic clinical summarization, including the capabilities of currently available EHR systems. Methods: We compared different aspects of general clinical summary screens used in twelve different EHR systems using a previously described conceptual model: AORTIS (Aggregation, Organization, Reduction, Interpretation and Synthesis). Results: We found a wide variation in the EHRs' summarization capabilities: all systems were capable of simple aggregation and organization of limited clinical content, but only one demonstrated an ability to synthesize information from the data. Conclusion: Improvement of the clinical summary screen functionality for currently available EHRs is necessary. Further research should identify strategies and methods for creating easy to use, well-designed clinical summary screens that aggregate, organize and reduce all pertinent patient information as well as provide clinical interpretations and synthesis as required. C1 [Laxmisan, A.] Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Laxmisan, A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [McCoy, A. B.; Sittig, D. F.] Univ Texas Hlth Sci Ctr Houston UTHlth, Sch Biomed Informat, Houston, TX USA. [Wright, A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. RP Laxmisan, A (reprint author), Baylor Coll Med Med, 2002 Holcombe Blvd, Houston, TX 77005 USA. EM archana.laxmisan@gmail.com RI McCoy, Allison/I-1951-2013 OI McCoy, Allison/0000-0003-2292-9147 FU Office of the National Coordinator for Health Information Technology [10510592] FX We thank Toby Samo, Chief Medical Officer at Allscripts for permission to use a screenshot of their summary screen. The authors would like to acknowledge Adolph Trudeau, Laura Fochtmann, Dario Giuse, Jacob McCoy, David Beck and others who provided information about the studied EHR systems and screens. This project was supported in part by Grant No. 10510592 for Patient-Centered Cognitive Support under the Strategic Health IT Advanced Research Projects Program (SHARP) from the Office of the National Coordinator for Health Information Technology. NR 39 TC 9 Z9 9 U1 1 U2 4 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 1869-0327 J9 APPL CLIN INFORM JI Appl. Clin. Inform. PY 2012 VL 3 IS 1 BP 80 EP 93 DI 10.4338/ACI-2011-11-RA-0066 PG 14 WC Medical Informatics SC Medical Informatics GA 120PG UT WOS:000317182500007 PM 22468161 ER PT J AU Williams, BR Bailey, FA Woodby, LL Wittich, AR Burgio, KL AF Williams, Beverly Rosa Bailey, F. Amos Woodby, Lesa L. Wittich, Angelina R. Burgio, Kathryn L. TI "A ROOM FULL OF CHAIRS AROUND HIS BED": BEING PRESENT AT THE DEATH OF A LOVED ONE IN VETERANS AFFAIRS MEDICAL CENTERS SO OMEGA-JOURNAL OF DEATH AND DYING LA English DT Article ID INTENSIVE-CARE-UNIT; OF-LIFE CARE; FAMILY-MEMBERS; HOSPITALIZED-PATIENTS; DYING PATIENTS; END; QUALITY; PATIENT; PERSPECTIVES; PERCEPTIONS AB Historically, death took place at home where family held vigil around the dying patient. Today, family presence is an important feature of death and dying in hospital settings. We used hermeneutic phenomenology to explore experiences of being present at the hospital death of a loved one. We conducted in-depth, face-to-face interviews with 78 recently bereaved next-of-kin of veterans who died in 6 Veterans Affairs (VA) Medical Centers in the Southeast United States. Two major themes emerged: 1) "settling in," characteristic of the experiences of wives and daughters in the initial phase of the patient's hospitalization; and 2) "gathering around," characteristic of the experiences of a wider array of family members as the patient neared death. An in-depth understanding of experiences of next-of-kin present at the hospital death of a loved one can increase staff awareness of family's needs and empower staff to develop policies and procedures for supporting family members. C1 [Williams, Beverly Rosa; Bailey, F. Amos; Woodby, Lesa L.; Wittich, Angelina R.; Burgio, Kathryn L.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Williams, Beverly Rosa; Bailey, F. Amos; Woodby, Lesa L.; Burgio, Kathryn L.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. RP Williams, BR (reprint author), Univ Alabama Birmingham, CH19 218K,1720 2nd Ave South, Birmingham, AL 35294 USA. EM BWilliams@aging.uab.edu NR 98 TC 2 Z9 2 U1 4 U2 5 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0030-2228 J9 OMEGA-J DEATH DYING JI Omega-J. Death Dying PY 2012 VL 66 IS 3 BP 231 EP 263 DI 10.2190/OM.66.3.c PG 33 WC Psychology, Multidisciplinary; Social Sciences, Biomedical SC Psychology; Biomedical Social Sciences GA 099WM UT WOS:000315654500003 PM 23617101 ER PT J AU Billue, KL Safford, MM Salanitro, AH Houston, TK Curry, W Kim, Y Allison, JJ Estrada, CA AF Billue, Katherine L. Safford, Monika M. Salanitro, Amanda H. Houston, Thomas K. Curry, William Kim, Yongin Allison, Jeroan J. Estrada, Carlos A. TI Medication intensification in diabetes in rural primary care: a cluster-randomised effectiveness trial SO BMJ OPEN LA English DT Article ID RE-AIM FRAMEWORK; ACHIEVABLE BENCHMARKS; QUALITY IMPROVEMENT; PHYSICIAN FEEDBACK; CLINICAL INERTIA; INTERVENTION; PATIENT; MANAGEMENT; BENEFICIARIES; HYPERTENSION AB Objective: To determine the effectiveness of a provider-based intervention to improve medication intensification among patients with diabetes. Design: Effectiveness cluster-randomised trial. Baseline and follow-up cross-sections of diabetes physicians' patients. Setting: Eleven U.S. Southeastern states, 2006-2008. Participants: 205 Rural primary care physicians, 95 completed the study. Intervention: Multicomponent interactive intervention including web-based continuing medical education (CME), performance feedback and quality improvement tools. Primary outcome measures: Medication intensification, a dose increase of an existing medication or the addition of a new class of medication for glucose, blood pressure and lipids control on any of the three most recent office visits. Results: Of 364 physicians attempting to register, 102 were randomised to the intervention and 103 to the control arms; 95 physicians (intervention, n=48; control, n=47) provided data on their 1182 of their patients at baseline (intervention, n=715; control, n=467) and 945 patients at follow-up (intervention, n=479; control, n=466). For A1c control, medication intensification increased in both groups (intervention, pre 26.4% vs post 32.6%, p=0.022; control, pre 24.8% vs post 31.1%, p=0.033) (intervention, adjusted OR (AOR) 1.37; 95% CI 1.06 to 1.76; control, AOR 1.41 (95% CI 1.06 to 1.89)); however, we observed no incremental benefit solely due to the intervention (group-by-time interaction, p=0.948). Among patients with the worst glucose control (A1c >9%), intensification increased in both groups (intervention, pre 34.8% vs post 62.5%, p=0.002; control, pre 35.7% vs post 61.4%, p=0.008). Conclusions: A wide-reach, low-intensity, web-based interactive multicomponent intervention had no significant incremental effect on medication intensification for control of glucose, blood pressure or lipids for patients with diabetes of physicians practising in the rural Southeastern USA. Trial registration: NCT00403091. C1 [Billue, Katherine L.; Safford, Monika M.; Curry, William; Kim, Yongin; Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham, AL USA. [Salanitro, Amanda H.] VA Tennessee Valley Healthcare Geriatr Res Educ C, Nashville, TN USA. [Salanitro, Amanda H.] Vanderbilt Univ, Nashville, TN USA. [Houston, Thomas K.] Bedford Vet Affairs Med Ctr, Beford, MA USA. [Houston, Thomas K.; Allison, Jeroan J.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Curry, William; Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Birmingham, MA USA. [Estrada, Carlos A.] Birmingham VAMC, Vet Affairs Natl Qual Scholars Program, Birmingham, MA USA. RP Estrada, CA (reprint author), Univ Alabama Birmingham, Birmingham, AL USA. EM cestrada@uab.edu RI Houston, Thomas/F-2469-2013 OI Allison, Jeroan/0000-0003-4472-2112 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [5R18DK065001]; Veterans Affairs National Quality Scholars Program FX This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5R18DK065001 to JJA. AHS and CAE were supported by the Veterans Affairs National Quality Scholars Program. The sponsors had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. NR 36 TC 2 Z9 2 U1 2 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2012 VL 2 IS 5 AR e000959 DI 10.1136/bmjopen-2012-000959 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 091MN UT WOS:000315053900014 ER PT J AU Myint, PK Kwok, CS Majumdar, SR Eurich, DT Clark, AB Espana, PP Man, SY Huang, DT Yealy, DM Angus, DC Capelastegui, A Rainer, TH Marrie, TJ Fine, MJ Loke, YK AF Myint, Phyo Kyaw Kwok, Chun Shing Majumdar, Sumit R. Eurich, Dean T. Clark, Allan B. Espana, Pedro P. Man, Shin Yan Huang, David T. Yealy, Donald M. Angus, Derek C. Capelastegui, Alberto Rainer, Timothy H. Marrie, Thomas J. Fine, Michael J. Loke, Yoon K. TI The International Community-Acquired Pneumonia (CAP) Collaboration Cohort (ICCC) study: rationale, design and description of study cohorts and patients SO BMJ OPEN LA English DT Article ID SEVERITY ASSESSMENT; PREDICTION RULE; VALIDATION; CURB-65; TOOL; METAANALYSIS; POPULATION; INFECTIONS; GUIDELINES; MANAGEMENT AB Objective: To improve the understanding of the determinants of prognosis and accurate risk stratification in community-acquired pneumonia (CAP). Design: Multicentre collaboration of prospective cohorts. Setting: 6 cohorts from the USA, Canada, Hong Kong and Spain. Participants: From a published meta-analysis of risk stratification studies in CAP, the authors identified and pooled individual patient-level data from six prospective cohort studies of CAP (three from the USA, one each from Canada, Hong Kong and Spain) to create the International CAP Collaboration Cohort. Initial essential inclusion criteria of meta-analysis were (1) prospective design, (2) in English language, (3) reported 30-day mortality and transfer to an intensive or high dependency care and (4) minimum 1000 participants. Common baseline patient characteristics included demographics, history and physical examination findings, comorbidities and laboratory and radiographic findings. Primary and secondary outcome measures: This paper reports the rationale, hypotheses and analytical framework and also describes study cohorts and patients. The authors aim to (1) compare the prognostic accuracy of existing CAP risk stratification tools, (2) assess patient-level determinants of prognosis, (3) improve risk stratification by combined use of scoring systems and (4) understand prognostic factors for specific patient groups. Results: The six cohorts assembled from 1991 to 2007 included 13 784 patients (median age 71 years, 54% men). Aside from one randomised controlled study, the remaining five were cohort studies, but all had similar inclusion criteria. Overall, there was 0%-6% missing data. A total of 6159 (44%) had severe pneumonia by Pneumonia Severity Index class IV/V. Mortality at 30 days was 8% (1036). Admission to intensive care or high dependency unit was also 8% (1059). Conclusions: International CAP Collaboration Cohort provides a pooled multicentre data set of patients with CAP, which will help us to better understand the prognosis of CAP. C1 [Myint, Phyo Kyaw; Kwok, Chun Shing; Clark, Allan B.; Loke, Yoon K.] Univ E Anglia, Norwich Med Sch, Dept Med, Norwich NR4 7TJ, Norfolk, England. [Majumdar, Sumit R.] Univ Alberta, Dept Med, Fac Med & Dent, Edmonton, AB, Canada. [Eurich, Dean T.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada. [Espana, Pedro P.; Capelastegui, Alberto] Hosp Galdakao, Serv Neumol, Galdakao, Bizkaia, Spain. [Man, Shin Yan; Rainer, Timothy H.] Chinese Univ Hong Kong, Prince Wales Hosp, Accid & Emergency Med Acad Unit, Shatin, Hong Kong, Peoples R China. [Huang, David T.; Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA. [Huang, David T.; Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, CRISMA Ctr, Pittsburgh, PA USA. [Yealy, Donald M.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Yealy, Donald M.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Marrie, Thomas J.] Dalhouse Univ, Halifax, NS, Canada. RP Myint, PK (reprint author), Univ E Anglia, Norwich Med Sch, Dept Med, Norwich NR4 7TJ, Norfolk, England. EM phyo.k.myint@uea.ac.uk RI Angus, Derek/E-9671-2012; Rainer, Timothy/I-2591-2013 OI Rainer, Timothy/0000-0003-3355-3237; Kwok, Chun Shing/0000-0001-7047-1586 FU Alberta Heritage Foundation; Alberta Innovates-Health Solutions; Canadian Institutes of Health Research FX None of the authors declare any conflict of interest except two authors, SRM: receives salary support awards from the Alberta Heritage Foundation and Alberta Innovates-Health Solutions (Health Scholar) and DTH: receives salary support awards from the Alberta Heritage Foundation and Canadian Institutes of Health Research. NR 40 TC 2 Z9 3 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2012 VL 2 IS 3 AR e001030 DI 10.1136/bmjopen-2012-001030 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 091JF UT WOS:000315044800069 ER PT J AU Roetker, NS Yonker, JA Lee, C Chang, V Basson, JJ Roan, CL Hauser, TS Hauser, RM Atwood, CS AF Roetker, Nicholas S. Yonker, James A. Lee, Chee Chang, Vicky Basson, Jacob J. Roan, Carol L. Hauser, Taissa S. Hauser, Robert M. Atwood, Craig S. TI Multigene interactions and the prediction of depression in the Wisconsin Longitudinal Study SO BMJ OPEN LA English DT Article ID NATIONAL-COMORBIDITY-SURVEY; DOPAMINE-RECEPTOR GENE; GENOME-WIDE ASSOCIATION; MAJOR DEPRESSION; ENVIRONMENT INTERACTION; ALZHEIMERS-DISEASE; HEALTHY-VOLUNTEERS; RISK-FACTORS; A1 ALLELE; BINDING AB Objectives: Single genetic loci offer little predictive power for the identification of depression. This study examined whether an analysis of gene-gene (G x G) interactions of 78 single nucleotide polymorphisms (SNPs) in genes associated with depression and age-related diseases would identify significant interactions with increased predictive power for depression. Design: A retrospective cohort study. Setting: A survey of participants in the Wisconsin Longitudinal Study. Participants: A total of 4811 persons (2464 women and 2347 men) who provided saliva for genotyping; the group comes from a randomly selected sample of Wisconsin high school graduates from the class of 1957 as well as a randomly selected sibling, almost all of whom are non-Hispanic white. Primary outcome measure: Depression as determine by the Composite International Diagnostic Interview-Short-Form. Results: Using a classification tree approach (recursive partitioning (RP)), the authors identified a number of candidate G x G interactions associated with depression. The primary SNP splits revealed by RP (ANKK1 rs1800497 (also known as DRD2 Taq1A) in men and DRD2 rs224592 in women) were found to be significant as single factors by logistic regression (LR) after controlling for multiple testing (p=0.001 for both). Without considering interaction effects, only one of the five subsequent RP splits reached nominal significance in LR (FTO rs1421085 in women, p=0.008). However, after controlling for G x G interactions by running LR on RP-specific subsets, every split became significant and grew larger in magnitude (OR (before)/(after): men: GNRH1 novel SNP: (1.43 -> 1.57); women: APOC3 rs2854116: (1.28 -> 1.55), ACVR2B rs3749386: (1.11 -> 2.17), FTO rs1421085: (1.32 -> 1.65), IL6 rs1800795: (1.12 -> 1.85)). Conclusions: The results suggest that examining G x G interactions improves the identification of genetic associations predictive of depression. 4 of the SNPs identified in these interactions were located in two pathways well known to impact depression: neurotransmitter (ANKK1 and DRD2) and neuroendocrine (GNRH1 and ACVR2B) signalling. This study demonstrates the utility of RP analysis as an efficient and powerful exploratory analysis technique for uncovering genetic and molecular pathway interactions associated with disease aetiology. C1 [Roetker, Nicholas S.; Yonker, James A.; Lee, Chee; Chang, Vicky; Roan, Carol L.; Hauser, Taissa S.; Hauser, Robert M.] Univ Wisconsin, Dept Sociol, Madison, WI 53706 USA. [Atwood, Craig S.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Basson, Jacob J.; Atwood, Craig S.] Univ Wisconsin, Dept Med, Madison Sch Med & Publ Hlth, Madison, WI USA. [Atwood, Craig S.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Joondalup, Australia. RP Atwood, CS (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. EM csa@medicine.wisc.edu RI Yonker, James/J-6561-2014 OI Yonker, James/0000-0002-9483-8511 FU National Institute on Aging [AG09775, AG21079, AG33285]; Vilas Estate Trust; National Science Foundation; Spencer Foundation; Graduate School of the University of Wisconsin-Madison FX This research uses data from the Wisconsin Longitudinal Study (WLS) of the University of Wisconsin-Madison. Since 1991, the WLS has been supported principally by the National Institute on Aging (AG09775, AG21079 and AG33285), with additional support from the Vilas Estate Trust, the National Science Foundation, the Spencer Foundation and the Graduate School of the University of Wisconsin-Madison. A public use file of data from the WLS is available from the Wisconsin Longitudinal Study, University of Wisconsin-Madison, 1180 Observatory Drive, Madison, Wisconsin 53706 and at http://www.ssc.wisc.edu/wlsresearch/data/. This material is the result of work supported with resources at the William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin. The opinions expressed herein are those of the authors. The contents do not represent the views of the Department of Veterans Affairs or the US Government. This is Geriatrics Research, Education and Clinical Center VA paper # 2012-03. NR 40 TC 9 Z9 10 U1 1 U2 9 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2012 VL 2 IS 4 AR e000944 DI 10.1136/bmjopen-2012-000944 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 091KW UT WOS:000315049300033 ER PT J AU Bartels, CM Saucier, JM Thorpe, CT Kind, AJH Pandhi, N Hansen, KE Smith, MA AF Bartels, Christie M. Saucier, Jessica M. Thorpe, Carolyn T. Kind, Amy J. H. Pandhi, Nancy Hansen, Karen E. Smith, Maureen A. TI Monitoring diabetes in patients with and without rheumatoid arthritis: a Medicare study SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID POSITIVE PREDICTIVE-VALUE; TRADITIONAL RISK-FACTORS; QUALITY-OF-CARE; MYOCARDIAL-INFARCTION; ADMINISTRATIVE DATA; ORTHOPEDIC-SURGERY; COMORBIDITIES; CLAIMS; COMPLICATIONS; SENSITIVITY AB Introduction: Diabetes mellitus is a key predictor of mortality in rheumatoid arthritis (RA) patients. Both RA and diabetes increase the risk of cardiovascular disease (CVD), yet understanding of how comorbid RA impacts the receipt of guideline-based diabetes care is limited. The purpose of this study was to examine how the presence of RA affected hemoglobin A1C (A1c) and lipid measurement in older adults with diabetes. Methods: Using a retrospective cohort approach, we identified beneficiaries >= 65 years old with diabetes from a 5% random national sample of 2004 to 2005 Medicare patients (N = 256,331), then examined whether these patients had comorbid RA and whether they received guideline recommended A1c and lipid testing in 2006. Multivariate logistic regression was used to examine the effect of RA on receiving guideline recommended testing, adjusting for baseline sociodemographics, comorbidities and health care utilization. Results: Two percent of diabetes patients had comorbid RA (N = 5,572). Diabetes patients with comorbid RA were more likely than those without RA to have baseline cardiovascular disease (such as 17% more congestive heart failure), diabetes-related complications including kidney disease (19% higher), lower extremity ulcers (77% higher) and peripheral vascular disease (32% higher). In adjusted models, diabetes patients with RA were less likely to receive recommended A1c testing (odds ratio (OR) 0.84, CI 0.80 to 0.89) than those without RA, but were slightly more likely to receive lipid testing (OR 1.08, CI 1.01 to 1.16). Conclusions: In older adults with diabetes, the presence of comorbid RA predicted lower rates of A1c testing but slightly improved lipid testing. Future research should examine strategies to improve A1c testing in patients with diabetes and RA, in light of increased CVD and microvascular risks in patients with both conditions. C1 [Bartels, Christie M.; Hansen, Karen E.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Rheumatol Sect, Madison, WI 53792 USA. [Saucier, Jessica M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. [Saucier, Jessica M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Dermatol, Madison, WI 53792 USA. [Thorpe, Carolyn T.] Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA 15240 USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Kind, Amy J. H.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Geriatr, Madison, WI 53792 USA. [Kind, Amy J. H.] William S Middleton Hosp, Geriatr Res Educ & Clin Ctr, US Dept Vet Affairs, Madison, WI 53705 USA. [Pandhi, Nancy] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI 53715 USA. [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Smith, Maureen A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI 53792 USA. RP Bartels, CM (reprint author), Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Rheumatol Sect, 600 N Highland Ave, Madison, WI 53792 USA. EM cb4@medicine.wisc.edu FU NIH-NIAMS [K23AR062381]; Health Innovation Program and Community-Academic Partnerships core of UW Clinical and Translational Science Award; NIH- NCATS [9U54TR000021] FX The authors would like to thank Robert Purvis for meticulous data preparation and Rebecca Schwei, Kristin Slovenkay and Colleen Brown for manuscript preparation. This project was supported by a training grant NIH-NIAMS K23AR062381 and the Health Innovation Program and Community-Academic Partnerships core of UW Clinical and Translational Science Award, previously NIH-NCRR1UL1RR025011, now NIH-NCATS grant 9U54TR000021. The Health Innovation Program provided support for data collection, analysis and manuscript formatting. No other funding source had a role in the design; collection, analysis and interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 35 TC 9 Z9 9 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2012 VL 14 IS 4 AR R166 DI 10.1186/ar3915 PG 9 WC Rheumatology SC Rheumatology GA 090JF UT WOS:000314974600010 PM 22809064 ER PT J AU Gorth, DJ Mauck, RL Chiaro, JA Mohanraj, B Hebela, NM Dodge, GR Elliott, DM Smith, LJ AF Gorth, Deborah J. Mauck, Robert L. Chiaro, Joseph A. Mohanraj, Bhavana Hebela, Nader M. Dodge, George R. Elliott, Dawn M. Smith, Lachlan J. TI IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1 beta-mediated degradation of nucleus pulposus in vitro SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID INTERLEUKIN-1 RECEPTOR ANTAGONIST; HUMAN INTERVERTEBRAL DISC; RHEUMATOID-ARTHRITIS; BACK-PAIN; INTRAARTICULAR INJECTION; THERAPEUTIC INTERVENTION; MATRIX DEGRADATION; PLGA MICROSPHERES; DEGENERATION; EXPRESSION AB Introduction: Inflammation plays a key role in the progression of intervertebral disc degeneration, a condition strongly implicated as a cause of lower back pain. The objective of this study was to investigate the therapeutic potential of poly(lactic-co-glycolic acid) (PLGA) microspheres loaded with interleukin-1 receptor antagonist (IL-1ra) for sustained attenuation of interleukin-1 beta (IL-1 beta) mediated degradative changes in the nucleus pulposus (NP), using an in vitro model. Methods: IL-1ra was encapsulated in PLGA microspheres and release kinetics were determined over 35 days. NP agarose constructs were cultured to functional maturity and treated with combinations of IL-1 beta and media conditioned with IL-1ra released from microspheres at intervals for up to 20 days. Construct mechanical properties, glycosaminoglycan content, nitrite production and mRNA expression of catabolic mediators were compared to properties for untreated constructs using unpaired Student's t-tests. Results: IL-1ra release kinetics were characterized by an initial burst release reducing to a linear release over the first 10 days. IL-1ra released from microspheres attenuated the degradative effects of IL-1 beta as defined by mechanical properties, glycosaminoglycans (GAG) content, nitric oxide production and mRNA expression of inflammatory mediators for 7 days, and continued to limit functional degradation for up to 20 days. Conclusions: In this study, we successfully demonstrated that IL-1ra microspheres can attenuate the degradative effects of IL-1 beta on the NP for extended periods. This therapeutic strategy may be appropriate for treating early-stage, cytokine-mediated disc degeneration. Ongoing studies are focusing on testing IL-1ra microspheres in an in vivo model of disc degeneration, as a prelude to clinical translation. C1 [Gorth, Deborah J.; Mauck, Robert L.; Chiaro, Joseph A.; Mohanraj, Bhavana; Dodge, George R.; Smith, Lachlan J.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. [Gorth, Deborah J.; Mauck, Robert L.; Chiaro, Joseph A.; Hebela, Nader M.; Dodge, George R.; Smith, Lachlan J.] Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Elliott, Dawn M.] Univ Delaware, Coll Engn, Dept Biomed Engn, Newark, DE 19716 USA. RP Smith, LJ (reprint author), Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 424 Stemmler Hall,3450 Hamilton Walk, Philadelphia, PA 19104 USA. EM lachlans@mail.med.upenn.edu FU Department of Veterans Affairs Merit Grant [01RX000211]; Penn Center for Musculoskeletal Disorders FX This study was funded by a Department of Veterans Affairs Merit Grant (01RX000211) and the Penn Center for Musculoskeletal Disorders. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. NR 53 TC 24 Z9 26 U1 0 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2012 VL 14 IS 4 AR R179 DI 10.1186/ar3932 PG 12 WC Rheumatology SC Rheumatology GA 090JF UT WOS:000314974600023 PM 22863285 ER PT J AU Singh, JA Lewallen, DG AF Singh, Jasvinder A. Lewallen, David G. TI Predictors of use of pain medications for persistent knee pain after primary Total Knee Arthroplasty: a cohort study using an institutional joint registry SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID SEVERE FUNCTIONAL LIMITATION; TOTAL HIP; AGE; REPLACEMENT; OUTCOMES; IMPACT; HOSPITALIZATIONS; DEPRESSION; MORBIDITY; PATTERNS AB Introduction: To study the use of pain medications for persistent index knee pain and their predictors after primary Total Knee Arthroplasty (TKA). Methods: The Mayo Total Joint Registry collects patient-reported data including pain medication use on all patients who undergo TKA. We used data from patients who underwent primary TKA from 1993-2005. We examined whether gender, age (reference, <= 60 yrs), body mass index (BMI; reference, <25 kg/m(2)), comorbidities measured by Deyo-Charlson index (5-point increase), anxiety and depression predicted use of pain medications (non-steroidal anti-inflammatory drugs (NSAIDs) and opioids) 2- and 5-years after primary TKA. Multivariable logistic regression additionally adjusted for operative diagnosis, American Society of Anesthesiologists (ASA) score, implant fixation and distance from the medical center. Results: 7,139 of the 10,957 eligible (65%) at 2-years and 4,234 of 7,404 eligible (57%) completed questionnaires. Significant predictors of NSAIDs use were (Odds ratio (95% confidence interval)): male gender at 2- and 5-years, 0.5 (0.4, 0.6) and 0.6 (0.5, 0.8); age >70-80 years, 0.7 (0.5, 0.9), 0.6 (0.4, 0.8); and depression, 1.4 (1.0, 1.8) and 1.7 (1.1, 2.5). BMI >= 40 was associated with NSAIDs use only at 2-years, 1.6 (1.1, 2.5). Significant predictors of opioid pain medication use at 2-and 5-years were: male gender, 0.5 (0.3, 0.9) and 0.4 (0.2, 0.8); age >70-80 years, 0.3 (0.1, 0.6), 0.3 (0.1, 0.8); and anxiety, 3.0 (1.6, 5.7) and 4.0 (1.7, 9.4). Conclusions: Female gender and younger age were associated with higher risk of use of NSAIDs and opioids after primary TKA. Depression was associated with higher NSAID use and anxiety with higher opioid pain medication use after primary TKA. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN 55905 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Mayo Clinic Orthopedic Surgery research funds; National Institutes of Health (NIH) [1 KL2 RR024151-01]; Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); National Institute of Aging, National Institutes of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); National Cancer Institute FX This material is the result of work supported with research grants from the Mayo Clinic Orthopedic Surgery research funds, National Institutes of Health (NIH) Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. JAS. is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Aging, National Institutes of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) and National Cancer Institute. NR 35 TC 13 Z9 13 U1 3 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2012 VL 14 IS 6 AR R248 DI 10.1186/ar4091 PG 9 WC Rheumatology SC Rheumatology GA 093LB UT WOS:000315192300024 PM 23157942 ER PT J AU Sharma, V Simpson, R LoPresti, E Schmeler, M AF Sharma, Vinod Simpson, Richard LoPresti, Edmund Schmeler, Mark TI Driving backwards using a semi-autonomous smart wheelchair system (DSS): A clinical evaluation SO APPLIED BIONICS AND BIOMECHANICS LA English DT Article DE Intelligent mobility aids (IMAs); collision avoidance; smart wheelchair; robotics; embedded distributed system; semi-autonomous system ID MOBILITY; RELIABILITY; VALIDATION; INSTRUMENT; COMMUNITY; FALLS; USERS; CARE AB Some wheelchair users have difficulty looking backward when backing up in confined spaces due to limited neck range of motion or low vision, which can lead to collisions which may result in personal injury or property damage. The Drive Safe System (DSS) was evaluated in a controlled laboratory setting with blindfolded able-bodied individuals on various backward driving tasks. Performance with the DSS was compared with a standard white cane used for navigation assistance by people with visual impairment. Results indicate that the DSS significantly reduced the number of collisions compared to using a cane (p = 0.0001) alone. There was no difference in task completion time when participants were using the cane or the DSS (p = 0.915). Users rated the DSS favourably as they experience less total workload (p = 0.026), less physical demand (p = 0.006), felt less frustrated (p = 0.002) and put less effort (p = 0.007) to achieve better performance when using the DSS, compared to using a cane. These findings suggest that the DSS can be a viable powered mobility solution for wheelchair users with visual impairments. C1 [Sharma, Vinod; Simpson, Richard] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15206 USA. [Sharma, Vinod; Simpson, Richard; Schmeler, Mark] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. [Simpson, Richard] VA Pittsburgh Healthcare Syst, Human Engn Res Lab, Pittsburgh, PA USA. [LoPresti, Edmund] AT Sci, Pittsburgh, PA USA. RP Sharma, V (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Bakery Sq 853,6465 Penn Ave,Suite 401, Pittsburgh, PA 15206 USA. EM vks3@pitt.edu; ris20@pitt.edu; edlopresti@at-sciences.com; schmeler@pitt.edu RI Simpson, Richard/G-5683-2015 OI Simpson, Richard/0000-0002-6306-9393 FU NIH [5R44HD040023-03]; NSF [0540865] FX Tara Minkus assisted Dr. Sharma with data collection. This research was funded by the NIH (grant #5R44HD040023-03) and the NSF (grant #0540865). NR 43 TC 0 Z9 0 U1 3 U2 17 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1176-2322 J9 APPL BIONICS BIOMECH JI Appl. Bionics Biomech. PY 2012 VL 9 IS 4 BP 347 EP 365 DI 10.3233/ABB-2011-0012 PG 19 WC Engineering, Biomedical; Robotics SC Engineering; Robotics GA 084DC UT WOS:000314515800001 ER PT J AU McDonald, CC Tanenbaum, JB Lee, YC Fisher, DL Mayhew, DR Winston, FK AF McDonald, Catherine C. Tanenbaum, Jason B. Lee, Yi-Ching Fisher, Donald L. Mayhew, Daniel R. Winston, Flaura K. TI Using Crash Data to Develop Simulator Scenarios for Assessing Novice Driver Performance SO TRANSPORTATION RESEARCH RECORD LA English DT Article ID DRIVING SIMULATOR; EMPIRICAL-EVALUATION; HAZARD ANTICIPATION; RISK PERCEPTION; ON-ROAD; EXPERIENCE; DURATION; EVALUATE; SAFETY AB Teenage drivers are at their highest crash risk in their first 6 months or first 1,000 nil of driving. Driver training, adult-supervised practice driving, and other interventions are aimed at improving driving performance in novice drivers. Previous driver training programs have enumerated thousands of scenarios, with each scenario requiring one or more skills. Although there is general agreement about the broad set of skills needed to become a competent driver, there is no consensus set of scenarios and skills to assess whether novice drivers are likely to crash or to assess the effects of novice driver training programs on the likelihood of a crash. The authors propose that a much narrower, common set of scenarios can be used to focus on the high-risk crashes of young drivers. Until recently, it was not possible to identify the detailed set of scenarios that were specific to high-risk crashes. However, an integration of police crash reports from previous research, a number of critical simulator studies, and a nationally representative database of serious teen crashes (the National Motor Vehicle Crash Causation Survey) now make identification of these scenarios possible. In this paper, the authors propose this novel approach and discuss how to create a common set of simulated scenarios and skills to assess novice driver performance and the effects of training and interventions as they relate to high-risk crashes. C1 [McDonald, Catherine C.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Tanenbaum, Jason B.; Lee, Yi-Ching; Winston, Flaura K.] Childrens Hosp Philadelphia, Div Gen Pediat, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA. [Fisher, Donald L.] Univ Massachusetts, Engn Lab 220A, Amherst, MA 01003 USA. [Mayhew, Daniel R.] Traff Injury Res Fdn, Ottawa, ON K2P 0B4, Canada. [Winston, Flaura K.] Univ Penn, Sch Med, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Winston, Flaura K.] Univ Penn, Sch Med, Perelman Sch Med, Leonard David Inst Hlth Econ, Philadelphia, PA 19104 USA. RP McDonald, CC (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth, Claire Fagin Hall,418 Curie Blvd,233 2L, Philadelphia, PA 19104 USA. EM mcdonalc@nursing.upenn.edu FU Pennsylvania Department of Health; National Institute of Nursing Research through the T32 Award Program; T32 Award Program; Center for Injury Research and Prevention FX This project was funded, in part, by a grant from the Pennsylvania Department of Health. This research was also supported by a grant from the National Institute of Nursing Research through the T32 Award Program. Catherine C. McDonald, a postdoctoral fellow, was supported by the T32 Award Program. The authors thank Marilyn S. Sommers, Nancy Kassam-Adams, and the Center for Injury Research and Prevention for their support. The authors acknowledge Allison E. Curry and Michael J. Kallan for their assistance with the National Motor Vehicle Crash Causation Survey data The authors are also indebted to the National Highway Traffic Safety Administration for the efforts to provide the data available in the National Motor Vehicle Crash Causation Survey. NR 41 TC 5 Z9 5 U1 1 U2 15 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0361-1981 J9 TRANSPORT RES REC JI Transp. Res. Record PY 2012 IS 2321 BP 73 EP 78 DI 10.3141/2321-10 PG 6 WC Engineering, Civil; Transportation; Transportation Science & Technology SC Engineering; Transportation GA 088TL UT WOS:000314859900011 PM 23543947 ER PT S AU Wang, HW Grindle, GG Candiotti, J Chung, CS Shino, M Houston, E Cooper, RA AF Wang, Hongwu Grindle, Garrett G. Candiotti, Jorge Chung, Chengshiu Shino, Motoki Houston, Elaine Cooper, Rory A. GP IEEE TI The Personal Mobility and Manipulation Appliance (PerMMA): a Robotic Wheelchair with Advanced Mobility and Manipulation SO 2012 ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC) SE IEEE Engineering in Medicine and Biology Society Conference Proceedings LA English DT Proceedings Paper CT 34th Annual International Conference of the IEEE Engineering-in-Medicine-and-Biology-Society (EMBS) CY AUG 28-SEP 01, 2012 CL San Diego, CA SP IEEE, Engn Med & Biol Soc (EMBS), CAS, SMC, PubMed, MEDLINE ID POWERED MOBILITY AB The Personal Mobility and Manipulation Appliance (PerMMA) is a recently developed personal assistance robot developed to provide people with disabilities and older adults enhanced assistance in both mobility and manipulation, which are two fundamental components for independently activities of daily life performing, community participation, and quality of life. Technologies to assist with mobility and manipulation are among the most important tools for clinicians, end users and caregivers; however, there are currently few systems that provide practical and coordinated assistance with mobility and manipulation tasks. The PerMMA was not only developed and evaluated to provide users and caregivers enhanced mobility and manipulation options, but also as a clinical tool as well as research platform. The development and evaluation of PerMMA are presented in the paper. C1 [Wang, Hongwu; Grindle, Garrett G.; Candiotti, Jorge; Chung, Chengshiu; Houston, Elaine; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. RP Wang, HW (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu RI Wang, Hongwu/J-6133-2013 OI Wang, Hongwu/0000-0002-6567-9144 NR 10 TC 4 Z9 4 U1 0 U2 2 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1557-170X BN 978-1-4577-1787-1 J9 IEEE ENG MED BIO PY 2012 BP 3324 EP 3327 PG 4 WC Engineering, Biomedical; Engineering, Electrical & Electronic SC Engineering GA BDH78 UT WOS:000313296503137 ER PT J AU Brady, KT Back, SE AF Brady, Kathleen T. Back, Sudie E. TI Childhood Trauma, Posttraumatic Stress Disorder, and Alcohol Dependence SO ALCOHOL RESEARCH-CURRENT REVIEWS LA English DT Article DE Alcohol dependence; alcohol use disorders; childhood; childhood trauma; trauma-related symptoms; posttraumatic stress disorder; coping with stress or anxiety; neurobiology; biological mechanisms; treatment; pharmacological intervention; behavioral intervention; integrative psychosocial intervention; adverse child-rearing environment ID SUBSTANCE USE DISORDERS; COOCCURRING PTSD; MATERNAL-CARE; ABUSE; EXPERIENCES; THERAPY; SYSTEMS; WOMEN; TRIAL; VICTIMIZATION AB Early-childhood trauma is strongly associated with developing mental health problems, including alcohol dependence, later in life. People with early-life trauma may use alcohol to help cope with trauma-related symptoms. This article reviews the prevalence of early-childhood trauma and its robust association with the development of alcohol use disorders and posttraumatic stress disorder. It also examines the potential biological mechanisms by which early adverse experiences can result in long-lasting changes in neurobiology underlying this vulnerability, as well as pharmacological and behavioral interventions. Recent investigations highlight the importance of assessing trauma among patients with alcohol use disorders and the positive benefits associated with the application of integrative psychosocial interventions that target both trauma-related symptoms and alcohol dependence. C1 [Brady, Kathleen T.] Med Univ S Carolina, Clin Neurosci Div, Charleston, SC 29425 USA. [Brady, Kathleen T.; Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Brady, KT (reprint author), Med Univ S Carolina, Clin Neurosci Div, Charleston, SC 29425 USA. FU NIDA NIH HHS [K24 DA-00435, K23 DA-021228] NR 52 TC 12 Z9 12 U1 2 U2 22 PU NATL INST ALCOHOL ABUSE ALCOHOLISM PI ROCKVILLE PA 6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA SN 1535-7414 J9 ALCOHOL RES-CURR REV JI Alcohol Res.-Curr. Rev. PY 2012 VL 34 IS 4 BP 408 EP 413 PG 6 WC Substance Abuse SC Substance Abuse GA 066QB UT WOS:000313234200005 PM 23584107 ER PT J AU Becker, HC AF Becker, Howard C. TI Effects of Alcohol Dependence and Withdrawal on Stress Responsiveness and Alcohol Consumption SO ALCOHOL RESEARCH-CURRENT REVIEWS LA English DT Article DE Alcohol consumption; alcohol dependence; chronic alcohol exposure; drinking behavior; withdrawal; relapse; stress; stress response; biological adaptation to stress; brain; brain stress pathway; hypothalamic-pituitary-adrenocortical axis; corticotropin-releasing factor; corticosteroids; norepinephrine; human studies; animal models ID CORTICOTROPIN-RELEASING-FACTOR; PITUITARY-ADRENAL AXIS; CHRONIC ETHANOL EXPOSURE; ANXIETY-LIKE BEHAVIOR; INCREASES ALLOPREGNANOLONE LEVELS; RECEPTOR ANTAGONIST ANTALARMIN; AMINOBUTYRIC-ACID RELEASE; NEUROACTIVE STEROIDS; VOLUNTARY ETHANOL; C57BL/6J MICE AB A complex relationship exists between alcohol-drinking behavior and stress. Alcohol has anxiety-reducing properties and can relieve stress, while at the same time acting as a stressor and activating the body's stress response systems. In particular, chronic alcohol exposure and withdrawal can profoundly disturb the function of the body's neuroendocrine stress response system, the hypothalamic-pituitary-adrenocortical (HPA) axis. A hormone, corticotropin-releasing factor (CRF), which is produced and released from the hypothalamus and activates the pituitary in response to stress, plays a central role in the relationship between stress and alcohol dependence and withdrawal. Chronic alcohol exposure and withdrawal lead to changes in CRF activity both within the HPA axis and in extrahypothalamic brain sites. This may mediate the emergence of certain withdrawal symptoms, which in turn influence the susceptibility to relapse. Alcohol-related dysregulation of the HPA axis and altered CRF activity within brain stress reward circuitry also may play a role in the escalation of alcohol consumption in alcohol-dependent individuals. Numerous mechanisms have been suggested to contribute to the relationship between alcohol dependence, stress, and drinking behavior. These include the stress hormones released by the adrenal glands in response to HPA axis activation (i.e., corticosteroids), neuromodulators known as neuroactive steroids, CRF, the neurotransmitter norepinephrine, and other stress-related molecules. C1 [Becker, Howard C.] Med Univ S Carolina, Dept Neurosci, Dept Psychiat & Behav Sci, Charleston Alcohol Res Ctr, Charleston, SC 29425 USA. [Becker, Howard C.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Becker, HC (reprint author), Med Univ S Carolina, Dept Neurosci, Dept Psychiat & Behav Sci, Charleston Alcohol Res Ctr, Charleston, SC 29425 USA. FU BLRD VA [I01 BX000813]; NIAAA NIH HHS [U01 AA014095, P50 AA010761, R01 AA018036, U01 AA020929] NR 151 TC 34 Z9 35 U1 1 U2 17 PU NATL INST ALCOHOL ABUSE ALCOHOLISM PI ROCKVILLE PA 6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA SN 1535-7414 J9 ALCOHOL RES-CURR REV JI Alcohol Res.-Curr. Rev. PY 2012 VL 34 IS 4 BP 448 EP 458 PG 11 WC Substance Abuse SC Substance Abuse GA 066QB UT WOS:000313234200009 PM 23584111 ER PT J AU Goranson, A Boehnlein, J Drummond, D AF Goranson, Anders Boehnlein, James Drummond, David TI Commentary: A Homicide-Suicide Assessment Model SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Editorial Material ID VETERANS AB In this issue of the Journal, Dr. Paolo Roma and colleagues review international research spanning 60 years and highlight the centrality of psychiatric factors in the phenomenon of homicide-suicide (H-S). This commentary examines several challenges presented by definitional variability and the use of general sources as data. We suggest directions for future research, particularly using the established violence literature, to move toward intervention and management of H-S. We also examine the similarities between H-S and stalking and reflect on the potential for the stalking literature to inform the understanding and management of H-S. J Am Acad Psychiatry Law 40:472-5, 2012 C1 [Goranson, Anders] Portland VA Med Ctr, Northwest Network, MIRECC, Portland, OR USA. [Goranson, Anders; Boehnlein, James; Drummond, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Boehnlein, James] VA NW Network MIRECC, Portland, OR USA. [Drummond, David] Drummond Consulting & Training Serv, Portland, OR USA. RP Goranson, A (reprint author), 3710 SW US Vet Hosp Way, Portland, OR 97239 USA. EM anders.goranson@va.gov NR 19 TC 1 Z9 1 U1 0 U2 2 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2012 VL 40 IS 4 BP 472 EP 475 PG 4 WC Law; Psychiatry SC Government & Law; Psychiatry GA 060GN UT WOS:000312764600004 PM 23233467 ER PT J AU Piel, J AF Piel, Jennifer TI In the Aftermath of State v. Becker: A Review of State and Federal Jury Instructions on Insanity Acquittal Disposition SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article AB An important topic related to the insanity defense is what jurors should be told about the disposition of a defendant found not guilty by reason of insanity (NGRI). In the federal court system, jurors are not instructed about the consequences of an NGRI verdict. State courts, however, are divided on the question. The federal precedent, Shannon v. United States, and the most recent state case to rule on NGRI juror instructions, State v. Becker, are reviewed in detail. What follows is the author's critique of the principal arguments for and against a jury instruction on NGRI disposition. The author argues in favor of a jury instruction on the consequences of an NGRI verdict. J Am Acad Psychiatry Law 40:537-46, 2012 C1 [Piel, Jennifer] Case Western Reserve Univ, Cleveland, OH 44106 USA. RP Piel, J (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM jennifer.piel@va.gov NR 24 TC 0 Z9 0 U1 0 U2 3 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2012 VL 40 IS 4 BP 537 EP 546 PG 10 WC Law; Psychiatry SC Government & Law; Psychiatry GA 060GN UT WOS:000312764600013 PM 23233476 ER PT J AU Deng, Y Zhao, J Sakurai, D Kaufman, KM Edberg, JC Kimberly, RP Kamen, DL Gilkeson, GS Jacob, CO Scofield, RH Langefeld, CD Kelly, JA Alarcon-Riquelme, ME Harley, JB Vyse, TJ Freedman, BI Gaffney, PM Sivils, KM James, JA Niewold, TB Cantor, RM Chen, W Hahn, BH Brown, EE Tsao, BP AF Deng, Y. Zhao, J. Sakurai, D. Kaufman, K. M. Edberg, J. C. Kimberly, R. P. Kamen, D. L. Gilkeson, G. S. Jacob, C. O. Scofield, R. H. Langefeld, C. D. Kelly, J. A. Alarcon-Riquelme, M. E. Harley, J. B. Vyse, T. J. Freedman, B. I. Gaffney, P. M. Sivils, K. M. James, J. A. Niewold, T. B. Cantor, R. M. Chen, W. Hahn, B. H. Brown, E. E. Tsao, B. P. CA BIOLUPUS & GENLES Networks PROFILE TI MicroRNA-3148 modulates differential gene expression of the SLE-associated TLR7 variant SO ARTHRITIS RESEARCH & THERAPY LA English DT Meeting Abstract CT Meeting of the Lupus - New Targets, New Approaches CY SEP 27-30, 2012 CL Whistler, CANADA C1 [Deng, Y.; Zhao, J.; Sakurai, D.; Cantor, R. M.; Chen, W.; Hahn, B. H.; Tsao, B. P.] Univ Calif Los Angeles, Los Angeles, CA USA. [Kaufman, K. M.; Harley, J. B.; Vyse, T. J.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH USA. [Kaufman, K. M.; Harley, J. B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Edberg, J. C.; Kimberly, R. P.; Brown, E. E.] Univ Alabama Birmingham, Birmingham, AL USA. [Kamen, D. L.; Gilkeson, G. S.] Med Univ S Carolina, Charleston, SC 29425 USA. [Jacob, C. O.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Scofield, R. H.; Kelly, J. A.; Alarcon-Riquelme, M. E.; Gaffney, P. M.; Sivils, K. M.; James, J. A.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Scofield, R. H.; James, J. A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Scofield, R. H.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Langefeld, C. D.] Wake Forest Univ Hlth Sci, Wake Forest, NC USA. [Alarcon-Riquelme, M. E.] Pfizer Univ Granada Junta Andalucia, Ctr Genom & Invest Oncol GENYO, Granada, Spain. [Vyse, T. J.] Kings Coll London, London, England. [Freedman, B. I.] Wake Forest Sch Med, Winston Salem, NC USA. [Niewold, T. B.] Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2012 VL 14 SU 3 MA A5 PG 2 WC Rheumatology SC Rheumatology GA 059OP UT WOS:000312715200006 ER PT J AU Barilla, HE Waldron, EA Plaksin, JR Segal, AG Findley, J Gehrman, P Jackson, NJ Grandner, MA Perlis, ML AF Barilla, H. E. Waldron, E. A. Plaksin, J. R. Segal, A. G. Findley, J. Gehrman, P. Jackson, N. J. Grandner, M. A. Perlis, M. L. TI RECRUITMENT STRATEGIES: WHAT METHODS YIELD THE MOST POTENTIAL PARTICIPANTS? SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Barilla, H. E.; Waldron, E. A.; Segal, A. G.; Findley, J.; Gehrman, P.; Perlis, M. L.] Univ Penn, Behav Sleep Med Program, Philadelphia, PA 19104 USA. [Waldron, E. A.] Philadelphia Coll Osteopath Med, Dept Psychol, Philadelphia, PA USA. [Plaksin, J. R.] NYU, Sch Med, New York, NY USA. [Segal, A. G.] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA. [Gehrman, P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Jackson, N. J.; Grandner, M. A.] Univ Penn, Dept Med, Div Sleep Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0702 BP A236 EP A237 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996501220 ER PT J AU Barilla, HE Perlis, ML Grandner, MA Gehrman, P AF Barilla, H. E. Perlis, M. L. Grandner, M. A. Gehrman, P. TI RELATIONSHIPS BETWEEN AGE AND INSOMNIA SYMPTOMS SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Barilla, H. E.; Perlis, M. L.; Gehrman, P.] Univ Penn, Behav Sleep Med Program, Philadelphia, PA 19104 USA. [Grandner, M. A.] Univ Penn, Dept Med, Div Sleep Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Gehrman, P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0058 BP A23 EP A24 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996500060 ER PT J AU Blanco-Centurion, C Liu, M Konadhode, R Pelluru, D van den Pol, A Shiromani, PJ AF Blanco-Centurion, C. Liu, M. Konadhode, R. Pelluru, D. van den Pol, A. Shiromani, P. J. TI OREXIN GENE TRANSFER INTO THE ZONA INCERTA NEURONS BLOCKS CATAPLEXY AND IMPROVES WAKE MAINTENANCE IN NARCOLEPTIC OREXIN-ATAXIN-3 TRANSGENIC MICE SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Blanco-Centurion, C.; Liu, M.; Konadhode, R.; Pelluru, D.; Shiromani, P. J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Shiromani, P. J.] Ralph H Johnson VAMC, Charleston, SC USA. [van den Pol, A.] Yale Univ, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0017 BP A9 EP A9 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996500019 ER PT J AU Bramoweth, AD Mosti, C Williams, JM Berry, RB McCrae, C AF Bramoweth, A. D. Mosti, C. Williams, J. M. Berry, R. B. McCrae, C. TI HEALTHCARE UTILIZATION PRE- AND POST-CBT FOR INSOMNIA SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Bramoweth, A. D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [Bramoweth, A. D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Mosti, C.] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA. [Williams, J. M.; McCrae, C.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA. [Berry, R. B.] Univ Florida, Dept Med, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 1321 BP A446 EP A446 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996502558 ER PT J AU Fung, CH Martin, JL Jouldjian, S Josephson, KR Alessi, CA AF Fung, C. H. Martin, J. L. Jouldjian, S. Josephson, K. R. Alessi, C. A. TI DIFFICULTY WITH USE OF POSITIVE AIRWAY PRESSURE EQUIPMENT AND ADHERENCE TO THERAPY AMONG OLDER VETERANS: A PILOT STUDY SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Fung, C. H.; Martin, J. L.; Jouldjian, S.; Josephson, K. R.; Alessi, C. A.] VA Greater Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. [Fung, C. H.; Martin, J. L.; Alessi, C. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0495 BP A169 EP A169 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996501014 ER PT J AU Fung, SJ Zhang, J Xi, M Sampogna, S Chase, MH AF Fung, S. J. Zhang, J. Xi, M. Sampogna, S. Chase, M. H. TI RECURRENT APNEA INDUCES APOPTOSIS IN HYPOGLOSSAL MOTONEURONS IN IN VIVO RATS SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Fung, S. J.; Zhang, J.; Xi, M.; Chase, M. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Fung, S. J.; Zhang, J.; Xi, M.; Sampogna, S.; Chase, M. H.] Websci Int, Los Angeles, CA USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0118 BP A44 EP A44 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996500120 ER PT J AU Gehrman, P Girsh, L McCloskey, S Kuna, ST AF Gehrman, P. Girsh, L. McCloskey, S. Kuna, S. T. TI TELEHEALTH DELIVERY OF CBT-I IN VETERANS SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Gehrman, P.; Girsh, L.; McCloskey, S.; Kuna, S. T.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Gehrman, P.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kuna, S. T.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0718 BP A242 EP A242 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996501236 ER PT J AU Gehrman, P Barilla, H Hall, MH Buysse, DJ Perlis, ML Gooneratne, N Ross, RJ AF Gehrman, P. Barilla, H. Hall, M. H. Buysse, D. J. Perlis, M. L. Gooneratne, N. Ross, R. J. TI STRESS REACTIVITY IN INSOMNIA SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Gehrman, P.; Barilla, H.; Perlis, M. L.; Ross, R. J.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gehrman, P.; Ross, R. J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Hall, M. H.; Buysse, D. J.] Univ Pittsburgh, Sleep Med Inst, Pittsburgh, PA USA. [Hall, M. H.; Buysse, D. J.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Gooneratne, N.] Univ Penn, Perelman Sch Med, Div Geriatr Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0679 BP A229 EP A229 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996501197 ER PT J AU Harb, GC Cook, JM Thompson, R Ross, RJ AF Harb, G. C. Cook, J. M. Thompson, R. Ross, R. J. TI RESCRIPTING NIGHTMARES OF VETERANS WITH PTSD: RELATION TO TREATMENT OUTCOME SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Harb, G. C.; Ross, R. J.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. [Cook, J. M.] Yale Univ, Sch Med, New Haven, CT USA. [Cook, J. M.] Natl Ctr PTSD, West Haven, CT USA. [Thompson, R.] Univ Illinois, Chicago, IL USA. [Ross, R. J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 1003 BP A338 EP A338 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996502241 ER PT J AU Hughes, JM Jouldjian, S Washington, D Alessi, CA Martin, JL AF Hughes, J. M. Jouldjian, S. Washington, D. Alessi, C. A. Martin, J. L. TI DOES COMORBID PTSD PREDICT SUBJECTIVE AND OBJECTIVE SLEEP DISTURBANCE AMONG WOMEN VETERANS? SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Hughes, J. M.; Jouldjian, S.; Alessi, C. A.; Martin, J. L.] VA Greater Los Angeles, Geriatr Res Educ & Clin Ctr, North Hills, CA USA. [Washington, D.; Alessi, C. A.; Martin, J. L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Washington, D.] VA Greater Los Angeles, Ctr Excellence Healthcare Provider Behav, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 1216 BP A409 EP A409 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996502454 ER PT J AU Lapierre, JL Kosenko, P Kodama, T Peever, J Mukhametov, L Lyamin, O Siegel, J AF Lapierre, J. L. Kosenko, P. Kodama, T. Peever, J. Mukhametov, L. Lyamin, O. Siegel, J. TI UNLIKE ACETYLCHOLINE, CORTICAL SEROTONIN RELEASE IS NOT LATERALIZED DURING ASYMMETRICAL SLOW WAVE SLEEP IN THE FUR SEAL SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Lapierre, J. L.; Lyamin, O.; Siegel, J.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. [Lapierre, J. L.; Lyamin, O.; Siegel, J.] Vet Adm Greater Los Angeles Healthcare Syst, Neurobiol Res, North Hills, CA USA. [Lapierre, J. L.; Peever, J.] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada. [Kosenko, P.; Mukhametov, L.; Lyamin, O.] Utrish Dolphinarium Ltd, Res Unit, Moscow, Russia. [Kosenko, P.] 2nd S Fed Univ, Rostov Na Donu, Russia. [Kodama, T.] Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Tokyo 113, Japan. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0064 BP A26 EP A26 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996500066 ER PT J AU Martin, JL Hughes, JM Jouldjian, S Washington, D Alessi, CA AF Martin, J. L. Hughes, J. M. Jouldjian, S. Washington, D. Alessi, C. A. TI PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE AMONG WOMEN VETERANS WITH INSOMNIA SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Martin, J. L.; Hughes, J. M.; Jouldjian, S.; Alessi, C. A.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Martin, J. L.; Washington, D.; Alessi, C. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Washington, D.] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 1258 BP A423 EP A424 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996502496 ER PT J AU Mosti, CB Williams, JM Bramoweth, AD Berry, RB McCrae, C AF Mosti, C. B. Williams, J. M. Bramoweth, A. D. Berry, R. B. McCrae, C. TI HEALTHCARE UTILIZATION OF INSOMNIA PATIENTS WITH COMORBID DEPRESSION AND/OR ANXIETY SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Mosti, C. B.; Williams, J. M.; Berry, R. B.; McCrae, C.] Univ Florida, Gainesville, FL USA. [Bramoweth, A. D.] Univ Pittsburgh, Pittsburgh, PA USA. [Berry, R. B.] Malcom Randall VA Med Ctr, Gainesville, FL USA. [Bramoweth, A. D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0739 BP A248 EP A248 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996501255 ER PT J AU Sherry, D Collins, EG AF Sherry, D. Collins, E. G. TI INFLUENCE OF SLEEP ON DYSPNEA, EMOTIONAL FUNCTION, AND PHYSICAL FUNCTION IN HEART FAILURE PATIENTS WITH CARDIAC RESYNCHRONIZATION THERAPY SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Sherry, D.; Collins, E. G.] US Dept Vet Affairs, Hines, IL USA. [Sherry, D.; Collins, E. G.] Univ Illinois, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0948 BP A319 EP A319 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996502186 ER PT J AU Soehner, AM Gruber, J Gershon, A Talbot, LS Eidelman, P Hairston, IS Harvey, AG AF Soehner, A. M. Gruber, J. Gershon, A. Talbot, L. S. Eidelman, P. Hairston, I. S. Harvey, A. G. TI DOES SLEEPING TOO LITTLE MAKE YOU FEEL TOO MUCH? AN INVESTIGATION OF SLEEP DURATION AND EMOTION REACTIVITY IN INTER-EPISODE BIPOLAR DISORDER AND HEALTHY ADULTS SO SLEEP LA English DT Meeting Abstract CT 26th Annual Meeting of the Association-of-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Assoc Profess Sleep Soc (APSS) C1 [Soehner, A. M.; Harvey, A. G.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Gruber, J.] Yale Univ, New Haven, CT USA. [Talbot, L. S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Talbot, L. S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Eidelman, P.] San Francisco Bay Ctr Cognit Therapy, Oakland, CA USA. [Hairston, I. S.] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0976 BP A329 EP A329 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996502214 ER PT J AU Waldron, EA Byrne, M Barilla, H Gehrman, P Findley, J Grandner, MA Jackson, NJ Perlis, ML AF Waldron, E. A. Byrne, M. Barilla, H. Gehrman, P. Findley, J. Grandner, M. A. Jackson, N. J. Perlis, M. L. TI DIFFERENCES IN INSOMNIA SYMPTOM SEVERITY AMONG PRIMARY INSOMNIA, INSOMNIA COMORBID WITH DEPRESSION OR INSOMNIA COMORBID WITH CHRONIC PAIN SO SLEEP LA English DT Meeting Abstract CT 26th Annual Meeting of the Association-of-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Assoc Profess Sleep Soc (APSS) C1 [Waldron, E. A.; Byrne, M.; Barilla, H.; Gehrman, P.; Findley, J.; Perlis, M. L.] Univ Penn, Behav Sleep Med Program, Philadelphia, PA 19104 USA. [Waldron, E. A.] Philadelphia Coll Osteopath Med, Dept Psychol, Philadelphia, PA USA. [Byrne, M.] Univ Sci, Dept Behav & Social Sci, Philadelphia, PA USA. [Gehrman, P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Grandner, M. A.; Jackson, N. J.] Univ Penn, Dept Med, Div Sleep Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0713 BP A240 EP A240 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996501231 ER PT J AU Waldron, EA Barilla, HE Segal, AG Plaksin, JR Findley, J Gehrman, P Grandner, MA Jackson, NJ Perlis, ML AF Waldron, E. A. Barilla, H. E. Segal, A. G. Plaksin, J. R. Findley, J. Gehrman, P. Grandner, M. A. Jackson, N. J. Perlis, M. L. TI EVALUATION OF COUNTY OF RESIDENCE ON INSOMNIA SEVERITY SO SLEEP LA English DT Meeting Abstract CT 26th Annual Meeting of the Association-of-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Assoc Profess Sleep Soc (APSS) C1 [Waldron, E. A.; Barilla, H. E.; Segal, A. G.; Findley, J.; Gehrman, P.; Perlis, M. L.] Univ Penn, Behav Sleep Med Program, Philadelphia, PA 19104 USA. [Waldron, E. A.] Philadelphia Coll Osteopath Med, Dept Psychol, Philadelphia, PA USA. [Segal, A. G.] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA. [Plaksin, J. R.] NYU, Sch Med, New York, NY USA. [Gehrman, P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Jackson, N. J.; Perlis, M. L.] Univ Penn, Dept Med, Div Sleep Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0712 BP A240 EP A240 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996501230 ER PT J AU Zhang, J Fung, SJ Xi, M Sampogna, S Chase, MH AF Zhang, J. Fung, S. J. Xi, M. Sampogna, S. Chase, M. H. TI HYPOCRETINERGIC RECEPTOR TYPE 1, NOT TYPE 2, IS EXPRESSED BY CANCER CELLS OF THE HUMAN COLON SO SLEEP LA English DT Meeting Abstract CT Annual Meeting of the Associated-Professional-Sleep-Societies (APSS) CY JUN 09-13, 2012 CL Boston, MA SP Associated Professi Sleep Soc (APSS) C1 [Zhang, J.; Fung, S. J.; Xi, M.; Sampogna, S.; Chase, M. H.] WebSci Int, Los Angeles, CA USA. [Zhang, J.; Fung, S. J.; Xi, M.; Chase, M. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2012 VL 35 SU S MA 0032 BP A14 EP A14 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 063KH UT WOS:000312996500034 ER PT S AU Frank, JA AF Frank, James A. BE Fromm, M Schulzke, JD TI Claudins and alveolar epithelial barrier function in the lung SO BARRIERS AND CHANNELS FORMED BY TIGHT JUNCTION PROTEINS I SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE alveolar epithelium; tight junction; claudin; acute lung injury; cancer ID TIGHT-JUNCTION PROTEINS; OVARIAN-CANCER; FLUID TRANSPORT; BREAST-CANCER; UP-REGULATION; II CELLS; EXPRESSION; PERMEABILITY; INJURY; IDENTIFICATION AB The alveolar epithelium of the lung constitutes a unique interface with the outside environment. This thin barrier must maintain a surface for gas transfer while being continuously exposed to potentially hazardous environmental stimuli. Small differences in alveolar epithelial barrier properties could therefore have a large impact on disease susceptibility or outcome. Moreover, recent work has focused attention on the alveolar epithelium as central to several lung diseases, including acute lung injury and idiopathic pulmonary fibrosis. Although relatively little is known about the function and regulation of claudin tight junction proteins in the lung, new evidence suggests that environmental stimuli can influence claudin expression and alveolar barrier function in human disease. This review considers recent advances in the understanding of the role of claudins in the breakdown of the alveolar epithelial barrier in disease and in epithelial repair. C1 [Frank, James A.] San Francisco VA Med Ctr, Dept Med, Div Pulm & Crit Care Med, No Calif Inst Res & Educ, San Francisco, CA 94121 USA. [Frank, James A.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA. [Frank, James A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. RP Frank, JA (reprint author), San Francisco VA Med Ctr, Dept Med, Div Pulm & Crit Care Med, No Calif Inst Res & Educ, 4150 Clement St,Box 111D, San Francisco, CA 94121 USA. EM James.frank@ucsf.edu FU NHLBI NIH HHS [R01 HL088440, R21 HL111707, R56 HL088440] NR 64 TC 16 Z9 16 U1 0 U2 12 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 BN 978-1-57331-873-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2012 VL 1257 BP 175 EP 183 DI 10.1111/j.1749-6632.2012.06533.x PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Multidisciplinary Sciences SC Biochemistry & Molecular Biology; Cell Biology; Science & Technology - Other Topics GA BDB53 UT WOS:000312485200021 PM 22671604 ER PT J AU Bansal, N Whooley, MA Regan, M McCulloch, CE Ix, JH Epel, E Blackburn, E Lin, J Hsu, CY AF Bansal, Nisha Whooley, Mary A. Regan, Mathilda McCulloch, Charles E. Ix, Joachim H. Epel, Elissa Blackburn, Elizabeth Lin, Jue Hsu, Chi-yuan TI Association between Kidney Function and Telomere Length: The Heart and Soul Study SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Kidney; Chronic kidney disease; Telomere ID CORONARY-ARTERY-DISEASE; CYSTATIN-C; CARDIOVASCULAR HEALTH; HEMODIALYSIS-PATIENTS; MONONUCLEAR-CELLS; MORTALITY; CREATININE; FAILURE; EVENTS; RISK AB Background: Telomere attrition is a novel risk factor for cardiovascular disease. Studies of telomere length in relation to kidney function are limited. We explored the association of kidney function with telomere length and telomere shortening. Methods: The Heart and Soul Study is a longitudinal study of patients with stable coronary heart disease. Measures of baseline kidney function included: serum creatinine, creatinine-derived estimated glomerular filtration rate (eGFR(CKD-EPI)), 24-hour urine measured creatinine clearance, cystatin C, cystatin C-derived estimated glomerular filtration rate (eGFRcys) and urine albumin to creatinine ratio. Telomere length was measured from peripheral blood leukocytes at baseline (n = 954) and 5 years later (n = 608). Linear regression models were used to test the association of kidney function with (i) baseline telomere length and (ii) change in telomere length over 5 years. Results: At baseline, mean eGFR(CKD-EPI) was 72.6 (+/- 21.5) ml/min/1.73 m(2), eGFRcys was 71.0 (+/- 23.1) ml/min/1.73 m(2) and ACR was 8.6 (+/- 12.3) mg/g. Only lower baseline eGFR(CKD-EPI) was associated with shorter baseline telomere length (9.1 (95% CI 1.2-16.9) fewer base pairs for every 5 ml/min/1.73 m(2) lower eGFR(CKD-EPI)). Lower baseline eGFR(CKD-EPI) (and all other measures of kidney function) predicted more rapid telomere shortening (10.8 (95% CI 4.3-17.3) decrease in base pairs over 5 years for every 5 ml/min/1.73 m(2) lower eGFR(CKD-EPI)). After adjustment for age, these associations were no longer statistically significant. Conclusions: In patients with coronary heart disease, reduced kidney function is associated with (i) shorter baseline telomere length and (ii) more rapid telomere shortening over 5 years; however, these associations are entirely explained by older age. Copyright (c) 2012 S. Karger AG, Basel C1 [Bansal, Nisha] Univ Calif San Francisco, Div Nephrol, Dept Med, San Francisco, CA 94143 USA. [Whooley, Mary A.; McCulloch, Charles E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Epel, Elissa] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Blackburn, Elizabeth; Lin, Jue] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. [Whooley, Mary A.; Regan, Mathilda] San Francisco VA Med Ctr, San Francisco, CA USA. [Ix, Joachim H.] Univ Calif San Diego, Nephrol Sect, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Family & Preventat Med, Div Preventat Med, San Diego, CA 92103 USA. RP Bansal, N (reprint author), Univ Calif San Francisco, Div Nephrol, Dept Med, 521 Parnassus Ave,Box 0532, San Francisco, CA 94143 USA. EM nisha.bansal@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [K23 DK088865, K24 DK92291]; National Heart Lung and Blood Institute [1R01HL096851]; American Heart Association Fellow-to-Faculty Transition Award; Sandra Daugherty Foundation; Department of Veterans Affairs; American Federation of Aging Research; Robert Wood Johnson Foundation; Nancy Kirwan Heart Research Fund; Ischemia Research and Education Foundation; NHLBI [R01 HL079235] FX This study was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK088865 to N.B. and K24 DK92291 to C.H.), National Heart Lung and Blood Institute (1R01HL096851) (J.H.I.), an American Heart Association Fellow-to-Faculty Transition Award (J.H.I.), and an award from the Sandra Daugherty Foundation (J.H.I.). The Heart and Soul Study was funded by the Department of Veterans Affairs, American Federation of Aging Research, Robert Wood Johnson Foundation, Nancy Kirwan Heart Research Fund, Ischemia Research and Education Foundation, and the NHLBI (R01 HL079235). NR 25 TC 10 Z9 11 U1 3 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2012 VL 36 IS 5 BP 405 EP 411 DI 10.1159/000343495 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 042SZ UT WOS:000311492600002 PM 23108000 ER PT J AU Bharadwaj, PR Verdile, G Barr, RK Gupta, V Steele, JW Lachenmayer, ML Yue, ZY Ehrlich, ME Petsko, G Ju, SL Ringe, D Sankovich, SE Caine, JM Macreadie, IG Gandy, S Martins, RN AF Bharadwaj, Prashant R. Verdile, Giuseppe Barr, Renae K. Gupta, Veer Steele, John W. Lachenmayer, M. Lenard Yue, Zhenyu Ehrlich, Michelle E. Petsko, Gregory Ju, Shulin Ringe, Dagmar Sankovich, Sonia E. Caine, Joanne M. Macreadie, Ian G. Gandy, Sam Martins, Ralph N. TI Latrepirdine (Dimebon (TM)) Enhances Autophagy and Reduces Intracellular GFP-A beta(42) Levels in Yeast SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; autophagy; latrepirdine; yeast model ID AMYLOID-BETA PEPTIDE; IMMUNODEFICIENCY-VIRUS TYPE-1; HUNTINGTONS-DISEASE MODELS; GREEN FLUORESCENT PROTEIN; SMALL-MOLECULE ENHANCERS; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; NONSPECIFIC AUTOPHAGY; NEURONAL CELLS; IN-VITRO AB Latrepirdine (Dimebon (TM)), an anti-histamine, has shown some benefits in trials of neurodegenerative diseases characterized by accumulation of aggregated or misfolded protein such as Alzheimer's disease (AD) and has been shown to promote the removal of alpha-synuclein protein aggregates in vivo. An important pathway for removal of aggregated or misfolded proteins is the autophagy-lysosomal pathway, which has been implicated in AD pathogenesis, and enhancing this pathway has been shown to have therapeutic potential in AD and other proteinopathies. Here we use a yeast model, Saccharomyces cerevisiae, to investigate whether latrepirdine can enhance autophagy and reduce levels of amyloid-beta (A beta)(42) aggregates. Latrepirdine was shown to upregulate yeast vacuolar (lysosomal) activity and promote transport of the autophagic marker (Atg8) to the vacuole. Using an in vitro green fluorescent protein (GFP) tagged A beta yeast expression system, we investigated whether latrepirdine-enhanced autophagy was associated with a reduction in levels of intracellular GFP-A beta(42). GFP-A beta(42) was localized into punctate patterns compared to the diffuse cytosolic pattern of GFP and the GFP-A beta(42) (19 : 34), which does not aggregate. In the autophagy deficient mutant (Atg8 Delta), GFP-A beta(42) showed a more diffuse cytosolic localization, reflecting the inability of this mutant to sequester GFP-A beta(42). Similar to rapamycin, we observed that latrepirdine significantly reduced GFP-A beta(42) in wild-type compared to the Atg8 Delta mutant. Further, latrepirdine treatment attenuated A beta(42)-induced toxicity in wild-type cells but not in the Atg8 Delta mutant. Together, our findings provide evidence for a novel mechanism of action for latrepirdine in inducing autophagy and reducing intracellular levels of GFP-A beta(42). C1 [Bharadwaj, Prashant R.; Verdile, Giuseppe; Barr, Renae K.; Gupta, Veer; Martins, Ralph N.] Edith Cowan Univ, Sch Med Sci, Ctr Excellence Alzheimers Dis Res & Care, Churchlands, WA 6018, Australia. [Verdile, Giuseppe; Martins, Ralph N.] Univ Western Australia, Sch Psychiat & Clin Neurosci, Crawley, WA, Australia. [Verdile, Giuseppe; Steele, John W.; Martins, Ralph N.] Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Nedlands, WA, Australia. [Bharadwaj, Prashant R.; Sankovich, Sonia E.; Caine, Joanne M.; Macreadie, Ian G.] CSIRO Preventat Hlth Flagship, Mat Sci & Engn, Melbourne, Vic, Australia. [Lachenmayer, M. Lenard; Yue, Zhenyu; Ehrlich, Michelle E.; Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Yue, Zhenyu] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. [Steele, John W.; Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY USA. [Steele, John W.; Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Ehrlich, Michelle E.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. [Ehrlich, Michelle E.] Mt Sinai Sch Med, Dept Paediat, New York, NY USA. [Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY USA. [Lachenmayer, M. Lenard] Univ Bonn, Dept Neurol, Bonn, Germany. [Petsko, Gregory; Ju, Shulin; Ringe, Dagmar] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biochem & Chem, Waltham, MA 02254 USA. [Macreadie, Ian G.] RMIT Univ, Sch Appl Sci, Bundoora, Vic, Australia. RP Martins, RN (reprint author), Hollywood Med Ctr, Suite 22,85 Monash Ave, Nedlands, WA 6009, Australia. EM r.martins@ecu.edu.au RI Macreadie, Ian/F-5997-2010 OI Macreadie, Ian/0000-0001-5335-7220 FU NHMRC [APP1009295]; McCusker Alzheimer's Research Foundation; Cure Alzheimer's Fund; NIH 12 [AG10491]; Fidelity Biosciences Research Initiative; Deutsche Forschungsgemeinschaft; NIGMS [T32M062754]; Medivation, Inc.; Amicus Pharmaceuticals FX The authors acknowledge the generous support of NH&MRC (APP1009295 to RM, GV, SG), McCusker Alzheimer's Research Foundation (RM, GV), Cure Alzheimer's Fund (SG) and NIH 12 (AG10491 to SG), and the Fidelity Biosciences Research Initiative (SJ, JL, DR, GAP), Deutsche Forschungsgemeinschaft (MLL). JWS is a trainee in the Integrated Pharmacological Sciences Training Program supported by grant T32M062754 from the NIGMS. MEE holds research grant support from Medivation, Inc. SG holds research grant support from Amicus Pharmaceuticals and is a consultant to the Pfizer-Janssen Alzheimer's Immunotherapy Alliance. NR 79 TC 25 Z9 25 U1 2 U2 9 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 32 IS 4 BP 949 EP 967 DI 10.3233/JAD-2012-120178 PG 19 WC Neurosciences SC Neurosciences & Neurology GA 039EP UT WOS:000311227200008 PM 22903131 ER PT J AU Eastman, KL Lutton, MC Raugi, GJ Sakamoto, MR McDowell, JA McFarland, LV Reiber, GE AF Eastman, Kristin L. Lutton, Marie C. Raugi, Gregory J. Sakamoto, Mandy R. McDowell, Jennifer A. McFarland, Lynne V. Reiber, Gayle E. TI A teledermatology care management protocol for tracking completion of teledermatology recommendations SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID OUTCOMES AB In July 2009 we implemented a 3-year store-and-forward teledermatology project to provide dermatology care to veterans living in rural and underserved areas of the US Pacific Northwest. We also developed a follow-up protocol and tracking system. Information about all completed teledermatology consultations was entered into a database, and major procedures and select medications were tracked. In the first 21 months, 8202 dermatology conditions in 5232 veterans were treated and 3370 major procedures carried out. Ninety-five percent of conditions were associated with no more than two teledermatology consultations, and no condition required more than ten consultations. In total, 1454 conditions were reviewed for clinical pathological correlation, and in 310 (21%) there was a subsequent clinical pathological correlation conference, resulting in a change in final diagnosis for 93 conditions. The follow-up was important in ensuring high quality patient care. C1 [Eastman, Kristin L.; Lutton, Marie C.; Sakamoto, Mandy R.; McDowell, Jennifer A.; McFarland, Lynne V.; Reiber, Gayle E.] VA Puget Sound Healthcare Syst, Hlth Serv R&D, Seattle, WA 98101 USA. [Eastman, Kristin L.; Raugi, Gregory J.] Univ Washington, Sch Med, Seattle, WA USA. [Eastman, Kristin L.; Reiber, Gayle E.] VA Puget Sound Healthcare Syst, Rehabil Res & Dev, Seattle, WA 98101 USA. [Raugi, Gregory J.] VA Puget Sound Healthcare Syst, Dermatol Sect, Hosp & Specialty Med Serv, Seattle, WA 98101 USA. [Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP McFarland, LV (reprint author), VA Puget Sound Healthcare Syst, Hlth Serv R&D, Metropolitan Pk W,1100 Olive Way,1400, Seattle, WA 98101 USA. EM lynne.mcfarland@va.gov FU US Department of Veterans Affairs; VISN 20 Office of Rural Health Services; VA Health Services Research and Development; [RCS 98-353] FX This work was funded by the US Department of Veterans Affairs, VISN 20 Office of Rural Health Services, VA Health Services Research and Development, and the Career Scientist Award (RCS 98-353) of Dr Gayle Reiber. The views expressed in this article do not necessarily reflect those of the Department of Veterans Affairs or the United States Government. NR 14 TC 4 Z9 4 U1 0 U2 2 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2012 VL 18 IS 7 BP 374 EP 378 DI 10.1258/jtt.2012.120417 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 043DE UT WOS:000311522300002 PM 23086980 ER PT J AU Lehavot, K Ben-Zeev, D Neville, RE AF Lehavot, Keren Ben-Zeev, Dror Neville, Robin E. TI Ethical Considerations and Social Media: A Case of Suicidal Postings on Facebook SO JOURNAL OF DUAL DIAGNOSIS LA English DT Article DE social media; Facebook; serious mental illness; suicide; ethics ID INFORMATION; SCHIZOPHRENIA; PSYCHOTHERAPY; DEPRESSION; MANAGEMENT; NETWORKING; STUDENTS; INTERNET; MYSPACE; SITE AB Social media sites such as Facebook are increasingly accessed and used by mental health professionals and clients alike, creating fertile ground for ethical challenges and complex decision making. We review a case report in which a clinician discovers suicidal ideation on Facebook (in the form of both photos and explicit statements) by a client with serious mental illness. Ethical issues relevant to this case and others involving social media are discussed, including the principles of beneficence and maleficence, issues of privacy and confidentiality, multiple relationships, clinical judgment, and informed consent. In using social media to obtain information about clients, we highlight potential benefits and harm, including harm to the therapeutic alliance, the difference and consequent impact of actual versus perceived privacy violations, and the necessity of obtaining the client's informed consent. (Journal of Dual Diagnosis, 8:341-346, 2012) C1 [Lehavot, Keren] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Lehavot, Keren] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Ben-Zeev, Dror] Dartmouth Psychiat Res Ctr, Geisel Sch Med Dartmouth, Lebanon, NH USA. [Ben-Zeev, Dror] Thresholds Dartmouth Res Ctr, Chicago, IL USA. [Neville, Robin E.] Thresholds Psychiat Rehabil Ctr, Chicago, IL USA. RP Lehavot, K (reprint author), 1660 S Columbian Way,116 POC, Seattle, WA 98108 USA. EM klehavot@uw.edu NR 34 TC 9 Z9 9 U1 4 U2 46 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1550-4263 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2012 VL 8 IS 4 SI SI BP 341 EP 346 DI 10.1080/15504263.2012.718928 PG 6 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA 035OJ UT WOS:000310956300011 ER PT J AU Oktay, JS Nedjat-Haiem, FR Davis, C Kern, KC AF Oktay, Julianne S. Nedjat-Haiem, Frances R. Davis, Cindy Kern, Kathleen C. TI Distress Screening: Experiences of Oncology Social Workers SO JOURNAL OF PSYCHOSOCIAL ONCOLOGY LA English DT Article DE cancer; oncology social work; distress screening; social workers; NCCN Distress Thermometer ID CANCER; THERMOMETER AB The purpose of this pilot study was to explore oncology social workers experiences with the introduction and use of distress screening tools with patients who are diagnosed with cancer. Focus groups were conducted with 15 oncology social workers, who were primarily employed in large hospitals or cancer centers. The results fell into three broad areas: initiating distress screening, adapting distress screening to the setting, and evaluating distress screening. Findings revealed that social workers face many decisions as they adapt distress screening to their settings, including when and how to measure distress, and how to refer patients to services. Social workers were concerned about being overwhelmed with referrals and sought to manage the screening to better identify those who are likely to benefit from services. This research suggests a need for further study, the development of practice guidelines, and training of oncology social workers. C1 [Oktay, Julianne S.] Univ Maryland, Sch Social Work, Baltimore, MD 21201 USA. [Nedjat-Haiem, Frances R.] HSR&D Ctr Excellence, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Davis, Cindy] Univ Tennessee, Coll Social Work, Nashville, TN USA. [Kern, Kathleen C.] Clifton T Perkins Hosp Ctr, Jessup, MD USA. RP Oktay, JS (reprint author), Univ Maryland, Sch Social Work, 525 W Redwood St, Baltimore, MD 21201 USA. EM joktay@ssw.umaryland.edu NR 17 TC 4 Z9 4 U1 0 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0734-7332 J9 J PSYCHOSOC ONCOL JI J. Psychosoc. Oncol. PY 2012 VL 30 IS 6 SI SI BP 652 EP 666 DI 10.1080/07347332.2012.721490 PG 15 WC Psychology, Social SC Psychology GA 030TT UT WOS:000310593700004 PM 23101549 ER PT J AU Bikle, DD AF Bikle, Daniel D. TI Protective actions of vitamin D in UVB induced skin cancer SO PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES LA English DT Review ID SQUAMOUS-CELL CARCINOMA; HUMAN EPIDERMAL-KERATINOCYTES; TRANSCRIPTION-COUPLED REPAIR; CALCIUM-SENSING RECEPTOR; BASAL-CELL; BETA-CATENIN; DNA-REPAIR; 1,25-DIHYDROXYVITAMIN D-3; ULTRAVIOLET-RADIATION; EXCISION-REPAIR AB Non-melanoma skin cancers (NMSC) are the most common type of cancer, occurring at a rate of over 1 million per year in the United States. Although their metastatic potential is generally low, they can and do metastasize, especially in the immune compromised host, and their surgical treatment is often quite disfiguring. Ultraviolet radiation (UVR) as occurs with sunlight exposure is generally regarded as causal for these malignancies, but UVR is also required for vitamin D synthesis in the skin. Based on our own data and that reported in the literature, we hypothesize that the vitamin D produced in the skin serves to suppress UVR epidermal tumor formation. In this review we will first discuss the evidence supporting the conclusion that the vitamin D receptor (VDR), with or without its ligand 1,25-dihydroxyvitamin D, limits the propensity for cancer formation following UVR. We will then explore three potential mechanisms for this protection: inhibition of proliferation and stimulation of differentiation, immune regulation, and stimulation of DNA damage repair (DDR). C1 [Bikle, Daniel D.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94112 USA. [Bikle, Daniel D.] San Francisco VA Med Ctr, Dept Dermatol, San Francisco, CA USA. [Bikle, Daniel D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Bikle, DD (reprint author), San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94112 USA. EM daniel.bikle@ucsf.edu FU American Institute for Cancer Research; VA Merit Review; Department of Defense [CA110338]; National Institute of Health [RO1 AR050023] FX This work was supported by grants from the American Institute for Cancer Research, the VA Merit Review, the Department of Defense (CA110338), and the National Institute of Health (RO1 AR050023). Much of the data referred to was generated in collaboration with Drs. Arnaud Teichert, Yuko Oda, Dennis Oh, and JoEllen Welsh. Teresa Tong and Victoria Lee provided administrative support. NR 132 TC 19 Z9 20 U1 1 U2 16 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1474-905X EI 1474-9092 J9 PHOTOCH PHOTOBIO SCI JI Photochem. Photobiol. Sci. PY 2012 VL 11 IS 12 BP 1808 EP 1816 DI 10.1039/c2pp25251a PG 9 WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical SC Biochemistry & Molecular Biology; Biophysics; Chemistry GA 039XP UT WOS:000311281900005 PM 22990497 ER PT J AU McDonald, LT LaRue, AC AF McDonald, Lindsay T. LaRue, Amanda C. TI Hematopoietic stem cell derived carcinoma-associated fibroblasts: a novel origin SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY LA English DT Review DE Hematopoietic stem cells; carcinoma associated fibroblasts; tumor associated fibroblasts; stem cell plasticity; tumor progression; metastasis ID PERIPHERAL-BLOOD FIBROCYTES; GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER-ASSOCIATED FIBROBLASTS; TUMOR-ASSOCIATED FIBROBLASTS; COLONY-STIMULATING FACTOR; PRIMARY MURINE STROMA; CIRCULATING FIBROCYTES; BREAST-CANCER; PROSTATE-CANCER AB Researchers have begun to appreciate the significant role that the microenvironment plays in tumorigenesis and are now shedding light on the role of the stroma in induction and progression of solid tumors. While the stroma of solid tumors is comprised of many cell types, including vascular and immune cells, one of the most prominent cell types in the tumor stroma is the fibroblast, called the carcinoma-associated fibroblast (CAF) or tumor-associated fibroblast (TAF). The interaction between CAFs and tumor cells is quite complex. CAFs have been implicated in tumor angiogenesis, immunosuppression, tumor cell proliferation and aggressiveness, genetic instability, and metastasis. However, their specific roles in each of these processes have only been partially elucidated. Determining the role of CAFs has been complicated by the fact that researchers have demonstrated heterogeneity in the stromal fibroblast population. This heterogeneity has brought about the concept of multiple origins for CAFs. While many origins of CAFs have been suggested, in our own laboratory we have identified a novel hematopoietic stem cell (HSC) origin of CAFs. Given the profound role of CAFs in tumor progression and prognosis, the CAF represents an exciting potential therapeutic target. The heterogeneity of the CAF population makes research directed at investigating the roles and origins of CAFs critical to development of such anti-tumor therapies. C1 [McDonald, Lindsay T.; LaRue, Amanda C.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29403 USA. [McDonald, Lindsay T.; LaRue, Amanda C.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [McDonald, Lindsay T.; LaRue, Amanda C.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. RP LaRue, AC (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Res Serv, 109 Bee St, Charleston, SC 29403 USA. EM laruerc@musc.edu FU Flow Cytometry and Cell Sorting Shared Resource; Cancer Center [P30 CA138313]; NIH/NCI [R01 CA148772]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs; Hollings Cancer Center [P30 CA138313] FX The research presented in this article was supported in part by the Flow Cytometry and Cell Sorting Shared Resource, funded by a Cancer Center Support Grant P30 CA138313, to the Hollings Cancer Center at the Medical University of South Carolina. The authors would like to specifically thank Dr. Haiqun Zeng for assistance in FACS sorting reviewed in this manuscript. We also thank Ms. Dayvia A. Laws for her assistance in manuscript preparation. The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government.; This work is supported in part by the NIH/NCI (R01 CA148772, ACL), the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs (Merit Award, ACL), and the Hollings Cancer Center (Translational Research Pilot Project, P30 CA138313, ACL). NR 77 TC 14 Z9 14 U1 0 U2 7 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 1936-2625 J9 INT J CLIN EXP PATHO JI Int. J. Clin. Exp. Pathol. PY 2012 VL 5 IS 9 BP 863 EP 873 PG 11 WC Oncology; Pathology SC Oncology; Pathology GA 033WN UT WOS:000310832200002 PM 23119103 ER PT J AU Chartier, M Carrico, AW Weiser, SD Kushel, MB Riley, ED AF Chartier, Maggie Carrico, Adam W. Weiser, Sheri D. Kushel, Margot B. Riley, Elise D. TI Specific psychiatric correlates of acute care utilization among unstably housed HIV-positive adults SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV/AIDS; homelessness; depression; stimulant abuse; healthcare utilization; acute care ID HEALTH-SERVICES UTILIZATION; SUBSTANCE-ABUSE TREATMENT; EMERGENCY-DEPARTMENT; CASE-MANAGEMENT; VULNERABLE POPULATIONS; HOMELESS PERSONS; RANDOMIZED-TRIAL; BEHAVIORAL-MODEL; MENTAL-HEALTH; HIV/AIDS AB The role of specific psychiatric diagnoses in emergency department use and/or inpatient hospitalizations (acute care) has not been extensively examined among HIV-infected, unstably housed persons. A community-recruited sample of 284 HIV-infected, unstably housed adults completed the Diagnostic Interview Schedule for DSM-IV. One-third of participants screened positive for major depression and stimulant use disorders. Sleeping on the street [adjusted odds ratio (AOR) = 4.21], major depression (AOR = 2.88) and stimulant use disorders (AOR = 4.45) were associated with greater odds of acute care use. Housing and effective treatment of depression and stimulant use disorders may decrease use of acute care services in this population. C1 [Chartier, Maggie] San Francisco VA Med Ctr, San Francisco, CA USA. [Chartier, Maggie] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Carrico, Adam W.; Weiser, Sheri D.] Univ Calif San Francisco, Sch Med, Ctr AIDS Prevent Studies, San Francisco, CA USA. [Carrico, Adam W.] Univ Calif San Francisco, Sch Nursing, Dept Community Hlth Syst, San Francisco, CA 94143 USA. [Weiser, Sheri D.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA USA. [Kushel, Margot B.] UCSF San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA USA. [Riley, Elise D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Chartier, M (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA. EM maggie.chartier@ucsf.edu FU NCRR NIH HHS [UL1 RR024131]; NIDA NIH HHS [DA15605, R01 DA015605] NR 39 TC 4 Z9 4 U1 1 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2012 VL 24 IS 12 BP 1514 EP 1518 DI 10.1080/09540121.2012.672720 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 029HA UT WOS:000310484200007 PM 22533713 ER PT J AU Choi, SY Fogelgren, B Zuo, XF Huang, LW McKenna, S Lingappa, VR Lipschutz, JH AF Choi, Soo Young Fogelgren, Ben Zuo, Xiaofeng Huang, Liwei McKenna, Sarah Lingappa, Vishwanath R. Lipschutz, Joshua H. TI Exocyst Sec10 Is Involved in Basolateral Protein Translation and Translocation in the Endoplasmic Reticulum SO NEPHRON EXPERIMENTAL NEPHROLOGY LA English DT Article DE Exocyst; Polarity; Translation; Endoplasmic reticulum ID SECRETORY PROTEINS; PRIMARY CILIOGENESIS; PLASMA-MEMBRANE; SEC6/8 COMPLEX; BETA-SUBUNIT; MDCK CELLS; CYSTOGENESIS; COMPONENTS; INTERACTS; DELIVERY AB Background: Protein translation and translocation at the rough endoplasmic reticulum (RER) are the first steps in the secretory pathway. The translocon through which newly made proteins are translocated into or across the RER membrane consists of three main subunits: Sec61 alpha, -beta, and -gamma. Sec61 beta facilitates translocation, and we and others have shown that the highly conserved eight-protein exocyst complex interacts with Sec61 beta. We have also shown that the exocyst is involved in basolateral, not apical, protein synthesis and delivery. Recently, however, exocyst involvement in apical protein delivery has been reported. Furthermore, we have shown that the exocyst is necessary for formation of primary cilia, organelles found on the apical surface. Methods: GST pulldown was performed on lysate of renal tubule cells to investigate biochemical interactions. Cell-free assays consisting of cell-free extracts from rabbit reticulocytes, pancreatic endoplasmic reticulum (ER) microsomal membranes, transcripts of cDNA from apical and basolateral proteins, ATP/GTP, amino acids, and S-35-methionine for protein detection were used to investigate the role of the exocyst in synthesis of polarized proteins. P-32-orthophosphate and immunoprecipitation with antibody against Sec61 beta was used to investigate Sec61 beta phosphorylation in exocyst Sec10-overexpressing cells. Results: Sec10 biochemically interacts with Sec61 beta using GST pulldown. Using cell-free assays, there is enhanced exocyst recruitment to endoplasmic reticulum membranes following exocyst depletion and basolateral G protein of vesicular stomatitis virus protein translation, compared to apical hemagglutinin of influenza virus protein translation. Finally, Sec10 overexpression increases Sec61 beta phosphorylation. Conclusion: These data confirm that the exocyst is preferentially involved in basolateral protein translation and translocation, and may well act through the phosphorylation of Sec61 beta. Copyright (C) 2012 S. Karger AG, Basel C1 [Lipschutz, Joshua H.] Univ Penn, Renal Electrolyte & Hypertens Div, Dept Med, Philadelphia, PA 19104 USA. [Lipschutz, Joshua H.] Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. [Lingappa, Vishwanath R.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA. [Lingappa, Vishwanath R.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Lipschutz, JH (reprint author), Univ Penn, Renal Electrolyte & Hypertens Div, Dept Med, Clin Res Bldg,Room 538A,415 Curie Blvd, Philadelphia, PA 19104 USA. EM jhlipsch@mail.med.upenn.edu FU VA (Merit Award); NIH [DK069909, DK047757, K01DK087852, K08DK093625]; University of Pennsylvania Research Foundation; Satellite Healthcare FX This work was supported in part by grants from the VA (Merit Award to J.H.L.), NIH (DK069909 and DK047757 to J.H.L.; K01DK087852 to B. F., K08DK093625 to L. H.), University of Pennsylvania Research Foundation (to J.H.L.), and Satellite Healthcare (Norman S. Coplon Extramural Research Grant to J.H.L.). NR 25 TC 2 Z9 2 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2129 J9 NEPHRON EXP NEPHROL JI Nephron Exp. Nephrol PY 2012 VL 120 IS 4 BP E133 EP E139 DI 10.1159/000342366 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 030NE UT WOS:000310576600003 PM 23037926 ER PT J AU Mills, KA Scherzer, R Starr, PA Ostrem, JL AF Mills, Kelly A. Scherzer, Rebecca Starr, Philip A. Ostrem, Jill L. TI Weight Change after Globus Pallidus Internus or Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease and Dystonia SO STEREOTACTIC AND FUNCTIONAL NEUROSURGERY LA English DT Article DE Deep brain stimulation; Parkinson's disease; Dystonia; Subthalamic nucleus; Globus pallidus internus; Weight change ID BODY-WEIGHT; ESSENTIAL TREMOR; THALAMIC-STIMULATION; GAIN; SURGERY; PALLIDOTOMY; EFFICACY; SAFETY AB Background: Weight gain has been described in Parkinson's disease (PD) patients after subthalamic nucleus (STN) deep brain stimulation (DBS). Objectives: We examined change in weight following DBS in both PD and dystonia patients to further investigate the role of disease and brain target (STN or globus pallidus internus, GPi) specificity. Methods: Data was retrospectively collected on 61 PD DBS patients (STN n = 31 or GPi n = 30) and on 36 dystonia DBS patients (STN n = 9 and GPi n = 27) before and after surgery. Annual change in body mass index (BMI) was evaluated with nonparametric tests between groups and multiple quantile regression. Results: PD patients treated with STN DBS had a small increase in median BMI while those with GPi had a small decrease in BMI. Dystonia patients treated with STN DBS had a greater increase in BMI per year compared to those treated with GPi DBS. Multivariable regression analyses for each disease showed little difference between targets in weight gain in those with PD, but STN target was strongly associated with weight gain in dystonia patients (STN vs. GPi, +7.99 kg, p = 0.012). Conclusions: Our results support previous reports of weight gain after DBS in PD. This is the first report to suggest a target-specific increase in weight following STN DBS in dystonia patients. Copyright (C) 2012 S. Karger AG, Basel C1 [Mills, Kelly A.; Ostrem, Jill L.] Univ Calif San Francisco, Surg Movement Disorders Ctr, Dept Neurol, San Francisco, CA 94115 USA. [Starr, Philip A.] Univ Calif San Francisco, Surg Movement Disorders Ctr, Dept Neurosurg, San Francisco, CA 94115 USA. [Scherzer, Rebecca] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA. [Mills, Kelly A.; Scherzer, Rebecca; Starr, Philip A.; Ostrem, Jill L.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Ostrem, JL (reprint author), Univ Calif San Francisco, Surg Movement Disorders Ctr, Dept Neurol, 1635 Divisadero St,Suite 502, San Francisco, CA 94115 USA. EM jill.ostrem@ucsf.edu FU University of California San Francisco Clinical and Translational Science Institute Resident Research Funding Award; Clinical and Translational Science Institute Strategic Opportunities Support Novel Clinical/Translational Methods Catalyst Awards; NIH/NCRR UCSF-CTSI [UL1RR024131]; MRI Interventions Inc.; St. Jude Medical; Medtronic Inc. FX Kelly Mills is funded by the University of California San Francisco Clinical and Translational Science Institute Resident Research Funding Award, he is also Co-PI on a grant from the Clinical and Translational Science Institute Strategic Opportunities Support Novel Clinical/Translational Methods Catalyst Awards, NIH/NCRR UCSF-CTSI grant No. UL1RR024131. Philip Starr is a consultant for Medtronic Inc. and Boston Scientific Inc. and holds a research grant from MRI Interventions Inc. (formerly called Surgivision). Jill Ostrem is a consultant for Ipsen Inc., Merz Inc., Boston Scientific Inc. and is on an advisory board for Ipsen Inc. and Merz Inc. She has received honoraria from Medtronic Inc. and Allergan Inc. and currently receives research grant funding from St. Jude Medical and MRI Interventions Inc. (formally called SurgiVision). She is also mentor for a fellowship grant from Medtronic Inc. NR 31 TC 15 Z9 15 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1011-6125 J9 STEREOT FUNCT NEUROS JI Stereotact. Funct. Neurosurg. PY 2012 VL 90 IS 6 BP 386 EP 393 DI 10.1159/000340071 PG 8 WC Neurosciences; Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA 027MU UT WOS:000310357500007 PM 22922491 ER PT J AU Tranah, GJ Nalls, MA Katzman, SM Yokoyama, JS Lam, ET Zhao, YQ Mooney, S Thomas, F Newman, AB Liu, YM Cummings, SR Harris, TB Yaffe, K AF Tranah, Gregory J. Nalls, Michael A. Katzman, Shana M. Yokoyama, Jennifer S. Lam, Ernest T. Zhao, Yiqiang Mooney, Sean Thomas, Fridtjof Newman, Anne B. Liu, Yongmei Cummings, Steven R. Harris, Tamara B. Yaffe, Kristine CA Hlth Aging & Body Composition Stud TI Mitochondrial DNA Sequence Variation Associated with Dementia and Cognitive Function in the Elderly SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Cognitive function; dementia; DNA sequencing; mitochondria; mtDNA; oxidative phosphorylation ID GENOME-WIDE ASSOCIATION; ALPHA-KETOGLUTARATE DEHYDROGENASE; CYTOCHROME-C-OXIDASE; HUMAN SUBSTANTIA-NIGRA; ACTIVITY ENERGY-EXPENDITURE; AMYLOID PRECURSOR PROTEIN; AMINO-ACID SUBSTITUTIONS; INDUCED OXIDATIVE STRESS; HUMAN SKELETAL-MUSCLE; ALZHEIMERS-DISEASE AB Mitochondrial dysfunction is a prominent hallmark of Alzheimer's disease (AD). Mitochondrial DNA (mtDNA) damage may be a major cause of abnormal reactive oxidative species production in AD or increased neuronal susceptibility to oxidative injury during aging. The purpose of this study was to assess the influence of mtDNA sequence variation on clinically significant cognitive impairment and dementia risk in the population-based Health, Aging, and Body Composition (Health ABC) Study. We first investigated the role of common mtDNA haplogroups and individual variants on dementia risk and 8-year change on the Modified Mini-Mental State Examination (3MS) and Digit Symbol Substitution Test (DSST) among 1,631 participants of European genetic ancestry. Participants were free of dementia at baseline and incidence was determined in 273 cases from hospital and medication records over 10-12 follow-up years. Participants from haplogroup T had a statistically significant increased risk of developing dementia (OR = 1.86, 95% CI = 1.23, 2.82, p = 0.0008) and haplogroup J participants experienced a statistically significant 8-year decline in 3MS (beta = -0.14, 95% CI = -0.27, -0.03, p = 0.0006), both compared with common haplogroup H. The m. 15244A>G, p.G166G, CytB variant was associated with a significant decline in DSST score (beta = -0.58, 95% CI -0.89, -0.28, p = 0.00019) and the m.14178T>C, p.I166V, ND6 variant was associated with a significant decline in 3MS score (beta = -0.87, 95% CI-1.31, -3.86, p = 0.00012). Finally, we sequenced the complete similar to 16.5 kb mtDNA from 135 Health ABC participants and identified several highly conserved and potentially functional nonsynonymous variants unique to 22 dementia cases and aggregate sequence variation across the hypervariable 2-3 regions that influences 3MS and DSST scores. C1 [Tranah, Gregory J.] UCSF, Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, San Francisco, CA 94107 USA. [Nalls, Michael A.] NIA, Neurogenet Lab, Intramural Res Program, Bethesda, MD 20892 USA. [Katzman, Shana M.; Zhao, Yiqiang; Mooney, Sean] Buck Inst Res Aging, Novato, CA USA. [Yokoyama, Jennifer S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Lam, Ernest T.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA. [Thomas, Fridtjof] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. [Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Liu, Yongmei] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA. [Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Tranah, GJ (reprint author), UCSF, Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA. EM gtranah@sfcc-cpmc.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU National Institute on Aging (NIA) [N01 AG62101, N01 AG62103, N01 AG62106, R01 AG028050, R03 AG032498, 1R01 AG032098-01A1]; NINR [R01 NR012459, Z01 AG000951]; NIH [T32 GM007175]; NLM [LM009722]; Intramural Research Program of the NIH, NIA; National Institutes of Health [HHSN268200782096C] FX This research was supported by National Institute on Aging (NIA) Contracts N01 AG62101; N01 AG62103; N01 AG62106; NIA grants R01 AG028050 and R03 AG032498, NINR grant R01 NR012459; and Z01 AG000951. E. T. L. was supported in part by NIH Training Grant T32 GM007175 and Y.Z. by NLM grant LM009722. This research was supported in part by the Intramural Research Program of the NIH, NIA. The genome-wide association study was funded by NIA grant 1R01 AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to Johns Hopkins University, contract number HHSN268200782096C. Data analyses for this study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, Maryland (http://biowulf.nih.gov). NR 170 TC 9 Z9 9 U1 3 U2 15 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 32 IS 2 BP 357 EP 372 DI 10.3233/JAD-2012-120466 PG 16 WC Neurosciences SC Neurosciences & Neurology GA 022QY UT WOS:000309977800010 PM 22785396 ER PT J AU Farr, SA Price, TO Banks, WA Ercal, N Morley, JE AF Farr, Susan A. Price, Tulin O. Banks, William A. Ercal, Nuran Morley, John E. TI Effect of Alpha-Lipoic Acid on Memory, Oxidation, and Lifespan in SAMP8 Mice SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alpha-lipoic acid; antioxidants; learning and memory; lifespan; SAMP8 mice ID SENESCENCE-ACCELERATED MOUSE; AGING RAT-HEART; ALZHEIMERS-DISEASE; BRAIN PROTEINS; C57BL/6 MICE; STRESS; DAMAGE; SUPPLEMENTATION; ANTIOXIDANTS; EXPRESSION AB Oxidative damage is associated with neurodegenerative disorders such as Alzheimer's disease (AD). The antioxidant alpha-lipoic acid has been found to improve memory in mouse models of AD. Here, we administered alpha-lipoic acid daily to SAMP8 mice starting at 11 months of age and continuing until death. We found that treatment with alpha-lipoic acid decreased survival from 34 weeks in those receiving vehicle to 20 weeks. A subset of 18 month old mice given alpha-lipoic acid for two weeks and then tested in an object-place recognition paradigm had improved memory. A second subset of 18 month old mice given alpha-lipoic acid for two weeks and tested in the Barnes maze had improved learning. After testing, the mice were sacrificed and indices of oxidative damage were measured in the brain tissue. The mice that received alpha-lipoic acid had significantly increased glutathione and decreased glutathione peroxidase and malondialdehyde indicating reversal of oxidative stress. These results indicate that alpha-lipoic acid improves memory and reverses indices of oxidative stress in extremely old SAMP8 mice, but decreases lifespan. These findings are similar to studies using other types of antioxidants. C1 [Farr, Susan A.] St Louis Univ, Sch Med, VA Med Ctr St Louis, Div Geriatr Med, St Louis, MO 63106 USA. [Farr, Susan A.] VA Med Ctr, Res & Dev Serv, St Louis, MO USA. [Price, Tulin O.; Morley, John E.] St Louis Univ, Sch Med, Div Endocrinol, St Louis, MO 63106 USA. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Ercal, Nuran] Missouri Univ Sci & Technol, Dept Chem, Rolla, MO USA. RP Farr, SA (reprint author), St Louis Univ, Sch Med, VA Med Ctr St Louis, Div Geriatr Med, 915 N Grand Blvd,151-JC, St Louis, MO 63106 USA. EM farrsa@slu.edu FU VA Medical Center, St. Louis, MO FX This work was supported by VA Medical Center, St. Louis, MO. NR 59 TC 20 Z9 21 U1 2 U2 12 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 32 IS 2 BP 447 EP 455 DI 10.3233/JAD-2012-120130 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 022QY UT WOS:000309977800017 PM 22785389 ER PT J AU Royall, DR Palmer, RF Vidoni, ED Honea, RA Burns, JM AF Royall, Donald R. Palmer, Raymond F. Vidoni, Eric D. Honea, Robyn A. Burns, Jeffrey M. TI The Default Mode Network and Related Right Hemisphere Structures may be the Key Substrates of Dementia SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Aging; cognition; dementia; g; functional status ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; CLINICAL DEMENTIA; CARDIORESPIRATORY FITNESS; HIPPOCAMPAL VOLUME; MISSING DATA; HUMAN BRAIN; MATTER LOSS; CONNECTIVITY; ATROPHY AB We have employed structural equation models to explicitly distinguish dementia-relevant variance in cognitive task performance (i.e., delta) from the variance that is unrelated to a dementing process (i.e., g'). Together g' and d comprise Spearman's "g". Although d represents only a minor fraction of the total variance in cognitive task performance, it is more strongly associated with dementia severity than is g'. In this analysis, we replicate delta in a new dataspace, the University of Kansas Brain Aging Project, and associate it specifically with regional grey matter atrophy by voxel-based morphometry of magnetic resonance imaging data. The latent variable d localizes to elements of the default mode network and related structures in the R hemisphere. C1 [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Royall, Donald R.; Palmer, Raymond F.; Vidoni, Eric D.; Honea, Robyn A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div, GRECC, San Antonio, TX USA. [Burns, Jeffrey M.] Univ Kansas, Med Ctr, KU Alzheimer & Memory Program, Dept Neurol, Kansas City, KS 66103 USA. RP Royall, DR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. EM royall@uthscsa.edu FU Julia and Van Buren Parr endowment for the study of Alzheimer's disease; National Institutes of Aging [R03AG026374, R21AG029615]; National Institute on Neurological Disorders and Stroke [K23NS058252]; University of Kansas General Clinical Research Center [M01RR023940]; University of Kansas Alzheimer's Disease Center [P30AG035982]; Heartland Institute for Clinical & Translational Research, University of Kansas Medical Center's CTSA [KL2 TR000119, UL1 TR00001]; [R01AG034614]; [R01AG033673]; [K01AG035042] FX This study was made possible by the Julia and Van Buren Parr endowment for the study of Alzheimer's disease. The sponsor had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Brain Aging Project is supported by grants R03AG026374 and R21AG029615 from the National Institutes of Aging, grant K23NS058252 from the National Institute on Neurological Disorders and Stroke. The University of Kansas General Clinical Research Center (M01RR023940) provided essential space, expertise, and nursing support. Dr. Burns and Vidoni are supported by the University of Kansas Alzheimer's Disease Center (P30AG035982). Dr. Burns is also supported by R01AG034614 and R01AG033673. Dr. Vidoni is also supported by the Heartland Institute for Clinical & Translational Research, University of Kansas Medical Center's CTSA, KL2 TR000119 & UL1 TR00001. Dr. Honea is supported by K01AG035042. NR 65 TC 26 Z9 26 U1 1 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 32 IS 2 BP 467 EP 478 DI 10.3233/JAD-2012-120424 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 022QY UT WOS:000309977800019 PM 22842866 ER PT J AU Wortzel, HS Blatchford, P Conner, L Adler, LE Binswanger, IA AF Wortzel, Hal S. Blatchford, Patrick Conner, Latoya Adler, Lawrence E. Binswanger, Ingrid A. TI Risk of Death for Veterans on Release From Prison SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID CORONARY-ARTERY-DISEASE; DEPRESSION; SUICIDE; ANXIETY; MEN; MORTALITY; COHORT; MODEL AB We sought to determine, among veterans released from Washington state prisons from 1999 through 2003, the risk of death from all causes, whether those veterans have faced a higher risk of death than have nonveterans, and whether having VA benefits decreased the risk of death. We linked data from a retrospective cohort study to data from the Veterans Benefit Administration. Mortality rates were compared between veteran and nonveteran former inmates. The crude rate of veteran mortality was 1,195 per 100,000 person-years, significantly higher than that of nonveterans (p<.001), but adjustment for demographic factors demonstrated no significant increased risk. VA benefits were associated with a reduced risk for all-cause deaths (hazard ratio, .376; 95% confidence interval, 0.18-0.79). Veterans share the heightened risk of death after release from prison faced by all released inmates and should be included in efforts to reduce the risks associated with transitioning from prison to the community. VA benefits appear to offer a protective effect, particularly against medical deaths. C1 [Wortzel, Hal S.] Denver Vet Affairs Med Ctr, Vet Integrated Serv Network VISN Mental Illness R, Educ & Clin Ctr MIRECC, Denver, CO USA. [Wortzel, Hal S.] Univ Colorado, Sch Med, Dept Psychiat, Div Forens Psychiat, Aurora, CO USA. [Wortzel, Hal S.] Univ Colorado, Neurobehav Disorders Program, Aurora, CO USA. [Blatchford, Patrick] Colorado Sch Publ Hlth, Aurora, CO USA. [Wortzel, Hal S.; Conner, Latoya; Adler, Lawrence E.] Denver Vet Hosp, VISN MIRECC 19, Denver, CO 80209 USA. [Binswanger, Ingrid A.] Univ Colorado, Dept Med, Div Gen Internal Med, Aurora, CO USA. RP Wortzel, HS (reprint author), Denver Vet Hosp, VISN MIRECC 19, 1055 Clermont St, Denver, CO 80209 USA. EM hal.wortzel@ucdenver.edu FU AHRQ HHS [K12 HS019464, K12HS019464]; NIDA NIH HHS [1R21DA031041-01, R21 DA031041] NR 22 TC 6 Z9 6 U1 1 U2 8 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2012 VL 40 IS 3 BP 348 EP 354 PG 7 WC Law; Psychiatry SC Government & Law; Psychiatry GA 021QE UT WOS:000309899600006 PM 22960917 ER PT S AU Kowalski, RM Giumetti, GW Schroeder, AN Reese, HH AF Kowalski, Robin M. Giumetti, Gary W. Schroeder, Amber N. Reese, Heather H. BE Wankel, LA Wankel, C TI CYBER BULLYING AMONG COLLEGE STUDENTS: EVIDENCE FROM MULTIPLE DOMAINS OF COLLEGE LIFE SO MISBEHAVIOR ONLINE IN HIGHER EDUCATION SE Cutting-edge Technologies in Higher Education LA English DT Article; Book Chapter ID E-MAIL; COMMUNICATION; VICTIMIZATION; PERSONALITY; PERFORMANCE; EXPERIENCES; SCHOOLS; YOUTH AB Although media and research accounts of cyber bullying suggest this misbehavior is localized primarily among middle school students, and that its frequency decreases with age, this chapter presents empirical data showing that cyber bullying occurs with considerable frequency among college students across multiple domains of life, specifically school and work. In Study 1, 28 male and 82 female undergraduate students completed a survey examining their online activities as well as their experiences with cyber bullying. Over 30% of the participants indicated that their first experience with cyber bullying was in college. No gender differences were observed with regard to victimization or perpetration, except with online gaming where males reported a higher rate of victimization than females. With regard to personality differences among victims and perpetrators, victims were lower in agreeableness than non-victims. Study 2 examined the prevalence of cyber bullying among 107 college students at work, as well as the negative outcomes linked to the experience of workplace cyber bullying. Nearly a third of the college student sample reported having been the target of cyber bullying within the past six months. Individuals in jobs in which the Internet is essential and racial minorities reported higher rates of cyber bullying at work. Additionally, cyber bullying was positively linked to several negative emotions, as well as burnout and job search effort. These findings have important implications not only for potential negative outcomes that college students may be facing at school and at work but also for organizational justice issues, as differential treatment at work can lead to lawsuits and other negative work outcomes. C1 [Kowalski, Robin M.; Schroeder, Amber N.] Clemson Univ, Ind Org Psychol Program, Clemson, SC 29634 USA. [Reese, Heather H.] US Dept Vet Affairs, Columbia, SC USA. [Giumetti, Gary W.] Georgia Coll, Milledgeville, GA 31061 USA. RP Kowalski, RM (reprint author), Clemson Univ, Ind Org Psychol Program, Clemson, SC 29634 USA. NR 64 TC 15 Z9 15 U1 3 U2 7 PU EMERALD GROUP PUBLISHING LTD PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY, W YORKSHIRE BD16 1WA, ENGLAND SN 2044-9968 BN 978-1-78052-456-6 J9 CUT TECHNOL HIGH ED PY 2012 VL 5 BP 293 EP 321 DI 10.1108/S2044-9968(2012)0000005016 PG 29 WC Education & Educational Research SC Education & Educational Research GA BAJ29 UT WOS:000304329500014 ER PT J AU Royall, DR Palmer, RF AF Royall, Donald R. Palmer, Raymond F. TI Estimating the Temporal Evolution of Alzheimer's Disease Pathology with Autopsy Data SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; longitudinal; neuropathology; old age ID NEUROFIBRILLARY TANGLES; COGNITIVE IMPAIRMENT; SENILE PLAQUES; MISSING DATA; DEMENTIA; MODERATORS; MEDIATORS; SEVERITY; INDEXES; WORK AB The temporal growth of Alzheimer's disease (AD) neuropathology cannot be easily determined because autopsy data are available only after death. We combined autopsy data from 471 participants in the Honolulu-Asia Aging Study (HAAS) into latent factor measures of neurofibrillary tangle and neuritic plaque counts. These were associated with intercept and slope parameters from a latent growth curve (LGC) model of 9-year change in cognitive test performance in 3244 autopsied and non-autopsied HAAS participants. Change in cognition fully mediated the association between baseline cognitive performance and AD lesions counts. The mediation effect of cognitive change on both AD lesion models effectively dates them within the period of cognitive surveillance. Additional analyses could lead to an improved understanding of lesion propagation in AD. C1 [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78284 USA. [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78284 USA. [Royall, Donald R.; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78284 USA. [Royall, Donald R.] S Texas Vet Hlth Syst, Audie L Murphy Div GRECC, San Antonio, TX USA. RP Royall, DR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM royall@uthscsa.edu FU Julia and Van Buren Parr professorship in Aging and Geriatric Psychiatry; NINDS R21 [NS048123-01, N01-AG-4-2149]; National Institute on Aging [U01 AG019349] FX HAAS data were provided by Lon R. White (LRW), the HAAS Principal Investigator but HAAS staff were not further involved in the analysis or interpretation of the data. DRR and RFP were funded by the Julia and Van Buren Parr professorship in Aging and Geriatric Psychiatry. The authors accept full responsibility for all analyses, results and interpretations.; This work has been supported by NINDS R21 Grant NS048123-01, contract N01-AG-4-2149, and grant U01 AG019349 from the National Institute on Aging. Portions of this work were presented at the 2011 AAICAD, Paris, France. NR 29 TC 3 Z9 3 U1 1 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 32 IS 1 BP 23 EP 32 DI 10.3233/JAD-2012-120430 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 016LA UT WOS:000309518600004 PM 22695618 ER PT J AU Wharton, W Stein, JH Korcarz, C Sachs, J Olson, SR Zetterberg, H Dowling, M Ye, SY Gleason, CE Underbakke, G Jacobson, LE Johnson, SC Sager, MA Asthana, S Carlsson, CM AF Wharton, Whitney Stein, James H. Korcarz, Claudia Sachs, Jane Olson, Sandra R. Zetterberg, Henrik Dowling, Maritza Ye, Shuyun Gleason, Carey E. Underbakke, Gail Jacobson, Laura E. Johnson, Sterling C. Sager, Mark A. Asthana, Sanjay Carlsson, Cynthia M. TI The Effects of Ramipril in Individuals at Risk for Alzheimer's Disease: Results of a Pilot Clinical Trial SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; angiotensin converting enzyme; antihypertensive; arterial function; blood pressure; clinical trial; cognition; hypertension; prevention; vascular risk ID ANGIOTENSIN-CONVERTING ENZYME; CEREBROSPINAL-FLUID; RECEPTOR BLOCKERS; COGNITIVE DECLINE; ACE-INHIBITORS; DEMENTIA; MEMORY; BRAIN; HYPERTENSION; PROGRESSION AB Research shows that certain antihypertensives taken during midlife confer Alzheimer's disease (AD) related benefits in later life. We conducted a clinical trial to evaluate the extent to which the angiotensin converting enzyme inhibitor (ACE-I), ramipril, affects AD biomarkers including cerebrospinal fluid (CSF) amyloid-beta (A beta) levels and ACE activity, arterial function, and cognition in participants with a parental history of AD. This four month randomized, double-blind, placebo-controlled, pilot clinical trial evaluated the effects of ramipril, a blood-brain-barrier crossing ACE-I, in cognitively healthy individuals with mild, or Stage I hypertension. Fourteen participants were stratified by gender and apolipoprotein E epsilon 4 (APOE epsilon 4) status and randomized to receive 5mg of ramipril or matching placebo daily. Participants were assessed at baseline and month 4 on measures of CSF A beta(1-42) and ACE activity, arterial function, and cognition. Participants were middle-aged (mean 54 y) and highly educated (mean 15.4 y), and included 50% men and 50% APOE epsilon 4 carriers. While results did not show a treatment effect on CSF A beta(1-42) (p = 0.836), data revealed that ramipril can inhibit CSF ACE activity (p = 0.009) and improve blood pressure, however, there were no differences between groups in arterial function or cognition. In this study, ramipril therapy inhibited CSF ACE activity and improved blood pressure, but did not influence CSF A beta(1-42). While larger trials are needed to confirm our CSF A beta results, it is possible that prior research reporting benefits of ACE-I during midlife may be attributed to alternative mechanisms including improvements in cerebral blood flow or the prevention of angiotensin II-mediated inhibition of acetylcholine. C1 [Wharton, Whitney; Stein, James H.; Korcarz, Claudia; Olson, Sandra R.; Dowling, Maritza; Gleason, Carey E.; Jacobson, Laura E.; Johnson, Sterling C.; Sager, Mark A.; Asthana, Sanjay; Carlsson, Cynthia M.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA. [Wharton, Whitney; Olson, Sandra R.; Dowling, Maritza; Ye, Shuyun; Gleason, Carey E.; Jacobson, Laura E.; Johnson, Sterling C.; Sager, Mark A.; Asthana, Sanjay; Carlsson, Cynthia M.] Univ Wisconsin, Alzheimers Dis Res Ctr, Madison, WI 53705 USA. [Wharton, Whitney; Olson, Sandra R.; Gleason, Carey E.; Jacobson, Laura E.; Johnson, Sterling C.; Asthana, Sanjay; Carlsson, Cynthia M.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Stein, James H.; Korcarz, Claudia; Sachs, Jane] Atherosclerosis Imaging Res Program, Div Cardiovasc Med, Madison, WI USA. Univ Wisconsin, Populat Hlth Inst, Madison, WI 53705 USA. [Zetterberg, Henrik] Univ Gothenburg, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Sahlgrenska Acad, Molndal, Sweden. [Dowling, Maritza; Ye, Shuyun] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53705 USA. [Underbakke, Gail] Univ Wisconsin, Prevent Cardiol Program, Madison, WI 53705 USA. [Sager, Mark A.; Asthana, Sanjay] Wisconsin Alzheimers Inst, Madison, WI USA. RP Wharton, W (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem VA Hosp, 2500 Overlook Terrace,GRECC D4211, Madison, WI 53705 USA. EM wlwharto@medicine.wisc.edu FU State of Wisconsin; Wisconsin Alzheimer's Institute (WAI) [R01AG027161]; National Center for Research Resources of the NIH [1UL1RR025011] FX The study was supported by a grants from the State of Wisconsin and the Wisconsin Alzheimer's Institute (WAI) R01AG027161 and from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources of the NIH 1UL1RR025011. We utilized the resources of the School of Medicine and Public Health at the University of Wisconsin (UW), the Wisconsin Alzheimer's Disease Research Center (UW ADRC) NIH P50 AG033514, UW Department of Medicine Division of Geriatrics and Gerontology, the Geriatric Research, Education and Clinical Center (GRECC) of the William S. Middleton Memorial Veterans Hospital, Madison WI and the UW Atherosclerosis Imaging Research Program. NR 53 TC 21 Z9 21 U1 0 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 32 IS 1 BP 147 EP 156 DI 10.3233/JAD-2012-120763 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 016LA UT WOS:000309518600014 PM 22776970 ER PT J AU Hong, O Chin, DL Kerr, MJ Ronis, DL AF Hong, OiSaeng Chin, Dal Lae Kerr, Madeleine J. Ronis, David L. TI Stages of Change in Hearing-protection Behavior, Cognition, and Hearing Status SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article DE stages of change; hearing protection; cognitive perceptions; construction workers; hearing ability ID CONSTRUCTION WORKERS; NOISE EXPOSURE; INTERVENTION; PREVENTION; MOTIVATION; READINESS; STUDENTS; SMOKING; MODEL AB Objective: To determine stages of hearing-protection behavioral change and their relationships with cognitions and hearing status. Method: A cross-sectional study of 769 construction workers who completed a survey and audiometric tests. Results: The majority of participants (over 64%) were in the preparation stage. Participants in the action/maintenance stage demonstrated significantly greater benefits, self-efficacy, and interpersonal influence; fewer barriers; and better hearing. This is the first study that shows significantly better health outcome, hearing ability, as the stage progresses. Conclusion: Study demonstrates preliminary validity of the stages of change with hearing-protection behavior. Future hearing-protection intervention should integrate the stages of change to increase effectiveness. C1 [Hong, OiSaeng; Chin, Dal Lae] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Kerr, Madeleine J.] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA. [Ronis, David L.] Univ Michigan, Sch Nursing, US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI 48109 USA. RP Hong, O (reprint author), Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. EM oisaeng.hong@nursing.ucsf.edu FU NIOSH CDC HHS [5R01 OH04034-01A1] NR 41 TC 0 Z9 0 U1 0 U2 5 PU PNG PUBLICATIONS PI OAK RIDGE PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA SN 1945-7359 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PY 2012 VL 36 IS 6 BP 811 EP 822 DI 10.5993/AJHB.36.6.8 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 014EN UT WOS:000309358000008 PM 23026039 ER PT J AU Yu, MK Lyles, CR Bent-Shaw, LA Young, BA AF Yu, Margaret K. Lyles, Courtney Rees Bent-Shaw, Luis A. Young, Bessie A. CA Pathways Authors TI Risk Factor, Age and Sex Differences in Chronic Kidney Disease Prevalence in a Diabetic Cohort: The Pathways Study SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Sex difference; Gender difference; Diabetic kidney disease ID GLOMERULAR-FILTRATION-RATE; RENAL-DISEASE; PROGRESSION; GENDER; DISPARITIES; MICROALBUMINURIA; METAANALYSIS; MELLITUS; THERAPY; TYPE-1 AB Background/Aims: Women with diabetes experience a disproportionately greater burden of diabetic kidney disease (DKD) risk factors compared to men; however, sex-specific differences in DKD are not well defined. The effect of age on sex differences in DKD is unknown. Methods: We performed a cross-sectional analysis of the prevalence of DKD (eGFR <60 ml/min/1.73 m(2) or microalbuminuria), advanced DKD (eGFR <30 ml/min/1.73 m(2)), and common DKD risk factors in the Pathways Study (n = 4,839), a prospective cohort study of diabetic patients from a managed care setting. Subjects were stratified by age <60 and >= 60 years to examine for differences by age. Logistic regression models examined the association between sex and prevalence of DKD and risk factors. Results: Women of all ages had 28% decreased odds of DKD (OR 0.72,95% CI 0.62-0.83); however, they had a greater prevalence of advanced DKD (OR 1.67, 95% CI 1.05-2.64), dyslipidemia (OR 1.42,95% CI 1.16-1.74), and obesity (OR 1.87, 95% CI 1.60-2.20) compared to men. Women had similar odds of hypertension and poor glycemic control as men. Women >= 60 years had increased odds of advanced DKD, hypertension, dyslipidemia, and obesity compared to similarly aged men. Women <60 years had increased odds of obesity compared to their male counterparts. Conclusion: Women with diabetes had an increased prevalence of advanced DKD and common DKD risk factors compared to men and these disparities were most prominent amongst the elderly. Copyright (c) 2012 S. Karger AG, Basel C1 [Yu, Margaret K.; Bent-Shaw, Luis A.; Young, Bessie A.] Univ Washington, Div Nephrol, Seattle, WA 98108 USA. [Yu, Margaret K.; Young, Bessie A.] Univ Washington, Dept Epidemiol, Seattle, WA 98108 USA. [Lyles, Courtney Rees; Young, Bessie A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98108 USA. [Yu, Margaret K.; Bent-Shaw, Luis A.; Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Kidney Res Inst, Seattle, WA USA. [Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. RP Young, BA (reprint author), Univ Washington, Div Nephrol, 1660 S Columbian Way,RDU 111A, Seattle, WA 98108 USA. EM youngb@u.washington.edu FU National Institutes of Health National Institute of Diabetes, Digestive, and Kidney Diseases [DK079745, T32 007467]; National Institute of Mental Health [MH41739, MH01643]; VA Puget Sound Health Care System, Seattle, Washington FX This work was supported by research grants by the National Institutes of Health National Institute of Diabetes, Digestive, and Kidney Diseases (DK079745, T32 007467) and National Institute of Mental Health (MH41739, MH01643). In addition, B.A.Y.'s contribution is supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. NR 26 TC 6 Z9 6 U1 1 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2012 VL 36 IS 3 BP 245 EP 251 DI 10.1159/000342210 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 014NW UT WOS:000309383800006 PM 22964976 ER PT J AU Vasquez, DA de Arellano, MA Reid-Quinones, K Bridges, AJ Rheingold, AA AF Vasquez, Desi Alonzo de Arellano, Michael A. Reid-Quinones, Kathryn Bridges, Ana J. Rheingold, Alyssa A. TI Peritraumatic Dissociation and Peritraumatic Emotional Predictors of PTSD in Latino Youth: Results from the Hispanic Family Study SO JOURNAL OF TRAUMA & DISSOCIATION LA English DT Article DE peritraumatic dissociation; PTSD; Latino; youth; shame ID POSTTRAUMATIC-STRESS-DISORDER; TERRORIST ATTACKS; MENTAL-HEALTH; UNITED-STATES; SEXUAL-ABUSE; CHILDREN; SYMPTOMS; SHAME; ADOLESCENTS; VICTIMS AB This is the 1st study to examine peritraumatic dissociation and peritraumatic emotions as they predict symptoms and diagnosis of posttraumatic stress disorder (PTSD) in Latino youth. Our aim was to test the hypothesis that the degree of peritraumatic dissociation would predict the number of PTSD symptoms and PTSD clinical diagnosis when the influences of other salient factors were statistically controlled. We also explored the possible contributions of peritraumatic emotional responses to PTSD symptomatology and PTSD diagnosis. We expected that peritraumatic dissociation would emerge as a significant predictor of PTSD. A total of 204 Latino youth (mean age = 12.37 years) completed semistructured individual clinical interviews with bilingual research assistants. These interviews assessed trauma exposure, peritraumatic responses, and current psychopathology. A linear regression analysis demonstrated significant relationships between lifetime number of traumatic events, peritraumatic dissociation, shame, and number of PTSD symptoms endorsed. Significant inverse (protective) relationships were demonstrated between anger and guilt and current PTSD symptomatology. Logistic regression analysis demonstrated significant relationships between peritraumatic dissociation, shame, lifetime number of traumatic events experienced, and PTSD diagnosis. The analyses examined both the number of PTSD symptoms as well as diagnosis of PTSD while simultaneously controlling for age, lifetime exposure to traumatic events, time residing in the United States, and gender. These results support an increasingly robust body of empirical literature suggesting that the peritraumatic dissociative and emotional responses to trauma are important predictors of future PTSD diagnosis. Possible cultural factors contributing to the dissociative responses in Latino youth and clinical implications are discussed. C1 [Vasquez, Desi Alonzo; de Arellano, Michael A.; Reid-Quinones, Kathryn; Rheingold, Alyssa A.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Bridges, Ana J.] Univ Arkansas, Dept Psychol, Fayetteville, AR 72701 USA. RP Vasquez, DA (reprint author), S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd 116B, San Antonio, TX 78229 USA. EM Desi.Vasquez@va.gov OI Stocker, Ryan/0000-0001-9271-266X FU NIMH NIH HHS [K01 MH001815, K01 MH001815-01, T32 MH018869, T32 MH18869-23]; PHS HHS [D40HP19640] NR 47 TC 2 Z9 2 U1 3 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1529-9732 J9 J TRAUMA DISSOCIATIO JI J. Trauma Dissociation PY 2012 VL 13 IS 5 BP 509 EP 525 DI 10.1080/15299732.2012.678471 PG 17 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 008ST UT WOS:000308977600002 PM 22989240 ER PT J AU Arentoft, A Byrd, D Robbins, RN Monzones, J Miranda, C Rosario, A Coulehan, K Fuentes, A Germano, KK D'Aquila, E Sheynin, J Fraser, F Morgello, S Mindt, MR AF Arentoft, Alyssa Byrd, Desiree Robbins, Reuben N. Monzones, Jennifer Miranda, Caitlin Rosario, Ana Coulehan, Kelly Fuentes, Armando Germano, Kaori Kubo D'Aquila, Erica Sheynin, Jacob Fraser, Felicia Morgello, Susan Mindt, Monica Rivera TI Multidimensional effects of acculturation on English-language neuropsychological test performance among HIV plus Caribbean Latinas/os SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Acculturation; Neuropsychology; HIV; Cognition; Latina; Latino ID AFRICAN-AMERICANS; SPEAKING; IMPAIRMENT; INFECTION; SAMPLES; SCORES; MEMORY AB Acculturation has been linked to neuropsychological performance in several ethnic groups. However, research among Latina/o samples has examined primarily Mexicans/Mexican Americans and has not examined Latina/o clinical populations of Caribbean descent. This study examined associations between a multidimensional acculturation measure and neuropsychological performance among 82 HIV+ Caribbean Latina/o adults. Multivariate results showed that US acculturation significantly predicted 11-14% of the variance in global neuropsychological functioning, verbal fluency, and processing speed, whereas Latina/o acculturation predicted 6-8% of the variance in motor and executive function (trend level associations). Both linguistic and nonlinguistic cultural factors had distinct effects on neuropsychological performance. C1 [Arentoft, Alyssa; Monzones, Jennifer; Miranda, Caitlin; Rosario, Ana; Coulehan, Kelly; Fuentes, Armando; Germano, Kaori Kubo; D'Aquila, Erica; Sheynin, Jacob; Fraser, Felicia; Mindt, Monica Rivera] Fordham Univ, Dept Psychol, New York, NY 10023 USA. [Arentoft, Alyssa] W Los Angeles VA Healthcare Ctr, Dept Psychol, Los Angeles, CA USA. [Byrd, Desiree; Morgello, Susan; Mindt, Monica Rivera] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Byrd, Desiree; Mindt, Monica Rivera] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Robbins, Reuben N.] Columbia Univ, HIV Ctr Clin & Behav Studies, Dept Psychiat, New York, NY USA. [Robbins, Reuben N.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Monzones, Jennifer] New Mexico VA Healthcare Ctr, Dept Psychol, Albuquerque, NM USA. [Rosario, Ana] NYU, Coll Arts & Sci, New York, NY USA. [Morgello, Susan] Mt Sinai Sch Med, Dept Pathol, New York, NY USA. [Morgello, Susan] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. RP Arentoft, A (reprint author), Fordham Univ, Dept Psychol, New York, NY 10023 USA. EM arentoft@fordham.edu FU NIMH [K23MH07971801, R24MH59724, U01MH083501, N01MH22005]; Northeast Consortium for Minority Faculty Development FX The authors wish to thank the Harlem Community Academic Partnership, the Manhattan HIV Care Network, and our participants for their contributions to our research. This research was supported by a K23 from NIMH (K23MH07971801) and an Early Career Development Award from the Northeast Consortium for Minority Faculty Development, both awarded to Monica Rivera Mindt; an R24 and U01 from NIMH (R24MH59724; U01MH083501) to Susan Morgello; and an N01 from NIMH (N01MH22005) subcontracted to Susan Morgello. NR 52 TC 3 Z9 3 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 EI 1744-411X J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2012 VL 34 IS 8 BP 814 EP 825 DI 10.1080/13803395.2012.683856 PG 12 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 008YK UT WOS:000308992300003 PM 22624844 ER PT B AU Pella, RD Hill, BD Singh, AN Hayes, JS Gouvier, WD AF Pella, Russell D. Hill, B. D. Singh, Ashvind N. Hayes, Jill S. Gouvier, Wm Drew BE Reynolds, CR Horton, AM TI Noncredible Performance in Mild Traumatic Brain Injury SO DETECTION OF MALINGERING DURING HEAD INJURY LITIGATION, SECOND EDITION LA English DT Article; Book Chapter ID POSTTRAUMATIC-STRESS-DISORDER; VERBAL-LEARNING TEST; SYMPTOM VALIDITY TEST; CLOSED-HEAD-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; ADULT INTELLIGENCE SCALE; RELIABLE DIGIT SPAN; CARD SORTING TEST; MEMORY TEST WCMT; RESPONSE BIAS C1 [Pella, Russell D.; Gouvier, Wm Drew] Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA. [Singh, Ashvind N.] Metropolitan State Hosp, Norwalk, CA 91325 USA. [Hill, B. D.] Brown Univ, Alpert Med Sch, Rhode Isl Hosp, Providence, RI USA. [Pella, Russell D.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Gouvier, WD (reprint author), Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA. EM wgouvie@lsu.edu OI Hill, Benjamin/0000-0002-5797-5082 NR 239 TC 6 Z9 6 U1 5 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4614-0441-5 PY 2012 BP 121 EP 150 DI 10.1007/978-1-4614-0442-2_3 D2 10.1007/978-1-4614-0442-2 PG 30 WC Psychology, Clinical; Neurosciences SC Psychology; Neurosciences & Neurology GA BAD69 UT WOS:000303852000003 ER PT J AU Armento, MEA Stanley, MA Marsh, L Kunik, ME York, MK Bush, AL Calleo, JS AF Armento, Maria E. A. Stanley, Melinda A. Marsh, Laura Kunik, Mark E. York, Michele K. Bush, Amber L. Calleo, Jessica S. TI Cognitive Behavioral Therapy for Depression and Anxiety in Parkinson's Disease: A Clinical Review SO JOURNAL OF PARKINSONS DISEASE LA English DT Review DE Parkinson's disease; depression; anxiety; CBT ID QUALITY-OF-LIFE; CONTROLLED-TRIAL; NONMOTOR SYMPTOMS; MAJOR DEPRESSION; DOUBLE-BLIND; PREVALENCE; DISABILITY; FEASIBILITY; ANTIDEPRESSANTS; INTERVENTION AB Parkinson's disease (PD) is the second most common neurodegenerative disorder. It is generally defined by its progressive motor features; but increased attention is being paid to its non-motor neuropsychiatric symptoms, which profoundly impact quality of life for patients and caregivers. Anxiety and depression are particularly problematic and are the strongest predictors of quality of life in PD. Recent research has focused on non-pharmacological approaches to treating depression and anxiety in patients with PD. Cognitive-behavioral therapy (CBT) is a potentially efficacious non-pharmacological treatment for mood and anxiety symptoms associated with PD. Accordingly, this review examines empirical studies of CBT-based treatments for depression and anxiety symptoms in PD. Medical Subject Headings were used in searches of PsychInfo and PubMed of English-language articles published in peer-reviewed journals, resulting in the identification of 10 articles. Four additional articles were identified from the references of these articles and upon the suggestions of experts, for 15 articles in all. Results of individual studies varied significantly; however, the randomized controlled trials showed encouraging results and support the need for further investigation of the utility of CBT for depressed and anxious patients with PD. CBT is potentially a useful treatment for patients with PD and comorbid depression and/or anxiety, but more systematic research will be necessary to measure its effects. C1 [Armento, Maria E. A.; Stanley, Melinda A.; Kunik, Mark E.; Bush, Amber L.; Calleo, Jessica S.] Michael E DeBakey VA Med Ctr, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA. [Armento, Maria E. A.; Stanley, Melinda A.; Marsh, Laura; Kunik, Mark E.; Bush, Amber L.; Calleo, Jessica S.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Marsh, Laura; York, Michele K.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Armento, Maria E. A.; Stanley, Melinda A.; Kunik, Mark E.] VA S Cent Mental Illness Res Educ & Clin Ctr MIRE, Houston, TX USA. [York, Michele K.] Parkinsons Dis Res Educ & Clin Ctr PADRECC, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Marsh, Laura; Calleo, Jessica S.] Michael E DeBakey Vet Affairs Med Ctr Mental Hlth, Houston, TX USA. RP Armento, MEA (reprint author), Hlth Serv Res & Dev Ctr Excellence, 2002 Holcombe Blvd,MEDVAMC 152, Houston, TX 77030 USA. EM armento@bcm.edu FU VA HSR&D Houston Center of Excellence [HFP90-020]; Michael E. DeBakey Veterans Affairs Medical Center; National Institute of Mental Health (NIMH) [RO1-MH069666]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX This work is the result of work supported with resources and the use of facilities at the VA HSR&D Houston Center of Excellence (HFP90-020) at the Michael E. DeBakey Veterans Affairs Medical Center and National Institute of Mental Health (NIMH grant RO1-MH069666 to ALB and LM). The views expressed reflect those of the authors and not necessarily those of the NIMH, National Institutes of Health, Department of Veterans Affairs or Baylor College of Medicine. The NIMH had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. The authors report no financial conflicts of interest.; This work is the result of work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and the VA HSR&D Houston Center of Excellence (HFP90-020). The views expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government or Baylor College of Medicine. NR 89 TC 16 Z9 16 U1 4 U2 30 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1877-7171 J9 J PARKINSON DIS JI J. Parkinsons Dis. PY 2012 VL 2 IS 2 BP 135 EP 151 DI 10.3233/JPD-2012-12080 PG 17 WC Neurosciences SC Neurosciences & Neurology GA 001UM UT WOS:000308485600007 PM 23939438 ER PT J AU Sakakima, H Khan, M Dhammu, TS Shunmugavel, A Yoshida, Y Singh, I Singh, AK AF Sakakima, Harutoshi Khan, Mushfiquddin Dhammu, Tajinder S. Shunmugavel, Anandakumar Yoshida, Yoshihiro Singh, Inderjit Singh, Avtar K. TI Stimulation of functional recovery via the mechanisms of neurorepair by S-nitrosoglutathione and motor exercise in a rat model of transient cerebral ischemia and reperfusion SO RESTORATIVE NEUROLOGY AND NEUROSCIENCE LA English DT Article DE GSNO; IR; motor exercise; neurorepair; neurobehavior; rehabilitation; S-nitrosylation; stroke ID TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; NF-KAPPA-B; NITRIC-OXIDE; EXPERIMENTAL STROKE; NEUROVASCULAR UNIT; GLUTATHIONE; ACTIVATION; PATHWAY; NITROSYLATION AB Purpose: Stroke disability stems from insufficient neurorepair mechanisms. Improvement of functions has been achieved through rehabilitation or therapeutic agents. Therefore, we combined exercise with a neurovascular protective agent, S-nitrosoglutathione (GSNO), to accelerate functional recovery. Methods: Stroke was induced by middle cerebral artery occlusion for 60 min followed by reperfusion in adult male rats. Animals were treated with vehicle (IR group), GSNO (0.25 mg/kg, GSNO group), rotarod exercise (EX group) and GSNO plus exercise (GSNO+EX group). The groups were studied for 14 days to determine neurorepair mechanisms and functional recovery. Results: Treated groups showed reduced infarction, decreased neuronal cell death, enhanced neurotrophic factors, and improved neurobehavioral functions. However, the GSNO+EX showed greater functional recovery (p < 0.05) than the GSNO or the EX group. A GSNO sub group, treated 24 hours after IR, still showed motor function recovery (p < 0.001). The protective effect of GSNO or exercise was blocked by the inhibition of Akt activity. Conclusions: GSNO and exercise aid functional recovery by stimulating neurorepair mechanisms. The improvements by GSNO and exercise depend mechanistically on the Akt pathway. A combination of exercise and GSNO shows greater functional recovery. Improved recovery with GSNO, even administered 24 hours post-IR, demonstrates its clinical relevance. C1 [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Sakakima, Harutoshi; Khan, Mushfiquddin; Dhammu, Tajinder S.; Shunmugavel, Anandakumar; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Sakakima, Harutoshi; Yoshida, Yoshihiro] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, 508 Childrens Res Inst,173 Ashley Ave, Charleston, SC 29425 USA. EM khanm@musc.edu FU Veteran Administration; NIH [NS-72511, NS-22576, NS-37766]; National Center for Research Resources [C06 RR018823, C06 RR015455] FX This work was supported by grants from Veteran Administration merit awards and NIH (NS-72511, NS-22576 and NS-37766). This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms. Joyce Bryan for her technical help, and Ms. Chara Williams for her secretarial assistance. We also acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable editing and correction of the manuscript. NR 46 TC 19 Z9 20 U1 0 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0922-6028 J9 RESTOR NEUROL NEUROS JI Restor. Neurol. Neurosci. PY 2012 VL 30 IS 5 BP 383 EP 396 DI 10.3233/RNN-2012-110209 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 004UO UT WOS:000308706800003 PM 22717646 ER PT J AU Nomura, Y Hurd, YL Pilowsky, DJ AF Nomura, Yoko Hurd, Yasmin L. Pilowsky, Daniel J. TI Life-Time Risk for Substance Use Among Offspring of Abusive Family Environment From the Community SO SUBSTANCE USE & MISUSE LA English DT Article DE child abuse; craving; parenting skills; risk ID ILLICIT DRUG-USE; CHILDHOOD SEXUAL-ABUSE; MIDDLE ADULTHOOD; NATIONAL SAMPLE; PHYSICAL ABUSE; MALTREATMENT; NEGLECT; ASSOCIATIONS; OUTCOMES; VIOLENCE AB The current study examined the cumulative risk, age of initiation, and functional impairments among adults with substance use problems (N = 1748) by child abuse status. Child abuse was associated with earlier initiation of marijuana, cocaine, and heroin use, and had greater risks for all the drugs studied (hazard ratios, 1.7-3.2). Furthermore, child abuse was associated with increased medical and functional impairments, including ER visits, health problems, drug dealing, drug dependence, and drug cravings. Provision of social services and parenting education during the perinatal period may prevent the long-term impact of child abuse on substance use and related impairments. The study's limitations are noted. C1 [Nomura, Yoko] CUNY, Queens Coll, Dept Psychol, Flushing, NY 11367 USA. [Nomura, Yoko; Hurd, Yasmin L.] Mt Sinai Sch Med, Dept Psychiat, Mt Sinai, NY USA. [Pilowsky, Daniel J.] Columbia Univ, Dept Epidemiolgy, New York, NY USA. [Hurd, Yasmin L.] James J Peters VA Med Ctr, Bronx, NY USA. [Hurd, Yasmin L.] Mt Sinai Sch Med, Dept Pharmacol Syst Therapeut, Mt Sinai, NY USA. [Hurd, Yasmin L.] Mt Sinai Sch Med, Dept Neurosci, Mt Sinai, NY USA. RP Nomura, Y (reprint author), CUNY, Queens Coll, Dept Psychol, 65-30 Kissena Blvd, Flushing, NY 11367 USA. EM yoko.nomura@qc.cuny.edu FU NIDA NIH HHS [R01 DA023214, R01 DA030359]; NIMH NIH HHS [K01 MH080062] NR 51 TC 8 Z9 8 U1 2 U2 11 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1082-6084 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2012 VL 47 IS 12 BP 1281 EP 1292 DI 10.3109/10826084.2012.695420 PG 12 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA 005CV UT WOS:000308729000005 PM 22780838 ER PT J AU Karmarkar, AM Dicianno, BE Graham, JE Cooper, R Kelleher, A Cooper, RA AF Karmarkar, Amol M. Dicianno, Brad E. Graham, James E. Cooper, Rosemarie Kelleher, Annmarie Cooper, Rory A. TI Factors Associated with Provision of Wheelchairs in Older Adults SO ASSISTIVE TECHNOLOGY LA English DT Article DE older adults; standard of care; wheelchair prescription; wheelchair seating and mobility clinic ID POWER MOBILITY; ASSISTIVE TECHNOLOGY; STROKE; GUIDELINES; PREDICTORS; VETERANS; SCOOTERS AB The objectives of this study were: to identify the factors that are associated with prescription of wheeled mobility devices for older adults, and to determine the effect that living setting has on the types of devices that older adults receive. Retrospective medical chart review at the Center for Assistive Technology on 337 older individuals. These individuals were aged >60 years, and each of them received a new wheeled mobility device from the center during 2007 or 2008. Data were analyzed in three tiers: tier 1 (manual versus powered mobility devices); tier 2 (motorized scooters versus power wheelchairs); and tier 3 (customized versus standard power wheelchairs). For tier 1, the factor associated with higher odds for receipt of manual wheelchairs versus powered were: cognitive limitations (OR = .03). For tier 2, diagnosis of cardio-vascular and pulmonary conditions were associated with prescription of motorized scooters (OR = 3.9). For tier 3, neurological conditions (OR = 3.1), male gender (OR = .37), institutional living (OR = .23), and lower age (OR = .96) were associated with receipt of customized power wheelchairs. This study objectively describes factors associated with prescription of wheeled mobility for older adults. This information can aid in development of guidelines and improving standards of practice for prescription of wheelchairs for older adults. C1 [Dicianno, Brad E.; Cooper, Rosemarie; Kelleher, Annmarie; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Karmarkar, Amol M.; Graham, James E.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX USA. [Dicianno, Brad E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Dicianno, Brad E.; Cooper, Rosemarie; Kelleher, Annmarie; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci, Pittsburgh, PA 15260 USA. [Dicianno, Brad E.; Cooper, Rosemarie; Kelleher, Annmarie; Cooper, Rory A.] Univ Pittsburgh, Med Ctr, Ctr Assist Technol, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,Bldg 4,2nd Floor,151R1-HD, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu RI Karmarkar, Amol/E-6030-2011 OI Karmarkar, Amol/0000-0001-8355-1585; Dicianno, Brad/0000-0003-0738-0192 NR 34 TC 5 Z9 5 U1 0 U2 14 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 J9 ASSIST TECHNOL JI Assist. Technol. PY 2012 VL 24 IS 3 BP 155 EP 167 DI 10.1080/10400435.2012.659795 PG 13 WC Rehabilitation SC Rehabilitation GA 996XX UT WOS:000308129200002 PM 23033733 ER PT J AU Wang, XL Chen, H Geng, Z Zhou, XH AF Wang, Xueli Chen, Hua Geng, Zhi Zhou, Xiaohua TI Using Auxiliary Data for Binomial Parameter Estimation with Nonignorable Nonresponse SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS LA English DT Article DE Identifiability; Information matrix; Nonignorable nonresponse; Odds ratio; Variance estimator ID MISSING OUTCOMES; REGRESSION; SUBJECT; MODELS AB Nonignorable nonresponse is a nonresponse mechanism that depends on the values of the variable having nonresponse. When an observed data of a binomial distribution suffer missing values from a nonignorable nonresponse mechanism, the binomial distribution parameters become unidentifiable without any other auxiliary information or assumption. To address the problems of non identifiability, existing methods mostly based on the log-linear regression model. In this article, we focus on the model when the nonresponse is nonignorable and we consider to use the auxiliary data to improve identifiability; furthermore, we derive the maximum likelihood estimator (MLE) for the binomial proportion and its associated variance. We present results for an analysis of real-life data from the SARS study in China. Finally, the simulation study shows that the proposed method gives promising results. C1 [Wang, Xueli] Beijing Univ Posts & Telecommun, Sch Sci, Beijing 100876, Peoples R China. [Wang, Xueli; Zhou, Xiaohua] Univ Washington, Dept Biostat, Washington, DC USA. [Chen, Hua; Geng, Zhi] Peking Univ, Sch Sci, Beijing 100871, Peoples R China. [Chen, Hua] Inst Appl Phys & Computat Math, Beijing 100088, Peoples R China. [Zhou, Xiaohua] VA Puget Sound Hlth Care Syst, NW HSR&D Ctr Excellence, Seattle, WA USA. [Zhou, Xiaohua] Peking Univ, Beijing Int Ctr Math Res, Beijing 100871, Peoples R China. RP Wang, XL (reprint author), Beijing Univ Posts & Telecommun, Sch Sci, Beijing 100876, Peoples R China. EM wangxlbupt@gmail.com FU National Natural Science Foundation of China [NSFC 10801019]; Fundamental Research Funds for the Central Universities [BUPT 2012RC0708] FX The authors would like to thank the Co-Editor, an Associate Editor, and anonymous referees for their valuable suggestions which greatly improved the presentation of this article. This research was supported by the National Natural Science Foundation of China (NSFC 10801019) and the Fundamental Research Funds for the Central Universities (BUPT 2012RC0708). Xiao-Hua (Andrew) Zhou, Ph.D., is presently a Core Investigator and Biostatistics Unit Director at the Northwest HSR&D Center of Excellence, Department of Veterans Affairs Medical Center, Seattle, WA. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 17 TC 0 Z9 0 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0361-0926 EI 1532-415X J9 COMMUN STAT-THEOR M JI Commun. Stat.-Theory Methods PY 2012 VL 41 IS 19 BP 3468 EP 3478 DI 10.1080/03610926.2011.620209 PG 11 WC Statistics & Probability SC Mathematics GA 001MW UT WOS:000308465800002 ER PT J AU Kane-Gill, SL Forsberg, EA Verrico, MM Handler, SM AF Kane-Gill, Sandra L. Forsberg, Elizabeth A. Verrico, Margaret M. Handler, Steven M. TI Comparison of Three Pharmacovigilance Algorithms in the ICU Setting A Retrospective and Prospective Evaluation of ADRs SO DRUG SAFETY LA English DT Article ID ADVERSE DRUG-REACTIONS; INTENSIVE-CARE-UNIT; HOSPITALIZED-PATIENTS; CAUSALITY ASSESSMENT; EVENTS; ERRORS; IMPUTABILITY; PRINCIPLES; PROPOSAL; SAFETY AB Background: Pharmacovigilance algorithms are used to assess the likelihood of adverse drug reaction (ADR) occurrence. The preferred instrument for use in the intensive care unit (ICU) is not established. Objective: The primary objective of this study was to compare the agreement between the Kramer algorithm, Naranjo criteria and Jones algorithm for the evaluation of ADRs in the ICU. A secondary objective was to compare the agreement between the same pharmacovigilance algorithms for ADR determination when applied in a retrospective versus concurrent fashion in the ICU. Study Design: There were two phases in this study. Phase I was the retrospective evaluation (i.e. after the patient was discharged from the hospital) conducted in patients admitted during July 2005 to June 2006. Phase II was the concurrent phase (i.e. while the patient was in the hospital) conducted over 6 weeks in 2008. Both phases were conducted at the University of Pittsburgh Medical Center and included adult patients admitted to the medical ICU. Intervention: In phase I, a random sample of 261 medication signals were evaluated individually for potential ADRs using the Kramer algorithm, Naranjo criteria and Jones algorithm. In phase II, an active medication monitoring system was used to detect five abnormal laboratory values, resulting in a random sample of 253 signals that were evaluated using the same three algorithms. Main Outcome Measure: Percentage agreement among the algorithms for all levels of causality was estimated using a kappa statistic for both phases of the study. Results: For phase I, the kappa values were all >0.7 ranging from 0.721 to 0.855 between instruments, with Naranjo versus Kramer having the highest kappa, which is considered excellent agreement. The kappa statistic between individual instruments for phase 11 are <0.7 ranging from 0.423 to 0.635, which is considered moderate agreement, with Naranjo versus Jones displaying the lowest kappa while still exhibiting moderate agreement. For phase II, the Kramer algorithm had better agreement with both the Naranjo criteria and the Jones algorithm. Conclusions: These instruments demonstrated similar results for evaluating ADRs in the ICU retrospectively, suggesting that instrument selection with any of the three instruments is reasonable. For concurrent ADR evaluations, there is greater variability in the level of causality obtained among pharmacovigilance algorithms and Kramer displayed better agreement with its comparators. A suggestion for a more definitive concurrent ADR assessment is to use more than one algorithm. This may be challenging in daily clinical practice; however, it is a reasonable expectation for research. C1 [Kane-Gill, Sandra L.] Univ Pittsburgh, Sch Pharm, Ctr Pharmacoinformat & Outcomes Res, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Forsberg, Elizabeth A.; Verrico, Margaret M.] Univ Pittsburgh Med Ctr Presbyterian Shadyside, Dept Pharm, Pittsburgh, PA USA. [Kane-Gill, Sandra L.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA. [Forsberg, Elizabeth A.] Univ Pittsburgh, St Margaret Hosp, Med Ctr, Dept Pharm, Pittsburgh, PA 15261 USA. [Handler, Steven M.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15261 USA. [Handler, Steven M.] Geriatr Pharmaceut Outcomes & Geroinformat Res &, Pittsburgh, PA USA. [Handler, Steven M.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA 15261 USA. [Handler, Steven M.] Vet Affairs Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. [Handler, Steven M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Kane-Gill, SL (reprint author), Univ Pittsburgh, Sch Pharm, Ctr Pharmacoinformat & Outcomes Res, Dept Pharm & Therapeut, 918 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA. EM SLK54@pitt.edu OI Kane-GIll, Sandra/0000-0001-7523-4846 FU Agency for Healthcare Research and Quality grant [R01-HS017695]; National Institute on Aging grant [K07AG033174] FX This work was funded in part by an Agency for Healthcare Research and Quality grant (R01-HS017695) and National Institute on Aging grant (K07AG033174) awarded to Dr Steven Handler. The authors have no conflict of interests to disclose. NR 48 TC 10 Z9 10 U1 0 U2 3 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0114-5916 J9 DRUG SAFETY JI Drug Saf. PY 2012 VL 35 IS 8 BP 645 EP 653 PG 9 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology GA 986DH UT WOS:000307320600005 PM 22720659 ER PT J AU Li, H Weiser-Evans, MCM Nemenoff, R AF Li, Howard Weiser-Evans, Mary C. M. Nemenoff, Raphael TI Anti- and Protumorigenic Effects of PPAR gamma in Lung Cancer Progression: A Double-Edged Sword SO PPAR RESEARCH LA English DT Review ID ACTIVATED-RECEPTOR-GAMMA; HEPATIC STELLATE CELLS; MACROPHAGE-GENE-EXPRESSION; HUMAN PROSTATE-CANCER; RETINOID-X-RECEPTOR; HUMAN BREAST-CANCER; REGULATORY T-CELLS; TUMOR PROGRESSION; IN-VITRO; HEPATOCELLULAR-CARCINOMA AB Peroxisome proliferator-activated receptor-gamma ( PPAR gamma) is a member of the nuclear receptor superfamily of ligand-activated transcription factors that plays an important role in the control of gene expression linked to a variety of physiological processes, including cancer. Ligands for PPAR. include naturally occurring fatty acids and the thiazolidinedione class of antidiabetic drugs. Activation of PPAR gamma in a variety of cancer cells leads to inhibition of growth, decreased invasiveness, reduced production of proinflammatory cytokines, and promotion of a more differentiated phenotype. However, systemic activation of PPAR gamma has been reported to be protumorigenic in some in vitro systems and in vivo models. Here, we review the available data that implicate PPAR gamma in lung carcinogenesis and highlight the challenges of targeting PPAR gamma in lung cancer treatments. C1 [Weiser-Evans, Mary C. M.; Nemenoff, Raphael] Univ Colorado Denver, Dept Med, Div Renal Dis & Hypertens, Aurora, CO 80045 USA. [Li, Howard] Univ Colorado Denver, Dept Med, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. [Li, Howard] Denver Vet Affairs Med Ctr, Dept Med, Pulm & Crit Care Sect, Denver, CO 80220 USA. [Nemenoff, Raphael] Univ Colorado, Dept Med, Div Renal Dis & Hypertens, Aurora, CO 80045 USA. RP Nemenoff, R (reprint author), Univ Colorado Denver, Dept Med, Div Renal Dis & Hypertens, Aurora, CO 80045 USA. EM raphael.nemenoff@ucdenver.edu OI Li, Howard/0000-0002-1230-2941 NR 121 TC 3 Z9 3 U1 0 U2 6 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-4757 J9 PPAR RES JI PPAR Res. PY 2012 AR 362085 DI 10.1155/2012/362085 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 997SF UT WOS:000308185700001 ER PT J AU Fargo, J Metraux, S Byrne, T Munley, E Montgomery, AE Jones, H Sheldon, G Kane, V Culhane, D AF Fargo, Jamison Metraux, Stephen Byrne, Thomas Munley, Ellen Montgomery, Ann Elizabeth Jones, Harlan Sheldon, George Kane, Vincent Culhane, Dennis TI Prevalence and Risk of Homelessness Among US Veterans SO PREVENTING CHRONIC DISEASE LA English DT Article ID MEN; PROPORTION AB Introduction Understanding the prevalence of and risk for homelessness among veterans is prerequisite to preventing and ending homelessness among this population. Homeless veterans are at higher risk for chronic disease; understanding the dynamics of homelessness among veterans can contribute to our understanding of their health needs. Methods We obtained data on demographic characteristics and veteran status for 130,554 homeless people from 7 jurisdictions that provide homelessness services, and for the population living in poverty and the general population from the American Community Survey for those same jurisdictions. We calculated prevalence of veterans in the homeless, poverty, and general populations, and risk ratios (RR) for veteran status in these populations. Risk for homelessness, as a function of demographic characteristics and veteran status, was estimated by using multivariate regression models. Results Veterans were overrepresented in the homeless population, compared with both the general and poverty populations, among both men (RR, 1.3 and 2.1, respectively) and women (RR, 2.1 and 3.0, respectively). Veteran status and black race significantly increased the risk for homelessness for both men and women. Men in the 45- to 54-year-old age group and women in the 18- to 29-year-old age group were at higher risk compared with other ages. Conclusion Our findings confirm previous research associating veteran status with higher risk for homelessness and imply that there will be specific health needs among the aging homeless population. This study is a basis for understanding variation in rates of, and risks for, homelessness in general population groups, and inclusion of health data from US Department of Veterans Affairs records can extend these results to identifying links between homelessness and health risks. C1 [Metraux, Stephen; Byrne, Thomas; Munley, Ellen; Montgomery, Ann Elizabeth; Jones, Harlan; Kane, Vincent; Culhane, Dennis] Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Metraux, Stephen] Univ Sci, Philadelphia, PA USA. [Byrne, Thomas; Montgomery, Ann Elizabeth; Jones, Harlan; Culhane, Dennis] Univ Penn, Philadelphia, PA 19104 USA. [Munley, Ellen] CUNY, Philadelphia, PA USA. [Sheldon, George] US Dept Vet Affairs, Washington, DC USA. RP Fargo, J (reprint author), Natl Ctr Homelessness Vet, 2810 Old Main Hill St, Logan, UT 84322 USA. EM jamison.fargo@usu.edu NR 27 TC 11 Z9 11 U1 4 U2 28 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JAN PY 2012 VL 9 AR 110112 DI 10.5888/pcd9.110112 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 977GI UT WOS:000306644300045 ER PT J AU Main, DS Ware, G Iwasaki, PG Burry, M Steiner, E Fedde, K Haverhals, LM AF Main, Deborah S. Ware, George Iwasaki, Patricia G. Burry, Mark Steiner, Emily Fedde, Katherine Haverhals, Leah M. TI Taking Neighborhood Health to Heart (TNH2H): Building a Community-Based Participatory Data System SO PREVENTING CHRONIC DISEASE LA English DT Article ID PHYSICAL-ACTIVITY; BIAS AB Background Healthy People 2020 calls for increased monitoring of local health and health disparities, but successful models of designing and implementing data collection systems for this purpose are lacking. Community Context We describe the process, methods, and outcomes of a community-based participatory research initiative, Taking Neighborhood Health to Heart, designed to collect and disseminate comprehensive health data from 5 diverse urban neighborhoods in Denver, Colorado. Methods Since its beginning in 2006, this initiative has involved community members in collection of individual health surveys from 1,146 households; audits of sidewalks, buildings, and other built environment features in 412 neighborhood blocks; audits of availability, price, and quality of fresh produce in 69 local stores; and audits of conditions and amenities in 20 local parks. Community members and researchers share, interpret, and disseminate these data through a joint data review and dissemination committee. Outcome Through our community-based data collection system, Taking Neighborhood Health to Heart has been able to collect, analyze, and disseminate locally relevant data on people and neighborhoods to monitor heath and health disparities. Interpretation Since 2006, the initiative has sustained its focus on community-based participatory research that targets collection and dissemination of local health data. We have used this information to identify salient health issues and advocate for neighborhood programs, policies, and environmental changes to built and social features of neighborhoods that have historically led to unequal opportunities and social disadvantage. C1 [Main, Deborah S.] Univ Colorado, Dept Hlth & Behav Sci, Denver, CO 80217 USA. [Ware, George] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Iwasaki, Patricia G.] Univ Denver, Denver, CO USA. [Haverhals, Leah M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Main, DS (reprint author), Univ Colorado, Dept Hlth & Behav Sci, 1201 5th St,Suite 280J,POB 173364, Denver, CO 80217 USA. EM Debbi.Main@ucdenver.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health grant [R21HL083866] FX TNH2H was funded by a National Heart, Lung, and Blood Institute, National Institutes of Health grant (R21HL083866) to Dr Main. We acknowledge the hard work and dedication of community members and researchers participating in the TNH2H Council, steering committee, data review and dissemination committee, and the food committee. NR 16 TC 0 Z9 0 U1 0 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JAN PY 2012 VL 9 AR 110058 DI 10.5888/pcd9.110058 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 977GI UT WOS:000306644300041 ER PT J AU Foroud, T Phillips, TJ AF Foroud, Tatiana Phillips, Tamara J. TI Assessing the Genetic Risk for Alcohol Use Disorders SO ALCOHOL RESEARCH-CURRENT REVIEWS LA English DT Review DE Alcohol dependence; alcoholism; genetics; genetic basis of alcoholism; genetic mapping; gene interactions; genetic technology; gene knockout technology; human studies; animal models ID UNITED-STATES; MICE; DEPENDENCE; ASSOCIATION; CONSUMPTION; PREVALENCE; EXPRESSION; AMYGDALA; ETHANOL; SAMPLE AB The past two decades have witnessed a revolution in the field of genetics which has led to a rapid evolution in the tools and techniques available for mapping genes that contribute to genetically complex disorders such as alcohol dependence. Research in humans and in animal models of human disease has provided important new information. Among the most commonly applied approaches used in human studies are family studies, case control studies, and genome-wide association studies. Animal models have been aimed at identifying genetic regions or individual genes involved in different aspects of alcoholism, using such approaches as quantitative trait locus analysis, genome sequencing, knockout animals, and other sophisticated molecular genetic techniques. All of these approaches have led to the identification of several genes that seem to influence the risk for alcohol dependence, which are being further analyzed. Newer studies, however, also are attempting to look at the genetic basis of alcoholism at the level of the entire genome, moving beyond the study of individual genes toward analyses of gene interactions and gene networks in the development of this devastating disease. C1 [Foroud, Tatiana] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46204 USA. [Phillips, Tamara J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Phillips, Tamara J.] Portland VA Med Ctr, Portland, OR USA. RP Foroud, T (reprint author), Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46204 USA. FU NIAAA NIH HHS [P60 AA010760] NR 23 TC 1 Z9 1 U1 4 U2 7 PU NATL INST ALCOHOL ABUSE ALCOHOLISM PI ROCKVILLE PA 6000 EXECUTIVE BLVD, ROCKVILLE, MD 20892-7003 USA SN 1535-7414 J9 ALCOHOL RES-CURR REV JI Alcohol Res.-Curr. Rev. PY 2012 VL 34 IS 3 BP 266 EP + PG 5 WC Substance Abuse SC Substance Abuse GA 980CU UT WOS:000306872000003 PM 23134042 ER PT J AU Hassija, CM Luterek, JA Naragon-Gainey, K Moore, SA Simpson, T AF Hassija, Christina M. Luterek, Jane A. Naragon-Gainey, Kristin Moore, Sally A. Simpson, Tracy TI Impact of emotional approach coping and hope on PTSD and depression symptoms in a trauma exposed sample of Veterans receiving outpatient VA mental health care services SO ANXIETY STRESS AND COPING LA English DT Article DE coping; hope; PTSD; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; EXPERIENTIAL AVOIDANCE; SOCIAL SUPPORT; PSYCHOLOGICAL DISTRESS; SEVERITY; VALIDATION; STRATEGIES; ANXIETY; STYLE; QUESTIONNAIRE AB The present investigation evaluates the relationship between coping style, dispositional hope, and posttraumatic stress disorder (PTSD) and depression symptom severity in a trauma-exposed Veteran sample. Specifically, we evaluated the adaptive value of emotional avoidant and approach coping strategies and perceptions of hope in a sample of 209 trauma-exposed Veterans receiving outpatient mental health care at a VA facility. Participants completed a life events questionnaire and inventories assessing coping, dispositional hope, and PTSD and depression symptom severity. Hierarchical regression analyses were conducted controlling for relevant demographic variables. Greater levels of emotional avoidance and lower levels of emotional expression were significantly associated with increased PTSD and depression symptom severity. Dispositional hope was positively associated with depression symptoms only and perceptions of hope moderated the association between emotional avoidance coping and depression symptoms. Findings highlight the value of emotional coping strategies and perceptions of hope in posttraumatic adjustment. Specifically, employing coping techniques that encourage emotional expression may promote improved adjustment among trauma-exposed individuals, while reduced perceptions of hope and the use of avoidant coping strategies may place individuals at greater risk for depression following exposure to traumatic events. C1 [Hassija, Christina M.; Luterek, Jane A.; Naragon-Gainey, Kristin; Moore, Sally A.; Simpson, Tracy] Vet Affairs Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle Div, Seattle, WA 98126 USA. [Hassija, Christina M.] Univ Wyoming, Dept Psychol, Laramie, WY 82071 USA. [Luterek, Jane A.; Moore, Sally A.; Simpson, Tracy] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Naragon-Gainey, Kristin] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA. [Moore, Sally A.] Evidence Based Treatment Ctr Seattle, Seattle, WA USA. RP Hassija, CM (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle Div, 1660 S Columbian Way, Seattle, WA 98126 USA. EM Chassija@uwyo.edu RI Schueter, nicos/A-3625-2014 NR 56 TC 10 Z9 10 U1 4 U2 15 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1061-5806 J9 ANXIETY STRESS COPIN JI Anxiety Stress Coping PY 2012 VL 25 IS 5 BP 559 EP 573 DI 10.1080/10615806.2011.621948 PG 15 WC Neurosciences; Psychiatry; Psychology, Multidisciplinary SC Neurosciences & Neurology; Psychiatry; Psychology GA 990PN UT WOS:000307643100006 PM 22059938 ER PT J AU Hawkins, OE Richmond, A AF Hawkins, Oriana E. Richmond, Ann TI The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis SO BREAST CANCER RESEARCH LA English DT Editorial Material ID MIGRATION AB The contribution of CXCR7 to the tumor microenvironment has introduced a new level of complexity to CXCL12 signaling in breast cancer. In the previous issue of Breast Cancer Research, Hernandez and colleagues delineate the roles of CXCR4 and CXCR7 in tumor invasion and metastasis. The authors demonstrate that co-expression of CXCR7 and CXCR4 results in inhibition of CXCL12-mediated invasion, reduced intravasation of tumor cells into the vasculature, and fewer lung metastases compared with parental tumors. The results of this study suggest the combination of small molecule inhibitors of CXCR4 and CXCR7 could dramatically reduce invasion, intravasation, and metastasis and could be highly beneficial for the treatment of invasive breast cancer. C1 [Hawkins, Oriana E.; Richmond, Ann] Vanderbilt Univ, Dept Canc Biol, Sch Med, US Dept Vet Affairs, Nashville, TN 37232 USA. RP Richmond, A (reprint author), Vanderbilt Univ, Dept Canc Biol, Sch Med, US Dept Vet Affairs, 2220 Pierce Ave,771 Preston Res Bldg, Nashville, TN 37232 USA. EM Ann.richmond@vanderbilt.edu RI Hawkins, Oriana/F-9801-2013 FU NCI NIH HHS [R01 CA034590, U54 CA163069] NR 8 TC 12 Z9 12 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-542X J9 BREAST CANCER RES JI Breast Cancer Res. PY 2012 VL 14 IS 1 AR 103 DI 10.1186/bcr3092 PG 3 WC Oncology SC Oncology GA 987UU UT WOS:000307444100003 PM 22293321 ER PT J AU Ho, L Zhao, W Dams-O'Connor, K Tang, CY Gordon, W Peskind, ER Yemul, S Haroutunian, V Pasinetti, GM AF Ho, Lap Zhao, Wei Dams-O'Connor, Kristen Tang, Cheuk Y. Gordon, Wayne Peskind, Elaine R. Yemul, Shrishailam Haroutunian, Vahram Pasinetti, Giulio Maria TI Elevated Plasma MCP-1 Concentration Following Traumatic Brain Injury as a Potential "Predisposition" Factor Associated with an Increased Risk for Subsequent Development of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; biomarker; long-term clinical TBI phenotypes; mild cognitive impairment; monocyte chemotactic protein-1; plasma; traumatic brain injury ID DIFFUSE AXONAL INJURY; MULTIPLE-SCLEROSIS; EXPRESSION; CHEMOKINES; PROTEIN; MECHANISMS; RAT; IDENTIFICATION; LOCALIZATION; INFLAMMATION AB We explored whether changes in the expression profile of peripheral blood plasma proteins may provide a clinical, readily accessible "window" into the brain, reflecting molecular alterations following traumatic brain injury (TBI) that might contribute to TBI complications. We recruited fourteen TBI and ten control civilian participants for the study, and also analyzed banked plasma specimens from 20 veterans with TBI and 20 control cases. Using antibody arrays and ELISA assays, we explored differentially-regulated protein species in the plasma of TBI compared to healthy controls from the two independent cohorts. We found three protein biomarker species, monocyte chemotactic protein-1 (MCP-1), insulin-like growth factor-binding protein-3, and epidermal growth factor receptor, that are differentially regulated in plasma specimens of the TBI cases. A three-biomarker panel using all three proteins provides the best potential criterion for separating TBI and control cases. Plasma MCP-1 contents are correlated with the severity of TBI and the index of compromised axonal fiber integrity in the frontal cortex. Based on these findings, we evaluated postmortem brain specimens from 7 mild cognitive impairment (MCI) and 7 neurologically normal cases. We found elevated MCP-1 expression in the frontal cortex of MCI cases that are at high risk for developing Alzheimer's disease. Our findings suggest that additional application of the three-biomarker panel to current diagnostic criteria may lead to improved TBI detection and more sensitive outcome measures for clinical trials. Induction of MCP-1 in response to TBI might be a potential predisposing factor that may increase the risk for development of Alzheimer's disease. C1 [Ho, Lap; Zhao, Wei; Yemul, Shrishailam; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Dams-O'Connor, Kristen; Gordon, Wayne] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. [Tang, Cheuk Y.; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA. [Peskind, Elaine R.] Univ Washington, Sch Med, VA NW Network Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave,Annenberg Bldg,Room 20-02, New York, NY 10029 USA. EM Giulio.Pasinetti@mssm.edu FU UW Alzheimer's Disease Research Center [P50AG05136]; Pacific Northwest Udall Center [P50NS062684]; ADRC [AG05138, PPG AG02219]; Department of Veterans Affairs Rehabilitation Research and Development; National Center for Research Resources (NCRR); National Institutes of Health (NIH) [UL1RR029887] FX This study was supported by UW Alzheimer's Disease Research Center (P50AG05136), Pacific Northwest Udall Center (P50NS062684), the ADRC (AG05138 and PPG AG02219), the Department of Veterans Affairs Rehabilitation Research and Development, and the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) (UL1RR029887). NR 72 TC 17 Z9 18 U1 1 U2 13 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 31 IS 2 BP 301 EP 313 DI 10.3233/JAD-2012-120598 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 986WS UT WOS:000307377300007 PM 22543850 ER PT J AU Cholerton, B Baker, LD Trittschuh, EH Crane, PK Larson, EB Arbuckle, M Saucedo, HH McCurry, SM Bowen, JD McCormick, WC Craft, S AF Cholerton, Brenna Baker, Laura D. Trittschuh, Emily H. Crane, Paul K. Larson, Eric B. Arbuckle, Matthew Saucedo, Hector Hernandez McCurry, Susan M. Bowen, James D. McCormick, Wayne C. Craft, Suzanne TI Insulin and Sex Interactions in Older Adults with Mild Cognitive Impairment SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Age-related memory disorders; aging; Alzheimer's disease; cognition; dementia; hyperinsulinemia; insulin; vascular ID AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E GENOTYPE; NORMAL GLUCOSE-TOLERANCE; HONOLULU HEART PROGRAM; IQ-ADJUSTED NORMS; ALZHEIMERS-DISEASE; CARDIOVASCULAR-DISEASE; DEGRADING ENZYME; DIABETES-MELLITUS; RISK-FACTORS AB Alzheimer's disease (AD) and other dementias are likely preceded by a protracted preclinical state. Thus, identification of biomarkers that signal potential points of intervention during this prodromal phase (during which patients are largely able to compensate for their cognitive deficits) is of paramount importance. Insulin is a pancreatic hormone with potent central nervous system effects, and insulin dysregulation has been implicated in the pathogenesis of both AD and vascular dementia. The aim of the current study was to determine whether circulating insulin differs as a function of mild cognitive impairment (MCI) diagnosis, and whether this relationship is mediated by sex and apolipoprotein E (APOE) genotype. A sample of 549 nondemented participants aged 65 and over from the Adult Changes in Thought community-based cohort underwent cognitive testing and blood draw to determine fasting levels of plasma insulin. Subjects were categorized as having normal cognitive functioning, amnestic MCI, or nonamnestic MCI. Results showed that the relationship between insulin and diagnostic category is moderated by sex, such that men with nonamnestic or amnestic MCI have higher fasting plasma insulin than cognitively normal men, while women with amnestic MCI have lower fasting plasma insulin than cognitively normal women. Exploratory analyses suggest that APOE epsilon 4 genotype may further influence the relationship between sex and insulin. Future research will help determine whether insulin dysregulation results in differential effects on vascular function and AD pathology as a function of sex and/or APOE genotype. C1 [Cholerton, Brenna; Baker, Laura D.; Trittschuh, Emily H.; Arbuckle, Matthew; Saucedo, Hector Hernandez; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Baker, Laura D.; Trittschuh, Emily H.; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Crane, Paul K.; Larson, Eric B.; McCormick, Wayne C.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Bowen, James D.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [McCurry, Susan M.] Univ Washington, Sch Med, Dept Psychosocial & Community Hlth, Seattle, WA USA. [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA. [Bowen, James D.] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA USA. RP Cholerton, B (reprint author), VA Puget Sound Hlth Care Syst, GRECC A 182,9600 Vet Dr SW, Tacoma, WA 98493 USA. EM bchol@u.washington.edu RI Crane, Paul/C-8623-2014 OI Crane, Paul/0000-0003-4278-7465 FU National Institute on Aging [R01AG024180, U01AG006781]; Department of Veterans Affairs; Group Health Research Institute FX This research was supported by National Institute on Aging grants R01AG024180 and U01AG006781, the Department of Veterans Affairs, and the Group Health Research Institute. The funding sources did not provide scientific input for the study. NR 67 TC 5 Z9 5 U1 1 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 31 IS 2 BP 401 EP 410 DI 10.3233/JAD-2012-120202 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 986WS UT WOS:000307377300015 PM 22571978 ER PT J AU Towsley, G Neradilek, MB Snow, AL Ersek, M AF Towsley, Gail Neradilek, Moni Blazej Snow, A. Lynn Ersek, Mary TI Evaluating the Cornell scale for depression in dementia as a proxy measure in nursing home residents with and without dementia SO AGING & MENTAL HEALTH LA English DT Article DE depression; proxy measure; nursing homes; dementia ID QUALITY-OF-LIFE; LONG-TERM-CARE; ALZHEIMERS-DISEASE; MAJOR DEPRESSION; OLDER-PEOPLE; SYMPTOMS; MANAGEMENT; PAIN; PREVALENCE; VALIDITY AB Objectives: We evaluated the use of the Cornell Scale for Depression in Dementia (CSDD) as a proxy measure. Study questions were: How do residents' self-reports on the CSDD compare with the nurse proxy CSDD ratings of the resident? How do characteristics of depression as rated by the resident CSDD and the nurse CSDD compare? To what extent are demographic and clinical variables associated with resident CSDD, nurse CSDD, and the discrepancy between resident and nurse CSDD scores? Methods: Residents and nurse proxy pairs (n = 395 pairs) from 28 nursing homes (NHs) participated. We calculated discrepancy scores for total and subscale CSDD scores, examined correlations between resident and nurse CSDD scores, and described rates of clinical depression using each of the scores. We conducted multivariate analyses to examine factors associated with resident and nurse CSDD and discrepancy scores. Results: On average, participants had mild cognitive impairment, were White, and female. Associations between resident and nurse CSDD were low (r = 0.16). The mean discrepancy score was -2.03 (SD = 5.28, p < 0.001), indicating that nurses evaluated residents as less depressed than residents evaluated themselves. Discrepancy scores were not associated with residents' cognitive status, but were associated with a measure of self-report reliability. Regression analyses indicated that depression diagnosis accounted for a small but significant association with resident CSDD, but was not significantly associated with nurse CSDD. Conclusion: These findings underscore the importance of obtaining resident input when assessing depression in NH residents with dementia, and educating NH nurses in the most effective ways to assess depression. C1 [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Towsley, Gail] Univ Utah, Coll Nursing, Salt Lake City, UT 84112 USA. [Neradilek, Moni Blazej] Mt Whisper Light Stat Consulting, Seattle, WA USA. [Snow, A. Lynn] Univ Alabama, Ctr Mental Hlth & Aging, Tuscaloosa, AL USA. [Snow, A. Lynn] Univ Alabama, Dept Psychol, Tuscaloosa, AL 35487 USA. [Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Natl VA PROMISE Ctr, Philadelphia, PA USA. RP Ersek, M (reprint author), Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. EM ersekm@nursing.upenn.edu FU National Institute of Nursing Research [R01NR009100] FX This study was supported by Award Number R01NR009100 from the National Institute of Nursing Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research or the National Institutes of Health. NR 40 TC 6 Z9 6 U1 3 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 J9 AGING MENT HEALTH JI Aging Ment. Health PY 2012 VL 16 IS 7 BP 892 EP 901 DI 10.1080/13607863.2012.667785 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 987TI UT WOS:000307440200011 PM 22486638 ER PT J AU Fallows, RR Hilsabeck, RC AF Fallows, Robert R. Hilsabeck, Robin C. TI WAIS-IV Visual Puzzles in a Mixed Clinical Sample SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Visual puzzles; WAIS-IV; Visuospatial; Perceptual reasoning; Intelligence ID FORM-BOARD TEST; SPATIAL ABILITY; SEX-DIFFERENCES; BATTERY; SCORES; TESTS AB Little is known about which cognitive functions underlie the new Visual Puzzles subtest of the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV). The purpose of this study was to investigate relationships between Visual Puzzles and common neuropsychological measures in a mixed clinical sample. A total of 44 veterans (75% men) were administered the WAIS-IV as part of a neuropsychological evaluation. Average age was 47.4 years (SD = 11.8), and average education was 13.8 years (SD = 2.3). Correlations were conducted to examine relationships between Visual Puzzles, demographic variables, and neuropsychological measures. Hierarchical regression analysis was used to determine which measures contributed the most variance to Visual Puzzles. Visual Puzzles correlated significantly with measures of visuospatial reasoning, verbal learning and recall, mental flexibility, processing speed, and naming, which accounted for 50% of the variance in Visual Puzzles performance. The results indicate that Visual Puzzles is not a pure measure of visuoperceptual reasoning, at least in a mixed clinical sample, because memory, mental flexibility, processing speed, and language abilities also contribute to successful performance of the task. Thus it may be important to consider other aspects of cognitive functioning when interpreting Visual Puzzles performance. C1 [Fallows, Robert R.; Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA. [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Hilsabeck, RC (reprint author), S Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter, San Antonio, TX 78229 USA. EM Robin.Hilsabeck@va.gov NR 26 TC 3 Z9 3 U1 1 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2012 VL 26 IS 6 BP 942 EP 950 DI 10.1080/13854046.2012.697193 PG 9 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 984ZK UT WOS:000307232300006 PM 22694190 ER PT J AU Kiewel, NA Wisdom, NM Bradshaw, MR Pastorek, NJ Strutt, AM AF Kiewel, Nicole A. Wisdom, Nick M. Bradshaw, Major R. Pastorek, Nicholas J. Strutt, Adriana M. TI A Retrospective Review of Digit Span-Related Effort Indicators in Probable Alzheimer's Disease Patients SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Malingering; Symptom validity testing; Forensic neuropsychology; Dementia assessment; Professional issues ID SYMPTOM VALIDITY TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; CLASSIFICATION ACCURACY; MEMORY IMPAIRMENT; TEST-PERFORMANCE; WAIS-III; COGNITIVELY INTACT; NORMATIVE DATA; TEST-SCORES AB There has been extensive research on the use of both stand-alone and embedded measures of effort in neuropsychological testing; however, relatively few studies have reported on their utility in the context of dementia. Previous studies that have examined the specificity of traditionally used cut-scores on embedded measures of effort with dementia samples have largely found high rates of false positive errors. The present study examined the specificity of several Digit Span derived embedded measures of effort in a large clinical sample of patients with probable Alzheimer's disease stratified by level of dementia severity. Of the measures that were examined, only the Vocabulary - Digit Span score demonstrated promising specificity through the moderate level of dementia severity. All of the remaining indices, including Reliable Digit Span, Digit Span Age-Corrected Scaled Score, and Longest Digits Forward (1 & 2 Trials), yielded unacceptable rates of false positive errors as dementia severity increased. The implications for these findings are discussed, including the limitations of importing methods of assessing effort from one sample to another. C1 [Bradshaw, Major R.; Strutt, Adriana M.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Kiewel, Nicole A.] Univ Houston, Dept Psychol, Houston, TX USA. [Wisdom, Nick M.] Mental Hlth Care Line, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Wisdom, Nick M.; Strutt, Adriana M.] Baylor Coll Med, Menninger Dept Psychiat, Houston, TX 77030 USA. [Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Pastorek, Nicholas J.] Rehabil Care Line, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Strutt, AM (reprint author), Baylor Coll Med, Dept Neurol, 6550 Fannin,Smith Tower 1801, Houston, TX 77030 USA. EM adrianam@bcm.edu NR 35 TC 3 Z9 4 U1 1 U2 9 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2012 VL 26 IS 6 BP 965 EP 974 DI 10.1080/13854046.2012.694478 PG 10 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 984ZK UT WOS:000307232300008 PM 22703555 ER PT J AU Resnik, L Reiber, G AF Resnik, Linda Reiber, Gayle TI Long-term Disabilities Associated With Combat Casualties: Measuring Disability and Reintegration in Combat Veterans SO JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS LA English DT Article ID TRAUMATIC BRAIN-INJURY; INTERNATIONAL CLASSIFICATION; COMMUNITY REINTEGRATION; HEALTH; PARTICIPATION; SERVICEMEMBERS; OUTCOMES AB Many physical and mental health problems associated with combat casualties affect the reintegration of service members into home and community life. Quantifying and measuring reintegration is important to answer questions about clinical, research, economic, and policy issues that directly affect combat veterans. Although the construct of participation presented in the International Statistical Classification of Diseases and Related Health Problems and in the International Classification of Functioning, Disability and Health provides a theoretical framework with which to understand and measure community reintegration in general, a measure was needed that specifically addressed the reintegration of combat veterans. To address this need, the Community Reintegration for Service Members global outcomes measure was developed. It consists of three scales, which measure extent of participation, perceived limitations, and satisfaction. The measure was validated in a general sample of veterans and in a sample of severely wounded service members. The computer-adapted test version shows good precision, reliability, construct validity, and predictive validity. C1 [Resnik, Linda] Brown Univ, Providence VA Med Ctr, Alpert Med Sch, Providence, RI 02912 USA. [Resnik, Linda] Brown Univ, Dept Hlth Serv Policy & Practice, Alpert Med Sch, Providence, RI 02912 USA. [Reiber, Gayle] Univ Washington, Hlth Serv Res & Dev Serv, Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Resnik, L (reprint author), Brown Univ, Providence VA Med Ctr, Alpert Med Sch, Providence, RI 02912 USA. NR 17 TC 4 Z9 4 U1 1 U2 8 PU AMER ACAD ORTHOPAEDIC SURGEONS PI ROSEMENT PA 6300 N RIVER ROAD, ROSEMENT, IL 60018-4262 USA SN 1067-151X J9 J AM ACAD ORTHOP SUR JI J. Am. Acad. Orthop. Surg. PY 2012 VL 20 SU 1 BP S31 EP S34 DI 10.5435/JAAOS-20-08-S31 PG 4 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 984NZ UT WOS:000307199000008 PM 22865133 ER PT J AU Leung, FW Aljebreen, A AF Leung, Felix W. Aljebreen, Abdulrahman TI Health Care Providers' Acceptance of Unsedated Colonoscopy Before and After a State-of-the-art Lecture on the Feasibility of the Option SO SAUDI JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Acceptance; health care providers; unsedated colonoscopy ID SEDATION; ENDOSCOPY; VETERANS AB Background/Aim: The impact of education on acceptance of unsedated colonoscopy by health care providers is unknown. To test the hypothesis that knowledge imparted by a lecture on unsedated colonoscopy is associated with its enhanced acceptance. Settings and Design: At the State-of-the-Art Lecture on "Unsedated colonoscopy: Is it feasible?" presented at the 8th Pan-Arab Conference on Gastroenterology, February, 2011, Riyadh, Saudi Arabia, a questionnaire survey of the audience was undertaken. Materials and Methods: An expectation questionnaire was administered before and after the lecture. Attendees responded anonymously. Statistical analysis used: The responses of a convenient sample of 49 attendees who provided completed responses to the questionnaire both before and after the lecture were analyzed. Data are expressed as frequency counts and means +/- SEM. Repeated measures analysis of variance (ANOVA), ANOVA with contrasts and Chi-square analysis (Statview II Program for Macintosh computers) were used to assess the data. A P value of <0.05 is considered significant. Results and Conclusions: The mean +/- SEM credibility score (maximum possible score=50) was 25.8 +/- 1.8 before and 33.3 +/- 2.1 after the lecture, with a significant improvement in mean score of 7.5 +/- 1.3 (P=0.001, paired t test). Nineteen (39%) respondents were not willing to consider unsedated colonoscopy for themselves before the lecture. This number decreased to 13 (27%) after the lecture. Before the lecture only 4(8%) respondents were willing to consider unsedated colonoscopy for themselves. After the lecture this number increased to 8(16%). The data suggest education of healthcare professionals regarding the feasibility of unsedated colonoscopy appears to enhance its acceptance as a credible patient care option at a Pan-Arab Gastroenterology Conference. C1 [Leung, Felix W.] VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Res Serv, Los Angeles, CA USA. [Leung, Felix W.] VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Med Serv, Los Angeles, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Aljebreen, Abdulrahman] King Khalid Univ Hosp, KSU, Riyadh 11472, Saudi Arabia. RP Leung, FW (reprint author), VAGLAHS, Sepulveda Ambulatory Care Ctr, 111G,16111 Plummer St, North Hills, CA 91343 USA. EM felixleung@socal.rr.com FU ACG Clinical Research Award; ASGE Career Development Award; Veterans Affairs Greater Los Angeles Healthcare System medical research funds FX Supported in part by 2009 ACG Clinical Research Award, 1985 ASGE Career Development Award, and Veterans Affairs Greater Los Angeles Healthcare System medical research funds. NR 18 TC 0 Z9 0 U1 0 U2 0 PU MEDKNOW PUBLICATIONS PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1319-3767 J9 SAUDI J GASTROENTERO JI Saudi J. Gastroenterol. PD JAN-FEB PY 2012 VL 18 IS 1 BP 50 EP 54 DI 10.4103/1319-3767.91736 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 980JZ UT WOS:000306890800010 PM 22249093 ER PT J AU Wilkinson, CW Peskind, ER Pagulayan, KF Colasurdo, EA Shofer, JB AF Wilkinson, C. W. Peskind, E. R. Pagulayan, K. F. Colasurdo, E. A. Shofer, J. B. TI CHRONIC PITUITARY DYSFUNCTION ASSOCIATED WITH COGNITIVE AND NEUROPSYCHIATRIC DEFICITS AFTER BLAST-RELATED MILD TRAUMATIC BRAIN INJURY SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, NW Network Mental Illness Res, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PY 2012 VL 27 SU 1 MA P-985 PG 1 WC Psychiatry SC Psychiatry GA 977WL UT WOS:000306695402007 ER PT J AU Kertesz, S Polli, D Holt, C Johnson-Roe, K Gordon, A Steward, J Borden, A Kim, T Stringfellow, E AF Kertesz, Stefan Polli, David Holt, Cheryl Johnson-Roe, Kay Gordon, Adam Steward, Jocelyn Borden, Allison Kim, Theresa Stringfellow, Erin TI Implications of Substance Abuse for Primary Care Quality of Homeless Patients SO SUBSTANCE ABUSE LA English DT Meeting Abstract C1 [Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2012 VL 33 IS 2 BP 220 EP 221 PG 2 WC Substance Abuse SC Substance Abuse GA 974UZ UT WOS:000306464200069 ER PT J AU Gordon, AJ Alford, DP AF Gordon, Adam J. Alford, Daniel P. TI Screening, Brief Intervention, and Referral to Treatment (SBIRT) Curricular Innovations: Addressing a Training Gap SO SUBSTANCE ABUSE LA English DT Editorial Material ID PRIMARY-CARE; ALCOHOL-PROBLEMS; EMERGENCY-DEPARTMENT; DRUG-USE; HEALTH; PHYSICIANS; MEDICINE; HOMELESS; BENEFIT; TIME C1 [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Alford, Daniel P.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Alford, Daniel P.] Boston Med Ctr, Boston, MA USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 34 TC 13 Z9 13 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2012 VL 33 IS 3 SI SI BP 227 EP 230 DI 10.1080/08897077.2011.640156 PG 4 WC Substance Abuse SC Substance Abuse GA 974UT UT WOS:000306463600001 PM 22737999 ER PT J AU Childers, JW Broyles, LM Hanusa, BH Kraemer, KL Conigliaro, J Spagnoletti, C McNeil, M Gordon, AJ AF Childers, Julie W. Broyles, Lauren M. Hanusa, Barbara H. Kraemer, Kevin L. Conigliaro, Joseph Spagnoletti, Carla McNeil, Melissa Gordon, Adam J. TI Teaching the Teachers: Faculty Preparedness and Evaluation of a Retreat in Screening, Brief Intervention, and Referral to Treatment SO SUBSTANCE ABUSE LA English DT Article DE Alcohol-related disorders; continuing education; faculty; medical education; substance abuse ID ATTITUDES; DISORDERS; EDUCATION AB Effective clinical faculty are essential for disseminating substance abuse screening, brief intervention, and referral to treatment (SBIRT). The authors developed an 8-hour SBIRT training for internal medicine faculty preceptors. Trainers conducted SBIRT lectures and small-group communication practice sessions. The authors assessed participants' (n = 27) knowledge, skills, and attitudes using an enhanced Alcohol and Alcohol Problems Perceptions Questionnaire (AAPPQ). Participants self-assessed their changes in SBIRT competence and comfort. Faculty trainees did not feel competent in SBIRT, particularly in intervention and referral to treatment. AAPPQ subscale scores were highest in Role Legitimacy and Motivation and lowest in Role Adequacy and Satisfaction. After training, faculty members reported greater likelihood of performing and teaching SBIRT. In some topic areas, faculty attending an SBIRT training reported limited knowledge and competence for treating drinkers; however, their interest and motivation for doing so was high. Ongoing faculty and organizational development efforts may help close these gaps. C1 [Childers, Julie W.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med,Sect Palliat Care & Med Eth, Pittsburgh, PA 15213 USA. [Broyles, Lauren M.; Hanusa, Barbara H.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Broyles, Lauren M.; Hanusa, Barbara H.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Kraemer, Kevin L.; McNeil, Melissa; Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Conigliaro, Joseph] NYU, Dept Internal Med, Langone Med Ctr, New York, NY USA. RP Childers, JW (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med,Sect Palliat Care & Med Eth, Iroqouis Bldg,Suite 405, Pittsburgh, PA 15213 USA. EM childersjw2@upmc.edu FU SBIRT Substance Abuse and Mental Health Service Administration (SAMHSA); SBIRT Center for Substance Abuse Treatment (CSAT) [1TI020263-01]; Division of General Internal Medicine, University of Pittsburgh School of Medicine FX This work was partially funded by the SBIRT in Medical Residency Training Program (Substance Abuse and Mental Health Service Administration (SAMHSA) and the Center for Substance Abuse Treatment (CSAT), 1TI020263-01, Principal Investigator: Janice Pringle, PhD). Additional infrastructure support funding was provided by the Division of General Internal Medicine, University of Pittsburgh School of Medicine. NR 16 TC 3 Z9 3 U1 2 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2012 VL 33 IS 3 SI SI BP 272 EP 277 DI 10.1080/08897077.2011.639686 PG 6 WC Substance Abuse SC Substance Abuse GA 974UT UT WOS:000306463600006 PM 22738004 ER PT J AU Satterfield, JM O'Sullivan, P Satre, DD Tsoh, JY Batki, SL Julian, K McCance-Katz, EF Wamsley, M AF Satterfield, Jason M. O'Sullivan, Patricia Satre, Derek D. Tsoh, Janice Y. Batki, Steven L. Julian, Kathy McCance-Katz, Elinore F. Wamsley, Maria TI Using Standardized Patients to Evaluate Screening, Brief Intervention, and Referral to Treatment (SBIRT) Knowledge and Skill Acquisition for Internal Medicine Residents SO SUBSTANCE ABUSE LA English DT Article DE Graduate medical education; SBIRT; standardized patients; substance use disorders AB Comprehensive clinical competency curricula for hazardous drinking and substance use disorders (SUDs) exists for medical students, residents, and practicing health care providers. Evaluations of these curricula typically focus on learner attitudes and knowledge, although changes in clinical skills are of greater interest and utility. The authors present a pre-post clinical skill evaluation of a 10-hour screening, brief intervention, and referral to treatment (SBIRT) curriculum for hazardous drinking and SUDs for primary care internal medicine residents using standardized patient examinations to better determine the impact of SBIRT training on clinical practice. Residents had large improvements in history taking, substance use screening skills, SUD assessment and diagnostic skills, and in SBIRT knowledge, including documentation, systems, and diversity issues. Residents made moderate improvements in brief intervention skills. Future SBIRT curricular evaluations would ideally include a controlled comparison with larger samples from multiple institutions. C1 [Satterfield, Jason M.; O'Sullivan, Patricia; Julian, Kathy; Wamsley, Maria] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Satre, Derek D.; Tsoh, Janice Y.; Batki, Steven L.; McCance-Katz, Elinore F.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Satre, Derek D.] Kaiser Permanente Div Res, San Francisco, CA USA. [Batki, Steven L.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. RP Satterfield, JM (reprint author), Univ Calif San Francisco, Div Gen Internal Med, 1545 Divisadero St,Box 0320, San Francisco, CA 94143 USA. EM Jsatter@medicine.ucsf.edu NR 8 TC 12 Z9 12 U1 1 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2012 VL 33 IS 3 SI SI BP 303 EP 307 DI 10.1080/08897077.2011.640103 PG 5 WC Substance Abuse SC Substance Abuse GA 974UT UT WOS:000306463600012 PM 22738010 ER PT J AU Bryant, MS Rintala, DH Hou, JG Rivas, SP Fernandez, AL Lai, EC Protas, EJ AF Bryant, M. S. Rintala, D. H. Hou, J. G. Rivas, S. P. Fernandez, A. L. Lai, E. C. Protas, E. J. TI The Relation of Falls to Fatigue, Depression and Daytime Sleepiness in Parkinson's Disease SO EUROPEAN NEUROLOGY LA English DT Article DE Parkinson's disease; Fatigue; Depressive symptomatology; Falls; Non-motor symptoms; Sleepiness ID QUALITY-OF-LIFE; NONMOTOR SYMPTOMS; RISK-FACTORS; SCALE; PREVALENCE; ATTENTION; SEVERITY; PEOPLE; SAMPLE AB Objective: To characterize non-motor symptoms in individuals with Parkinson's disease (PD) who experience falls compared to those who do not fall. Methods: Fifty-four individuals with PD were studied. Thirty-six were fallers and 18 were non-fallers. Fatigue was assessed by the Iowa Fatigue Scale. Excessive daytime sleepiness was assessed by the Epworth Sleepiness Scale, and depressive symptomatology was assessed by the short-form Center for Epidemiologic Studies Depression Scale. Results: Compared to non-fallers, fallers had more severe disability, greater general physical fatigue (p = 0.024), lower energy levels (p = 0.042) and less productivity (p = 0.007). Fallers had more depressive symptomatology than the non-fallers (p = 0.01). Excessive daytime sleepiness was not different between the two groups (p = 0.695). Conclusions: Individuals with PD who fell had more severe motor and non-motor symptoms than those who did not fall. These non-motor symptoms included physical fatigue, energy, productivity and depressive symptomatology. Copyright (C) 2012 S. Karger AG, Basel C1 [Bryant, M. S.; Rivas, S. P.; Fernandez, A. L.; Protas, E. J.] Univ Texas Med Branch, Sch Hlth Profess, Galveston, TX USA. [Bryant, M. S.; Rintala, D. H.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Bryant, M. S.; Hou, J. G.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Hou, J. G.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Lai, E. C.] Methodist Neurol Inst, Houston, TX USA. RP Bryant, MS (reprint author), Rehabil Res MEDVAMC 153, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mon.bryant@yahoo.com FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [K12 HD055929, R01 HD051844]; National Institute of Neurological Disorders and Stroke FX This work was supported in part by grant K12 HD055929 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke and grant R01 HD051844 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 45 TC 8 Z9 8 U1 0 U2 7 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0014-3022 J9 EUR NEUROL JI Eur. Neurol. PY 2012 VL 67 IS 6 BP 326 EP 330 DI 10.1159/000335877 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 966ZG UT WOS:000305875300002 PM 22555623 ER PT J AU Bansal, N Hsu, CY Whooley, M Berg, AH Ix, JH AF Bansal, Nisha Hsu, Chi-yuan Whooley, Mary Berg, Anders H. Ix, Joachim H. TI Relationship of Urine Dopamine with Phosphorus Homeostasis in Humans: The Heart and Soul Study SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Urine dopamine; Phosphorus; Kidney; Proximal tubule ID CORONARY-ARTERY-DISEASE; PHOSPHATE EXCRETION; CYSTATIN-C; CARDIOVASCULAR-DISEASE; DEPRESSIVE SYMPTOMS; PARATHYROID-HORMONE; SERUM PHOSPHORUS; REMNANT KIDNEY; RENAL DOPAMINE; OK CELLS AB Background: Urine dopamine (DA) is produced in the proximal tubule and has been found to increase in response to dietary phosphorus intake, and to contribute to greater urinary phosphorus excretion in animal models. Whether urine DA is associated with phosphorus homeostasis in humans is uncertain. Methods: This was a cross-sectional study of 884 outpatients. DA was measured from 24-hour urine collections. We examined cross-sectional associations between urine DA and serum phosphorus, 24-hour urine phosphorus (as an indicator of dietary phosphorus absorption), fractional excretion of phosphorus (FEphos), fibroblast growth factor (FGF)-23, and parathyroid hormone (PTH). Models were adjusted for age, sex, race, eGFR, albuminuria, hypertension, heart failure, tobacco use, body mass index, and diuretic use. Results: Mean age was 66.6 +/- 11 years and mean eGFR was 71 +/- 21.3 ml/min/1.73 m(2). The mean urine DA was 193 +/- 86 mu g/day, mean serum phosphorus was 3.6 +/- 0.6 mg/dl, mean daily urine phosphorus excretion was 671 8 312 mg/day, and mean FEphos was 17 +/- 9%. In adjusted models, each standard deviation higher DA was associated with 78.4 mg/day higher urine phosphorus and 0.9% lower FEphos (p < 0.05 for both). There was no statistically significant association between urine DA, serum phosphorus, FGF-23 or PTH in adjusted models. Conclusions: Higher dietary phosphorus absorption is associated with higher urine DA in humans, consistent with animal models. However, higher urine DA is not associated with FGF-23 or PTH, suggesting that known mechanisms of renal tubular handling of phosphorus may not be involved in the renal dopamine-phosphorus regulatory pathway in humans. Copyright (C) 2012 S. Karger AG, Basel C1 [Bansal, Nisha] Univ Calif San Francisco, Div Nephrol, Dept Med, San Francisco, CA 94143 USA. [Whooley, Mary] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Whooley, Mary] San Francisco VA Med Ctr, San Francisco, CA USA. [Berg, Anders H.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Family & Preventat Med, Div Preventat Med, San Diego, CA 92103 USA. RP Bansal, N (reprint author), Univ Calif San Francisco, Div Nephrol, Dept Med, 521 Parnassus Ave,Box 0532, San Francisco, CA 94143 USA. EM nisha.bansal@ucsf.edu FU American Kidney Fund; National Institute of Diabetes and Digestive and Kidney Diseases [K23 DK088865, K24 DK92291]; National Heart Lung and Blood Institute [1R01HL096851]; American Heart Association; Sandra Daugherty Foundation; Department of Veterans Affairs; American Federation of Aging Research; Robert Wood Johnson Foundation; Nancy Kirwan Heart Research Fund; Ischemia Research and Education Foundation; NHLBI [R01 HL079235] FX This study was supported by grants from the American Kidney Fund (N.B.), National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK088865 to N.B. and K24 DK92291 to C.H.), National Heart Lung and Blood Institute (1R01HL096851) (J.H.I.), an American Heart Association Fellow-to-Faculty Transition Award (J.H.I.), and an award from the Sandra Daugherty Foundation (J.H.I.). The Heart and Soul Study was funded by the Department of Veterans Affairs, American Federation of Aging Research, Robert Wood Johnson Foundation, Nancy Kirwan Heart Research Fund, Ischemia Research and Education Foundation, and the NHLBI (R01 HL079235). NR 28 TC 1 Z9 1 U1 0 U2 15 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2012 VL 35 IS 6 BP 483 EP 490 DI 10.1159/000338483 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 966BP UT WOS:000305812100001 PM 22572568 ER PT J AU Nieuwsma, JA Trivedi, RB McDuffie, J Kronish, I Benjamin, D Williams, JW AF Nieuwsma, Jason A. Trivedi, Ranak B. McDuffie, Jennifer Kronish, Ian Benjamin, Dinesh Williams, John W., Jr. TI BRIEF PSYCHOTHERAPY FOR DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Review DE depression; psychotherapy; primary healthcare; meta-analysis; review; systematic; psychotherapy; brief ID RANDOMIZED CONTROLLED-TRIAL; PROBLEM-SOLVING TREATMENT; PRIMARY-CARE PATIENTS; COGNITIVE-BEHAVIOR THERAPY; MINOR DEPRESSION; MAJOR DEPRESSION; TELEPHONE PSYCHOTHERAPY; DYSTHYMIA; DISORDER; MINDFULNESS AB Objective: Because evidence-based psychotherapies of 12 to 20 sessions can be perceived as too lengthy and time intensive for the treatment of depression in primary care, a number of studies have examined abbreviated psychotherapy protocols. The purpose of this study was to conduct a systematic review and meta-analysis to determine the efficacy of brief psychotherapy (i.e., <= 8 sessions) for depression. Methods: We used combined literature searches in PubMed, EMBASE, PsycINFO, and an Internet-accessible database of clinical trials of psychotherapy to conduct two systematic searches: one for existing systematic reviews and another for randomized controlled trials (RCTs). Included studies examined evidence-based psychotherapy(s) of eight or fewer sessions, focused on adults with depression, contained an acceptable control condition, were published in English, and used validated measures of depressive symptoms. Results: We retained 2 systematic reviews and 15 RCTs evaluating cognitive behavioral therapy, problem-solving therapy, and mindfulness-based cognitive therapy. The systematic reviews found brief psychotherapies to be more efficacious than control, with effect sizes ranging from -0.33 to -0.25. Our meta-analysis found six to eight sessions of cognitive behavioral therapy to be more efficacious than control (ES -0.42, 95% CI -0.74 to -0.10, I-2 = 56%). A sensitivity analysis controlled for statistical heterogeneity but showed smaller treatment effects (ES -0.24, 95% Cl -0.42 to -0.06, I-2 = 0%). Conclusions: Depression can be efficaciously treated with six to eight sessions of psychotherapy, particularly cognitive behavioral therapy and problem-solving therapy. Access to non-pharmacologic treatments for depression could be improved by training healthcare providers to deliver brief psychotherapies. (Inn. J. Psychiatry in Medicine 2012;43:129-151) C1 [Nieuwsma, Jason A.] Durham VA MIRECC, Durham, NC USA. [Nieuwsma, Jason A.; McDuffie, Jennifer; Williams, John W., Jr.] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Trivedi, Ranak B.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Trivedi, Ranak B.] Univ Washington, Seattle, WA 98195 USA. [McDuffie, Jennifer; Williams, John W., Jr.] Durham VA Evidence Synth Program, Durham, NC USA. [Kronish, Ian] Columbia Univ, Med Ctr, New York, NY 10027 USA. [Benjamin, Dinesh] Carolina Behav Care, Durham, NC USA. RP Nieuwsma, JA (reprint author), VA Midatlantic MIRECC, Legacy Towers 800B,411 W Chapel Hill St, Durham, NC 27701 USA. EM jason.nieuwsma@duke.edu OI Kronish, Ian/0000-0003-0945-2380 FU Department of Veterans Affairs FX The Department of Veterans Affairs Evidence-based Synthesis Program funded this review. The views and opinions in this manuscript are those of the authors and do not reflect those of the VA. NR 46 TC 17 Z9 17 U1 2 U2 19 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2012 VL 43 IS 2 BP 129 EP 151 DI 10.2190/PM.43.2.c PG 23 WC Psychiatry SC Psychiatry GA 964WP UT WOS:000305727700003 PM 22849036 ER PT J AU Banks, WA AF Banks, W. A. TI The Blood-Brain Barrier: Neuroinflammation and Neurodegenerative Disease SO CELL TRANSPLANTATION LA English DT Meeting Abstract CT 19th Annual Meeting of the American-Society-for-Neural-Therapy-and-Repair CY APR 26-28, 2012 CL Clearwater Beach, FL SP Amer Soc Neural Therapy & Repair C1 [Banks, W. A.] Univ Washington, Sch Med, Dept Med,Div Gerontol & Geriatr Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU COGNIZANT COMMUNICATION CORP PI ELMSFORD PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA SN 0963-6897 J9 CELL TRANSPLANT JI Cell Transplant. PY 2012 VL 21 IS 4 BP 773 EP 774 PG 2 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA 961VP UT WOS:000305497900016 ER PT J AU Jubran, A AF Jubran, Amal TI Nurses and ventilators SO CRITICAL CARE LA English DT Editorial Material ID CONTROLLED-TRIAL; OUTCOMES AB In the previous issue of Critical Care, Rose and colleagues report the results of a survey on the frequency with which ICU nurses are involved in decision-making in ventilator management. About 63 to 88% of the decisions were made by nurses in collaboration with physicians, and as much as 68% of ventilator adjustments were performed by nurses independent of physicians. Nurse involvement in decision-making was twice as likely in ICUs that use weaning protocols. The ICU nurse performs many roles, the most important being the continuous observation of a patient. The diversion of a nurse's attention from constant vigilance by performing tasks of no benefit, such as the use of weaning protocols, would be a most unfortunate turn of events. C1 [Jubran, Amal] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA. [Jubran, Amal] Loyola Univ, Med Ctr, Div Pulm & Crit Care Med, Maywood, IL 60153 USA. RP Jubran, A (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, 111N,5th Ave & Roosevelt Rd, Hines, IL 60141 USA. EM ajubran@lumc.edu NR 8 TC 2 Z9 2 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PY 2012 VL 16 IS 1 AR 115 DI 10.1186/cc11186 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 960MU UT WOS:000305393400049 PM 22369739 ER PT J AU Fang, MA Heiney, C Yentes, JM Harada, ND Masih, S Perell-Gerson, KL AF Fang, Meika A. Heiney, Constance Yentes, Jennifer M. Harada, Nancy D. Masih, Sulabha Perell-Gerson, Karen L. TI Clinical and Spatiotemporal Gait Effects of Canes in Hip Osteoarthritis SO PM&R LA English DT Article ID KNEE OSTEOARTHRITIS; ASSISTIVE DEVICES; MUSCLE MOMENTS; PAIN; EPIDEMIOLOGY; PREVENTION; MANAGEMENT; WALKERS; WALKING AB Objective: To investigate the effects of cane use on spatiotemporal gait parameters, pain, and function in adults with hip osteoarthritis (OA). Design: Prospective observational study. Setting: An academic tertiary Veterans Affairs Healthcare Center. Participants: Thirteen adults with symptomatic hip OA and 13 healthy adults. Methods: We undertook gait analysis in all subjects with an optoelectronic camera system. Pain, stiffness, and physical function in subjects with hip OA were assessed with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Main Outcome Measurements: Baseline spatiotemporal measures of unaided gait were obtained for healthy subjects. Baseline and 4-week spatiotemporal gait parameters were assessed for hip OA subjects while they walked with and without a cane. Participants with hip OA completed the WOMAC at baseline and after 4 weeks of cane use. Results: At baseline when walking unaided, the subjects with hip OA (age range 60-75 years) had a significantly slower gait velocity, shorter affected limb stride length, and longer double-stance time compared with healthy control subjects. When walking with a cane, they had a reduction in gait velocity (P < .05) caused by a decrease in cadence (P < .05) compared with walking unaided. After 4 weeks of cane use, the participants with hip OA demonstrated significant improvements in gait velocity (P < .05) and double-stance time (P < .05) when walking with a cane in comparison with baseline data. There was no improvement in pain and function after 4 weeks of cane use, a period in which only approximately 60% of the hip OA subjects used the cane 6 or more times per week. Conclusions: Initial use of a cane led to decreased gait velocity and cadence in people with hip OA compared with walking unaided. This difference in gait velocity diminished after they practiced walking with the cane. Inconsistent use of the cane may have contributed to the lack of improvement in the subjects' hip OA pain and function. PM R 2012;4:30-36 C1 [Fang, Meika A.; Heiney, Constance; Harada, Nancy D.; Masih, Sulabha; Perell-Gerson, Karen L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Fang, Meika A.; Harada, Nancy D.; Masih, Sulabha] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Yentes, Jennifer M.] Univ Nebraska, Nebraska Biomech Core Facil, Omaha, NE 68182 USA. [Perell-Gerson, Karen L.] Georgia Gwinnett Coll, Sch Sci & Technol, Lawrenceville, GA USA. RP Fang, MA (reprint author), Rheumatol Sect 111J,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM meika.fang@med.va.gov OI Yentes, Jennifer/0000-0001-6550-7759 FU Southern California Arthritis Foundation FX This work was supported by an Innovative Research Grant from the Southern California Arthritis Foundation. NR 36 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 J9 PM&R JI PM&R PD JAN PY 2012 VL 4 IS 1 BP 30 EP 36 DI 10.1016/j.pmrj.2011.08.534 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 961BF UT WOS:000305438200006 PM 22088853 ER PT J AU Gaffo, AL Jacobs, DR Lewis, CE Mikuls, TR Saag, KG AF Gaffo, Angelo L. Jacobs, David R., Jr. Lewis, Cora E. Mikuls, Ted R. Saag, Kenneth G. TI Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; URIC-ACID LEVELS; RACIAL-DIFFERENCES; KIDNEY-DISEASE; RENAL-DISEASE; UNITED-STATES; CARDIA; PREVALENCE; BLACK AB Introduction: Findings that African-American race/ethnicity is associated with higher concentrations of serum urate have not been adjusted for possible confounding factors or have not explored this question as a primary outcome. We tested this hypothesis in a bi-racial cohort of younger African-American and white men and women. Methods: Data from 5,049 participants at the Coronary Artery Risk Development in Young Adults (CARDIA) cohort baseline (1985 to1986) and follow-up for up to 20 years of individuals without hyperuricemia (defined as a serum urate of 6.8 mg/dL or more) at baseline were utilized. We determined associations between race, serum urate and the development of hyperuricemia in sex-specific cross-sectional and longitudinal analyses. Confounding factors examined included: age at enrollment, body mass index, development of hypertension, glomerular filtration rate, medication use, diet and alcohol intake and menopausal symptoms in women. Results: Referent to whites, African-American men and women had significantly lower concentrations of serum urate at baseline. African-American men had an essentially equal risk of developing incident hyperuricemia during follow-up compared with white men (multivariable adjusted HR = 1.12 (0.88 to1.40)). African-American women developed a significantly increased risk of hyperuricemia when compared to white women (HR = 2.31 (1.34 to 3.99)). Conclusions: Young African-American men and women had lower concentrations of serum urate than whites. During longitudinal follow-up, African-American women had a significantly increased risk of developing hyperuricemia when compared with white women, a difference that was not observed in men. Differences in production of serum urate or a more rapid decline in fractional excretion of serum urate are potential, albeit still unproven, explanations for these findings in African-American women. C1 [Gaffo, Angelo L.; Saag, Kenneth G.] Div Rheumatol, Birmingham, AL 35294 USA. [Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA. [Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, N-0316 Oslo, Norway. [Lewis, Cora E.] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Sect Rheumatol & Immunol, Omaha, NE 68198 USA. RP Saag, KG (reprint author), Div Rheumatol, 172 Shelby Interdisciplinary Biomed Res Bldg,1825, Birmingham, AL 35294 USA. EM ksaag@uab.edu FU University of Alabama at Birmingham, Coordinating Center [N01-HC-95095]; University of Alabama at Birmingham, Field Center [N01-HC-48047]; University of Minnesota, Field Center and Diet Reading Center [N01-HC 48048]; Northwestern University, Field Center [N01-HC-48049]; Kaiser Foundation Research Institute [N01-HC-48050]; University of California, Irvine, Echocardiography Reading Center [N01-HC-45134]; Harbor-UCLA Research Education Institute, Computed Tomography Reading Center [N01-HC-05187]; Wake Forest University [N01-HC-45205]; New England Medical Center from the National Heart, Lung and Blood Institute [N01-HC-45204] FX Work on this manuscript was supported (or partially supported) by contracts: University of Alabama at Birmingham, Coordinating Center, N01-HC-95095; University of Alabama at Birmingham, Field Center, N01-HC-48047; University of Minnesota, Field Center and Diet Reading Center (Year 20 Exam), N01-HC 48048; Northwestern University, Field Center, N01-HC-48049; Kaiser Foundation Research Institute, N01-HC-48050; University of California, Irvine, Echocardiography Reading Center (Year 5 and 10), N01-HC-45134; Harbor-UCLA Research Education Institute, Computed Tomography Reading Center (Year 15 Exam), N01-HC-05187; Wake Forest University (Year 20 Exam), N01-HC-45205; New England Medical Center (Year 20 Exam), N01-HC-45204 from the National Heart, Lung and Blood Institute. NHLBI had input into the overall design and conduct of the CARDIA study. NR 32 TC 11 Z9 11 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2012 VL 14 IS 1 AR R4 DI 10.1186/ar3552 PG 7 WC Rheumatology SC Rheumatology GA 951CQ UT WOS:000304698800018 PM 22225548 ER PT J AU Nabatian, AS Bashir, MM Wysocka, M Sharma, M Werth, VP AF Nabatian, Adam S. Bashir, Muhammad M. Wysocka, Maria Sharma, Meena Werth, Victoria P. TI Tumor necrosis factor alpha release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID HUMAN DENDRITIC CELLS; TNF-ALPHA; ENDOTHELIAL-CELLS; SKIN DISEASES; ERYTHEMATOSUS; RECEPTORS; PSORIASIS; CYTOKINES; LESIONS; ACCUMULATION AB Introduction: Several studies have reported that TNF alpha is substantially increased within skin lesions of patients with discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE) and dermatomyositis (DM) compared to controls. Elevated TNF alpha has been reported in the sera of some patients with systemic lupus erythematosus, DLE and SCLE, but not in the sera of patients with DM. Because of the key pathogenic role of autoimmunity in these diseases, in this study we sought to evaluate TNF alpha production by a readily available source of immune cells (namely, peripheral blood mononuclear cells (PBMCs)) taken from controls and from patients with cutaneous lupus or DM. Methods: Freshly isolated PBMCs were cultured overnight, and TNF alpha protein accumulation in conditioned medium was determined. In addition, flow cytometry using cell-type-specific markers was performed to determine the sources of TNF alpha. One-way analysis of variance and Dunnett's multiple comparisons test were performed for statistical comparisons. Results: Accumulation of TNF alpha protein in conditioned medium containing PBMCs from DLE patients, but not from SCLE, TLE or DM patients, was significantly greater (19-fold) than that from controls (P < 0.001). In DLE PBMCs, increased TNF alpha was produced by circulating monocytes and myeloid dendritic cells (mDCs). The mean TNF alpha fluorescence intensity, but not the total number, of both monocytes and mDCs (P < 0.01) from DLE patients was significantly greater (2.3-fold) than that of controls. There were significantly more (13.3-fold) mDCs with intracellular TNF alpha in blood from DLE patients (P < 0.001) and DM patients (P < 0.001) compared to controls. Most importantly, a positive correlation was seen in DLE patients between their disease activity measured using the Cutaneous Lupus Erythematosus Disease Area and Severity Index and TNF alpha protein secretion (r = 0.61, P < 0.08). Conclusions: TNF alpha protein production by PBMCs is greater in DLE patients than in patients with other cutaneous forms of lupus and DM or in controls. Flow cytometric studies demonstrated that circulating monocytes and mDCs contributed to this increased TNF alpha production. Monocytes and mDCs are present in lesional skin, and the increased TNF alpha production by these cells and other PBMCs likely increase the number of inflammatory cells seen in DLE skin relative to other subsets of cutaneous lupus erythematosus and DM. These results provide a possible biological explanation for the denser infiltrate seen in DLE relative to DM. C1 [Nabatian, Adam S.; Bashir, Muhammad M.; Sharma, Meena; Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Nabatian, Adam S.; Bashir, Muhammad M.; Wysocka, Maria; Sharma, Meena; Werth, Victoria P.] Univ Penn, Dept Dermatol, Sch Med, Philadelphia, PA 19104 USA. [Nabatian, Adam S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA. RP Werth, VP (reprint author), Philadelphia Vet Affairs Med Ctr, 38th & Woodland Ave, Philadelphia, PA USA. EM werth@mail.med.upenn.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; National Institutes of Health (NIH) [K24-AR 02207] FX This study was supported in part by a merit review grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, and by National Institutes of Health (NIH) grant K24-AR 02207 (to VPW).). In addition, funding was provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. NR 36 TC 9 Z9 9 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2012 VL 14 IS 1 AR R1 DI 10.1186/ar3549 PG 11 WC Rheumatology SC Rheumatology GA 951CQ UT WOS:000304698800015 PM 22217359 ER PT J AU Shamloo, BK Chhabra, P Freedman, AN Potosky, A Malin, J Smith, SW AF Shamloo, Behrooz K. Chhabra, Pankdeep Freedman, Andrew N. Potosky, Arnold Malin, Jennifer Smith, Sheila Weiss TI Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality Analysis SO DRUG SAFETY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; METASTATIC COLORECTAL-CANCER; INTRAVITREAL BEVACIZUMAB; TUMOR-GROWTH; ANGIOGENESIS; CARCINOMA; RECEPTOR; CELLS; SURVEILLANCE AB Background: Bevacizumab is the first in its class, vascular endothelial growth factor (VEGF) inhibitor that was initially approved by the US FDA in 2004 for the treatment of metastatic colon cancer and other solid tumors. Pre-approval clinical trials, particularly for oncology drugs, are limited in their ability to detect certain adverse effects and, therefore, the FDA and pharmaceutical sponsors collect and monitor reports of adverse events (AEs) following approval. Objective: The purpose of this study was to screen the FDA's Adverse Event Reporting System (AERS) database for novel AEs that may be attributed to bevacizumab. Methods: The FDA AERS database was used to identify all AE reports for bevacizumab from February 2004 to September 2009. Disproportionality analysis was conducted for bevacizumab against all other drugs in the background by setting statistical significance at proportional reporting ratio (PRR) >= 2, observed case count >= 3 and chi-square >= 4. Subsequent clinical evaluation was performed to determine the clinical relevance of the findings and to group related events. Results: A total of 523 Preferred Terms (PTs) were disproportionally reported; following clinical review 63 (12%) were found to be both unlabelled and of clinical importance. These PTs were grouped into 15 clinical disorder groups. Among the clinical disorders, electrolyte abnormalities had the greatest number of reports (n=426) followed by cardiovascular events (n=421), gastrointestinal events (n=345), nervous system disorders (n=106) and pneumonitis (n=96). On sensitivity analysis, a number of clinically important unlabelled disorders, such as necrotizing fasciitis, vessel wall disorders, arrhythmia and conduction disorder and autoimmune thrombocytopenia still met the statistical significance criteria. Conclusions: During the study period, out of 12 010 AE reports mentioning bevacizumab, it was listed as the suspect drug in 94.2% of the reports. Our disproportionality analysis identified many events that are already recognized as AEs of bevacizumab, but it also identified a number of clinically important unlabelled terms, which if confirmed in future studies would have potential implications for use of bevacizumab in clinical practice. C1 [Chhabra, Pankdeep; Smith, Sheila Weiss] Univ Maryland, Ctr Drug Safety, Sch Pharm, Baltimore, MD 21201 USA. [Shamloo, Behrooz K.] Univ Nevada, Sch Med, Nevada Canc Inst, Las Vegas, NV 89154 USA. [Freedman, Andrew N.] NCI, NIH, Bethesda, MD 20892 USA. [Potosky, Arnold] Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA. [Malin, Jennifer] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Smith, SW (reprint author), Univ Maryland, Ctr Drug Safety, Sch Pharm, 220 Arch St,12th Floor, Baltimore, MD 21201 USA. EM sweiss@rx.umaryland.edu NR 37 TC 10 Z9 11 U1 0 U2 2 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0114-5916 J9 DRUG SAFETY JI Drug Saf. PY 2012 VL 35 IS 6 BP 507 EP 518 PG 12 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology GA 955TF UT WOS:000305043100008 PM 22612854 ER PT J AU Royall, DR Palmer, RF O'Bryant, SE AF Royall, Donald R. Palmer, Raymond F. O'Bryant, Sid E. CA Texas Alzheimer's Res Care TI Validation of a Latent Variable Representing the Dementing Process SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Aging; cognition; dementia; functional status; g ID MILD COGNITIVE IMPAIRMENT; AMERICAN-NEUROPSYCHIATRIC-ASSOCIATION; MINI-MENTAL-STATE; GENERAL INTELLIGENCE; INSTRUMENTAL ACTIVITIES; COMMUNITY DWELLERS; COMPLEX ACTIVITIES; FUNCTIONAL STATUS; PERFORMANCE; DIAGNOSIS AB The cognitive correlates of functional status are essential to dementia case-finding. Nevertheless, cognitive performance is a generally weak predictor of functional outcomes. We have employed structural equation models to explicitly distinguish functional status, and therefore "dementia-relevant" variance in cognitive task performance (i.e., delta) from the variance that is unrelated to a dementing process (i.e., g'). Together, g' + delta encompass Spearman's g. Although delta represents only a small fraction of the total variance in cognitive task performance, it is more strongly associated with dementia status than is g'. In this study, we validate delta in a well characterized Alzheimer's disease cohort, the Texas Alzheimer's Research and Care Consortium. Our approach results in "error free" continuous variables. This suggests that delta can serve as a dementia specific endophenotype. As a result, future studies may be able to associate delta with inflammatory and genetic biomarkers. C1 [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Royall, Donald R.; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Royall, Donald R.] S Texas Vet Hlth Syst Audie L Murphy Div GRECC, San Antonio, TX USA. [O'Bryant, Sid E.] Univ N Texas Hlth Sci Ctr, Dept Internal Med, Ft Worth, TX USA. [O'Bryant, Sid E.] Univ N Texas Hlth Sci Ctr, Inst Aging & Alzheimers Dis Res, Ft Worth, TX USA. RP Royall, DR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM royall@uthscsa.edu OI O'Bryant, Sid/0000-0003-0582-5266 FU Texas Council on Alzheimer's Disease and Related Disorders FX This study was made possible by the Texas Alzheimer's Research Consortium (TARCC) funded by the state of Texas through the Texas Council on Alzheimer's Disease and Related Disorders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 20 Z9 20 U1 1 U2 6 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 30 IS 3 BP 639 EP 649 DI 10.3233/JAD-2012-120055 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 955OX UT WOS:000305031400015 PM 22451315 ER PT S AU Antony, BJ Abramoff, MD Sonka, M Kwon, YH Garvin, MK AF Antony, Bhavna J. Abramoff, Michael D. Sonka, Milan Kwon, Young H. Garvin, Mona K. BE Haynor, DR Ourselin, S TI Incorporation of Texture-based Features in Optimal Graph-Theoretic Approach with Application to the 3-D Segmentation of Intraretinal Surfaces in SD-OCT Volumes SO MEDICAL IMAGING 2012: IMAGE PROCESSING SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging - Image Processing CY FEB 06-09, 2012 CL San Diego, CA SP SPIE, Agilent Technol, Diamond SA, DQE Instruments Inc, eMagin, Isuzu Glass Co Ltd, Medtron Inc, Ocean Thin Films Inc DE Graph-theoretic approach; texture features; multiple surface segmentation; optical coherence tomography; intra-retinal surfaces ID GABOR FILTERS; SEARCH; IMAGES; MOTION AB While efficient graph-theoretic approaches exist for the optimal (with respect to a cost function) and simultaneous segmentation of multiple surfaces within volumetric medical images, the appropriate design of cost functions remains an important challenge. Previously proposed methods have used simple cost functions or optimized a combination of the same, but little has been done to design cost functions using learned features from a training set, in a less biased fashion. Here, we present a method to design cost functions for the simultaneous segmentation of multiple surfaces using the graph-theoretic approach. Classified texture features were used to create probability maps, which were incorporated into the graph-search approach. The efficiency of such an approach was tested on 10 optic nerve head centered optical coherence tomography (OCT) volumes obtained from 10 subjects that presented with glaucoma. The mean unsigned border position error was computed with respect to the average of manual tracings from two independent observers and compared to our previously reported results. A significant improvement was noted in the overall means which reduced from 9.25 +/- 4.03 mu m to 6.73 +/- 2.45 mu m (p < 0.01) and is also comparable with the inter-observer variability of 8.85 +/- 3.85 mu m. C1 [Abramoff, Michael D.; Garvin, Mona K.] US Dept Vet Affairs, Iowa City, IA 20571 USA. [Antony, Bhavna J.; Abramoff, Michael D.; Sonka, Milan; Garvin, Mona K.] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA. [Abramoff, Michael D.; Sonka, Milan; Kwon, Young H.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA. RP Garvin, MK (reprint author), US Dept Vet Affairs, Iowa City, IA 20571 USA. EM bantony@engineering.uiowa.edu; mona-garvin@uiowa.edu FU NIH [EY018853, EY017066] FX This work was supported in part by NIH grants R01 EY018853 and EY017066 and and the Department of Veterans Affairs Rehabilitation Research and Development Division (Iowa City Center for the Prevention and Treatment of Visual Loss and Career Development Award; Dr. Garvin) NR 16 TC 2 Z9 2 U1 0 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-8963-0 J9 PROC SPIE PY 2012 VL 8314 AR 83141G DI 10.1117/12.911491 PG 11 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BAN14 UT WOS:000304820000050 ER PT B AU Fan, VS Giardino, ND AF Fan, Vincent S. Giardino, Nicholas D. BE Nici, L Wallack, RZ TI Anxiety and Depression SO CHRONIC OBSTRUCTIVE PULMONARY DISEASE: CO-MORBIDITIES AND SYSTEMIC CONSEQUENCES SE Respiratory Medicine Series LA English DT Article; Book Chapter DE Depression; Anxiety; COPD; Comorbidity; Quality of life; Exacerbation; Mortality; Diagnosis; Medication; Pharmacotherapy; Treatment ID OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; C-REACTIVE PROTEIN; RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; COGNITIVE-BEHAVIORAL THERAPY; INTERFERON-ALPHA THERAPY; COPD PATIENTS; MAJOR DEPRESSION; FUNCTIONAL STATUS AB Increasing evidence suggests that depression and anxiety are important comorbidities in COPD, and are associated with a number of adverse outcomes including worse health-related quality of life, an increased risk of exacerbations, and a higher mortality. The burden of depression in COPD is higher than in the general population, and many patients remain undiagnosed. Although treatment of depression and anxiety may include medications or pharmacotherapy, many patients with depressive symptoms do not receive treatment. C1 [Fan, Vincent S.] Univ Washington, Sch Med, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Giardino, Nicholas D.] Univ Michigan, Dept Psychiat, VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48109 USA. RP Fan, VS (reprint author), Univ Washington, Sch Med, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM Vincent.Fan@va.gov; ngiardin@med.umich.edu NR 144 TC 1 Z9 1 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60761-672-6 J9 RESPIR MED SER PY 2012 BP 95 EP 118 DI 10.1007/978-1-60761-673-3_7 D2 10.1007/978-1-60761-673-3 PG 24 WC Cardiac & Cardiovascular Systems; Medicine, General & Internal SC Cardiovascular System & Cardiology; General & Internal Medicine GA BZD38 UT WOS:000301157200007 ER PT B AU Hokari, M Yenari, MA AF Hokari, Masaaki Yenari, Midori A. BE Lapchak, PA Zhang, JH TI Hypothermia to Identify Therapeutic Targets for Stroke Treatment SO TRANSLATIONAL STROKE RESEARCH: FROM TARGET SELECTION TO CLINICAL TRIALS SE Springer Series in Translational Stroke Research LA English DT Article; Book Chapter ID FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; DELAYED POSTISCHEMIC HYPOTHERMIA; DAMAGE COOL AID; NF-KAPPA-B; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; INTRACEREBRAL HEMORRHAGE; RAT-BRAIN AB Hypothermia has emerged as a viable neuroprotectant at the clinical level. The reasons for its protective effect arc likely due to its ability to affect multiple facets of ischemic brain injury. While at times difficult to implement in humans due to various comorbidities, hypothermia can also be viewed as a tool by which neuroprotective targets may be identified. In this review, we discuss optimal conditions for therapeutic hypothermia, as evidenced by laboratory studies, as well as many of the effects of cooling on several cell death and cell survival pathways. The collective scientific literature indicates that temperature need only be decreased by a few degrees in order to confer protection, but early cooling and cooling of somewhat long duration (12-24 h) seem to be the more critical factors that determine success. Hypothermia seems to halt many damaging processes that lead to brain tissue injury, while upregulating factors that aid in its recovery. However, it should be noted that not all forms of brain injury benefit front therapeutic cooling. While global and focal cerebral ischemia appears to benefit from hypothermia, it is less clear whether brain hemorrhage responds in the same way. Thus, the laboratory literature also emphasizes the importance of careful preclinical studies prior to applying such concepts to humans. C1 [Hokari, Masaaki; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Hokari, Masaaki; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM karimasa@med.hokudai.ac.jp; Yenari@alum.mit.edu NR 100 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-9529-2 J9 SPR SER TRANSL STROK PY 2012 BP 305 EP 320 DI 10.1007/978-1-4419-9530-8_15 D2 10.1007/978-1-4419-9530-8 PG 16 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BAC01 UT WOS:000303777600016 ER PT S AU Whitfield-Gabrieli, S Ford, JM AF Whitfield-Gabrieli, Susan Ford, Judith M. BE NolenHoeksema, S TI Default Mode Network Activity and Connectivity in Psychopathology SO ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 8 SE Annual Review of Clinical Psychology LA English DT Article; Book Chapter DE resting state; schizophrenia; depression ID RESTING HUMAN BRAIN; STATE FUNCTIONAL CONNECTIVITY; MEDIAL PREFRONTAL CORTEX; TREATMENT-RESISTANT DEPRESSION; POSITRON-EMISSION-TOMOGRAPHY; FREQUENCY BOLD FLUCTUATIONS; ANTERIOR CINGULATE CORTEX; MAJOR DEPRESSION; BIPOLAR DISORDER; WORKING-MEMORY AB Neuropsychiatric disorders are associated with abnormal function of the default mode network (DMN), a distributed network of brain regions more active during rest than during performance of many attention-demanding tasks and characterized by a high degree of functional connectivity (i.e., temporal correlations between brain regions). Functional magnetic resonance imaging studies have revealed that the DMN in the healthy brain is associated with stimulus-independent thought and self-reflection and that greater suppression of the DMN is associated with better performance on attention-demanding tasks. In schizophrenia and depression, the DMN is often found to be hyperactivated and hyperconnected. In schizophrenia this may relate to overly intensive self-reference and impairments in attention and working memory. In depression, DMN hyperactivity may be related to negative rumination. These findings are considered in terms of what is known about psychological functions supported by the DMN, and alteration of the DMN in other neuropsychiatric disorders. C1 [Whitfield-Gabrieli, Susan] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Ford, Judith M.] Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. RP Whitfield-Gabrieli, S (reprint author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA. EM swg@mit.edu NR 188 TC 323 Z9 334 U1 15 U2 112 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 1548-5943 BN 978-0-8243-3908-1 J9 ANNU REV CLIN PSYCHO JI Annu. Rev. Clin. Psychol. PY 2012 VL 8 BP 49 EP + DI 10.1146/annurev-clinpsy-032511-143049 PG 37 WC Psychology, Clinical; Psychology SC Psychology GA BAH99 UT WOS:000304200200004 PM 22224834 ER PT J AU Bramoweth, AD Taylor, DJ AF Bramoweth, Adam D. Taylor, Daniel J. TI Chronic Insomnia and Health Care Utilization in Young Adults SO BEHAVIORAL SLEEP MEDICINE LA English DT Article ID EPWORTH SLEEPINESS SCALE; QUALITY-OF-LIFE; PSYCHIATRIC-DISORDERS; GENERAL-POPULATION; ECONOMIC BURDEN; INDIRECT COSTS; UNITED-STATES; DEPRESSION; INVENTORY; EPIDEMIOLOGY AB Chronic insomnia is prevalent, contributes a significant economic burden, and people with insomnia have increased health care utilization (HCU). The purpose of this study was to investigate the relationship between chronic insomnia and HCU in a population with fewer medical/mental health problems, using current operational definitions of chronic insomnia and multiple measures of HCU. Participants with chronic insomnia had greater HCU than normal sleepers. Participants with chronic insomnia plus a comorbid condition had greater HCU than normal sleepers with a medical/mental health problem and participants with only chronic insomnia. The relationship between chronic insomnia and HCU was moderated by comorbid medical/mental health problems. Early identification and intervention of chronic insomnia may help reduce HCU and costs associated with chronic insomnia. C1 [Bramoweth, Adam D.] Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [Taylor, Daniel J.] Univ N Texas, Dept Psychol, Ft Worth, TX USA. RP Bramoweth, AD (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr,151R-H, Pittsburgh, PA 15206 USA. EM adam.bramoweth@va.gov OI Bramoweth, Adam/0000-0002-3535-0292 NR 55 TC 9 Z9 9 U1 1 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1540-2002 J9 BEHAV SLEEP MED JI Behav. Sleep Med. PY 2012 VL 10 IS 2 BP 106 EP 121 DI 10.1080/15402002.2011.587067 PG 16 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 945ME UT WOS:000304277100003 PM 22468929 ER PT J AU Ravona-Springer, R Moshier, E Schmeidler, J Godbold, J Akrivos, J Rapp, M Grossman, HT Wysocki, M Silverman, JM Haroutunian, V Beeri, MS AF Ravona-Springer, Ramit Moshier, Erin Schmeidler, James Godbold, James Akrivos, Jimmy Rapp, Michael Grossman, Hillel T. Wysocki, Michael Silverman, Jeremy M. Haroutunian, Vahram Beeri, Michal Schnaider TI Changes in Glycemic Control are Associated with Changes in Cognition in Non-Diabetic Elderly SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Cognition; elderly; glucose control; HbA1c; non-diabetic ID MINI-MENTAL-STATE; ALZHEIMER-DISEASE; OLDER-ADULTS; GLYCATED HEMOGLOBIN; DIABETES-MELLITUS; ALL-CAUSE; DEMENTIA; IMPAIRMENT; BRAIN; POPULATION AB The aim of the present study was to examine the relationship of changes in long term glucose levels as measured by Hemoglobin A1c (HbA1c) with simultaneous changes in cognition. The sample included in the present analysis consisted of 101 community dwelling non-diabetic elderly subjects participating in ongoing longitudinal studies of cognition. Subjects were included in this study if they were cognitively normal at baseline, had at least one co-temporaneous follow-up assessment of HbA1c and the Mini Mental State Exam (MMSE), and complete data on age, gender, race, and years of education. MMSE decline over time was the main outcome measure. In TOBIT mixed regression models, MMSE was the dependent variable and HbA1c the time-varying covariate. Sociodemographic (age, gender, and education), cardiovascular (hypertension and APOE4 status), and lifestyle (smoking and physical activity) covariates were included in the statistical model. After adjusting for age at follow-up, there was a decrease of 1.37 points in the MMSE (p = 0.0002) per unit increase in HbA1c. This result remained essentially unchanged after adjusting also for gender and education (p = 0.0005), cardiovascular factors (p = 0.0003), and lifestyle (p = 0.0006). Additionally, results remained very similar after excluding subjects with potentially incipient diabetes with HbA1c between 6 and 7. These findings suggest that in non-diabetic non-demented elderly subjects, an increase in HbA1c over time is associated with cognitive decline. Such results may have broad clinical applicability since manipulation of glucose control, even in non-diabetics, may affect cognitive performance, perhaps enabling preventive measures against dementia. C1 [Ravona-Springer, Ramit] Chaim Sheba Med Ctr, Ramat Gan, Israel. [Moshier, Erin; Godbold, James] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA. [Schmeidler, James; Akrivos, Jimmy; Grossman, Hillel T.; Wysocki, Michael; Silverman, Jeremy M.; Haroutunian, Vahram; Beeri, Michal Schnaider] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Rapp, Michael] Humboldt Univ, Dept Psychiat, D-10099 Berlin, Germany. [Grossman, Hillel T.; Silverman, Jeremy M.; Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Ravona-Springer, R (reprint author), Chaim Sheba Med Ctr, Memory Clin, IL-52621 Tel Hashomer, Israel. EM ramit.ravona@sheba.health.gov.il FU NIA [K01 AG023515-01, R01 AG034087, P01 AG02219, P50 AG05138]; Irma T. Hirschl award; Berkman Trust; Leir Foundation FX Supported by NIA grants K01 AG023515-01 and R01 AG034087 for Dr. Beeri, P01 AG02219 for Drs. Haroutunian and Schmeidler, and P50 AG05138 for Drs. Sano and Schmeidler, as well as by the Irma T. Hirschl award for Dr. Beeri and the Berkman Trust and Leir Foundation for Dr. Haroutunian. NR 46 TC 32 Z9 32 U1 2 U2 8 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 30 IS 2 BP 299 EP 309 DI 10.3233/JAD-2012-120106 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 947BD UT WOS:000304400700007 PM 22426020 ER PT J AU Yehia, BR Long, JA Stearns, CR French, B Tebas, P Frank, I AF Yehia, Baligh R. Long, Judith A. Stearns, Cordelia R. French, Benjamin Tebas, Pablo Frank, Ian TI Impact of transitioning from HIV clinical trials to routine medical care on clinical outcomes and patient perceptions SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; transitions in care; patient perceptions; clinical outcomes; clinical trials ID ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; SEQUENTIAL 3-DRUG REGIMENS; PROTEASE INHIBITOR THERAPY; CD4 CELL COUNT; INITIAL TREATMENT; VIROLOGICAL RESPONSE; INFECTED PATIENTS; ADHERENCE; PREDICTORS AB Participation in antiretroviral therapy clinical trials (ART-RCTs) offers many advantages including access to new drugs, close monitoring, and cost savings. These same benefits may pose a risk to patients ending ART-RCTs and returning to routine care; as they may experience changes to their drug regimen, decreased monitoring, and new out-of-pocket costs. We aimed to evaluate this transition and determine its effects on viral outcomes and patient perceptions. A retrospective cohort was assembled from participants of naive ART-RCTs at the University of Pennsylvania between 1 January 2000 and 31 December 2009. Data were collected in the 12 months prior to and after trial completion. Multivariable logistic regression was used to evaluate viral failure rates and to identify factors associated with viral failure. Qualitative interviews were held with a subset of patients. Content analysis was used to identify thematic differences between patients with viral failure and those with viral suppression. In total, 116 patients enrolled in 5 ART-RCTs from 2000 to 2009. Viral failure was observed in 39 patients (34%). Nonwhites, high enrollment CD4 count, and trial completion in 1999-2002 were risk factors for failure. Patients transitioning from ART-RCTs to routine care had a 20% increased odds of failure (Adjusted Odds Ratio 1.20 (95% CI[ 0.37, 3.88])). Nine patients with viral suppression and three with viral failure in the year after trail completion were interviewed. Suppressed patients were more eager to continue trial participation, nervous about leaving the trial, and felt prepared to return to routine care. In contrast, those with viral failure were less concerned about the transition. These findings suggest that the posttrial period may be a vulnerable time for patients. Patients without a healthy fear of transitioning from ART-RCTs to routine care may be at increased risk of viral failure. Focus should be given to assisting patients during this transition. C1 [Yehia, Baligh R.; Long, Judith A.; Stearns, Cordelia R.; Tebas, Pablo; Frank, Ian] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Long, Judith A.] Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA USA. [French, Benjamin] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Yehia, BR (reprint author), Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. EM byehia@upenn.edu NR 42 TC 1 Z9 1 U1 1 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2012 VL 24 IS 6 BP 769 EP 777 DI 10.1080/09540121.2011.630368 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 944LS UT WOS:000304204400013 PM 22106980 ER PT J AU Brawner, BM Gomes, MM Jemmott, LS Deatrick, JA Coleman, CL AF Brawner, B. M. Gomes, M. M. Jemmott, L. S. Deatrick, J. A. Coleman, C. L. TI Clinical depression and HIV risk-related sexual behaviors among African-American adolescent females: Unmasking the numbers SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV/AIDS; depression; adolescents; African-American; mixed methods ID RANDOMIZED CONTROLLED-TRIAL; REDUCTION INTERVENTIONS; PSYCHIATRIC OUTPATIENTS; SUBSTANCE USE; SYMPTOMS; VALIDITY; PHQ-9; PREDICTORS; INFECTION; ADULTS AB Clinically depressed and nondepressed African-American adolescent females aged 13-19 years (N = 131) were interviewed and surveyed to determine the relationship between depression and HIV risk-related sexual behaviors. Narratives indicate that the psychopathology ofdepression may create situations where the target population could become exposed to HIV. Specifically, depressed participants described feelings of loneliness, isolation, and wanting somebody to "comfort them" as aspects of depression that affect the decisions they make about sex and relationships. In essence, sex was viewed as a stress reliever, an anti-depressant and a way to increase self-esteem. They shared that even if they did not feel like having sex, they might just "git it over wit" so their partners would stop asking. Some also discussed financial and emotional stability offered by older, more sexually experienced partners. These age-discordant relationships often translated into trusting that their partners knew what was best for their sexual relationships (i.e., having unprotected sex). Sixty-nine percent (n = 88) of the sample reported engaging in sexual activity. Given their mean age (16 +/- 1.9 years) participants had been sexually active for 2 +/- 1.8 years. The adolescents reported an average of 2 +/- 1.8 sexual partners within the past three months. Depressed participants reported a higher frequency of having ever had sex (78% vs. 59%, chi(2) = 5.236, p = 0.022), and had a higher mean number ofsexual partners (2 vs. 1, t = - 2.023, p = 0.048) and sexual encounters under the influence of drugs and alcohol (8 vs. 2, t = - 3.078, p = 0.005) in the past three months. The results of this study can guide the modification and/or development of tailored HIV/sexually transmitted infection (STI) prevention programs. The findings provide explicit, psychologically and culturally relevant information regarding the interaction between depression, self-medicating behaviors and risk for HIV/STIs among clinically depressed African-American adolescent females. C1 [Brawner, B. M.; Jemmott, L. S.; Deatrick, J. A.; Coleman, C. L.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Gomes, M. M.] Virginia Commonwealth Univ, Sch Nursing, Richmond, VA USA. RP Brawner, BM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. EM brawnerb@nursing.upenn.edu FU CMHS SAMHSA HHS [5SM058566-02]; NINR NIH HHS [P20 NR008361-05, P20 NR008361, P20NR008361] NR 40 TC 14 Z9 14 U1 2 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2012 VL 24 IS 5 BP 618 EP 625 DI 10.1080/09540121.2011.630344 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 936AK UT WOS:000303563100011 PM 22292603 ER PT J AU Kindy, MS Yu, J Zhu, H El-Amouri, SS Hook, V Hook, GR AF Kindy, Mark S. Yu, Jin Zhu, Hong El-Amouri, Salim S. Hook, Vivian Hook, Gregory R. TI Deletion of the Cathepsin B Gene Improves Memory Deficits in a Transgenic Alzheimer's Disease Mouse Model Expressing A beta PP Containing the Wild-Type beta-Secretase Site Sequence SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Amyoid-beta; amyoid-beta protein precursor; cathepsin B; gene knockout; protease ID AMYLOID PRECURSOR PROTEIN; IN-VIVO; SYNAPTIC PLASTICITY; PARTIAL REDUCTION; MESSENGER-RNA; MICE; BACE1; BRAIN; INHIBITORS; ENZYME AB Therapeutic agents that improve the memory loss of Alzheimer's disease (AD) may eventually be developed if drug targets are identified that improve memory deficits in appropriate AD animal models. One such target is beta-secretase which, in most AD patients, cleaves the wild-type (WT) beta-secretase site sequence of the amyloid-beta protein precursor (A beta PP) to produce neurotoxic amyloid-beta (A beta). Thus, an animal model representing most AD patients for evaluating beta-secretase effects on memory deficits is one that expresses human A beta PP containing the WT beta-secretase site sequence. BACE1 and cathepsin B (CatB) proteases have beta-secretase activity, but gene knockout studies have not yet validated that the absence of these proteases improves memory deficits in such an animal model. This study assessed the effects of deleting these protease genes on memory deficits in the AD mouse model expressing human A beta PP containing the WT beta-secretase site sequence and the London gamma-secretase site (A beta PPWT/Lon mice). Knockout of the CatB gene in the A beta PPWT/Lon mice improved memory deficits and altered the pattern of A beta-related biomarkers in a manner consistent with CatB having WT beta-secretase activity. But deletion of the BACE1 gene had no effect on these parameters in the A beta PPWT/Lon mice. These data are the first to show that knockout of a putative beta-secretase gene results in improved memory in an AD animal model expressing the WT beta-secretase site sequence of A beta PP, present in the majority of AD patients. CatB may be an effective drug target for improving memory deficits in most AD patients. C1 [Kindy, Mark S.; Yu, Jin; Zhu, Hong] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kindy, Mark S.] Appl Neurotechnol Inc, Charleston, SC USA. [El-Amouri, Salim S.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol, Cincinnati, OH USA. [Hook, Vivian] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA. [Hook, Vivian] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Hook, Vivian] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA. [Hook, Vivian] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Hook, Gregory R.] Amer Life Sci Pharmaceut, San Diego, CA USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, 114 Doughty St,Room 503, Charleston, SC 29425 USA. EM kindyms@musc.edu FU National Institute on Aging, National Institutes of Health, Bethesda, MD [R21 AG0311963, R44 AG030865, R44 AG032784]; Alzheimer's Drug Discovery Foundation, New York City, NY [20100304]; Alzheimer's Association FX This work was supported by grants R21 AG0311963, R44 AG030865, and R44 AG032784 from the National Institute on Aging, National Institutes of Health, Bethesda, MD, and grant no. 20100304 from the Alzheimer's Drug Discovery Foundation, New York City, NY to American Life Science Pharmaceuticals (ALSP), and a grant from the Alzheimer's Association to Dr. Vivian Hook. NR 41 TC 18 Z9 18 U1 0 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 29 IS 4 BP 827 EP 840 DI 10.3233/JAD-2012-111604 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 937RC UT WOS:000303674900011 PM 22337825 ER PT J AU Friedlander, AH Lopez-Lopez, J Velasco-Ortega, E AF Friedlander, Arthur H. Lopez-Lopez, Jose Velasco-Ortega, Eugenio TI Diagonal ear lobe crease and atherosclerosis: A review of the medical literature and dental implications SO MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL LA English DT Article DE Diagonal ear lobe crease; atherosclerosis disease; calcified carotid artery; atheromas; panoramic radiographs ID CORONARY-ARTERY-DISEASE; EARLOBE CREASE; CARDIOVASCULAR-DISEASE; HEART-DISEASE; RISK-FACTORS; ALL-CAUSE; THICKNESS; ASSOCIATION; MORTALITY; DEATH AB In Spain a significant number of individuals die from atherosclerotic disease of the coronary and carotid arteries without having classic risk factors and prodromal symptoms. The diagonal ear lobe crease (DELC) has been characterized in the medical literature as a surrogate marker which can identify high risk patients having occult atherosclerosis. This topic however has not been examined in either the medical or dental literature emanating from Spain. The majority of clinical, angiography and postmortem reports support the premise that DELC is a valuable extravascular physical sign able to distinguish some patients at risk of succumbing to atherosclerosis of the coronary arteries. A minority of studies have however failed to support this hypothesis. More recently reports using B mode ultrasound have also linked DELC to atherosclerosis of the carotid artery and another report has related DELC to the presence of calcified carotid artery atheromas on panoramic radiographs. DELC is readily visible during head and neck cancer screening examinations. In conjunction with the patient's medical history, vital signs, and panoramic radiograph, the DELC may assist in atherosclerotic risk assessment. C1 [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA. [Friedlander, Arthur H.] UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Lopez-Lopez, Jose] Univ Barcelona, Sch Dent, Dept Stomatol, Catalonia, Spain. [Velasco-Ortega, Eugenio] Univ Seville, Dept Stomatol, Sch Dent, Andalucia, Spain. RP Lopez-Lopez, J (reprint author), Dept Odontostomatol, Bellvitge Univ Campus,Pabellon Gobierno 2A Planta, Barcelona 08907, Spain. EM 18575jll@gmail.com NR 39 TC 6 Z9 7 U1 0 U2 2 PU MEDICINA ORAL S L PI VALENCIA PA CALLE DANIEL BALACIART N 4 PTA 17, VALENCIA, 46020, SPAIN SN 1698-4447 J9 MED ORAL PATOL ORAL JI Med. Oral Patol. Oral Cir. Bucal PD JAN PY 2012 VL 17 IS 1 BP E153 EP E159 AR 17390 DI 10.4317/medoral.17390 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 936SH UT WOS:000303609800026 PM 21743392 ER PT J AU Williams, BR Sawyer, P Allman, RM AF Williams, Beverly Rosa Sawyer, Patricia Allman, Richard M. TI Wearing the Garment of Widowhood: Variations in Time Since Spousal Loss Among Community-Dwelling Older Adults SO JOURNAL OF WOMEN & AGING LA English DT Article DE widow; bereavement; older women; Black women; community-dwelling; social isolation ID SOCIAL-ISOLATION; MARITAL-STATUS; HEALTH; WOMEN; SUPPORT; LIFE; BEREAVEMENT; FAMILY; CARE; PERSPECTIVES AB We examine how the passage of time since spousal loss varies by social and demographic characteristics, using data from the University of Alabama at Birmingham Study of Aging. In multivariate analyses, African American race, female sex, lower income, and higher risk of social isolation had significant and independent associations with variation in time since spousal loss. African American women were at highest risk for long-term widowhood. Accurate characterizations of widowhood among community-dwelling older adults must consider variation in the length of time individuals are living as widowed persons and socioeconomic concomitants of long-term widowhood. C1 [Williams, Beverly Rosa] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Div Gerontol Geriatr & Palliat Care,Dept Med, Birmingham, AL 35233 USA. [Williams, Beverly Rosa; Sawyer, Patricia; Allman, Richard M.] UAB Ctr Aging, Birmingham, AL USA. [Williams, Beverly Rosa; Allman, Richard M.] Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. RP Williams, BR (reprint author), Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Div Gerontol Geriatr & Palliat Care,Dept Med, GRECC 11G,700 19th St S, Birmingham, AL 35233 USA. EM Beverly.williams3@va.gov FU NIA NIH HHS [R01 AG015062, P30AG031054, P30 AG031054, R01 AG16062]; NIDA NIH HHS [R01 DA016062] NR 48 TC 2 Z9 2 U1 0 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0895-2841 J9 J WOMEN AGING JI J. Women Aging PY 2012 VL 24 IS 2 BP 126 EP 139 DI 10.1080/08952841.2012.639660 PG 14 WC Gerontology; Women's Studies SC Geriatrics & Gerontology; Women's Studies GA 936FF UT WOS:000303575600004 PM 22486476 ER PT J AU Peterson, LM Helweg-Larsen, M Volpp, KG Kimmel, SE AF Peterson, Laurel M. Helweg-Larsen, Marie Volpp, Kevin G. Kimmel, Stephen E. TI Heart attack risk perception biases among hypertension patients: The role of educational level and worry SO PSYCHOLOGY & HEALTH LA English DT Article DE comparative optimism; heart attack risk; hypertension; perceived risk; risk inaccuracy; worry ID SOCIOECONOMIC-STATUS; CARDIOVASCULAR RISK; RACIAL DISPARITIES; CANCER WORRY; HEALTH-RISK; INFORMATION; KNOWLEDGE; BEHAVIOR; SMOKERS; VACCINATION AB Risk biases such as comparative optimism (thinking one is better off than similar others) and risk inaccuracy (misestimating one's risk compared to one's calculated risk) for health outcomes are common. Little research has investigated racial or socioeconomic differences in these risk biases. Results from a survey of individuals with poorly controlled hypertension (N=813) indicated that participants showed (1) comparative optimism for heart attack risk by underestimating their heart attack risk compared to similar others, and (2) risk inaccuracy by overestimating their heart attack risk compared to their calculated heart attack risk. More highly educated participants were more comparatively optimistic because they rated their personal risk as lower; education was not related to risk inaccuracy. Neither race nor the federal poverty level was related to risk biases. Worry partially mediated the relationship between education and personal risk. Results are discussed as they relate to the existing literature on risk perception. C1 [Peterson, Laurel M.] George Washington Univ, Dept Psychol, Washington, DC 20052 USA. [Helweg-Larsen, Marie] Dickinson Coll, Dept Psychol, Carlisle, PA 17013 USA. [Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA USA. [Volpp, Kevin G.] Perelman Sch Med, Dept Med, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Kimmel, Stephen E.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Kimmel, Stephen E.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Peterson, LM (reprint author), George Washington Univ, Dept Psychol, Washington, DC 20052 USA. EM laurel_p@gwmail.gwu.edu NR 37 TC 5 Z9 5 U1 3 U2 6 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0887-0446 J9 PSYCHOL HEALTH JI Psychol. Health PY 2012 VL 27 IS 6 BP 737 EP 751 DI 10.1080/08870446.2011.626856 PG 15 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary SC Public, Environmental & Occupational Health; Psychology GA 936GX UT WOS:000303580000007 PM 22148955 ER PT J AU Egede, LE Dismuke, C Echols, C AF Egede, Leonard E. Dismuke, Clara Echols, Carrae TI Racial/Ethnic Disparities in Mortality Risk Among US Veterans With Traumatic Brain Injury SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HEALTH-CARE-SYSTEM; RACIAL DISPARITIES; ETHNIC DISPARITIES; FUNCTIONAL OUTCOMES; ADMINISTRATIVE DATA; REHABILITATION; RACE; MODERATE; COHORT AB Objectives. We examined the association of race/ethnicity with mortality risk in a national cohort of US veterans clinically diagnosed with traumatic brain injury. Methods. Between January 1, 2006 and December 31, 2006, we obtained data from a national cohort study of 7885 non-Hispanic White, 1748 Non-Hispanic Black, 314 Hispanic, and 4743 other or missing race/ethnicity veterans clinically diagnosed with traumatic brain injury in Veterans Affairs medical centers and community-based outpatient clinics. Results. Overall mortality at 48 months was 6.7% in Hispanic, 2.9% in non-Hispanic White, and 2.7% in non-Hispanic Black veterans. Compared with non-Hispanic White, Hispanic ethnicity was positively associated with a higher mortality risk (hazard ratio [HR]=2.33; 95% confidence interval [CI]=1.49, 3.64) in the race/ethnicity-only adjusted model. After adjusting for sociodemographic characteristics and comorbidities, Hispanic ethnicity continued to be positively associated (HR=1.61; 95% CI=1.00, 2.58) with a higher mortality risk relative to non-Hispanic White ethnicity. Conclusions. Hispanic ethnicity is positively associated with higher mortality risk among veterans clinically diagnosed with traumatic brain injury. More research is needed to understand the reasons for this disparity. (Am J Public Health. 2011;102:S266-S271. doi:10.2105/AJPH.2011.300176) C1 [Egede, Leonard E.; Dismuke, Clara] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Egede, Leonard E.; Dismuke, Clara; Echols, Carrae] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU Veterans Health Administration Health Services Research and Development (HSRD) [REA 08-261] FX This study was funded by the Veterans Health Administration Health Services Research and Development (HSR&D) program (grant REA 08-261). NR 34 TC 6 Z9 6 U1 1 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PY 2012 VL 102 SU 2 BP S266 EP S271 DI 10.2105/AJPH.2011.300176 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 928FV UT WOS:000302969500021 PM 21852658 ER PT J AU Werner, RM Norton, EC Konetzka, RT Polsky, D AF Werner, Rachel M. Norton, Edward C. Konetzka, R. Tamara Polsky, Daniel TI Do consumers respond to publicly reported quality information? Evidence from nursing homes SO JOURNAL OF HEALTH ECONOMICS LA English DT Article DE Report cards; Quality information; Nursing home care; Nursing home demand ID REPORT CARDS; MARKET SHARE; CHOICE; IMPACT AB Public reporting of quality information is designed to address information asymmetry in health care markets. Without public reporting, consumers may have little information to help them differentiate quality among providers, giving providers little incentive to compete on quality. Public reporting enables consumers to choose highly ranked providers. Using a four-year (2000-2003) panel dataset, we examine the relationship between report card scores and patient choice of nursing home after the Centers for Medicare and Medicaid Services began publicly reporting nursing home quality information on postacute care in 2002. We find that the relationship between reported quality and nursing home choice is positive and statistically significant suggesting that patients were more likely to choose facilities with higher reported post-acute care quality after public reporting was initiated. However, the magnitude of the effect was small. We conclude that there has been minimal consumer response to information in the post-acute care market. Published by Elsevier B.V. C1 [Werner, Rachel M.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Werner, Rachel M.; Polsky, Daniel] Univ Penn, Philadelphia, PA 19104 USA. [Norton, Edward C.] Univ Michigan, Ann Arbor, MI 48109 USA. [Konetzka, R. Tamara] Univ Chicago, Chicago, IL 60637 USA. RP Werner, RM (reprint author), Philadelphia VA Med Ctr, 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu; ecnorton@umich.edu; konetzka@uchicago.edu; polsky@mail.med.upenn.edu OI , Edward/0000-0003-4555-0631 FU Agency for Healthcare Research and Quality [R01 HS016478-01]; VA HSR&D Career Development Award FX This research was funded by a grant from the Agency for Healthcare Research and Quality (R01 HS016478-01). Rachel Werner is funded in part by a VA HSR&D Career Development Award. The authors thank Ying Fan, David Grabowski, and Alan Zaslavsky for helpful comments on an earlier draft of this manuscript, and seminar participants at Imperial College London, Harvard Health Care Policy, University of South Florida, University of Miami at Ohio, and the University of Michigan. NR 28 TC 32 Z9 32 U1 1 U2 21 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-6296 EI 1879-1646 J9 J HEALTH ECON JI J. Health Econ. PD JAN PY 2012 VL 31 IS 1 BP 50 EP 61 DI 10.1016/j.jhealeco.2012.01.001 PG 12 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 928GW UT WOS:000302972200005 PM 22307033 ER PT J AU Murray, DR Mummidi, S Valente, AJ Yoshida, T Somanna, NK Delafontaine, P Dinarello, CA Chandrasekar, B AF Murray, David R. Mummidi, Srinivas Valente, Anthony J. Yoshida, Tadashi Somanna, Naveen K. Delafontaine, Patrice Dinarello, Charles A. Chandrasekar, Bysani TI beta 2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE Signal transduction; Transcription; Cloning; Molecular mechanism; Adrenergic stimulation; Heart failure ID NF-KAPPA-B; NATRIURETIC-PEPTIDE GENE; HEART-FAILURE; BETA(2)-ADRENERGIC RECEPTOR; INFLAMMATORY CYTOKINES; TRANSCRIPTION FACTORS; CARDIAC-HYPERTROPHY; PRESSURE-OVERLOAD; RESPONSE ELEMENT; FAILING HEART AB Both the sympathetic nervous system and the proinflammatory cytokine interleukin-18 (IL-18) play key roles in the pathophysiology of the hypertrophied failing heart IL-18 binding protein (IL-18BP), a natural inhibitor of IL-18, counters its biological effects. beta-AR stimulation induces IL-18 expression, but whether it also regulates IL-18BP is not known. Here we demonstrate that the beta-AR agonist isoproterenol (ISO) increases steady state IL-18BP mRNA and protein levels in adult mouse cardiomyocytes in a beta(2)-AR-dependent manner. We cloned mouse Il18bp 5'cis-regulatory region, and identified putative CREB and C/EBP beta transcription factor-binding sites. Forced expression of mutant CREB or C/EBP beta knockdown markedly attenuated ISO-induced Il18bp transcription and deletion or mutation of CREB and C/EBP motifs in the Il18bp promoter reduced ISO-induced promoter-reporter gene activity. ISO induced CREB and C/EBI beta activation in cardiomyocytes via PI3K/Akt and ERK1/2. Importantly, ISO-induced hypertrophy in vitro was dependent on IL-18 induction as it was blunted by IL-18 neutralizing antibodies and forced expression of IL-18BP. Moreover, ISO-induced hypertrophy was markedly attenuated in IL-18 null and IL-18BP transgenic mice. These data support the novel concept that beta-AR activation, in addition to inducing cardiomyocyte hypertrophy via IL-18, concomitantly induces a countering effect by stimulating IL-18BP expression, and that ISO-induced cardiomyocyte hypertrophy may result from a net effect of IL-18 and IL-18BP induction. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Yoshida, Tadashi; Delafontaine, Patrice; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA. [Murray, David R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Mummidi, Srinivas; Valente, Anthony J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Somanna, Naveen K.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Dinarello, Charles A.] Univ Colorado, Dept Med, Aurora, CO USA. [Chandrasekar, Bysani] SE Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA 70161 USA. RP Chandrasekar, B (reprint author), Tulane Univ, Sch Med, Inst Heart & Vasc, 1430 Tulane Ave,SL-48, New Orleans, LA 70112 USA. EM bchandra@tulane.edu RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 FU Veterans Affairs Office of Research and Development- Biomedical Laboratory Research and Development Service [1IO1BX000246]; NHLBI [HL-86787]; [I01BX007080]; [AI043279]; [HL-70241]; [HL-80682]; [AI15614] FX This work was supported by the Veterans Affairs Office of Research and Development- Biomedical Laboratory Research and Development Service Award 1IO1BX000246 and the NHLBI Grant HL-86787 (to BC). SM is supported by I01BX007080 and AI043279. PD is a supported by HL-70241 and HL-80682. CAD is supported by AI15614. The contents of this report do not represent the views of the Department of Veterans Affairs or the United States Government. NR 43 TC 14 Z9 17 U1 0 U2 7 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD JAN PY 2012 VL 52 IS 1 BP 206 EP 218 DI 10.1016/j.yjmcc.2011.09.022 PG 13 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA 932FE UT WOS:000303275000024 PM 22004899 ER PT J AU Smits, JAJ Minhajuddin, A Thase, ME Jarrett, RB AF Smits, Jasper A. J. Minhajuddin, Abu Thase, Michael E. Jarrett, Robin B. TI Outcomes of Acute Phase Cognitive Therapy in Outpatients with Anxious versus Nonanxious Depression SO PSYCHOTHERAPY AND PSYCHOSOMATICS LA English DT Article DE Cognitive therapy; Major depressive disorder; Anxious depression; Treatment outcome ID STAR-ASTERISK-D; RECURRENT DEPRESSION; MAJOR DEPRESSION; CONTINUATION PHASE; BEHAVIOR-THERAPY; ANXIETY SYMPTOMS; SOCIAL PHOBIA; DISORDER; FLUOXETINE; RELAPSE AB Objective: Compared to nonanxious depressed patients, anxious depressed patients respond less to pharmacotherapy, prompting consideration of alternate treatments. Based on the transdiagnostic principles of cognitive therapy (CT), we predicted that anxious depressed patients would respond as well to CT as nonanxious depressed patients. Method: Adults (n = 523) with recurrent major depressive disorder received 12-14 weeks of CT as part of the Continuation Phase Cognitive Therapy Relapse Prevention Trial. Anxious depressed patients (n = 264; 50.4%) were compared to nonanxious depressed patients (n = 259; 49.6%) on demographic variables, initial severity, attrition, and rates and patterns of response and remission. Results: Anxious depressed patients presented with greater illness severity and had significantly lower response (55.3 vs. 68.3%) and remission rates (26.9 vs. 40.2%) based on clinician-administered measures. By contrast, smaller between-group differences for attrition, and for response (59.1 vs. 64.9%) and remission (41.7 vs. 48.7%) rates on self-report measures were not significant. Further, anxious depressed patients had greater speed of improvement on self-reported anxiety symptom severity and clinician-rated depressive and anxiety symptom severity measures. Conclusion: Consistent with prior reports, anxious depressed patients presented with greater severity and, following CT, had lower response and remission rates on clinician-administered scales. However, anxious depressed patients improved more rapidly and response and remission rates on self-report measures were not significantly different from nonanxious depressed patients. Our findings suggest that anxious depressed patients may simply need additional time or more CT sessions to reach outcomes fully comparable to those of less anxious patients. Copyright (C) 2012 S. Karger AG, Basel C1 [Smits, Jasper A. J.] So Methodist Univ, Dept Psychol, Dedman Coll, Dallas, TX 75275 USA. [Minhajuddin, Abu; Jarrett, Robin B.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. RP Smits, JAJ (reprint author), So Methodist Univ, Dept Psychol, Dedman Coll, POB 750442, Dallas, TX 75275 USA. EM jsmits@smu.edu RI Smits, Jasper/A-4350-2008 OI Smits, Jasper/0000-0001-7128-9807; Smits, Jasper/0000-0003-1633-9693 FU National Institute of Mental Health (NIMH) [K24MH001571, R01MH058397, R0IMH069619, R01MH058356, R01MH069618]; Eli Lilly Co.; CT; Forest; GlaxoSmithKline; Otsuka; Rexahn; Agency for Healthcare Research and Quality; American Psychiatric Publishing Inc.; Guilford Publications; Herald House; W.W. Norton Co. Inc.; National Institutes of Health [R01MH075889, R01DA027533]; Oxford University Press; Merck FX This report was supported by Grants No. K24MH001571, R01MH058397 and R0IMH069619 (to Robin B. Jarrett, PhD) and R01MH058356 and R01MH069618 (to Michael E. Thase, MD) from the National Institute of Mental Health (NIMH).; We appreciate the support of the NIMH. We wish to acknowledge the unrestricted support of Eli Lilly & Co., who provided the fluoxetine and matched pill placebo for use in the continuation phase of this research until 2006. Thereafter, study materials were purchased and prepared to appear identical for both sites by the pharmacy at the University of Texas Southwestern Medical Center at Dallas.; Dr. Smits is currently supported by the National Institutes of Health Grants No. R01MH075889 and R01DA027533 and receives royalties from Oxford University Press. During the past 3 years, he has received grant support from Organon/Schering-Plough (now Merck).; Dr. Thase has served as a consultant to and was a member of various advisory boards for Eli Lilly & Co. and received honoraria for talks sponsored by this company. In addition to Eli Lilly & Co., during the past 3 years Dr. Thase has consulted with, served on advisory boards for or received honoraria for talks from: Aldolor, Alkermes, AstraZeneca, Bristol-Myers Squibb, Dey, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Lundbeck, MedAvante Inc., Merck, Neuronetics Inc., Otsuka, Pam Lab, Pfizer Pharmaceuticals, PGx (now Forest), PharmaNeuroboost, Rexahn, Schering-Plough, Shire US Inc., Supernus Pharmaceuticals, Transcept Pharmaceuticals, and Wyeth Pharmaceuticals (now Pfizer). During the past 2 years, he has received grant support from Eli Lilly & Co., Forest, GlaxoSmithKline, Otsuka, and Rexahn, in addition to funding from the National Institutes of Mental Health and the Agency for Healthcare Research and Quality. He has equity holdings in MedAvante Inc. and has received royalties from American Psychiatric Publishing Inc., Guilford Publications, Herald House, and W.W. Norton & Co. Inc. One book currently promoted by American Psychiatric Publishing Inc. specifically pertains to CT. Dr. Thase also discloses that his spouse is an employee of Embryon Inc. (formerly Advogent and Cardinal Health), which does business with several pharmaceutical companies that market medications used to treat depression.; Dr. Jarrett's medical center receives fees from the CT she provides to patients. Dr. Jarrett is a paid consultant to the NIMH. NR 30 TC 14 Z9 14 U1 2 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0033-3190 J9 PSYCHOTHER PSYCHOSOM JI Psychother. Psychosom. PY 2012 VL 81 IS 3 BP 153 EP 160 DI 10.1159/000334909 PG 8 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 929SY UT WOS:000303087200003 PM 22398963 ER PT J AU Kutner, NG Zhang, R Huang, YJ Johansen, KL AF Kutner, Nancy G. Zhang, Rebecca Huang, Yijian Johansen, Kirsten L. TI Impact of Race on Predialysis Discussions and Kidney Transplant Preemptive Wait-Listing SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Education; Kidney transplantation; Preemptive wait-listing; Race; United States Renal Data System ID RENAL-TRANSPLANTATION; PATIENT EDUCATION; ACCESS; DIALYSIS; DISPARITIES AB Background/Aims: US registry data have consistently shown that blacks are less likely than whites to be wait-listed before beginning dialysis. Methods: The Comprehensive Dialysis Study (CDS) was a special study conducted by the US Renal Data System (USRDS) in which a national cohort of patients who began maintenance dialysis therapy in 2005-2007 were asked whether kidney transplantation (KT) had been discussed with them before they started dialysis. Using responses from black and white CDS participants and information from the USRDS, we investigated preemptive wait-listing as a function of patient-reported predialysis KT discussion. Results: Among those reporting early KT discussion, 31.0% of patients preemptively wait-listed were black, compared to 27.5% of those not preemptively wait-listed. Two thirds of preemptively wait-listed patients had received nephrology care more than 12 months before starting dialysis and reported that KT was discussed with them 12 months or more before dialysis. Early KT discussion and higher serum albumin and hemoglobin levels remained significant predictors of preemptive wait-listing in an adjusted logistic regression analysis. Among those preemptively wait-listed, 33% of blacks and 60% of whites had received a transplant by September 30, 2009 (study end date). Conclusion: Early KT discussion appeared to reduce barriers to black patients' waiting list placement before the start of dialysis, which in turn may facilitate earlier access to a deceased donor organ transplant. Copyright (C) 2012 S. Karger AG, Basel C1 [Kutner, Nancy G.] Emory Univ, Dept Rehabil Med, Rehabil Qual Life Special Studies Ctr, US Renal Data Syst, Atlanta, GA 30322 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA. RP Kutner, NG (reprint author), Emory Univ, Dept Rehabil Med, Rehabil Qual Life Special Studies Ctr, US Renal Data Syst, Atlanta, GA 30322 USA. EM nkutner@emory.edu FU National Institutes of Health [HHSN267200715004C, N01-DK-7-5004] FX This study was supported by contract HHSN267200715004C, ADB No. N01-DK-7-5004 (N.G.K.), from the National Institutes of Health. NR 20 TC 12 Z9 12 U1 6 U2 7 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2012 VL 35 IS 4 BP 305 EP 311 DI 10.1159/000336891 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 927HB UT WOS:000302896900001 PM 22414927 ER PT J AU Li, YM Shlipak, MG Grunfeld, C Choi, AI AF Li, Yongmei Shlipak, Michael G. Grunfeld, Carl Choi, Andy I. TI Incidence and Risk Factors for Acute Kidney Injury in HIV Infection SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Acute kidney injury; HIV; Chronic kidney disease; Proteinuria; Hypoalbuminemia ID ACUTE-RENAL-FAILURE; HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE; ASSOCIATION; SURVIVAL AB Background/Aims: Although HIV-infected persons are at higher risk for acute kidney injury (AKI) during hospitalization compared with their uninfected counterparts, risk factors for AKI are not well-defined. We aimed to describe the evolving incidence of AKI among HIV-infected individuals and to identify important AKI risk factors. Methods: We conducted a prospective cohort study of 56,823 HIV-infected persons in the Department of Veterans Affairs Clinical Case Registry. Outcomes were: AKI (acute in-hospital serum creatinine increase of >= 0.3 mg/dl, or a relative increase by 50% or greater), and dialysis-requiring AKI. We used proportional hazards regressions to identify risk factors. Results: From its peak in 1995 at 62 per 1,000 person-years, the incidence of AKI declined after the introduction of highly active antiretroviral therapy (HAART) in 1996 to a low point of 25 per 1,000 person-years in 2006. Incidence of dialysis-requiring AKI declined in the early 1990s, but doubled between 2000 and 2006. Using multivariate proportional hazard regression, we identified the following strong risk factors for AKI: chronic kidney disease (eGFR <60 ml/min/1.73 m(2)) (5.38, 95% CI: 5.11-5.67), proteinuria (1.78, 1.70-1.87), low serum albumin (<3.7 mg/dl) (5.24, 4.82-5.71), low body mass index (<18.5 kg/m(2)) (1.69, 1.54-1.86), cardiovascular disease (1.77, 1.66-1.89), low CD4 count (<200 cells/mm(3)) (2.54, 2.33-2.77), and high viral load (>= 100,000 copies/ml) (2.51, 2.28-2.75). In addition, there was substantial heterogeneity in the strengths of risk factors for dialysis-requiring AKI before and after the introduction of HAART. Conclusions: Although AKI incidence has decreased during the HAART era, it remains common in HIV-infected persons and appears attributable to both kidney-and HIV-related factors. Copyright (C) 2012 S. Karger AG, Basel C1 [Li, Yongmei; Shlipak, Michael G.; Grunfeld, Carl; Choi, Andy I.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.; Choi, Andy I.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU National Institutes of Health [K23DK080645-01A1, K23AI65244, R01 DK066488-01, 1R03AG034871-01] FX This study was supported by grants from the National Institutes of Health (K23DK080645-01A1, K23AI65244, R01 DK066488-01, 1R03AG034871-01). These funding sources had no involvement in the design or execution of this study. NR 28 TC 9 Z9 9 U1 1 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2012 VL 35 IS 4 BP 327 EP 334 DI 10.1159/000337151 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 927HB UT WOS:000302896900004 PM 22456100 ER PT S AU Lai, TL Lavori, PW Shih, MC AF Lai, Tze Leung Lavori, Philip William Shih, Mei-Chiung BE Insel, PA Amara, SG Blaschke, TF TI Adaptive Trial Designs SO ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 SE Annual Review of Pharmacology and Toxicology LA English DT Review; Book Chapter DE group-sequential; variance spending; Bayesian methods; randomization ID SAMPLE-SIZE ADJUSTMENT; CLINICAL-TRIALS; CONDITIONAL POWER; ERROR AB We review adaptive designs for clinical trials, giving special attention to the control of the Type I error in late-phase confirmatory trials, when the trial planner wishes to adjust the final sample size of the study in response to an unblinded analysis of interim estimates of treatment effects. We point out that there is considerable inefficiency in using the adaptive designs that employ conditional power calculations to reestimate the sample size and that maintain the Type I error by using certain weighted test statistics. Although these adaptive designs have little advantage over familiar group-sequential designs, our review also describes recent developments in adaptive designs that are both flexible and efficient. We also discuss the use of Bayesian designs, when the context of use demands control over operating characteristics (Type I and II errors) and correction of the bias of estimated treatment effects. C1 [Lai, Tze Leung; Lavori, Philip William] Stanford Univ, Dept Stat, Stanford, CA 94305 USA. [Lai, Tze Leung; Lavori, Philip William; Shih, Mei-Chiung] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Shih, Mei-Chiung] US Dept Vet Affairs, Cooperat Studies Program, Mountain View, CA 94043 USA. RP Lai, TL (reprint author), Stanford Univ, Dept Stat, Stanford, CA 94305 USA. EM Lavori@Stanford.edu FU NCATS NIH HHS [UL1 TR001085]; NCI NIH HHS [P30 CA124435]; NCRR NIH HHS [UL1 RR025744] NR 24 TC 8 Z9 8 U1 0 U2 10 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0362-1642 BN 978-0-8243-0452-2 J9 ANNU REV PHARMACOL JI Annu. Rev. Pharmacol. Toxicol. PY 2012 VL 52 BP 101 EP 110 DI 10.1146/annurev-pharmtox-010611-134504 PG 10 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA BZK49 UT WOS:000301839600006 PM 21838549 ER PT J AU Harris, AHS Kivlahan, D Barnett, PG Finney, JW AF Harris, Alex H. S. Kivlahan, Daniel Barnett, Paul G. Finney, John W. TI Longer Length of Stay Is Not Associated with Better Outcomes in VHA's Substance Abuse Residential Rehabilitation Treatment Programs SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH LA English DT Article ID ADDICTION SEVERITY INDEX; PATTERN-MIXTURE MODELS; MISSING DATA; TIME SPENT; ALCOHOLISM; CARE AB Are longer stays in Veterans Health Administration (VHA) substance abuse residential rehabilitation treatment programs (SARRTPs) associated with better substance-related outcomes? To investigate, up to 50 new patients were randomly selected from each of 28 randomly selected programs (1,307 patients). The goal was to examine if patient and program average length of stay (ALOS) were associated with improvement on Addiction Severity Index (ASI) Alcohol and Drug composite scores in covariate-adjusted, multi-level regression models. Patients in programs with ALOS greater than 90 days tended to have more mental health treatment prior to the index episode and less severe substance-related symptoms, but more homelessness. At follow-up, programs longer than 90 days had the least improvement in the ASI Alcohol composite and significantly less improvement than programs with ALOSs of 15 to 30 and 31 to 45 days (both p<0.05). Therefore, in VHA SARRTPs, ALOS greater than 90 days cannot be justified by the substance use disorder severity of the patients served or the magnitude of the clinical improvement observed. C1 [Harris, Alex H. S.; Barnett, Paul G.; Finney, John W.] Stanford Univ, Ctr Hlth Care Evaluat, VA Palo Alto Hlth Care Syst, Sch Med, Menlo Pk, CA 94025 USA. [Kivlahan, Daniel] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Barnett, Paul G.] Stanford Univ, Hlth Econ Resource Ctr, VA Palo Alto Hlth Care Syst, Sch Med, Menlo Pk, CA 94025 USA. RP Harris, AHS (reprint author), Stanford Univ, Ctr Hlth Care Evaluat, VA Palo Alto Hlth Care Syst, Sch Med, 795 Willow Rd,MC152, Menlo Pk, CA 94025 USA. EM alexander.harris2@va.gov; Daniel.Kivlahan@va.govPhD; Paul.Barnett@va.gov; John.Finney@va.gov FU VA Substance Use Disorders Quality Enhancement Research Initiative; Health Service Research and Development Service [RRP 09-393, SUS 99-015] FX This study was funded by the VA Substance Use Disorders Quality Enhancement Research Initiative and Health Service Research and Development Service (grants nos. RRP 09-393 and SUS 99-015). NR 27 TC 2 Z9 2 U1 3 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1094-3412 J9 J BEHAV HEALTH SER R JI J. Behav. Health Serv. Res. PD JAN PY 2012 VL 39 IS 1 BP 68 EP 79 DI 10.1007/s11414-011-9250-2 PG 12 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 928QZ UT WOS:000302999300007 PM 21732222 ER PT J AU Dawes, SE Palmer, BW Meeks, T Golshan, S Kasckow, J Mohamed, S Zisook, S AF Dawes, Sharron E. Palmer, Barton W. Meeks, Thomas Golshan, Shahrokh Kasckow, John Mohamed, Somaia Zisook, Sidney TI Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression? SO NEUROPSYCHOBIOLOGY LA English DT Article DE Schizophrenia; Citalopram; Cognition; Subsyndromal depression ID BIPOLAR DISORDER; PERFORMANCE; FAMILIES; SCALE AB Background: Subsyndromal symptoms of depression (SSD) in patients with schizophrenia are common and clinically important. While treatment of depression in major depressive disorder may partially ameliorate cognitive deficits, the cognitive effects of antidepressant medications in patients with schizophrenia or schizoaffective disorder and SSD are unknown. Methods: The goal of this study was to assess the impact of SSD and their treatment on cognition in participants with schizophrenia or schizoaffective disorder aged 6 40 years. Participants were randomly assigned to a flexible dose treatment with citalopram or placebo augmentation of their current medication for 12 weeks. An ANCOVA compared improvement in the cognitive composite scores, and a linear model determined the moderation of cognition on treatment effects based on the Hamilton Depression Rating Scale and the Calgary Depression Rating Scale scores between treatment groups. Results: There were no differences between the citalopram and placebo groups in changes in cognition. Baseline cognitive status did not moderate antidepressant treatment response. Conclusions: Although there are other cogent reasons why SSD in schizophrenia warrant direct intervention, treatment does not substantially affect the level of cognitive functioning. Given the effects of cognitive deficits associated with schizophrenia on functional disability, there remains an ongoing need to identify effective means of directly ameliorating them. Copyright (C) 2012 S. Karger AG, Basel C1 [Zisook, Sidney] Univ Calif San Diego, Dept Psychiat, Div Geriatr Psychiat, San Diego, CA 92161 USA. [Golshan, Shahrokh; Zisook, Sidney] Vet Affairs San Diego Healthcare Syst, Dept Psychiat, San Diego, CA USA. [Palmer, Barton W.; Zisook, Sidney] San Diego Vet Med Res Fdn, San Diego, CA USA. [Kasckow, John] MIRECC, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John] CHERP, Pittsburgh, PA USA. [Kasckow, John] UPMC Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Mohamed, Somaia] Vet Affairs New England Mental Illness Res Educ &, West Haven, CT USA. [Mohamed, Somaia] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Zisook, S (reprint author), Univ Calif San Diego, Dept Psychiat, Div Geriatr Psychiat, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM szisook@ucsd.edu FU Citalopram Augmentation of Older Patients with Schizophrenia [RO-1 MH 063931]; NIMH [MH66248, MH19934, P30 MH080002]; Department of Veterans Affairs; VISN 4 MIRECC [R01 MH6398]; VISN 4 CPPF FX This work was supported by RO-1 MH 063931 Citalopram Augmentation of Older Patients with Schizophrenia (S.Z.), NIMH grants MH66248, MH19934, P30 MH080002 and the Department of Veterans Affairs. J.K. was supported by R01 MH6398, the VISN 4 MIRECC and a VISN 4 CPPF award. NR 24 TC 3 Z9 3 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0302-282X EI 1423-0224 J9 NEUROPSYCHOBIOLOGY JI Neuropsychobiology PY 2012 VL 65 IS 3 BP 168 EP 172 DI 10.1159/000331141 PG 5 WC Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 926ZX UT WOS:000302875300009 PM 22456094 ER PT S AU Navarro, A Taylor, ZD Matolek, AZ Weltman, A Ramaprasad, V Huang, S Beenhouwer, DO Haake, DA Gupta, V Grundfest, WS AF Navarro, Artemio Taylor, Zachary D. Matolek, Anthony Z. Weltman, Ahuva Ramaprasad, Vidyunmala Huang, Sean Beenhouwer, David O. Haake, David A. Gupta, Vijay Grundfest, Warren S. BE VoDinh, T MahadevanJansen, A Grundfest, WS TI Bacterial Biofilm Disruption using Laser-Generated Shockwaves SO ADVANCED BIOMEDICAL AND CLINICAL DIAGNOSTIC SYSTEMS X SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Advanced Biomedical and Clinical Diagnostic Systems X CY JAN 22-24, 2012 CL San Francisco, CA SP SPIE DE laser; shockwaves; biofilm; infections; S. epidermidis; wound; healing ID NB SAPPHIRE INTERFACES; SPALLATION TECHNIQUE; TENSILE-STRENGTH; IN-VITRO; ULTRASOUND; THERAPY; WAVES; INTERLAYERS; PHACOLYSIS; CHEMISTRY AB Bacterial related infections are a burden on the healthcare industry. A system was built to test the efficacy of laser generated shockwaves on S. epidermidis biofilms (RP62A) grown on polystyrene surfaces. The system is based on a Q-switched, ND:YAG pulsed laser with an output wavelength of 1.064 mu m that ablates titanium-coated soda-lime glass. Results show that the system is capable of generating stress profiles that can effectively delaminate biofilm structures from polymer surfaces. C1 [Navarro, Artemio; Gupta, Vijay] Univ Calif Los Angeles, Dept Mech Engn, 420 Westwood Plaza, Los Angeles, CA 90095 USA. [Taylor, Zachary D.; Ramaprasad, Vidyunmala; Huang, Sean; Gupta, Vijay; Grundfest, Warren S.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA. [Beenhouwer, David O.; Haake, David A.; Grundfest, Warren S.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. [Beenhouwer, David O.; Haake, David A.] VA Greater Los Angeles Hlthcare Syst, Los Angeles, CA 90073 USA. RP Navarro, A (reprint author), Univ Calif Los Angeles, Dept Mech Engn, 420 Westwood Plaza, Los Angeles, CA 90095 USA. NR 31 TC 1 Z9 1 U1 1 U2 5 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-8857-2 J9 PROC SPIE PY 2012 VL 8214 AR UNSP 82141H DI 10.1117/12.908661 PG 8 WC Engineering, Biomedical; Optics; Imaging Science & Photographic Technology SC Engineering; Optics; Imaging Science & Photographic Technology GA BZR44 UT WOS:000302567700029 ER PT J AU Manning, KJ Clarke, C Lorry, A Weintraub, D Wilkinson, JR Duda, JE Moberg, PJ AF Manning, Kevin J. Clarke, Christina Lorry, Alan Weintraub, Daniel Wilkinson, Jayne R. Duda, John E. Moberg, Paul J. TI Medication Management and Neuropsychological Performance in Parkinson's Disease SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Parkinson's disease; Medication management; Instrumental activities of daily living; Aging ID MILD COGNITIVE IMPAIRMENT; ADHERENCE; DEMENTIA; DIAGNOSIS; MOCA AB Medication non-adherence is associated with chronic disease and complex medication schedules, and Parkinson's disease (PD) patients also frequently have cognitive impairments that may interfere with effective medication management. The current study quantitatively assessed the medication management skills of PD patients and probed the neurocognitive underpinnings and clinical correlates of this skill. A total of 26 men with PD completed a neuropsychological battery and a modified version of the Hopkins Medication Schedule (HMS), a standard test of a person's ability to understand and implement a routine prescription medication. Estimated adherence rates from performance on the HMS were low. Memory, executive functioning, and processing speed were strongly related to different components of the HMS. A range of neuropsychological abilities is associated with the ability to understand and implement a medication schedule and pillbox in individuals with PD. C1 [Manning, Kevin J.] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA. [Manning, Kevin J.; Weintraub, Daniel; Moberg, Paul J.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Clarke, Christina] Ralph H Johnson Vet Affairs Med Ctr, Dept Pharm, Charleston, SC USA. [Lorry, Alan] Philadelphia Vet Affairs Med Ctr, Dept Pharm, Philadelphia, PA USA. [Lorry, Alan; Weintraub, Daniel; Wilkinson, Jayne R.; Duda, John E.; Moberg, Paul J.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel; Wilkinson, Jayne R.; Duda, John E.; Moberg, Paul J.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. RP Manning, KJ (reprint author), Drexel Univ, Dept Psychol, PSA Bldg,3141 Chestnut St, Philadelphia, PA 19104 USA. EM kevin.j.manning@gmail.com FU NIMH NIH HHS [K23 MH067894] NR 31 TC 11 Z9 11 U1 1 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2012 VL 26 IS 1 BP 45 EP 58 DI 10.1080/13854046.2011.639312 PG 14 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 922JN UT WOS:000302543300005 PM 22150514 ER PT J AU Skordis, N Efstathiou, E Kyriakides, TC Savvidou, A Savva, SC Phylactou, LA Shammas, C Neocleous, V AF Skordis, Nicos Efstathiou, Elisavet Kyriakides, Tassos C. Savvidou, Antria Savva, Savvas C. Phylactou, Leonidas A. Shammas, Christos Neocleous, Vassos TI Epidemiology of Type 1 diabetes mellitus in Cyprus: rising incidence at the dawn of the 21st century SO HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM LA English DT Article DE Epidemiology; Incidence; Type 1 Diabetes Mellitus ID ECOLOGICAL ANALYSIS; FINNISH CHILDREN; DRINKING-WATER; CHILDHOOD; WORLDWIDE; ONSET; RISK; DIAGNOSIS; NITRATE; TIME AB OBJECTIVE: The incidence of Type 1 diabetes mellitus (T1DM) in Greek-Cypriot children aged less than 15 years between 1990 and 2009 was examined along with gender differences concerning the age of onset and the seasonal variation at manifestation of the disease. DESIGN: All newly diagnosed cases of T1DM in children less than 15 years old were registered with the capture-recapture method from 1990 until 2009. RESULTS: The overall mean annual incidence during these 20 years is 12.46 per 100,000. A comparison of the incidence between the two decades (1990-1999 vs 2000-2009) indicated a rising trend, from 10.80 per 100,000 person-years during the first decade to 14.44 per 100,000 person-years during the second decade. There was an overall male predominance (M/F: 1.05), which is in agreement with the male predominance in the population less than 15 years of age, except for the group who manifested T1DM at ages 10-15 years where females prevail. The percentage of children who developed T1DM at ages 0-5 years in the total T1DM population increased in the second decade (26.4% vs 19.0%), and significantly more children were diagnosed during the cold months as opposed to the warm months (p < 0.001). CONCLUSION: The incidence of T1DM in Cyprus is rising. The identification of causative environmental factors will theoretically explain this phenomenon and new preventive strategies can therefore potentially be developed. C1 [Skordis, Nicos; Efstathiou, Elisavet; Savvidou, Antria] Makarios Hosp, Paediat Endocrine Unit, Dept Paediat, CY-1474 Nicosia, Cyprus. [Kyriakides, Tassos C.] Yale Univ, Yale Ctr Analyt Sci, Sch Publ Hlth, West Haven, CT USA. [Kyriakides, Tassos C.] US Dept Vet Affairs, VA Cooperat Studies Program Coordinating Ctr, West Haven, CT USA. [Savva, Savvas C.] Res & Educ Inst Child Hlth, Nicosia, Cyprus. [Phylactou, Leonidas A.; Shammas, Christos; Neocleous, Vassos] Cyprus Inst Neurol & Genet, Nicosia, Cyprus. RP Skordis, N (reprint author), Makarios Hosp, Paediat Endocrine Unit, Dept Paediat, CY-1474 Nicosia, Cyprus. EM nskordis@cytanet.com.cy NR 37 TC 6 Z9 6 U1 1 U2 6 PU HELLENIC ENDOCRINE SOC PI ATHENS PA 14 ALEXANDRAS AVE, ATHENS, 106 82, GREECE SN 1109-3099 J9 HORM-INT J ENDOCRINO JI Horm.-Int. J. Endocrinol. Metab. PD JAN-MAR PY 2012 VL 11 IS 1 BP 86 EP 93 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 921RN UT WOS:000302495100009 PM 22450348 ER PT J AU Adamus, G Brown, L Andrew, S Meza-Romero, R Burrows, GG Vandenbark, AA AF Adamus, Grazyna Brown, Lori Andrew, Shayne Meza-Romero, Roberto Burrows, Gregory G. Vandenbark, Arthur A. TI Neuroprotective Effects of Recombinant T-cell Receptor Ligand in Autoimmune Optic Neuritis in HLA-DR2 Mice SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID PROMISING THERAPEUTIC APPROACH; MULTIPLE-SCLEROSIS; TRANSGENIC MICE; TREATMENT TRIAL; FOLLOW-UP; ENCEPHALOMYELITIS; MYELIN; RISK; PEPTIDE; UVEITIS AB PURPOSE. Optic neuritis (ON) is a condition involving primary inflammation, demyelination, and axonal injury in the optic nerve and leads to apoptotic retinal ganglion cell (RGC) death, which contributes to the persistence of visual loss. Currently, ON has no effective treatment. The goal was to determine the effectiveness of immunotherapy with recombinant T-cell receptor ligand (RTL) in preventing ON in humanized HLA-DR2 transgenic mice. METHODS. Experimental autoimmune encephalomyelitis (EAE) was induced with myelin oligodendrocyte glycoprotein in humanized HLA-DR2 (DR beta 1* 1501) transgenic mice. Five consecutive doses of RTL342M were administrated at the onset of ON. The development of autoimmune ON was assessed by histopathology at different time points. The levels of myelin loss, axonal loss, and RGC damage were examined by immunofluorescence. RESULTS. HLA-DR2 mice developed chronic ON 2 days before EAE characterized by progressive neurodegeneration in both organs. RTL342M significantly suppressed inflammation in the optic nerve and spinal cord and provided protection for at least 30 days. Examination of myelin loss showed a marked suppression of demyelination and an increase in myelin recovery in the optic nerve. Moreover, RTL342M treatment revealed a neuroprotective effect on optic nerve axons and RGCs in retinas at postimmunization (PI) day 62. CONCLUSIONS. RTL342M suppressed clinical and histologic signs of EAE/ON by preventing the recruitment of inflammatory cells into the optic nerve and showed neuroprotective effects against ON. However, to achieve full therapeutic benefit, more doses may be needed. These findings suggest a possible clinical application of this novel class of T-cell-tolerizing drugs for patients with optic neuritis. (Invest Ophthalmol Vis Sci. 2012; 53: 406-412) DOI:10.1167/iovs.11-8419 C1 [Adamus, Grazyna; Brown, Lori] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA. [Vandenbark, Arthur A.] Dept Vet Affairs Med Ctr, Res Serv, Portland, OR USA. [Andrew, Shayne; Meza-Romero, Roberto; Burrows, Gregory G.] Portland VA Med Ctr, R&D31, Portland, OR USA. [Burrows, Gregory G.] Oregon Hlth & Sci Univ, Dept Biochem, Portland, OR 97239 USA. [Burrows, Gregory G.; Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. RP Adamus, G (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, BRB L467AD,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM adamusg@ohsu.edu FU National Eye Institute [EY17781]; National Institutes of Health [NIH NS047661]; Research to Prevent Blindness; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX Supported by National Eye Institute Grant EY17781 (GA) and National Institutes of Health Grant NIH NS047661 (AAV) and an unrestricted grant from Research to Prevent Blindness (CEI). This material is based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 36 TC 6 Z9 6 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 2012 VL 53 IS 1 BP 406 EP 412 DI 10.1167/iovs.11-8419 PG 7 WC Ophthalmology SC Ophthalmology GA 924LY UT WOS:000302694500059 PM 22167100 ER PT J AU Rowles, J Duan, CM AF Rowles, Joanna Duan, Changming TI Perceived Racism and Encouragement Among African American Adults SO JOURNAL OF MULTICULTURAL COUNSELING AND DEVELOPMENT LA English DT Article ID MENTAL-HEALTH; DISCRIMINATION; SOCIALIZATION; EXPERIENCES; IDENTITY AB The effects of spirituality, racial socialization, and ethnic pride on encouragement in the face of racism among African American adults (N = 201) were investigated. The negative relationship between perceived racism and encouragement disappeared when spirituality, ethnic pride, and a racial socialization history were entered into the regression equation. C1 [Rowles, Joanna] Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA 90073 USA. [Duan, Changming] Univ Kansas, Dept Psychol & Res Educ, Lawrence, KS 66045 USA. RP Rowles, J (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, 11301 Wilshire Blvd,Bldg 206, Los Angeles, CA 90073 USA. EM Joanna.rowles@va.gov NR 20 TC 3 Z9 3 U1 1 U2 1 PU WILEY PERIODICALS, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA SN 0883-8534 J9 J MULTICULT COUNS D JI J. Multicult. Couns. Dev. PD JAN PY 2012 VL 40 IS 1 BP 11 EP 23 DI 10.1111/j.2161-1912.2012.00002.x PG 13 WC Psychology, Applied SC Psychology GA 922LF UT WOS:000302547800002 ER PT J AU Coviello, DM Cornish, JW Lynch, KG Boney, TY Clark, CA Lee, JD Friedmann, PD Nunes, EV Kinlock, TW Gordon, MS Schwartz, RP Nuwayser, ES O'Brien, CP AF Coviello, Donna M. Cornish, James W. Lynch, Kevin G. Boney, Tamara Y. Clark, Cynthia A. Lee, Joshua D. Friedmann, Peter D. Nunes, Edward V. Kinlock, Timothy W. Gordon, Michael S. Schwartz, Robert P. Nuwayser, Elie S. O'Brien, Charles P. TI A Multisite Pilot Study of Extended-Release Injectable Naltrexone Treatment for Previously Opioid-Dependent Parolees and Probationers SO SUBSTANCE ABUSE LA English DT Article DE Extended-release naltrexone; opioid dependence; Depotrex; addiction pharmacotherapy; offenders; heroin ID ADDICTION SEVERITY INDEX; METHADONE-MAINTENANCE; RANDOMIZED-TRIAL; COCAINE USE; FOLLOW-UP; BUPRENORPHINE; PLACEBO; INDIVIDUALS; RELIABILITY; PREDICTORS AB A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders. C1 [Coviello, Donna M.; Cornish, James W.; Lynch, Kevin G.; Boney, Tamara Y.; Clark, Cynthia A.; O'Brien, Charles P.] Univ Penn, Philadelphia, PA 19104 USA. [Cornish, James W.; O'Brien, Charles P.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Lee, Joshua D.] NYU, Bellevue Hosp, New York, NY USA. [Friedmann, Peter D.] Rhode Isl Hosp, Vet Affairs Med Ctr, Providence, RI USA. [Friedmann, Peter D.] Brown Univ, Providence, RI 02912 USA. [Nunes, Edward V.] Columbia Univ, New York, NY USA. [Kinlock, Timothy W.; Gordon, Michael S.; Schwartz, Robert P.] Friends Res Inst, Baltimore, MD USA. [Kinlock, Timothy W.] Univ Baltimore, Baltimore, MD 21201 USA. [Nuwayser, Elie S.] Biotek Inc, Woburn, MA USA. RP Coviello, DM (reprint author), Treatment Res Ctr, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. EM coviello_d@mail.trc.upenn.edu FU National Institute on Drug Abuse [R01-DA-012268-05]; Dana foundation FX The study was supported by grants from the National Institute on Drug Abuse (R01-DA-012268-05) and the Dana foundation. NR 42 TC 25 Z9 25 U1 3 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2012 VL 33 IS 1 SI SI BP 48 EP 59 DI 10.1080/08897077.2011.609438 PG 12 WC Substance Abuse SC Substance Abuse GA 923HE UT WOS:000302609500007 PM 22263713 ER PT J AU Huddle, TS AF Huddle, Thomas S. TI Honesty Is an Internal Norm of Medical Practice and the Best Policy SO AMERICAN JOURNAL OF BIOETHICS LA English DT Editorial Material C1 [Huddle, Thomas S.] Univ Alabama, Sch Med, Birmingham, AL 35294 USA. [Huddle, Thomas S.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Huddle, TS (reprint author), Univ Alabama, Sch Med, 1530 3rd Ave S, Birmingham, AL 35294 USA. EM thuddle@uab.edu NR 9 TC 1 Z9 1 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1526-5161 J9 AM J BIOETHICS JI Am. J. Bioeth. PY 2012 VL 12 IS 3 BP 15 EP 17 DI 10.1080/15265161.2012.656812 PG 3 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA 919BW UT WOS:000302296600004 PM 22416742 ER PT J AU Badesch, DB Feldman, J Keogh, A Mathier, MA Oudiz, RJ Shapiro, S Farber, HW McGoon, M Frost, A Allard, M Despain, D Dufton, C Rubin, LJ AF Badesch, David B. Feldman, Jeremy Keogh, Anne Mathier, Michael A. Oudiz, Ronald J. Shapiro, Shelley Farber, Harrison W. McGoon, Michael Frost, Adaani Allard, Martine Despain, Darrin Dufton, Christopher Rubin, Lewis J. CA ARIES 3 Study Grp TI ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension SO CARDIOVASCULAR THERAPEUTICS LA English DT Article DE Ambrisentan; Non-Group 1 patient population; Prostacyclin analog therapy; Pulmonary hypertension; Sildenafil therapy ID CLINICAL-PRACTICE GUIDELINES; ARTERIAL-HYPERTENSION; DOUBLE-BLIND; FIBROSIS AB Introduction: Ambrisentan is an oral, once daily, endothelin receptor antagonist approved for treatment of pulmonary arterial hypertension (PAH). Previous studies of ambrisentan were limited to patients with Group 1 PAH and often excluded patients receiving other pulmonary hypertension (PH) therapies. Aims: ARIES-3 was an open-label study evaluating efficacy and safety of ambrisentan in patients with various PH etiologies and background PH medications. Patients received 5 mg ambrisentan once daily for 24 weeks. The primary endpoint was change from baseline in 6-minute walk distance (6MWD) at week 24. Results: A total of 224 patients with PH due to idiopathic and familial PAH (31%), connective tissue disease (18%), chronic hypoxemia (22%), chronic thromboembolic disease (13%), or other etiologies (16%) were enrolled and 53% of patients received stable background PAH therapies. After 24 weeks of therapy, an increase in 6MWD (+21 m; 95% CI: 1229) and a decrease in B-type natriuretic peptide (26%; 95% CI: 34 to 16%) was observed in the overall population compared to baseline; however, increases in 6MWD were not observed in several non-Group 1 PH subpopulations. Peripheral edema, headache, and dyspnea were the most common adverse events. Conclusion: This study reconfirms the results of previous placebo-controlled studies, which demonstrate that ambrisentan is well tolerated and provides benefit in patients with PAH. Definitive conclusions regarding the safety and efficacy of ambrisentan in specific non-Group 1 PH etiologies cannot be determined and larger, controlled studies will be necessary to determine the efficacy and safety of ambrisentan in these populations. C1 [Badesch, David B.] Univ Colorado, Clin Res Ctr, Aurora, CO 80045 USA. [Feldman, Jeremy] Arizona Pulm Specialists Ltd, Phoenix, AZ USA. [Keogh, Anne] St Vincents Hosp, Sydney, NSW 2010, Australia. [Mathier, Michael A.] Univ Pittsburgh, Pittsburgh, PA USA. [Oudiz, Ronald J.] Harbor UCLA Med Ctr, LA Biomed Res Inst, Torrance, CA 90509 USA. [Shapiro, Shelley] VA Greater Angeles VA Healthcare Syst, Los Angeles, CA USA. [Shapiro, Shelley] David Geffen UCLA Sch Med, Los Angeles, CA USA. [Farber, Harrison W.] Boston Univ, Sch Med, Boston, MA 02118 USA. [McGoon, Michael] Mayo Clin, Rochester, MN USA. [Frost, Adaani] Baylor Coll Med, Houston, TX 77030 USA. [Allard, Martine; Despain, Darrin; Dufton, Christopher] Gilead Sci Inc, Foster City, CA 94404 USA. [Rubin, Lewis J.] UCSD, La Jolla, CA USA. RP Badesch, DB (reprint author), Univ Colorado, Clin Res Ctr, Leprino Bldg,Rm 536,12401 E 17th Ave, Aurora, CO 80045 USA. EM David.Badesch@ucdenver.edu OI Farber, Harrison/0000-0002-0297-7902 FU Gilead Sciences Inc., Foster City, California, USA FX This study was sponsored by Gilead Sciences Inc., Foster City, California, USA. NR 21 TC 35 Z9 40 U1 0 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1755-5914 J9 CARDIOVASC THER JI Cardiovasc. Ther. PY 2012 VL 30 IS 2 BP 93 EP 99 DI 10.1111/j.1755-5922.2011.00279.x PG 7 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 907UE UT WOS:000301443500010 PM 21884013 ER PT J AU Theruvath, TP Jones, JA Ikonomidis, JS AF Theruvath, Tom P. Jones, Jeffrey A. Ikonomidis, John S. TI Matrix Metalloproteinases and Descending Aortic Aneurysms: Parity, Disparity, and Switch SO JOURNAL OF CARDIAC SURGERY LA English DT Review ID SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR-BETA; ASCENDING THORACIC AORTA; INCREASED PLASMA-LEVELS; IN-SITU LOCALIZATION; TISSUE INHIBITORS; ABDOMINAL-AORTA; MURINE MODEL; INTERSTITIAL COLLAGENASE; DILATATIVE PATHOLOGY AB Central to the pathologic changes in developing aortic aneurysms are alterations in the abundance and activity of proteases, of which the most important for aneurysm production comprise the matrix metalloproteinase (MMP) family. In this review, literature demonstrating the role of MMPs in the development of aortic aneurysms is presented, with emphasis on the parity and disparity between the thoracic and abdominal aorta. Furthermore, the role of embryologic cellular origins and evidence of phenotypic switch will be addressed in terms of how this process alters MMP production during aneurysm development. doi: 10.1111/j.1540-8191.2011.01315.x (J Card Surg 2012;27:81-90) C1 [Ikonomidis, John S.] Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Ikonomidis, JS (reprint author), Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg, 25 Courtenay Dr, Charleston, SC 29425 USA. EM ikonomij@musc.edu FU NIH/NHLBI [R21 HL089170, R01 HL102121] FX This manuscript was supported by NIH/NHLBI grants R21 HL089170 and R01 HL102121. NR 100 TC 12 Z9 14 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0886-0440 J9 J CARDIAC SURG JI J. Card. Surg. PD JAN PY 2012 VL 27 IS 1 BP 81 EP 90 DI 10.1111/j.1540-8191.2011.01315.x PG 10 WC Cardiac & Cardiovascular Systems; Surgery SC Cardiovascular System & Cardiology; Surgery GA 917JX UT WOS:000302172000020 PM 21958052 ER PT J AU Byers, AL Arean, PA Yaffe, K AF Byers, Amy L. Arean, Patricia A. Yaffe, Kristine TI Low Use of Mental Heat Services Among Older Americans With Mood and Anxiety Disorders SO PSYCHIATRIC SERVICES LA English DT Article ID COMORBIDITY-SURVEY-REPLICATION; WORLD-HEALTH-ORGANIZATION; RANDOMIZED CONTROLLED-TRIAL; REDUCING SUICIDAL IDEATION; PRIMARY-CARE PATIENTS; LATE-LIFE DEPRESSION; UNITED-STATES; NCS-R; FUTURE-RESEARCH; ADULTS AB Objective: It is unclear why late-life mood and anxiety disorders are highly undertreated, despite being common among older adults. Thus this study examined prevalence of and key factors associated with nonuse of mental health services among older community-dwelling adults with these disorders. Methods: The sample included 348 participants aged 55 years or older who met 12-month criteria for DSM-IV mood and anxiety disorders and responded to the National Comorbidity Survey Replication (NCS-R), a population-based probability sample. Analyses included frequency measures and logistic regression with weights and complex design corrected statistical tests. Key factors associated with not using mental health services were determined in a final multivariable model based on a systematic approach that accounted for a comprehensive list of potential predictors. Results: Approximately 70% of older adults with mood and anxiety disorders did not use services. Those who were from racial-ethnic minority groups, were not comfortable with discussing personal problems, were married or cohabitating, and had middle- versus high-income status had increased odds of not using mental health services. In addition, respondents with mild versus serious disorders, no chronic pain complaints, and low versus high perceived cognitive impairment had greater odds of nonuse. Conclusions: Results indicate that improvements are needed in the following areas to combat the very high number of mood and anxiety disorders that go untreated in older Americans: awareness of need, comfort in discussing personal problems with a health care professional, and screening and other prevention efforts. (Psychiatric Services 63:66-72, 2012) C1 [Byers, Amy L.; Arean, Patricia A.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, Mental Hlth Res Serv, San Francisco, CA USA. RP Byers, AL (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,116H, San Francisco, CA 94121 USA. EM amy.byers@ucsf.edu FU National Institute of Mental Health [MH079093, MH074717, U01-MH60220]; National Institute on Aging [AG031155]; Substance Abuse and Mental Health Services Administration [044708]; Robert Wood Johnson Foundation; John W. Alden Trust FX This work was supported by grants MH079093 and MH074717 from the National Institute of Mental Health and by grant AG031155 from the National Institute on Aging. The NCS-R was supported by grant U01-MH60220 from the National Institute of Mental Health, with supplemental support from the National Institute on Drug Abuse, the Substance Abuse and Mental Health Services Administration, grant 044708 by the Robert Wood Johnson Foundation, and the John W. Alden Trust. The views and opinions expressed in this report are those of the authors and should not be construed otherwise. NR 53 TC 27 Z9 27 U1 2 U2 8 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2012 VL 63 IS 1 BP 66 EP 72 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 917NP UT WOS:000302184900013 PM 22227762 ER PT J AU Wisneski, AD Azadani, AN Matthews, PB Chitsaz, S Guccione, JM Ge, L Tseng, EE AF Wisneski, A. D. Azadani, A. N. Matthews, P. B. Chitsaz, S. Guccione, J. M. Ge, L. Tseng, E. E. TI A Quantitative Approach to Pulmonary Autograft Remodeling After the Ross Procedure SO CARDIOLOGY LA English DT Meeting Abstract C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. San Francisco VA Med Ctr, Dept Surg, San Francisco, CA USA. RI Chitsaz, Sam/C-4586-2008 NR 0 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 J9 CARDIOLOGY JI Cardiology PY 2012 VL 121 IS 2 BP 144 EP 144 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 916WL UT WOS:000302133800122 ER PT J AU McFarland, LV Raugi, GJ Taylor, LL Reiber, GE AF McFarland, Lynne V. Raugi, Greg J. Taylor, Leslie L. Reiber, Gayle E. TI Implementation of an education and skills programme in a teledermatology project for rural veterans SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID CONSULT SYSTEM; CARE; DERMATOLOGY; WORKFORCE AB In July 2009 we implemented a store-and-forward teledermatology project to provide dermatology care to veterans living in underserved rural areas of the Pacific Northwest region of the US. We also developed an educational programme for rural primary care providers and imaging technicians. Participants were tested and their competencies were assessed at baseline and during a two-year project. Participation in a comprehensive education programme improved the knowledge of dermatology diagnosis and treatment care plans. All of the providers were performing dermatology procedures (e.g. biopsies, excisions, cauteries) after two years and more patients were being seen at their rural clinics than when the teledermatology project began (85% vs 39%). After two years, 71% of the providers and 56% of the imaging technicians had completed surgical training sessions and all passed their competency assessments. The educational component of the teledermatology project created teams of primary care health-care providers and imaging technicians with improved dermatology educational levels and new dermatology skills. C1 [McFarland, Lynne V.; Taylor, Leslie L.; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA 98101 USA. [McFarland, Lynne V.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA. [Raugi, Greg J.] VA Puget Sound Hlth Care Syst, Div Dermatol, Seattle, WA 98101 USA. [Raugi, Greg J.] Univ Washington, Dept Med, Seattle, WA USA. [Reiber, Gayle E.] Univ Washington, Dept Hlth Serv & Epidemiol, Seattle, WA 98195 USA. RP McFarland, LV (reprint author), VA Puget Sound Hlth Care Syst, Dept Vet Affairs, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Lynne.McFarland@va.gov FU US Department of Veterans Affairs; VISN 20 Office of Rural Health Services; VA Health Services Research and Development FX The work was funded by the US Department of Veterans Affairs, the VISN 20 Office of Rural Health Services and VA Health Services Research and Development. Parts of the work were presented at the VISN20 Teledermatology Summer Conferences, Seattle, WA, 14 June 2010 and 13 June 2011 and at the HSR&D National Meeting, National Harbor, MA, 16 February 2011. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. NR 16 TC 10 Z9 10 U1 0 U2 0 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2012 VL 18 IS 2 BP 66 EP 71 DI 10.1258/jtt.2011.110518 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 912PE UT WOS:000301811300002 PM 22198956 ER PT J AU Stewart, S O'Riley, A Edelstein, B Gould, C AF Stewart, Sarah O'Riley, Alisa Edelstein, Barry Gould, Christine TI A Preliminary Comparison of Three Cognitive Screening Instruments in Long Term Care: The MMSE, SLUMS, and MoCA SO CLINICAL GERONTOLOGIST LA English DT Article DE assessment; cognitive screening; dementia; memory ID MINI-MENTAL-STATE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; EDUCATIONAL-LEVEL; DEMENTIA; IMPAIRMENT; VALIDITY; RELIABILITY; POPULATION; VALIDATION AB The Mini-Mental State Examination (MMSE) is a widely utilized cognitive screening instrument. Despite its popularity, there are problems with this instrument. Many researchers have questioned the utility of the MMSE when used among adults without cognitive impairment. Additionally, the MMSE lacks tasks targeting a wider variety of cognitive domains. Finally, the MMSE is no longer in the public domain and may be too costly for some settings. Given these problems, some mental health settings may be obliged to utilize another instrument, such as the Montreal Cognitive Assessment (MoCA) or the Saint Louis Mental Status Examination (SLUMS). The present pilot study examined the current literature related to the MoCA, SLUMS, and MMSE and compared performances on these measures across a sample of participants. A within-subject design was utilized to compare performance on the MMSE, MoCA, and SLUMS in a sample of 40 long-term care residents (aged 48-89). Several participants appeared to lack clinically significant cognitive deficits as assessed by the MMSE, but demonstrated clinically significant deficits as assessed by the MoCA or SLUMS. The MMSE was significantly positively correlated with both the MoCA (r = .90) and the SLUMS (r = .83). The results of this pilot study have important implications regarding how to choose an appropriate replacement for the MMSE for practitioners who utilize cognitive screening instruments. C1 [Stewart, Sarah] S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA. [O'Riley, Alisa] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Edelstein, Barry; Gould, Christine] W Virginia Univ, Morgantown, WV 26506 USA. RP Stewart, S (reprint author), S Texas Vet Healthcare Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Sarah.Stoner@va.gov NR 50 TC 6 Z9 6 U1 1 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0731-7115 J9 CLIN GERONTOLOGIST JI Clin. Gerontol. PY 2012 VL 35 IS 1 BP 57 EP 75 DI 10.1080/07317115.2011.626515 PG 19 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 911RZ UT WOS:000301738600005 ER PT J AU Teerlink, JR Iragui, VJ Mohr, JP Carson, PE Hauptman, PJ Lovett, DH Miller, AB Pina, IL Thomson, S Varosy, PD Zile, MR Cleland, JGF Givertz, MM Metra, M Ponikowski, P Voors, AA Davison, BA Cotter, G Wolko, D DeLucca, P Salerno, CM Mansoor, GA Dittrich, H O'Connor, CM Massi, BM AF Teerlink, John R. Iragui, Vicente J. Mohr, Jay P. Carson, Peter E. Hauptman, Paul J. Lovett, David H. Miller, Alan B. Pina, Ileana L. Thomson, Scott Varosy, Paul D. Zile, Michael R. Cleland, John G. F. Givertz, Michael M. Metra, Marco Ponikowski, Piotr Voors, Adriaan A. Davison, Beth A. Cotter, Gad Wolko, Denise DeLucca, Paul Salerno, Christina M. Mansoor, George A. Dittrich, Howard O'Connor, Christopher M. Massi, Barry M. TI The Safety of an Adenosine A(1)-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment Findings from PROTECT SO DRUG SAFETY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; A(1) RECEPTOR ANTAGONIST; ACUTE ISCHEMIC-STROKE; KW-3902 AB Background: Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes. Objective: The aim of this analysis was to evaluate the safety of rolofylline, an adenosine A(1)-receptor antagonist, in patients with acute heart failure. Methods: The effect of rolofylline was investigated in patients hospitalized for acute heart failure with impaired renal function. Intravenous rolofylline 30 mg or placebo was infused over 4 hours daily for up to 3 days. Adverse events (AEs) and serious AEs (SAEs) were recorded from baseline through 7 and 14 days, respectively, and clinical events were adjudicated through 60 days. Results: Of 2033 patients enrolled, 2002 received study drug randomized 2: 1 to rolofylline or placebo. Rolofylline and placebo were associated with a similar risk of pre-specified groups of AEs or SAEs, other than selected neurological events. Investigator-reported seizures occurred in 11(0.8%) rolofylline-treated patients and zero patients receiving placebo (p = 0.02). Stroke occurred in 21(1.6%) patients assigned to rolofylline compared with 3 (0.5%) placebo-treated patients through 60 days with a greater risk for stroke in the rolofylline group (hazard ratio 3.49; 95% CI 1.04, 11.71; p = 0.043). There was no temporal relation to rolofylline administration and no specific stroke subtype or clinical characteristics that predicted stroke in the rolofylline group. Conclusions: Rolofylline treatment was associated with an increased seizure rate, an anticipated complication of A(1)-receptor antagonists. An unanticipated, disproportionate increase in strokes in the rolofylline-treated patients emerged, although no clear temporal relation, aetiology, stroke subtype or interacting factor suggestive of a causal mechanism was identified. Further research into stroke as a potential complication of adenosine-modulating therapies is required. Additionally, this study underscores the value of longer follow-up durations for AEs, even for agents with short treatment periods, such as in acute heart failure. C1 [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA. [Teerlink, John R.; Lovett, David H.; Massi, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Iragui, Vicente J.] Univ Calif San Diego, San Diego, CA 92103 USA. [Carson, Peter E.] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Hauptman, Paul J.] St Louis Univ, Sch Med, St Louis, MO USA. [Miller, Alan B.] Univ Florida, Hlth Sci Ctr, Jacksonville, FL 32209 USA. [Pina, Ileana L.] Cleveland Vet Affairs Med Ctr, Cleveland, OH USA. [Pina, Ileana L.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Thomson, Scott] Univ Calif San Diego, San Diego Vet Affairs Med Ctr, San Diego, CA 92103 USA. [Varosy, Paul D.] Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA. [Varosy, Paul D.] Univ Colorado, Denver, CO 80202 USA. [Zile, Michael R.] RHJ Dept Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England. [Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Davison, Beth A.; Cotter, Gad] Momentum Res Inc, Durham, NC USA. [Wolko, Denise; DeLucca, Paul; Salerno, Christina M.] Merck Res Labs, N Wales, PA USA. [Mansoor, George A.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard] NovaCardia Inc, San Diego, CA USA. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Mohr, Jay P.] Columbia Univ, Coll Phys & Surg, New York, NY USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol Sect, 111C,4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu RI Teerlink, John/D-2986-2012; Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Davison, Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016; Metra, Marco/0000-0001-6691-8568 FU NovaCardia, a subsidiary of Merck FX Funding for this study was provided by NovaCardia, a subsidiary of Merck. Representatives of the sponsor were directly involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review and approval of the manuscript.; The authors declare the following conflicts of interest in relation to the content of this study: Peter E. Carson received honorarium for services on the Clinical Events Committee; John G.F. Cleland received fees for work as a PROTECT steering committee member, and consulted with Merck on an international advisory board. He has also received support for travel and speakers' bureaus; Gad Cotter has received consulting fee/honorarium and is an employee of Momentum Research Inc., who provided consulting services to NovaCardia; Beth Davison received consulting fee/honorarium and is an employee of Momentum Research Inc., who provided consulting services to NovaCardia; Paul De Lucca is an employee of Merck and has received stock options as part of his employee compensation, and has received travel payments; Howard Dittrich received consulting fee/honorarium and support for travel, and is an employee of NovaCardia (acquired by Merck in 2007). He is also a consultant to Merck, with stock ownership of NovaCardia and Merck, and had a patent issued (no money was received); Michael M. Givertz received institutional research support for participation in the PROTECT study, and has served as a Scientific Advisory Baord member for Merck; Paul J. Hauptman was a member of the Clinical Events Committee and a site co-principal investigator on the PROTECT study. He received funding from NovaCardia and Merck; Vicente lragui served as a consultant, and received honoraria for conduct of the research but not for preparation of the manuscript; David H. Lovett received payments for the PROTECT Clinical Events Committee from Merck/NovaCardia, and has received payments for work as a member of Merck's speakers' bureau; George A. Mansoor is an employee of Merck, owns stock options in Merck and has received travel payments; Barry M. Massie received compensation for consultation from the sponsor, Merck/NovaCardia, for time spent on the design and oversight of this trial in his capacity of co-principal investigator and has received support for travel; Marco Metra has received honoraria for participation in advisory boards and speeches from Bayer, Corthera, Merck, Novartis and Servier, in addition to support for travel; Alan D. Miller received payments for work as a member of the Clinical Events Committee of the PROTECT study; J.P. Mohr received payments for the PROTECT Clinical Events Committee from Merck/NovaCardia; Christopher O'Connor received research funding from NovaCardia/Merck; Ileana Pina was a member of the Clinical Endpoints Committee that adjudicated events in the trial and received honoraria for the time involved in the adjudication work. Members were blinded during the entire process; Piotr Ponikowski received payments from NovaCardia/Merck for work performed on the PROTECT study and received honoraria from Merck as a speaker; Christina Salerno is an employee of Merck and discloses ownership of stock options and receipt of travel payments; John Teerlink received payments for clinical research for services as the Chairperson on the Clinical Events Committee for the PROTECT study; Scott Thomson occasionally consults for Merck and has previously consulted to NovaCardia; Paul D. Varosy was a member of the blinded, independent Clinical Endpoints Committee for the PROTECT study. In this capacity, he adjudicated clinical endpoints but was blinded to the patients' randomization status. All processes were conducted in compliance with FDA-mandated Good Clinical Practice. He received compensation for this work from Merck, which funded the study.; Last funding was received in July 2009; Adriaan Voors received payments for work performed on the PROTECT study from NovaCardia/Merck. In addition, Dr Voors received speakers' fees and advisory board payments from NovaCardia/Merck; Denise Wolko is an employee of Merck, owns stock or stock options in the company and has received travel payments; Michael R. Zile served as a member of the Events Committee of the PROTECT study and received an honorarium to perform this task. NR 26 TC 18 Z9 18 U1 1 U2 2 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0114-5916 J9 DRUG SAFETY JI Drug Saf. PY 2012 VL 35 IS 3 BP 233 EP 244 PG 12 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology GA 910DT UT WOS:000301618100005 PM 22339573 ER PT J AU Wang, TY Mancuso, JJ Kazmi, SMS Dwelle, J Sapozhnikova, V Willsey, B Ma, LL Qiu, JZ Li, XK Dunn, AK Johnston, KP Feldman, MD Milner, TE AF Wang, Tianyi Mancuso, J. Jacob Kazmi, S. M. Shams Dwelle, Jordan Sapozhnikova, Veronika Willsey, Brian Ma, Li L. Qiu, Jinze Li, Xiankai Dunn, Andrew K. Johnston, Keith P. Feldman, Marc D. Milner, Thomas E. TI Combined two-photon luminescence microscopy and OCT for macrophage detection in the hypercholesterolemic rabbit aorta using plasmonic gold nanorose SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE atherosclerosis; macrophage; nanorose; two-photon luminescence microscopy; optical coherence tomography; photothermal wave imaging ID OPTICAL COHERENCE TOMOGRAPHY; CORONARY-ARTERY-DISEASE; ATHEROSCLEROTIC PLAQUE STABILITY; CENTRAL-NERVOUS-SYSTEM; MYOCARDIAL-INFARCTION; IRON-OXIDE; IN-VIVO; MAGNETIC-RESONANCE; NANOPARTICLE; INFLAMMATION AB Background and Objectives The macrophage is an important early cellular marker related to risk of future rupture of atherosclerotic plaques. Two-channel two-photon luminescence (TPL) microscopy combined with optical coherence tomography (OCT) was used to detect, and further characterize the distribution of aorta-based macrophages using plasmonic gold nanorose as an imaging contrast agent. Study Design/Materials and Methods: Nanorose uptake by macrophages was identified by TPL microscopy in macrophage cell culture. Ex vivo aorta segments (8 x 8 x 2 mm(3)) rich in macrophages from a rabbit model of aorta inflammation were imaged by TPL microscopy in combination with OCT. Aorta histological sections (5 mm in thickness) were also imaged by TPL microscopy. Results: Merged two-channel TPL images showed the lateral and depth distribution of nanorose-loaded macrophages (confirmed by RAM-11 stain) and other aorta components (e.g., elastin fiber and lipid droplet), suggesting that nanorose-loaded macrophages are diffusively distributed and mostly detected superficially within 20 mm from the luminal surface of the aorta. Moreover, OCT images depicted detailed surface structure of the diseased aorta. Conclusions: Results suggest that TPL microscopy combined with OCT can simultaneously reveal macrophage distribution with respect to aorta surface structure, which has the potential to detect vulnerable plaques and monitor plaque-based macrophages overtime during cardiovascular interventions. Lasers Surg. Med. 44:49-59, 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Wang, Tianyi; Kazmi, S. M. Shams; Dwelle, Jordan; Qiu, Jinze; Dunn, Andrew K.; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Mancuso, J. Jacob; Sapozhnikova, Veronika; Li, Xiankai; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Willsey, Brian; Ma, Li L.; Johnston, Keith P.] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA. [Feldman, Marc D.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Milner, TE (reprint author), Univ Texas Austin, Dept Biomed Engn, 1 Univ Stn,C0800, Austin, TX 78712 USA. EM terra.laser@gmail.com RI Dunn, Andrew/I-9527-2014 OI Ma, Li/0000-0002-0959-5616 FU American Society for Laser Medicine and Surgery; Veterans Administration; Welch Foundation [F-1319]; NSF [CBET-0968038]; Department of Energy Center for Frontiers of Subsurface Energy Security FX The authors would like to acknowledge the technical support from the University of Texas Health Science Center at San Antonio. This study was supported in part by a travel grant from the American Society for Laser Medicine and Surgery to Wang, a Veterans Administration merit grant to Feldman, a Welch Foundation grant F-1319 and NSF grant CBET-0968038 to Johnston, and the Department of Energy Center for Frontiers of Subsurface Energy Security. NR 55 TC 3 Z9 3 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 EI 1096-9101 J9 LASER SURG MED JI Lasers Surg. Med. PD JAN PY 2012 VL 44 IS 1 BP 49 EP 59 DI 10.1002/lsm.21153 PG 11 WC Dermatology; Surgery SC Dermatology; Surgery GA 875ZS UT WOS:000299076500007 ER PT J AU Sun, F Park, NS Roff, LL Klemmack, DL Parker, M Koenig, HG Sawyer, P Allman, RM AF Sun, Fei Park, Nan S. Roff, Lucinda L. Klemmack, David L. Parker, Michael Koenig, Harold G. Sawyer, Patricia Allman, Richard M. TI Predicting the trajectories of depressive symptoms among southern community-dwelling older adults: The role of religiosity SO AGING & MENTAL HEALTH LA English DT Article DE depressive symptoms; HLM; religiosity; trajectories ID MENTAL-HEALTH; PHYSICAL HEALTH; SOCIAL SUPPORT; RISK-FACTORS; SPIRITUALITY; INVOLVEMENT; PREVALENCE; CARE; SERVICES AB Background: This study examined the effects of religiosity on the trajectories of depressive symptoms in a sample of community-dwelling older adults over a four-year period in a Southern state in the US. Methods: Data from the University of Alabama at Birmingham (UAB) Study of Aging were analyzed using a hierarchical linear modeling (HLM) method. This study involved 1000 participants aged 65 and above (M age = 75 at baseline, SD = 5.97) and data were collected annually from 1999 to 2003. The Geriatric Depression Scale measured depressive symptoms; the Duke University Religion Index measured religious service attendance, prayer, and intrinsic religiosity; and control variables included sociodemographics, health, and social and economic factors. Results: The HLM analysis indicated a curvilinear trajectory of depressive symptoms over time. At baseline, participants who attended religious services more frequently tended to report fewer depressive symptoms. Participants with the highest levels of intrinsic religiosity at baseline experienced a steady decline in the number of depressive symptoms over the four-year period, while those with lower levels of intrinsic religiosity experienced a short-term decline followed by an increase in the number of depressive symptoms. Implications: In addition to facilitating access to health, social support and financial resources for older adults, service professionals might consider culturally appropriate, patient-centered interventions that boost the salutary effects of intrinsic religiosity on depressive symptoms. C1 [Sun, Fei] Arizona State Univ, Sch Social Work, Phoenix, AZ 85069 USA. [Park, Nan S.] Univ S Florida, Sch Social Work, Tampa, FL USA. [Roff, Lucinda L.; Klemmack, David L.; Parker, Michael] Univ Alabama, Sch Social Work, Tuscaloosa, AL USA. [Koenig, Harold G.] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Sawyer, Patricia] Univ Alabama, Ctr Aging, Birmingham, AL USA. [Allman, Richard M.] Birmingham VA Med Ctr, Birmingham, AL USA. [Allman, Richard M.] Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. RP Sun, F (reprint author), Arizona State Univ, Sch Social Work, Phoenix, AZ 85069 USA. EM fei.sun.1@asu.edu RI Koenig, Harold/F-7379-2011 FU National Institute on Aging [R01 AG15062, P30 AG031054] FX The project described was supported in part from grants R01 AG15062 and P30 AG031054 from the National Institute on Aging. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health. The authors also acknowledge the assistance of the John A. Harford Foundation's Geriatric Social Work Faculty Scholars Program. NR 48 TC 13 Z9 13 U1 1 U2 10 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 J9 AGING MENT HEALTH JI Aging Ment. Health PY 2012 VL 16 IS 2 BP 189 EP 198 DI 10.1080/13607863.2011.602959 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 909BG UT WOS:000301536400008 PM 22032625 ER PT J AU Tripathi, M Vibha, D Gupta, P Bhatia, R Srivastava, MVP Vivekanandhan, S Singh, MB Prasad, K Dergalust, S Mendez, MF AF Tripathi, Manjari Vibha, Deepti Gupta, Praveen Bhatia, Rohit Srivastava, M. V. Padma Vivekanandhan, S. Singh, Mamta Bhushan Prasad, Kameshwar Dergalust, Sunita Mendez, Mario F. TI Risk factors of dementia in North India: a case-control study SO AGING & MENTAL HEALTH LA English DT Article DE risk factors; dementia; diet; life style; apolipoprotein E ID INCIDENT ALZHEIMER-DISEASE; MILD COGNITIVE IMPAIRMENT; VASCULAR DEMENTIA; PROSPECTIVE COHORT; POPULATION; HOMOCYSTEINE; DECLINE; PREVALENCE; POLYMORPHISM; CHOLESTEROL AB Objective: The prevalence of dementia in northern India is among the lowest in the world but reasons are unclear. The aim of the study was to evaluate the risk and protective factors for dementia in North India. Methods: In a case-control study, we investigated demographic, medical, genetic, dietary, lifestyle, and sociocultural protective and risk factors associated with dementia. Results: 150 patients of dementia (118 males and 32 females) and 150 healthy controls (112 males and 38 females) were included in the study. Diabetes, depression, hyperhomocysteinemia, hyperlipidemia, APOE epsilon 4 gene, BMI, use of saturated fatty acids, pickles in diet, urban living, and lack of exercise were associated with independent risk of dementia. Various dietary factors and sociocultural factors, like cognitively stimulating activities, active socialization, living in joint families, increased intake of polyunsaturated fats, fruits, and salads conferred protection against dementia. Conclusions: Dietary, lifestyle, and sociocultural interventions may be protective against dementia. C1 [Tripathi, Manjari; Vibha, Deepti; Gupta, Praveen; Bhatia, Rohit; Srivastava, M. V. Padma; Singh, Mamta Bhushan; Prasad, Kameshwar] All India Inst Med Sci, Dept Neurol, New Delhi, India. [Vivekanandhan, S.] All India Inst Med Sci, Dept Neurobiochem, New Delhi, India. [Dergalust, Sunita] W Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Mendez, Mario F.] Greater Los Angeles VA Med Ctr, UCLA Sch Med, Neurobehav Unit, Los Angeles, CA USA. RP Tripathi, M (reprint author), All India Inst Med Sci, Dept Neurol, New Delhi, India. EM manjari.tripathi@gmail.com NR 50 TC 10 Z9 10 U1 2 U2 21 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 J9 AGING MENT HEALTH JI Aging Ment. Health PY 2012 VL 16 IS 2 BP 228 EP 235 DI 10.1080/13607863.2011.583632 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 909BG UT WOS:000301536400012 PM 21714688 ER PT J AU Ezra, N Binder, SW Behroozan, D AF Ezra, Navid Binder, Scott W. Behroozan, Daniel TI Plasma Cell Balanitis Presenting in a Patient with a History of Syphilis SO AMERICAN JOURNAL OF CLINICAL DERMATOLOGY LA English DT Article ID PIMECROLIMUS 1-PERCENT CREAM; CARBON-DIOXIDE LASER; ZOONS BALANITIS; TOPICAL TACROLIMUS; GLANS-PENIS; CIRCUMCISION; ERYTHROPLASIA; CARCINOMA; VULVITIS; QUEYRAT AB Plasma cell balanitis (PCB), also knows as Zoon balanitis, is a benign asymptomatic but chronic and erosive inflammatory condition of the glans penis and prepuce that generally affects uncircumcised men in later years. Clinical presentation involves a single, shiny, well defined reddish patch. We describe the first case of PCB ever reported in a patient with a previous history of syphilis, and include a review of the current literature. A 57-year-old Hispanic man with a remote history of syphilis presented with a 6-month nonhealing, granulating ulcer of the foreskin and glans penis that had been repeatedly mistaken for syphilis and treated unsuccessfully with circumcision 3 weeks previously. Biopsy of the glans penis demonstrated sections with denuded chronic granulation tissue showing a fibrotic stroma with numerous blood vessels and a mixed inflammatory infiltrate including scattered plasma cells. It is important to differentiate PCB from a syphilitic chancre in a patient presenting with a nonhealing penile lesion. This case report demonstrates that these entities may be seen in the same patient at different times. C1 [Behroozan, Daniel] Dermatol Inst So Calif, Santa Monica, CA 90405 USA. [Ezra, Navid; Behroozan, Daniel] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA. [Binder, Scott W.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatopathol, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Behroozan, Daniel] W Los Angeles Vet Adm Med Ctr, Dermatol Serv, Los Angeles, CA USA. RP Behroozan, D (reprint author), Dermatol Inst So Calif, 2221 Lincoln Blvd,Suite 100, Santa Monica, CA 90405 USA. EM db@dermsurgery.net NR 37 TC 1 Z9 3 U1 0 U2 1 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1175-0561 J9 AM J CLIN DERMATOL JI Am. J. Clin. Dermatol. PY 2012 VL 13 IS 2 BP 129 EP 133 PG 5 WC Dermatology SC Dermatology GA 910EG UT WOS:000301619400006 PM 21992223 ER PT J AU Dichter, ME Gelles, RJ AF Dichter, Melissa E. Gelles, Richard J. TI Women's Perceptions of Safety and Risk Following Police Intervention for Intimate Partner Violence SO VIOLENCE AGAINST WOMEN LA English DT Article DE battering; intimate partner violence; revictimization ID WIFE ASSAULT RECIDIVISM; DOMESTIC VIOLENCE; PROTECTIVE FACTORS; BATTERED WOMEN; ABUSE; VICTIMIZATION; BEHAVIOR; VICTIMS; SHELTER; REABUSE AB Police intervention is a primary response to intimate partner violence (IPV) but does not guarantee a victim's future safety. This study sought to identify factors associated with IPV survivors' perceptions of safety and risk of revictimization following police intervention. One hundred sixty-four women completed a questionnaire, and 11 of those women also took part in qualitative interviews. The findings revealed that feeling unsafe and perceiving oneself to be at risk of future violence is associated with experiencing particular forms of IPV, including battering, lethality threats, and sexual violence. Having support from others and distance from the partner helps women feel safe. C1 [Dichter, Melissa E.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Gelles, Richard J.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Dichter, ME (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM mdichter@sp2.upenn.edu FU NCIPC CDC HHS [1R49CE001226-01, R49 CE001226] NR 50 TC 12 Z9 12 U1 5 U2 31 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-8012 J9 VIOLENCE AGAINST WOM JI Violence Against Women PD JAN PY 2012 VL 18 IS 1 BP 44 EP 63 DI 10.1177/1077801212437016 PG 20 WC Women's Studies SC Women's Studies GA 906OJ UT WOS:000301355300004 PM 22411298 ER PT J AU Gaffo, AL Saag, KG AF Gaffo, Angelo L. Saag, Kenneth G. TI Drug Treatment of Hyperuricemia to Prevent Cardiovascular Outcomes Are We There Yet? SO AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS LA English DT Article ID SERUM URIC-ACID; NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; BLOOD-PRESSURE; GLOMERULAR HYPERTENSION; HEART-FAILURE; INCIDENT HYPERTENSION; METABOLIC SYNDROME; DECISION-ANALYSIS; OXIDATIVE STRESS AB Data supporting an association between high levels of serum urate and cardiovascular disease have continued to emerge. Basic science data, small clinical trials, and epidemiologic studies have provided support for the idea of a true causal effect. In this paper, we present evidence about the association between hyperuricemia and selected cardiovascular diseases. Although data generated so far compellingly support pharmacologic urate-lowering therapy in selected cases with high cardiovascular risk, further evidence is necessary before widely advocating this approach to prevent cardiovascular outcomes putatively associated with hyperuricemia. C1 [Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL USA. [Gaffo, Angelo L.; Saag, Kenneth G.] Univ Alabama, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. RP Saag, KG (reprint author), FOT 820,1530 3rd Ave S, Birmingham, AL 35294 USA. EM ksaag@uab.edu FU Takeda; Savient; Merck FX Dr Saag is a consultant to Takeda, Savient, and Merck. He has received research grants from Takeda, Savient, and Merck. Dr Gaffo has no conflicts of interest to declare. NR 58 TC 6 Z9 7 U1 0 U2 2 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1175-3277 J9 AM J CARDIOVASC DRUG JI Am. J. Cardiovasc. Drugs PY 2012 VL 12 IS 1 BP 1 EP 6 PG 6 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 905NE UT WOS:000301278100001 PM 22204636 ER PT J AU Mariappan, MM AF Mariappan, Meenalakshmi M. TI Signaling Mechanisms in the Regulation of Renal Matrix Metabolism in Diabetes SO EXPERIMENTAL DIABETES RESEARCH LA English DT Review ID MESSENGER-RNA TRANSLATION; GLYCOGEN-SYNTHASE KINASE-3-BETA; ACTIVATED PROTEIN-KINASE; UPSTREAM BINDING-FACTOR; RICTOR-MTOR COMPLEX; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; HIGH GLUCOSE; ANGIOTENSIN-II; MESANGIAL CELLS AB Renal hypertrophy and accumulation of extracellular matrix proteins are among cardinal manifestations of diabetic nephropathy. TGF beta system has been implicated in the pathogenesis of these manifestations. Among signaling pathways activated in the kidney in diabetes, mTOR- (mammalian target of rapamycin-) regulated pathways are pivotal in orchestrating high glucose-induced production of ECM proteins leading to functional and structural changes in the kidney culminating in adverse outcomes. Understanding signaling pathways that influence individual matrix protein expression could lead to the development of new interventional strategies. This paper will highlight some of the diverse components of the signaling network stimulated by hyperglycemia with an emphasis on extracellular matrix protein metabolism in the kidney in diabetes. C1 Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, S Texas Vet Healthcare Syst, San Antonio, TX 78229 USA. RP Mariappan, MM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, S Texas Vet Healthcare Syst, MC7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM malini@uthscsa.edu FU NIH; American Diabetes Association; Juvenile Diabetes Research Foundation; National Kidney Foundation of South and Central Texas; VA merit review program FX The author thanks his mentor Dr. B. S. Kasinath for critically reading the paper and for giving comments and advice. Work contained in this paper was supported by the NIH, VA merit review program, and American Diabetes Association awarded to B. S. Kasinath and Juvenile Diabetes Research Foundation and the National Kidney Foundation of South and Central Texas awarded to M. M. Mariappan. The author regrets that due to space limitations many seminal publications could not be cited. NR 115 TC 20 Z9 21 U1 0 U2 2 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-5214 J9 EXP DIABETES RES JI Exp. Diabetes Res. PY 2012 AR 749812 DI 10.1155/2012/749812 PG 10 WC Endocrinology & Metabolism; Medicine, Research & Experimental SC Endocrinology & Metabolism; Research & Experimental Medicine GA 906NF UT WOS:000301351400001 ER PT J AU Mizwicki, MT Menegaz, D Zhang, J Barrientos-Duran, A Tse, S Cashman, JR Griffin, PR Fiala, M AF Mizwicki, Mathew T. Menegaz, Danusa Zhang, Jun Barrientos-Duran, Antonio Tse, Stephen Cashman, John R. Griffin, Patrick R. Fiala, Milan TI Genomic and Nongenomic Signaling Induced by 1 alpha,25(OH)(2)-Vitamin D-3 Promotes the Recovery of Amyloid-beta Phagocytosis by Alzheimer's Disease Macrophages SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; chloride channel; ClC-3; curcumin; hydrogen-deuterium exchange; nongenomic; nuclear vitamin D receptor; phagocytosis; 1 alpha,25(OH)(2)-vitamin D-3 ID VITAMIN-D-RECEPTOR; CHLORIDE CHANNELS; ANION CHANNELS; PROTEIN-KINASE; ENSEMBLE MODEL; CELLS; CLC-3; THERAPEUTICS; PATHWAYS; CIC-3 AB Brain clearance of amyloid-beta (A beta(42)) by innate immune cells is necessary for maintenance of normal brain function. Phagocytosis of soluble A beta(42) by Alzheimer's disease (AD) macrophages is defective, recovered in all "Type I and Type II" AD patients by 1 alpha,25(OH)(2)-vitamin D-3 (1,25D3) and blocked by the nuclear vitamin D receptor (VDR) antagonist (23S)-25-dehydro-1 alpha(OH)-vitamin D-3-26,23-lactone (MK). Bisdemethoxycurcumin (BDC) is a VDR ligand and additive with 1,25D3 in promoting A beta(42) phagocytosis by Type I, but not by Type II macrophages. Here, we define the following intracellular mechanisms regulated by 1,25D3 that are associated with recovery of phagocytosis and consistent with the selectivity of BDC: 1) 1,25D3 potentiates a 4,4-diisothiocyanostilbene-2,2-disulfonic acid-sensitive chloride channel (i.e., ClC-3) currents in both Type I and II AD macrophages, but curcumin only potentiates the currents in Type I cells; 2) 1,25D3 is particularly effective in upregulating ClC-3 mRNA expression in Type II peripheral blood mononuclear cells (PBMCs) while both 1,25D3 and the BDC analog, C180, upregulate VDR mRNA, repressed by A beta(42) in Type II PBMCs; and 3) 1,25D3-induced A beta(42) phagocytosis is attenuated by the calcium-dependent ClC-3 blocker, inositol 3,4,5,6-tetraphosphate (IP4), in both AD Types and by the MEK1/2 inhibitor U0126 only in Type II macrophages. VDR hydrogen/deuterium exchange coupled mass spectrometry and computational results show differences between the abilities of 1,25D3 and curcuminoids to stabilize VDR helices associated with the regulation of gene transcription. The structure-function results provide evidence that 1,25D3 activation of VDR-dependent genomic and nongenomic signaling, work in concert to recover dysregulated innate immune function in AD. C1 [Mizwicki, Mathew T.; Menegaz, Danusa; Barrientos-Duran, Antonio] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA. [Zhang, Jun; Griffin, Patrick R.] Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL USA. [Tse, Stephen; Fiala, Milan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Tse, Stephen; Fiala, Milan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cashman, John R.] Human BioMol Res Inst, San Diego, CA USA. RP Mizwicki, MT (reprint author), UCLA CHS, 650 Charles E Young Dr S,Room 23-338, Los Angeles, CA 90095 USA. EM mtmizwicki@gmail.com; fiala@mednet.ucla.edu FU Fundacion Alfonso Martin Escudero; NIH [DK-09012-048] FX A.B-D would like to acknowledge his post-doctoral fellowship supported by Fundacion Alfonso Martin Escudero. MTM would like to acknowledge support from Anthony W. Norman (NIH grant: DK-09012-048) and his mentorship. NR 50 TC 30 Z9 31 U1 0 U2 10 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 29 IS 1 BP 51 EP 62 DI 10.3233/JAD-2011-110560 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 903SB UT WOS:000301139000005 PM 22207005 ER PT J AU Ishii, S Streim, JE Saliba, D AF Ishii, Shinya Streim, Joel E. Saliba, Debra TI A Conceptual Framework for Rejection of Care Behaviors: Review of Literature and Analysis of Role of Dementia Severity SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Review DE Rejection of care; challenging behavior; disruptive behavior; conceptual framework; meta-analysis ID NURSING-HOME RESIDENTS; QUALITY-OF-LIFE; VERSION NPI-NH; MILD COGNITIVE IMPAIRMENT; LOWERED STRESS THRESHOLD; SKILL-BUILDING PROGRAM; E E4 ALLELE; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC SYMPTOMS; PSYCHOLOGICAL SYMPTOMS AB Rejection of care behaviors is common in the geriatric population, especially among patients with dementia. Nonetheless, the concept of rejection of care is not well defined and existing psychosocial theoretical models fall short of capturing complex relationships between factors associated with rejection of care. We propose a definition of rejection of care and develop a conceptual framework of rejection of care incorporating 7 components: intrinsic factors, match between needs and environmental resources, behavior state, antecedents, individual preferences, rejection of care behaviors, and consequences. A literature search yielded 55 studies that examined the associations between rejection of care and factors of the conceptual framework. We quantitatively synthesized studies focused on dementia severity and rejection of care. The literature review demonstrated that rejection of care is more prevalent among patients with dementia or functional impairment, associated with some mutable factors, and is triggered by specific antecedents in the context of daily personal care provision and associated with various adverse outcomes. The meta-analysis provided evidence that severe dementia is associated with higher likelihood of developing rejection of care behaviors compared with mild to moderate dementia. We also found that research on unmet needs, antecedents, and individual preferences has been scarce. The direction of further research is discussed. Copyright (C) 2012 - American Medical Directors Association, Inc. C1 [Ishii, Shinya; Saliba, Debra] VA Greater Los Angeles Healthcare Syst, VA Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Streim, Joel E.] Philadelphia Vet Affairs VA Med Ctr, Vet Integrated Serv Network 4 VISN 4, Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA. [Streim, Joel E.; Saliba, Debra] Univ Penn, Dept Psychiat, Geriatr Psychiat Sect, Philadelphia, PA 19104 USA. [Saliba, Debra] VA HSR&D Ctr Excellence Study Healthcare Provider, Los Angeles, CA USA. [Saliba, Debra] UCLA JH Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, Debra] RAND Corp, Santa Monica, CA USA. RP Ishii, S (reprint author), VA Greater Los Angeles Healthcare Syst, VA Geriatr Res Educ & Clin Ctr, 11301 Wilshire Blvd,Bldg 220,Room 302, Los Angeles, CA 90073 USA. EM sishii@mednet.ucla.edu FU US Department of Veterans Affairs, Veterans Health Administration, VA Health Services Research & Development (HSR&D) Service through the VA Greater Los Angeles HSR&D Center of Excellence [SDR 03-217]; VA Office of Academic Affairs; Centers for Medicare & Medicaid Services FX This work was funded by the US Department of Veterans Affairs, Veterans Health Administration, VA Health Services Research & Development (HSR&D) Service through the VA Greater Los Angeles HSR&D Center of Excellence (Project # SDR 03-217), the VA Office of Academic Affairs, and the Centers for Medicare & Medicaid Services. NR 110 TC 13 Z9 13 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD JAN PY 2012 VL 13 IS 1 BP 11 EP U40 DI 10.1016/j.jamda.2010.11.004 PG 15 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 898HT UT WOS:000300733100010 PM 21450222 ER PT J AU Castle, NG Wagner, LM Ferguson, JC Smith, ML Handler, SM AF Castle, Nicholas G. Wagner, Laura M. Ferguson, Jamie C. Smith, Mary Lindsey Handler, Steven M. TI Alcohol Misuse and Abuse in Assisted Living SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Letter C1 [Castle, Nicholas G.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA. [Wagner, Laura M.] Baycrest Geriatr Healthcare Syst, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada. [Smith, Mary Lindsey] Univ Pittsburgh, Dept Psychiat, Mental Illness Res Educ & Clin Ctr, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Handler, Steven M.] Univ Pittsburgh, Sch Med,Vet Affairs Pittsburgh Healthcare Syst, Dept Biomed Informat,Geriatr Res Educ & Clin Ctr,, LTC Hlth Informat Technol,UPMC Senior Communities, Pittsburgh, PA USA. RP Castle, NG (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA. OI Handler, Steven/0000-0002-3940-3224 FU AHRQ HHS [1 RO3 HS0165347-01A1] NR 3 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD JAN PY 2012 VL 13 IS 1 BP E7 EP E7 DI 10.1016/j.jamda.2011.06.010 PG 1 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 898HT UT WOS:000300733100004 PM 21764389 ER PT J AU Hanlon, JT Aspinall, SL AF Hanlon, Joseph T. Aspinall, Sherrie L. TI Renal Function Equations to Use to Guide Prescribing of Primarily Renally Cleared Medications for Older Adults SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Letter ID ELDERLY HOSPITALIZED-PATIENTS; GLOMERULAR-FILTRATION-RATE; ADVERSE DRUG-REACTIONS; PHARMACOKINETICS C1 [Hanlon, Joseph T.; Aspinall, Sherrie L.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hanlon, Joseph T.] Pittsburgh VA Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Med Geriatr, Pittsburgh, PA USA. [Hanlon, Joseph T.; Aspinall, Sherrie L.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Hanlon, Joseph T.; Aspinall, Sherrie L.] Univ Pittsburgh, Geriatr Pharmaceut & Gero Informat Res & Training, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Bioinformat, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Aspinall, Sherrie L.] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. RP Hanlon, JT (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD JAN PY 2012 VL 13 IS 1 BP E6 EP E6 DI 10.1016/j.jamda.2011.06.014 PG 1 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 898HT UT WOS:000300733100003 ER PT J AU Gudis, D Zhao, KQ Cohen, NA AF Gudis, David Zhao, Ke-qing Cohen, Noam A. TI Acquired cilia dysfunction in chronic rhinosinusitis SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Review ID CIGARETTE-SMOKE EXPOSURE; OUTER DYNEIN ARMS; SIGNAL-TRANSDUCTION MECHANISMS; MAMMALIAN RESPIRATORY-TRACT; BRONCHIAL EPITHELIAL-CELLS; SURFACE LIQUID VOLUME; BEAT FREQUENCY; CHRONIC SINUSITIS; MUCOCILIARY CLEARANCE; AIRWAY EPITHELIUM AB Background: Cilia are complex and powerful cellular structures of the respiratory mucosa that play a critical role in airway defense. Respiratory epithelium is lined with cilia that perform an integrated and coordinated mechanism called mucociliary clearance. Mucociliary clearance is the process by which cilia transport the mucus blanket overlying respiratory mucosa to the gastrointestinal tract for ingestion. It is the primary means by which the airway clears pathogens, allergens, debris, and toxins. The complex structure and regulatory mechanisms that dictate the form and function of normal cilia are not entirely understood, but it is clear that ciliary dysfunction results in impaired respiratory defense. Methods: A literature review of the current knowledge of cilia dysfunction in chronic rhinosinsusitis was conducted. Results: Ciliary dysfunction may be primary, the result of genetic mutations resulting in abnormal cilia structure, or, more commonly, secondary, the result of environmental, infectious, or inflammatory stimuli that disrupt normal motility or coordination. Patients with chronic rhinosinusitis (CRS) have been found to have impaired mucociliary clearance. Many biochemical, environmental, and mechanical stimuli have been shown to influence ciliary beat frequency, and common microbial pathogens of respiratory mucosa such as Pseudomonas aeruginosa and Haemophilus influenzae have developed toxins that appear to interrupt normal mucociliary function. Furthermore, inflammatory mediators known to be present in patients with CRS appear to impair secondarily mucociliary clearance. Conclusion: The goal of this article is to summarize the recent developments in the understanding of cilia dysfunction and mucociliary clearance in CRS. (Am J Rhinol Allergy 26, 1-6, 2012; doi: 10.2500/ajra.2012.26.3716) C1 [Gudis, David; Zhao, Ke-qing; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Zhao, Ke-qing] Fudan Univ, Eye & Ear Nose & Throat Hosp, Dept Otorhinolaryngol Head & Neck Surg, Sch Shanghai Med, Shanghai 200433, Peoples R China. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Div Otolaryngol, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM Noam.Cohen@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 NR 92 TC 36 Z9 36 U1 0 U2 6 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD JAN-FEB PY 2012 VL 26 IS 1 BP 1 EP 6 DI 10.2500/ajra.2012.26.3716 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 898VB UT WOS:000300769300012 PM 22391065 ER PT J AU Wise, SK Schlosser, RJ AF Wise, Sarah K. Schlosser, Rodney J. TI Subcutaneous and sublingual immunotherapy for allergic rhinitis: What is the evidence? SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; HOUSE-DUST MITE; DOUBLE-BLIND; PEDIATRIC-PATIENTS; CLINICAL-EFFICACY; FATAL REACTIONS; POLLEN TABLET; DOUBLE-DUMMY; SAFETY; CHILDREN AB Background: Increasing interest in sublingual immunotherapy (SLIT) among practitioners and patients has resulted in numerous publications and clinical trials in recent years. With the clinical growth of SLIT, discussions of its efficacy, safety, and immunologic effects have intensified, as have comparisons to subcutaneous immunotherapy (SCIT). In the United States, SCIT has been the traditional form of immunotherapy for inhalant allergy and is the only immunotherapy method approved by the U. S. Food and Drug Administration at this time. The similarities and differences between SLIT and SCIT are often discussed, yet clinical studies directly comparing these immunotherapy methods are scarce. Methods: A literature review of specific issues and controversies between SLIT and SCIT for allergic rhinitis was conducted. Results: Safety, efficacy, and immunologic effects of these two immunotherapy techniques are reviewed. Conclusion: Unanswered questions relating to SLIT are examined. (Am J Rhinol Allergy 26, 18-22, 2012; doi: 10.2500/ajra.2012.26.3691) C1 [Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Wise, Sarah K.] Emory Univ, Dept Otolaryngol Head & Neck Surg, Atlanta, GA 30322 USA. [Schlosser, Rodney J.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM schlossr@musc.edu NR 47 TC 11 Z9 15 U1 1 U2 8 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD JAN-FEB PY 2012 VL 26 IS 1 BP 18 EP 22 DI 10.2500/ajra.2012.26.3691 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA 898VB UT WOS:000300769300015 PM 22391071 ER PT J AU Ruggiero, KJ Resnick, HS Paul, LA Gros, K McCauley, JL Acierno, R Morgan, M Galea, S AF Ruggiero, Kenneth J. Resnick, Heidi S. Paul, Lisa A. Gros, Kirstin McCauley, Jenna L. Acierno, Ron Morgan, Mark Galea, Sandro TI Randomized controlled trial of an internet-based intervention using random-digit-dial recruitment: the Disaster Recovery Web project SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Disaster mental health; Internet intervention; Randomized controlled trial; Hurricane Ike; Posttraumatic stress ID POSTTRAUMATIC-STRESS-DISORDER; GENERALIZED ANXIETY DISORDER; STATE WORRY QUESTIONNAIRE; SEPTEMBER-11 TERRORIST ATTACKS; POST-RAPE PSYCHOPATHOLOGY; 2004 FLORIDA HURRICANES; NEW-YORK-CITY; IN-PERSON; PANIC DISORDER; MENTAL-HEALTH AB Disasters occur with high frequency throughout the world and increase risk for development of mental health problems in affected populations. Research focused on the development and evaluation of secondary prevention interventions addressing post-disaster mental health has high potential public-health impact. Toward this end, internet-based interventions (IBIS) are particularly attractive in that they: (1) offer a low-cost means of delivering standardized, targeted, personalized intervention content to a broad audience: and (2) are easily integrated within a stepped care approach to screening and service delivery. We describe a unique study design intended to evaluate an IBI with a disaster-affected population-based sample. Description and rationale are provided for sampling selection and procedures, selection of assessment measures and methods, design of the intervention, and statistical evaluation of critical outcomes. Unique features of this intervention include the use of a population-based sample, telephone and internet-based assessments, and development of a highly individualized web-based intervention. Challenges related to the development and large-scale evaluation of IBIs targeting post-disaster mental health problems, as well as implications for future research and practice are discussed. (C) 2011 Elsevier Inc. All rights reserved. C1 [Ruggiero, Kenneth J.; Resnick, Heidi S.; Paul, Lisa A.; Gros, Kirstin; McCauley, Jenna L.; Acierno, Ron] Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Morgan, Mark] Abt SRBI, New York, NY 10001 USA. [Galea, Sandro] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA. RP Ruggiero, KJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St,MSC861, Charleston, SC 29425 USA. EM ruggierk@musc.edu FU National Institute of Mental Health [R34 MH77149, R01 MH081056, P60 MH082598] FX This research was supported by National Institute of Mental Health Grants R34 MH77149 (PI: KJ Ruggiero), R01 MH081056 (PI: KJ Ruggiero), and P60 MH082598 (PI: FH Norris). All views and opinions expressed herein are those of the authors and do not necessarily reflect those of the funding agency or respective institutions. We acknowledge the important contributions of Wendy Muzzy and Kye Welsh of the Medical University of South Carolina, and of Daniel Loew of Abt SRBI. NR 87 TC 13 Z9 13 U1 7 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD JAN PY 2012 VL 33 IS 1 BP 237 EP 246 DI 10.1016/j.cct.2011.10.001 PG 10 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 889KL UT WOS:000300072500034 PM 22008248 ER PT J AU Larauche, M Mulak, A Tache, Y AF Larauche, Muriel Mulak, Agata Tache, Yvette TI Stress and visceral pain: From animal models to clinical therapies SO EXPERIMENTAL NEUROLOGY LA English DT Review DE Colorectal distension; CRF receptor; Irritable bowel syndrome; Mast cells; Stress; Visceral pain ID IRRITABLE-BOWEL-SYNDROME; CORTICOTROPIN-RELEASING-FACTOR; FUNCTIONAL GASTROINTESTINAL DISORDERS; NEONATAL MATERNAL SEPARATION; RECEPTOR-MEDIATED MECHANISMS; ANTERIOR CINGULATE CORTEX; LOCUS-COERULEUS NEURONS; CENTRAL-NERVOUS-SYSTEM; DSS-INDUCED COLITIS; ROBALZOTAN TARTRATE MONOHYDRATE AB Epidemiological studies have implicated stress (psychosocial and physical) as a trigger of first onset or exacerbation of irritable bowel syndrome (IBS) symptoms of which visceral pain is an integrant landmark. A number of experimental acute or chronic exteroceptive or interoceptive stressors induce visceral hyperalgesia in rodents although recent evidence also points to stress-related visceral analgesia as established in the somatic pain field. Underlying mechanisms of stress-related visceral hypersensitivity may involve a combination of sensitization of primary afferents, central sensitization in response to input from the viscera and dysregulation of descending pathways that modulate spinal nociceptive transmission or analgesic response. Biochemical coding of stress involves the recruitment of corticotropin releasing factor (CRF) signaling pathways. Experimental studies established that activation of brain and peripheral CRF receptor subtype 1 plays a primary role in the development of stress-related delayed visceral hyperalgesia while subtype 2 activation induces analgesic response. In line with stress pathways playing a role in IBS, nonpharmacologic and pharmacologic treatment modalities aimed at reducing stress perception using a broad range of evidence-based mind-body interventions and centrally-targeted medications to reduce anxiety impact on brain patterns activated by visceral stimuli and dampen visceral pain. (C) 2011 Elsevier Inc. All rights reserved. C1 [Larauche, Muriel] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, W Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. [Larauche, Muriel; Mulak, Agata; Tache, Yvette] Univ Calif Los Angeles, Ctr Neurobiol Stress, Div Digest Dis, Dept Med,David Geffen Sch Med, Los Angeles, CA 90073 USA. [Larauche, Muriel; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mulak, Agata] Wroclaw Med Univ, Dept Gastroenterol & Hepatol, PL-50556 Wroclaw, Poland. RP Larauche, M (reprint author), Univ Calif Los Angeles, CURE Digest Dis Res Ctr, W Los Angeles VA Med Ctr, 11301 Wilshire Blvd,Bldg 115,Rm 111, Los Angeles, CA 90073 USA. EM mlarauche@mednet.ucla.edu OI Larauche, Muriel/0000-0003-3320-3675 FU NIH [R01 DK-57238, DK 33061, P50 DK-64539] FX This review is part of studies supported by the VA Research Career Scientist Award, NIH grants R01 DK-57238 and DK 33061 and P50 DK-64539 (YT). The authors thank Miss E. Hu for reviewing the manuscript. NR 368 TC 75 Z9 78 U1 3 U2 42 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 EI 1090-2430 J9 EXP NEUROL JI Exp. Neurol. PD JAN PY 2012 VL 233 IS 1 BP 49 EP 67 DI 10.1016/j.expneurol.2011.04.020 PG 19 WC Neurosciences SC Neurosciences & Neurology GA 890CY UT WOS:000300123900007 PM 21575632 ER PT J AU Erickson, MA Niehoff, ML Farr, SA Morley, JE Dillman, LA Lynch, KM Banks, WA AF Erickson, Michelle A. Niehoff, Michael L. Farr, Susan A. Morley, John E. Dillman, Lucy A. Lynch, Kristin M. Banks, William A. TI Peripheral Administration of Antisense Oligonucleotides Targeting the Amyloid-beta Protein Precursor Reverses A beta PP and LRP-1 Overexpression in the Aged SAMP8 Mouse Brain SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Abcb1; amyloid-beta peptides; amyloid-beta protein precursor; antisense; blood-brain barrier; LRP1; oligonucleotides; Pgp; RAGE; SAMP8 ID RECEPTOR-RELATED PROTEIN; SENESCENCE-ACCELERATED MOUSE; METHIONINE-ENKEPHALIN LEVELS; ALZHEIMERS-DISEASE; OBJECT RECOGNITION; CYTOPLASMIC DOMAIN; WATER MAZE; BARRIER; MEMORY; PEPTIDE AB The senescence accelerated mouse-prone 8 (SAMP8) mouse model of Alzheimer's disease has a natural mutation leading to age-related increases in the amyloid-beta protein precursor (A beta PP) and amyloid-beta (A beta) in the brain, memory impairment, and deficits in A beta removal from the brain. Previous studies show that centrally administered antisense oligonucleotide directed against A beta PP can decrease A beta PP expression and A beta production in the brains of aged SAMP8 mice, and improve memory. The same antisense crosses the blood-brain barrier and reverses memory deficits when injected intravenously. Here, we give 6 mu g of A beta PP or control antisense 3 times over 2 week intervals to 12 month old SAMP8 mice. Object recognition test was done 48 hours later, followed by removal of whole brains for immunoblot analysis of A beta PP, low-density lipoprotein-related protein-1 (LRP-1), p-glycoprotein (Pgp), receptor for advanced glycation endproducts (RAGE), or ELISA of soluble A beta(40). Our results show that A beta PP antisense completely reverses a 30% age-associated increase in A beta PP signal (p < 0.05 versus untreated 4 month old SAMP8). Soluble A beta(40) increased with age, but was not reversed by antisense. LRP-1 large and small subunits increased significantly with age (147.7%, p < 0.01 and 123.7%, p < 0.05 respectively), and A beta PP antisense completely reversed these increases (p < 0.05). Pgp and RAGE were not significantly altered with age or antisense. Antisense also caused improvements in memory (p < 0.001). Together, these data support the therapeutic potential of A beta PP antisense and show a unique association between A beta PP and LRP-1 expression in the SAMP8 mouse. C1 [Erickson, Michelle A.; Dillman, Lucy A.; Lynch, Kristin M.; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Erickson, Michelle A.; Dillman, Lucy A.; Lynch, Kristin M.; Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Erickson, Michelle A.] St Louis Univ, Dept Physiol & Pharmacol, St Louis, MO 63103 USA. [Niehoff, Michael L.; Farr, Susan A.; Morley, John E.] Vet Affairs Med Ctr St Louis, St Louis, MO USA. [Niehoff, Michael L.; Farr, Susan A.; Morley, John E.] St Louis Univ, Sch Med, Dept Internal Med, Div Geriatr, St Louis, MO USA. RP Banks, WA (reprint author), Bldg 1,Rm 810A,1660 Columbian Way, Seattle, WA 98108 USA. EM bankswa@slu.edu FU VA Merit Review; National Institutes of Health [AG029839] FX This work was funded by VA Merit Review and the National Institutes of Health (AG029839). NR 64 TC 22 Z9 22 U1 3 U2 8 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2012 VL 28 IS 4 BP 951 EP 960 DI 10.3233/JAD-2011-111517 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 898DL UT WOS:000300715600019 PM 22179572 ER PT J AU Osorio, EY Zhao, WG Espitia, C Saldarriaga, O Hawel, L Byus, CV Travi, BL Melby, PC AF Osorio, E. Yaneth Zhao, Weiguo Espitia, Claudia Saldarriaga, Omar Hawel, Leo Byus, Craig V. Travi, Bruno L. Melby, Peter C. TI Progressive Visceral Leishmaniasis Is Driven by Dominant Parasite-induced STAT6 Activation and STAT6-dependent Host Arginase 1 Expression SO PLOS PATHOGENS LA English DT Article ID NITRIC-OXIDE SYNTHASE; MESSENGER-RNA EXPRESSION; T-CELL RESPONSES; INDIAN KALA-AZAR; CUTANEOUS LEISHMANIASIS; INTERFERON-GAMMA; IN-VIVO; ALTERNATIVE ACTIVATION; L-ARGININE; IFN-GAMMA AB The clinicopathological features of the hamster model of visceral leishmaniasis (VL) closely mimic active human disease. Studies in humans and hamsters indicate that the inability to control parasite replication in VL could be related to ineffective classical macrophage activation. Therefore, we hypothesized that the pathogenesis of VL might be driven by a program of alternative macrophage activation. Indeed, the infected hamster spleen showed low NOS2 but high arg1 enzyme activity and protein and mRNA expression (p < 0.001) and increased polyamine synthesis (p < 0.05). Increased arginase activity was also evident in macrophages isolated from the spleens of infected hamsters (p < 0.05), and arg1 expression was induced by L. donovani in primary hamster peritoneal macrophages (p < 0.001) and fibroblasts (p < 0.01), and in a hamster fibroblast cell line (p < 0.05), without synthesis of endogenous IL-4 or IL-13 or exposure to exogenous cytokines. miRNAi-mediated selective knockdown of hamster arginase 1 (arg1) in BHK cells led to increased generation of nitric oxide and reduced parasite burden (p < 0.005). Since many of the genes involved in alternative macrophage activation are regulated by Signal Transducer and Activator of Transcription-6 (STAT6), and because the parasite-induced expression of arg1 occurred in the absence of exogenous IL-4, we considered the possibility that L. donovani was directly activating STAT6. Indeed, exposure of hamster fibroblasts or macrophages to L. donovani resulted in dose-dependent STAT6 activation, even without the addition of exogenous cytokines. Knockdown of hamster STAT6 in BHK cells with miRNAi resulted in reduced arg1 mRNA expression and enhanced control of parasite replication (p < 0.0001). Collectively these data indicate that L. donovani infection induces macrophage STAT6 activation and STAT6-dependent arg1 expression, which do not require but are amplified by type 2 cytokines, and which contribute to impaired control of infection. C1 [Osorio, E. Yaneth; Zhao, Weiguo; Espitia, Claudia; Saldarriaga, Omar; Travi, Bruno L.; Melby, Peter C.] S Texas Vet Hlth Care Syst, Dept Vet Affairs Med Ctr, Res Serv, San Antonio, TX USA. [Osorio, E. Yaneth; Zhao, Weiguo; Espitia, Claudia; Travi, Bruno L.; Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Saldarriaga, Omar; Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Hawel, Leo; Byus, Craig V.] Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA. RP Osorio, EY (reprint author), Univ Texas Med Branch, Dept Internal Med, Ctr Trop Dis, Galveston, TX 77555 USA. EM melby@uthscsa.edu FU National Institutes of Allergy and Infectious Diseases, National Institutes of Health [AI061624]; Department of Veteran Affairs FX This work was supported by funding from the National Institutes of Allergy and Infectious Diseases, National Institutes of Health (AI061624) and the Department of Veteran Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 105 TC 23 Z9 25 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD JAN PY 2012 VL 8 IS 1 AR e1002417 DI 10.1371/journal.ppat.1002417 PG 17 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 898UI UT WOS:000300767100007 PM 22275864 ER PT J AU Williams, EC Bryson, CL Sun, HL Chew, RB Chew, LD Blough, DK Au, DH Bradley, KA AF Williams, Emily C. Bryson, Chris L. Sun, Haili Chew, Ryan B. Chew, Lisa D. Blough, David K. Au, David H. Bradley, Katharine A. TI Association between Alcohol Screening Results and Hospitalizations for Trauma in Veterans Affairs Outpatients SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE alcohol screening; trauma; AUDIT-C; brief alcohol counseling intervention ID PRIMARY-CARE PATIENTS; PRIMARY-HEALTH-CARE; ALL-CAUSE MORTALITY; BRIEF INTERVENTION; PROBLEM DRINKING; CASE-CROSSOVER; SCORES; RISK; POPULATION; AUDIT AB Background: Alcohol consumption is a risk factor for traumatic injury, but it is unknown whether responses to alcohol screening questionnaires administered routinely in primary care are associated with subsequent hospitalization for traumatic injury. Objective: We evaluated the association between alcohol screening scores and the risk for subsequent hospitalizations for trauma among Veterans Affairs (VA) general medicine patients. Method: This study included VA outpatients (n = 32,623) at seven sites who returned mailed surveys (1997-1999). Alcohol Use Disorders Identification Test Consumption (AUDIT-C) scores grouped patients into six drinking categories representing nondrinkers, screen-negative drinkers, and drinkers who screened positive for mild, moderate, severe, and very severe alcohol misuse (scores 0, 1-3, 4-5, 6-7, 8-9, 10-12, respectively). VA administrative and Medicare data identified primary discharge diagnoses for trauma. Cox proportional hazard models were used to estimate the risk of trauma-related hospitalization for each drinking group adjusted for demographics, smoking, and comorbidity. Results: Compared with screen-negative drinkers, patients with severe and very severe alcohol misuse (AUDIT-C 8-9 and = 10) were at significantly increased risk for trauma-related hospitalization over the follow-up period (adjusted hazard ratios AUDIT-C: 8-9 2.06, 95% confidence interval (CI) 1.31-3.24 and AUDIT-C >= 10 2.13, 95% CI 1.32-3.42). Conclusions: Patients with severe and very severe alcohol misuse had a twofold increased risk of hospital admission for trauma compared to drinkers without alcohol misuse. Scientific Significance: Alcohol screening scores could be used to provide feedback to patients regarding risk of trauma-related hospitalization. Findings could be used by providers during brief alcohol-related interventions with patients with alcohol misuse. C1 [Williams, Emily C.; Bryson, Chris L.; Sun, Haili; Au, David H.; Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev HSR& D NW Ctr Excellenc, Seattle, WA USA. [Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Sci, Seattle, WA 98195 USA. [Bryson, Chris L.; Chew, Lisa D.; Au, David H.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Chew, Ryan B.] Overlake Hosp, Med Ctr, Bellevue, WA USA. [Chew, Lisa D.] Univ Washington, Harborview Med Ctr, Adult Med Clin, Seattle, WA 98104 USA. [Blough, David K.] Univ Washington, Dept Pharm, Seattle, WA 98104 USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev HSR& D NW Ctr Excellence, 1100 OliveWay,Suite 1400, Seattle, WA 98101 USA. EM emily.williams3@va.gov NR 37 TC 17 Z9 17 U1 1 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0095-2990 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD JAN PY 2012 VL 38 IS 1 BP 73 EP 80 DI 10.3109/00952990.2011.600392 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 896HC UT WOS:000300555300011 PM 21797815 ER PT J AU Post, JB Morin, KG Sano, M Jegede, AB Langhoff, E Spungen, AM AF Post, James B. Morin, Kel G. Sano, Mary Jegede, Adejoke B. Langhoff, Erik Spungen, Ann M. TI Increased Presence of Cognitive Impairment in Hemodialysis Patients in the Absence of Neurological Events SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Cognitive impairment; Chronic kidney disease; Hemodialysis ID CHRONIC KIDNEY-DISEASE; BRAIN; DEMENTIA; COHORT AB Background/Aims:Cognitive impairment (CI) is highly prevalent among hemodialysis (HD) patients and is associated with increased morbidity and mortality. The aim was to compare cognitive function in HD patients with no history of stroke or dementia and well-matched controls. Studies are required to determine the impact of HD and chronic kidney disease-specific risks on CI. Methods: 76 outpatients (50 receiving outpatient HD and 26 with normal kidney function matched for age and comorbidity) underwent a cross-sectional observational study. HD patients were well dialyzed and had optimal hemoglobin levels. A battery of eight neuropsychological tests was used. Outcomes included assessment scores of neurocognitive testing and prevalence and subtype of CI. Results: Compared to controls, HD subjects had significantly lower composite scores for each tested cognitive domain. In each domain except memory, the percentage of subjects with impairment was significantly higher in HD subjects than controls. Differences between the groups were independent of vascular and dementia risk factors. 82% of HD subjects met criteria for Cl versus 50% of controls. Non-amnestic subtype of Cl was more prevalent in both groups. Conclusion: Well-dialyzed HD patients with optimized hemoglobin levels and with no history of stroke or dementia performed significantly worse on multiple measures of cognition compared to controls. A higher prevalence of non-memory impairment may suggest an underlying vascular versus neurodegenerative mechanism. HD and chronic kidney disease-specific risk factors may contribute to early Cl not readily detected by routine screening methods. Copyright (C) 2011 S. Karger AG, Basel C1 [Post, James B.; Langhoff, Erik] James J Peters VA Med Ctr, Div Nephrol, Bronx, NY 10468 USA. [Post, James B.; Morin, Kel G.; Jegede, Adejoke B.; Spungen, Ann M.] James J Peters VA Med Ctr, VA RR&D Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Sano, Mary] James J Peters VA Med Ctr, VA RR&D, Bronx, NY 10468 USA. [Post, James B.; Langhoff, Erik] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Post, JB (reprint author), James J Peters VA Med Ctr, Div Nephrol, 130 W Kingsbridge Rd,4C-12 Outpatient Renal Pract, Bronx, NY 10468 USA. EM james.post@va.gov FU VA VISN; VA RRD CDA [B5050W]; VA RR&D Center of Excellence [B4162C]; NIH/NIA Alzheimer's Disease Research Center [AG005138] FX Funding for this project was provided by the VA VISN 3 Seed Grant Program, VA RR&D CDA 2 #B5050W, VA RR&D Center of Excellence #B4162C and NIH/NIA Alzheimer's Disease Research Center #AG005138. NR 24 TC 13 Z9 13 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2012 VL 35 IS 2 BP 120 EP 126 DI 10.1159/000334871 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 896UY UT WOS:000300598100003 PM 22212437 ER PT J AU Hooper, DG Bolton, VE Sutton, JS Guilford, FT Straus, DC Najvar, LK Wiederhold, NP Kirkpatrick, WR Patterson, TF AF Hooper, Dennis G. Bolton, Vincent E. Sutton, John S. Guilford, Frederick T. Straus, David C. Najvar, Laura K. Wiederhold, Nathan P. Kirkpatrick, William R. Patterson, Thomas F. TI Assessment of Aspergillus fumigatus in Guinea Pig Bronchoalveolar Lavages and Pulmonary Tissue by Culture and Realtime Polymerase Chain Reaction Studies SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES LA English DT Article DE Aspergillus fumigatus; Realtime PCR; bronchoalveolar lavages ID INVASIVE ASPERGILLOSIS; TRANSPLANT RECIPIENTS; QUANTITATIVE PCR; GALACTOMANNAN; INFECTIONS; PRINCIPLES; BURDEN; ASSAYS; MODEL AB In this study we pursued a diagnostic target in Aspergillus fumigatus (AF) by using qualitative Realtime PCR combined with proprietary DNA primers and a hydrolysis probe specific for this fungal target. Qualitative Realtime PCR is a diagnostic tool that utilizes Realtime PCR technology and detects the presence or absence target specific DNA within a predetermined detection range. Respiratory tissue and fluids from experimentally infected guinea pigs were tested by extracting DNA from the samples which were amplified and detected using AF specific DNA primers and probe. This study included qualitative evaluations of all specimens for the presence of the DNA of AF. The findings in the tissues after AF infection were compared to the numbers of spores in aerosolized samples used to inoculate the animals. Results demonstrated that the specific probe and primer set could detect the presence or absence of AF DNA in the sample. The qualitative detection limit of the assay ranged from 6 x 10(4) copies to 6 copies. Since blood cultures are rarely positive for Aspergillosis, our data indicate that qualitative Realtime PCR, in combination with the appropriate DNA primers and probe can serve as an effective diagnostic tool in the early detection of fungal infections. C1 [Hooper, Dennis G.; Bolton, Vincent E.] RealTime Labs Inc, Carrollton, TX 75010 USA. [Sutton, John S.] S&S BioConsulting LLC, Austin, TX 78660 USA. [Guilford, Frederick T.] Your Energy Syst, Los Altos, CA 94022 USA. [Straus, David C.] Texas Tech Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Lubbock, TX 79430 USA. [Najvar, Laura K.; Wiederhold, Nathan P.; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Najvar, Laura K.; Kirkpatrick, William R.; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Div Pharmacotherapy, Austin, TX 78712 USA. RP Hooper, DG (reprint author), RealTime Labs Inc, 4100 Fairway Court,600, Carrollton, TX 75010 USA. EM dhooper@realtimelab.com OI Patterson, Thomas /0000-0002-9513-7127; Wiederhold, Nathan/0000-0002-2225-5122 NR 24 TC 0 Z9 0 U1 0 U2 8 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1661-6596 J9 INT J MOL SCI JI Int. J. Mol. Sci. PD JAN PY 2012 VL 13 IS 1 BP 726 EP 736 DI 10.3390/ijms13010726 PG 11 WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary SC Biochemistry & Molecular Biology; Chemistry GA 890ZE UT WOS:000300184800048 PM 22312282 ER PT J AU Keating, NL Malin, JL AF Keating, Nancy L. Malin, Jennifer L. TI Providing Cancer Care: Individual or Team Sport? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID MEDICAL HOME C1 [Keating, Nancy L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Keating, Nancy L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA. [Malin, Jennifer L.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. RP Keating, NL (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM keating@hcp.med.harvard.edu NR 11 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2012 VL 27 IS 1 BP 3 EP 4 DI 10.1007/s11606-011-1922-3 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 873LD UT WOS:000298883900002 PM 22086752 ER PT J AU Kind, AJH Thorpe, CT Sattin, JA Walz, SE Smith, MA AF Kind, Amy J. H. Thorpe, Carolyn T. Sattin, Justin A. Walz, Stacy E. Smith, Maureen A. TI Provider Characteristics, Clinical-Work Processes and Their Relationship to Discharge Summary Quality for Sub-Acute Care Patients SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE discharge documentation; hospital discharge quality; discharge summary; transitions in care; work processes ID HOSPITAL DISCHARGE; GENERAL-PRACTITIONERS; INTERNAL-MEDICINE; STROKE; COMMUNICATION; TRANSITIONS; CONTINUITY; PHYSICIANS; SAFETY; HOME AB Discharge summaries play a pivotal role in the transitional care of patients discharged to sub-acute care facilities, but the best ways to facilitate document completeness/quality remain unknown. To examine the relationship among clinical-work processes, provider characteristics, and discharge summary content to identify approaches that promote high-quality discharge documentation. Retrospective cohort study. All hip fracture and stroke patients discharged to sub-acute care facilities during 2003-2005 from a large Midwestern academic medical center (N = 489). Patients on hospice/comfort care were excluded. We abstracted 32 expert-recommended components in four categories ('patient's medical course,' 'functional/cognitive ability at discharge,' 'future plan of care,' and 'name/contact information') from the discharge summaries of sample patients. We examined predictors for the number of included components within each category using Poisson regression models. Predictors included work processes (document completion in relation to discharge day; completion time of day) and provider characteristics (training year; specialty). Historical components (i.e., 'patient's medical course' category) were included more often than components that directly inform the admission orders in the sub-acute care facility (i.e., 'future plan of care'). In this latter category, most summaries included a discharge medication list (99%), disposition (90%), and instructions for follow-up (91%), but less frequently included diet (68%), activity instructions (58%), therapy orders (56%), prognosis/diagnosis communication to patient/family (15%), code status (7%), and pending studies (6%). 'Future plan of care' components were more likely to be omitted if a discharge summary was created > 24 h after discharge (incident rate ratio = 0.91, 95% confidence interval = 0.84-0.98) or if an intern created the summary (0.90, 0.83-0.97). Critical component omissions in discharge summaries were common, and were associated with delayed document creation and less experienced providers. More research is needed to understand the impact of discharge documentation quality on patient/system outcomes. C1 [Kind, Amy J. H.] William S Middleton Hosp, US Dept Vet Affairs, Geriatr Res Educ & Clin Ctr GRECC, Madison, WI 53705 USA. [Kind, Amy J. H.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Geriatr, Madison, WI USA. [Thorpe, Carolyn T.; Walz, Stacy E.; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Sattin, Justin A.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Walz, Stacy E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. RP Kind, AJH (reprint author), William S Middleton Hosp, US Dept Vet Affairs, Geriatr Res Educ & Clin Ctr GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ajk@medicine.wisc.edu FU National Institute on Aging [K23AG034551]; National Institute of Health [1KL2RR025012-01, 1UL1RR025011]; National Center for Research Resources, National Institutes of Health [1UL1RR025011] FX This project was supported by a National Institute on Aging Beeson Career Development Award (K23AG034551, National Institute on Aging, The American Federation for Aging Research, The John A. Hartford Foundation, The Atlantic Philanthropies, and The Starr Foundation) and by a K-L2 through the National Institute of Health grant 1KL2RR025012-01 [Institutional Clinical and Translational Science Award (UW-Madison) 1UL1RR025011 (KL2) program of the National Center for Research Resources, National Institute of Health]. Additional support was provided by the University of Wisconsin (UW) Hartford Center of Excellence in Geriatrics, the UW School of Medicine and Public Health from The Wisconsin Partnership Program, the Health Innovation Program, the UW Hospitals and Clinics, and the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR), grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health. The Health Innovation Program assisted with data management and with manuscript formatting. No other funding source had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. NR 26 TC 22 Z9 23 U1 2 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2012 VL 27 IS 1 BP 78 EP 84 DI 10.1007/s11606-011-1860-0 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 873LD UT WOS:000298883900015 PM 21901489 ER PT J AU Minemura, N Dhaliwal, G Tierney, LM AF Minemura, Nobuyoshi Dhaliwal, Gurpreet Tierney, Lawrence M., Jr. TI Against All Odds SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE clinical reasoning ID TUBERCULOUS MYOSITIS; PATIENT; ENTITY C1 [Minemura, Nobuyoshi] Natl Sanat Tama Zenshoen, Div Internal Med, Higashimurayama, Tokyo 1898550, Japan. [Dhaliwal, Gurpreet; Tierney, Lawrence M., Jr.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet; Tierney, Lawrence M., Jr.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Minemura, N (reprint author), Natl Sanat Tama Zenshoen, Div Internal Med, 4-1-1 Aoba Cho, Higashimurayama, Tokyo 1898550, Japan. EM ici01059@mbj.nifty.com NR 10 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2012 VL 27 IS 1 BP 125 EP 128 DI 10.1007/s11606-011-1830-6 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 873LD UT WOS:000298883900023 PM 21879373 ER PT J AU Chang, TI Tanner, JM Harada, ND Garrett, NR Friedlander, AH AF Chang, Tina I. Tanner, Jeffrey M. Harada, Nancy D. Garrett, Neal R. Friedlander, Arthur H. TI Prevalence of calcified carotid artery atheromas on the panoramic images of patients with syndrome Z, coexisting obstructive sleep apnea, and metabolic syndrome SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY LA English DT Article ID CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; RISK-FACTORS; FOLLOW-UP; INTERMITTENT HYPOXIA; OXIDATIVE STRESS; BLOOD-PRESSURE; ATHEROSCLEROSIS; ADULTS AB Objectives. The objective of this study was to compare the prevalence of calcified carotid artery atheromas (CCAAs) on panoramic images of individuals (n = 31) with obstructive sleep apnea (OSA) with individuals (n = 117) with syndrome Z (SZ: OSA with concomitant metabolic syndrome [MetS]). Study design. Images of patients with OSA or SZ referred from the Sleep Service to Dentistry were evaluated. Descriptive statistics and t tests (Bonferroni correction) were conducted to determine significant differences between atheroma prevalence and proatherogenic factors (age, apnea-hypopnea index, body mass index, lipid profile, blood pressure, glucose) between OSA and SZ groups. Results. Individuals with OSA had an atheroma prevalence of 35% and those with SZ 42% (P = .52). Individuals with SZ also had significantly more severe atherogenic profiles (obesity, dyslipidemia, hyperglycemia) than OSA patients (P <= .05). Greatest CCAA prevalence (63%) was evidenced by SZ patients with severe OSA and moderate MetS. Conclusion. Individuals with SZ have significantly greater atherogenic burden and slightly higher prevalence of CCAAs when compared with individuals with OSA. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:134-141) C1 [Tanner, Jeffrey M.; Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Dent Serv, Oral & Maxillofacial Surg Sect, Los Angeles, CA 90073 USA. [Harada, Nancy D.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Garrett, Neal R.] Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont Biomat & Hosp Dent, Los Angeles, CA 90024 USA. [Harada, Nancy D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Torrance, CA USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Dent Serv, Oral & Maxillofacial Surg Sect, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov FU Department of Veterans Affairs; University of California; National Center for Research Resources, National Institutes of Health [C06 RR-14529-01] FX The financial support of this project was limited to the full-time salaries paid to the authors by the Department of Veterans Affairs and the University of California. Elements of this investigation were conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06 RR-14529-01 from the National Center for Research Resources, National Institutes of Health. NR 59 TC 1 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-4403 J9 OR SURG OR MED OR PA JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. PD JAN PY 2012 VL 113 IS 1 BP 134 EP 141 DI 10.1016/j.tripleo.2011.07.039 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 898ZW UT WOS:000300781900016 PM 22669072 ER PT B AU Spitz, DR McCormick, ML Oberley, TD AF Spitz, Douglas R. McCormick, Michael L. Oberley, Terry D. BE Spitz, DR Dornfeld, KJ Krishnan, K Gius, D TI Oxidative Stress in Cancer Biology and Therapy Preface SO OXIDATIVE STRESS IN CANCER BIOLOGY AND THERAPY SE Oxidative Stress in Applied Basic Research and Clinical Practice LA English DT Editorial Material; Book Chapter ID HUMAN TUMOR-CELLS; DEPRIVATION-INDUCED CYTOTOXICITY; GLUCOSE DEPRIVATION; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; H2O2 MEDIATE; ENZYMOLOGY C1 [Spitz, Douglas R.; McCormick, Michael L.] Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA. [Oberley, Terry D.] Univ Wisconsin, Mol & Environm Toxicol Ctr, Sch Med & Publ Hlth, Madison, WI USA. [Oberley, Terry D.] Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI USA. [Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. RP Spitz, DR (reprint author), Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA. NR 19 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-1-61779-396-7 J9 OXID STRESS APPL BAS JI Oxid. Stress Appl. Basic Res. Clin. Pract. PY 2012 BP V EP VII D2 10.1007/978-1-61779-397-4 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA BYQ04 UT WOS:000299709300001 ER PT B AU Shan, WH Zhong, WX Swanlund, J Oberley, TD AF Shan, Weihua Zhong, Weixiong Swanlund, Jamie Oberley, Terry D. BE Spitz, DR Dornfeld, KJ Krishnan, K Gius, D TI Oxidative Stress in Prostate Cancer SO OXIDATIVE STRESS IN CANCER BIOLOGY AND THERAPY SE Oxidative Stress in Applied Basic Research and Clinical Practice LA English DT Article; Book Chapter ID MANGANESE SUPEROXIDE-DISMUTASE; CARCINOMA-CELL-LINES; FACTOR-KAPPA-B; REACTIVE OXYGEN; INTRAEPITHELIAL NEOPLASIA; ANTIOXIDANT ENZYMES; PROTEIN EXPRESSION; ANDROGEN RECEPTOR; HYDROGEN-PEROXIDE; SEQUENCE VARIANTS AB Prostate cancer primarily affects older men and is the second leading cause of cancer deaths in males in the USA. Known risk factors for prostate carcinogenesis include age, race, and family history, while possible risk factors include diet, lifestyle, androgens, and inflammation. At least three of these known or potential risk factors (androgens, inflammation, and age) are indirectly linked by the fact that each may result in and/or be derived from oxidative stress. Low levels of reactive oxygen species (ROS) participate in many important physiological and pathological processes in the cell, including proliferation, cell cycle progression, migration, angiogenesis, invasion/metastasis, and inhibition of apoptosis, features that cancer cells might regulate to facilitate progression to a more aggressive phenotype. High levels of ROS/oxidative stress are capable of causing damage to various cellular constituents, including DNA, proteins, and lipids. Elevated levels of ROS, due to increased ROS production or impaired antioxidant defense systems, have been implicated in prostate carcinogenesis. Specific redox compartmental oxidation, which is believed to function as a mechanism for specificity in redox signaling and oxidative stress, is also manifested in prostate cancer. In this chapter, we present and analyze recent findings and ideas relating oxidative stress to prostate cancer and discuss their implications for future studies. C1 [Shan, Weihua; Oberley, Terry D.] Univ Wisconsin, Mol & Environm Toxicol Ctr, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Zhong, Weixiong; Oberley, Terry D.] Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI USA. [Zhong, Weixiong; Swanlund, Jamie; Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. RP Oberley, TD (reprint author), Univ Wisconsin, Mol & Environm Toxicol Ctr, Sch Med & Publ Hlth, Madison, WI 53706 USA. EM toberley@wisc.edu NR 153 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-1-61779-396-7 J9 OXID STRESS APPL BAS JI Oxid. Stress Appl. Basic Res. Clin. Pract. PY 2012 BP 301 EP 331 DI 10.1007/978-1-61779-397-4_15 D2 10.1007/978-1-61779-397-4 PG 31 WC Medicine, General & Internal SC General & Internal Medicine GA BYQ04 UT WOS:000299709300016 ER PT J AU Katz, IR McCarthy, JF Ignacio, RV Kemp, J AF Katz, Ira R. McCarthy, John F. Ignacio, Rosalinda V. Kemp, Janet TI Suicide Among Veterans in 16 States, 2005 to 2008: Comparisons Between Utilizers and Nonutilizers of Veterans Health Administration (VHA) Services Based on Data From the National Death Index, the National Violent Death Reporting System, and VHA Administrative Records SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID MILITARY SERVICE; FIREARM SUICIDE; US VETERANS; RISK; CARE; POPULATION; MORTALITY; AFFAIRS; DEPRESSION; PATIENT AB Objectives. We sought to compare suicide rates among veterans utilizing Veterans Health Administration (VHA) services versus those who did not. Methods. Suicide rates from 2005 to 2008 were estimated for veterans in the 16 states that fully participated in the National Violent Death Reporting System (NVDRS), using data from the National Death Index, NVDRS, and VHA records. Results. Between 2005 and 2008, veteran suicide rates differed by age and VHA utilization status. Among men aged 30 years and older, suicide rates were consistently higher among VHA utilizers. However, among men younger than 30 years, rates declined significantly among VHA utilizers while increasing among nonutilizers. Over these years, an increasing proportion of male veterans younger than 30 years received VHA services, and these individuals had a rising prevalence of diagnosed mental health conditions. Conclusions. The higher rates of suicide for utilizers of VHA among veteran men aged 30 and older were consistent with previous reports about which veterans utilize VHA services. The increasing rates of mental health conditions in utilizers younger than 30 years suggested that the decreasing relative rates in this group were related to the care provided, rather than to selective enrollment of those at lower risk for suicide. (Am J Public Health. 2012;102:S105-S110. doi: 10.2105/AJPH.2011.300503) C1 [Katz, Ira R.; McCarthy, John F.; Ignacio, Rosalinda V.; Kemp, Janet] US Dept Vet Affairs, Washington, DC USA. [Katz, Ira R.; McCarthy, John F.; Ignacio, Rosalinda V.] VA Off Mental Hlth Operat, Richmond, VA 23219 USA. RP McCarthy, JF (reprint author), VA Serious Mental Illness Treatment Resource & Ev, Bldg 14,Room D0129,2800 Plymouth Rd, Ann Arbor, MI 48109 USA. EM John.McCarthy2@VA.gov FU VA Office of Mental Health Services FX This study was funded by the VA Office of Mental Health Services. NR 39 TC 20 Z9 20 U1 2 U2 12 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PY 2012 VL 102 SU 1 BP S105 EP S110 DI 10.2105/AJPH.2011.300503 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 893EO UT WOS:000300338600027 PM 22390582 ER PT J AU Magruder, KM Yeager, D Brawman-Mintzer, O AF Magruder, Kathyrn M. Yeager, Derik Brawman-Mintzer, Olga TI The Role of Pain, Functioning, and Mental Health in Suicidality Among Veterans Affairs Primary Care Patients SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHIATRIC INTERVIEW MINI; RELIABILITY; VALIDITY; RISK; COMORBIDITY; POPULATION; PREVALENCE; ADULTS; SF-36 AB Objectives. We examined suicidality, pain, functioning, and psychiatric disorders among veterans in primary care by using both self-report and clinical measures of pain and mental health to determine correlates that might be clinically useful in primary care settings. Methods. Data were from 884 Veterans Affairs patients enrolled in a regional 4-site cross-sectional study. Patients were administered measures that assessed functioning (including pain) and psychiatric disorders. Data were merged with medical records for clinical pain indicators. Results. Overall, 9.1% (74 of 816) of patients indicated suicidal ideation, with those who were middle-aged, unemployed because of disability, had less than college education, and served in a warzone most likely to consider suicidality. Suicidal patients had worse functioning (measured by the Short Form-36) than did nonsuicidal patients in every domain, including bodily pain, and were more likely to meet criteria for a psychiatric diagnosis. However, when pain and mental health were jointly considered, only mental health (both psychiatric diagnosis and mental health functioning) was related to suicidality. Conclusions. Although providers should be alert to the possibility of suicidality in patients with pain, they should be vigilant when patients have a psychiatric disorder or poor mental health. (Am J Public Health. 2012;102:S118-S124. doi:10.2105/AJPH.2011.300451) C1 [Magruder, Kathyrn M.; Yeager, Derik; Brawman-Mintzer, Olga] Ralph H Johnson VA Med Ctr, Mental Hlth Serv Line, Charleston, SC 29401 USA. [Magruder, Kathyrn M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Mil Sci Div, Dept Med,Biostat & Epidemiol Div, Charleston, SC USA. RP Yeager, D (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv Line, 109 Bee St, Charleston, SC 29401 USA. EM yeagerde@musc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [VCR 99-010-2, SHP 08-160] FX This article is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (VCR 99-010-2 and SHP 08-160). NR 30 TC 9 Z9 9 U1 1 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PY 2012 VL 102 SU 1 BP S118 EP S124 DI 10.2105/AJPH.2011.300451 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 893EO UT WOS:000300338600029 PM 22390584 ER PT J AU Ishii, S Cauley, JA Crandall, CJ Srikanthan, P Greendale, GA Huang, MH Danielson, ME Karlamangla, AS AF Ishii, Shinya Cauley, Jane A. Crandall, Carolyn J. Srikanthan, Preethi Greendale, Gail A. Huang, Mei-Hua Danielson, Michelle E. Karlamangla, Arun S. TI Diabetes and Femoral Neck Strength: Findings from The Hip Strength Across the Menopausal Transition Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID BONE-MINERAL DENSITY; FRACTURE RISK; OSTEOPOROTIC FRACTURES; BODY-COMPOSITION; OLDER WOMEN; MELLITUS; ASSOCIATION; HEALTH; MEN; MASS AB Context: Diabetes mellitus is associated with increased hip fracture risk, despite being associated with higher bone mineral density in the femoral neck. Objective: The objective of the study was to test the hypothesis that composite indices of femoral neck strength, which integrate dual-energy x-ray absorptiometry derived femoral neck size, femoral neck areal bone mineral density, and body size and are inversely associated with hip fracture risk, would be lower in diabetics than in nondiabetics and be inversely related to insulin resistance, the primary pathology in type 2 diabetes. Design: This was a cross-sectional analysis. Setting and Participants: The study consisted of a multisite, multiethnic, community-dwelling sample of 1887 women in pre- or early perimenopause. Outcome Measurements: Composite indices for femoral neck strength in different failure modes (axial compression, bending, and impact) were measured. Results: Adjusted for age, race/ethnicity, menopausal stage, body mass index, smoking, physical activity, calcium and vitamin D supplementation, and study site, diabetic women had higher femoral neck areal bone mineral density [+0.25 SD, 95% confidence interval (CI) (+0.06, +0.44) SD] but lower composite strength indices [-0.20 SD, 95% CI (-0.38, -0.03) SD for compression, -0.19 SD, 95% CI (-0.38, -0.003) SD for bending, -0.19 SD, 95% CI (-0.37, -0.02) SD for impact] than non-diabetic women. There were graded inverse relationships between homeostasis model-assessed insulin resistance and all three strength indices, adjusted for the same covariates. Conclusions: Despite having higher bone density, diabetic women have lower indices of femoral neck strength relative to load, consistent with their documented higher fracture risk. Insulin resistance appears to play an important role in bone strength reduction in diabetes. (J Clin Endocrinol Metab 97: 190-197, 2012) C1 [Ishii, Shinya] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Cauley, Jane A.; Danielson, Michelle E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Greendale, Gail A.; Huang, Mei-Hua; Karlamangla, Arun S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Crandall, Carolyn J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Srikanthan, Preethi] Univ Calif Los Angeles, David Geffen Sch Med, Res Ctr Alhambra, Dept Med,Div Clin Epidemiol & Preventat Med, Alhambra, CA 91801 USA. RP Ishii, S (reprint author), Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan. EM sishii@ucla.edu OI Cauley, Jane A/0000-0003-0752-4408 FU National Institutes of Health (NIH), Department of Health and Human Services, through the National Institute on Aging (NIA); National Institute of Nursing Research; NIH Office of Research on Women's Health [NR004061, AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495]; NIA [AG026463, AG028748, AG033067]; Veterans Affairs Greater Los Angeles Healthcare System Geriatric Research, Education, and Clinical Center; Veterans Affairs FX SWAN was supported by the National Institutes of Health (NIH), Department of Health and Human Services, through the National Institute on Aging (NIA), the National Institute of Nursing Research, and the NIH Office of Research on Women's Health (Grants NR004061, AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, and AG012495). The Hip Strength Through the Menopausal Transition was supported by NIA Grant AG026463. The SWAN Hip Strength Substudy was supported by NIA Grant AG028748. The current study was also supported by NIA Grant AG033067. S.I. was supported by the Veterans Affairs Greater Los Angeles Healthcare System Geriatric Research, Education, and Clinical Center; and the Veterans Affairs Advanced Geriatrics Fellowship. NR 40 TC 32 Z9 34 U1 1 U2 8 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2012 VL 97 IS 1 BP 190 EP 197 DI 10.1210/jc.2011-1883 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 893YM UT WOS:000300393800051 PM 22072739 ER PT J AU Bekris, LM Lutz, F Yu, CE AF Bekris, Lynn M. Lutz, Franziska Yu, Chang-En TI Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE SO JOURNAL OF HUMAN GENETICS LA English DT Article DE APOC1; APOE; BCR; enhancer; luciferase reporter assay; ME1; regulation; TOMM40 ID GENOME-WIDE ASSOCIATION; APOLIPOPROTEIN-E GENE; ONSET ALZHEIMERS-DISEASE; LINKAGE DISEQUILIBRIUM; SUSCEPTIBILITY GENES; QUANTITATIVE TRAIT; PROTEIN-LEVELS; EXPRESSION; BRAIN; RISK AB Genetic variation within the apolipoprotein E gene (APOE) locus is associated with late-onset Alzheimer's disease risk and quantitative traits as well as apoE expression in multiple tissues. The aim of this investigation was to explore the influence of APOE locus cis-regulatory element enhancer region genetic variation on regional gene promoter activity. Luciferase reporter constructs containing haplotypes of APOE locus gene promoters; APOE, APOC1 and TOMM40, and regional putative enhancers; TOMM40 intervening sequence (IVS) 2-4, TOMM40 IVS6 poly-T, as well as previously described enhancers; multienhancer 1 (ME1), or brain control region (BCR), were evaluated for their effects on luciferase activity in three human cell lines. Results of this investigation demonstrate that in SHSY5Y cells, the APOE promoter is significantly influenced by the TOMM40 IVS2-4 and ME1, and the TOMM40 promoter is significantly influenced by the TOMM40 IVS6 poly-T, ME1 and BCR. In HepG2 cells, the TOMM40 promoter is significantly influenced by all four enhancers, whereas the APOE promoter is not influenced by any of the enhancers. The main novel finding of this investigation was that multiple APOE locus cis-elements influence both APOE and TOMM40 promoter activity according to haplotype and cell type, suggesting that a complex transcriptional regulatory structure modulates regional gene expression. Journal of Human Genetics (2012) 57, 18-25; doi: 10.1038/jhg.2011.123; published online 17 November 2011 C1 [Bekris, Lynn M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Bekris, Lynn M.; Lutz, Franziska; Yu, Chang-En] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Bekris, LM (reprint author), Univ Washington, Dept Med, Div Gerontol & Geriatr Med, VA Puget Sound Hlth Care Syst, Box 358280 VAPSHCS GRECC S182,1660 S Columbian Wa, Seattle, WA 98108 USA. EM lbekris@u.washington.edu FU US Department of Veterans Affairs; Office of Research and Development Biomedical Laboratory; National Institutes of Health/National Institutes on Aging [1K99AG034214-01A1] FX This work was supported in part by the US Department of Veterans Affairs, Office of Research and Development Biomedical Laboratory Research Program and the National Institutes of Health/National Institutes on Aging Grant 1K99AG034214-01A1. We thank J Anthony Gill for the editing of the manuscript. NR 33 TC 36 Z9 36 U1 2 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1434-5161 J9 J HUM GENET JI J. Hum. Genet. PD JAN PY 2012 VL 57 IS 1 BP 18 EP 25 DI 10.1038/jhg.2011.123 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 892PI UT WOS:000300297700006 PM 22089642 ER PT J AU Sanchez-Reilly, S Ross, JS AF Sanchez-Reilly, Sandra Ross, Jeanette S. TI Hospice and Palliative Medicine: Curriculum Evaluation and Learner Assessment in Medical Education SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; STUDENTS; COMPETENCES; PROJECT; RESIDENTS; OUTCOMES; SCHOOLS AB Major efforts have been pursued to improve palliative care education for physicians at all levels of their training. Such changes include the incorporation of palliative care curriculum and guidelines, an established process for competency-based evaluation and certification, faculty development, innovative educational experiences, the improvement of textbooks, and the establishment of accredited palliative medicine fellowships. Hospice and palliative medicine (HPM) has been clearly defined as a subspecialty and a crucial area of medical education. As innovative curricular approaches have become available to educate medical and other interprofessional trainees, this article aims to describe different models and methods applied in curriculum evaluation, tailoring such approaches to the field of palliative medicine. A stepwise process of curriculum development and evaluation is described, focusing on available curriculum evaluation competency-based tools for each level of learners. As HPM evolves and its educational programs grow, curriculum evaluation will provides invaluable feedback to institutions and programs in many ways. C1 [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA. [Ross, Jeanette S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Ross, Jeanette S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, GEC, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78229 USA. RP Sanchez-Reilly, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr Gerontol & Palliat Med, 7703 Floyd Curl Dr,MC 7875, San Antonio, TX 78229 USA. EM sanchezreill@uthscsa.edu NR 58 TC 10 Z9 10 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD JAN PY 2012 VL 15 IS 1 BP 116 EP 122 DI 10.1089/jpm.2011.0155 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 891HK UT WOS:000300207600021 PM 22268408 ER PT J AU Ho, L Varghese, M Wang, J Zhao, W Chen, F Knable, LA Ferruzzi, M Pasinetti, GM AF Ho, Lap Varghese, Merina Wang, Jun Zhao, Wei Chen, Fei Knable, Lindsay Alexis Ferruzzi, Mario Pasinetti, Giulio M. TI Dietary supplementation with decaffeinated green coffee improves diet-induced insulin resistance and brain energy metabolism in mice SO NUTRITIONAL NEUROSCIENCE LA English DT Article DE Alzheimer's disease; Dementia; Mitochondria; Chlorogenic acid; Coffee ID CHLOROGENIC ACID; ALZHEIMERS-DISEASE; BODY-WEIGHT; HUMANS; CONSUMPTION; RISK; TEA; CAFFEINE; OBESITY AB Objectives: There is accumulating evidence that coffee consumption may reduce risk for type 2 diabetes, a known risk factor for Alzheimer's and other neurological diseases. Coffee consumption is also associated with reduced risk for Alzheimer's disease and non-Alzheimer's dementias. However, preventive and therapeutic development of coffee is complicated by the cardiovascular side effects of caffeine intake. As coffee is also a rich source of chlorogenic acids and many bioactive compounds other than caffeine, we hypothesized that decaffeinated coffee drinks may exert beneficial effects on the brain. Methods: We have investigated whether dietary supplementation with a standardized decaffeinated green coffee preparation, Svetol (R), might modulate diet-induced insulin resistance and brain energy metabolism dysfunction in a high-fat diet mouse model. Results: As expected, dietary supplementation with Svetol (R) significantly attenuated the development of high-fat diet-induced deficits in glucose-tolerance response. We have also found that Svetol (R) treatment improved brain mitochondrial energy metabolism as determined by oxygen consumption rate. Consistent with this evidence, follow-up gene expression profiling with Agilent whole-genome microarray revealed that the decaffeinated coffee treatment modulated a number of genes in the brain that are implicated in cellular energy metabolism. Discussion: Our evidence is the first demonstration that dietary supplementation with a decaffeinated green coffee preparation may beneficially influence the brain, in particular promoting brain energy metabolic processes. C1 [Ho, Lap; Varghese, Merina; Wang, Jun; Zhao, Wei; Chen, Fei; Knable, Lindsay Alexis; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Ferruzzi, Mario] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA. [Ferruzzi, Mario] Purdue Univ, Dept Foods & Nutr, W Lafayette, IN 47907 USA. [Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, Annenberg Bldg,Room 20-06,1468 Madison Ave & 100, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu OI Varghese, Merina/0000-0002-1517-3903 NR 28 TC 16 Z9 16 U1 1 U2 16 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1028-415X J9 NUTR NEUROSCI JI Nutr. Neurosci. PD JAN PY 2012 VL 15 IS 1 BP 37 EP 45 DI 10.1179/1476830511Y.0000000027 PG 9 WC Neurosciences; Nutrition & Dietetics SC Neurosciences & Neurology; Nutrition & Dietetics GA 894HE UT WOS:000300416900006 PM 22305652 ER PT J AU Yaffe, K Laffan, AM Harrison, SL Redline, S Spira, AP Ensrud, KE Ancoli-Israel, S Stone, KL AF Yaffe, Kristine Laffan, Alison M. Harrison, Stephanie Litwack Redline, Susan Spira, Adam P. Ensrud, Kristine E. Ancoli-Israel, Sonia Stone, Katie L. TI Sleep-Disordered Breathing, Hypoxia, and Risk of Mild Cognitive Impairment and Dementia in Older Women EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material AB Up to 60% of older adults have sleep-disordered breathing, a disorder characterized by recurrent arousals from sleep and intermittent hypoxemia. Cognitive impairment is also common in older populations. Several cross-sectional studies have reported an association between sleep-disordered breathing and poor cognition. However, other studies have found no association, and the majority of studies showing an association had deficiencies in design and methodology. Therefore, it is unclear whether sleep-disordered breathing precedes impaired cognition in the elderly population. The present investigation, a substudy of the Study of Osteoporotic Fractures, was designed to determine prospectively whether sleep-disordered breathing is associated with mild cognitive impairment and dementia, increasing the risk of its development 5 years later. Potential mechanisms (hypoxia, sleep fragmentation, and sleep duration) to explain a positive association with cognitive dysfunction were also investigated. Sleep-disordered breathing was measured objectively with overnight polysomnography in 298 women without dementia (mean age: 82.3 years) from 2002 to 2004. The apnea-hypopnea index (the number of apnea plus hypopnea events per hour of sleep) was determined. Sleep-disordered breathing was defined as an index of 15 or more events per hour. Cognitive status (normal, dementia, or mild cognitive impairment) was determined in all participants between 2006 and 2008 at a mean follow-up of 4.7 years. Univariate and multivariate logistic regression models were used to examine the associations in women with (n = 105) and without (n = 193) dementia. Multivariate models were adjusted for potential confounders (demographic risk factors and comorbidities), including age, race, body mass index, educational attainment, smoking status, presence of diabetes or hypertension, use of medication (antidepressants, benzodiazepines, or nonbenzodiazepine anxiolytics), and baseline cognitive scores. Of the 298 women in the analysis, 105 (35.2%) had sleep-disordered breathing. The affected women were more likely to develop mild cognitive impairment or dementia than women without sleep-disordered breathing (44.8% vs. 31.1%); the adjusted odds ratio (aOR) was 1.85, with a 95% confidence interval (CI) of 1.11-3.08 (P = 0.02). A higher incidence of mild cognitive impairment or dementia was found for 2 measures of apnea or hypopnea: an oxygen desaturation index: >= 15 (aOR, 1.71; 95% CI, 1.04-2.83) and a high percentage of total sleep time (>7%) (aOR, 2.04; 95% CI, 1.10-3.78). No significant association in the adjusted data was observed for the sleep fragmentation or sleep duration measures. These findings suggest that older women with sleep-disordered breathing are at increased risk of developing cognitive impairment 5 years later compared with those without sleep-disordered breathing. C1 [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Laffan, Alison M.; Harrison, Stephanie Litwack; Stone, Katie L.] Calif Pacific Med Ctr, San Francisco Coordinating Ctr, San Francisco, CA USA. [Redline, Susan] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA. [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Spira, Adam P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Epidemiol, Minneapolis, MN USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Community Hlth, Minneapolis, MN USA. [Ensrud, Kristine E.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 3 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD JAN PY 2012 VL 67 IS 1 BP 34 EP 36 DI 10.1097/OGX.0b013e3182439f33 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 891MD UT WOS:000300220300016 ER PT J AU Weintraub, D Dietz, N Duda, JE Wolk, DA Doshi, J Xie, SX Davatzikos, C Clark, CM Siderowf, A AF Weintraub, Daniel Dietz, Nicole Duda, John E. Wolk, David A. Doshi, Jimit Xie, Sharon X. Davatzikos, Christos Clark, Christopher M. Siderowf, Andrew TI Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease SO BRAIN LA English DT Article DE Alzheimer's disease; dementia; mild cognitive impairment; Parkinson's disease; neurodegeneration ID DEMENTIA RATING-SCALE; LEWY BODIES; ELASTIC REGISTRATION; MCI PATIENTS; BASE-LINE; IMPAIRMENT; HALLUCINATIONS; HIPPOCAMPAL; BETA; CLASSIFICATION AB Research suggests overlap in brain regions undergoing neurodegeneration in Parkinson's and Alzheimer's disease. To assess the clinical significance of this, we applied a validated Alzheimer's disease-spatial pattern of brain atrophy to patients with Parkinson's disease with a range of cognitive abilities to determine its association with cognitive performance and decline. At baseline, 84 subjects received structural magnetic resonance imaging brain scans and completed the Dementia Rating Scale-2, and new robust and expanded Dementia Rating Scale-2 norms were applied to cognitively classify participants. Fifty-nine non-demented subjects were assessed annually with the Dementia Rating Scale-2 for two additional years. Magnetic resonance imaging scans were quantified using both a region of interest approach and voxel-based morphometry analysis, and a method for quantifying the presence of an Alzheimer's disease spatial pattern of brain atrophy was applied to each scan. In multivariate models, higher Alzheimer's disease pattern of atrophy score was associated with worse global cognitive performance (beta = -0.31, P = 0.007), including in non-demented patients (beta = -0.28, P = 0.05). In linear mixed model analyses, higher baseline Alzheimer's disease pattern of atrophy score predicted long-term global cognitive decline in non-demented patients [F(1, 110) = 9.72, P = 0.002], remarkably even in those with normal cognition at baseline [F(1, 80) = 4.71, P = 0.03]. In contrast, in cross-sectional and longitudinal analyses there was no association between region of interest brain volumes and cognitive performance in patients with Parkinson's disease with normal cognition. These findings support involvement of the hippocampus and parietal-temporal cortex with cognitive impairment and long-term decline in Parkinson's disease. In addition, an Alzheimer's disease pattern of brain atrophy may be a preclinical biomarker of cognitive decline in Parkinson's disease. C1 [Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel; Duda, John E.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA. [Weintraub, Daniel; Dietz, Nicole; Duda, John E.; Wolk, David A.; Clark, Christopher M.; Siderowf, Andrew] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Doshi, Jimit; Davatzikos, Christos] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Clark, Christopher M.] Avid Radiopharmaceut, Philadelphia, PA 19104 USA. RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU Department of Health of the Commonwealth of Pennsylvania [SAP4100027296, 2001-77]; National Institute of Neurological Disorders and Strokes [NS-053488]; National Institute of Aging [R01-14971, P30-AG10124] FX This work was supported by a health research grant [grant number SAP4100027296] awarded by the Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement under Act 2001-77, the National Institute of Neurological Disorders and Strokes [NS-053488], and the National Institute of Aging [R01-14971 and P30-AG10124]. NR 77 TC 54 Z9 56 U1 2 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD JAN PY 2012 VL 135 BP 170 EP 180 DI 10.1093/brain/awr277 PN 1 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 888ZX UT WOS:000300044400024 PM 22108576 ER PT J AU Nguyen, CA Akiba, Y Kaunitz, JD AF Nguyen, C. A. Akiba, Y. Kaunitz, J. D. TI Recent Advances in Gut Nutrient Chemosensing SO CURRENT MEDICINAL CHEMISTRY LA English DT Review DE Fatty acids; amino acids; bile acids; G Protein-coupled receptors; enteroendocrine cells; gut hormones; cholecystokinin; glucagon-like peptide; metabotropic glutamate receptor; TIR2/TIR3; SGLT1; transgenic mice; obesity; diabetes ID PROTEIN-COUPLED RECEPTOR; GLUCAGON-LIKE PEPTIDE-1; GASTRIC-ACID-SECRETION; FREE FATTY-ACIDS; EXTRACELLULAR CA2+-SENSING RECEPTOR; SODIUM-GLUCOSE COTRANSPORTER; CALCIUM-SENSING RECEPTOR; CANDIDATE TASTE RECEPTOR; RAT DUODENAL MUCOSA; CELL-LINE STC-1 AB The field of gut nutrient chemosensing is evolving rapidly. Recent advances have uncovered the mechanism by which specific nutrient components evoke multiple metabolic responses. Deorphanization of G protein-coupled receptors (GPCRs) in the gut has helped identify previously unliganded receptors and their cognate ligands. In this review, we discuss nutrient receptors, their ligand preferences, and the evoked neurohormonal responses. Family A GPCRs includes receptor GPR93, which senses protein and proteolytic degradation products, and free fatty acid-sensing receptors. Short-chain free fatty acids are ligands for FFA2, previously GPR43, and FFA3, previously GPR41. FFA1, previously GPR40, is activated by long-chain fatty acids with GPR120 activated by medium-and long-chain fatty acids. The GPR119 agonist ethanolamide oleoylethanolamide (OEA) and bile acid GPR131 agonists have also been identified. Family C receptors ligand preferences include L-amino acids, carbohydrate, and tastants. The metabotropic glutamate receptor (mGluR), calcium-sensing receptor (CaR), and GPCR family C, group 6, subtype A receptor (GPRC6A) mediate L-amino acid-sensing. Taste receptors have a proposed role in intestinal chemosensing; sweet, bitter, and umami evoke responses in the gut via GPCRs. The mechanism of carbohydrate-sensing remains controversial: the heterodimeric taste receptor T1R2/T1R3 and sodium glucose cotransporter 1 (SGLT-1) expressed in L cells are the two leading candidates. Identification of specific nutrient receptors and their respective ligands can provide novel therapeutic targets for the treatment of diabetes, acid reflux, foregut mucosal injury, and obesity. C1 [Kaunitz, J. D.] W Los Angeles VAMC, Dept Med, Los Angeles, CA 90073 USA. [Nguyen, C. A.] W Los Angeles Vet Affairs Med Ctr, Dept Nutr, Los Angeles, CA 90073 USA. [Akiba, Y.] W Los Angeles Vet Affairs Med Ctr, Dept Res, Los Angeles, CA 90073 USA. [Akiba, Y.; Kaunitz, J. D.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA. [Akiba, Y.; Kaunitz, J. D.] CURE DDRC Digest Dis Ctr, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), W Los Angeles VAMC, Dept Med, 11301 Wilshire Blvd,Bldg 114,Suite 217E, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [R01 DK054221] NR 90 TC 20 Z9 20 U1 3 U2 33 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 0929-8673 J9 CURR MED CHEM JI Curr. Med. Chem. PD JAN PY 2012 VL 19 IS 1 BP 28 EP 34 PG 7 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 890XH UT WOS:000300179300005 PM 22300073 ER PT J AU Tache, Y AF Tache, Y. TI Brainstem Neuropeptides and Vagal Protection of the Gastric Mucosal Against Injury: Role of Prostaglandins, Nitric Oxide and Calcitonin-Gene Related Peptide in Capsaicin Afferents SO CURRENT MEDICINAL CHEMISTRY LA English DT Review DE Adrenomedullin; CGRP; ethanol; ghrelin; nitric oxide; prostaglandins; TRH; vagus ID THYROTROPIN-RELEASING-HORMONE; CENTRAL-NERVOUS-SYSTEM; DORSAL MOTOR NUCLEUS; URETHANE-ANESTHETIZED RATS; PYY-PREFERRING RECEPTORS; ACID-SECRETION; TRH ANALOG; INTRACISTERNAL TRH; ADAPTIVE CYTOPROTECTION; MESSENGER-RNA AB Earlier experimental studies indicated that the integrity of vagal pathway was required to confer gastric protection against damaging agents. Several peptides located in the brainstem initially identified to influence vagal outflow to the stomach, as assessed by electrophysiological approach or by vagal dependent alterations of gastric secretory and motor function, were investigated for their influence in the vagal regulation of the resistance of the gastric mucosa to injury. Thyrotropin releasing hormone (TRH), or its stable TRH analog, RX-77368, injected at low doses into the cisterna magna or the dorsal motor nucleus (DMN) was the first peptide reported to protect the gastric mucosa against ethanol injury through stimulation of vagal cholinergic pathways, inducing the release of gastric prostaglandins/nitric oxide (NO) and the recruitment of efferent function of capsaicin sensitive afferent fibers containing calcitonin-gene related peptide (CGRP). Activation of endogenous TRH-TRH1 receptor signaling located in the brainstem plays a role in adaptive gastric protection against damaging agents. Since then, an expanding number of peptides, namely peptide YY, CGRP, adrenomedullin, amylin, glugacon-like peptide, opioid peptides acting on, 1 or 2 receptors, nocicpetin, nocistatin, ghrelin, leptin and TLQP-21, a peptide derived from VGF prohormone, have been reported to act in the brainstem to afford gastric protection against ethanol injury largely through similar peripheral effectors mechanisms than TRH. Therefore gastric prostaglandins and CGRP/NO pathways represent a common final mechanism through which brain peptides confer vagally mediated gastroprotection against injury. A better understanding of brain circuitries through which these peptides are released will provide new strategies to recruit integrated and multifaceted gastroprotective mechanisms. C1 [Tache, Y.] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Tache, Y.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Div Digest Dis, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), Univ Calif Los Angeles, CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU Veteran Affairs Research Career Scientist Award; National Institute of Health [DK-33061, DK-57238, DK-41301] FX Yvette Tache is in receipt of Veteran Affairs Research Career Scientist Award and Merit Award and National Institute of Health grants R01grants, DK-33061 and DK-57238, and Center grant DK-41301 (Animal core). We thank Ms. Eugenia Hu for helping in the preparation of the manuscript. No potential conflict of interest. NR 129 TC 27 Z9 30 U1 0 U2 4 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 0929-8673 J9 CURR MED CHEM JI Curr. Med. Chem. PD JAN PY 2012 VL 19 IS 1 BP 35 EP 42 PG 8 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 890XH UT WOS:000300179300006 PM 22300074 ER PT J AU Rosendorff, C Go, O Schmeidler, J Silverman, JM Beeri, MS AF Rosendorff, Clive Go, Orson Schmeidler, James Silverman, Jeremy M. Beeri, Michal S. TI Correlation of arterial blood pressure and compliance with left ventricular structure and function in the very elderly SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Blood pressure; arterial stiffness; arterial compliance; myocardial remodeling; left ventricular hypertrophy; elderly ID PULSE CONTOUR ANALYSIS; PRESERVED EJECTION FRACTION; HEART-FAILURE; TISSUE DOPPLER; LOW PREVALENCE; WAVE VELOCITY; HYPERTENSION; AGE; IMPACT; ECHOCARDIOGRAPHY AB There are very few data on the relationship between systolic blood pressure (SBP), diastolic blood pressure (DBP), arterial compliance, and left ventricular structure and function, particularly left ventricular hypertrophy (LVH), in the very elderly (>75 years). SBP and arterial stiffness increase with age, and the question is: which of the two is the main stimulus to LVH? This is a cross-sectional study to compare blood pressure and arterial stiffness measures with regard to their correlations with echocardiographic parameters of LV structure and function, controlling for age and cardiovascular risk factors, in a very elderly population. Arterial stiffness was determined by radial pulse waveform using pulse contour analysis. LV dimensions were measured by transthoracic M-mode echocardiography, and diastolic function by tissue Doppler measurements of diastolic mitral annular velocities. There were 179 subjects, all male, with a mean age of 81.8 years. Using age-adjusted partial correlations, SBP, DBP, and mean arterial pressure (MAP) were correlated with parameters of LV structure and function. Correlation coefficients were: SBP versus left ventricular mass index (LVMI), r = 0.246; SBP versus early diastolic mitral annular velocity (MAV), r = 0.179; DBP versus LVMI, r = 0.199; DBP versus MAV, r = 0.199; MAP versus LVMI, r = 0.276; and MAP versus MAV, r = 0.206, all with P <.05. However, neither capacitative nor reflective arterial compliance was significantly correlated with any parameter of LV structure and function. After controlling for age and 10 cardiovascular and metabolic risk factors, the correlation between blood pressure and the measured LV parameters was substantially unchanged, as was the lack of correlation between indices of arterial compliance and the LV indices. Arterial blood pressure is correlated with LV structure and function in the very elderly, but arterial stiffness, as measured by diastolic pulse contour analysis, is not. J Am Soc Hypertens 2012;6(1):48-55. Published by Elsevier Inc on behalf of American Society of Hypertension. C1 [Rosendorff, Clive; Go, Orson] James J Peters VA Med Ctr, Dept Med, Bronx, NY 10468 USA. [Rosendorff, Clive] Mt Sinai Sch Med, Dept Med Cardiol, New York, NY USA. [Schmeidler, James; Silverman, Jeremy M.; Beeri, Michal S.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, Dept Med, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov FU National Institute of Aging of the National Institutes of Health [AGO-02219] FX Supported by a Program Project Grant from the National Institute of Aging of the National Institutes of Health (AGO-02219), "Clinical and Biological Studies of Early Alzheimer's Disease; Project 4: Age at Onset and Cardiovascular Risk Factors in Very Late Onset Cognitive Decline and Alzheimer's Disease." NR 40 TC 2 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD JAN-FEB PY 2012 VL 6 IS 1 BP 48 EP 55 DI 10.1016/j.jash.2011.10.004 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 887XQ UT WOS:000299965800006 PM 22243840 ER EF